EANM23
WORLD LEADING MEETING

FINAL PROGRAMME

36th
Annual Congress of the European Association of Nuclear Medicine

VIENNA

SEPTEMBER 9 – 13, 2023

eanm23.eanm.org

TABLE OF CONTENTS

WORLD LEADING MEETING EANM'23
SEPTEMBER 9–13, 2023

WORDS OF WELCOME

BY THE CONGRESS CHAIR

VALENTINA GARIBOTTO

EANM CONGRESS CHAIR 2023–2025

Dear colleagues,

It is my great honour to invite you to the 36th Annual EANM Congress on behalf of the European Association of Nuclear Medicine. This year's event will be held in Vienna from September, 9–13.

We are able to meet in person again for this edition of the EANM Congress, meaning we will enjoy the fantastic science and face-to-face interchange the occasion offers while also continuing to bolster our growth as a specialist community.

Our present is bright, and our future is even more promising. Our relevance for diagnostics and therapy continues to increase, new tools and tracers have been established, and ongoing research and innovation are consistently providing fresh solutions for validation and testing. The number of joint projects with other disciplines and societies continues to grow with more and more communities recognising the important help that Nuclear Medicine can provide their patients and in answering their questions. This is the main reason for the unusual date of this year's EANM Congress, as we wanted to avoid clashing with a major event with whom we have a big overlap in participants and industry involvements. We plan to return to our usual mid-October dates in 2024.

The number of visitors to the Congress continues to rise year after year with the 2022 edition of the event welcoming an unprecedented 7000 participants. The many innovative features you discovered and liked in Barcelona last year will be present once more, including sessions specifically devoted to exchange and discussion. Please prepare your questions across the year and get ready to challenge our experts during the Congress! We want to make sure that you return home with input and suggestions that allow each and every one of you to contribute to the success of our field in your daily work.

Needless to say, we should not simply sit back and enjoy our success. We must continue to provide convincing evidence of the positive impact our chosen field has in a complex world of limited resources, meaning we should constantly strive for a more efficient, accessible and sustainable Nuclear Medicine. This year's scientific programme will help you deal with such issues thanks to superb material combined with multidisciplinary sessions. And as we know that fun helps foster collaboration and cooperation, some of them will also be uniquely entertaining. On top of this, we hope for your numerous contributions and input via the abstract submission, which is now open. Share your work with the nuclear medicine community!

We have prepared content that will maximise opportunities for exchange and networking for all those who travel to Vienna for EANM'23. On the other hand, we still want to reach as large an audience as possible, just as virtual congresses have done, including anyone that cannot make it to Vienna for this year's congress. For this reason, selected content will also be made available online and will remain accessible afterwards so that everyone can benefit from it in a way which fits around each individual's schedule.

In summary, we are working to provide you all with a special, first-rate congress tailored to your needs and wishes. Join us and savour every moment of it!

Valentina Garibotto
EANM Congress Chair 2023–2025

WORDS OF WELCOME | FINAL PROGRAMME

BOARD & SCIENTIFIC PROGRAMME COUNCIL

EANM BOARD

President 2023–2024
Rudi A.J.O. Dierckx (Netherlands)

President Elect 2023–2024
Paola Anna Erba (Italy)

Committee Coordinator 2023–2024
Felix Mottaghy (Germany)

Congress Chair 2023–2025
Valentina Garibotto (Switzerland)

Education Chair 2023–2025
Sona Balogova (Slovakia)

Secretary/Treasurer 2023
Wolfgang Wadsak (Austria)

Scientific Liaison Officer 2023–2024
Michel Koole (Belgium)

SCIENTIFIC PROGRAMME COUNCIL

Congress Chair 2023–2025
Valentina Garibotto (Switzerland)

Bone & Joint
Salvatore Annunziata (Italy), Tim van den Wyngaert (Belgium)

Cardiovascular
Mark Lubberink (Sweden), Fabien Hyafil (France)

Dosimetry
Silvano Gnesin (Switzerland), Johannes Tran-Gia (Germany)

Inflammation & Infection
Domenico Albano (Italy), Olivier Gheysens (Belgium)

Neuroimaging
Antoine Verger (France), Silvia Morbelli (Italy)

Oncology & Theranostics
Matthias Eiber (Germany), Karolien Goffin (Belgium)

Paediatrics
Pinar Kiratli (Türkiye), Pietro Zucchetta (Italy)

Physics
Mathieu Hatt (France), Dimitris Visvikis (France)

Radiation Protection
Lidia Cunha (Portugal), Uta Eberlein (Germany)

Radiopharmaceutical Sciences
Filippo Lodi (Italy), Johnny Vercouillie (France)

Thyroid
Alfredo Campennì (Italy), Michael Kreissl (Germany)

Translational Molecular Imaging & Therapy
Margret Schottelius (Switzerland), Pedro Fragoso Costa (Germany)

Technologists
Agata Pietrzak (Poland), Luisa Pereira (United Kingdom)

SESSION COORDINATORS

SESSION COORDINATORS

EANM thanks all Session Coordinators for their huge engagement in organising the session details and speakers.

Albano, D. (Italy)
Ambrosini, V. (Italy)
Antunovic, L. (Italy)
Barthel, H. (Germany)
Beheshti, M. (Austria)
Campennì (Italy)
Caobelli, F. (Switzerland)
Carrilho Vaz, S (Portugal)
Cecchin, D. (Italy)
Chiti, A. (Italy)
Costa, G. (Portugal)
Cunha, L. (Portugal)
De Geus-Oei, L. (Netherlands)
Eberlein, U. (Germany)
Evangelista, L. (Italy)
Fragoso Costa, P. (Germany)
Fraioli, F. (United Kingdom)
Garibotto, V. (Switzerland)
Gear, J. (United Kingdom)
Gheysens, O. (Belgium)
Gotthardt, M. (Netherlands)
Graham, R. (United Kingdom)
Grana C. (Italy)
Guedj, E. (France)
Hatt, M. (France)
Herrmann, K. (Germany)
Holm, S. (Denmark)
Humbert, O. (France)
Hyafil, F. (France)
Kedves, A. (Hungary)
Kiratli, P. (Türkiye)
Koebe, C. (Germany)
Kreissl, M. (Germany)
Lubberink, M. (Sweden)
Massalha, S. (Israel)
Minguez Gabiana, P. (Spain)
Morbelli, S. (Italy)
Nanni, C. (Italy)
Noriega, E. Spain
Olianti, C. (Italy)
Pereira, L. (United Kingdom)
Petranovic, P. (Croatia)
Pietrzak, A. (Poland)
Rischpler, C. (Germany)
Salaün, P. (France)
Santos, A. (Portugal)
Schottelius, M. (Switzerland)
Shi, K. (Switzerland)
Stokke, Caroline (Norway)
Strand Olsen, R. (Denmark)
Turco, P. (Italy)
Van Leeuwen, F. (Netherlands)
Verburg, F. (Netherlands)
Verger, A. (France)
Violante, L. (Portugal)
Visvikis, D. (France)
Vrachimis, V. (Cyprus)
Werner, R. (Germany)
Zhang-Yin, J. (Belgium)

EANM'23 REVIEWERS

Abgral, R. (France)
Acampa, W. (Italy)
Adam, J. (Netherlands)
Agostini, D. (France)
Ahmadzadehfar, H. (Germany)
Akdemir, Umit Ö. (Türkiye)
Albano, D. (Italy)
Albert, Nathalie L. (Germany)
Aloj, L. (United Kingdom)
Altini, C. (Italy)
Ambrosini, V. (Italy)
Ametamey, S. (Switzerland)
Annunziata, S. (Italy)
Armstrong, I. (United Kingdom)
Artiko, V. (Serbia)
Balkay, L. (Hungary)
Ballinger, J. (Canada)
Bar-Sever, Z. (Israel)
Barthel, H. (Germany)
Bauckneht, M. (Italy)
Beer, A. (Germany)
Behe, M. (Switzerland)
Beheshti, M. (Germany)
Ben-Haim, S. (Israel)
Bergström, K. (Finland)
Bernhardt, P. (Sweden)
Bernsen, M. (Netherlands)
Berti, V. (Italy)
Biassoni, L. (United Kingdom)
Bilgin, Bedriye E. (Türkiye)
Bogović Crnčić, T. ()
Booij, J. (Netherlands)
Botelho, Maria Filomena R. (Portugal)
Bozkurt, Murat F. (Türkiye)
Brenner, W. (Germany)
Brian, D. (United Kingdom)
Brouwers, Adrienne H. (Netherlands)
Bucerius, J. (Netherlands)
Buchert, R. (Germany)
Burroni, L. (Italy)
Buvat, I. (France)
Cai, W. (United States Of America)
Camoni, L. (Italy)
Campennì, A. (Italy)
Caobelli, F. (Switzerland)
Carrilho Vaz, S. (Portugal)
Castellucci, P. (Italy)
Ceci, F. (Italy)
Chakravartty, R. (United Kingdom)
Chouin, N. (France)
Cicone, F. (Switzerland)
Cook, Gary J.r. (United Kingdom)
Cornelissen, B. (United Kingdom)
Costa, G. (Portugal)
Covens, P. (Belgium)
Cremonesi, M. (Italy)
Crivellaro, C. (Italy)
Cuocolo, A. (Italy)
Da Pieve, C. (United Kingdom)
Dalm, S. (Netherlands)
Daou, D. (France)
Darcourt, J. (France)
De Geus-Oei, Lioe-F. (Netherlands)
De Keizer, B. (Netherlands)
De Palma, D. (Italy)
De Swart, J. (Netherlands)
Delgado-Bolton, Roberto C. (Spain)
Deroose, C. (Belgium)
Deuther-Conrad, W. (Germany)
Dickson, J. (United Kingdom)
Dierickx, Lawrence O. (France)
Drzezga, A. (Germany)
Eberlein, U. (Germany)
Ertay, T. (Türkiye)
Evangelista, L. (Italy)
Everaert, H. (Belgium)
Ezziddin, S. (Germany)
Farsad, M. (Italy)
Fendler, W. (Germany)
Fernández Léon, A. (Spain)
Ferrari, C. (Italy)
Fischer, Barbara M. (Denmark)
Flux, G. (United Kingdom)
Forrer, F. (Switzerland)
Forsback, S. (Finland)
Fragoso Costa, P. (Germany)
Fraioli, F. (United Kingdom)
Gaberšček, S. (Slovenia)
Gabriel, M. (Austria)
Gallowitsch, Hans-J. (Austria)
Gear, J. (United Kingdom)
Georgoulias, P. (Greece)
Gheysens, O. (Belgium)
Giammarile, F. (France)
Gillings, N. (Denmark)
Gimelli, A. (Italy)
Giovanella, L. (Switzerland)
Girotto, N. (Croatia)
Glatting, G. (Germany)
Gnanasegaran, G. (United Kingdom)
Goffin, K. (Belgium)
Gourni, E. (Switzerland)
Graf, S. (Austria)
Graham, R. (United Kingdom)
Grana, Chiara M. (Italy)
Grötzinger, C. (Germany)
Guedj, E. (France)
Haberkorn, U. (Germany)
Halldin, C. (Sweden)
Handkiewicz-Junak, D. (Poland)
Hartman, N. (United Kingdom)
Hendrikse, H. (Netherlands)
Herrmann, K. (Germany)
Heskamp, S. (Netherlands)
Hess, S. (Denmark)
Hesse, S. (Germany)
Hicks, R. (Australia)
Hindorf, C. (Sweden)
Hoffmann, M. (Austria)
Hofman, M. (Australia)
Holm, S. (Denmark)
Howell, R. (United States Of America)
Hubalewska-Dydejczyk, A. (Poland)
Hyafil, F. (France)
Iagaru, A. (United States Of America)
Jamar, F. (Belgium)
Karabacak, Neşe I. (Türkiye)
Kedves, A. (Hungary)
Kirac, S. (Türkiye)
Kirienko, M. (Italy)
Kirjavainen, A. (Finland)
Kiss, O. (Germany)
Kluge, R. (Germany)
Kobe, C. (Germany)
Kolenc, P. (Slovenia)
Koranda, P. (Czech Republic)

EANM'23 REVIEWERS

Kostkiewicz, M. (Poland)
Kotzerke, J. (Germany)
Koutsikos, J. (Greece)
Kráčmerova, T. (Czech Republic)
Kraeber-Bodéré, F. (France)
Krämer, S. (Switzerland)
Kresnik, E. (Austria)
Kucuk, Nuriye O. (Türkiye)
Kunikowska, J. (Poland)
Kurth, J. (Germany)
Kuwert, T. (Germany)
Langbein, T. (Germany)
Langsteger, W. (Austria)
Lasnon, C. (France)
Lassmann, M. (Germany)
Lavelli, V. (Italy)
Laverman, P. (Netherlands)
Leccisotti, L. (Italy)
Lemos Pereira, E. (Portugal)
Lodi, F. (Italy)
Luporsi, M. (France)
Maes, A. (Belgium)
Maldonado, A. (Spain)
Manevska, N. (North Macedonia)
Mapelli, P. (Italy)
Marengo, M. (Italy)
Massalha, S. (Israel)
Mihailovic, J. (Serbia)
Mikolajczak, R. (Poland)
Milan, E. (Italy)
Mindt, Thomas L. (Austria)
Minguez Gabiña, P. (Spain)
Mitjavila Casanovas, M. (Spain)
Monteiro, M. (Switzerland)
Morigi, Joshua J. (Australia)
Morland, D. (France)
Mu, L. (Switzerland)
Någren, Kjell A. (Denmark)
Nanni, C. (Italy)
Niculae, D. (Romania)
Nonnekens, J. (Netherlands)
Noriega Alvarez, E. (Spain)
Notta, P. (Spain)
Ocak, Emine M. (Türkiye)
Oebro Fosbøl, M. (Denmark)
Olianti, C. (Italy)
Oprea-Lager, Daniela-E. (Netherlands)
Orlhac, F. (France)
Orlova, A. (Sweden)
Orrù, Maria T. (Italy)
Oyen, Wim J.g. (United Kingdom)
Ozgen Kiratli, P. (Türkiye)
Palmedo, H. (Germany)
Palmieri, A. (Italy)
Panagiotidis, E. (Greece)
Papathanasiou, N. (Greece)
Pappata, S. (Italy)
Pascual, T. (Austria)
Payoux, P. (France)
Peñuelas Sánchez, I. (Spain)
Pereira, L. (United Kingdom)
Petranović Ovčariček, P. (Hungary)
Piciu, D. (Romania)
Pietrzak, A. (Poland)
Pilkington, P. (Spain)
Plachcinska, A. (Poland)
Poeppel, T. (Germany)
Prassopoulos, V. (Greece)
Pruim, J. (Netherlands)
Rabiner, I. (United Kingdom)
Rac, S. (Croatia)
Rausch, I. (Austria)
Redondo, F. (Chile)
Resende Geão, A. (Portugal)
Rijpkema, M. (Netherlands)
Rischpler, C. (Germany)
Rodríguez-Fraile, M. (Spain)
Rogasch, J. (Germany)
Roivainen, A. (Finland)
Rominger, A. (Switzerland)
Rossetti, C. (Italy)
Santos, Ana I. (Portugal)
Saraste, A. (Finland)
Sattler, B. (Germany)
Schäfers, M. (Germany)
Schibli, R. (Switzerland)
Schottelius, M. (Switzerland)
Sciagrà, R. (Italy)
Seimbille, Y. (Netherlands)
Semah, F. (France)
Sera, T. (Hungary)
Sestini, S. (Italy)
Siclari, G. (Italy)
Signore, A. (Italy)
Slart, R. (Netherlands)
Smith, G. (United Kingdom)
Sollini, M. (Italy)
Stefanescu, C. (Romania)
Stokke, C. (Norway)
Stokkel, M. (Netherlands)
Strand Olsen, R. (Denmark)
Strigari, L. (Italy)
Strömvall, Anne L. (Sweden)
Sundin, A. (Sweden)
Teräs, M. (Finland)
Terwinghe, C. (Belgium)
Testanera, G. (United Kingdom)
Todde, S. (Italy)
Tolboom, N. (Netherlands)
Tosi, G. (Italy)
Tran-Gia, J. (Germany)
Treglia, G. (Switzerland)
Tuncel, M. (Türkiye)
Turco, P. (Italy)
Türkmen, C. (Türkiye)
Vaccaro, I. (Italy)
Van Den Wyngaert, T. (Belgium)
Van Dongen, G. (Netherlands)
Van Lith, S. (Netherlands)
Van Velden, Floris Hugo P. (Netherlands)
Vanhove, C. (Belgium)
Veit-Haibach, P. (Canada)
Verberne, Hein J. (Netherlands)
Verburg, F. (Netherlands)
Verger, A. (France)
Vidal Sicart, S. (Spain)
Vlajkovic, M. (Serbia)
Vriens, D. (Netherlands)
Walz, J. (France)
Windhorst, Albert D. (Netherlands)
Zanoni, L. (Italy)
Zerizer, I. (United Kingdom)
Zhang-Yin, J. (France)
Ziegler, Sibylle I. (Germany)

FINAL PROGRAMME | GENERAL INFORMATION

EANM'23 CHAIRPERSONS

(AS PER JULY 24, 2023)

EANM thanks all Session Coordinators for their huge engagement in organising the session details and speakers.

Caobelli, F. (Switzerland)
Lopci, E. (Italy)
Pietrzak, Agata K. (Poland)
Acampa, W. (Italy)
Adam, J. (Netherlands)
Albano, D. (Italy)
Albert, N. (Germany)
Ambrosini, V. (Italy)
Annunziata, S. (Italy)
Atay, Ö. (Türkiye)
Backhaus, P. (Germany)
Bailly, C. (France)
Bajuk Studen, K. (Slovenia)
Behe, M. (France)
Beheshti, M. (Austria)
Beyder, D. (United States of America)
Brosch-Lenz, J. (Germany)
Burger, I. (Switzerland)
Carrilho Vazc, S. (Portugal)
Castellucci, P. (Italy)
Ceci, F. (Italy)
Chakravartthy, R. (United Kingdom)
Chiti, A. (Italy)
Costa, G. (Portugal)
Cremonesi, M. (Italy)
Dalm, S. (Netherlands)
De Keizer, B. (Netherlands)
Deandreis, D. (Italy)
Delker, A. (Germany)
Deroose, C. (Belgium)
Dickson, J. (United Kingdom)
Dimitrakopoulou-Strauss, A. (Germany)
Eberlein, U. (Germany)
Eder, Ann-C. (Germany)
Eiber, M. (Germany)
Elvas, F. (Netherlands)
Fani, M. (Switzerland)
Fendler, W. (Germany)
Ferrari, C. (Italy)
Ferro, P. (Italy)
Fischer, Barbara M. (Denmark)
Fragoso Costa, P. (Germany)
Fraioli, F. (United Kingdom)
Georgoulias, P. (Greece)
Giovanella, L. (Switzerland)
Glatting, G. (Germany)
Glaudemans, A. (Netherlands)
Gnesin, S. (Switzerland)
Goffin, K. (Belgium)
Gourni, E. (Switzerland)
Graham, R. (United Kingdom)
Grana, C. (Italy)
Guedj, E. (France)
Hatt, M. (France)
Herrmann, K. (Germany)
Hess, S. (Denmark)
Holm, S. (Denmark)
Imbert, L. (France)
Kinggård Federspiel, M. (Denmark)
Kiratli, P. (Türkiye)
Kluge, R. (Germany)
Kobe, C. (Germany)
Kopka, K. (Germany)
Kreissl, M. (Germany)
Kreissl, Michael C. (Germany)
Kunikowska, J. (Poland)
Lairez, O. (France)
Lan, X. (CHINA)
Larsson Stromvall, A. (Sweden)
Lassmann, M. (Germany)
Lubberink, M. (Sweden)
Lückerath, K. (Germany)
Maccauro, M. (Italy)
Massalha, S. (Israel)
Mínguez Gabiña, P. (Spain)
Nanni, C. (Italy)
Noriega-Álvarez, E. (Spain)
Papp, L. (Austria)
Petranović Ovčariček, P. (Croatia)
Prieto Azcárate, E. (Spain)
Resende Geao, A. (Portugal)
Richetta, E. (Italy)
Rogasch, J. (Germany)
Roldao Pereira, L. (United Kingdom)
Sachpedis, C. (Germany)
Salas Ramirez, M. (Germany)
Salaün, Pierre-Y. (France)
Santos, A. (Portugal)
Santos, Ana I. (Portugal)
Saraste, A. (Finland)
Schottelius, M. (Switzerland)
Seimbille, Y. (Netherlands)
Shengelia, N. (Georgia)
Shi, K. (Switzerland)
Slart, R. (Netherlands)
Sollini, M. (Italy)
Sorensen, J. (Sweden)
Taieb, D. (France)
Testanera, G. (United Kingdom)
Tolboom, N. (Netherlands)
Traub Weidinger, T. (Austria)
Treglia, G. (Switzerland)
Turco, P. (Italy)
van der Laken, J. (Netherlands)
van der Meulen, N. (Switzerland)
Van Velden, F. (Netherlands)
van Weehaeghe, D. (Belgium)
Vanhove, C. (Belgium)
Verger, A. (France)
Vidal-Sicart, S. (Spain)
Violante, L. (Portugal)
Virgolini, I. (Austria)
Vrachimis, A. Cyprus
Vraka, C. (Austria)
Vriens, D. (Netherlands)
Watabe, T. (Japan)
Werner, R. (Germany)
Withofs, N. (Belgium)
Yakushev, I. (Germany)

EANM NATIONAL SOCIETIES: DELEGATES / DEPUTIES

SOCIETY	DELEGATE	DEPUTY
Armenian Society of Nuclear Medicine	V. Barsegian	M. Grigoryan
Austrian Society of Nuclear Medicine	M. Gabriel	T. Traub-Weidinger
Azerbaijan Society of Nuclear Medicine	F. Novruzov	A. Aliyev
Belgian Society of Nuclear Medicine	N. Withofs	V. Shelfhout
Bosnian Society of Nuclear Medicine	A. Basic	S. Zarac Bobic
British Nuclear Medicine Society	R. Graham	S. Dizdarevic
Bulgarian Society of Nuclear Medicine	V. Hadzhiyska	Z. Dancheva
Croatian Society of Nuclear Medicine	D. Snajder Mujkic	A. Baric Zizic
Cyprus Society of Nuclear Medicine	A. Vrachimis	D. Kyprianou
Czech Society of Nuclear Medicine	M. Simanek	P. Koranda
Danish Society of Clinical Physiology and Nuclear Medicine	P. Hovind	M. Reichkendler
Dutch Society of Nuclear Medicine	A. Glaudemans	R. Keijsers
Estonian Nuclear Medicine Society	I. Muoni	T. Karner
Finnish Society of Nuclear Medicine	H.Mussalo	K. Timonen
Macedonian Society of Nuclear Medicine	D. Miladinova	A. Ugrinska
French Society of Nuclear Medicine	P-Y. Salaun	F. Cachin
German Society of Nuclear Medicine	M. Luster	M. Schafers
George de Hevesy Hungarian Society of NM	T. Gyorke	G. Trencsenyi
Georgian Nuclear Medicine Specialists Association	N. Shengelia	K. Shamatava
Hellenic Society of Nuclear Medicine & Biology	S. Chatziioannou	V. Valotassiou

SOCIETY	DELEGATE	DEPUTY
Icelandic Society of Nuclear Medicine	to be nominated	to be nominated
Irish Nuclear Medicine Association	R. Killeen	K. O'Regan
Israeli Society of Nuclear Medicine	Z. Bar-Sever	Z. Keidar
Italian Society of Nuclear Medicine	R. Giubbini	M.Kirienko
Latvian Society of Nuclear Medicine	M. Kalnina	J. Kedrova
Lithuanian Society of Nuclear Medicine	S. Sediene	D. Vajauskas
Luxembourg Society of Nuclear Medicine	C. Als	J. Zhang-Yin
Maltese Association of Radiologists and Nuclear Medicine Physicians	M.A. Aquilina	A. Mallia
Norwegian Society of Nuclear Medicine	T.C. Adamsen	R. Sundset
Polish Society of Nuclear Medicine	A. Sowa-Staszczak	A. Pietrzak
Portuguese Society of Nuclear Medicine	A.P. Moreira	R. Silva
Romanian Society of Nuclear Medicine	D. Piciu	C.R. Stolniceanu
Serbian Nuclear Medicine Society	J. Mihailovic	V. Artiko
Slovak Society of Nuclear Medicine	L. Kaliska	E. Takacsova
Slovenian Society of Nuclear Medicine	I. Zagar	K. Zaletel
Spanish Society of Nuclear Medicine	M. J. Garcia-Velloso.	R. Ruano Perez
Swedish Society of Nuclear Medicine	E. Tragardh	A. Stromvall Larsson
Swiss Society of Nuclear Medicine	F. Forrer	M. Wissmeyer
Turkish Society of Nuclear Medicine	Z. Ozcan	L.O. Atay
Ukrainian Society of Nuclear Medicine	to be nominated	to be nominated

UEMS/EBNM NATIONAL SOCIETIES: DELEGATES / DEPUTIES

COUNTRY	DELEGATE	DEPUTY
AUSTRIA	Rainer Lipp	Michael Gabriel
BELGIUM	Karoline Spaepen	Gerard Moulin-Romsee
BULGARIA	Elena Piperkova	Antonia Dencheva Tzonevska
CROATIA	Drazen Huic	Sanja Kusačić Kuna
CYPRUS	Rena K. Demetriadou	
CZECH REPUBLIC	Otto Lang	Milan Kaminek
DENMARK	Peter Hovind	Michala Reichkendler
ESTONIA	Eve Kelk	Anne Poksi
FINLAND	Kirsi Timonen	Jukka Kemppainen
FRANCE	Eric Gremillet	Jean-Louis Pelletier
GERMANY	Winfried Brenner	Martin Gotthardt
GREECE	Sophia Koukouraki	Ioannis Iakovou
HUNGARY	Laszlo Pavics	Istvan Szilvasi
IRELAND	Stephen Skehan	Ronan McDermott
ITALY	Giuseppe Rubili	Desirè Deandreis
LATVIA	Ilga Vevere	Antra Berzina
LITHUANIA	Donatas Vajauskas	Nemira Jurkienė
LUXEMBOURG	Patrick Paulus	Christian Picard
MALTA	Mark Anthony Aquilina	Andrew Mallia

COUNTRY	DELEGATE	DEPUTY
THE NETHERLANDS	N.J. Wyndaele	Lenka Pereira Arias-Bouda
NORWAY	Tom Christian Holm Adamsen	Rune Sundset
POLAND	Miroslaw Dziuk	Bozena Birkenfeld
PORTUGAL	Lucilia Salgado	
ROMANIA	Gabriel Andries	Raluca Mititelu
SERBIA	Vera Artiko	Jasna Mihailovic
SLOVAKIA	Andrej Vondrak	Pavol Povinec
SLOVENIA	Simona Gaberscek	Damjana Hrastnik
SPAIN	Angel Sorriano	Francesca Pons
SWEDEN	Cecilia Wassberg	Elin Trägårdh
SWITZERLAND	Ariane Boubaker	John Prior
UNITED KINGDOM	Yong Du	Dr. Sabina Dizdarevic

Nominated from UEMS Associate Member Countries

TÜRKIYE	Gulay ALTUN	Zehra Ozcan

Nominated from UEMS Observer Countries

ISRAEL	Adam Steinmetz	Michael Reuben Quastel
JORDAN	Akam Al-Ibraheem	

UEMS/EBNM COMMITTEES

EXECUTIVE COMMITTEE

President	S. Mirzaei (Austria)
Secretary & Treasurer	R. Hustinx (Belgium)
Member	A. Boubaker (Switzerland)

FELLOWSHIP EXAMINATION

Chair	Z. Özcan (Türkiye)
Members	A. Boubaker (Switzerland)
	Z. Ozcan (Türkiye)
	J. R. Garcia Garzón (Spain)
	S.Vaz (Portugal)
	I. Kulakiene (Lithuania)

EDUCATION & SYLLABUS

Chair	R. Hustinx (Belgium)
Members	J. Darcourt (France)
	H. B. Sayman (Türkiye)
	D. Huic (Croatia)
	T.V. Bogsrud (Norway)
	P Castellucci (Italy)

CME ACCREDITATION

Chair	M. Farsad (Italy)
Members	E. Lopci (Italy)
	A. Haug (Austria)
	S. Sillanmäki (Finland)

ACCREDITATION OF NUCLEAR MEDICINE DEPARTMENTS & TRAINING CENTRES

Chair	J. Prior (Switzerland)
Committee Members	A. García-Burillo (Spain)
	N. Mutlukoca (Norway)
	P.A.L. Van Boxem (Belgium)
	M.L. Hall (United Kingdom)
Corresponding Members:	A. Jiménez Heffernan (Spain)
	I. Sippo-Tujunen (Finland)
	N.G. Hartman (United Kingdom)
	S.E. Bouyoucef (Algeria)
	A. Ciarmiello (Italy)
	R. Zakavi (Iran)
	I. Iakovou (Greece)
	L. Torres (Cuba)

GENERAL INFORMATION

Hint: Please note that only cashless payments are accepted at the congress venue.

AUDIO & VIDEO RECORDINGS

Audio and/or video recordings during the congress are strictly prohibited and must not be made without prior written permission of the EANM Executive Office.

CERTIFICATE OF ATTENDANCE

The EANM'23 Certificate of Attendance will be available in your myEANM area after the overall EANM Congress evaluation is submitted.

CLOSING SESSION & FAREWELL COCKTAIL

All registered delegates and accompanying persons are cordially invited to the Closing Ceremony & Farewell Cocktail Wednesday, September 13, 2023 – 11:25-12:15. The Closing Ceremony will be held at the Hall A of the ACV – Austria Center Vienna and the subsequent Farewell Cocktail in Foyers on Level 2.

Austria Center Vienna (ACV)
Bruno-Kreisky-Platz 1
1220 Vienna, Austria

CME CREDITS & CERTIFICATES

The EANM'23 Congress has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) for a maximum of 24 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

To acquire CME credits, attendees must scan their congress badge upon first arrival at the congress venue and upon entering each CME session. For CME sessions, an evaluation form for each session attended and the overall congress evaluation must be completed. CME Sessions will be streamed live and are also available on-demand after the congress until November 13, 2023 (23:59 CEST).

To obtain your CME certificate(s), please visit your myEANM area. In the section EANM'23 > Certificates, the certificate(s) will be available within 24 hours after you have scanned your congress badge.

CONGRESS APP

Enhance your Congress experience to the fullest with the EANM'23 Congress App. Access all the essential information right at your fingertips, ranging from the comprehensive Scientific Programme to the Exhibitors List, the Venue Maps, and much more.

Personalise your Congress schedule effortlessly and evaluate sessions conveniently on your smart device, ensuring a smooth process to receive your CME credits.

Download the EANM'23 Congress App now.

COVID-19 SAFETY PROTOCOL

The entrance rules will be handled according to the national requirements in Vienna in September 2023. Currently, Austria has no restrictions regarding congress attendance.

CONGRESS BAG

In line with our commitment to reducing unnecessary waste, we are introducing the 'Bring Your Old Bag' (BYOB) Initiative this year. Instead of providing new congress bags, we encourage attendees to bring their bags from previous EANM congresses. Don't miss out on the opportunity to win one of three registrations for EANM'24.

How to Engage: Visit our photo booth located in the Entrance Hall, next to the 'EANM Sustainability Wall'. Capture a photo of yourself with your treasured Congress bag. Pin your photo with the completed giveaway entry slip and drop it into the designated 'BYOB Box'.

The lucky winners will be drawn after the Congress and will be announced on September 27, 2023, on the EANM's social media channels (Facebook, Twitter, LinkedIn (EANM)).

CONGRESS e-POSTER AREA

As every year, the e-Poster Area gives you the possibility to see all uploaded e-Posters of EANM'23. You can search for authors, topics and keywords. The onsite e-Poster Area is located in the Foyer on Level 1. The e-Poster system can also be accessed online via the virtual congress platform. The online access will remain open until November 13, 2023 (23:59 CEST).

CONGRESS LANGUAGE

The congress language is English. No simultaneous translation will be provided.

CONGRESS OFFICE

The congress office is located on Level 0 at the ACV – Austria Center Vienna and will be open during the following days and times:

Saturday, September 9, 2023:	07:30–18:00
Sunday, September 10, 2023:	07:30–18:00
Monday, September 11, 2023:	07:30–18:00
Tuesday, September 12, 2023:	07:30–18:00
Wednesday, September 13, 2023:	07:30–12:00

CONGRESS SELF CHECK-IN

Our convenient Self-Check-In stations in the Entrance Hall will help you collect your name badge without waiting in queues. Please make sure to bring your QR code and a personal ID.

Saturday, September 9, 2023:	07:30–21:45
Sunday, September 10, 2023:	07:30–18:00
Monday, September 11, 2023:	07:30–18:00
Tuesday, September 12, 2023:	07:30–18:00
Wednesday, September 13, 2023:	07:30–12:00

CONGRESS VENUE

Austria Center Vienna (ACV)
Bruno-Kreisky-Platz 1
1220 Vienna, Austria
URL: **www.acv.at**

The ACV is within 2 minutes' walking distance from the metro station Kaisermühlen VIC, right behind the Vienna International Center and United Nations headquarters. The Metro U1 (red line) is the only one connecting the city centre with the ACV.

DATES & DEADLINES

August 29, 2023:	Advanced Registration Deadline (August 29, the on-site registration fee applies)
September 9, 2023:	Opening Ceremony & Welcome Reception
September 13, 2023:	Closing Ceremony & Farewell Cocktail
November 13, 2023:	Deadline for on-demand content and evaluation (23:59 CEST)

EANM EXECUTIVE OFFICE

Schmalzhofgasse 26
1060 Vienna, Austria
Phone: +43 1 890 44 27
Fax: +43 1 890 44 27-9
Email: office@eanm.org
Web: **www.eanm.org**

EANM LIVE ONLINE TV

Whether you are attending this year's EANM Congress in-person or online - you are invited to join Roy Sheppard and his expert guests for a NEW addition to the Congress experience - two daily fast-moving LIVE ONLINE TV shows each day.

Each morning at 08:30 and each afternoon at 17:15 you will be able to listen to leading experts from all areas of nuclear medicine who will be discussing upcoming sessions you really can't afford to miss - and at the end of each day they'll be commenting on the most fascinating sessions they attended that day.

EANM MEMBERS' ASSEMBLY

The Members' Assembly will be held on Sunday, September 10, 2023 - 08:00-11:00 in the Hall G1 on Level -2.

Please note: Only EANM members in good standing (having paid their membership dues for the year 2023) are eligible to attend the Members' Assembly.

ENVIRONMENTAL AWARENESS

We have implemented numerous sustainability initiatives at EANM'23 reflecting our commitment to reducing our environmental impact and to offering you a greener congress experience.

To give you a comprehensive insight into our sustainability efforts, we invite you to explore our Sustainability Wall, conveniently situated in the Entrance Hall. Here, you can easily view key highlights of our initiatives at a glance.

FOOD & BEVERAGE

At the Austria Center Vienna, we are pleased to offer a variety of food and beverage outlets for your convenience. **Please note that only cashless payments are accepted at the congress venue.**

Here is an overview of the different locations, their opening hours, and what they have to offer:

Leberkas-Pepi
Located at the Main Entrance (outside)
Sunday to Tuesday: 10:00–15:00

Cafe MOTTO
Located in the Entrance Hall, Level 0
Saturday: 13:00–18:00
Sunday to Tuesday: 09:00–16:00

Espressomobil
Located in the Entrance Hall, Level 0
Sunday to Tuesday: 09:00–15:00
Wednesday: 09:00–11:00

Gelatomobil
Located in the Entrance Hall , Level 0
Sunday to Tuesday: 10:00–16:00

Foyer A Outlet
Located in Foyer A, Level 2
Sunday to Tuesday: 11:00–14:30
Warm dishes and beverages

Hall X2 Outlet
Located in Hall X2, Level –2
Sunday to Tuesday: 09:00–16:00
Simple warm dishes, snacks, beverages, and coffee

Halle X3, X4 Outlets
Located in Hall X3 and X4, Level –2 & 0
Sunday to Tuesday: 09:00–16:00
Beverages and Snacks.

Please note that the availability of certain items may be subject to change, and we recommend checking with the respective outlets for any updates.

INSURANCE & LIABILITY

Neither the organisers nor the Conference Bureau will assume any responsibility whatsoever for damage or injury to persons or property during the congress. It is recommended that participants arrange for their personal travel and health insurance.

INTERNATIONAL MEETINGS AND ANNOUNCEMENTS BOARD

Visit the International Meetings and Announcement Board in Hall X2 (opposite the food and beverage outlet) to get information on upcoming events in Nuclear Medicine and more.

INTERNET CORNER

Internet access and limited printing possibilities will be provided at stations located in the Foyer on Level 1. Please limit the viewing time to max. 5 minutes per person.

LIVE STREAM

All ticket holders for the online access will automatically get access to the online content. Onsite congress ticket holders (except Day Ticket holders, Exhibitors and Accompanying Persons) will also be granted full online access.

The following sessions will be live-streamed and will also be available on-demand until November 13, 2023 (23:59 CEST): Opening Ceremony, incl. Highlights Lecture, all 14 CME Sessions (incl. CME credits collection), all 8 CTE Sessions, and the Closing Ceremony. All live streamed Satellite Symposia will also be included (approx. 6 symposia).

The credits for the CME sessions can be collected on-demand (for online and onsite participants).

LOST & FOUND

A lost and found service will be provided at the EANM registration desk for the duration of the congress.

MEDIA

By attending the event, each participant acknowledges and agrees to grant EANM the right at the congress to record, film, photograph or capture the likeness of such participant and its representatives in any media now available and in the future developed and to use, copy, modify, distribute, broadcast or otherwise disseminate at any time and on a global basis such media, without any further approval from or payment to such participant or any of its representatives.

MEDICAL FACILITIES

Medical assistance service will be available throughout the congress.

MOBILE PHONES

Out of respect for other participants, you are requested to refrain from making phone calls in a lecture room. Your mobile device should always be on silent mode when you are in the congress centre.

NAME BADGES

Badges for the congress will be issued on-site between September 9 and September 13, 2023. The badges must be collected in person.

A confirmation email, including a QR code, will be issued upon successful completion of registration. With this QR and a valid photo ID, the name badge can be printed onsite in the registration.

OPENING CEREMONY & WELCOME RECEPTION

All registered delegates and accompanying persons are cordially invited to the Opening Ceremony & Welcome Reception Saturday, September 9, 2023, from 18:00–21:45.

The Opening Ceremony, **including the Highlights Lecture,** will be held at the Hall A of the ACV – Austria Center Vienna, and the subsequent Welcome Reception will be in the Foyers on Level 2.

Austria Center Vienna (ACV)
Bruno-Kreisky-Platz 1
1220 Vienna, Austria

PARKING

Private cars can be parked at an additional cost in the ACV – Austria Centre Vienna parking areas. The costs for a day are € 15,00, € 25,00 for two days, € 35,00 for three days or € 45,00 for a week pass. Further information can be found on the website of the ACV: **www.acv.at**

PUBLIC TRANSPORT TICKET (PTT)

In Vienna, no complimentary or reduced public transport tickets can be offered. You can buy the tickets either on the "Wiener Linien" homepage online or at ticket machines, which can be found in each metro station in Vienna. Please find further information **here.**

Please note that this ticket is non-refundable, and neither ENITED nor EANM is responsible for the purchase of public transport tickets. All enquiries should be directed to the municipal public transport provider Wiener Linien.

If you have any questions, please contact the Online-Ticketshop-Team at or call the hotline +43-1-7909-100.

REGISTRATION DESK

The registration desk at the entrance Level 0 of the ACV – Austria Center Vienna will be open:

Saturday, September 9, 2023:	07:30–21:45
Sunday, September 10, 2023:	07:30–18:00
Monday, September 11, 2023:	07:30–18:00
Tuesday, September 12, 2023:	07:30–18:00
Wednesday, September 13, 2023:	07:30–12:00

REVIEW CENTRE

The Review Centre gives you the opportunity to check the PowerPoint presentations which have already been presented during the EANM'23 Congress. So, in case you have missed a session, you can view the slides here afterwards. The Review Centre is located in the Foyer on Level 1. The slides will not be accessible online.

SOCIAL MEDIA AND NEWSLETTER

For up-to-date information, follow us on our social media channels and subscribe to the congress newsletter!

Facebook	**@officialEANM**
X (formerly Twitter)	**@officialEANM**
LinkedIn	**@officialEANM**
YouTube	**@officialEANM**
Flickr	**@officialEANM**
Congress Newsletter	subscribe/unsubscribe **here**

Don't forget to use our hashtag #EANM23 when posting on social media.

VIENNA INFORMATION DESK

The Vienna Information Desk with a guide at the entrance level of the ACV (Congress Centre) will be open:

Sunday, September 10, 2023:	09:00–19:00
Monday, September 11, 2023:	09:00–19:00

VISA

All foreign visitors entering Austria must possess valid passports. A valid identity card is sufficient for citizens from the European Union Member countries.

PLEASE CHECK THE CURRENT VISA REQUIREMENTS WITH THE NEAREST AUSTRIAN CONSULATE/EMBASSY IN YOUR COUNTRY BEFORE YOUR DEPARTURE TO AUSTRIA.

All registered congress participants with a completed/paid registration can download a visa invitation letter within their **myEANM Area**!

WI-FI

Free WI-FI will be available at the EANM'23 Congress throughout the congress venue.

The login credentials are:
Network: EANM
Password: eanm2023

YOUNG PROFESSIONALS LOUNGE

We invite all students and junior attendees to the EANM'23 Young Professionals Lounge, a dedicated space to enjoy a refreshment, have a quiet corner to rest, work and network during the Congress (registration type permitting).

Make sure you attend the casual and interactive Lunch Talks featuring high-level nuclear medicine experts and highly motivated EANM volunteers. The speakers will share their experiences within the association and their professional journeys. Find the schedule and more details **here**.

EANM Young Professionals Lounge
Open daily – Hall L1 – Level 1

Join the new EANM'23 Young Professionals Lounge, a dedicated space for students and junior attendees to enjoy refreshments, a quiet corner to rest, work and network during the Annual Congress (registration type permitting).

Be sure to attend the informal and interactive Lunch Talks, featuring high-level nuclear medicine experts and highly motivated EANM volunteers sharing their experiences within the Association and their professional journeys.

Sunday, September 10, 2023
13:15–14:00 CEST:

Family, Nuclear Medicine career & Volunteer job
Laura Evangelista, Italy

Monday, September 11, 2023
13:15–14:00 CEST:

Harnessing the power of EANM: My journey – your opportunity
Tim Van den Wyngaert, Belgium

Tuesday, September 12, 2023
13:15–14:00 CEST:

What to do when you are young … engage with the EANM?
Michel Koole, Belgium

YPL
YOUNG PROFESSIONALS LOUNGE

LEVEL –2

EANM Arena	
Hall D	Special Track (Debates, Challenge the Experts, Round Table)
Lecture Halls	
Hall G1	Theranostics Track, Special Symposia, Case Report Sessions
Hall G2	e-Poster Sessions
Hall K	Technologists' Track
Meeting Rooms	-2.16, -2.31, -2.36, -2.47-48, -2.61-62, -2.63, -2.85–86
Industry Hospitality Suite	-2.13, -2.14, -2.18-19, -2.33, -2.34, -2.35, -2.45, -2.46, -2.64, -2.65, -2.66, -2.84, -2.91
Exhibition Halls	X2, X3, X4, Catering Area



LEVEL 0

Entrance Hall	Registration, Self Check-In, Cloakroom, EANM Area, Meeting Point
Lecture Halls	
Hall E1	Learn & Improve Professionals Skills (LIPS) Track
Hall E2	M2M Track
Hall F1	TROP / Featured Sessions
Hall F2	TROP / Featured Sessions Joint Symposia Special Symposia
Speaker Preview Room	0.94–95
Meeting Rooms	0.11–12, 0.14, 0.96–97
Suite F	EANM Congress Office
Offices	0.31 - 0.51

LEVEL 1

Gallery	Societies Village ESMIT Area
Foyer L1	E-Poster Area Internet Corner Review Centre
Hall L1	Young Professionals Lounge
EANM Committee Meetings	1.61–1.86



LEVEL 2

Lecture Halls	
Hall A	Opening Ceremony CME Sessions Plenary Sessions Closing Session
Hall B	Cutting Edge Science Track
Hall C	Clinical Oncology Track
Foyer ABC	Welcome Reception Area
Foyer A	Delegates Catering Area, Farewell Drink



PROGRAMME OVERVIEW
SATURDAY, SEPTEMBER 9, 2023

Location/ Time	Hall A				Location/ Time
08:00–08:30					08:00–08:30
08:30–09:00					08:30–09:00
09:00–09:30					09:00–09:30
09:30–10:00					09:30–10:00
10:00–10:30					10:00–10:30
10:30–11:00					10:30–11:00
11:00–11:30		**Advisory Council Meeting** (11:00–13:00) Room 1.86			11:00–11:30
11:30–12:00					11:30–12:00
12:00–12:30					12:00–12:30
12:30–13:00					12:30–13:00
13:00–13:30					13:00–13:30
13:30–14:00					13:30–14:00
14:00–14:30			**Delegates' Assembly** (14:00–16:00) Hall F2	**Committee Meetings** (14:00–17:45)	14:00–14:30
14:30–15:00					14:30–15:00
15:00–15:30					15:00–15:30
15:30–16:00					15:30–16:00
16:00–16:30					16:00–16:30
16:30–17:00					16:30–17:00
17:00–17:30					17:00–17:30
17:30–18:00					17:30–18:00
18:00–18:30	**Opening Ceremony including Awards Ceremony** (18:00–18:35) *101* **Plenary 1 Highlights Lecture** (18:35–19:35) **Welcome Reception** (19:45–21:45)				18:00–18:30
18:30–19:00					19:30–20:30
20:30–21:00					20:30–21:00
21:00–21:30					21:00–21:30
21:30–22:00					21:30–22:00

WORLD LEADING MEETING — EANM'23
SEPTEMBER 9–13, 2023

PROGRAMME OVERVIEW
SUNDAY, SEPTEMBER 10, 2023

Location/ Time	Hall A	Hall D – Arena	Hall E1	Hall E2	Hall B	Hall C	Hall F1	Hall F2	Hall G2	Hall K	Hall G1	Location/ Time
	LIVE STREAM									LIVE STREAM		
08:00–08:30	201 **CME 1** Inflammation & Infection Committee **Infection and Inflammation – New Guidelines**	202 **Special Track** Cardiovascular Committee **Debate: Myocardial Perfusion Imaging after ISCHEMIA Trial**	203 **LIPS** ***Interactive Session*** Oncology & Theranostics Committee **Novelties in Radionuclide Therapy**	204 **M2M Track TROP Session** Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee **At the Nucleus: Radionuclide Production**	205 **Cutting Edge Science Track TROP Session** Physics Committee **Quality Control, Performance, Standardisation**	206 **Clinical Oncology Track TROP Session** Oncology & Theranostics Committee **Prostate Cancer Staging**	207 **Featured Session** Neuroimaging Committee **Methods in NeuroImaging: Spotlight on Brain Connectivity**	208 **TROP Session** Paediatrics Committee **Paediatric PET/CT & PET/MR**	209 **e-Poster Presentations Session 1** Oncology & Theranostics Committee **Neuroendocrine Tumours and Gynaecological Malignancies**	210 **Technologists' Track Opening CTE 1** Technologists Committee / SNMMI **Technologists' Guide Launch – Gastro Intestinal Molecular Imaging Studies**	**Members' Assembly** (08:00–11:00)	08:00–08:30
08:30–09:00												08:30–09:00
09:00–09:30												09:00–09:30
09:30–10:00	301 **CME 2** Translational Molecular Imaging & Therapy + Oncology & Theranostics + Radiopharmaceutical Sciences Committee **FAP – Moving Towards Therapy**	302 **Special Track** Thyroid Committee **Challenge the Expert: Integrated Diagnostics of Thyroid Disease**	303 **LIPS** ***Interactive Session*** Radiation Protection + Physics Committee / EFOMP **Careers in Radiation Protection**	304 **M2M Track TROP Session** Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee **Validating Methodology: In Vitro and in Vivo Models**	305 **Cutting Edge Science Track Featured Session** Physics Committee **Radiomics**	306 **Clinical Oncology Track Featured Session** Oncology & Theranostics Committee **Haematological Disease**	307 **TROP Session** Neuroimaging Committee **Amyloid, Tau and More in Neurodegenerative Disorders**	308 **Joint Symposium 1** Cardiovascular + Inflammation & Infection Committee / EACVI **PET in Valvular Diseases – All In!**	309 **e-Poster Presentations Session 2** Paediatrics Committee **Paediatric Nuclear Medicine & Adults General Nuclear Medicine**	310 **Technologists' Track CTE 2** Technologists Committee **Head and Neck Molecular Imaging – Updates and Perspectives**		09:30–10:00
10:00–10:30												10:00–10:30
10:30–11:00												10:30–11:00
11:00–11:30												11:00–11:30
11:30–12:00	401 **Plenary 2** **New Imaging Techniques – Jump Aboard or Watch and Wait**											11:30–12:00
12:00–12:30												12:00–12:30
12:30–13:00												12:30–13:00
13:00–13:30	**Lunch Break**			**Satellite Symposium Monrol Nuclear Products**			**Satellite Symposium TELIX**	**Satellite Symposium Springer Healthcare IME (supported by an educational grant from Lilly)**		**Satellite Symposium Pfizer**	**EANM Lunch Break Session** **Presentation Skills for Medical Professionals**	13:00–13:30
13:30–14:00												13:30–14:00
14:00–14:30												14:00–14:30
14:30–15:00												14:30–15:00
15:00–15:30	501 **CME 3** Cardiovascular Committee **Nuclear Imaging in Cardiac Amyloidosis – What Else?**	502 **Special Track** Oncology & Theranostics Committee **Challenge the Expert: Risk in Diagnostic and Therapeutic Nuclear Medicine**	503 **LIPS** ***Interactive Session*** Thyroid Committee **Rational Use of PET/CT with 18F-FDG in DTC**	504 **M2M Track TROP Session** Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee **Radioligand Therapy - New and Old Targets**	505 **Cutting Edge Science Track TROP Session** Dosimetry Committee **From Cells to Human via the Fish**	506 **Clinical Oncology Track TROP Session** Oncology & Theranostics Committee **Gastrointestinal Malignancies**	507 **TROP Session** Paediatrics Committee **Adults General Nuclear Medicine**	508 **Joint Symposium 2** Oncology & Theranostics Committtee / EORTC **Nuclear Medicine Imaging of the Immune System**	509 **e-Poster Presentations Session 3** Inflammation & Infection Committee **More on Infection and Inflammation Imaging**	510 **Technologists' Track Oral Presentations 1** Technologists Committee **SPECT-CT in Diagnosis and Therapy**	511 **Theranostics Track Featured Session** Oncology & Theranostics Committee / EARL **Old but Novel Techniques**	15:00–15:30
15:30–16:00												15:30–16:00
16:00–16:30												16:00–16:30
16:30–17:00	601 **CME 4** Oncology & Theranostics Committee **Update in Multiple Myeloma**	602 **Special Track** Dosimetry Committee **Challenge the Expert: Dosimetry Live**	603 **LIPS** ***Interactive Session*** Oncology & Theranostics Committee **Residents for Residents**	604 **M2M Track TROP Session** Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee **Novel Imaging Targets in Oncology**	605 **Cutting Edge Science Track TROP Session** Physics Committee **Segmentation and Denoising**	606 **Clinical Oncology Track TROP Session** Oncology & Theranostics Committee **Neuroendocrine tumours Treatment**	607 **TROP Session** Cardiovascular Committee **Functional Imaging, Plaque and Total-Body PET**	608 **TROP Session** Inflammation & Infection Committee **Infection and Inflammation Imaging: New Frontiers**	609 **e-Poster Presentations Session 4** Thyroid Committee **Thyroid and Parathyroid Disease**	610 **Technologists' Track CTE 3** Technologists Committee **Patient Care in Nuclear Medicine**	611 **Special Symposium 1** EANM / EARL **Harmonisation and Accreditation Accelerate Research and Clinical Translation**	16:30–17:00
17:00–17:30												17:00–17:30
17:30–18:00												17:30–18:00
18:00–18:30												18:00–18:30

PROGRAMME OVERVIEW | FINAL PROGRAMME

WORLD LEADING MEETING — EANM'23
SEPTEMBER 9–13, 2023

PROGRAMME OVERVIEW
MONDAY, SEPTEMBER 11, 2023

Location/ Time	Hall A	Hall D – Arena	Hall E1	Hall E2	Hall B	Hall C	Hall F1	Hall F2	Hall G2	Hall K	Hall G1	Location/ Time
	LIVE STREAM									LIVE STREAM		
08:00–08:30	*701* **CME 5** Oncology & Theranostics Committee **Will the Microenvironment Become Even More Important in Nuclear Medicine?**	*702* **Special Track** Neuroimaging Committee **Debate: What is the Best Tracer for Molecular Brain Tumour Imaging?**	*703* **LIPS** ***Interactive Session*** Cardiovascular Committee **Challenges in MBF Quantification with PET and SPECT**	*704* **M2M Track TROP Session** Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee **Imaging Inflammatory Processes in Cardiovascular Diseases**	*705* **Cutting Edge Science Track Featured Session** Physics Committee **Imaging Guided Surgery**	*706* **Clinical Oncology Track TROP Session** Oncology & Theranostics Committee **Neuroendocrine Tumours – Diagnosis**	*707* **TROP Session** Paediatrics Committee **Neuroblastoma & Non-PET Paediatric Studies**	*708* **Special Symposium 2** Inflammation & Infection Committee **Usefulness of PET in the Evaluation of Inflammatory Rheumatisms**	*709* **e-Poster Presentations Session 5** Physics Committee **SPECT/CT, PET/CT, PET/MR Quantitating Imaging**	*710* **Technologists' Track Oral Presentations 2** Technologists Committee **All about PET-CT!**	*711* **Theranostics Track TROP Session** Oncology & Theranostics Committee **What's New in Prostate Cancer?**	08:00–08:30
08:30–09:00												08:30–09:00
09:00–09:30												09:00–09:30
09:30–10:00	*801* **CME 6** Dosimetry Committee **Understanding Radiobiology for Dosimetry-Guided Molecular Radiotherapy**	*802* **Special Track** Translational Molecular Imaging & Therapy + Oncology & Theranostics + Radiopharmaceutical Sciences Committee **Round Table: Dialogue with the Treating Physician**	*803* **LIPS** ***Interactive Session*** Neuroimaging + Cardiovascular + Inflammation & Infection Committee **Molecular Imaging to Solve the Problem of Long COVID**	*804* **M2M Track TROP Session** Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee **TME and Therapy: Direct Targeting and Secondary Effects**	*805* **Cutting Edge Science Track TROP Session** Physics Committee **Image Reconstruction and Data Corrections**	*806* **Clinical Oncology Track Featured Session** Oncology & Theranostics Committee **FAP Imaging**	*807* **TROP Session** Cardiovascular Committee **Clinical Perfusion Imaging with PET**	*808* **Featured Session** Thyroid Committee **Iodine-131 Therapy and Beyond in differentiated Thyroid Cancer**	*809* **e-Poster Presentations Session 6** Oncology & Theranostics Committee **Prostate Cancer**	*810* **Technologists' Track CTE 4** Technologists Committee **Prostate Cancer Theranostics**	*811* **Special Symposium 3** EANM / EJNMMI **You, the EANM and the EJNMMI**	09:30–10:00
10:00–10:30												10:00–10:30
10:30–11:00												10:30–11:00
11:00–11:30												11:00–11:30
11:30–12:00	*901* **Plenary 3** **Radiotheranostics: What´s New?**											11:30–12:00
12:00–12:30												12:00–12:30
12:30–13:00												12:30–13:00
13:00–13:30	**Lunch Break**			**Satellite Symposium Spectrum Dynamics**		**Satellite Symposium GE HealthCare**	**Satellite Symposium Siemens Healthineers**	**Satellite Symposium Curium**		**Satellite Symposium Eckert & Ziegler**	**EANM Lunch Break Session** **How to be Upbeat in a Downbeat World**	13:00–13:30
13:30–14:00												13:30–14:00
14:00–14:30												14:00–14:30
14:30–15:00												14:30–15:00
15:00–15:30	*1001* **CME 7** Thyroid + Dosimetry Committee **New NM Guidelines of Benign Thyroid Disease**	*1002* **Special Track** **EANM Sanjiv Sam Gambhir Award – Compete and Win!**	*1003* **LIPS** ***Interactive Session*** Inflammation & Infection Committee **Tips and Tricks in the Study of Prosthesis Infection**	*1004* **M2M Track TROP Session** Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee **New Roads Towards FAP-Directed Theranostics**	*1005* **Cutting Edge Science Track TROP Session** Dosimetry Committee **Clinical Dosimetry I ^{177}Lu / ^{225}Ac and ^{161}Tb RLT**	*1006* **Clinical Oncology Track Featured Session** Oncology & Theranostics Committee **Melanoma**	*1007* **TROP Session** Neuroimaging Committee **Imaging Neurotransmission in Movement Disorders**	*1008* **Joint Symposium 3** Translational Molecular Imaging & Therapy + Oncology & Theranostics + Physics Committee / EAU **Metastases Directed Prostate Cancer Surgery - Translational Challenges and Possibilities**	*1009* **e-Poster Presentations Session 7** Cardiovascular Committee **Cardiovascular Imaging e-Posters**	*1010* **Technologists' Track Technologists' e-Poster Presentations Session** Technologists Committee **Techs' e-Posters**	*1011* **TROP Session** Case Report Session 1 **Learning from Single Cases in Theranostics**	15:00–15:30
15:30–16:00												15:30–16:00
16:00–16:30												16:00–16:30
16:30–17:00	*1101* **CME 8** Oncology & Theranostics Committee **Assessing Response to Peptide Receptor Radionuclide Therapy in Patients with Neuroendocrine Tumours**		*1103* **LIPS** ***Interactive Session*** Cardiovascular Committee **Stiff to Sweet - Infiltration and Inflammation**	*1104* **M2M Track TROP Session** Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee **Efficient Radiolabelling: Key for Clinical Translation**	*1105* **Cutting Edge Science Track TROP Session** Radiation Protection Committee **Current Issues of Radiation Protection**	*1106* **Clinical Oncology Track TROP Session** Oncology & Theranostics Committee **Prostate Cancer Biochemical Recurrence**	*1107* **TROP Session** Inflammation & Infection Committee **Vasculitis and Endocarditis: Current and New Evidence**	*1108* **TROP Session** T hyroid Committee **Iodine-131 Therapy in Differentiated Thyroid Cancer: Present and Future Perspective**	*1109* **e-Poster Presentations Session 8** Neuroimaging Committee **E-Poster Neurology: It's in the Brain!**	*1110* **Technologists' Track CTE 5** Technologists Committee **Cardiac Inflammatory Disease**	*1111* **TROP Session** Case Report Session 2 **Successful Molecular Targeting in Oncology**	16:30–17:00
17:00–17:30		*1102* **Special Track** Physics Committee **Debate: AI in Nuclear Medicine: Fear or Embrace?**										17:00–17:30
17:30–18:00												17:30–18:00
18:00–18:30												18:00–18:30

PROGRAMME OVERVIEW | FINAL PROGRAMME

WORLD LEADING MEETING — EANM'23
SEPTEMBER 9–13, 2023

PROGRAMME OVERVIEW
TUESDAY, SEPTEMBER 12, 2023

Location/ Time	Hall A	Hall D – Arena	Hall E1	Hall E2	Hall B	Hall C	Hall F1	Hall F2	Hall G2	Hall K	Hall G1	Location/ Time
	LIVE STREAM									LIVE STREAM		
08:00–08:30	*1201* **CME 9** Bone & Joint + Physics Committee **Current Bone SPECT/CT (including 360 CZT)**	*1202* **Special Track** Radiation Protection Committee **Round Table: Establishing and Running a Theranostics Centre in a Clinical Setting**	*1203* **LIPS** ***Interactive Session*** Paediatrics Committee **Paediatric Nephro-Urology – Beyond Hydro-Nephrosis**	*1204* **M2M Track TROP Session** Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee **Imaging the Brain from all Angles**	*1205* **Cutting Edge Science Track TROP Session** Physics Committee **Total Body PET Methods**	*1206* **Clinical Oncology Track TROP Session** Oncology & Theranostics Committee **Gynaecological Malignancies**	*1207* **Featured Session** Neuroimaging Committee **Breadth of Tracers and Approaches in Neuro-Oncology**	*1208* **Joint Symposium 4** Dosimetry Committee / ESTRO **Dosimetry in Different Modalities - Where We Are and Where We Want To Be**	*1209* **e-Poster Presentations Session 9** Physics Committee **Artificial Intelligence and Radiomics**	*1210* **Technologists' Track CTE 6** Technologists Committee **Extravasation Incidents Management**	*1211* **Special Symposium 4** **Lung Scintigraphy for Pulmonary Embolism Diagnosis and long term Management**	08:00–08:30
08:30–09:00												08:30–09:00
09:00–09:30												09:00–09:30
09:30–10:00												09:30–10:00
10:00–10:30	*1301* **CME 10** Radiation Protection + Paediatrics Committee + Women´s Empowerment Task Force **Radiation Protection in Motherhood and Childhood – What is so Special?**	*1302* **Special Track** Physics + Oncology & Theranostics Committee **Debate: Whole Body Parametric Imaging**	*1303* **LIPS** ***Interactive Session*** Neuroimaging Committee **The Sunrise of Alpha-Synuclein in Vivo Brain Imaging**	*1304* **M2M Track TROP Session** Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee **Emerging Theranostic Concepts**	*1305* **Cutting Edge Science Track TROP Session** Physics Committee **Quantitative SPECT/CT Imaging**	*1306* **Clinical Oncology Track TROP Session** Oncology & Theranostics Committee **Lung**	*1307* **TROP Session** Cardiovascular Committee **Plaque, Fibrosis and Cardio-Oncology**	*1308* **TROP Session** Thyroid Committee **^{18}F-FDG and Novel Tracers in the Diagnostic Management of Patients with Thyroid Cancers**	*1309* **e-Poster Presentations Session 10** Oncology & Theranostics Committee **Haematological and Abdominal Malignancies / Localised Treatments**	*1310* **Technologists' Track Oral Presentations 3** Technologists Committee **NM Technologists: Competencies and Training**	*1311* **Theranostic´s Track** Oncology & Theranostics Committee **What's New in Neuroendocrine Tumours?**	10:00–10:30
10:30–11:00												10:30–11:00
11:00–11:30												11:00–11:30
11:30–12:00	*1401* **Plenary 4** **Diagnostic Imaging: Proven Beyond Doubt? incl. Marie Curie Lecture**											11:30–12:00
12:00–12:30												12:00–12:30
12:30–13:00												12:30–13:00
13:00–13:30	**Lunch Break**			**Satellite Symposium United Imaging**				**Satellite Symposium ABX GmbH**		**Satellite Symposium Novartis**		13:00–13:30
13:30–14:00												13:30–14:00
14:00–14:30												14:00–14:30
14:30–15:00												14:30–15:00
15:00–15:30	*1501* **CME 11** Paediatrics Committee **Paediatric Lymphoma and Update on FDG**	*1502* **Special Track** Neuroimaging Committee **Challenge the Expert: Amyloid vs Tau PET - Which is First in Suspected Alzheimer Patients? Germany versus Italy**	*1503* **LIPS** ***Interactive Session*** Bone & Joint Committee **Pitfalls and Common Bony Findings in PET-CT/MRI Using Novel Tracers**	*1504* **M2M Track TROP Session** Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee **Imaging the Components of the TME**	*1505* **Cutting Edge Science Track TROP Session** Physics Committee **AI Methods and Applications**	*1506* **Clinical Oncology Track TROP Session** Oncology & Theranostics Committee **Prostate Cancer Treatment**	*1507* **TROP Session** Cardiovascular Committee **Perfusion**	*1508* **Joint Symposium 5** Oncology & Theranostics Committee / ESMO **Prostate Cancer Theranostics: Where Do We Go?**	*1509* **e-Poster Presentations Session 11** Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee **Novel Therapeutic Approaches**	*1510* **Technologists' Track CTE 7** Technologists & Thyroid Committee **Molecular Thyroid Imaging - Qualitative and Quantitative Approaches**	*1511* **EU Policy Symposium 1** Policy & Regulatory Affairs Committee **Supply & Shortages of Radiopharmaceuticals**	15:00–15:30
15:30–16:00												15:30–16:00
16:00–16:30												16:00–16:30
16:30–17:00	*1601* **CME 12** Physics + Oncology & Theranostics + Translational Molecular Imaging & Therapy + Technologists Committee **Long Axial Field-of-View PET Scanners – A Copernical Revolution**	*1602* **Special Track** Bone & Joint + Cardiovascular Committee **Debate: NaF PET in Cardiology and MSK: Pro or Cons?**	*1603* **LIPS** ***Interactive Session*** Neuroimaging + Inflammation & Infection Committee **The Role of FDG PET in the Diagnosis of Auto-Immune Encephalitis**	*1604* **M2M Track TROP Session** Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee **Understanding and Improving RLT**	*1605* **Cutting Edge Science Track TROP Session** Physics Committee **Data Analysis**	*1606* **Clinical Oncology Track TROP Session** Oncology & Theranostics Committee **Head and Neck Imaging**	*1607* **TROP Session** Neuroimaging Committee **New PET Tracers for Brain Imaging**	*1608* **TROP Session** Thyroid Committee **Nuclear Medicine Imaging in Thyroid and Parathyroid Disorders**	*1609* **e-Poster Presentations Session 12** Dosimetry Committee **Dosimetry Simphony**	*1610* **Technologists' Track CTE 8** Technologists Committee **Gynaecological Studies**	*1611* **EU Policy Symposium 2** Policy & Regulatory Affairs Committee **Regulatory Challenges of Radiopharmaceuticals**	16:30–17:00
17:00–17:30												17:00–17:30
17:30–18:00												17:30–18:00
18:00–18:30												18:00–18:30

PROGRAMME OVERVIEW | FINAL PROGRAMME

WORLD LEADING MEETING — EANM'23
SEPTEMBER 9–13, 2023

PROGRAMME OVERVIEW
WEDNESDAY, SEPTEMBER 13, 2023

Location/ Time	Hall A	Hall D – Arena	Hall E1	Hall E2	Hall B	Hall C	Hall F1	Hall F2	Hall G2	Hall K	Hall G1	Location/ Time
	LIVE STREAM									LIVE STREAM		
08:00–08:30	*1701* **CME 13** Translational Molecular Imaging & Therapy + Oncology & Theranostics + Radiopharmaceutical Sciences Committee **Diagnostic Imaging and Theranostics in Breast Cancer – Old Targets, New Tracers**	*1702* **Special Track** Oncology & Theranostics Committee / EHA **Debate: Staging Lymphoma – Ann Arbour Outdated and Replaced by Metabolic Tumour Volume?**	*1703* **LIPS** ***Interactive Session*** Dosimetry Committee **Case Reading – Dosimetry in SIRT**	*1704* **TROP Session** Dosimetry Committee **Clinical Dosimetry II - Tutti Frutti**	*1705* **Cutting Edge Science Track** **Featured Session** Physics Committee **Dynamic Imaging**	*1706* **Clinical Oncology Track** **TROP Session** Oncology & Theranostics Committee **Localised Treatments**	*1707* **TROP Session** Cardiovascular Committee **Heart Failure, Sarcoidosis and Amyloidosis**	*1708* **Joint Symposium 6** Neuroimaging Committee / EAN **Progress in Multimodal Imaging of Parkinson's Disease**	*1709* **e-Poster Presentations Session 13** Oncology & Theranostics Committee **Head and Neck Tumours, Lung, Melanoma and Others**	*1710* **Technologists' Track Mini Courses** Technologists Committee *1710a* **Mini Course 1** (08:00–09:00) **Radiotherapy Planning Using PET/CT and PET/MR** *1710b* **Mini Course 2** (09:05–10:05) **AI in the Technologists Practice** *1710c* **Mini Course 3** (10:15–11:15) **Phantoms Management**	*1711* **TROP Session** Case Report Session 3 **Every Day a Discovery with FAP and Novel Targets**	08:00–08:30
08:30–09:00												08:30–09:00
09:00–09:30												09:00–09:30
09:30–10:00	*1801* **CME 14** Neuroimaging Committee **Modern Imaging of Paediatric Epilepsy**	*1802* **Special Track** Women´s Empowerment Task Force **Round Table: Women in Science – Special Focus on Nuclear Medicine**	*1803* **LIPS** ***Interactive Session*** Translational Molecular Imaging & Therapy + Physics + Radiation Protection + Oncology & Theranostics + Ethics Committee **Beta Emitters for Radioguided Surgery – Challenges and Opportunities**	*1804* **M2M Track** **TROP Session** Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee **New Therapeutic Radiopharmaceutical**	*1805* **Cutting Edge Science Track** **TROP Session** Dosimetry Committee **Clinical Dosimetry III Time & Co**	*1806* **Clinical Oncology Track** **TROP Session** Oncology & Theranostics Committee **Radiomics**	*1807* **TROP Session** Inflammation & Infection Committee **COVID-19: Isn't it over yet?**	*1808* **Featured Session** Bone & Joint Committee **Unconventional Bone & Joint: FAPI and Beyond**	*1809* **e-Poster Presentations Session 14** Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee **New Imaging Agents**		*1811* **TROP Session** Case Report Session 4 **FDG and Conventional Imaging: Still Surprising!**	09:30–10:00
10:00–10:30												10:00–10:30
10:30–11:00												10:30–11:00
11:00–11:30												11:00–11:30
11:30–12:00	*1901* **Closing Session**											11:30–12:00
12:00–12:30	**Farewell Drink**											12:00–12:30

- Plenary Sessions
- CME Sessions
- Special Track
- Learn & Improve Professional Skills (LIPS) Track
- Joint Symposia
- M2M Track
- Cutting Edge Science Track
- Clinical Oncology Track
- Special Symposium
- Featured/TROP Session
- e-Poster Presentations
- Technologists' Track Session

PROGRAMME OVERVIEW | FINAL PROGRAMME

SCIENTIFIC PROGRAMME

INVITED SPEAKER SESSIONS

PLENARY SESSIONS

1

Saturday, September 9, 2023 | 18:35–19:35 | Hall A

Highlights Lecture

Presenters: Silvia Morbelli (Italy), Sophie Veldhuijzen van Zanten (Netherlands), Hein Verberne (Netherlands), David Kersting (Germany)

2

Sunday, September 10, 2023 | 11:30–13:00 | Hall A

New Imaging Techniques – Jump Aboard or Watch and Wait

Chairpersons: Laetitia Imbert (Nancy, France), Dimitris Visvikis (Brest, France)

- Francesca M. Buffa (Milan, Italy): **AI Technology: Living up to Expectations?**
- Laetitia Imbert (Nancy, France): **SPECT/CT CZT based Systems: Jump Aboard**
- John Dickson (London, UK): **SPECT/CT CZT based Systems: Watch and Wait?**
- Antonia Dimitrakopoulou-Strauss (Heidelberg, Germany): **Total Body PET: Opportunities and Challenges**
- Axel Rominger (Bern, Switzerland): **Total Body PET: Jump Aboard**
- Simon Wan (London, UK): **PET/MR: Is it still worth it?**
- May Abdel-Wahab (Vienna, AU): **Innovation and Sustainability in Nuclear Medicine: the IAEA Perspective**

3

Monday, September 11, 2023 | 11:30–13:00 | Hall A

Radiotheranostics: What´s New?

Chairpersons: Cristina Nanni (Bologna, Italy), Ken Herrmann (Essen, Germany)

- Jonathan Strosberg (Tampa, USA): **PRRT in Neuroendocrine Tumours as a Paradigm for Progress in Radiopharmaceuticals: Where are we and where will we be?**
- Michael Hofman (Melbourne, AUS): **2023: PSMA state of the art**
- Sandra Heskamp (Nijmegen, The Netherlands): **PSMA 2.0**
- Andreas Buck (Würzburg, Germany): CXCR4: **Ready for Prime Time!**
- Katharina Lückerath (Essen, Germany): **Targeting the tumour microenvironment: next breakthrough?!**
- Lena Unterrainer (Munich, Germany / Los Angeles, USA): **Dark Horses of Theranostics**

4

Tuesday, September 12, 2023 | 11:30–13:00 | Hall A

Diagnostic Imaging: Proven Beyond Doubt? (incl. Marie Curie Lecture)

Chairpersons: Valentina Garibotto (Geneva, Switzerland), Pedro Fragoso Costa (Essen, Germany)

- Josée Zijlstra (Amsterdam, The Netherlands): **FDG PET imaging and lymphomas: a proven certainty?**
- Sofia Carrilho Vaz (Lisbon, Portugal): **PET imaging in every oncological guideline: what is still missing?**
- Alexander Drzezga (Cologne, Germany): **Marie Curie Lecture: Impact without a cure: prospective evidence for diagnostic neuroimaging**
- Danilo Neglia (Pisa, Itlay): **Cardiac imaging: prospective studies and the EURECA registry**
- Mathieu Gauthé (Grenoble, France): **Cost effectiveness molecular imaging studies**
- Jens Kleesiek (Essen, Germany): **Real world data: an answer to all questions?**

CONTINUING MEDICAL EDUCATION (CME) SESSIONS

1
Sunday, September 10, 2023 | 08:00–09:30 | Hall A
Inflammation & Infection Committee
Infection and Inflammation - New Guidelines

2
Sunday, September 10, 2023 | 09:45–11:15 | Hall A
Translational Molecular Imaging & Therapy + Oncology and Theranostics + Radiopharmaceutical Sciences Committee
FAP - Moving Towards Therapy

3
Sunday, September 10, 2023 | 15:00–16:30 | Hall A
Cardiovascular Committee
Nuclear Imaging in Cardiac Amyloidosis - What Else?

4
Sunday, September 10, 2023 | 16:45–18:15 | Hall A
Oncology and Theranostics Committee
Update in Multiple Myeloma

5
Monday, September 11, 2023 | 08:00–09:30 | Hall A
Oncology & Theranostics Committee
Will the Microenvironment Become Even More Important in Nuclear Medicine?

6
Monday, September 11, 2023 | 09:45–11:15 | Hall A
Dosimetry Committee
Understanding Radiobiology for Dosimetry-Guided Molecular Radiotherapy

7
Monday, September 11, 2023 | 15:00–16:30 | Hall A
Thyroid + Dosimetry Committee
New NM Guidelines of Benign Thyroid Disease

CONTINUING MEDICAL EDUCATION (CME) SESSIONS

8
Monday, September 11, 2023 | 16:45–18:15 | Hall A
Oncology & Theranostics Committee
Assessing Response to Peptide Receptor Radionuclide Therapy in Patients with Neuroendocrine Tumours

9
Tuesday, September 12, 2023 | 08:00–09:30 | Hall A
Bone and Joint + Physics Committee
Current Bone SPECT/CT (including 360 CZT)

10
Tuesday, September 12, 2023 | 09:45–11:15 | Hall A
Radiation Protection + Paediatrics Committee and Women's Empowerment Task Force
Radiation Protection in Motherhood and Childhood - What is so Special?

11
Tuesday, September 12, 2023 | 15:00–16:30 | Hall A
Paediatrics Committee
Pediatric Lymphoma and Update on FDG

12
Tuesday, September 12, 2023 | 16:45–18:15 | Hall A
Translational Molecular Imaging & Therapy + Oncology & Theranostics + Physics + Technologists Committee
Long Axial Field-of-View PET Scanners - A Copernical Revolution

13
Wednesday, September 13, 2023 | 08:00–09:30 | Hall A
Translational Molecular Imaging & Therapy + Oncology & Theranostics + Radiopharmaceutical Sciences Committee
Diagnostic Imaging and Theranostics in Breast Cancer - Old Targets, New Tracers

14
Wednesday, September 13, 2023 | 09:30–11:15 | Hall A
Neuroimaging + Paediatrics Committee
Modern Imaging of Paediatric Epilepsy

TECHNOLOGISTS' TRACK

The Technologists Committee places a massive effort into delivering the most up-to-date and highest-quality educational initiatives. All sessions of this track are aimed specifically at the technologist audience.

PLENARY SESSIONS

1 Saturday, September 9, 2023 | 18:35–19:35 | Hall A
Highlights Lecture

2 Sunday, September 10, 2023 | 11:30–13:00 | Hall A
New Imaging Techniques – Jump Aboard or Watch and Wait

3 Monday, September 11, 2023 | 11:30–13:00 | Hall A
Radiotheranostics: What´s New?

4 Tuesday, September 12, 2023 | 11:30–13:00 | Hall A
Diagnostic Imaging: Proven Beyond Doubt?
(incl. Marie Curie Lecture)

CTE SESSIONS

1 Sunday, September 10, 2023 | 08:00–09:30 | Hall K
Technologists Committee / SNMMI
Technologists' Guide Launch –
Gastro Intestinal Molecular Imaging Studies

2 Sunday, September 10, 2023 | 09:45–11:15 | Hall K
Technologists Committee
Head and Neck Molecular Imaging – Updates and Perspectives

3 Sunday, September 10, 2023 | 16:45–18:15 | Hall K
Technologists Committee
Patient Care in Nuclear Medicine

4 Monday, September 11, 2023 | 09:45–11:15 | Hall K
Technologists Committee
Prostate Cancer Theranostics

5 Monday, September 11, 2023 | 16:45–18:15 | Hall K
Technologists & Thyroid Committee
Cardiac Inflammatory Disease

6 Tuesday, September 12, 2023 | 08:00–09:30 | Hall K
Technologists Committee
Extravasation Incidents Management

7 Tuesday, September 12, 2023 | 15:00–16:30 | Hall K
Technologists Committee
Molecular Thyroid Imaging - Qualitative and Quantitative Approaches

8 Tuesday, September 12, 2023 | 16:45–18:15 | Hall K
Technologists & Thyroid Committee
Gynaecological Studies

IN ADDITION TO THE CTE SESSIONS THE TECHNOLOGISTS' TRACK INCLUDES 3 MINI COURSES:

1 Wednesday, September 13, 2023 | 08:00–09:00 | Hall K
Technologists Committee
Radiotherapy Planning Using PET/CT and PET/MR

2 Wednesday, September 13, 2023 | 09:05–10:05 | Hall K
Technologists Committee
AI in the Technologists Practice

3 Wednesday, September 13, 2023 | 10:15–11:15 | Hall K
Technologists Committee
Phantoms Management

TECHNOLOGISTS' ORAL PRESENTATIONS

1 Sunday, September 10, 2023 | 15:00–16:30 | Hall K
Technologists Committee
SPECT-CT in Diagnosis and Therapy

2 Monday, September 11, 2023 | 08:00–09:30 | Hall K
Technologists Committee
All about PET-CT!

3 Tuesday, September 12, 2023 | 09:45–11:15 | Hall K
Technologists Committee
NM Technologists: Competencies and Training

TECHNOLOGISTS' e-POSTER PRESENTATIONS

1 Monday, September 11, 2023 | 15:00–16:30 | Hall K
Technologists Committee
Technologists' e-Poster Presentations Session

SPECIAL TRACK

1
Sunday, September 10, 2023 | 08:00–09:30 | Hall D (Arena)
Cardiovascular Committee
Debate: Myocardial Perfusion Imaging after ISCHEMIA Trial

2
Sunday, September 10, 2023 | 09:45–11:15 | Hall D (Arena)
Thyroid Committee
Challenge the Expert: Integrated Diagnostics of Thyroid Disease

3
Sunday, September 10, 2023 | 15:00–16:30 | Hall D (Arena)
Oncology & Theranostics Committee
Challenge the Expert: Risk in Diagnostic and Therapeutic Nuclear Medicine

4
Sunday, September 10, 2023 | 16:45–18:15 | Hall D (Arena)
Dosimetry Committee
Challenge the Expert: Dosimetry Live

5
Monday, September 11, 2023 | 08:00–09:30 | Hall D (Arena)
Neuroimaging Committee
Debate: What is the Best Tracer for Molecular Brain Tumour Imaging?

6
Monday, September 11, 2023 | 09:45–11:15 | Hall D (Arena)
Translational Molecular Imaging & Therapy + Radiopharmaceutical Sciences + Oncology & Theranostics Committee
Round Table: Dialogue with the Treating Physician

7
Monday, September 11, 2023 | 15:00–16:30 | Hall D (Arena)
EANM Sanjiv Sam Gambhir Award – Compete and Win!

8
Monday, September 11, 2023 | 17:15–18:15 | Hall D (Arena)
Physics Committee
Debate: AI in Nuclear Medicine: Fear or Embrace?

9
Tuesday, September 12, 2023 | 08:00–09:30 | Hall D (Arena)
Radiation Protection Committee
Round Table: Establishing and Running a Theranostics Centre in a Clinical Setting

10
Tuesday, September 12, 2023 | 09:45–11:15 | Hall D (Arena)
Physics + Oncology & Theranostics Committee
Debate: Whole Body Parametric Imaging

11
Tuesday, September 12, 2023 | 15:00–16:30 | Hall D (Arena)
Neuroimaging Committee
Challenge the Expert: Amyloid or Tau PET – What First in Alzheimer Dementia Patients? Germany versus Italy

12
Tuesday, September 12, 2023 | 16:45–18:15 | Hall D (Arena)
Bone & Joint + Cardiovascular Committee
Debate: NaF PET in Cardiology and MSK: Pro or Cons?

13
Wednesday, September 13, 2023 | 08:00–09:30 | Hall D (Arena)
Oncology & Theranostics Committee
Debate: Staging Lymphoma – Ann Arbour Outdated and Replaced by Metabolic Tumour Volume?

14
Wednesday, September 13, 2023 | 09:45–11:15 | Hall D (Arena)
EANM Women's Empowerement Initiative
Round Table: Women in Science – Special Focus on Nuclear Medicine

JOINT SYMPOSIA

1
Sunday, September 10, 2023 | 09:45–11:15 | Hall F2
Cardiovascular + Inflammation & Infection Committee + EACVI
PET in Valvular Diseases – All In!

2
Sunday, September 10, 2023 | 15:00–16:30 | Hall F2
Oncology & Theranostics Committtee / EORTC
Nuclear Medicine Imaging of the Immune System

3
Monday, September 11, 2023 | 15:00–16:30 | Hall F2
Translational Molecular Imaging & Therapy + Oncology & Theranostics + Physics Committee / EAU
Metastases Directed Prostate Cancer Surgery – Translational Challenges and Possibilities

4
Tuesday, September 12, 2023 | 08:00–09:30 | Hall F2
Dosimetry Committee + ESTRO
Dosimetry in Different Modalities – Where We Are and Where We Want to Be

5
Tuesday, September 12, 2023 | 15:00–16:30 | Hall F2
Oncology & Theranostics Committee + ESMO
Prostate Cancer Theranostics: Were Do We Go?

6
Wednesday, September 13, 2023 | 08:00–09:30 | Hall F2
Neuroimaging Committee + EAN
Progress in Multimodal Imaging of Parkinson's Disease

SPECIAL SYMPOSIA

1
Sunday, September 10, 2023 | 16:45–18:15 | Hall G1
EANM/EARL
Harmonisation and Accreditation Accelerate Research and Clinical Translation

2
Monday, September 11, 2023 | 08:00–09:30 | Hall F2
Inflammation & Infection Committee
Usefullness of PET in the Evaluation of Inflammatory Rheumatisms

3
Tuesday, September 12, 2023 | 09:45–11:15 | Hall G1
EANM / EJNMMI
You, the EANM and the EJNMMI

4
Tuesday, September 12, 2023 | 08:00–09:30 | Hall G1
Lung Scintigraphy for Pulmonary Embolism Diagnosis and Long-Term Management

EU POLICY SYMPOSIA

1
Tuesday, September 12, 2023 | 15:00–16:30 | Hall G1
Policy & Regulatory Affairs Committee
Supply & Shortages of Radiopharmaceuticals

2
Tuesday, September 12, 2023 | 16:45–18:15 | Hall G1
Policy & Regulatory Affairs Committee
Regulatory Challenges of Radiopharmaceuticals

LEARN & IMPROVE PROFESSIONAL SKILLS (LIPS) TRACK

1
Sunday, September 10, 2023 | 08:00–09:30 | Hall E1
Oncology & Theranostics Committee
Novelties in Radionuclide Therapy

2
Sunday, September 10, 2023 | 09:45–11:15 | Hall E1
Radiation Protection + Physics Committee / EFOMP
Careers in Radiation Protection

3
Sunday, September 10, 2023 | 15:00–16:30 | Hall E1
Thyroid Committee
Rational Use of PET/CT with 18F-FDG in DTC

4
Sunday, September 10, 2023 | 16:45–18:15 | Hall E1
Oncology & Theranostics Committee
Residents for Residents

5
Monday, September 11, 2023 | 08:00–09:30 | Hall E1
Cardiovascular Committee
Challenges in MBF Quantification with PET and SPECT

6
Monday, September 11, 2023 | 09:45–11:15 | Hall E1
Neuroimaging + Cardiovascular + Inflammation & Infection Committee
Molecular Imaging to Solve the Problem of Long COVID

7
Monday, September 11, 2023 | 15:00–16:30 | Hall E1
Inflammation & Infection Committee
Tips and Tricks in the Study of Prosthesis Infection

8
Monday, September 11, 2023 | 16:45–18:15 | Hall E1
Cardiovascular Committee
Stiff to Sweet – Infiltration and Inflammation

9
Tuesday, September 12, 2023 | 08:00–09:30 | Hall E1
Paediatrics Committee
Paediatric Nephro-Urology – Beyond Hydro-Nephrosis

10
Tuesday, September 12, 2023 | 09:45–11:15 | Hall E1
NeuroimagingCommittee
The Sunrise of Alpha-Synuclein in Vivo Brain Imaging

11
Tuesday, September 12, 2023 | 15:00–16:30 | Hall E1
Bone & Joint Committee
Pitfalls and Common Bony Findings in PET-CT/MRI using Novel Tracers

12
Tuesday, September 12, 2023 | 16:45–18:15 | Hall E1
Neuroimaging + Inflammation & Infection Committee
The Role of FDG PET in the Diagnosis of Auto-Immune Encephalitis

13
Wednesday, September 13, 2023 | 08:00–09:30 | Hall E1
Case Reading - Dosimetry in SIRT

14
Wednesday, September 13, 2023 | 09:45–11:15 | Hall E1
Beta Emitters for Radioguided Surgery - Challenges and Opportunities

CLINICAL ONCOLOGY TRACK – TROP & FEATURED SESSIONS:

206
Sunday, September 10, 2023 | 08:00 – 09:30 | Hall C
Oncology & Theranostics Committee – TROP Session
Prostate Cancer Staging

306
Sunday, September 10, 2023 | 09:45 – 11:15 | Hall C
Oncology & Theranostics Committee – FEATURED Session
Haematological Disease

506
Sunday, September 10, 2023 | 15:00 – 16:30 | Hall C
Oncology & Theranostics Committee – TROP Session
Gastrointestinal Malignancies

606
Sunday, September 10, 2023 | 16:45 – 18:15 | Hall C
Oncology & Theranostics Committee – TROP Session
Neuroendocrine Tumours Treatment

706
Monday, September 11, 2023 | 08:00 – 09:30 | Hall C
Oncology & Theranostics Committee – TROP Session
Neuroendocrine Tumours – Diagnosis

806
Monday, September 11, 2023 | 09:45 – 11:15 | Hall C
Oncology & Theranostics Committee – FEATURED Session
FAP Imaging

1006
Monday, September 11, 2023 | 15:00 – 16:30 | Hall C
Oncology & Theranostics Committee – FEATURED Session
Melanoma

1106
Monday, September 11, 2023 | 16:45 – 18:15 | Hall C
Oncology & Theranostics Committee – TROP Session
Prostate Cancer Biochemical Recurrence

1206
Tuesday, September 12, 2023 | 08:00 – 09:30 | Hall C
Oncology & Theranostics Committee – TROP Session
Gynaecological Malignancies

1306
Tuesday, September 12, 2023 | 09:45 – 11:15 | Hall C
Oncology & Theranostics Committee – TROP Session
Lung

1506
Tuesday, September 12, 2023 | 15:00 – 16:30 | Hall C
Oncology & Theranostics Committee – TROP Session
Prostate Cancer Treatment

1606
Tuesday, September 12, 2023 | 16:45 – 18:15 | Hall C
Oncology & Theranostics Committee – TROP Session
Head and Neck Imaging

1706
Wednesday, September 13, 2023 | 08:00 – 09:30 | Hall C
Oncology & Theranostics Committee – TROP Session
Localised Treatments

1806
Wednesday, September 13, 2023 | 09:45 – 11:15 | Hall C
Oncology & Theranostics Committee – TROP Session
Radiomics

CUTTING EDGE SCIENCE TRACK – TROP & FEATURED SESSIONS

205 Sunday, September 10, 2023 | 08:00 – 09:30 | Hall B
Physics Committee – TROP Session
Quality Control, Performance, Standardisation

305 Sunday, September 10, 2023 | 09:45 – 11:15 | Hall B
Physics Committee – FEATURED Session
Radiomics

505 Sunday, September 10, 2023 | 15:00 – 16:30 | Hall B
Dosimetry Committee – TROP Session
From Cells to Human via the Fish

605 Sunday, September 10, 2023 | 16:45 – 18:15 | Hall B
Physics Committee – TROP Session
Segmentation and Denoising

705 Monday, September 11, 2023 | 08:00 – 09:30 | Hall B
Physics Committee – FEATURED Session
Imaging Guided Surgery

805 Monday, September 11, 2023 | 09:45 – 11:15 | Hall B
Physics Committee – TROP Session
Image Reconstruction and Data Corrections

1005 Monday, September 11, 2023 | 15:00 – 16:30 | Hall B
Dosimetry Committee – TROP Session
^{177}Lu / ^{225}Ac and ^{161}Tb RLT

1105 Monday, September 11, 2023 | 16:45 – 18:15 | Hall B
Radiation Protection Committee – TROP Session
Current Issues of Radiation Protection

1205 Tuesday, September 12, 2023 | 08:00 – 09:30 | Hall B
Physics Committee – TROP Session
Total Body PET Methods

1305 Tuesday, September 12, 2023 | 09:45 – 11:15 | Hall B
Physics Committee – TROP Session
Quantitative SPECT/CT Imaging

1505 Tuesday, September 12, 2023 | 15:00 – 16:30 | Hall B
Physics Committee – TROP Session
AI Methods and Applications

1605 Tuesday, September 12, 2023 | 16:45 – 18:15 | Hall B
Physics Committee – TROP Session
Data Analysis

1705 Wednesday, September 13, 2023 | 08:00 – 09:30 | Hall B
Physics Committee – FEATURED Session
Dynamic Imaging

1805 Wednesday, September 13, 2023 | 09:45 – 11:15 | Hall B
Dosimetry Committee – TROP Session
Clinical Dosimetry III-Time & Co

M2M TRACK – TROP & FEATURED SESSIONS

204 Sunday, September 10, 2023 | 08:00 – 09:30 | Hall E2
Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee – TROP Session
At the Nucleus: Radionuclide Production

304 Sunday, September 10, 2023 | 09:45 – 11:15 | Hall E2
Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee – TROP Session
Validating Methodology: In Vitro and in Vivo Models

504 Sunday, September 10, 2023 | 15:00 – 16:30 | Hall E2
Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee – TROP Session
Radioligand Therapy – New and Old Targets

604 Sunday, September 10, 2023 | 16:45 – 18:15 | Hall E2
Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee – TROP Session
Novel Imaging Targets in Oncology

704 Monday, September 11, 2023 | 08:00 – 09:30 | Hall E2
Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee – TROP Session
Imaging Inflammatory Processes in Cardiovascular Disease

804 Monday, September 11, 2023 | 09:45 – 11:15 | Hall E2
Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee – TROP Session
TME and Therapy: Direct Targeting and Secondary Effects

1004 Monday, September 11, 2023 | 15:00 – 16:30 | Hall E2
Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee – TROP Session
New Roads Towards FAP-Directed Theranostics

1104 Monday, September 11, 2023 | 16:45 – 18:15 | Hall E2
Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee Committee – TROP Session
Efficient Radiolabelling: Key for Clinical Translation

1204 Tuesday, September 12, 2023 | 08:00 – 09:30 | Hall E2
Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee – TROP Session
Imaging the Brain from all Angles

1304 Tuesday, September 12, 2023 | 09:45 – 11:15 | Hall E2
Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee – TROP Session
Emerging Theranostic Concepts

1504 Tuesday, September 12, 2023 | 15:00 – 16:30 | Hall E2
Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee – TROP Session
Imaging the Components of the TME

1604 Tuesday, September 12, 2023 | 16:45 – 18:15 | Hall E2
Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee – TROP Session
Understanding and Improving RLT

1704 Wednesday, September 13, 2023 | 08:00 – 09:30 | Hall E2
Dosimetry Committee – TROP Session
Clinical Dosimetry II – Tutti Frutti

1804 Wednesday, September 13, 2023 | 09:45 – 11:15 | Hall E2
Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee – TROP Session
New Therapeutic Radiopharmaceuticals

FURTHER ORAL PRESENTATIONS – TROP & FEATURED SESSIONS

207 Sunday, September 10, 2023 | 08:00 – 09:30 | Hall F1
Neuroimaging Committee – FEATURED Session
Methods in NeuroImaging: Spotlight on Brain Connectivity

208 Sunday, September 10, 2023 | 08:00 – 09:30 | Hall F2
Paediatrics Committee – TROP Session
Paediatric PET/CT & PET/MR

307 Sunday, September 10, 2023 | 09:45 – 11:15 | Hall F1
Neuroimaging Committee – TROP Session
Amyloid, Tau and More in Neurodegenerative Disorders

507 Sunday, September 10, 2023 | 15:00 – 16:30 | Hall F1
Paediatrics Committee – TROP Session
Adults General Nuclear Medicine

607 Sunday, September 10, 2023 | 16:45 – 18:15 | Hall F1
Cardiovascular Committee- TROP Session
Functional Imaging, Plaque and Total-Body PET

608 Sunday, September 10, 2023 | 16:45 – 18:15 | Hall F2
Inflammation & Infection Committee – TROP Session
Infection and Inflammation Imaging: New Frontiers

707 Monday, September 11, 2023 | 08:00 – 09:30 | Hall F1
Paediatrics Committee – TROP Session
Neuroblastoma & Non-PET Paediatric Studies

807 Monday, September 11, 2023 | 09:45 – 11:15 | Hall F1
Cardiovascular Committee – TROP Session
Clinical Perfusion Imaging with PET

808 Monday, September 11, 2023 | 09:45 – 11:15 | Hall F2
Thyroid Committee – FEATURED Session
Iodine-131 Therapy and Beyond in Differentiated Thyroid Cancer

1007 Monday, September 11, 2023 | 15:00 – 16:30 | Hall F1
Neuroimaging Committee – TROP Session
Imaging Neurotransmission in Movement Disorders

1107 Monday, September 11, 2023 | 16:45 – 18:15 | Hall F1
Inflammation & Infection Committee – TROP Session
Vasculitis and Endocarditis: Current and New Evidence

FURTHER ORAL PRESENTATIONS – TROP & FEATURED SESSIONS

1108 Monday, September 11, 2023 | 16:45 – 18:15 | Hall F2
Thyroid Committee – TROP Session
Iodine-131 Therapy in Differentiated Thyroid Cancer: Present and Future Perspective

1207 Tuesday, September 12, 2023 | 08:00 – 09:30 | Hall F1
Neuroimaging Committee – FEATURED Session
Breadth of Tracers and Approaches in Neuro-Oncology

1307 Tuesday, September 12, 2023 | 09:45 – 11:15 | Hall F1
Cardiovascular Committee – TROP Session
Plaque, Fibrosis and Cardio-Oncology

1308 Tuesday, September 12, 2023 | 09:45 – 11:15 | Hall F2
Thyroid Committee – TROP Session
^{18}F-FDG and Novel Tracers in the Diagnostic Management of Patients with Thyroid Cancers

1507 Tuesday, September 12, 2023 | 15:00 – 16:30 | Hall F1
Cardiovascular Committee – TROP Session
Perfusion

1607 Tuesday, September 12, 2023 | 16:45 – 18:15 | Hall F1
Neuroimaging Committee – TROP Session
New PET Tracers for Brain Imaging

1608 Tuesday, September 12, 2023 | 16:45 – 18:15 | Hall F2
Thyroid Committee – TROP Session
Nuclear Medicine Imaging in Thyroid and Parathyroid Disorders

1707 Wednesday, September 12, 2023 | 08:00 – 09:30 | Hall F1
Cardiovascular Committee – TROP Session
Heart Failure, Sarcoidosis and Amyloidosis

1807 Wednesday, September 12, 2023 | 09:45 – 11:15 | Hall F1
Inflammation & Infection Committee – TROP Session
COVID-19: Isn't it over yet?

1808 Wednesday, September 12, 2023 | 09:45 – 11:15 | Hall F2
Bone & Joint Committee – FEATURED Session
COVID-19: Isn't it over yet?

E-POSTER PRESENTATIONS

209 Sunday, September 10, 2023 | 08:00 – 09:30 | Hall G2
Oncology & Theranostics Committee
Neuroendocrine Tumours and Gynaecological Malignancies

309 Sunday, September 10, 2023 | 09:45 – 11:15 | Hall G2
Paediatrics Committee
Paediatric Nuclear Medicine & Adults General Nuclear Medicine

509 Sunday, September 10, 2023 | 15:00 – 16:30 | Hall G2
Inflammation & Infection Committee
More on Infection and Inflammation Imaging

609 Sunday, September 10, 2023 | 16:45 – 18:15 | Hall G2
Thyroid Committee
Thyroid and Parathyroid Disease

709 Monday, September 11, 2023 | 08:00 – 09:30 | Hall G2
Physics Committee
SPECT/CT, PET/CT, PET/MR Quantitating Imaging

809 Monday, September 11, 2023 | 09:45 – 11:15 | Hall G2
Oncology & Theranostics Committee
Prostate Cancer

1009 Monday, September 11, 2023 | 15:00 – 16:30 | Hall G2
Cardiovascular Committee
Cardiovascular Imaging e-Posters

1109 Monday, September 11, 2023 | 16:45 – 18:15 | Hall G2
Neuroimaging Committee
E-Poster Neurology: It's in the Brain!

1209 Tuesday, September 12, 2023 | 08:00 – 09:30 | Hall G2
Physics Committee
Artificial Intelligence and Radiomics

1309 Tuesday, September 12, 2023 | 09:45 – 11:15 | Hall G2
Oncology & Theranostics Committee
Haematological and Abdominal Malignancies / localised Treatments

1509 Tuesday, September 12, 2023 | 15:00 – 16:30 | Hall G2
Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee
Novel Therapeutic Approaches

1609 Tuesday, September 12, 2023 | 16:45 – 18:15 | Hall G2
Dosimetry Committee
Dosimetry Symphony

1709 Wednesday, September 13, 2023 | 08:00 – 09:30 | Hall G2
Oncology & Theranostics Committee
Head and Neck Tumours, Lung, Melanoma and Others

1809 Wednesday, September 13, 2023 | 09:45 – 11:15 | Hall G2
Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee
New Imaging Agents

CASE REPORT SESSIONS

1 Monday, September 11, 2023 | 15:00–16:30 | Hall G1
Learning from Single Cases in Theranostics

2 Monday, September 11, 2023 | 16:45–18:15 | Hall G1
Successful Molecular Targeting in Oncology

3 Wednesday, September 13, 2023 | 08:00–09:30 | Hall G1
Every Day a Discovery with FAP and Novel Targets

4 Wednesday, September 13, 2023 | 09:45–11:15 | Hall G1
FDG and Conventional Imaging: Still Surprising!

AWARDS

The EANM will bestow several awards throughout the EANM'23.

EANM MARIE CURIE AWARD

Each year, the prestigious EANM Marie Curie Award honours the best abstract submission of the year. This year, the Marie Curie Award will be granted by the EANM President 2023-2024, Rudi Dierckx, during the EANM Congress Opening Ceremony. **Details: Saturday, September 9, 2023 - 18:00–18:35 CEST – Hall A.**

EANM YOUNG AUTHORS' AWARD

(Kindly supported by United Imaging Healthcare)

The EANM Young Authors' Award aims to support young and talented nuclear medicine investigators. This year, three promising young authors were selected for their outstanding abstracts. The awardees will be able to present their results during the Congress. **Details: Monday, September 11, 2023 - 14:30–15:00 – Exhibition Hall X4, Stand 420**

EANM SANJIV SAM GAMBHIR YOUNG INVESTIGATOR AWARD

(Kindly supported by Telix Pharmaceuticals)

The EANM Sanjiv Sam Gambhir Young Investigator Award aims to encourage collaboration between young professionals from all around the world. The winner of the EANM Sanjiv Sam Gambhir Young Investigator Award will be offered a 3-month visitorship at Stanford University. The jury has selected six candidates, who will fight for this prestigious award in a dedicated session. **Details: Monday, September 11, 2023 - 15:00–16:30 CEST – Hall D (Arena).**

EANM TECHNOLOGISTS' AWARD

(Kindly supported by United Imaging Healthcare)

The purpose of the Technologists' Award is to encourage Nuclear Medicine Technologists to present the abstract of their research project. Four EANM Technologists' Awards will be granted during the EANM'23. **Details: Tuesday, September 12, 2023 - 16:30 CEST – Hall K**

EJNMMI AWARDS

Once again, this year, the EANM and Springer will honour outstanding articles published across the whole journal family with the EJNMMI Awards. **Details: Winners will be notified directly.**

Oral Sessions

OC

Saturday, September 9, 2023, 18:00 - 18:35
Hall A

Opening Ceremony including Awards Ceremony

OP-001
Opening Ceremony including Awards Ceremony
V. Garibotto;
University Hospitals and University of Geneva, Geneva, SWITZERLAND.

101

Saturday, September 9, 2023, 18:35 - 19:35
Hall A

Plenary 1: Highlights Lecture

OP-002
Highlight Lecture
S. Veldhuijzen van Zanten;
Erasmus Medical Center, Amsterdam, NETHERLANDS.

OP-003
Highlight Lecture
S. Morbelli;
San Martino Hospital, University of Genoa, Genoa, ITALY.

OP-004
Highlight Lecture
D. Kersting;
University Hospital, Essen, Department of Nuclear Medicine, Essen, GERMANY.

OP-005
Highlight Lecture
H. Verberne;
University of Amsterdam, NETHERLANDS.

201

Sunday, September 10, 2023, 08:00 - 09:30
Hall A

CME 1 - Inflammation & Infection Committee: Infection and Inflammation - New Guidelines

OP-006
New Guidelines about Infection
G.Abikhzer;
Nuclear Medicine, Jewish General Hospital, Quebec, CANADA.

OP-007
New Guidelines about Inflammation
O. Gheysens;
Nuclear Medicine Department, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, BELGIUM.

OP-008
FUO Guidelines
D. Albano;
Nuclear Medicine Department, Università degli Studi di Brescia, ASST Spedali Civili of Brescia, Brescia, ITALY .

OP-009
Diabetic Foot Guidelines
R. Chakravarthy;
Nuclear Medicine department, Kings College London Hospital Trust, Shrewsbury, UNITED KINGDOM .

202

Sunday, September 10, 2023, 08:00 - 09:30
Hall D (Arena)

Debate 1 - Cardiovascular Committee: Myocardial Perfusion Imaging after ISCHEMIA

OP-010
Anatomical imaging with coronary CTA is all I need!
A. Rossi;
UniversityHospital of Zurich, Zurich, SWITZERLAND.

OP-011
Myocardial perfusion imaging: let's go with the flow!
M. Mallah;
Houston Methodist Academic Institute, Houston, UNITED STATES OF AMERICA.

OP-012
Debate

203

Sunday, September 10, 2023, 08:00 - 09:30
Hall E1

LIPS Session 1 - Oncology & Theranostics Committee: Novelties in Radionuclide Therapy

OP-013
Emerging radiopharmaceuticals in radionuclide therapy
L. Unterrainer;
LMU Munich, Department of Nuclear Medicine, Munich, GERMANY.

OP-014
Intra-arterial Peptide Receptor Radionuclide Therapy
A. Braat;
UniversityMedical Center Utrecht, Department of Radiology and Nuclear Medicine, Utrecht, GERMANY.

OP-015
Pancreatic cancer treatment with P-32
Z. Win;
Imperial College Healthcare NHS Trust Hammersmith, St Mary's and Charing Cross Hospitals, Department of Nuclear Medicine, London, UNITED KINGDOM.

204

Sunday, September 10, 2023, 8:00 AM - 9:30 AM
Hall E2

M2M Track - TROP Session: Translational Molecular Imaging & Therapy Committee + Radiopharmaceutical Sciences Committee: At the Nucleus: Radionuclide Production

OP-016
Terbium-149 production: a pragmatic view of its clinical potential
N. van der Meulen[1], *P. V. Grundler*[1], *Z. Talip*[1], *C. Favaretto*[1], *C. C. Hillhouse*[1], *U. Koester*[2], *K. Johnston*[3], *R. Schibli*[1], *R. Eichler*[1], *C. Mueller*[1];
[1]Paul Scherrer Institut, Villigen, SWITZERLAND, [2]ILL, Grenoble, FRANCE, [3]CERN, Geneva, SWITZERLAND.

OP-017
Small-scale production of ^{161}Tb for preclinical studies
M. Skálová, *J. Kozempel, M. Vlk, K. Ondrák Fialová, L. Ondrák;*
Department of Nuclear Chemistry, Faculty of Nuclear Sciences and Physical Engineering, Czech Technical University in Prague, Prague, CZECH REPUBLIC.

OP-018
Separation and Purification of ^{225}Ac for Targeted Alpha Therapy Radiopharmaceuticals
E. Yalcintas Bethune, *J. F. Camacaro, S. Chatterjee, C. P. Dunckley, H. A. Fitzgerald, E. Harman, A. L. Lakes, Z. Liao, L. M. Lilley, R. C. Ludwig, K. M. McBride, A. Younes;*
TerraPower LLC, Bellevue, WA, UNITED STATES OF AMERICA.

OP-019
Cyclotron based production of ^{64}Cu/^{67}Cu diagnostic and theragnostic pair
J. Lee, *J. Park;*
Korea Atomic Energy Research Institute, Jeollabuk-do Jeongeup-si, KOREA, REPUBLIC OF.

OP-020
Production of Lanthanum-133 via the^{134}Ba(p,2n)^{133}La Nuclear Reaction with High Radionuclide Purity for Theranostic Purposes
S. Brühlmann[1,2], *M. Kreller*[1], *H. Pietzsch*[1], *K. Kopka*[1,2], *C. Mamat*[1,2], *M. Walther*[1], *F. Reissig*[1];
[1]Helmholtz-Zentrum Dresden-Rossendorf, Dresden, GERMANY, [2]Technische Universität Dresden, Dresden, GERMANY.

OP-021
Neutron Capture-Based Production via Power Reactor and Potential Market Penetration
C. Horne[1], *J. Quirt*[1], *M. Flagg*[2];
[1]Laurentis Energy Partners (subsidiary of Ontario Power Generation), Pickering, ON, CANADA, [2]BWXT Medical, Kanata, ON, CANADA.

OP-022
Testing new resins for ^{225}Ac separation
O. Lebeda[1], *K. Ondrák Fialová*[1], *L. Ondrák*[1], *S. Happel*[2], *J. Ráliš*[1], *M. Kleinová*[1], *I. Dovhyi*[2];
[1]Nuclear Physics Institute of the CAS, Husinec-Rez, CZECH REPUBLIC, [2]TRISKEM International, Bruz, FRANCE.

OP-023
Production of gallium-68 using IBA and GE liquid target system - comparison and optimization
A. Uhlending, *V. Hugenberg;*
Institute of Radiology, Nuclear Medicine and Molecular Imaging, Heart and Diabetes Center North Rhin, Bad Oeynhausen, GERMANY.

OP-024
Radium targets for cyclotron production of Ac-225 in view of targeted alpha therapy
A. Kellerbauer[1], *R. Malmbeck*[1], *C. De Almeida Carrapiço*[1], *E. Jajcisinova*[1,2], *Rachel Eloirdi*[1], *Ondrej Lebeda*[3], *Alfred Morgenstern*[1];
[1]European Commission, Joint Research Centre, Karlsruhe, GERMANY, [2]KU Leuven, Leuven, BELGIUM, [3]Nuclear Physics Institute of the CAS, Řež, CZECH REPUBLIC.

205

Sunday, September 10, 2023, 8:00 AM - 9:30 AM
Hall B

Cutting Edge Science Track - TROP Session: Quality Control, Performance, Standardisation

OP-025
An academic/industrial PET raw data standardisation initiative
K. Thielemans[1], *A. L. Kesner*[2], *E. Asma*[3], *J. Cabello*[4], *M. J. Cook*[5], *M. Hansen*[6], *J. Jones*[4], *N. A. Karakatsanis*[7], *E. K. Leung*[8], *P. Markiewicz*[9], *S. Prevrhal*[10], *A. Rahmim*[11], *B. Saboury*[12], *J. Stairs*[6], *S. Stute*[13], *H. Tashima*[14], *G. Wells*[15];
[1]*Institute of Nuclear Medicine, London, UNITED KINGDOM,* [2]*Memorial Sloan Kettering Cancer Center, New York, NY, UNITED STATES OF AMERICA,* [3]*Canon Medical Research UNITED STATES OF AMERICA, Vernon Hills, IL, UNITED STATES OF AMERICA,* [4]*Siemens Medical Solutions UNITED STATES OF AMERICA, Inc, Knoxville, TN, UNITED STATES OF AMERICA,* [5]*GE HealthCare, Waukesha, IL, UNITED STATES OF AMERICA,* [6]*Microsoft Research, Redmond, WA, UNITED STATES OF AMERICA,* [7]*Weill Cornell Medical College, Cornell University, New York, NY, UNITED STATES OF AMERICA,* [8]*UIH America, Inc., Houston, TX, UNITED STATES OF AMERICA,* [9]*University College London, London, UNITED KINGDOM,* [10]*Philips Research, Hamburg, GERMANY,* [11]*University of British Columbia, Vancouver, BC, CANADA,* [12]*National Institutes of Health (NIH) - Clinical Center, Bethesda, MD, UNITED STATES OF AMERICA,* [13]*Nantes University Hospital, CRCI2NA, Nantes, FRANCE,* [14]*National Institutes for Quantum Science and Technology, Chiba, JAPAN,* [15]*University of Ottawa Heart Institute, Ottawa, ON, CANADA.*

OP-026
A reference-free PET quality metric using multi-scale sharpness index
F. Moradi[1], *P. Gurunath Bharathi*[1], *M. Khalighi*[1], *K. Su*[2], *M. Spangler-Bickell*[2];
[1]*Stanford University, Stanford, CA, UNITED STATES OF AMERICA,* [2]*GE Healthcare, Waukesha, WI, UNITED STATES OF AMERICA.*

OP-027
Mitigating SUV Uncertainties Using Total Body PET Imaging
C. L. C. Smith[1,2], *G. J. C. Zwezerijnen*[1,2], *M. den Hollander*[1], *J. Weijland*[1], *M. Yaqub*[1,2], *R. Boellaard*[1,2];
[1]*Amsterdam UMC location Vrije Universiteit Amsterdam, Department of Radiology and Nuclear Medicine, Boelelaan 1117, Amsterdam, NETHERLANDS,* [2]*Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, NETHERLANDS.*

OP-028
Calibration Procedures for Radionuclide Calibrators to Achieve Traceable Activity Measurements for Lu-177
V. Reijonen[1], *P. Toroi*[2], *M. Tenhunen*[1];
[1]*Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, FINLAND,* [2]*STUK - Radiation and Nuclear Safety Authority, Helsinki, FINLAND.*

OP-029
Accuracy of absolute quantification for high count rate holmium-166 SPECT/CT
L. E. L. Westlund Gotby[1], *D. Lobeek*[1], *J. Roosen*[1], *M. de Bakker*[1], *M. W. Konijnenberg*[1,2], *J. F. W. Nijsen*[1];
[1]*Department of Medical Imaging, Radboud University Medical Center, Nijmegen, NETHERLANDS,* [2]*Department of Radiology and Nuclear Medicine, Erasmus Medical Center, Rotterdam, NETHERLANDS.*

OP-030
Design and Development of a Phantom for Commissioning and Quality Assurance of Intraoperative Gamma Probes
A. Stapleton, *O. Berry, J. Grey, R. Harding, L. McKinley, E. Norman;*
Royal Surrey County Hospital, Guildford, UNITED KINGDOM.

OP-031
Design and manufacture of a 3D printed phantom for PET quality control
J. Robinson[1,2], *D. Rushforth*[1,2], *I. Murray*[1,2], *G. Flux*[1,2], *J. Gear*[1,2];
[1]*The Royal Marsden NHS Foundation Trust, Sutton, UNITED KINGDOM,* [2]*The Institute of Cancer Research, London, UNITED KINGDOM.*

OP-032
Automatic trending and analysis of SPECT daily quality control data with optical character recognition AI
T. Pan, *S. Ding, O. Mawlawi;*
The University of Texas, M.D. Anderson Cancer Center, Houston, TX, UNITED STATES OF AMERICA

OP-033
AI-Based Automatic Positioning in a Digital-BGO PET/CT Scanner: Efficacy and Impact
J. Kennedy[1,2], *T. Palchan-Hazan*[1], *Z. Keidar*[1,2];
[1]*Rambam - Health Care Campus, Haifa, ISRAEL,* [2]*Ruth and Bruce Rappaport Faculty of Medicine, Technion–Israel Institute of Technology, Haifa, ISRAEL.*

206

Sunday, September 10, 2023, 8:00 AM - 9:30 AM
Hall C

Clinical Oncology Track - TROP Session: Prostate Cancer Staging

OP-034
Association of aggressive prostate cancer features on whole-mount pathology with quantitative measures on PSMA PET
I. Sonni[1,2], *D. H. Kim*[1], *A. Ter-Pogosyan*[1], *T. Grogan*[1], *N. Barroso*[1], *P. Ahuja*[1], *J. Calais*[1], *A. Sisk*[1], *S. Raman*[1];
[1]*University of California, Los Angeles, Los Angeles, CA, UNITED STATES OF AMERICA,* [2]*Università Magna Graecia, Catanzaro, ITALY.*

OP-035
The role of PSMA PET/CT in the diagnosis of clinically significant prostate cancer
A. Kibar[1], *O. E. Sahin*[1], *S. Asa*[1], *M. Demirbilek*[2], *S. Bilgic*[3], *B. Onal*[2], *L. Kabasakal*[1];
[1]*Istanbul University-Cerrahpasa, Cerrahpasa Faculty of Medicine, Department of Nuclear Medicine, Istanbul, TÜRKIYE,* [2]*Istanbul University-Cerrahpasa, Cerrahpasa Faculty of Medicine, Department of Urology, Istanbul, TÜRKIYE,* [3]*Sirnak State Hospital, Department of Nuclear Medicine, Sirnak, TÜRKIYE.*

OP-036
In-depth analysis of PSMA PET/CT and mpMRI discrepancies in prostate cancer detection with histopathology gold standard
I. Sonni[1,2], *S. Doddipalli*[1], *M. Deol*[1], *D. Ban*[1], *H. Kim*[1], *T. Grogan*[1], *N. Barroso*[1], *P. Ahuja*[1], *Y. Zong*[1], *A. Sisk*[1], *J. Calais*[1], *R. Reiter*[1], *S. Raman*[1];
[1]*University of California, Los Angeles, Los Angeles, CA, UNITED STATES OF AMERICA,* [2]*Università Magna Graecia, Catanzaro, ITALY.*

OP-037
Baseline PSMA PET-CT is prognostic for treatment failure in men with intermediate-to-high risk prostate cancer: 54 months follow-up of the proPSMA randomised trial
M. Hofman[1], *V. Kasivisvanathan*[1], *E. Link*[1], *N. Lawrentschuk*[1], *J. O'Brien*[1], *J. P. Buteau*[1], *M. Roberts*[2], *R. Francis*[3], *C. Tang*[4], *I. Vela*[5], *P. Thomas*[6], *N. Rutherford*[7], *J. M. Martin*[6], *M. Frydenberg*[8], *R. Shakher*[9], *L. Wong*[10], *K. Taubman*[11], *S. Lee*[12], *E. Hsiao*[13], *M. Nottage*[14], *I. Kirkwood*[15], *A. Iravani*[1], *S. Williams*[1], *D. Murphy*[1];
[1]*Peter MacCallum Cancer Centre, Melbourne, AUSTRALIA,* [2]*Royal Brisbane and Women's Hospital, Brisbane, AUSTRALIA,* [3]*The University of Western Australia, Perth, AUSTRALIA,* [4]*Sir Charles Gairdner Hospital, Perth, AUSTRALIA,* [5]*Princess Alexandra Hospital, Brisbane, AUSTRALIA,* [6]*Royal Brisbane and Women's Hospital, Brisbane, AUSTRALIA,* [7]*Hunter New England Health, Newcastle, AUSTRALIA,* [8]*Monash University, Melbourne, AUSTRALIA,* [9]*1Monash Health Imaging, Melbourne, AUSTRALIA,* [10]*St Vincent's Health Melbourne, Melbourne, AUSTRALIA,* [11]*St Vincent's Health, Melbourne, AUSTRALIA,* [12]*Austin Health, Melbourne, AUSTRALIA,* [13]*Royal North Shore Hospital, Sydney, AUSTRALIA,* [14]*Dr Jones and Partners Medical Imaging, Adelaide, AUSTRALIA,* [15]*Royal Adelaide Hospital, Adelaide, AUSTRALIA.*

OP-038
Radio-guided surgery with DROP-IN beta probe for 68Ga-PSMA, in high-risk prostate cancer patients eligible for robotic-assisted radical prostatectomy.
F. Ceci[1], *F. Collamati*[2], *S. Luzzago*[3], *F. A. Mistretta*[3], *L. Muraglia*[1], *G. Renne*[4], *R. Mirabelli*[2], *S. Morganti*[5], *O. De Cobelli*[3], *N. Fusco*[4], *G. Musi*[3];
[1]*Division of Nuclear Medicine, IEO European Institute of Oncology, IRCCS, Milan, ITALY,* [2]*INFN National Institute of Nuclear Physics, Section of Rome, Rome, ITALY,* [3]*Division of Urology, IEO European Institute of Oncology, IRCCS, Milan, ITALY,* [4]*Division of Pathology, IEO European Institute of Oncology, IRCCS, Milan, ITALY,* [5]*INFN National Institute of Nuclear Physics, Section of Rome, Milan, ITALY.*

OP-039
[68Ga]PSMA PET/CT vs. mpMRI in patients with suspicion of prostate cancer and previous negative biopsy: preliminary data from PROSPET-BX trial.
E. Lopci, *M. Lazzeri, L. Disconzi, P. Colombo, A. Saita, D. Maffei, V. Fasulo, R. Hurle, K. Marzo, L. Leonardi, R. Peschechera, A. Benetti, S. Zandegiacomo, L. Pasini, J. Jandric, R. Zanca, P. Casale, M. Rodari, L. Balzarini, G. Guazzoni, N. Buffi, G. Lughezzani;*
IRCCS - Humanitas Research Hospital, Rozzano MI, ITALY.

OP-040
Pre-surgical 68Ga-PSMA-11 PET for biochemical recurrence risk assessment: a surrogate of Pelvic Lymph Node Dissection? Follow-up analysis of a Multicenter Prospective Phase 3 Imaging Trial.
L. Djaileb[1], *W. Armstrong*[2], *D. Thompson*[3], *A. Gafita*[2], *A. Farolfi*[2], *T. Grogan*[2], *M. Cooperberg*[4], *P. Carroll*[5], *S. Washington*[4], *R. Reiter*[6], *J. Czernin*[2], *H. Thomas*[3], *J. Calais*[2];
[1]*University Grenoble-Alpes, INSERM, CHU Grenoble Alpes, Nuclear Medicine Department, LRB, Grenoble, FRANCE,* [2]*UCLA, Los Angeles, CA, UNITED STATES OF AMERICA,* [3]*Department of Radiology and Biomedical Imaging, University of California, San Francisco, CA, UNITED STATES OF AMERICA,* [4]*Department of Urology, University of California, San Francisco, CA, UNITED STATES OF AMERICA,* [5]*Department of Urology, University of California, San Francisco, UCSF, CA, UNITED STATES OF AMERICA,* [6]*Institute of Urologic Oncology, University of California, Los Angeles, CA, UNITED STATES OF AMERICA.*

OP-041
Updated Automated PROMISE assessment: Treatment response evaluation approach on metastatic prostate cancer patients based on PSMA PET/CT
S. Duriseti[1,2], *H. Sahlstedt*[3], *J. Brynolfsson*[3], *G. Berenji*[1,2], *S. Tsai*[2], *N. Kane*[1], *W. Fendler*[4], *M. Rettig*[1,2], *N. Nickols*[1,2];
[1]*University of California, Los Angeles, Los Angeles, CA, UNITED STATES OF AMERICA,* [2]*Greater Los Angeles VA Medical Center, Los Angeles, CA, UNITED STATES OF AMERICA,* [3]*Exini Diagnostics AB, Lund, SWEDEN,* [4]*University of Essen, Essen, GERMANY.*

OP-042
PSMA PET/CT for the Targeting of Prostate Biopsies: Additional Value over MRI?
C. J. W. M. Morré[1], *J. J. Boer*[1], *S. P. Rynja*[1], *M. J. Hagens*[2], *M. A. Noordzij*[1];
[1]*Spaarne Gasthuis, Hoofddorp, NETHERLANDS,* [2]*Antoni van Leeuwenhoek cancer institute, Amsterdam, NETHERLANDS.*

207

Sunday, September 10, 2023, 8:00 AM - 9:30 AM
Hall F1

Neuroimaging Committee - Featured Session: Methods in NeuroImaging: Spotlight on Brain Connectivity

OP-043
The Molecular Connectivity in Neurology
M. Perovnik; *University Medical Centre Ljubljana, Ljubljana, SLOVENIA.*

OP-044
Aging and changes in intrinsic connectivity networks of the brain
S. Ha, *I. Chung, W. Ryoo, J. Min, S. Kwon, J. O;*
The Catholic University of Korea, Seoul, KOREA, REPUBLIC OF.

OP-045

Dynamic reconfiguration of metabolic brain connectivity during progression from MCI to Alzheimer's disease dementia

S. Caminiti[1], *A. Galli*[2], *A. Sala*[3], *M. Inglese*[4], *L. Presotto*[5], *C. Tassorelli*[1], *D. Perani*[6], *the Alzheimer's Disease Neuroimaging Initiative;*
[1]*Department of Brain and Behavioral Sciences, University of Pavia, Pavia, ITALY,* [2]*Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, ITALY,* [3]*GIGA Consciousness, University of Liege, Liege, BELGIUM,* [4]*Department of Biomedicine and Prevention, University of Rome Tor Vergata, Roma, ITALY,* [5]*Department of Physics, University of Milano-Bicocca, Milano, ITALY,* [6]*Vita-Salute San Raffaele University, Milano, ITALY.*

OP-046

Is energy consumption linked to structural and functional connectivity in the healthy human brain?

Y. Mayr[1], *A. Lizarraga*[1], *A. Sala*[1,2,3], *I. Yakushev*[1];
[1]*Department of Nuclear Medicine, Klinikum rechts der Isar, Technical University of Munich, Munich, GERMANY,* [2]*Coma Science Group, GIGA-Consciousness, University of Liege, Liege, BELGIUM,* [3]*Centre du Cerveau2, University Hospital of Liege, Liege, BELGIUM.*

OP-047

Cortical stimulation-induced ictal [^{99m}Tc]Tc-HMPAO SPECT for surgery planning in epilepsy patients

T. Pyka[1], *S. Barlatey*[2], *K. Krieger*[1], *C. Friedrichs-Maeder*[3], *K. Schindler*[3], *A. Rominger*[1], *M. Baud*[3];
[1]*Department of Nuclear Medicine, Inselspital Bern, Bern, SWITZERLAND,* [2]*Department of Neurosurgery, Inselspital Bern, Bern, SWITZERLAND,* [3]*Department of Neurology, Inselspital Bern, Bern, SWITZERLAND.*

OP-048

The Value of ^{18}F-FDG PET/MRI in the Preoperative Localization of Epileptogenic Zone in Patients With Drug-resistant Epilepsy

C. Zeng[1], *H. Zhou*[2], *X. Ling*[1], *Y. Tang*[1], *Z. Tan*[1], *H. Wu*[1], *Y. Cheng*[1], *J. Shang*[1], *Q. Guo*[3], *H. Xu*[1];
[1]*Department of Nuclear Medicine, The First Affiliated Hospital of Jinan University, Guangzhou, CHINA,* [2]*Department of Radiology, Central People's Hospital of Zhanjiang, Zhanjiang, CHINA,* [3]*Epilepsy Center, Guangdong 999 Brain Hospital, Affiliated Brain Hospital of Jinan University, Guangzhou, CHINA.*

OP-049

Effects of Deep Learning-based Quantification for Amyloid PET on Visual Reading: A retrospective, multicenter, multireader study

H. Ryoo[1], *K. Cho*[2], *Y. Kim*[3], *S. Ha*[4], *S. Kwon*[4], *R. Lee*[5], *J. Seok*[6], *S. Kang*[7], *Y. Kang*[2], *B. Kim*[7], *J. Jeong*[8], *H. Yoon*[9], *M. Yoo*[10], *G. Kim*[11], *J. Choi*[12], *J. Park*[12], *E. Lee*[13], *J. Kim*[14], *H. Song*[14], *K. Park*[14], *J. Ha*[15], *A. Chong*[15], *S. Jang*[16], *J. Bang*[16], *I. Hong*[17], *S. Choi*[17], *S. Jeong*[18], *I. Jo*[18], *H. Choi*[2,19,20];
[1]*Department of Nuclear Medicine, Seoul National University Bundang Hospital, Seongnam, KOREA, REPUBLIC OF,* [2]*Department of Nuclear Medicine, Seoul National University Hospital, Seoul, KOREA, REPUBLIC OF,* [3]*Department of Nuclear Medicine, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul, KOREA, REPUBLIC OF,* [4]*Division of Nuclear Medicine, Department of Radiology, College of Medicine, The Catholic University of Korea, Seoul, KOREA, REPUBLIC OF,* [5]*Department of Nuclear Medicine, Chung-Ang University Gwangmyeong Hospital, Gwangmyeong, KOREA, REPUBLIC OF,* [6]*Department of Nuclear Medicine, Chung-Ang University Hospital, Seoul, KOREA, REPUBLIC OF,* [7]*Department of Nuclear Medicine, Ewha Womans University Seoul Hospital, Ewha Womans University College of Medicine, Seoul, KOREA, REPUBLIC OF,* [8]*Department of Neurology, Ewha Womans University Seoul Hospital, Ewha Womans University College of Medicine, Seoul, KOREA, REPUBLIC OF,* [9]*Department of Nuclear Medicine, Ewha Womans University Mokdong Hospital, Ewha Womans University College of Medicine, Seoul, KOREA, REPUBLIC OF,* [10]*Department of Nuclear Medicine, Inha University Hospital, Incheon, KOREA, REPUBLIC OF,* [11]*Department of Neurology, Ewha Womans University Mokdong Hospital, Ewha Womans University College of Medicine, Seoul, KOREA, REPUBLIC OF,* [12]*Department of Nuclear Medicine, Soonchunhyang University Bucheon Hospital, Bucheon, KOREA, REPUBLIC OF,* [13]*Department of Neurology, Soonchunhyang University Bucheon Hospital, Bucheon, KOREA, REPUBLIC OF,* [14]*Department of Nuclear Medicine, Chonnam National University Hospital, Gwangju, KOREA, REPUBLIC OF,* [15]*Department of Nuclear Medicine, Chosun University School of Medicine, Gwangju, KOREA, REPUBLIC OF,* [16]*Department of Nuclear Medicine, CHA Bundang Medical Center, CHA University, Seongnam, KOREA, REPUBLIC OF,* [17]*Department of Nuclear Medicine, Kyung Hee University Hospital, Kyung Hee University School of Medicine, Seoul, KOREA, REPUBLIC OF,* [18]*Department of Nuclear Medicine, Kyungpook National University Chilgok Hospital, Daegu, KOREA, REPUBLIC OF,* [19]*Institute of Radiation Medicine, Medical Research Center, Seoul National University College of Medicine, Seoul, KOREA, REPUBLIC OF,* [20]*Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul, KOREA, REPUBLIC OF.*

OP-050

Brain metabolic correlates of Cytokine Release Syndrome and Immune effector cell-associated neurotoxicity in patients with Diffuse Large B-Cell Lymphoma (DLCBL) treated with CAR-T

T. Di Raimondo[1], *M. Gambella*[2], *A. Raiola*[2], *F. D'Amico*[1], *L. Sofia*[1], *F. Lanfranchi*[1], *C. Ghiggi*[2], *C. Lapucci*[3], *G. Sambuceti*[1], *M. Bauckneht*[1], *M. Inglese*[3], *E. Angelucci*[2], *S. Morbelli*[1];
[1]*Nuclear Medicine Unit, Department of Health Sciences (DISSAL), University of Genoa, Genova, ITALY,* [2]*Department of Hematology and Cellular Therapy, IRCCS Ospedale Policlinico San Martino, Genova, ITALY,* [3]*Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINOGMI), IRCCS Ospedale Policlinico San Martino, University of Genoa, Genova, ITALY.*

OP-051

A pilot study comparing myelin measurements from [18F]-Florbetaben PET and quantitative T1 map imaging in multiple sclerosis (MS)

L. Sofia[1], *M. Donegani*[1], *A. Donniaquio*[2], *A. Chincarini*[3], *L. Roccatagliata*[4], *M. Pardini*[2], *R. Gianeri*[3], *F. Sensi*[3], *F. D'Amico*[1], *T. Di Raimondo*[1], *C. Bagnara*[5], *M. Riondato*[1], *G. Novi*[6], *A. Laroni*[2], *A. Murialdo*[6], *G. Ribizzi*[6], *A. Uccelli*[2], *M. Inglese*[2], *S. Morbelli*[1];
[1]*Nuclear Medicine Unit, Department of Health Sciences, University of Genoa, Genoa, ITALY,* [2]*Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINOGMI), University of Genoa, Genoa, Genoa, ITALY,* [3]*National Institute of Nuclear Physics (INFN), Genoa section, Genoa., Genoa, ITALY,* [4]*Neuroradiology Unit, University of Genoa, Genoa, Genoa, ITALY,* [5]*Medical Physics, IRCCS Policlinico San Martino, Genoa, Genoa, ITALY,* [6]*Division of Neurology, IRCCS Policlinico San Martino, Genoa, Genoa, ITALY.*

208

Sunday, September 10, 2023, 8:00 AM - 9:30 AM
Hall F2

Paediatrics Committee - TROP Session: Paediatric PET/CT & PET/MR

OP-052

Predictive value of FDG PET/CT parameters in pediatric Hodgkin Lymphoma: initial results of an Italian prospective study

E. Lopci[1], *C. Elia*[2], *V. De Re*[2], *L. Mussolin*[3], *A. Piccardo*[4], *A. Cistaro*[5], *P. Zucchetta*[6], *E. Borsatti*[2], *M. Bianchi*[7], *S. Buffardi*[8], *P. Farruggia*[9], *A. Garaventa*[10], *A. Sala*[11], *L. Vinti*[12], *C. Mauz-Koeholz*[13], *M. Mascarin*[2];
[1]*IRCCS - Humanitas Research Hospital, Rozzano MI, ITALY,* [2]*CRO, Aviano, ITALY,* [3]*Pediatric Hemato-Oncology Clinic, Padoa, ITALY,* [4]*Galliera Hospital, Genoa, ITALY,* [5]*Salus Alliance Medical, Genoa, ITALY,* [6]*Padova University Hospital, Padoa, ITALY,* [7]*Regina Margherita Hospital, Turin, ITALY,* [8]*Hospital Santobono-Pausilipon, Naples, ITALY,* [9]*A.R.N.A.S. Ospedali Civico, Palermo, ITALY,* [10]*IRCCS G.Gaslini Hospital, Genoa, ITALY,* [11]*Hospital San Gerardo, Monza, ITALY,* [12]*Ospedale Bambino Gesù, Rome, ITALY,* [13]*Zentrum für Kinderheilkunde der Justus-Liebig-Universität Gießen, Gießen, GERMANY.*

OP-053

Interim TLG and MTV vs Deauville Score as Predictors in Pediatric Non-Hodgkin Lymphoma Patients

G. KAYA[1], *B. Volkan Salancı*[1], *B. Aydın*[2], *P. Özgen Kıratlı*[1];
[1]*Hacettepe University Medical School Department of Nuclear Medicine, Ankara, TÜRKIYE,* [2]*Hacettepe University Medical School Department of Pediatric Oncology, Ankara, TÜRKIYE.*

OP-054

Application value of 18F-FDG PET/MR whole body imaging in children's rhabdomyosarcoma staging

S. Yun;
Hangzhou Universal Imaging diagnostic center, Hangzhou, CHINA

OP-055

Prognostic Value of 18FDG PET/CT Parameters for the Outcome in Pediatric Sarcoma Patients

B. Soydas Turan[1], *B. Volkan-Salancı*[2], *G. B. Aydın*[3], *P. Özgen Kıratlı*[2];
[1]*Etlik City Hospital, Department of Nuclear Medicine, Ankara, TÜRKIYE,* [2]*Hacettepe University Faculty of Medicine, Department of Nuclear Medicine, Ankara, TÜRKIYE,* [3]*Hacettepe University Faculty of Medicine, Department of Pediatric Oncology, Ankara, TÜRKIYE.*

OP-056

Bone marrow involvement detection by FDG PET-CT in newly diagnosed Ewing Sarcomas : comparison to bone marrow aspiration and biopsy, and assessment of visual interpretation criteria with junior doctors

V. Isnardi[1], *A. Guinot*[1], *H. Bahri*[1], *E. Paquet*[1], *M. Fazel*[1], *L. Besson*[2], *M. Brahmi*[1], *N. Corradini*[1], *P. Marec-Berard*[1];
[1]*Lumen Centre Léon Bérard, Lyon, FRANCE,*
[2]*University Hospital, Saint Etienne, FRANCE.*

OP-057

Role of F18 FDG PET/CT inEwing's Sarcoma Family Of Tumours (ESFT)

A. Tiwary Vyas[1], *A. Vyas*[2];
[1]*Janakpuri Superspeciality Hospital, New Delhi, INDIA,*
[2]*Max Superspeciality Hospital Vaishali, New Delhi, INDIA.*

OP-058

Pediatric tumor patients scanned with a long axial field of view scanner - a single center experience of reduced administered doses of [^{18}F]FDG

C. Bregenzer[1], *K. Krieger*[1], *H. Sari*[1,2], *K. Zeimpekis*[1], *N. Gözlügöl*[1], *Â. Cardoso*[1], *Â. Mendes*[1], *A. Rominger*[1], *A. Afshar-Oromieh*[1];
[1]*Department of Nuclear Medicine, Inselspital, University Hospital Bern, University of Bern, Bern, SWITZERLAND,* [2]*Advanced Clinical Imaging Technology, Siemens Healthcare AG, Lausanne, SWITZERLAND.*

OP-059

Sedation-free pediatric ^{18}F-FDG imaging on totalbody PET/CT with the assistance of artificial intelligence

X. Zhou[1], *S. Xue*[2], *Q. Xia*[1], *A. Rominger*[2], *J. Liu*[1], *K. Shi*[2];
[1]*Shanghai Jiaotong University, Shanghai, CHINA,* [2]*Inselspital, Bern University Hospital, University of Bern, Bern, SWITZERLAND.*

209

Sunday, September 10, 2023, 8:00 AM - 9:30 AM
Hall G2

e-Poster Presentations Session 1 - Oncology & Theranostics Committee: Neuroendocrine Tumours and Gynecological Malignancies

EPS-002
SPECT and SPECT/CT Somatostatin Receptor Scintigraphy in the Follow-Up of Neuroendocrine Neoplasms of Appendix
V. Artiko, *J. Petrovic, D. Sobic Saranovic, N. Petrovic;*
Center for Nuclear Medicine, University Clinical Center of Serbia, Faculty of Medicine University of Belgrade, Belgrade, SERBIA.

EPS-003
Total tumour volume in a GEP-NET patient cohort treated with intraarterial Lu-177 DOTATATE PRRT
H. Schmid, *S. Kunte, G. Sheikh, A. Holzgreve, P. Bartenstein, L. Unterrainer, M. Zacherl;*
Departement of Nuclear Medicine University Hospital, LMU Munich, Munich, GERMANY.

EPS-004
Somatostatin receptor antagonist PET/CT imaging provides better staging of lymph node than contrast enhanced CT prior to lymph node dissection in patients with duodenum and pancreatic neuroendocrine tumors
W. Zhu, *B. Yin, X. Wang, M. Liu, Q. Xu, W. Wu, L. Huo;*
Peking Union Medical College Hospital, Beijing, CHINA.

EPS-005
Normalization and 2-bit-quantization of PSMA-PET using the visual miPSMA Score for training an deep learning AI for prostate cancer detection
B. Schemmer;
Uniklinik Bonn, Bonn, GERMANY.

EPS-006
Retrospective Analysis of 666 Gallium-68 Labeled Somatostatin Receptor Antagonist PET/CT Imaging in Over 500 Patients: Experience from a Single Center in China
W. Zhu[1], *M. Liu*[1], *Y. Cheng*[1], *R. Jia*[2], *C. Bai*[1], *L. Huo*[1];
[1]*Peking Union Medical College Hospital, Beijing, CHINA,* [2]*The Fifth Medical Center, General Hospital of PLA, Beijing, CHINA.*

EPS-007
[^{18}F]F-Al-NOTA-Octreotide versus [111In]In-DTPA-Octreotide for neuroendocrine tumours imaging: results of first 10 patients
B. Arruda Matheos de Lima[1], *R. C. M. Felix*[1], *P. B. Pujatti*[1], *D. A. Bulzico*[1], *M. P. Carneiro*[1], *M. A. S. Cardoso*[1], *M. L. Gomes*[1], *T. T. Guimarães*[1], *J. W. E. Silva*[1], *E. R. Oliveira*[1], *C. H. F. Costa*[1], *R. G. Silva*[1], *A. C. Bispo*[2], *D. M. Zouain*[2];
[1]*Brazilian National Cancer Institute, Rio de Janeiro, BRAZIL,* [2]*R2IBF Radiopharmaceuticals, Rio de Janeiro, BRAZIL.*

EPS-008
Quantification of ^{177}Lu-DOTATATE uptake in neuroendocrine tumors using a fast whole-body 360° CZT-SPECT/CT camera for monitoring and prediction of treatment response
C. Boursier[1,2,3], *J. Grangeret*[1], *E. Chevalier*[1], *G. Karcher*[3], *L. Imbert*[1,2,3], *P. Marie*[1,2,3];
[1]*Université de Lorraine, Department of Nuclear Medicine, CHRU Nancy, Vandoeuvre-les-Nancy, FRANCE,* [2]*Université de Lorraine, IADI, INSERM U1254, Nancy, FRANCE,* [3]*Nancyclotep Imaging Platform, Nancy, FRANCE.*

EPS-009
Bone marrow absorbed doses during treatment with [177Lu]Lu-DOTATATE assuming a specific uptake in the red marrow
L. Hagmarker[1], *J. Svensson*[2], *T. Rydén*[1], *M. Van Essen*[3], *A. Sundlöv*[4], *P. Gjertsson*[3], *K. Sjögreen Gleisner*[5], *P. Bernhardt*[1];
[1]*Department of Radiation Physics, Gothenburg, SWEDEN,* [2]*Sahlgrenska Academy, Gothenburg, SWEDEN,* [3]*Department of Clinical Physiology, Gothenburg, SWEDEN,* [4]*Department of Oncology and Pathology, Clinical Sciences, Lund, SWEDEN,* [5]*Department of Radiation Physics, Lund, SWEDEN.*

EPS-010
Inpatient admissions for hormone secretion management in patients with neuroendocrine neoplasms treated with [177Lu]Lu-DOTA-Octreotate therapy over a 3-year period at a single high volume treatment centre
L. Neeson[1], *E. Boehm*[1], *T. Akhurst*[2], *R. Alipour*[1], *A. Cardin*[1], *C. Chiang*[1], *M. Hofman*[1], *M. Lee*[1], *M. Michael*[2], *A. S. Ravi Kumar*[2], *N. Sachithanandan*[1], *J. Saghebi*[1], *H. Wong*[1], *G. Kong*[2];
[1]*Peter MacCallum Cancer Centre, Melbourne, AUSTRALIA,* [2]*Peter MacCallum Cancer Centre and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, AUSTRALIA.*

EPS-011
Impact of volumetric parameters applied to ^{177}Lu-DOTATATE SPECT-CT in the survival of NET patients after PRRT
S. Menendez-Sanchez[1], *V. Betech-Antar*[1], *E. Guillen*[2], *J. Rosales*[1], *L. Garcia-Belaustegui*[2], *A. Bronte*[1], *J. Bastidas*[1], *T. Cuenca*[1], *P. Echegoyen*[1], *A. Chopitea*[1], *E. Prieto*[1], *J. Martí-Climent*[1], *J. Arbizu*[1];
[1]*Clínica Universidad de Navarra, Pamplona, Navarra, SPAIN,* [2]*Clínica Universidad de Navarra, Madrid, SPAIN.*

EPS-012
Metabolic tumor volume response on FDG-PET after [^{131}I]MIBG radiotherapy in patients with metastatic pheochromocytomas and paragangliomas predicts their prognosis
J. Takenaka[1,2], *S. Watanabe*[1,2], *T. Abe*[3], *T. Tsuchikawa*[4], *S. Takeuchi*[5], *K. Hirata*[1,2,6], *R. Kimura*[1,7], *N. Wakabayashi*[1,2], *N. Shinohara*[3], *K. Kudo*[1,6,7];
[1]*Department of Diagnostic Imaging, Graduate School of Medicine, Hokkaido University, Sapporo, JAPAN,* [2]*Department of Nuclear Medicine, Hokkaido University Hospital, Sapporo, JAPAN,* [3]*Department of Renal and Genitourinary surgery, Hokkaido University Graduate School of Medicine, Sapporo, JAPAN,* [4]*Department of Gastroenterological Surgery II, Hokkaido University Graduate School of Medicine, Sapporo, JAPAN,* [5]*Department of Medical Oncology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, JAPAN,* [6]*Division of Medical AI Education and Research, Hokkaido University Graduate School of Medicine, Sapporo, JAPAN,* [7]*Department of Diagnostic and Interventional Radiology, Hokkaido University Hospital, Sapporo, JAPAN.*

EPS-013
Late toxicity after peptide receptor radioligand therapy (PRRT) therapy in neuroendocrine neoplasm.
D. Handkiewicz-Junak, *A. Sygula, A. Ledwon, K. Hassse-Lazar, B. Jurecka-Lubieniecka, E. Paliczka-Cieślik, A. Kropinska, T. Olczyk, T. Gawlik;*
Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice, POLAND.

EPS-014
RadioLigand Therapy: is it time to move towards a different dosimetric approach?
A. Filice[1], *R. Durmo*[1], *F. Fioroni*[2], *E. Grassi*[2], *C. Coruzzi*[1], *G. Besutti*[3], *S. Fanello*[4], *A. Frasoldati*[5], *S. Cavuto*[6], *L. Savoldi*[6], *A. Versari*[1];
[1]*Nuclear Medicine Unit Azienda USL-IRCCS, Reggio Emilia, ITALY,* [2]*Medical Physics Unit Azienda USL-IRCCS, Reggio Emilia, ITALY,* [3]*Radiology Unit, Azienda USL-IRCCS, Reggio Emilia, ITALY,* [4]*Medical Oncology Unit Azienda USL-IRCCS, Reggio Emilia, ITALY,* [5]*Department of Endocrinology and Metabolism Unit Azienda USL-IRCCS, Reggio Emilia, ITALY,* [6]*Clinical Trials and Statitistics Unit Azienda USL-IRCCS, Reggio Emilia, ITALY.*

EPS-015
Value Of Early Metabolic Response For Predicting Axillary Pathological Complete Response During Neoadjuvant Systemic Therapy In Triple-negative And Her2-positive Breast Cancers: Impact Of Molecular Subtypes
L. Guichard, *P. Nunes, C. Jankowski, A. Bertaut, S. Ladoire, E. Michel, C. Coutant, A. Cochet, J. Alberini;*
Centre George Francois Leclerc, Dijon, FRANCE.

EPS-016
Detection of HER2-low lesions using HER2-targeted PET imaging in patients with HER2-negative metastatic breast cancer
R. Yeh[1], *S. K. Lyashchenko*[1], *B. M. Zeglis*[1,2], *J. S. Lewis*[1], *G. A. Ulaner*[3,1];
[1]*Memorial Sloan Kettering Cancer Center, New York, NY, UNITED STATES OF AMERICA,* [2]*Hunter College - City University of New York, New York, NY, UNITED STATES OF AMERICA,* [3]*Hoag Family Cancer Institute, Irvine, CA, UNITED STATES OF AMERICA.*

EPS-017
Clinical utility of [18F]FDG PET/CT in triple-negative breast cancer patients treated with neoadjuvant chemotherapy with or without immunotherapy
R. Seban[1], *E. Arnaud*[2], *D. Loirat*[2], *L. Cabel*[2], *P. Cottu*[2], *L. Djerroudi*[3], *S. Hescot*[1], *P. Loap*[4], *C. Bonneau*[5], *F. Bidard*[6], *V. Huchet*[7], *N. Jehanno*[7], *A. Berenbaum*[1], *L. Champion*[1], *I. Buvat*[8];
[1]*Department of Nuclear Medicine and Endocrine Oncology, Institut Curie, Saint-Cloud, FRANCE,* [2]*Department of Medical Oncology, Institut Curie, Paris, FRANCE,* [3]*Department of Pathology, Institut Curie, Paris, FRANCE,* [4]*Department of Radiation Oncology, Institut Curie, Saint-Cloud, FRANCE,* [5]*Department of Surgery, Institut Curie, Saint-Cloud, FRANCE,* [6]*Department of Medical Oncology, Institut Curie, UVSQ/Paris-Saclay University, Saint-Cloud, FRANCE,* [7]*Department of Nuclear Medicine, Institut Curie, Paris, FRANCE,* [8]*Laboratoire d'Imagerie Translationnelle en Oncologie, Inserm U1288, PSL University, Institut Curie, Orsay, FRANCE.*

EPS-018
Dynamic ^{18}F-FLT PET Radiomics: a Novel and Promising Approach for an Improved Breast Cancer Prognosis Prediction
M. Inglese[1,2], *M. Ferrante*[1], *T. Boccato*[1], *N. Toschi*[1,3];
[1]*University of Rome Tor Vergata, Rome, ITALY,* [2]*Imperial College London, London, UNITED KINGDOM,* [3]*Athinoula A. Martinos Center for Biomedical Imaging, Boston, MA, UNITED STATES OF AMERICA.*

EPS-019
The Influence of Histological Subtypes and Tumour Grade on the Performance of [^{18}F]FDG-PET/CT and [^{18}F]FES-PET/CT in Staging Patients with Estrogen Receptor Positive Breast Cancer
J. J. Knip[1,2], *R. Iqbal*[1,2], *A. van Zweeden*[3], *L. H. Mammatas*[4], *J. J. M. Teunissen*[4], *S. van der Velde*[1], *E. Barbé*[1], *K. M. Duvivier*[1], *D. E. Oprea-Lager*[1], *A. D. Windhorst*[1], *R. Boellaard*[1], *C. W. Menke-van der Houven van Oordt*[1,2];
[1]*Amsterdam UMC, Amsterdam, NETHERLANDS,* [2]*Cancer Center Amsterdam, Amsterdam, NETHERLANDS,* [3]*Ziekenhuis Amstelland, Amstelveen, NETHERLANDS,* [4]*Reinier de Graaf Gasthuis, Delft, NETHERLANDS.*

EPS-020
Utility of 18F-FDG PET-CT in the evaluation of para-aortic lymph nodes in the staging of locally advanced cervical cancer
G. Cuesta Domingo[1], *C. Rodríguez Rey*[1], *A. Ortega Candil*[1], *R. Cano Carrizal*[2], *P. Nespral*[1], *P. Bascuñana*[1], *P. Romero Fernández*[1], *A. Berardinelli Isea*[1], *M. Meneses Navas*[1], *M. Cabrera Martín*[1];
[1]*Department of Nuclear Medicine, Instituto de Investigación Sanitaria San Carlos (IdISSC). Hospital Clínico San Carlos, Universidad Complutense., Madrid, SPAIN,* [2]*Department of Cardiology, Hospital Infanta Sofia, Madrid, SPAIN.*

EPS-021
Surgical evidence-based comparison of ^{68}Ga-FAPI PET/MRI and DW-MRI for assisting debulking surgery decision in ovarian cancer
X. Li[1], *F. Kang*[1], *S. Liu*[2], *T. Han*[3], *J. Wang*[1];
[1]*Department of Nuclear Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, CHINA,* [2]*Department of Gynaecology and Obstetrics, Xijing Hospital, Fourth Military Medical University, Xi'an, CHINA,* [3]*Department of Nuclear Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, CHINA.*

210

Sunday, September 10, 2023, 08:00 - 09:30
Hall K

CTE 1 - Technologists Committee / SNMMI: Technologists' Guide launch – Gastro Intestinal Molecular Imaging Studies Launch

OP-060
Introduction
A. Pietrzak;
Greater Poland Cancer Centre, Nuclear Medicine Department, Poznan, POLAND.

OP-061
Hepatobiliary and spleen studies
D. Gilmore;
Massachusetts College of Pharmacy and Health Sciences, Boston, UNITED STATES OF AMERICA.

OP-062
Scintigraphy of gastroesophageal reflux, pulmonary aspiration and gastric emptying in children
Z. Bar-Sever;
Schneider Children's Medical Center Israel, Department of Nuclear Medicine, Petah Tikva, ISRAEL.

OP-063
Oncological studies (SPECT & PET)
R. Massa;
The Christie NHS Foundation Trust, Nuclear Medicine Department, Manchester, UNITED KINGDOM.

301

Sunday, September 10, 2023, 09:45 - 11:15
Hall A

CME 2 - Translational Molecular Imaging & Therapy + Oncology & Theranostics + Radiopharmaceutical Sciences Committee: FAP - Moving Towards Therapy

OP-064
FAP Inhibitors and Substrates
J. Milul;
Postdoctoral Scientist at Universitätsspital Basel, University Hospital Basel, University of Basel, Basel, SWITZERLAND.

OP-065
Dosimetric Aspects in FAP Radioligand Therapies
W. Fendler;
Department of Nuclear Medicine, West German Cancer Center (WTZ), University Hospital Essen, University of Duisburg-Essen, Essen, GERMANY.

OP-066
RLT Using Cancer-Associated Fibroblasts as Target in Solid Tumors: First Clinical Experiences
C. Nanni;
*NuclearMedicine,
IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY.*

OP-067
Theranostic FAP Inhibitors: From Monomers for Diagnosis to Dimers for Therapy?
F. Rösch;
Department of Chemistry-TRIGA, Institute of Nuclear Chemistry, Johannes Gutenberg University, Mainz, GERMANY.

302

Sunday, September 10, 2023, 09:45 - 11:15
Hall D (Arena)

Challenge the Expert 1 - Thyroid Committee: Integrated Diagnostics of Thyroid Disease

OP-068
Integrated Diagnostics of Thyroid Disease
*D. Deandreis; Nuclear Medicine, Universita degli Studi di Torino,
Turin, ITALY*

303

Sunday, September 10, 2023, 09:45 - 11:15
Hall E1

LIPS Session 2 - Radiation Protection Committee / EFOMP: Careers in Radiation Protection

OP-072
The current status of the medical physicist profession in Europe
E. Amato;
Universityof Messina, Department of Biomedical Sciences, Messina, ITALY.

OP-073
Requirements for the medical physicist training in Europe.
D. Visvikis;
National Institute of Health and Medical Research (INSERM), Medical Imaging Processing Lab, Paris, FRANCE.

OP-074
Building and maintaining competence in radiation protection of nuclear medicine professionals
J. Vassileva ;
International Atomic Energy Agency, Radiation Protection of Patients Unit, Vienna, AUSTRIA.

304

Sunday, September 10, 2023, 9:45 AM - 11:15 AM
Hall E2

M2M Track - TROP Session: Validating Methodology: In Vitro and in Vivo Models

OP-076
Role and Impact of Anaesthetic Procedures for Preclinical Radiotracer Development Using Small Animal Positron Emission Tomography-Computed Tomography Imaging
T. Ebenhan[1,2], *C. H. S. Driver*[1,3], *C. Swanepoel*[1], *J. Visser*[1];
[1]*Preclinical Imaging Facility, Nuclear Medicine Reseach Infrastructure NPC, Pretoria, SOUTH AFRICA,* [2]*Nuclear Medicine, University of Pretoria, Pretoria, SOUTH AFRICA,* [3]*Radiochemistry, Necsa, Pelindaba, SOUTH AFRICA.*

OP-077
Feasibility of in vivo small animal imaging using a clinical total-body PET/CT scanner
J. Mannheim[1,2], *W. Lan*[3], *M. A. Krueger*[1], *C. la Fougère*[2,3], *F. P. Schmidt*[1,3];
[1]*Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, Eberhard-Karls University Tuebingen, Tuebingen, GERMANY,* [2]*Cluster of Excellence iFIT (EXC 2180) "Image Guided and Functionally Instructed Tumor Therapies", University of Tuebingen, Tuebingen, GERMANY,* [3]*Department of Nuclear Medicine and Clinical Molecular Imaging, University hospital Tuebingen, Tuebingen, GERMANY.*

OP-078
Is multiple-mouse PET/MR imaging possible in preclinical oncology?
A. Courteau[1,2], *A. Oudot*[2], *R. Garipov*[3], *P. Doughty*[3], *J. McGrath*[3], *A. Cochet*[1,2,4], *F. Brunotte*[1], *J. M. Vrigneaud*[1,2];
[1]*ICMUB laboratory, UMR CNRS 6302, University of Burgundy, Dijon, FRANCE,* [2]*Georges-François Leclerc Cancer Centre, Unicancer, Dijon, FRANCE,* [3]*MR Solutions Ltd, Guildford, UNITED KINGDOM,* [4]*CHU François Mitterrand, Dijon, FRANCE.*

OP-079
In situ tumour response PET imaging without radiopharmaceuticals in particle therapy: a feasibility study in rats
C. Toramatsu, *A. Mohammadi, N. Nitta, C. Seki, Y. Ikoma, I. Kanno, T. Yamaya;
National Institutes for Quantum Science and Technology (QST),
Chiba, JAPAN.*

OP-080
Demonstrating the Quantitative Potential of Terbium-161 SPECT/CT Imaging: An Anthropomorphic Phantom Study
F. Westerbergh[1], *N. P. van der Meulen*[2,3], *C. Müller*[3], *A. Grings*[4], *P. Ritt*[4], *P. Bernhardt*[1,5];
[1]*Department of Medical Radiation Sciences, Institute of Clinical Sciences, University of Gothenburg, Gothenburg, SWEDEN,* [2]*Laboratory of Radiochemistry, Paul Scherrer Institute, Villigen-PSI, SWITZERLAND,* [3]*Center for Radiopharmaceutical Sciences, Paul Scherrer Institute, Villigen-PSI, SWITZERLAND,* [4]*Clinic of Nuclear Medicine, University Hospital Erlangen, Erlangen, GERMANY,* [5]*Department of Medical Physics and Biomedical Engineering (MFT), Sahlgrenska University Hospital, Gothenburg, SWEDEN.*

OP-081
RadioFACS reveals [^{18}F]FDG uptake in a KRAS induced lung cancer model is driven by immune cells but not tumor cell metabolism
C. Vraka[1], *M. Homolya*[2], *T. Patsch*[1], *A. Spittler*[3], *E. Casanova*[2], *S. Grünert*[1], *M. Hacker*[1], *C. Philippe*[1];
[1]*Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, AUSTRIA,* [2]*Institute of Pharmacology, Center of Physiology and Pharmacology, Medical University of Vienna, Vienna, AUSTRIA,* [3]*Core Facility Flow Cytometry and Department of Surgery, Research Laboratories, Medical University of Vienna, Vienna, AUSTRIA.*

OP-082
Impact of inoculation-driven immune response on TSPO and amino acid PET imaging in experimental orthotopic glioblastoma
L. Gold[1], *E. Barci*[2], *M. Brendel*[1], *M. Orth*[3], *J. Cheng*[2], *S. V. Kirchleitner*[4], *L. M. Bartos*[1], *L. M. Unterrainer*[1], *L. Kaiser*[1], *S. Ziegler*[1], *L. Weidner*[5], *M. J. Riemenschneider*[5], *M. Unterrainer*[1], *C. Belka*[3], *J. Tonn*[4], *P. Bartenstein*[1], *M. Niyazi*[3], *L. von Baumgarten*[4], *R. Kälin*[2], *R. Glass*[2], *N. L. Albert*[1], *A. Holzgreve*[1];
[1]*Department of Nuclear Medicine, University Hospital, LMU Munich, Munich, GERMANY,* [2]*Neurosurgical Research, Department of Neurosurgery, University Hospital, LMU Munich, Munich, GERMANY,* [3]*Department of Radiation Oncology, University Hospital, LMU Munich, Munich, GERMANY,* [4]*Department of Neurosurgery, University Hospital, LMU Munich, Munich, GERMANY,* [5]*Department of Neuropathology, Regensburg University Hospital, Regensburg, GERMANY.*

OP-083
From 2D to 3D: Developing an improved in vitro model for radiopharmaceutical evaluation
L. van den Brink, *M. J. Klomp, S. Erkens-Schulze, W. M. van Weerden, S. U. Dalm;
Erasmus Medisch Centrum, Rotterdam, NETHERLANDS.*

OP-084
Theranostic Digital Blueprint Predicts Higher Therapeutic Efficacy using Radiopharmaceuticals with Higher Albumin Affinity
A. Fele Paranj[1], *C. Uribe*[1], *F. Benard*[2], *A. Rahmim*[1], *B. Saboury*[3];
[1]*University of British Columbia, Vancouver, BC, CANADA,* [2]*BC Cancer, Vancouver, BC, CANADA,* [3]*National Institutes of Health (NIH), Bethesda, MD, UNITED STATES OF AMERICA.*

305

Sunday, September 10, 2023, 9:45 AM - 11:15 AM
Hall B

Cutting Edge Science Track - Featured Session: Radiomics

OP-085
State of the Art and Perspectives
M. Hatt;
INSERM, Brest, FRANCE.

OP-086
Prognostic value of [^{18}F]FDG PET radiomics to detect peritoneal and distant metastases in locally advanced gastric cancer - a side-study of the prospective multicentre PLASTIC study
W. A. Noortman[1], *L. C. E. Pullen*[2], *L. Triemstra*[3], *C. de Jongh*[3], *F. J. Rademaker*[2], *R. Spijkerman*[2], *G. M. Kalisvaart*[1], *E. C. Gertsen*[3], *L. F. de Geus-Oei*[1], *N. Tolboom*[3], *W. O. de Steur*[1], *M. Dantuma*[2], *R. H. J. A. Slart*[4], *R. van Hillegersberg*[3], *P. D. Siersema*[5], *J. P. Ruurda*[3], *F. H. P. van Velden*[1], *E. Vegt*[6], *PLASTIC Study Group;*
[1]*Leiden University Medical Center, Leiden, NETHERLANDS,* [2]*University of Twente, Enschede, NETHERLANDS,* [3]*University Medical Center Utrecht, Utrecht, NETHERLANDS,* [4]*University Medical Center Groningen, Groningen, NETHERLANDS,* [5]*Radboud University Medical Center, Nijmegen, NETHERLANDS,* [6]*Erasmus University Medical Center, Rotterdam, NETHERLANDS.*

OP-087
Feasibility and reproducibility of radiomic features in real world whole-body [18F]FDG PET/CT oncology studies
C. S. Constantino, *M. Silva, F. P. M. Oliveira, D. C. Costa; Champalimaud Clinical Centre, Champalimaud Foundation, Lisbon, PORTUGAL.*

OP-088
Explainable machine learning model to diagnose giant cell arteritis based on texture features in aortic [18F]FDG-PET images
H. Vries[1,2], *G. van Praagh*[1], *P. Nienhuis*[1], *L. Alic*[2], *R. Slart*[1,2]; *[1]University Medical Centre Groningen, Groningen, NETHERLANDS, [2]University of Twente, Enschede, NETHERLANDS.*

OP-089
PET-CT Radiomics of Lung Cancer with Local Nodes; Dissemination Features are Linked to Survival
K. Albattat, *C. Marshall, R. Smith, N. Morley; Cardiff University, Cardiff, UNITED KINGDOM.*

OP-090
The Effect of Feature Selection Methods on Prognostic Analysis of 18F-FDG PET Radiomics in Lymphoma
L. Yong[1], *X. Wong*[1], *Y. Chen*[2,3], *S. Liu*[1,3], *H. Lin*[4,5], *K. Lue*[1]; *[1]Tzu Chi University of Science and Technology, Hualien, TAIWAN, [2]Tzu Chi University, Hualien, TAIWAN, [3]Hualien Tzu Chi Hospital, Hualien, TAIWAN, [4]Chang Gung University, Taoyuan, TAIWAN, [5]Keelung Chang Gung Memorial Hospital, Keelung, TAIWAN.*

OP-091
Exploring Correlations between PSA Levels and PSMA-PET Images in Recurrent Prostate Cancer using Machine Learning, Tensor Radiomics and Deep Features Analysis
A. Toosi[1], *S. Harsini*[2], *H. Abdollahi*[1], *F. Bénard*[2,3], *C. F. Uribe*[2,3], *A. Rahmim*[1,4,3]; *[1]Department of Integrative Oncology, BC Cancer Research Institute, Vancouver, BC, CANADA, [2]BC Cancer, Vancouver, BC, CANADA, [3]Department of Radiology, University of British Columbia, Vancouver, BC, CANADA, [4]Department of Physics and Astronomy, University of British Columbia, Vancouver, BC, CANADA.*

OP-092
Improving Outcome Prediction in Multicentric Data: Novel Harmonization Techniques and MCA-Based Imputation for Radiomic Feature Analysis
N. Abdallah[1], *J. Marion*[2], *C. Tauber*[1], *T. Carlier*[3], *P. Chauvet*[2], *M. Hatt*[4]; *[1]Imaging & Brain, INSERM, Tours, FRANCE, [2]LARIS, Angers, FRANCE, [3]CRCINA, INSERM, CNRS, Université d'Angers, Université de Nantes, Nantes, FRANCE, [4]LaTIM, INSERM, Brest, FRANCE.*

OP-093
DEBI-NN: Distance-Encoding Biomorphic-Informational Neural Networks in PET Radiomics
B. Ecsedi, *D. Haberl, C. P. Spielvogel, T. Traub-Weidinger, M. Hacker, L. Papp; Medical University of Vienna, Vienna, AUSTRIA.*

306

Sunday, September 10, 2023, 9:45 AM - 11:15 AM
Hall C

Clinical Oncology Track - Featured Session: Haematological Disease

OP-094
Haematological Disease

OP-095
Significance of 11C-acetate PET/CT for the prediction of complete remission post induction therapy in newly diagnosed multiple myeloma: a prospective study
S. Chen, *Y. Wong, K. Wu, J. C. Chim, C. Ho; Hong Kong Sanatorium & Hospital, Hong Kong, HONG KONG.*

OP-096
A prospective comparison of 68Ga-Pentixafor PET/CT and 18F-FDG PET/CT for the detection of intramedullary and extramedullary lesions in multiple myeloma
S. Tang, *Y. Wang, Y. Tian, C. Li, Z. Xiao, J. Chen, Y. He; Department of nuclear medicine, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, CHINA.*

OP-097
Assessment of the Diagnostic and Staging Potential of 68Ga-Pentixafor PET/CT in Multiple Myeloma - A Comparison With 18F-FDG PET/CT
L. Aridhasan Meenakshi, *V. Rajaraman, B. Dubashi, D. Halanaik; Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, INDIA.*

OP-098
Prognostic value of FDG PET/CT biomarkers in patients withrecurrent/refractary MM treated with CAR-T Cells
V. Betech-Antar, *F. Minguez, L. Tamariz, A. Bronte, M. Romera, J. Rosales, J. Bastidas, S. Menendez-Sanchez, M. Panizo, S. Huerga, J. San-Miguel, P. Rodriguez-Otero, M. García-Velloso; Clínica Universidad de Navarra, Pamplona, SPAIN.*

OP-099
Multicenter development of a PET-based risk assessment tool for product-specific outcome prediction in large B-cell lymphoma patients undergoing CAR T-cell therapy
C. Voltin[1], *S. Flossdorf*[2], *A. Paccagnella*[3], *M. Winkelmann*[4], *J. Heger*[1], *B. Casadei*[3], *L. Beckmann*[1], *K. Herrmann*[2], *N. Kutsch*[1], *P. Borchmann*[1], *S. Fanti*[3], *W. G. Kunz*[4], *M. Subklewe*[4], *C. Kobe*[1], *P. L. Zinzani*[3], *M. Stelljes*[5], *K. S. Roth*[1], *A. Drzezga*[1], *R. Noppeney*[2], *H. C. Reinhardt*[2], *B. von Tresckow*[2], *R. Seifert*[2,5], *J. C. Albring*[5], *V. Blumenberg*[4], *A. Farolfi*[3], *P. Gödel*[1], *C. Hanoun*[2]; *[1]University of Cologne, Cologne, GERMANY, [2]University of Duisburg-Essen, Essen, GERMANY, [3]University of Bologna, Bologna, ITALY, [4]Ludwig Maximilian University of Munich, Munich, GERMANY, [5]University of Münster, Münster, GERMANY.*

OP-100
Performance of PET/CT using [18F]Fludarabine for initial staging and therapeutic evaluation of symptomatic multiple myeloma (MM) patients in first line treatment or first relapse : preliminary results of an exploratory multicenter phase 2 study
C. François[1], *M. Santiago-Ribeiro*[2,3], *B. Jamet*[4], *S. Guillouet*[5], *C. Perrio*[5], *A. Abbas*[6], *F. Gourand*[5], *S. Querellou*[7,8], *T. Chalopin*[9], *C. Dubegny*[4], *C. Touzeau*[10,11], *N. Blin*[10,11], *F. Kraeber-Bodéré*[4,11], *C. Bodet-Milin*[4,11]; *[1]Nuclear Medicine department, Lille University Hospital, Lille, FRANCE, [2]Nuclear Medicine department, Tours University Hospital, Tours, FRANCE, [3]UMR 1253, iBrain, Université de Tours, Inserm, Tours, FRANCE, [4]Nuclear Medicine department, Nantes University Hospital, Nantes, FRANCE, [5]Normandie Univ, UNICAEN, CEA, CNRS, UAR 3408 Cyceron, Bd Henri Becquerel, 14000, Caen, FRANCE, [6]Normandie univ, UNICAEN, PSL Université Paris, EPHE, INSERM, U1077, CHU de Caen, GIP Cyceron, Neuropsychologie et Imagerie de la Mémoire Humaine, 14000, Caen, FRANCE, [7]Nuclear Medicine department, Brest University Hospital, Brest, FRANCE, [8]GETBO UMR U_1304, Inserm, UBO, Brest, FRANCE, [9]Hematology department, Tours University Hospital, Tours, FRANCE, [10]Hematology department, Nantes University Hospital, Nantes, FRANCE, [11]Nantes Université, Angers Université, INSERM, CNRS, CRCI2NA, Nantes, FRANCE.*

OP-101
Patterns of PET positive residual tissue at early interim staging and risk of treatment failure in advanced-stage Hodgkin's Lymphoma: an analysis of the randomized phase III HD18 trial by the German Hodgkin Study Group
J. Ferdinandus[1], *L. van Heek*[1], *K. S. Roth*[1], *M. Dietlein*[1], *H. Eich*[2], *C. Baues*[1], *P. Borchmann*[1], *C. Kobe*[1], *German Hodgkin Study Group; [1]University Hospital Cologne, Cologne, GERMANY, [2]University Hospital Münster, Münster, GERMANY.*

OP-102
Combining Baseline and End of Treatment Quantitative PET Parameters to Improve Progression-Free Survival Prediction in DLBCL
G. Zwezerijnen[1], *A. L. Bes*[2], *M. W. Heymans*[3], *U. Dührsen*[4], *J. Eertink*[2], *S. Wiegers*[1], *P. Lugtenburg*[5], *A. Hüttmann*[4], *L. Kurch*[6], *C. Hanoun*[4], *N. Mikhaeel*[7], *L. Ceriani*[8], *E. Zucca*[9], *S. Czibor*[10], *T. Györke*[10], *M. Chamuleau*[2], *S. Fanti*[11], *S. Lee*[12], *J. Zijlstra*[2], *S. Barrington*[13], *R. Boellaard*[1]; *[1]Amsterdam UMC, Vrije Universiteit Amsterdam, department of Radiology and Nuclear Medicine, Cancer Center Amsterdam, Amsterdam, NETHERLANDS, [2]Amsterdam UMC, Vrije Universiteit Amsterdam, department of Hematology, Cancer Center Amsterdam, Amsterdam, NETHERLANDS, [3]Amsterdam UMC, Vrije Universiteit Amsterdam, department of Epidemiology and Data Science, Amsterdam Public Health research institute, Amsterdam, NETHERLANDS, [4]Department of Hematology, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, GERMANY, [5]Erasmus MC Cancer Institute, University Medical Center Rotterdam, department of Hematology, Rotterdam, Rotterdam, NETHERLANDS, [6]Klinik und Poliklinik für Nuklearmedizin, Universitätsklinikum Leipzig, Leipzig, GERMANY, [7]Department of Clinical Oncology, Guy's Cancer Centre and School of Cancer and Pharmaceutical Sciences, King's College London University, London, UNITED KINGDOM, [8]Department of Nuclear Medicine and PET/CT Centre, IIMSI - Imaging Institute of Southern Switzerland, Bellinzona, Università della Svizzera Italiana, Bellinzona Switzerland; SAKK - Swiss Group for Clinical Cancer Research, Bern, SWITZERLAND, [9]Department of Oncology, IOSI - Oncology Institute of Southern Switzerland, Bellinzona; Università della Svizzera Italiana, Bellinzona, Switzerland; SAKK - Swiss Group for Clinical Cancer Research, Bern, SWITZERLAND, [10]Department of Nuclear Medicine, Medical Imaging Centre, Semmelweis University, Budapest, HUNGARY, [11]Nuclear Medicine department, Sant'Orsola-Malpighi Hospital, Bologna, ITALY, [12]Department of Molecular Imaging and Therapy, Austin Health, Melbourne, AUSTRALIA, [13]King's College London and Guy's and St Thomas' PET Centre, School of Biomedical Engineering and Imaging Sciences, King's Health Partners, Kings College London, London, UNITED KINGDOM.*

307

Sunday, September 10, 2023, 9:45 AM - 11:15 AM
Hall F1

Neuroimaging Committee - TROP Session: Amyloid, Tau and More in Neurodegenerative Disorders Tau

OP-103
Quantification of baseline amyloid load in individuals with subjective cognitive decline can identify future risk of amyloid accumulation
G. Kolinger[1], *M. Marquié*[2,3], *O. Sotolongo-Grau*[2], *N. Roé-Vellvé*[1], *E. Pérez-Martínez*[1], *N. Koglin*[1], *A. Stephens*[1], *J. Tartari*[2], *Á. Sanabria*[2,3], *A. García-Sánchez*[2], *L. Tárraga*[2,3], *A. Ruiz*[2,3], *S. Bullich*[1], *M. Boada*[2,3]; *[1]Life Molecular Imaging GmbH, Berlin, GERMANY, [2]Ace Alzheimer Center Barcelona – Universitat Internacional de Catalunya, Barcelona, SPAIN, [3]Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos III, Madrid, SPAIN.*

OP-104
Association of plasma glial fibrillary acidic protein with neurofibrillary tau tangles in the brain and cognitive decline independent of amyloid-B
D. Peretti[1], *F. Ribaldi*[1,2], *C. Boccalini*[1,3,4], *M. Marizzoni*[5], *N. Ashton*[6,7,8], *H. Zetterberg*[6,9,10], *K. Blennow*[6], *G. Frisoni*[1,2], *V. Garibotto*[1,2]; *[1]University of Geneva, Geneva, SWITZERLAND, [2]Geneva University Hospitals, Geneva, SWITZERLAND, [3]Vita-Salute San Raffaele University, Milan, ITALY, [4]IRCCS San Raffaele Scientific Institute, Milan, ITALY, [5]IRCCS Istituto Centro Sand Giovanni di Dio Fatebenefratelli, Brescia, ITALY, [6]The SahIgrenska Academy at the University of Gothenburg, MoIndal, SWEDEN, [7]Maurice Wohl Clinical Neuroscience Institute, London, UNITED KINGDOM, [8]NIHR Biomedical Research Centre for Mental Health & Biomedical Research Unit for Dementia at South London & Maudsley NHS Foundation, London, UNITED KINGDOM, [9]University College London, London, UNITED KINGDOM, [10]Hong Kong Center for Neurodegenerative Diseases, Hong Kong, CHINA.*

OP-105
The functional long-distance relationship of amyloid and tau pathology
M. Hoenig[1], *A. Weller*[2], *E. Doering*[3], *G. Bischof*[4], *A. Drzezga*[4], *T. van Eimeren*[4]; *[1]Research Center Juelich, Juelich, GERMANY, [2]University of Cologne, Cologne, GERMANY, [3]German Center for Neurodegenerative Diseases, Bonn, GERMANY, [4]University Clinic Cologne, Cologne, GERMANY.*

OP-106

Validation of a topographic visual assessment method for ^{18}F-Flortaucipir based on Subtype and Stage Inference Model (SuStaIn)

G. Mathoux[1,2], *C. Boccalini*[3,4], *A. Arnone*[3], *D. E. Peretti*[3], *M. Scheffler*[5], *G. B. Frisoni*[6,7], *V. Garibotto*[2,3,8];
[1]*Università degli Studi di Milano-Bicocca, Monza, ITALY,* [2]*Division of Nuclear Medicine and Molecular Imaging, Geneva University Hospitals, Geneva, SWITZERLAND,* [3]*Laboratory of Neuroimaging and Innovative Molecular Tracers (NIMTlab), Geneva University Neurocenter and Faculty of Medicine, University of Geneva, Geneva, SWITZERLAND,* [4]*Università Vita e Salute San Raffaele, Milano, ITALY,* [5]*Division of Radiology, Geneva University Hospitals, Geneva, SWITZERLAND,* [6]*Memory Clinic, Department of Rehabilitation and Geriatrics, Geneva University and University Hospitals, Geneva, SWITZERLAND,* [7]*Laboratory of Neuroimaging of Aging (LANVIE), University of Geneva, Geneva, SWITZERLAND,* [8]*CIBM Center for Biomedical Imaging, Geneva, SWITZERLAND.*

OP-107

A Biological Staging Scheme for Alzheimer's disease: Results from the Tau Propagation over Time (T-POT) Cohort

E. Doering[1], *M. Hönig*[2], *V. Dzialas*[1], *J. Lothmann*[1], *K. Giehl*[2], *H. Theis*[3], *E. Jäger*[1], *G. Andrassy*[1], *A. Bauer*[2], *D. Elmenhorst*[2], *T. Kroll*[2], *A. Matusch*[2], *P. Krapf*[4], *B. Neumaier*[4], *C. Lerche*[5], *L. Tellmann*[5], *S. Frensch*[2], *P. Zeyen*[6], *F. Sand*[6], *N. Richter*[6], *F. Jessen*[6], *Ö. Onur*[3], *A. Ramirez*[6], *T. van Eimeren*[3], *A. Drzezga*[1], *G. Bischof*[1];
[1]*University of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Nuclear Medicine, Cologne, GERMANY,* [2]*Research Center Jülich, Institute of Neuroscience and Medicine - Molecular Organization of the Brain (INM-2), Juelich, GERMANY,* [3]*University of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Neurology, Cologne, GERMANY,* [4]*Research Center Jülich, Institute of Neuroscience and Medicine - Nuclear Chemistry (INM-5), Juelich, GERMANY,* [5]*Research Center Jülich, Institute of Neuroscience and Medicine - Medical Imaging Physics (INM-4), Juelich, GERMANY,* [6]*University of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Psychiatry, Cologne, GERMANY.*

OP-108

[^{18}F]PI-2620 PET Imaging of 3R Pick Tau in Frontotemporal Lobar Degeneration - A Multi-Centre Study

H. Barthel[1], *M. Brendel*[2], *V. Villemagne*[3], *K. Marek*[4], *T. van Eimeren*[5], *M. Rullmann*[1], *M. Schroeter*[1], *D. Saur*[1], *M. Patt*[1], *J. Classen*[1], *J. Seibyl*[4], *A. Drzezga*[5], *O. Sabri*[1], *German Imaging Initiative for Tauopathies;*
[1]*Leipzig University Medical Centre, Leipzig, Germany, GERMANY,* [2]*Ludwig Maximillian University Munich, Munich, GERMANY,* [3]*University of Pittsburgh, Pittsburgh, AL, UNITED STATES OF AMERICA,* [4]*InviCRO, Boston, MA, UNITED STATES OF AMERICA,* [5]*University of Cologne, Cologne, GERMANY.*

OP-109

Tau-PET signal in Alzheimer's disease is related to immune activation and synaptic signaling measured with CSF proteomics

E. Van de Giessen, *R. M. Rikken, E. Vromen, E. M. Coomans, D. Visser, F. Barkhof, L. E. Collij, R. Boellaard, S. V. S. Golla, B. N. M. van Berckel, R. Ossenkoppele, A. den Braber, J. Vijverberg, W. M. van der Flier, Y. A. L. Pijnenburg, C. E. Teunissen, P. J. Visser, B. Tijms;*
Amsterdam UMC, Amsterdam, NETHERLANDS.

OP-110

Regional Desynchronization of Microglial Activity is Associated with Cognitive Decline in Alzheimer's Disease

A. Zatcepin[1,2], *J. Gnörich*[1,2], *B. Rauchmann*[3], *L. M. Bartos*[1], *N. Franzmeier*[4,5,6], *M. Malpetti*[7], *X. Xiang*[8,9], *Y. Shi*[2], *S. Parhizkar*[10], *M. Grosch*[11], *K. Wind-Mark*[1,2], *S. T. Kunte*[1], *L. Beyer*[1], *G. Biechele*[1], *A. Finze*[1], *F. Eckenweber*[1], *P. Bartenstein*[1], *S. Tahirovic*[2], *M. Simons*[2,4,6], *C. Haass*[2,8,6], *R. Rupprecht*[12], *N. L. Albert*[1,13,14], *G. U. Höglinger*[2,15,16], *S. I. Zielger*[1], *M. Brendel*[1,2,6];
[1]*Department of Nuclear Medicine, University Hospital, LMU Munich, Munich, GERMANY,* [2]*German Center for Neurodegenerative Diseases (DZNE), Munich, GERMANY,* [3]*Department of Radiology, University Hospital, LMU Munich, Munich, GERMANY,* [4]*Institute for Stroke and Dementia Research, University Hospital, LMU Munich, Munich, GERMANY,* [5]*Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, SWEDEN,* [6]*Munich Cluster for Systems Neurology (SyNergy), Munich, GERMANY,* [7]*Department of Clinical Neurosciences, Cambridge University Hospitals NHS Trust, University of Cambridge, Cambridge, UNITED KINGDOM,* [8]*Biomedical Center (BMC), Division of Metabolic Biochemistry, Faculty of Medicine, LMU Munich, Munich, GERMANY,* [9]*CAS Key Laboratory of Brain Connectome and Manipulation, the Brain Cognition and Brain Disease Institute, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen-Hong Kong Institute of Brain Science-Shenzhen Fundam. Res. Inst., Shenzhen, CHINA,* [10]*Department of Neurology, Washington University in St. Louis, St. Louis, MO, UNITED STATES OF AMERICA,* [11]*German Center for Vertigo and Balance Disorders, University Hospital of Munich, LMU Munich, Munich, GERMANY,* [12]*Department of Psychiatry and Psychotherapy, Molecular Neurosciences, University of Regensburg, Regensburg, GERMANY,* [13]*German Cancer Consortium (DKTK), Partner Site Munich, German Cancer Research Center (DKFZ), Heidelberg, GERMANY,* [14]*Bavarian Cancer Research Center (BZKF), Erlangen, GERMANY,* [15]*Department of Neurology, University Hospital, LMU Munich, Munich, GERMANY,* [16]*Department of Neurology, Hannover Medical School, Hannover, GERMANY.*

OP-111

PET-based synaptic density measure, its amyloid-independent association with APOE e4 in cognitively impaired individuals

K. He[1], *F. Xie*[1], *Y. Huang*[2], *K. Chen*[3], *Y. Guan*[1], *B. Li*[4], *J. Wang*[5], *Q. Huang*[5];
[1]*Department of Nuclear Medicine & PET Center, Huashan Hospital, Fudan University, Shanghai, CHINA,* [2]*PET Center, Department of Radiology and Biomedical Imaging, Yale University School of Medicine, New Haven, New Haven, CT, UNITED STATES OF AMERICA,* [3]*Banner Alzheimer Institute, Arizona State University, University of Arizona and Arizona Alzheimer's Consortium, Phoenix, AZ, UNITED STATES OF AMERICA,* [4]*Clinical Neuroscience Center, Ruijin Hospital,Shanghai Jiao Tong University School of Medicine, Shanghai, CHINA,* [5]*Department of Nuclear Medicine & PET Center, Huashan Hospital, Fudan University, Shanghai, CHINA.*

308

Sunday, September 10, 2023, 09:45 - 11:15
Hall F2

Joint Symposium 1 - Cardiovascular + Inflammation & Infection Committee / EACVI: PET in Valvular Diseases - All In!

OP-112

Endocarditis

P. Erba;
Department of Nuclear Medicine, Ospedale Papa Giovanni XXIII, Bergamo, ITALY.

OP-113

Calcification

J. Kwiecinski;
Department of interventional cardiology and angiology, Institute of Cardiology, Warsaw, POLAND.

OP-114

Myocardial Inflammation and Fibrosis

F. Bengel;
Department of Nuclear Medicine, Hannover Medical School, Hannover, GERMANY.

309

Sunday, September 10, 2023, 9:45 AM - 11:15 AM
Hall G2

e-Poster Presentations Session 2 - Paediatrics Committee: Paediatric Nuclear Medicine & Adults General Nuclear Medicine

EPS-022

Gravity-Assisted Diuresis Renography with method F+10(sp) for clinical management and post-operative assessment of primary megaureter.

G. Tartaglione[1], *F. P. Ieria*[1], *N. Foschi*[2];
[1]*Cristo Re Hospital, Nuclear Medicine, Rome, ITALY,* [2]*Urology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, ITALY.*

EPS-023

Evaluation of the use of [^{99m}Tc]Tc-MAG3 in the quantification of effective renal plasmatic flow in patients with autosomal dominant renal polycystosis. Preliminary data

L. Baz-Sanz, *R. Maestre-Cutillas, G. Rubio-Fernández, M. Álvarez-Nadal, L. Cebollada-Cameo, R. Castro-Velasco, C. Juan-Piriz, J. Pérez-Iruela;*
Hospital Ramón y Cajal, Madrid, SPAIN.

EPS-024

Comparison Between In Vivo Gates Method and In Vitro Plasma Sampling Technique for Glomerular Filtration Rate Measurement in Voluntary Kidney Donors

M. Radulovic, *M. Sisic, B. Miljuš, L. Radosavcev, B. Ajdinovic;*
Institute of Nuclear Medicine, Military Medical Academy, Belgrade, SERBIA.

EPS-025

Glomerular filtration rate quantification in patients on antiretroviral therapy. Preliminary data

L. Baz-Sanz, *R. Maestre-Cutillas, G. Rubio-Fernández, V. Lopes-Martin, L. Cebollada-Cameo, M. Vaquero-Palomo, S. Horcas-Villaverde, J. Pérez-Iruela;*
Hospital Ramón y Cajal, Madrid, SPAIN.

EPS-026

Body surface area as a determining factor in assessing glomerular filtration rate

G. Rubio-Fernández, *R. Maestre-Cutillas, L. Baz-Sanz, L. Cebollada-Cameo, V. Lopes-Martín, M. Vaquero-Palomo, S. Horcas-Villaverde, J. Pérez-Iruela;*
Hospital Ramón y Cajal, Madrid, SPAIN.

EPS-027

Estimation of GFR Using Camera Based Method- Is There Any Role of CT?

S. Garg[1], *S. G. Ravindra*[1], *A. Khurana*[1], *K. J. Das*[2], *A. Singhal*[2], *V. Jaiswal*[2], *C. S. Bal*[1];
[1]*All India Institute of Medical Sciences, New Delhi, INDIA,* [2]*National Cancer Institute - AIIMS, Jhajjar, INDIA.*

EPS-028

Predictive role of ^{18}F-FDG PET/CT in renal function in patients with kidney disease

H. Jiao, *Y. Qiu, Z. Chen, Y. Fan, L. Kang;*
Peking University First Hospital Beijing, CHINA.

EPS-029

Clinical Significance of SPECT/CT Imaging in Dynamic Renal Scintigraphy for Work-up of Patients with Different Nephro-urological Conditions

T. Sofiyanski[1], *S. Sergieva*[1], *M. Dimcheva*[1], *B. Robev*[2];
[1]*Sofia Cancer Center, Sofia, BULGARIA,* [2]*University Hospital St. Ivan Rilski, Sofia, BULGARIA.*

EPS-030

Added value of SPECT/CT to Planar Lymphoscintigraphy in Patients with Secondary Extremity Lymphedema: A Retrospective Cohort Study

H. Yoon[1], *D. Kim*[2], *K. Woo*[3], *B. Kim*[1], *J. Kim*[4];
[1]*Department of Nuclear Medicine, Ewha Womans University School of Medicine, Seoul, KOREA, REPUBLIC OF,* [2]*Department of Emergency Medicine, Incheon St. Mary's Hospital, The Catholic University of Korea, Incheon, KOREA, REPUBLIC OF,* [3]*Department of Plastic Surgery, Ewha Womans University School of Medicine, Seoul, KOREA, REPUBLIC OF,* [4]*Department of Nuclear Medicine Ewha Womans University Mokdong Hospital, Seoul, KOREA, REPUBLIC OF.*

EPS-031

Analysis and clinical response to bile acid sequestrants of patients with diarrhoea and borderline ^{75}SeHCAT results

S. Bondia-Bescós, *P. Notta, M. Pudis, B. Hervás-Sanz, J. Díaz-Moreno, A. Rodriguez-Gasen, A. Palomar-Muñoz, J. Robles-Barba, M. Cortés-Romera;*
Nuclear Medicine-PET (IDI) Department, Bellvitge University Hospital, Barcelona, SPAIN.

EPS-032
Ukrainian experience of interictal FDG PET/CT brain scan for pharmacoresistant epilepsy in children as a part of a presurgical assessment
O. Oliinichenko[1], *M. Tkachenko*[2];
[1]*Kyiv Center of Nuclear Medicine, Kyiv, UKRAINE,*
[2]*Bogomolets National Medical University, Kyiv, UKRAINE.*

EPS-033
Age variations in the normal physiological distribution of 18F-FDG
J. Hagerman[1], *D. Minarik*[2], *E. Trädgårdh*[1], *J. Oddstig*[2];
[1]*Clinical Physiology and Nuclear Medicine, Skåne University Hospital, Lund/Malmö, SWEDEN,* [2]*Radiation Physics, Skåne University Hospital, Lund/Malmö, SWEDEN.*

EPS-034
The impact of the COVID-19 pandemic on oncological disease extent in children at FDG PET/MR staging
Y. Xu;
Hangzhou Universal Medical Imaging Diagnostic Center, Hangzhou, CHINA.

EPS-035
^{18}F-FDG PET/MR Imaging findings of pediatric neuroblastoma with different MYCN amplification status
J. Liang;
杭州通用医学影像诊断中心,杭州, *CHINA.*

EPS-036
Value of qPET in Pediatric Patients With Hodgkin Lymphoma
M. Mehesen[1,2], *E. Moussa*[3,2], *M. S. Zaghloul*[1,2], *M. Elwakeel*[1,2], *W. Elsayed*[1,2], *N. Ali*[1,2];
[1]*National Cancer Institute., Cairo, EGYPT,*
[2]*Children's Cancer Hospital Egypt, Cairo, EGYPT,*
[3]*Menoufya University, Menoufya, EGYPT.*

EPS-037
Role of semi-quantitative assessment of ^{123}I-MIBG uptake in pediatric neuroblastoma.Does semiquantitative evaluation of uptake improve the diagnostic accuracy of^{123}I-MIBG scintigraphy in pediatric neuroblastoma ?
C. Altini[1], *M. Villani*[1], *M. Pizzoferro*[1], *A. Castellano*[2], *A. Serra*[2], *M. De Ioris*[2], *D. Ciucci*[3], *C. Polito*[3], *E. Solfaroli Camillocci*[3], *V. Cannatà*[3], *E. Villanucci*[1], *V. Nicoloso*[1], *G. Marchetti*[1], *M. Garganese*[1];
[1]*IRCCS Bambino Gesù Children's Hospital, Nuclear Medicine Unit, Imaging Department, Rome, ITALY,*
[2]*IRCCS Bambino Gesù Children's Hospital, Department of Oncohematology, Rome, ITALY,* [3]*IRCCS Bambino Gesù Children's Hospital, Medical Physics Unit, Rome, ITALY.*

EPS-038
Dynamic Renal Scintigraphy In Pediatric Hydronephrosis: Imapct In Therapeutic Decision
L. Zaabar[1,2], *M. ElOuni*[3], *T. Ben Ghachem*[1,2], *D. Ben Sellem*[1,2], *B. Letaief*[1,2], *A. Mhiri*[1,2];
[1]*Salah Azaeiz Institute, Tunis, TUNISIA,* [2]*Faculté de Médecine de Tunis, Tunis, TUNISIA,* [3]*Health Ministery, Tunis, TUNISIA.*

EPS-039
Predicting the clinical outcome of antenatally detected unilateral pelvi-ureteric junction obstuction.
R. Belakroum;
Central Military Hospital, Algiers, ALGERIA.

EPS-040
A Classic Never Goes Out of Style: Fusion Kidney Malformations, a 10 Years Retrospective Analysis
I. Grierosu[1,2], *R. Tibu*[2], *I. Starcea*[1,3], *A. Mocanu*[3], *R. Bogos*[3], *T. Lazaruc*[3], *R. Stamate*[2], *L. Rau*[2], *D. Raileanu*[2], *V. Cernov*[2], *A. Iacoban*[1], *W. Jalloul*[1], *T. Ionescu*[1], *C. Stolniceanu*[1], *A. Statescu*[2], *C. Stefanescu*[1,2];
[1]*UMF, Iasi, ROMANIA,* [2]*County Emergency Hospital „Sf. Spiridon", Iasi, ROMANIA,* [3]*Emergency Children Hospital „Sf. Maria", Iasi, ROMANIA.*

EPS-041
Risk of renal damage in children with VUR grade III according to ^{99m}Tc-DMSA scan grading
D. Chroustova[1], *J. Trnka*[1], *J. Langer*[1], *I. Urbanova*[2], *L. Cerna*[1], *R. Kocvara*[1];
[1]*Charles University, 1st Faculty of Medicine and General University Hospital, Prague, CZECH REPUBLIC,* [2]*University Hospital Bulovka, Prague, CZECH REPUBLIC.*

310

Sunday, September 10, 2023, 09:45 - 11:15
Hall K

CTE 2 - Technologists Committee: Head and Neck Updates

OP-116
Head and Neck molecular imaging – state of the art
W. Cholewiński;
Greater Poland Cancer Centre/Poznan University of Medical Sciences, Nuclear Medicine/ Electroradiology Department, Poznan, POLAND.

OP-117
Head and Neck cancer patient management using the PET-MRI method
M. Kinggaard Federspiel;
Rigshospitalet, Copenhagen, DENMARK.

OP-118
New radiopharmaceuticals for Head and Neck tumours evaluation and therapy
G. Gorgoni;
IRCCS Sacro Cuore, Department of Radiopharmacy, Negrar di Valpolicella Verona, ITALY.

401

Sunday, September 10, 2023, 11:30 - 13:00
Hall A

Plenary 2: New Imaging Techniques - Jump Aboard or Watch and Wait

OP-119
Introduction by Chairpersons

OP-120
AI technology: living up to expectations?
F. Buffa;
Bocconi University, Department of Computing Sciences, Milan, ITALY.

OP-121
SPECT/CT CZT based systems: jump aboard
L. Imbert;
CHRU Nancy, Nancy, FRANCE.

OP-122
SPECT/CT CZT based systems: watch and wait?
J. Dickson;
UniversityCollege London Hospitals, Institute of Nuclear Medicine, London, UNITED KINGDOM.

OP-123
Total Body PET: watch and wait?
A. Dimitrakopoulou-Strauss;
German Cancer Research Center, Heidelberg, GERMANY.

OP-124
Total Body PET: jump aboard
A. Rominger;
Universityof Bern, Inselspital, Dept. of Nuclear Medicine, Bern, SWITZERLAND.

OP-125
PET/MR: is it still worth it?
S. Wan;
UniversityCollege London Hospitals, Institute of Nuclear Medicine, London, UNITED KINGDOM.

OP-126
Innovation and sustainability in Nuclear Medicine: the IAEA perspective
May Abdel-Wahab;
IAEA, Vienna, AUSTRIA

501

Sunday, September 10, 2023, 15:00 - 16:30
Hall A

CME 3 - Cardiovascular Committee: Nuclear Imaging in Cardiac Amyloidosis - What Else?

OP-127
Background and novel therapies
M. Papathanasiou;
UniversityHospital Essen, University Duisburg-Essen, West German Heart- and Vascular Center, Department of Cardiology and Vascular Medicine, Essen, GERMANY.

OP-128
Bone scan – all you need to know
O. Lairez;
Cardiology Department, Rangueil University Hospital, Toulouse, FRANCE.

OP-129
PET – do we really need it?
D. Genovesi;
Fondazione Toscana Gabriele Monasterio, Division of Nuclear Medicine, Pisa, ITALY.

OP-130
Nuclear imaging for therapy response
H. Tingen;
UniversityMedical Center G, Groningen, NETHERLANDS.

502

Sunday, September 10, 2023, 15:00 - 16:30
Hall D (Arena)

Challenge the Expert 2 - Oncology & Theranostics Committee: Risk in Diagnostic and Therapeutic Nuclear Medicine

OP-131
Radiation risks in Nuclear Medicine: informed consent and effective communication
S. Leide Svegborn;
Skåne University Hospital, Department of Radiation Physics, Malmö, SWEDEN.

OP-132
Challenger cases
R. Teixeira Ferreira;
Hospital Garcia de Orta, E.P.E., Department of Nuclear Medicine, Almada, PORTUGAL.

OP-133a
Challenger cases
J. Castro Ferro;
Department of Nuclear Medicine, Instituto Português de Oncologia do Porto Francisco Gentil, E.P.E, Porto, PORTUGAL.

OP-133b
Challenger cases
B. Ribeiro Pereira;
Department of Nuclear Medicine, Centro Hospitalar Universitário de São João, E.P.E, Porto, PORTUGAL.

OP-133c
Challenger cases
M. Monteiro;
Department of Nuclear Medicine, Centro Hospitalar e Universitário de Coimbra, E.P.E, Coimbra, PORTUGAL.

503

Sunday, September 10, 2023, 15:00 - 16:30
Hall E1

LIPS Session 3 - Thyroid Committee: Rational Use of PET/CT with 18F-FDG in DTC

OP-134
Adding FDG-PET to the diagnostic work-up of indeterminate thyroid nodules: expensive gadget or cost-effective?
L. de Geus-Oei;
Leiden University Medical Center (LUMC), Department of Radiology, Leiden, NETHERLANDS.

OP-135
18F-FDG in staging DTC: when and why
S. Kusacic Kuna;
Clinical Department of Nuclear Medicine and Radiation Protection, University Hospital Centre, Zagreb, CROATIA

OP-136
Role of 18F-FDG in restaging DTC and as a tool for response evaluation
M. Tuncel;
Department of Nuclear Medicine, Hacettepe University, Ankara, TÜRKIYE.

504
Sunday, September 10, 2023, 3:00 PM - 4:30 PM
Hall E2

M2M Track - TROP Session: Radioligand Therapy - New and Old Targets

OP-137
Preclinical Characterization of a Novel EphA2-Targeted Peptide Radioligand for Treatment of Solid Tumors
G. Li[1], *R. Clift*[1], *S. Richardson*[1], *T. Ehara*[2], *H. Yanagida*[2], *I. Hung*[1], *Z. Amso*[1], *K. Salvador*[1], *M. Guest*[1], *G. Han*[1], *A. Bhat*[1], *D. Cole*[1], *E. Bischoff*[1];
[1]RayzeBio, San Diego, CA, UNITED STATES OF AMERICA, [2]PeptiDream, Kawasaki-Shi, JAPAN.

OP-138
Preclinical Characterization of a Novel Peptide Binder to Glypican-3 for Targeted Radiopharmaceutical Therapy of Hepatocellular Carcinoma
G. Li[1], *F. Lin*[1], *R. Clift*[1], *T. Ehara*[2], *H. Yanagida*[2], *S. Horton*[1], *K. Salvador*[1], *S. Richardson*[1], *M. Guest*[1], *A. Noncovich*[1], *A. Bhat*[1], *G. Han*[1];
[1]RayzeBio, San Diego, CA, UNITED STATES OF AMERICA, [2]PeptiDream, Kawasaki, JAPAN.

OP-139
A Novel Anti-L1CAM Antibody-Radionuclide-Conjugate (ARC) as New Treatment Option for Ovarian Cancer
C. Geraths[1], *M. Behe*[2], *D. Winkler*[1], *M. Hackebeil*[1], *A. Blanc*[2], *T. Chiorazzo*[2], *S. Imobersteg*[2], *R. van der Kant*[3,4], *J. Schymkowitz*[3,4], *F. Rousseau*[3,4];
[1]CIS Pharma AG, Bubendorf, SWITZERLAND, [2]Paul-Scherrer-Institut, Villigen, SWITZERLAND, [3]Switch Laboratory - VIB KU Leuven Center for Brain and Disease Research, Leuven, BELGIUM, [4]KU Leuven - Department of Cellular and Molecular Medicine, Leuven, BELGIUM.

OP-140
In vitro evaluation of [^{225}Ac]Ac-DOTA-C595 for pancreatic ductal adenocarcinoma
A. Hull[1], *W. Hsieh*[2], *W. Tieu*[3], *A. Borysenko*[4], *D. Bartholomeusz*[2], *E. Bezak*[1];
[1]University of South Australia, Adelaide, AUSTRALIA, [2]SA Medical Imaging, Adelaide, AUSTRALIA, [3]The University of Adelaide, Adelaide, AUSTRALIA, [4]Environment Protection Authority, Adelaide, AUSTRALIA.

OP-141
Preclinical Comparison of the GRPR Antagonists AMTG and RM2 Labelled With Terbium-161 and Lutetium-177 - A PRISMAP Project
T. Günther[1], *N. Holzleitner*[1], *T. Cwojdzinski*[1], *R. Beck*[1], *N. Urtz-Urban*[1], *C. C. Hillhouse*[2], *P. V. Grundler*[2], *N. P. van der Meulen*[2], *Z. Talip*[2], *S. Ramaekers*[3], *M. Van de Voorde*[3], *B. Ponsard*[3], *A. Casini*[1];
[1]Technical University of Munich, Garching, GERMANY, [2]Paul Scherrer Institute, Villingen, SWITZERLAND, [3]Belgian Nuclear Research Centre, Mol, BELGIUM.

OP-142
Preclinical Evaluation of a ^{68}Ga/^{177}Lu-based CXCR4 Radioligand: A Theranostic Tool Against Advanced Prostate Cancer
I. Astiazaran-Rascon[1,2], *H. Kuo*[1], *H. Merkens*[1], *N. Colpo*[1], *P. Ng*[1], *C. Ong*[2,3], *Y. Wang*[1,2,3], *K. Lin*[1,2], *F. Bénard*[1,2];
[1]BC Cancer, Vancouver, BC, CANADA, [2]University of British Columbia, Vancouver, BC, CANADA, [3]Vancouver Prostate Center, Vancouver, BC, CANADA.

OP-143
Albumin Binder-modified Radiolabeled Heterodimer Probe for Cancer Imaging and Therapy
B. Yang, *Y. Gai, X. Song, X. Lv, Y. Long, Y. Wang, Y. Feng, R. An, X. Lan;*
Dept of Nuclear Medicine and PET center,Union Hospital, Tongji Medical College,HUST, Wuhan, CHINA.

OP-144
Preclinical Evaluation of [^{212}Pb]VMT-α-NET Targeted Alpha Therapy for High-Risk Metastatic Neuroblastoma
D. Liu[1], *J. T. Ewald*[1], *Z. Dai*[2], *C. Robels-Plannels*[3], *B. S. Cagle*[1], *S. N. Rodman III*[1], *M. Li*[1], *R. Rastogi*[2], *E. Sagastume*[1], *F. L. Johnson*[1], *D. Zepeda-Orozco*[3], *M. K. Schultz*[1,2];
[1]Perspective Therapeutics Inc, Coralville, IA, UNITED STATES OF AMERICA, [2]University of Iowa, Iowa City, IA, UNITED STATES OF AMERICA, [3]Nationwide Children's Hospital, Columbus, OH, UNITED STATES OF AMERICA.

OP-145
Preclinical Evaluation of ^{225}Ac-rhPSMA-10.1, a Novel Radiohybrid PSMA Compound for Targeted Alpha Therapy of Prostate Cancer
V. Vassileva[1], *B. Waldron*[1], *A. Wurzer*[2], *C. D'Alessandria*[2], *R. Veggerby Grønlund*[3], *M. Wikke Hallund*[3], *D. Gauden*[1], *D. Stevens*[1], ***C. Foxton***[1];
[1]Blue Earth Therapeutics, Oxford, UNITED KINGDOM, [2]Department of Nuclear Medicine, Technical University of Munich, Munich, GERMANY, [3]Minerva Imaging, Ølstykke, DENMARK.

505
Sunday, September 10, 2023, 3:00 PM - 4:30 PM
Hall B

Cutting Edge Science Track - TROP Session: From Cells to Human via the Fish

OP-146
Radiosensitivity of neuroendocrine cancer cells to ^{177}Lu-DOTATATE and radiobiological implications for peptide radionuclide therapy
G. Tamborino[1,2], *P. Engbers*[2,1], *T. de Wolf*[2,1], *T. Reuvers*[2,1], *M. Konijnenberg*[1], *J. Nonnekens*[2,1];
[1]Department of Radiology and Nuclear Medicine, Erasmus University Medical Center, Rotterdam, NETHERLANDS, [2]Department of Molecular Genetics, Erasmus University Medical Center, Rotterdam, NETHERLANDS.

OP-147
Stochastic microscale dosimetry in breast cancer micrometastasis model for alpha-emitter radiopharmaceutical therapy
R. Bastiaannet, *M. Hasan, I. Liatsou, R. F. Hobbs, G. Sgouros;*
Johns Hopkins University School of Medicine, Baltimore, MD, UNITED STATES OF AMERICA.

OP-148
Nephron Morphology Influences the Dosimetry of Microscopic Renal Tissues of Non-Uniform Activity Distributions of Alpha Particle and Low Energy Electron Emitters
M. Andersson[1,2], *N. Goudin*[3], *M. Pontoglio*[4], *H. Levillain*[2], *N. Reynaert*[2], *C. Saldarriaga Vargas*[1];
[1]Belgian Nuclear Research Centre (SCK CEN), Mol, BELGIUM, [2]Faculté de Médecine, Université Libre de Bruxelles (ULB), Brussels, BELGIUM, [3]Necker Bioimage Analysis platform SFR Necker US24/UAR 3633, Paris, FRANCE, [4]Institut National de la Santé et de la Recherche Médicale, Centre National de la Recherche Scientifique, Université de Paris, Paris, FRANCE.

OP-149
Small-scale anatomical modeling of the salivary gland for alpha-particle and beta-article radiopharmaceutical therapy
R. Hobbs, *I. Marsh, R. Bastiaannet, I. Liatsou, C. Brayton, K. Gabrielson, T. Yusufaly;*
Johns Hopkins, Baltimore, MD, UNITED STATES OF AMERICA.

OP-150
Zebrafish embryos as experimental model to advance pre-clinical research in nuclear medicine
C. Morgat[1,2], *G. Siefried*[3,4], *S. Bodin*[1,2], *F. Cavelier*[5], *E. Hindié*[1,2,6], *M. Khatib*[3];
[1]Nuclear Medicine Department - University Hospital of Bordeaux, Bordeaux, FRANCE, [2]INCIA, University of Bordeaux, CNRS, EPHE, UMR 5287, Bordeaux, FRANCE, [3]RyTME, Bordeaux Institute of Oncology (BRIC)-UMR1312 Inserm, Pessac, FRANCE, [4]Xenofish, Pessac, FRANCE, [5]Institut des Biomolécules Max Mousseron IBMM, UMR 5247 Pôle Chimie Balard, Montpellier, FRANCE, [6]Institut Universitaire de France, Paris, FRANCE.

OP-151
Biodistribution and dosimetry of lipiodol with various beta emitters: a preclinical study
A. Dieudonne[1], *R. Santus*[2], *P. Vera*[1], *S. Becker*[1], *X. Violas*[2];
[1]LITIS-Quantif, Centre Henri Becquerel, Rouen, Rouen, FRANCE, [2]Research and Development Division, Laboratoire Guerbet, Aulnay-sous-Bois, FRANCE.

OP-152
DNA damage repair in PBMCs after internal ex vivo irradiation with ^{177}Lu
I. Strobel[1], *H. Scherthan*[2], *J. Hahn*[1], *J. Müller*[2], *S. Schumann*[1], *A. K. Buck*[1], *M. Port*[2], *M. Lassmann*[1], *U. Eberlein*[1];
[1]Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, GERMANY, [2]Bundeswehr Institute of Radiobiology affiliated to the University of Ulm, Munich, GERMANY.

OP-153
From bench to bedside: ^{64}Cu/^{177}Lu 1C1m-Fc anti TEM-1: mice-to-human dosimetry extrapolations for future theranostic applications
J. Delage[1], *N. Chouin*[2], *M. Cherel*[3], *S. M. Dunn*[4], *N. Schaefer*[5], *A. Faivre-Chauvet*[3], *J. O. Prior*[5], *S. Gnesin*[6];
[1]Radiopharmacy Unit, Department of Pharmacy, Lausanne University Hospital and University of Lausanne, Lausanne, SWITZERLAND, [2]University of Nantes, Inserm, CNRS, University of Angers, Oniris, CRCI2NA, Nantes, FRANCE, [3]University of Nantes, CHU Nantes, CNRS, Inserm, CRCINA, Nantes, FRANCE, [4]LAbCore, Ludwig Institute for Cancer Research, Lausanne University Hospital and University of Lausanne, Epalinges, SWITZERLAND, [5]Department of Nuclear Medicine and Molecular Imaging, Lausanne University Hospital and University of Lausanne, Lausanne, SWITZERLAND, [6]Institute of Radiation Physics, Lausanne University Hospital and University of Lausanne, Lausanne, SWITZERLAND.

OP-154
Simulations of the relative effectiveness of tumor stroma and cancer cell targeting radiopharmaceuticals
Y. Song[1,2], *J. Brosch-Lenz*[1], *C. D'Alessandria*[1], *K. Shi*[3], *W. Weber*[1];
[1]Department of Nuclear Medicine, Klinikum rechts der Isar, Technische Universität München, Munich, GERMANY, [2]Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, CHINA, [3]Department of Nuclear Medicine, Inselspital, University of Bern, Bern, SWITZERLAND.

506
Sunday, September 10, 2023, 3:00 PM - 4:30 PM
Hall C

Clinical Oncology Track - TROP Session: Gastrointestinal Malignancies

OP-155

Evaluation of [64Cu]Cu-ATSM PET-CT as a response predictor to neoadjuvant therapy in locally advanced rectal cancer: preliminary results

M. Le Thiec[1], *L. Ferrer*[1,2], *M. Colombié*[1], *M. Lacombe*[3], *A. Devillers*[4], *P. Salaün*[5,6], *S. Hiret*[1], *J. Raimbourg*[1], *L. Doucet*[1], *E. Rio*[1], *S. Lesourd*[4], *P. Tremolières*[3], *M. Heymann*[1,7], *N. Varmenot*[1,2], *A. Vidal*[8,9,10], *F. Haddad*[8,9,10], *N. Allam*[1], *M. Chérel*[1,2], *F. Kraeber-Bodéré*[11,2], *L. Campion*[1], *M. Bourgeois*[11,2,8], *C. Rousseau*[1,2];
[1]*ICO Gauducheau, Saint Herblain, FRANCE,* [2]*Nantes Université, Univ Angers, INSERM, CNRS, CRCI2NA, Nantes, FRANCE,* [3]*ICO Papin, Angers, FRANCE,* [4]*Cancer Institute Eugène Marquis, Rennes, FRANCE,* [5]*University Hospital, Brest, FRANCE,* [6]*UMR Inserm 1304 GETBO, University Western Brittany, Brest, FRANCE,* [7]*Research pathology platform, Tumor Heterogeneity and Precision Medicine, Saint-Herblain, FRANCE,* [8]*Arronax, Saint-Herblain, FRANCE,* [9]*SUBATECH, IMT Atlantique, CNRS/IN2P3, Nantes, FRANCE,* [10]*Université de Nantes, Nantes, FRANCE,* [11]*CHU Nantes, Nantes, FRANCE.*

OP-156

The effect of free thyroxine on glucose metabolic activity in primary hepatic neoplasm: A study of PET-CT scans

Z. Zhao[1], *X. Wang*[2], *J. Xiao*[1], *D. Wang*[1], *Z. Luo*[1];
[1]*Affiliated Hospital of Guangdong Medical University, Zhanjiang, CHINA,* [2]*Children's Hospital Affiliated to Zhengzhou University, Zhengzhou, CHINA.*

OP-157

Assesment of biological parameters of esophageal cancer in pre-, and post-treatment 18F-FDG-PET/CT in patient with early relapse.

A. Filipczuk[1], *A. Lewandowska*[1], *A. Pietrzak*[1], *W. Cholewiński*[2];
[1]*Greater Poland Cancer Center, Poznan, POLAND,* [2]*Medical University of Poznan, Poznan, POLAND.*

OP-158

Comparison of ^{18}F-FDG PET/CT and ^{18}F-FDG PET/MRI in Detection of Liver Lesions in Hepatocellular Carcinoma for Staging and Restaging

B. Demir[1], *C. Soydal*[1], *E. Dursun*[1], *M. Araz*[1], *D. Kuru Oz*[2], *N. O. Kucuk*[1];
[1]*Ankara University School of Medicine Department of Nuclear Medicine, Ankara, TÜRKIYE,* [2]*Ankara University School of Medicine Department of Radiology, Ankara, TÜRKIYE.*

OP-159

A proposed first-line treatment regime for Lenvitinib or Nivolumab based on dual-tracer PET/CT may improve progression free survival for advanced stage HCC patients

S. Chen, *S. Cheung, K. Cheng, Y. Yip, W. Leung, C. Ho;*
Hong Kong Sanatorium & Hospital, Hong Kong, HONG KONG.

OP-160

18F-Fluorodeoxyglucose (FDG) and 18F-Fluorocholine (FCH) Positron Emission Tomography (PET) as Early Predictive Factorsof Overall Survival in Patients With Advanced Hepatocellular Carcinoma Treated WithSorafenib: a prospectivemulticentricstudy

V. BESSON[1], *C. Tabouret-Viaud*[1], *A. Fouquier*[2], *J. Bronowicki*[3], *E. Chevalier*[4], *A. Heurgue*[5], *D. Papathanassiou*[6], *J. Blanc*[7], *J. Pinaquy*[8], *L. Bengrine*[9], *X. Palard*[10], *H. Bourien*[11], *A. Bertaut*[2], *S. Manfredi*[12], *A. Cochet*[13];
[1]*Department of Nuclear Medicine, Centre Georges François Leclerc, Dijon, FRANCE,* [2]*Department of Statistics, Centre Georges-François Leclerc, Dijon, FRANCE,* [3]*Department of Gastro-Enterology and Hepatology, University Hospital of Nancy, Nancy, FRANCE,* [4]*Department of Nuclear Medicine, University Hospital of Nancy, Nancy, FRANCE,* [5]*Department of Hepato-Gastro-Enterology, University Hospital of Reims, Reims, FRANCE,* [6]*Department of Nuclear Medicine, Institut Jean Godinot, Reims, FRANCE,* [7]*Department of Hepato-Gastro-Enterology, University Hospital of Bordeaux, Bordeaux, FRANCE,* [8]*Department of Nuclear Medicine, University Hospital of Bordeaux, Bordeaux, FRANCE,* [9]*Department of Medical Oncology, Centre Georges-François Leclerc, Dijon, FRANCE,* [10]*Department of Nuclear Medicine, Centre Eugene-Marquis, Rennes, FRANCE,* [11]*Department of Medical Oncology, Centre Eugene-Marquis, Rennes, FRANCE,* [12]*Department of Hepato-Gastro-Enterology, Dijon, FRANCE,* [13]*ICMUB, UMR CNRS 6302, University of Burgundy, Dijon, FRANCE.*

OP-161

Assessing the performance of ^{68}Ga-Fibroblast activating protein inhibitor-04 (FAPI) PET/CT in the diagnosis of cholangiocarcinoma - A prospective pilot study.

D. Halanaik, *V. Rajaraman, L. Aridhasan Meenakshi, A. Jeba Selvaraj, B. Pottakkat;*
Jawaharlal Institute of postgraduate medical education and Research, Puducherry, INDIA.

OP-162

Static and Dynamic^{68}Ga-FAPI PET/CT in Mass Forming Pancreatitis and Pancreatic Ductal Adenocarcinomas (PDAC)

M. Preussig[1], *M. Lang*[2], *C. Schroeter*[1], *E. Gutjahr*[3], *U. Haberkorn*[1], *M. Röhrich*[1];
[1]*Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, GERMANY,* [2]*Department of General, Visceral, and Transplantation Surgery, University Hospital Heidelberg, Heidelberg, GERMANY,* [3]*Department of Pathology, University Hospital Heidelberg, Heidelberg, GERMANY.*

OP-163

The Role of [^{68}Ga]Ga-DOTA-FAPI-04 PET/CT on Detecting Lesions and Altering Stage in Patients With Digestive System Malignencies With Non-FDG-avid Lesions

G. Beydagi[1], *N. Alan-Selcuk*[1], *K. Akcay*[1], *E. Demirci*[1], *O. Sonmez*[2], *M. Ocak*[3], *T. Toklu*[1], *S. Celik*[4], *B. B. Oven*[4], *L. Kabasakal*[1,5];
[1]*Yeditepe University, Department of Nuclear Medicine, Istanbul, TÜRKIYE,* [2]*Yeditepe University, Faculty of Medicine, Istanbul, TÜRKIYE,* [3]*Istanbul University, Faculty of Pharmacy, Department of Pharmaceutical Technology, Istanbul, TÜRKIYE,* [4]*Yeditepe University, Department of Medical Oncology, Istanbul, TÜRKIYE,* [5]*Istanbul Unıversity-Cerrahpasa, Department of Nuclear Medicine, Istanbul, TÜRKIYE.*

507

Sunday, September 10, 2023, 3:00 PM - 4:30 PM
Hall F1

Paediatrics Committee - TROP Session: Adults General Nuclear Medicine

OP-164

The value of chemokine receptor type 4 targeted PET imaging in primary aldosteronism preoperative localization diagnosis compared with adrenal venous sampling

N. Lu[1], *C. Li*[1], *Y. Tian*[1], *Z. Xiao*[1], *D. Xing*[1], *J. Zhong*[1], *W. Li*[1], *D. Zeng*[1], *W. Luo*[1], *H. Guo*[1], *Z. Meng*[2], *Y. He*[1];
[1]*Department of Nuclear Medicine, Zhongnan Hospital of Wuhan University, Wuhan, CHINA,* [2]*Department of Urology, Zhongnan Hospital of Wuhan University, Wuhan, CHINA.*

OP-165

Incidental Findings on ^{18}F-Fluorocholine PET for Parathyroid Imaging

A. Namazova[1], *A. NAZARI*[1], *B. Ince*[2], *S. Sağer*[1], *K. Sonmezoğlu*[1];
[1]*Istanbul University-Cerrahpaşa, Department of Nuclear Medicine, Istanbul, TÜRKIYE,* [2]*Istanbul University-Cerrahpaşa, Department of Nucleer Medicine, Istanbul, TÜRKIYE.*

OP-166

Correlation between kidney ^{18}F-FDG uptake and renal function in patients with chronic kidney disease.

F. Dondi[1], *A. Talin*[2], *D. Albano*[2], *A. Calabrò*[2], *M. T. Volpe*[2], *P. Furtuna*[2], *F. Bertagna*[2];
[1]*Spedali Civili di Brescia, Brescia, ITALY,* [2]*Università degli Studi di Brescia, Brescia, ITALY.*

OP-167

Renal blood flow quantification for the evaluation of stress induced kidney imaging using Rubidium-82 PET/CT

A. van de Burgt[1,2], *F. H. P. van velden*[2], *F. Smit*[1,2], *L. F. de Geus-Oei*[2,3,4], *I. A. Dekkers*[2];
[1]*Alrijne hospital, Leiderdorp, NETHERLANDS,* [2]*Leiden University Medical Center, Leiden, NETHERLANDS,* [3]*University of Twente, Enschede, NETHERLANDS,* [4]*Delft University of Technology, Delft, NETHERLANDS.*

OP-168

Segmentation and Volumetric Analysis of Pulmonary Reperfusion after Pulmonary Thromboembolism using Lung Perfusion SPECT/CT

N. Alvarez Mena, *F. Sebastián Palacid, M. García Aragón, R. Zambrano Infantino, A. Hurtado Romero, R. Ruano Pérez;*
Hospital Clínico Universitario de Valladolid, Valladolid, SPAIN.

OP-169

Could FAPI and MIBI scans help in diagnostic dilemmas in interstitial lung disease (ILD) for distinguishing fibroinflammatory process? Ongoing translational exploratory study

M. Assadi[1], *M. Bahtouee*[2], *E. Jafari*[1], *R. Mazarei*[2], *M. Khazaei*[3];
[1]*Department of Nuclear Medicine, Molecular Imaging, and Theranostics, Bushehr Medical University Hospital, School of Medicine, Bushehr University of Medical Sciences, Bushehr, IRAN, ISLAMIC REPUBLIC OF,* [2]*Department of Internal Medicine (Division of Pulmonary Medicine), Bushehr Medical Center Hospital, Bushehr University of Medical Sciences, Bushehr, IRAN, ISLAMIC REPUBLIC OF,* [3]*Department of Radiology, Bushehr Medical Center Hospital, Bushehr University of Medical Sciences, Bushehr, IRAN, ISLAMIC REPUBLIC OF.*

OP-170

The Role Of [^{99m}Tc] Sodium Pertechnetate Pulmonary Ventilation Single Photon Emission Computed Tomography/Computed Tomography (Spect/Ct) In The Early Location Of Prolonged Pulmonary Air Lack In Adults. Our Experience.

A. Peñaherrera Cepeda, *F. Gómez Caminero, J. Villanueva Curto, J. Badell Martínez, E. Campaña Díaz, P. García Talavera, E. Martín Gómez, S. Rama Alonso, M. Fuentes Gago., P. Tamayo Alonso;*
Complejo asistencial universitario de Salamanca, Salamanca, SPAIN.

OP-171

Oropharyngoesophageal scintigraphy (OPES) in Systemic Sclerosis Patients: A Valuable Tool for Evaluating Dysphagia

A. Marciano[1], *M. Di Battista*[2], *M. Scarpuzza*[1], *A. Ambrogio*[1], *G. Nonne*[1], *A. Leo*[1], *E. Esposito*[1], *A. Valevich*[2], *M. Grosso*[1], *D. Volterrani*[1];
[1]*Nuclear Medicine, Department of Translational Research and New Technology in Medicine, University of Pisa, Pisa, ITALY,* [2]*Rheumatology Unit, University of Pisa, Pisa, ITALY.*

OP-172

Correlation Between Lymphoscintigraphy And Clinical Staging In Diagnosis Of Lymphedema

A. Kilicaslan, *B. Okudan Tekin;*
Ankara City Hospital, Ankara, TÜRKIYE.

508

Sunday, September 10, 2023, 15:00 - 16:30
Hall F2

Joint Symposium 2 - Oncology & Theranostics Committtee / EORTC: Nuclear Medicine Imaging of the Immune System

OP-173

Molecular Imaging of the Immune System

W. Cai;
Universityof Wisconsin, Molecular Imaging and Nanotechnology Laboratory, Madison, UNITED STATES OF AMERICA.

OP-174
Radiolabeled Markers of Immune Response
S. Heskamp;
Radboud University Medical Center, Department of Medical Imaging (Nuclear Medicine), Nijmegen, NETHERLANDS.

OP-175
Imaging Tumor Metabolism and its Heterogeneity
E. Lopci;
IRCCS–Humanitas Research Hospital, Nuclear Medicine, Milan, ITALY.

OP-176
Translating Immuno-PET for immune-oncology treatments into the Clinic
E. G. E. de Vries;
UniversityMedical Centre Groningen, Department of Medical Oncology, Groningen, NETHERLANDS.

509

Sunday, September 10, 2023, 3:00 PM - 4:30 PM
Hall G2

e-Poster Presentations Session 3 - Inflammation & Infection Committee: More on Infection and Inflammation Imaging

EPS-042
Role of scintigraphy in the staging of necrotizing otitis externa in diabetics
T. Ben Ghachem, *R. Ghodhbane, L. Zaabar, I. Slim, A. Mhiri; Salah Azaiez Institute, Tunis, TUNISIA.*

EPS-043
A promising tool for excluding knee and hip prosthetic infection with a novel semiquantitative index in double-phase bone scintigraphy
R. Zambrano Infantino, *J. Piñerúa-Gonsálves, F. Sebastian Palacid, N. Álvarez Mena, M. Alonso Rodríguez, M. García Aragón, B. Pérez López, C. Gamazo Laherran, M. González Soto, R. Ruano Pérez;*
Hospital Clínico Universitario de Valladolid, Valladolid, SPAIN.

EPS-044
Assessment of disease severity in Sjögren's syndrome using semi- quantitative parameters on salivary gland scintigraphy.
T. Singhal, *P. Singh, A. Rehman, K. Kandula, G. Parida, P. Kumar, K. Bishnoi, R. Emerson, S. Patro, K. Agrawal; AIIMS Bhubaneswar, Bhubaneswar, INDIA.*

EPS-045
Oral Gallium -67 citrate Scintigraphy as a new highlighter for guided biopsiescolonoscopy in Inflammatory bowel disease.
J. Calegaro[1], *J. Tajra*[1,2], *J. Tajra*[3];
[1]*Secretaria de Estado de Saúde, Brasília, BRAZIL,*
[2]*Hospital de Base do Distrito Federal, Brasilia, BRAZIL,*
[3]*Centro Universitário UNIEURO, Brasília, BRAZIL.*

EPS-046
Evolving Nuclear Imaging of Infection - The South African Initiative for Novel Radiopharmaceuticals
T. Ebenhan[1,2], *A. H. Mdlophane*[3,4], *J. Duvenhage*[1], *C. A. Grouws*[5,1], *M. Kaths-Lundie*[6], *O. Gheysens*[7], *T. Govender*[8,3], *T. Naicker*[5,3], *H. G. Kruger*[5], *J. Zeevaart*[4,2,3], *M. M. Sathekge*[3,9];
[1]*Preclinical Imaging Facility, Nuclear Medicine Reseach Infrastructure NPC, Pretoria, SOUTH AFRICA,* [2]*Nuclear Medicine, University of Pretoria, Pretoria, SOUTH AFRICA,* [3]*Nuclear Medicine Reseach Infrastructure NPC, Pretoria, SOUTH AFRICA,* [4]*Radiochemistry, Necsa, Pelindaba, SOUTH AFRICA,* [5]*Catalysis and Peptide Research Unit, University of KwaZulu Natal, Durban, SOUTH AFRICA,* [6]*Radiochemistry, Sefako Makgatho Health Science University, Pretoria, SOUTH AFRICA,* [7]*Department of Nuclear Medicine, Cliniques Universitaires Saint- Luc, and Institute of Clinical and Experimental Research, Université Catholique de Louvain, Leuven, BELGIUM,* [8]*Department of Chemistry, University of Zululand, KwaDlangezwa, SOUTH AFRICA,* [9]*Nuclear Medicine and Steve Biko Academic Hospital, University of Pretoria, Pretoria, SOUTH AFRICA.*

EPS-047
The Importance of FDG PET/CT in the Diagnosis of Left Ventricular Asist Device Infection
Y. Okar, *I. Sezgin, R. Horal, M. Urhan, B. Akkas;*
Sultan Abdulhamid Han Training and Research Hospital, Istanbul, TÜRKIYE.

EPS-048
Clinical Value and Utility of the ^{18}F-FDG PET/CT in Detecting Prosthetic Infection After the Aortic Valve and Thoracic Aorta Reconstruction.
V. Carrero-Vásquez[1], *I. Sánchez-Rodríguez*[1], *F. Escrihuela-Vidal*[2], *L. Gracia-Sánchez*[1], *P. Notta*[1], *M. Pudis*[1], *S. Bondia-Bescós*[1], *A. Blasco*[3], *B. Hervas-Sanz*[1], *C. Martínez-Ramos*[1], *P. Perlaza-Jiménez*[1], *M. Cortés-Romera*[1];
[1]*Nuclear Medicine Department, Bellvitge University Hospital, Barcelona, SPAIN,* [2]*Infectious Diseases Department. Bellvitge University Hospital., Barcelona, SPAIN,* [3]*Cardiovascular Surgery Department, Bellvitge University Hospital, Barcelona, SPAIN.*

EPS-049
Role of [18F]FDG PET/CT in patients with suspected ventricular assist device infection. Experience in a PET/CT dedicated cardio center.
B. Hervás Sanz[1], *L. M. Gràcia-Sánchez*[1], *I. E. Sánchez-Rodríguez*[1], *P. C. Notta*[1], *V. A. Carrero-Vásquez*[1], *C. Martínez-Ramos*[1], *A. Palomar-Muñoz*[1], *M. Pudis*[1], *S. Bondia-Bescós*[1], *J. L. Díaz-Moreno*[1], *C. Díez-López*[2], *J. González-Costello*[2], *L. Herrador-Galindo*[2], *F. Escrihuela-Vidal*[3], *N. Sabé-Fernández*[3], *D. Ortiz-Berbel*[4], *K. Osorio-Higa*[4], *M. Cortés-Romera*[1];
[1]*Nuclear Medicine-PET (IDI) Department, Bellvitge University Hospital-IDIBELL, L'Hospitalet de Llobregat, SPAIN,* [2]*Cardiology Department, Bellvitge University Hospital-IDIBELL, L'Hospitalet de Llobregat, SPAIN,* [3]*Infectious Disease Department, Bellvitge University Hospital-IDIBELL, L'Hospitalet de Llobregat, SPAIN,* [4]*Cardiovascular Surgery Department, Bellvitge University Hospital-IDIBELL, L'Hospitalet de Llobregat, SPAIN.*

EPS-050
Asesessment Of Splenic And Bone Hypermetabolism As Indirect Signs Of Infection/ Inflammation In Patients With Suspected Infective Endocarditis Or Implantable Cardiac Device Infection.
A. Padilla Bermejo[1], *F. J. Pena Pardo*[1], *M. Amo Salas*[2], *M. N. Sicilia Pozo*[1], *C. Lucas Lucas*[1], *M. Contreras Ameduri*[1], *L. García Zoghby*[3], *M. Cruz Montijano*[3], *E. Noriega Álvarez*[1], *A. M. García Vicente*[3], *Á. Soriano Castrejón*[3], *M. P. Talavera Rubio*[1], *V. M. Poblete García*[1];
[1]*Nuclear Medicine Department, University General Hospital of Ciudad Real, Ciudad Real, SPAIN,* [2]*Mathematics Department, Castilla la Mancha University of Ciudad Real, Ciudad Real, SPAIN,* [3]*Nuclear Medicine Department, University General Hospital of Toledo, Toledo, SPAIN.*

EPS-051
Assessment in clinical practice of the valvular uptake index with [18F]FDG-PET/CT in patients with prosthetic valve endocarditis
S. Guzmán Ortiz, *B. Rodriguez Alfonso, K. Velásquez Díaz, I. Obedkova, M. Grajeda Gallardo;*
Puerta de Hierro University Hospital, Madrid, SPAIN.

EPS-052
Utility of PET/CT with ^{18}F-FDG for the localization of malignant and pre-malignant colorectal disease and its correlation with different microorganisms in patients studied for suspected prosthetic infective endocarditis and/or intracardiac devices.
J. Badell, *F. Gómez-Caminero López, P. García-Talavera San Miguel, J. C. Cañadas Salazar, E. Campaña Díaz, S. López Puche, S. Rama Alonso, E. Casillas Sagrado, P. Tamayo Alonso;*
Hospital Clinico Universitario de Salamanca, Salamanca, SPAIN.

EPS-053
The Role of [18F]FDG-PET/MRI in Patients with Large-Vessel Vasculitis
G. Argalia[1], *M. Fogante*[2], *G. Biscontini*[1], *F. M. Fringuelli*[1], *A. Palucci*[1], *C. Romagnolo*[1], *C. Cottignoli*[1], *N. Schicchi*[2], *P. Esposto Pirani*[2], *P. Fraticelli*[3], *L. Burroni*[1];
[1]*Nuclear Medicine, Department of Radiological Sciences, University Hospital of Marche, Ancona, ITALY,* [2]*Radiology, Department of Radiological Sciences, University Hospital of Marche, Ancona, ITALY,* [3]*Internal Medicine, Department of Radiological Sciences, University Hospital of Marche, Ancona, ITALY.*

EPS-054
Role of 18F-FDG PET/CT in patients with Hemophagocytic lymphohistiocytosis (HLH)
R. Goel, *K. Chandekar, N. A. Damle, Y. Dharmashaktu, C. Bal, R. Kumar, M. Tripathi, P. Kumar;*
All India Institute of Medical Sciences (AIIMS), New Delhi, INDIA.

EPS-055
Establishing The Ideal Time Point In Imaging Patients With ^{99m}Tc-Ethambutol Scintigraphy In Extrapulmonary Tuberculosis
D. Khan, *N. A. Damle, S. Sagar, A. Ghazal, V. Tiwari, C. Bal, M. Tripathi, S. Sikdar, P. Ranjan, V. Manhas, P. Kumar;*
AIIMS Delhi, Delhi, INDIA.

EPS-056
^{18}F-FDG PET/CT metabolic parameters as predictors of immune status and disease severity in the patients with non-tuberculous mycobacteria
D. Chen[1], *Y. Chen*[2], *S. Yang*[1], *T. Li*[1], *K. Liu*[1], *Z. Wang*[1], *T. Zhang*[1], *G. Wang*[1], *K. Zhao*[1], *X. Su*[1];
[1]*Department of Nuclear Medicine, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, CHINA,* [2]*State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, Hangzhou, CHINA.*

EPS-057
Correlation of Total Lesion Glycolysis with Inflammatory and Immune Biomarkers in Talaromyces Marneffei Infection Patients: A Cross-sectional and Longitudinal FDG PET/CT Study
W. Bao[1], *X. Zhang*[1], *Q. Huang*[1], *S. Ren*[1], *F. Hua*[2], *C. Zuo*[1], *F. Xie*[1], *Y. Guan*[1];
[1]*Huashan Hospital, Shanghai, CHINA,*
[2]*Longhua Hospital, Shanghai, CHINA.*

EPS-058
Head-to-head comparison of ^{18}F-FDG PET and labelled leucocyte scintigraphy for the monitoring of treatment response in malignant external otitis
S. Melki[1], *M. Hurstel*[1], *A. Vasseur*[2], *D. Nguyen*[2], *C. Rumeau*[2], *A. Verger*[1,3];
[1]*Department of Nuclear Medicine and Nancyclotep, University Hospital of Nancy, Nancy, FRANCE,* [2]*Department of ENT, University Hospital of Nancy, Nancy, FRANCE,* [3]*IADI, INSERM, UMR 1254, Université de Lorraine, 54000, Nancy, FRANCE.*

EPS-059
Dynamic [^{18}F]FDG PET/CT imaging with a LAFOV PET/CT camera system to differentiate between infection and inflammation.
N. D. van Rijsewijk, *J. H. van Snick, F. F. A. Ijpma, M. Wouthuyzen-Bakker, J. van Sluis, A. W. J. M. Glaudemans;*
University Medical Center Groningen, Groningen, NETHERLANDS.

EPS-060
Exploring the clinical ambit of ^{68}Ga-NOTA-UBI PET/CT as an infection imaging technique
N. Damle, *Y. Dharmashaktu, A. Singhal, S. Ballal, R. Goel, S. D. Maurya, V. Tiwari, A. Gawande, S. Sagar, J. Jaleel, C. Bal, M. Ansari, V. Kumar;*
All India Institute of Medical Sciences, New Delhi, INDIA.

EPS-061
Correlation Between Emotional and Psychological Symptoms and Brain Glucose Metabolism on PET/CT in Patients with Long Covid
L. Wichert-Ana, *D. L. Ferreira, L. E. Lopes-Santos, A. C. Trevisan, G. D. Angelis, J. S. Sakamoto, B. G. Coretti, L. Alexandre-Santos, M. P. Foss, O. Y. Fukumori, M. Kato, F. A. Pitella, V. Tumas, F. B. Rodrigues;*
Ribeirão Preto Medical School - University of São Paulo, Ribeirao Preto, BRAZIL.

EPS-062

Brain Perfusion SPECT, DAT SPECT, and [18F]FDG PET/CT and PET/MRI Findings in Patients with Long COVID

L. Wichert-Ana[1], *L. S. C. Wellingta*[1], *L. E. Lopes-Santos*[1], *K. J. C. C. Lacerda*[1], *V. R. Sá*[2], *F. E. Padovan-Neto*[2];
[1]*Ribeirão Preto Medical School - University of São Paulo, Ribeirao Preto, BRAZIL,* [2]*Department of Psychology, Faculty of Philosophy, Sciences and Letters of Ribeirão Preto, University of São Paulo, Ribeirao Preto, BRAZIL.*

510

Sunday, September 10, 2023, 3:00 PM - 4:30 PM

Hall K

Technologists Oral Presentations 1: SPECT-CT in Diagnosis and Therapy

OP-177

Deep learning-based abnormality classification in ^{123}I-ioflupane SPECT imaging

T. Yamao, *R. Yamakuni, N. Takahashi, K. Miwa, Y. Kaneko, N. Miyaji, H. Ito;*
Fukushima Medical University, Fukushima, JAPAN.

OP-178

Quantitative evaluation of SPECT/CT performance for therapeutic Lu177 radionuclide with NEMA standards

P. Dwivedi[1], *V. Sawant*[1], *A. Jha*[2], *V. Rangarajan*[2];
[1]*Advanced Centre for Treatment Research and Education In Cancer, Mumbai, INDIA,* [2]*Tata Memorial Hospital, Mumbai, INDIA.*

OP-179

Broad quantification calibration of various isotopes for quantitative analysis and the assessment of their SUVs in a SPECT/CT scanner

H. Ko, *J. Choi, S. Park;*
Asan Medical Center, Seoul, KOREA, REPUBLIC OF.

OP-180

Differential Diagnosis of Lewy Body Dementia andAlzheimer's Disease in ECD SPECT Images Using 2D and 3D CNN Methods

Y. Ni[1], *Z. Lin*[1], *S. Tsen*[1], *M. Pai*[2], *P. Chiu*[3], *G. Hung*[4], *K. Lin*[5], *I. Hsiao*[6], *C. Chang*[7], *Y. Chang*[8];
[1]*Health Physics Division, Institute of Nuclear Energy Research, Atomic Energy Council, Taoyuan, TAIWAN,* [2]*Alzheimer's Disease Research Center, National Cheng Kung University Hospital, Taiwan, TAIWAN,* [3]*Department of Neurology, Show Chwan Memorial Hospital, Changhua, TAIWAN,* [4]*Department of Nuclear Medicine, Chang Bing Show Chwan Memorial Hospital, Changhua, TAIWAN,* [5]*Department of Nuclear Medicine and Molecular Imaging Center, Linkou Chang Gung Memorial Hospi-tal, Taoyuan, TAIWAN,* [6]*Department of Medical Imaging and Radiological Sciences & Healthy Aging Center, Chang Gung University, Taoyuan, TAIWAN,* [7]*Department of Neurology, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, TAIWAN,* [8]*Department of Neurology, Institute of translational research in biomedicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung, TAIWAN.*

OP-181

Validation of dramatic CT topogram dose reduction with use of tin filter

K. Christensen[1], *P. C. Holdgaard*[1], *L. L. Østergård*[1], *N. A. Bebbington*[2];
[1]*Lillebaelt University Hospital, Vejle, Vejle, DENMARK,* [2]*Siemens Healthcare A/S, Aarhus, DENMARK.*

OP-182

Clinical Application of SPECT Phantoms Created Using Paper Phantoms

T. Nagahara[1], *T. Katafuchi*[2], *T. Inagaki*[1], *R. Isobe*[1], *K. Kato*[1];
[1]*Nagoya University Graduate School of Medicine, Nagoya, JAPAN,* [2]*Gifu University, Gifu, JAPAN.*

OP-183

SPECT/CT-ONLY Imaging for Sentinel Lymph Node Biopsy in Breast Cancer: Efficient and Effective

B. Bosveld[1], *R. A. Valdés Olmos*[2], *W. van der Bruggen*[1], *C. D. Bavelaar-Croon*[3], *B. F. Bulten*[1];
[1]*Slingeland Hospital, Doetinchem, NETHERLANDS,* [2]*Leiden University Medical Center, Leiden, NETHERLANDS,* [3]*Alexander Monro Hospital, Bilthoven, NETHERLANDS.*

OP-184

Contamination of the Isolation Room After Iodine-131 Ablation Treatment

K. Levänen, *N. Miettinen, H. Leskinen, J. Heikkinen;*
Department of Radiology and Nuclear Medicine, The wellbeing services county of South Savo, Mikkeli, FINLAND.

OP-185

Dose rate evaluation of patients performing diagnostic Nuclear Medicine procedures

A. Santos, *P. Colarinha;*
Hospital Cuf Descobertas, Lisbon, PORTUGAL.

511

Sunday, September 10, 2023, 3:00 PM - 4:30 PM

Hall G1

Theranostics Track - Oncology & Theranostics Committee / EARL - Featured Session: Old but Novel Techniques

OP-186

K. Herrmann;
University Hospital Essen, Department of Nuclear Medicine, Essen, GERMANY.

OP-187

Predictive value of [18F]F-Choline and PSMA-based quantitative parameters for response to [177Lu]Lu-PSMA-617 therapy in mCRPC: The added value of dynamic FDG acquisition using Patlak method

S. Miet[1], *B. Maucherat*[1], *P. Baumgartner*[1], *E. Picot-Dilly*[1], *P. Lalire*[1], *A. Morel-Thierry*[1], *D. Rusu*[1], *M. Le Thiec*[1], *V. Nicolas*[2], *F. Rolland*[1], *C. Rousseau*[2], *L. Ferrer*[2];
[1]*ICO René Gauducheau, F-44800 Saint-Herblain, Nantes, FRANCE,* [2]*ICO René Gauducheau, F-44800 Saint-Herblain, Nantes Université, Univ Angers, INSERM, CNRS, CRCI2NA, F-44000, Nantes, FRANCE.*

OP-188

FAP-Targeted Radiopeptide Therapy using^{177}Lu-, ^{225}Ac-and90Y-labeled 3BP-3940 in Diverse Advanced Solid Tumors: First-in-Humans Results

J. Zhang[1], *V. Jakobsson*[1], *A. Mishra*[2], *A. Eismant*[2], *L. Greifenstein*[2], *C. Kramer*[2], *A. Klega*[2], *C. Landvogt*[2], *C. Mueller*[2], *R. P. Baum*[2];
[1]*National University of Singapore, Singapore, SINGAPORE,* [2]*Curanosticum Wiesbaden-Frankfurt, Center for Advanced Radiomolecular Precision Oncology, Wiesbaden, GERMANY.*

OP-189

Static and dynamic 68Ga-FAPI-46 PET in 18F-FDG-negative pulmonary lesions - target validation and imaging properties

M. Roehrich, *J. Daum, J. Hoppner, F. Eichhorn, K. Schlamp, E. Gutjahr, H. Winter, U. Haberkorn;*
University Hospital Heidelberg, Heidelberg, GERMANY.

OP-190

^{68}Ga-FAPI-46 vs ^{18}F-FDG PET/CT and contrast-enhanced CT in patients with advanced gastrointestinal stroma tumors (GIST)

T. Bartel[1], *K. M. Pabst*[1], *A. Milosevic*[2], *S. Bauer*[3], *J. Falkenhorst*[3], *H. Lanzafame*[1], *I. A. Mavroeidi*[3], *M. Nader*[1], *J. T. Siveke*[3,4,5], *K. Herrmann*[1], *R. Hamacher*[3], *W. P. Fendler*[1];
[1]*Department of Nuclear Medicine, West German Cancer Center, University Hospital Essen, Essen, GERMANY,* [2]*Department of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Essen, GERMANY,* [3]*Department of Medical Oncology, West German Cancer Center, University Hospital Essen, Essen, Germany, Essen, GERMANY,* [4]*Bridge Institute of Experimental Tumor Therapy, West German Cancer Center, University Hospital Essen, Essen, GERMANY,* [5]*Division of Solid Tumor Translational Oncology, German Cancer Consortium (DKTK, Partner Site Essen) and German Cancer Research Center, DKFZ, Heidelberg, GERMANY.*

OP-191

Radiolabeled Somatostatin Receptor Antagonist versus Agonist for Peptide Receptor Radionuclide Therapy in Patients with Therapy-resistant Meningiomas - Phase 0 Part of the Promenade Study

C. Eigler[1], *L. McDougall*[1], *A. Bauman*[1], *P. Bernhardt*[2], *M. Hentschel*[1], *K. A. Blackham*[1], *G. Nicolas*[1], *M. Fani*[1], *D. Cordier*[1], *D. Wild*[1];
[1]*University Hospital Basel, Basel, SWITZERLAND,* [2]*University of Gothenburg, Gothenburg, SWEDEN.*

OP-192

Inter-institutional differences and common ground in ^{177}Lu-PSMA radionuclide therapy: International survey in 95 theranostic centers

A. Farolfi[1,2], *W. Armstrong*[2], *L. Djaileb*[3], *A. Gafita*[4], *M. Hotta*[2], *M. Auerbach*[2], *L. Unterrainer*[2], *W. P. Fendler*[5], *M. Rettig*[6], *M. Eiber*[7], *M. Hofman*[8], *B. Hadaschik*[9], *K. Herrmann*[5], *J. Czernin*[2], *J. Calais*[2], *M. Benz*[2];
[1]*Division of Nuclear Medicine, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY,* [2]*Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, CA, UNITED STATES OF AMERICA,* [3]*Nuclear Medicine Department, Univ. Grenoble Alpes, INSERM, CHU Grenoble Alpes, Grenoble, FRANCE,* [4]*The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, UNITED STATES OF AMERICA,* [5]*Department of Nuclear Medicine and German Cancer Consortium (DKTK), University Hospital Essen, University of Duisburg-Essen, Essen, GERMANY,* [6]*Department of Urology, University of California Los Angeles, Los Angeles, CA, UNITED STATES OF AMERICA,* [7]*Department of Nuclear Medicine, Klinikum Rechts Der Isar, Technical University of Munich, Munich, GERMANY,* [8]*Prostate Cancer Theranostics and Imaging Centre of Excellence, Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, Melbourne, AUSTRALIA,* [9]*Department of Urology, University of Duisburg-Essen and German Cancer Consortium-University Hospital Essen, Essen, GERMANY.*

OP-193

Safety and dosimetry evaluation of personalized dose I131-apamistamab prior to HCT in the phase 3 SIERRA trial for patients with relapsed/refractory acute myeloid leukemia (R/R AML)

N. Pandit-Taskar[1], *M. Natwa*[2], *M. Chen*[3], *W. Yap*[4], *G. Wiseman*[5], *E. Leung*[6], *A. Desai*[7], *P. Brodin*[7], *E. Haeuber*[7], *A. Nahar*[7], *R. L. Wahl*[8];
[1]*Molecular Imaging and Therapy, Memorial Sloan Kettering Cancer Center, New York, NY, UNITED STATES OF AMERICA,* [2]*Ohio State University, Columbus, OH, UNITED STATES OF AMERICA,* [3]*Yale New Haven Hospital, New Haven, CT, UNITED STATES OF AMERICA,* [4]*University of Kansas Medical Center, Kansas City, KS, UNITED STATES OF AMERICA,* [5]*Mayo Clinic Rochester, Rochester, MN, UNITED STATES OF AMERICA,* [6]*The Ottawa Hospital, Ottawa, ON, CANADA,* [7]*Actinium Pharmaceuticals, Inc., New York, NY, UNITED STATES OF AMERICA,* [8]*Washington University St. Louis, St. Louis, MO, UNITED STATES OF AMERICA.*

OP-194

^{89}Zr-DFO-girentuximab PET/CT imaging for clear cell renal cell carcinoma - ZIRCON study results of diagnostic performance, including in very small lesions

S. Martina[1], *P. Mulders*[2], *B. M. Shuch*[3], *A. J. Pantuck*[3], *M. A. Morris*[4], *V. Master*[5], *A. Scott*[6,7,8], *C. van Praet*[9], *C. Bailly*[10], *B. Önal*[11,12], *T. Aksoy*[13], *R. Merkx*[2], *D. M. Schuster*[5], *S. Lee*[14], *N. Pandit-Taskar*[15,16], *A. C. Fan*[17], *L. Tauchmanova*[1], *K. Schmidt*[18], *P. Allman*[19], *K. Vadali*[1], *C. Hayward*[1], *J. Bernhard*[20];
[1]*Telix Pharmaceuticals, Melbourne, AUSTRALIA,* [2]*Radboud University Medical Center, Nijmegen, NETHERLANDS,* [3]*UCLA, Los Angeles, CA, UNITED STATES OF AMERICA,* [4]*Advanced Molecular Imaging and Therapy, Glen Burnie, MD, UNITED STATES OF AMERICA,* [5]*Emory University School of Medicine, Atlanta, GA, UNITED STATES OF AMERICA,* [6]*Austin Health, Melbourne, AUSTRALIA,* [7]*University of Melbourne, Melbourne, AUSTRALIA,* [8]*Olivia Newton-John Cancer Research Institute, Melbourne, AUSTRALIA,* [9]*Universitair Ziekenhuis Gent, Gent, BELGIUM,* [10]*Nantes University Hospital, Nantes, FRANCE,* [11]*Istanbul University, Istanbul, TÜRKIYE,* [12]*Cerrahpasa Medical, Istanbul, TÜRKIYE,* [13]*Istanbul Training and Research Hospital, Istanbul, TÜRKIYE,* [14]*Austin Health, Heidelberg, AUSTRALIA,* [15]*Memorial Sloan Kettering Cancer Center, New York, NY, UNITED STATES OF AMERICA,* [16]*Weil Cornell Medical Center, New York, NY, UNITED STATES OF AMERICA,* [17]*Stanford University School of Medicine, Stanford, CA, UNITED STATES OF AMERICA,* [18]*ABX-CRO advanced pharmaceutical services Forschungsgesellschaft mbH, Dresden, GERMANY,* [19]*Premier Research, Morrisville, NC, UNITED STATES OF AMERICA,* [20]*CHU de Bordeaux, Bordeaux, FRANCE.*

601

Sunday, September 10, 2023, 16:45 - 18:15
Hall A

CME 4 - Oncology & Theranostics Committee: Update in Multiple Myeloma

OP-195
Genomic vs FDG Patterns
C. Nanni;
IRCCS Azienda Ospedaliero-Universitaria di Bologna, Nuclear Medicine, Bologna, ITALY.

OP-196
Radioligand Therapy
A. Buck;
UniversityHospital Würzburg, Dept. Of Nuclear Medicine, Wurzburg, GERMANY.

OP-197
FDG PET/CT, DWI or Both?
C. Mesguich;
NuclearMedicine Department, Centre Hospitalier Universitaire de Bordeaux, Pessac, FRANCE.

OP-198
ImmunoPET
F. Krabere-Bodere;
NuclearMedicine department, CHU Nantes, ICO, CRCINA, Nantes University, Nantes, FRANCE.

602

Sunday, September 10, 2023, 16:45 - 18:15
Hall D (Arena)

Challenge the Expert 3 - Dosimetry Committee: Dosimetry Live

OP-199
Dosimetry Calculation Live on Stage
M. Konijnenberg;
Eurasmus MC, Radiology & Nuclear Medicine, Rotterdam, NETHERLANDS.

OP-200
Dosimetry Calculation Live on Stage
J. Gear;
Royal Marsden NHSFT, Sutton , UNITED KINGDOM.

OP-201
Dosimetry Calculation Live on Stage
C. Stokke;
Division of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, NORWAY, Department of Physics, University of Oslo, Oslo, NORWAY.

603

Sunday, September 10, 2023, 16:45 - 18:15
Hall E1

LIPS Session 4 - Oncology & Theranostics Committee: Residents for Residents

OP-206
PET/CT cases in thoracic oncological disorders
R. Metz;
CHU Nantes, Service de Médecine Nucléaire, Nantes, FRANCE.

OP-207
PET/CT cases in abdominal/pelvic oncological disorders
S. Himmen;
UniversityHospital Essen, Nuclear Medicine, Essen, GERMANY.

OP-208
PET/CT cases in neurology
S. Sperti;
Universityof Padova, Nuclear Medicine, Padova, ITALY.

OP-209
PET/CT cases in infectious diseases
S. Erdkamp;
Amsterdam UMC, Department of Radiology and Nuclear Medicine, Amsterdam, NETHERLANDS.

604

Sunday, September 10, 2023, 4:45 PM - 6:15 PM
Hall E2

M2M Track - TROP Session: Novel Imaging Targets in Oncology

OP-212
Computer-Aided Development of Trop-2-Targeted Peptides for Radiotheranostic Applications for Pancreatic Cancer
H. Hong[1], *J. Hu*[1], *Y. Cong*[1], *X. Li*[1], *Y. Wang*[2];
[1]Nanjing University, Nanjing, CHINA, [2]China Pharmaceutical University, Nanjing, CHINA.

OP-213
Glioblastoma and Pancreatic Adenocarcinoma - Versatile radiolabeled probe targeting Low Density Lipoprotein Receptors (LDLR)
I. Tworowska[1], *L. Flores*[1], *X. Qu*[1], *C. Malicet*[2], *R. Zielinski*[3], *P. Lecorche*[1], *E. Delpassand*[4], *J. Temsamani*[5];
[1]RadioMedix Inc., Houston, TX, UNITED STATES OF AMERICA, [2]Vect-Horus, Marseille, FRANCE, [3]MDAnderson, Houston, TX, UNITED STATES OF AMERICA, [4]RadioMedix, Houston, TX, UNITED STATES OF AMERICA, [5]Vect-Horus, Marseille Cedex 15, FRANCE.

OP-214
Preparation and preclinical evaluation of ACE1 targeting molecular probe ^{68}Ga-DOTA-BPP
Q. Zhang, *Z. Yang, Z. Hua;*
Peking University Cancer Hospital, Beijing, CHINA.

OP-215
Construction of a novel PET probe of Iodine-124 labeled ADC for Trop-2 targeting and Micro-PET imaging
Z. Zeng[1], *D. Li*[1], *X. Yan*[2], *L. Li*[1], *J. Ding*[1], *X. Sheng*[2], *H. Zhu*[1], *Z. Yang*[1];
[1]Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Beijing, CHINA, [2]Department of Genitourinary Oncology, Peking University Cancer Hospital & Institute, Beijing, CHINA.

OP-216
Immuno-PET Imaging of Tumor Mesothelin Expression with Gallium-68 Radiolabeled Nanobody
X. Lv[1,2], *Z. Xu*[3], *X. Song*[1,2], *Y. Gai*[1,2], *D. Jiang*[1,2], *P. Lei*[3], *W. Wei*[4], *Y. Zhang*[1,2], *R. An*[1,2], *X. Lan*[1,2];
[1]Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, CHINA, [2]Hubei Province Key Laboratory of Molecular Imaging, Wuhan, CHINA, [3]Department of Immunology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, CHINA, [4]Department of Nuclear Medicine, Institute of Clinical Nuclear Medicine, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, CHINA.

OP-217
CD70-targeted immunoPET imaging of renal carcinomas
X. Zhou, *Q. Xia, J. Liu, W. Wei;*
shanghai jiaotong university, Shanghai, CHINA.

OP-218
Screening, development and preliminary evaluation of CLDN18.2 specific peptide PET probes
Z. Wang[1], *C. Zhao*[2], *J. Ding*[1], *H. Zhu*[1];
[1]Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Key Laboratory for Research Evaluation of Radiopharmaceuticals (National Medical Products Administration), Department of Nuclear Medicine, Peking University Cance, Beijing, CHINA, [2]Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Biochemistry and Molecular Biology, Peking University Cancer Hospital and Institute, Beijing, Beijing, CHINA.

OP-219
Immuno-PET of Colorectal Cancer with A CEA-Targeted ^{68}Ga-Nanobody: From Bench to Bedside
L. Li[1], *X. Lin*[1], *X. Ma*[1], *F. Liu*[1], *B. Jia*[2], *Z. Yang*[1];
[1]Peking University Cancer Hospital & Institute, Beijing, CHINA, [2]Peking University, Beijing, CHINA.

OP-220
Increasing the Tumor-to-Blood Ratio by Click-Cleavable Radioimmunoimaging with [^{89}Zr]Zr-DFO-Trans-Cyclooctene-Trastuzumab in Mice
K. E. de Roode[1,2], *M. Vlastara*[1], *R. Rossin*[1], *F. J. M. Hoeben*[3], *M. Boswinkel*[2], *L. H. J. Kleijn*[1], *J. Nagarajah*[2], *S. Heskamp*[2], *M. Rijpkema*[2], *M. S. Robillard*[1];
[1]Tagworks Pharmaceuticals, Nijmegen, NETHERLANDS, [2]Department of Medical Imaging, Radboud University Medical Centre, Nijmegen, NETHERLANDS, [3]SyMO-Chem, Eindhoven, NETHERLANDS.

605

Sunday, September 10, 2023, 4:45 PM - 6:15 PM
Hall B

Cutting Edge Science Track - TROP Session: Segmentation and Denoising

OP-221
Deep learning is a promising tool for fully automatic malignant lesions identification and segmentation in whole-body bone scans
F. Oliveira, *Â. Silva, J. Castanheira, M. Silva, C. Constantino, D. C. Costa;*
Champalimaud Foundation, Lisboa, PORTUGAL.

OP-222
Using a 3-D UNet artificial intelligence model to segment PSMA-avid lesions in ^{68}Ga-PSMA-11 PET/CT images
E. Greenblatt[1], *M. Maker*[1], *A. Kadumberi*[1], *S. Wail*[2], *P. Kuo*[1];
[1]Invicro, Needham, MA, UNITED STATES OF AMERICA, [2]Telix Pharmaceuticals, North Melbourne, AUSTRALIA.

OP-223
A Feature-Based Ensemble of 3D U-Nets for Computed Tomography (CT) Lung Lobe Segmentation
E. Amini[1,2], *R. Klein*[1,3,4];
[1]Ottawa Hospital Research Institute, Ottawa, ON, CANADA, [2]Carleton University, Ottawa, ON, CANADA, [3]The Ottawa Hospital Department of Nuclear Medicine, Ottawa, ON, CANADA, [4]University of Ottawa Department of Medicine, Ottawa, ON, CANADA.

OP-224
Improving Automated Lesion Detection and Segmentation in PET/CT Scans: A Comparative Study of 3D UNet-Based Configurations
M. Namías, *Y. V. Rotstein Habarnau;*
Fundación Centro Diagnóstico Nuclear, Buenos Aires, ARGENTINA.

OP-225
A Hybrid Neural Network Architecture to improve low-dose PET Image Reconstruction
S. Kaviani[1], *A. Sanaat*[2], *M. Mokri*[1], *C. Cohalan*[3], *J. Carrier*[1,4];
[1]Université de Montréal, Montréal, QC, CANADA, [2]University of Geneva, Geneva, SWITZERLAND, [3]CHUM - Centre hospitalier de l'Université de Montréal, Montréal, QC, CANADA, [4]CHUM - Centre hospitalier de l'Université de Montréal, Montreal, QC, CANADA.

OP-226
A deep learning method for the recovery of standard-dose imaging quality from ultra-low-dose PET on wavelet domain
S. Xue[1], *F. Liu*[1], *H. Wang*[2], *M. Viscione*[1], *R. Guo*[2], *A. Rominger*[1], *B. Li*[2], *K. Shi*[1];
[1]University of Bern, Bern, SWITZERLAND, [2]Shanghai Jiao Tong University School of Medicine, Shanghai, CHINA.

OP-227

Sequential Deep Learning Image Enhancement Models Improve Diagnostic Confidence, Lesion Detectability and Image Reconstruction Time in PET

M. Dedja[1], *A. Mehranian*[2], *K. M. Bradley*[3], *M. D. Walker*[1], *S. D. Wollenweber*[4], *R. Johnsen*[4], *D. R. McGowan*[1,5];
[1]*Oxford University Hospitals, Oxford, UNITED KINGDOM,* [2]*GE Healthcare, Oxford, UNITED KINGDOM,* [3]*Cardiff University, Cardiff, UNITED KINGDOM,* [4]*GE Healthcare, Waukesha, WI, UNITED STATES OF AMERICA,* [5]*University of Oxford, Oxford, UNITED KINGDOM.*

OP-228

The Effect of Multimodal Anatomical Images in Deep Learning-enhanced Low-dose Amyloid PET Imaging

S. Kuo[1], *M. Lee*[1], *C. Ko*[2], *K. T. Chen*[1];
[1]*National Taiwan University, Taipei, TAIWAN,* [2]*National Taiwan University Hospital, Taipei, TAIWAN.*

OP-229

Iterative Deep-Learning Denoising in Bone SPECT-CT Reconstruction Based on Simulations from Clinical Data

O. Ziv, *B. Yuzefovich, J. Sachs, G. Kovalski;*
GE Healthcare, Haifa, ISRAEL.

606

Sunday, September 10, 2023, 4:45 PM - 6:15 PM
Hall C

Clinical Oncology Track - TROP Session: Neuroendocrine Tumors Treatment

OP-230

A phase I theranostic study evaluating the safety and tolerability of ^{177}Lu-satoreotide tetraxetan with ^{68}Ga-satoreotide trizoxetan companion imaging in participants with extensive-stage small-cell lung cancer (ES-SCLC) on atezolizumab maintenance therapy

L. Emmett[1], *J. Cardaci*[2], *K. O'Byrne*[3], *S. Arulananda*[4], *A. Prawira*[5], *B. Pais*[6,7], *M. Crumbaker*[1], *N. Lenzo*[8];
[1]*St Vincent's Hospital, Sydney, AUSTRALIA,* [2]*Hollywood Private Hospital, Nedlands, AUSTRALIA,* [3]*Princess Alexandra Hospital, Brisbane, AUSTRALIA,* [4]*Monash Health, Clayton, AUSTRALIA,* [5]*Obatica, Zetland, AUSTRALIA,* [6]*Ariceum Therapeutics, Berlin, GERMANY,* [7]*SRT-Biomedical, Soest, NETHERLANDS,* [8]*GenesisCare, Murdoch, AUSTRALIA.*

OP-231

Evaluation of Progression-Free Survival (PFS) in Patients with Advanced, Non-resectable, Progressive GEP-NET Treated Using Combine Radioligand and CAPTEM therapy.

J. Cwikla[1], *A. Zrajkowska*[2], *G. Nowicka*[3], *J. Pałucki*[4], *N. Seklecka*[2], *A. Kolasińska-Ćwikła*[4];
[1]*University of Warmia and Mazury, Olsztyn, POLAND,* [2]*Diagnostic and Therapy Center – "Gammed" Warsaw, Poland, Warsaw, POLAND,* [3]*Warsaw Medical University, Warsaw, POLAND,* [4]*Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, POLAND.*

OP-232

Safety and organs-at-risk dosimetry in patients with gastroenteropancreatic neuroendocrine tumours (GEP-NETs) treated with ^{177}Lu-DOTATATE peptide receptor radionuclide therapy (PRRT): data from prospective phase II clinical trial

M. Mileva[1], *C. Van Bogaert*[2], *G. Marin*[3], *H. Levillain*[3], *C. Artigas*[1], *C. Marin*[3], *R. Danieli*[3], *A. Deleporte*[4], *C. Jungels*[4], *B. Vanderlinden*[3], *Z. Wimana*[1,5], *A. Hendlisz*[4], *P. Flamen*[1], *I. Karfis*[1];
[1]*Nuclear Medicine Department, Institut Jules Bordet, H.U.B, Brussels, BELGIUM,* [2]*Nuclear Medicine Department, Hôpital Erasme, H.U.B, Brussels, BELGIUM,* [3]*Medical Physics Department, Institut Jules Bordet, H.U.B, Brussels, BELGIUM,* [4]*Medical Oncology Department, Institut Jules Bordet, H.U.B, Brussels, BELGIUM,* [5]*Radiopharmacy Department, Institut Jules Bordet, H.U.B, Brussels, BELGIUM.*

OP-233

Efficacy and Safety of 177Lu-DOTATATE in Lung Neuroendocrine Tumors: A multicenter study

M. Mitjavila Casanovas[1], *V. Pubul*[2], *P. Belló*[3], *B. Miguel*[4], *J. Cano*[5], *D. Balaguer*[6], *A. García-Burillo*[7], *A. Mariño Méndez*[8], *E. Rodeño*[9], *A. Custodio*[10], *A. Piñeiro*[11], *L. García-Cañamaque*[12], *M. Castellon*[13], *M. Orduña*[14], *A. Carmona-Bayonas*[15], *P. Jimenez-Fonseca*[16];
[1]*Hospital Universitario Puerta de Hierro Majadahonda, Madrid, SPAIN,* [2]*Hospital Complejo Universitario Santiago, Santiago de Compostela, SPAIN,* [3]*Hospital Universitario La Fe, Valencia, SPAIN,* [4]*Hospital Universitario de Burgos, Burgos, SPAIN,* [5]*Hospital General Universitario de Ciudad Real, Ciudad Real, SPAIN,* [6]*Hospital Universitario Doctor Peset, Valencia, SPAIN,* [7]*Hospital Universitario Vall d'Hebron, Barcelona, SPAIN,* [8]*Hospital Universitario Central Asturias, Oviedo, SPAIN,* [9]*Hospital Universitario Cruces, Bilbao, SPAIN,* [10]*Hospital Universitario La Paz, Madrid, SPAIN,* [11]*Hospital Universitario Virgen de las Nieves, Granada, SPAIN,* [12]*HM Hospitales Madrid, Madrid, SPAIN,* [13]*Hospital Universitario Virgen de la Arrixaca, Murcia, SPAIN,* [14]*Hospital Ramón y Cajal, Madrid, SPAIN,* [15]*Hospital Universitario Morales Meseguer, Murcia, SPAIN,* [16]*Hospital Universitario Central de Asturias, Oviedo, SPAIN.*

OP-234

Cylindrical TGR as Early Radiological Predictor of RLT Progression in GEPNETs. A Proof of Concept

F. Scalorbi[1], *E. Garanzini*[1], *G. Calareso*[1], *C. Marzi*[2], *S. Mazzaglia*[3], *G. Di Rocco*[1,4], *G. Argiroffi*[1], *L. Mascitti*[1,4], *M. Cuomo*[1,4], *S. Pusceddu*[1], *M. Milione*[1], *M. Baccini*[2], *E. Seregni*[1], *A. Marchianò*[1], *M. Maccauro*[1];
[1]*Istituto Nazionale Tumori Milano, Milan, ITALY,* [2]*Department of Statistics, Computer Science, Applications (DiSIA), University of Florence, Firenze, ITALY,* [3]*ASST Santi Paolo e Carlo, San Paolo University Hospital, Milan, ITALY,* [4]*University of Milan, Milan, ITALY.*

OP-235

Safety and Efficacy of Lu-177-DOTATATE in Metastatic or Inoperable Pheochromocytoma/ Paraganglioma: An Interim Analysis

F. Lin[1], *J. Carrasquillo*[1], *J. del Rivero*[1], *I. Shami*[1], *Z. Joy*[1], *B. Turkbey*[1], *J. Klubo*[1], *Y. Teng*[2], *A. Jha*[1], *E. Mena*[1], *M. L. Lindenberg*[1], *C. Chen*[1], *P. Herscovitch*[1], *C. Millo*[1], *K. Pacak*[1];
[1]*National Institutes of Health, Bethesda, MD, UNITED STATES OF AMERICA,* [2]*Henry M Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, UNITED STATES OF AMERICA.*

OP-236

Efficacy and safety of dosimetry-based, personalized ^{177}Lu-DOTATATE PRRT of neuroendocrine tumours: an update from the P-PRRT trial

M. Morin, *F. A. Buteau, A. Beaulieu, F. Arsenault, G. Bouvet, A. Desy, N. Lafrenière, G. April, J. M. Beauregard;*
Department of Radiology and Nuclear Medicine, and Cancer Research Center, Université Laval, Quebec City, Canada; Department of Medical Imaging, and Research Center (Oncology Axis), CHU de Québec – Université Laval, Quebec City, QC, CANADA.

OP-237

Extended Peptide Receptor Radionuclide Therapy: Evaluation of Nephrotoxicity and Therapeutic Effectiveness in Neuroendocrine Tumor Patients Receiving More Than Four Treatment Cycles

X. Fan[1], *T. Zhao*[2], *V. Jakobsson*[2], *X. Chen*[2], *R. P. Baum*[3], *J. Zhang*[2];
[1]*Department of Nuclear Medicine, Shanghai Tenth People's Hospital, Tongji University School of Medici, Shanghai, CHINA,* [2]*Department of Diagnostic Radiology Yong Loo Lin School of Medicine, National University of Singapore, Singapore, SINGAPORE,* [3]*CURANOSTICUM Wiesbaden-Frankfurt, Center for Advanced Radiomolecular Precision Oncology, Wiesbaden, GERMANY.*

OP-238

Outcome prediction in patients with gastroenteropancreatic neuroendocrine tumours (GEP-NETs) treated with ^{177}Lu-DOTATATE peptide receptor radionuclide therapy (PRRT): results from a prospective phase II clinical trial

M. Mileva[1], *G. Marin*[2], *H. Levillain*[2], *C. Artigas*[1], *C. Van Bogaert*[3], *C. Marin*[2], *R. Danieli*[2], *A. Deleporte*[4], *C. Jungels*[4], *B. Vanderlinden*[2], *Z. Wimana*[1,5], *A. Hendlisz*[4], *P. Flamen*[1], *I. Karfis*[1];
[1]*Nuclear Medicine Department, Institut Jules Bordet, H.U.B, Brussels, BELGIUM,* [2]*Medical Physics Department, Institut Jules Bordet, H.U.B, Brussels, BELGIUM,* [3]*Nuclear Medicine Department, Hôpital Erasme, H.U.B, Brussels, BELGIUM,* [4]*Medical Oncology Department, Institut Jules Bordet, H.U.B, Brussels, BELGIUM,* [5]*Radiopharmacy Department, Institut Jules Bordet, H.U.B, Brussels, BELGIUM.*

607

Sunday, September 10, 2023, 4:45 PM - 6:15 PM
Hall F1

Cardiovascular Committee - TROP Session: Functional Imaging, Plaque and Total-Body PET

OP-239

Comparing left ventricular function derived from CMR and gated ^{13}N-ammonia PET-MPI - An evaluation of reproducibility using hybrid PET/MR

D. F. Sager[1], *N. Manz*[2], *S. Manser*[2], *L. Laubscher*[3], *A. W. Stark*[4], *J. Schuetze*[4], *P. A. Kaufmann*[1], *C. Grani*[4], *R. R. Buechel*[1];
[1]*Department of Nuclear Medicine, University Hospital Zurich, Zurich, SWITZERLAND,* [2]*Faculty of Medicine, University of Bern, Bern, SWITZERLAND,* [3]*Department of Health Science and Technology, ETH Zurich, Zurich, SWITZERLAND,* [4]*Department of Cardiology, University Hospital Bern, Bern, SWITZERLAND.*

OP-240

Use of First-Pass Non-Gated ^{15}O-water PET for Evaluation of Left Heart Remodelling and Cardiac Function in Severe Mitral Regurgitation

J. Sigfridsson, *H. J. Harms, J. Bergsten, M. Lubberink, T. Kero, T. Baron, F. A. Flachskampf, J. Sörensen;*
Uppsala University, Uppsala, SWEDEN.

OP-241

Added value of automatic coronary artery calcium scoring from low dose CT ^{15}O-water PET scans in MACE prediction in comparison to the reference, calcium scoring CT scans.

M. Dobrolinska[1], *R. Jukema*[2], *S. van Velzen*[3], *P. van Diemen*[3], *M. Greuter*[1], *N. Prakken*[1], *N. van der Werf*[4], *P. Raijmakers*[3], *R. Slart*[1], *P. Knaapen*[3], *I. Isgum*[3], *I. Danad*[4];
[1]*UMCG, Groningen, NETHERLANDS,* [2]*UMC Amsterdam, Amsterdam, NETHERLANDS,* [3]*Amsterdam UMC, Amsterdam, NETHERLANDS,* [4]*UMC Utrecht, Utrecht, NETHERLANDS.*

OP-242

Impact of data driven motion correction on accuracy of summed stress and rest scores measured with NH3 cardiac PET.

S. Lazarenko[1], *L. van Wunnik*[1], *F. M. van der Zant*[1], *T. S. Martinez-Lucio*[2], *O. I. Mendoza-Ibañez*[2], *C. Hayden*[3], *B. Spottiswoode*[3], *R. J. J. Knol*[1];
[1]*Noordwest Ziekenhuisgroep, Alkmaar, NETHERLANDS,* [2]*University Medical Centre Groningen, Groningen, NETHERLANDS,* [3]*Siemens Medical Solutions United States Of America, Inc., Knoxville, TN, UNITED STATES OF AMERICA.*

OP-243

The role of motion correction tools in left ventricular function parameters as measured by gated ^{13}N-NH$_3$ PET/CT

T. Martinez-Lucio[1], *R. J. J. Knol*[2], *O. I. Mendoza-Ibanez*[1], *L. van Wunnik*[2], *F. M. van der Zant*[2], *C. Tsoumpas*[1], *R. H. J. A. Slart*[1], *S. V. Lazarenko*[2];
[1]*University Medical Center Groningen, Groningen, NETHERLANDS,* [2]*Northwest Clinics Alkmaar, Alkmaar, NETHERLANDS.*

OP-244

The prognostic value of non-perfusion parameters on CZT SPECT in patients with normal myocardial perfusion imaging: a large scale single-center retrospective cohort study.

K. Ko[1], *C. Lin*[2], *L. Tang*[2], *C. Liu*[2], *D. Wang*[3];
[1]*National Taiwan University Cancer Center, Taipei, TAIWAN,* [2]*National Taiwan University Hospital, Taipei, TAIWAN,* [3]*Tri-Service General Hospital, Taipei, TAIWAN.*

OP-245

A machine-learning-based prediction model of lethal arrhythmic events by using the^{123}I-meta-iodobenzylguanidine derived late heart-to-mediastinum ratio: Application into separate Japanese and European cohorts

K. Nakajima[1], *T. Doi*[2], *T. Nakata*[3], *H. Tada*[1], *D. O. Verschure*[4], *V. Frantellizzi*[5], *H. J. Verberne*[6];
[1]*Kanazawa University, Kanazawa, JAPAN,* [2]*Teine Keijinkai Hospital, Sapporo, JAPAN,* [3]*Hokodate-Goryoukaku Hospital, Hokodate, JAPAN,* [4]*Zaans Medical Center, Zaans, NETHERLANDS,* [5]*Sapienza University of Rome, Rome, ITALY,* [6]*University of Amsterdam, Amsterdam, NETHERLANDS.*

OP-246
Long-axial field-of-view PET/CT scanners improve the detection of inflamed coronary artery plaques with [^{68}Ga]Ga-DOTA-TOC imaging
C. Mingels, C. Bregenzer, N. Gözlügöl, L. Knappe, I. Alberts, A. Rominger, ***F. Caobelli****;*
Department of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, SWITZERLAND.

OP-247
Adequacy of whole-body parametric imaging of regional tissue perfusion using the recent total-body PET system and i.v. ^{15}O-water
H. Iida[1]*, H. Merisaari*[2]*, N. Ono*[3]*, N. Kudomi*[4]*, T. Tolvanen*[5]*, V. Saunavaara*[5]*, H. Sari*[6]*, J. Knuuti*[1]*, L. Nummenmaa*[1]*, P. Nuutila*[1]*;*
[1]Turku PET Centre, University of Turku and Turku University Hospital, Turku, FINLAND, [2]Department of Radiology, University of Turku, Turku, FINLAND, [3]Nara Institute of Science and Technology, Ikoma, JAPAN, [4]Kagawa University School of Medicine, Kagawa, JAPAN, [5]Department of Medical Physics, Turku University Hospital, Turku, FINLAND, [6]Advanced Clinical Imaging Technology, Siemens Healthcare AG, Lausanne, SWITZERLAND.

608
Sunday, September 10, 2023, 4:45 PM - 6:15 PM
Hall F2

Inflammation & Infection Committee - TROP Session: Infection and Inflammation Imaging: New Frontiers

OP-248
^{99m}Tc-Ethambutol Single Photon Emission Computed Tomography/Computed Tomography (SPECT/CT) Scan in Pulmonary Tuberculosis: Correlation of ^{99m}Tc-Ethambutol Avidity with CT Manifestations
F. Aghahosseini[1,2]*, Y. Salehi*[1,2]*, S. Farzanefar*[1,2]*, M. Abbasi*[1,2]*, F. Saboktakin*[1,2]*, N. Vahidfar*[1,2]*, P. Sheikhzadeh*[1]*;*
[1]Tehran University of Medical Science, Tehran, IRAN, ISLAMIC REPUBLIC OF, [2]Nuclear Medicine Department, Valiasr Hospital, Imam Khomeini Complex Hospital, Tehran, IRAN, ISLAMIC REPUBLIC OF.

OP-249
Head to head comparison of ultrasound and Tc - 99m glucosamine SPECT/CT imaging of patients with rheumatoid arthritis of the knee.
O. Evbuomwan*, G. Engelbrecht;*
University Of The Free State, Bloemfontein, SOUTH AFRICA.

OP-250
SUV-Based Assessment of Known or Suspected Polyarthritis on Double-Phase Whole-Body Bone Tomoscintigraphies Provided by a High-Speed CZT Camera
F. Rajadhas[1]*, C. Morizot*[2]*, D. Loeuille*[2]*, I. Chary-Valckenaere*[2]*, V. Roch*[1]*, P. Marie*[1,3]*, L. Imbert*[1,3]*, A. Bahloul*[1,3]*;*
[1]CHRU-Nancy, Department of Nuclear Medicine and Nancyclotep Imaging Platform, Nancy, FRANCE, [2]CHRU-Nancy, Department of Rheumatology, Nancy, FRANCE, [3]Université de Lorraine, INSERM U1254, IADI, Nancy, FRANCE.

OP-251
Assessing the augmentive value of 18F-FDG PET/CT over 99mTc-MDP bone scan in distinguishing infection from aseptic loosening of prostheses.
S. Shamim*, H. Khairwa, S. Sagar, D. Khan, K. Sivashankar, N. Kundu, N. Kumar, G. Arora, R. Kumar;*
AIIMS New Delhi, Delhi, INDIA.

OP-252
[^{18}F]FDG PET/CT identified infections and inflammation in persistent critical illness
B. van Leer*, K. M. Demenaga, M. W. N. Nijsten, J. H. van Snick, R. H. J. A. Slart, A. W. J. M. Glaudemans, J. Pillay;*
UMCG, Groningen, NETHERLANDS.

OP-253
Comparison of [^{18}F]FDG and [^{18}F]DPA714 for the visualization of the pathogenesis of pulmonary tuberculosis in rhesus monkeys (Macaca mulatta)
M. Stammes[1]*, M. Vierboom*[1]*, C. Sombroek*[1]*, J. Bakker*[1]*, R. Vervenne*[1]*, S. Hofman*[1]*, A. Windhorst*[2]*, J. Langermans*[1,3]*, F. Verreck*[1]*;*
[1]BPRC, Rijswijk, NETHERLANDS, [2]Amsterdam UMC, Amsterdam, NETHERLANDS, [3]Utrecht University, Utrecht, NETHERLANDS.

OP-254
68Ga-triacetylfusarinine C (TAFC) Siderophore PET/CT for Detection of Invasive Aspergillus Infection: the SPECIFIC Clinical Trial Protocol
S. M. Levy[1,2,3]*, B. Z. Sim*[4,2]*, M. Haskali*[1,2]*, C. Decristoforo*[5]*, H. Haas*[6]*, M. Slavin*[4,2]*, M. Hofman*[1,2]*, A. Douglas*[4,2]*;*
[1]Molecular Imaging and Therapeutic Nuclear Medicine, Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, AUSTRALIA, [2]Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, AUSTRALIA, [3]Department of Nuclear Medicine, The Royal Melbourne Hospital, Melbourne, AUSTRALIA, [4]Department of Infectious Diseases, Peter MacCallum Cancer Centre, Melbourne, AUSTRALIA, [5]Department of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, AUSTRIA, [6]Institute of Molecular Biology, Biocenter, Medical University of Innsbruck, Innsbruck, AUSTRIA.

OP-255
FAPI PET/CT Imaging of Pulmonary Hypertension Caused by Fibrosing Mediastinitis and FAPI Radiotargeted Therapy
L. Song*, Z. Wu, C. Zan;*
First Hospital of Shanxi Medical University, Taiyuan, CHINA.

OP-256
Increased Colonic TSPO Expression in Inflammatory Bowel Diseases by the Translocator Protein 18kDa Radioligand [18F]DPA-714
Q. He[1]*, D. Jiang*[2]*, Y. Guan*[2]*, A. Fei*[1]*, F. Xie*[2]*;*
[1]Department of General Medicine, Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine., Shanghai, CHINA, [2]Department of Nuclear Medicine & PET center, Huashan Hospital, Fudan University, Shanghai, CHINA.

609
Sunday, September 10, 2023, 4:45 PM - 6:15 PM
Hall G2

e-Poster Presentations Session 4 - Thyroid Committee: Thyroid and Parathyroid Disease

EPS-063
Implementing a Clinical Pathway for Treatment with I 131 for Differentiated Thyroid Cancer: Evaluation of Quality Objectives
J. Cruz Vasquez*, A. Alonso Echarte, I. Blanco Saiz, E. Anda Apiñaniz, A. Alomar Casanovas, I. Saura Lopez, A. Barrera Cerpa, N. Rudic Chipe, M. Ribelles Segura, E. Goñi Gironés, A. Camarero Salazar;*
Hospital Universitario de Navarra, Pamplona, SPAIN.

EPS-064
FNA-Tg in Metastatic Lymph Node Predictions Local Recurrence Following Lateral Neck Dissection in Papillary Thyroid Carcinoma
Y. Yang[1]*, X. Jia*[1]*, J. Hui*[2]*, A. Yang*[1]*, R. Gao*[1]*;*
[1]the First Affiliated Hospital of Xi 'an Jiaotong University, Xi 'an, Shaanxi, CHINA, [2]Shaanxi Cancer Hospital, Xi 'an, Shaanxi, CHINA.

EPS-065
Role of ^{18}F-NaF PET/CT on bone evaluation in patients with differentiated thyroid cancer undergoing radioactive iodine therapy and ^{18}F-FDG PET/CT: preliminary results
F. Volpe[1]*, C. Nappi*[1]*, E. Zampella*[1]*, E. Nicolai*[2]*, L. Piscopo*[1]*, D. Bianco*[3]*, C. Vallone*[1]*, F. Volpicelli*[1]*, M. Falzarano*[1]*, L. Pace*[4]*, A. Cuocolo*[1]*, M. Klain*[1]*;*
[1]Department of Advanced Biomedical Sciences, University Federico II, Naples, Italy, Napoli, ITALY, [2]IRCCS SDN, Diagnostic Imaging, Naples, Napoli, ITALY, [3]CIRA - Italian Aerospace Research Centre, Capua, ITALY, Capua, ITALY, [4]Dipartimento di Medicina, Chirurgia e Odontoiatria "Scuola Medica Salernitana" /DIPMED, Salerno, ITALY.

EPS-066
Correlation of thyroglobulin reduction index after ^{131}I therapy with RECIST1.1 assessment results in DTC with microscopic pulmonary metastases
T. Tian*, R. Huang;*
West China Hospital, Sichuan University, Chengdu, CHINA.

EPS-067
Towards clinical translation of a novel antibody-based ^{177}Lu-labeled radiopharmaceutical for treatment of anaplastic thyroid cancer
A. Mortensen[1,2]*, H. Berglund*[2]*, T. Mohajer Shojai*[2]*, H. Lotsholm Persson*[3]*, A. Stenman*[1]*, P. Jha*[2]*, C. Juhlin*[1]*, P. Bernhardt*[4]*, J. Zedenius*[1]*, F. Frejd*[2]*, M. Nestor*[2,3,3]*;*
[1]Karolinska Institutet, Stockholm, SWEDEN, [2]Uppsala University, Uppsala, SWEDEN, [3]Science for Life Laboratory, Stockholm, SWEDEN, [4]University of Gothenburg, Gothenburg, SWEDEN.

EPS-068
Differentiating subcentometer pulmonary metastases in differentiated thyroid cancer patients by integration of machine learning and deep learning: a retrospective, multicenter study
X. Gao*;*
Department of Radiology, Zhejiang Cancer Hospital, Hangzhou, CHINA.

EPS-069
Modeling Clinical Radioiodine Uptake by Using Organoids Derived from Differentiated Thyroid Cancer
X. Zhang[1]*, J. Liu*[2]*, Z. Li*[2]*, R. Huang*[1]*;*
[1]Department of Nuclear Medicine, West China Hospital, Sichuan University, Chengdu, CHINA, [2]Department of Thyroid Surgery, West China Hospital Sichuan University, Chengdu, CHINA.

EPS-070
Cytoreductive efficacy of radioiodine treatment in hyperfunctioning thyroid nodules.
A. Alomar*, I. Blanco, F. Lozada, A. Irigaray, J. Pineda, M. Ollero, I. Saura, J. Cruz, A. Barrera, N. Rudic, M. Ribelles, A. Camarero, E. Anda, E. Goñi;*
Hospital Universitario de Navarra (HUN), Pamplona, SPAIN.

EPS-071
The effect of radioiodine therapy I-131 in patients with non-toxic nodular goitre
S. Abdelrazek*, J. Mysliwiec, P. Szumowski, W. Madra, L. Zukowski;*
Department of Nuclear Medicine, Medical University of Bialystok,
Bialystok, POLAND.

EPS-072
Variables Associated With Positive [^{18}F]F-Choline Pet/Ct Uptake In Primary Hyperparathyroidism With Negative [^{99m}Tc]Tc-Mibi Scintigraphy
M. Guerra Gómez*, J. Cuenca Cuenca, N. Valerdiz Menéndez, A. Rodríguez Pajuelo, J. Tirado Hospital, J. Jiménez-Hoyuela García;*
University Hospital Virgen del Rocío, Seville, SPAIN.

EPS-073
Incremental value of Tc-99m-sestamibi SPECT/CT in patients with positive planar scintigraphy in the detection of additional lesions in patients with Primary hyperparathyroidism
R. Goel*, N. Damle, Y. Dharmashaktu, C. Bal, P. Kumar, A. Goyal, R. Gupta, Y. Gupta, R. Aphale, G. Puri, S. Chumber;*
All India Institute of Medical Sciences (AIIMS), New Delhi, INDIA.

EPS-074
18F-Choline PET/MR for the Localization of Hyperplastic Parathyroid: Preliminary Analysis from a Monocentric Study
C. Gagliani*, P. Bartoletti, V. Camozzi, S. Sperti, F. Torresan, M. Iacobone, L. Evangelista;*
Azienda Ospedaliera Universitaria di Padova, Padova, ITALY.

EPS-075
CXCR4-directed [^{68}Ga]Ga-PentixaFor PET/CT as a novel diagnostic modality in primary aldosteronism
A. Chaman Baz[1]*, M. Gotthardt*[1]*, W. Spiering*[2]*, B. de Keizer*[2]*, J. Deinum*[1]*, J. F. Langenhuijsen*[1]*;*
[1]Radboudumc, Nijmegen, NETHERLANDS, [2]UMC Utrecht, Utrecht, NETHERLANDS.

EPS-076
Role of 68Ga-DOTANOC, 18F-FDOPA and 68 Ga-Exendin PET/CT imaging in adult patients with Hyperinsulinemic Hypoglycemia(HI)
S. Sagar, *N. A. Damle, D. Khan, P. Kumar, C. Bal, M. Tripathi, N. Tandon, Y. Gupta;*
AIIMS, Delhi, INDIA.

EPS-077
Association between BAT detection (and activity) with FDG PET/CT and cancer prognostic: an Artificial Intelligence (AI) enhanced systematic review.
P. Jané[1], *E. Jané*[2], *E. Pirazzo Teixeira*[1], *V. Garibotto*[1], *K. Gariani*[3];
[1]*Service of Nuclear Medicine and Molecular Imaging, Hôpitaux Universitaires de Genève, Genève, SWITZERLAND,* [2]*Universidad Politécnica de Madrid, Madrid, SPAIN,* [3]*Service of Endocrinology, Diabetes, Nutrition and Therapeutic education, Hôpitaux Universitaires de Genève, Genève, SWITZERLAND.*

EPS-078
^{68}Ga-DOTATATE PET/CT versus ^{18}F- FDG PET/CT in TENIS syndrome - Impact in management and theranostics strategies - Pilot study
L. Almeida[1], *A. Santos*[1], *T. O. Costa*[2], *M. Araújo*[1], *L. Assumpção*[1], *M. Lima*[1], *T. Souza*[1], *D. Wittmann*[1], *E. Etchebehere*[1];
[1]*Campinas University, Campinas, BRAZIL,* [2]*Ebserh, Bahia, BRAZIL.*

EPS-079
Role of Integrated ^{18}F-Fluorocholine PET/4DCT in the localization of culprit lesions in patients with primary hyperparathyroidism
Y. Dharmashaktu, *N. A. Damle, C. Bal, M. Tripathi, P. Kumar, R. N. Wakankar, S. Chumber, Y. Gupta, D. K, S. Agarwal, C. Kumar, R. Goel;*
All India Institute of Medical Sciences, Delhi, INDIA.

EPS-080
18F-Fluorocholine PET/CT and scintigraphy detection rate stratified by PTH levels in parathyroid imaging
N. Jacquet-Francillon, *I. Morelec, M. Dietz, A. Clotagatide, J. Tordo, L. Al-Mansour, S. Isal, A. Flaus;*
Hospices Civils de Lyon, Lyon, FRANCE.

EPS-081
Concordance between 18F-Fluorocholine PET-CT and surgery in the localization of parathyroid adenomas in patients with primary hyperparathyroidism
P. Daudén Oñate[1], *A. Ortega Candil*[1], *C. Rodríguez Rey*[1], *G. Cuesta Domingo*[1], *S. Ochagavía Cámara*[1], *R. Cano Carrizal*[2], *I. Domínguez Serrano*[1], *S. Mera Carreiro*[1], *M. Meneses Navas*[1], *P. Nespral Torres*[1], *P. Romero Fernández*[1], *A. Berardinelli*[1], *M. Cabrera Martín*[1], *P. Bascuñana Almarcha*[1];
[1]*Hospital Clínico San Carlos, Madrid, SPAIN,* [2]*Hospital Infanta Sofía, Madrid, SPAIN.*

EPS-082
Impact of Radioactive Iodine on Survival outcomes for Differentiated Thyroid Carcinoma - Understanding the Factors at Play
A. Al ibraheem, *U. Al-Rasheed, A. S. Abdlkadir, N. Mashhadani, S. Ruzzeh, D. A. Al-Adhami, I. Mohamad, B. Hamdan, R. Kheetan, M. E. Juweid, A. Mansour, F. Istatieh;*
King Hussein Cancer Center, Amman, JORDAN.

EPS-083
Differential serum miRNA profile in well differentiated thyroid cancer and benign thyroid disease. Prognosis of patients with this miRNA profile five years after radioiodine treatment
O. Bourogianni[1], *N. Kapsoritakis*[1], *E. Tsitoura*[2], *A. Tsaroucha*[1], *G. Lamprakopoulos*[1], *M. Stathaki*[1], *E. Papadaki*[1], *S. Koukouraki*[3];
[1]*Department of Nuclear Medicine, University Hospital of Crete, Heraklion, GREECE,* [2]*Laboratory of Molecular and Cellular Pneumonology, Medical School, University of Crete, HERAKLION, GREECE,* [3]*Department of Nuclear Medicine, Medical School, University of Crete, Heraklion, GREECE.*

610

Sunday, September 10, 2023, 16:45 - 18:15
Hall K

CTE 3 - Technologists Committee: Patient Care in Nuclear Medicine

OP-257
Improving understanding of patients' experience
A. Grilo;
Escola Superior de Tecnologia da Saúde, Instituto Politécnico, Lisbon, PORTUGAL.

OP-258
Looking beyond the images: practical examples in paediatrics
I. Baeta;
Kings College Hospital NHS Foundation Trust, Nuclear Medicine and PET/CT Department, London, UNITED KINGDOM.

OP-259
Shaping patient experience in PET-CT, PET-MRI, and Clinical Trials
P. Turco;
Department of Medicine DIMED, University-Hospital of Padova, Padova, ITALY.

611

Sunday, September 10, 2023, 16:45 - 18:15
Hall G1

Special Symposium 1 - EANM/EARL: Harmonisation and Accreditation Accelerate Research and Clinical Translation

OP-260
To EARL" or "Not To EARL" in Clinical Practice?
S. Stroobants;
Antwerp University Hospital, Antwerp, BELGIUM.

OP-261
EARL 1 and EARL 2. Where are we now?
I. Hristova;
EARL, Vienna, AUSTRIA.

OP-262
Accreditation for Brain PET studies
R. Boellaard;
Amsterdam UMC, Amsterdam, NETHERLANDS.

OP-263
Harmonisation in quantitative SPECT and its challenges
J. Tran-Gia;
Universitätsklinikum Würzburg, Würzburg, GERMANY.

701

Monday, September 11, 2023, 08:00 - 09:30
Hall A

CME 5 - Oncology & Theranostics Committee: Will the Microenvironment Become Even More Important in Nuclear Medicine?

OP-269
The future of the oldest Megaimportant Nuclear Medicine marker of the menvironment
S. Carrilho Vaz;
Champalimaud Centre for the Unknown, Champalimaud Foundation, Department of Nuclear Medicine - Radiopharmacology, Lisbon, PORTUGAL.

OP-270
Hypoxia - The importance of spotting such a hostile menvironment
W. Weber;
Technical University of Munich, Department of Nuclear Medicine, Munich, GERMANY.

OP-271
Immune system – Immunotherapy enthusiasm will fuel new techniques in Nuclear Medicine?
N. Schäfer;
Lausanne University Hospital, Nuclear Medicine and Molecular Imaging Department, Lausanne, SWITZERLAND.

OP-272
Cancer-associated fibroblasts - Highlighting no-malignant cells that are in the dark, serving malignant cells
S. Dalm;
Erasmus MC, Radiology & Nuclear Medicine Department, Rotterdam, NETHERLANDS.

702

Monday, September 11, 2023, 08:00 - 09:30
Hall D (Arena)

Debate 2 - Neuroimaging Committee: What is the Best Tracer for Molecular Brain Tumour Imaging?

OP-273
Conventional tracers: Is it all about amino acid tracers or is there still a role for FDG?
F. Cicone;
Dipartimento di Medicina Sperimentale e Clinica (DMSC) Università degli Studi "Magna Graecia" di Catanzaro (ITALY) Università degli Studi "Magna Graecia" di Catanzaro, Catanzaro, ITALY.

OP-274
Novel radiotracers: why do we need more than amino acid tracers?
N. Albert;
Klinikum der Ludwig-Maximilians-Universität, Munich, GERMANY.

703

Monday, September 11, 2023, 08:00 - 09:30
Hall E1

LIPS Session 5 - Cardiovascular + Physics Committee: Challenges in MBF Quantification

OP-279
Patient motion and data-driven motion correction
I. Armstrong;
Manchester University NHS Foundation Trust, Nuclear Medicine, Manchester, UNITED KINGDOM.

OP-280
SPECT: is there anybody out there?
L. Imbert;
CHRU Nancy Brabois, Nuclear Medicine Department, Nancy, FRANCE.

OP-281
Accuracy of MBF estimates and cut-off values
M. Lubberink;
Uppsala University, Nuclear Medicine & PET, Uppsala, SWEDEN.

OP-282
Challenges of using quantification in clinical practise
I. Danad;
Utrecht University Medical Centre / Amsterdam University Medical Centre, Cardiology, Utrecht, NETHERLANDS.

704

Monday, September 11, 2023, 8:00 AM - 9:30 AM
Hall E2

M2M Track - TROP Session: Imaging Inflammatory Processes in Cardiovascular Diseases

OP-284

Dynamic Expression of Myocardial Sigma-1 Receptor in Doxorubicin-Induced Cardiomyopathy using Radioiodine Labeled 2-[4-(2-iodophenyl) piperidino]cyclopentanol (OI5V) Imaging

Z. Chen[1], *H. Wakabayashi*[1], *H. Mori*[1], *T. Hiromasa*[1], *X. Zhang*[1], *T. Kozaka*[2], *K. Ogawa*[3], *S. Kinuya*[1], *J. Taki*[4,1];
[1]*Department of Nuclear Medicine, Kanazawa University Hospital, Kanazawa, JAPAN,* [2]*Division of Probe Chemistry for Disease Analysis, Research Center for Experimental Modeling of Human Disease, Kanazawa University, Kanazawa, JAPAN,* [3]*Institute for Frontier Science Initiative, Kanazawa University, Kanazawa, JAPAN,* [4]*PET Center, Kanazawa Advanced Medical Center, Kanazawa, JAPAN.*

OP-285

Early evaluation of organ fibrosis in Angiotensin II-induced hypertensive mouse model using ^{68}Ga-FAPi46 PET

J. Byun[1,2,3], *Y. Kim*[1,3], *Y. Lee*[1], *J. Paeng*[1], *K. Kang*[1], *G. Cheon*[1];
[1]*Department of Nuclear Medicine, Seoul National University Hospital, Seoul, KOREA, REPUBLIC OF,* [2]*Department of Biomedical Sciences, Seoul National University, Seoul, KOREA, REPUBLIC OF,* [3]*Cancer Research Institute, Seoul National University, Seoul, KOREA, REPUBLIC OF.*

OP-286

The evolution and prognostic value of ^{68}Ga-Pentixafor uptake in the myocardium after acute infarction

P. Wu[1,2], *S. He*[3], *M. Yan*[1], *H. Wang*[1,2], *X. Liu*[4], *Z. Xiang*[1], *L. Xu*[1,5], *Y. Zhao*[1,5], *X. Li*[6], *M. Hacker*[6], *Z. Wu*[1,2], *S. Li*[1,2];
[1]*Department of Nuclear Medicine, First Hospital of Shanxi Medical University, Taiyuan, CHINA,* [2]*Shanxi Key Laboratory of Molecular Imaging, Shanxi Medical University, Taiyuan, CHINA,* [3]*Department of Radiology, First Hospital of Shanxi Medical University, Taiyuan, CHINA,* [4]*Department of Radiology, Shanxi Bethune Hospital(Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical University), Taiyuan, CHINA,* [5]*Collaborative Innovation Center for Molecular Imaging of Precision Medicine, Shanxi Medical University, Taiyuan, CHINA,* [6]*Division of Nuclear Medicine, Department of Biomedical Imaging and ImageGuided Therapy, Medical University of Vienna, Vienna, AUSTRIA.*

OP-287

Translocator protein 18kDa positron emission tomography imaging of ^{18}F-FDPA in rabbits with vulnerable atherosclerosis plaques

W. Dong, *J. Jiao, T. Mou, Y. Zhang, H. Mi;*
Beijing Anzhen Hospital, Beijing, CHINA.

OP-288

^{99m}Tc-AFN: A Nanobody-Based SPECT Radiotracer with Clinical Potential for Noninvasive Monitoring of Fibroblast Activity After Myocardial Infarction

X. Zhang[1], *Z. Ai*[1], *C. Li*[2], *B. Jia*[2], *M. Yang*[1];
[1]*Department of Nuclear Medicine, Beijing Chaoyang Hospital, Beijing, CHINA,* [2]*Medical Isotopes Research Center and Department of Radiation Medicine, School of Basic Medical Sciences, Peking University, Beijing, CHINA.*

OP-289

Temporal characterisation of inflammation and active collagen biosynthesis in the rat heart post myocardial infarction, using novel Positron Emission Tomography (PET) radiotracers.

V. Reid[1,2], *M. G. MacAskill*[1,2], *K. Pandya*[1], *A. Arcidiacono*[1], *C. Alcaide Corral*[1,2], *T. E. F. Morgan*[1,2], *V. Balogh*[1], *L. M. Riley*[3], *T. Fujisawa*[1], *N. L. Mills*[1,4], *R. J. Lennen*[1,2], *M. A. Jansen*[1,2], *G. A. Gray*[1], *A. H. Baker*[1,5], *D. E. Newby*[1], *A. Sutherland*[3], *A. A. S. Tavares*[1,2];
[1]*Centre for Cardiovascular Sciences, University of Edinburgh, Edinburgh, UNITED KINGDOM,* [2]*Edinburgh Imaging, University of Edinburgh, Edinburgh, UNITED KINGDOM,* [3]*School of Chemistry, University of Glasgow, Glasgow, UNITED KINGDOM,* [4]*The Usher Institute, University of Edinburgh, Edinburgh, UNITED KINGDOM,* [5]*CARIM, School for Cardiovascular Diseases, Maastricht University, Maastricht, NETHERLANDS.*

OP-290

Positive Protective Effects of Sigma-1 Receptor Stimulation with Fluvoxamine after Myocardial Ischemia and Reperfusion in Rat

X. Zhang[1], *H. Wakabayashi*[1], *H. Mori*[1], *T. Hiromasa*[1], *Z. Chen*[1], *T. Kozaka*[2], *K. Ogawa*[3], *S. Kinuya*[1], *J. Taki*[1,4];
[1]*Department of Nuclear Medicine, Kanazawa University Hospital, Kanazawa, Ishikawa, JAPAN,* [2]*Division of Probe Chemistry for Disease Analysis, Research Center for Experimental Modeling of Human Disease, Kanazawa University, Kanazawa, Ishikawa, JAPAN,* [3]*Institute for Frontier Science Initiative, Kanazawa University, Kanazawa, Ishikawa, JAPAN,* [4]*PET Center, Kanazawa Advanced Medical Center, Kanazawa, Ishikawa, JAPAN.*

OP-291

C-X-C Motif Chemokine Receptor 4-Directed PET Signal in the Arterial Tree is not Consistently Linked to Calcified Plaque Burden and Cardiovascular Risk

N. Hasenauer[1], *A. Kosmala*[1], *S. E. Serfling*[1], *K. Michalski*[1], *M. Fröhlich*[2], *N. Dreher*[1], *P. E. Hartrampf*[1], *T. Higuchi*[1,3], *A. K. Buck*[1], *A. Weich*[2,4], *T. Reiter*[5], *R. A. Werner*[1,4,6];
[1]*Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, GERMANY,* [2]*Internal Medicine II, University Hospital Würzburg, Würzburg, GERMANY,* [3]*Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, JAPAN,* [4]*NET-Zentrum Würzburg, European Neuroendocrine Tumor Society Center of Excellence (ENETS CoE), University Hospital Würzburg, Würzburg, GERMANY,* [5]*Internal Medicine I, University Hospital Würzburg, Würzburg, GERMANY,* [6]*Johns Hopkins School of Medicine, The Russel H Morgan Department of Radiology and Radiological Sciences, Baltimore, MD, UNITED STATES OF AMERICA.*

OP-292

Molecular Imaging in Cardio-Oncology: Detecting Cardiotoxicity of Breast Cancer Treatments Through Radionuclide Ventriculography and Novel Cardiac Biomarkers Assessment

A. Lazar[1], *M. Mutuleanu*[1,2], *I. Irimescu*[1,3], *R. Maaz*[1], *C. Petroiu*[1], *M. Gherghe*[1,2];
[1]*Institute of Oncology "Professor Doctor Alexandru Trestioreanu", Bucharest, ROMANIA,* [2]*University of Medicine and Pharmacy "Carol Davila", Bucharest, ROMANIA,* [3]*Applied Sciences Doctoral School, Politehnica University, Bucharest, ROMANIA.*

705

Monday, September 11, 2023, 8:00 AM - 9:30 AM
Hall B

Cutting Edge Science Track - Featured Session: Imaging Guided Surgery

OP-293

Surgical Radioguidance with Beta emitting Radionuclides

P. Fragoso Costa;
Department of Nuclear Medicine at University Hospital Essen, Essen, GERMANY.

OP-294

Translation of a drop-in beta probe for robotic radio guided surgery

F. Collamati[1], *R. Mirabelli*[1], *R. Faccini*[2], *F. Ceci*[3], *E. Bertani*[4], *G. Musi*[5], *M. N. van Oosterom*[6], *F. van Leeuwen*[7], *S. Morganti*[1];
[1]*INFN Rome, Roma, ITALY,* [2]*Università Roma Sapienza, Roma, ITALY,* [3]*1.IEO European Institute of Oncology, Nuclear Medicine, Milano, ITALY,* [4]*2.IEO European Institute of Oncology, Division of Digestive Surgery, Milano, ITALY,* [5]*IEO European Institute of Oncology, Division of Urology, Milano, ITALY,* [6]*Leiden University Medical Center | Interventional Molecular Imaging Laboratory, Department of Radiology, Leiden, NETHERLANDS,* [7]*Leiden University Medical Center | Interventional Molecular Imaging Laboratory, Department of Radiology, Leiden, ITALY.*

OP-295

Live Nuclear/X-ray Imaging during Radioembolization Interventions using a Novel Hybrid C-arm Scanner

M. Dietze, *M. B. M. Meddens, R. van Rooij, A. J. A. T. Braat, B. de Keizer, R. C. G. Bruijnen, M. G. E. H. Lam, M. L. J. Smits, H. W. A. M. de Jong;*
University Medical Center Utrecht, Utrecht, NETHERLANDS.

OP-296

Investigation of a CZT-based hand-held gamma-camera for pre-clinical imaging of alpha-emitter ^{225}Ac

D. Roth[1], *Z. Ells*[2], *M. Dahlbom*[2], *J. Strand*[3,4], *C. Mona*[2,5], *P. Jean Jean*[2,5], *M. Ljungberg*[1], *S. Strand*[1];
[1]*Medical Radiation Physics, Lund, Lund University, Lund, SWEDEN,* [2]*Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California – Los Angeles, Los Angeles, CA, UNITED STATES OF AMERICA,* [3]*Department of Clinical Sciences Lund, Oncology, Lund University, Lund, SWEDEN,* [4]*Department of Hematology, Oncology, Radiation Physics, Skåne University Hospital, Lund University, Lund, SWEDEN,* [5]*Jonsson Comprehensive Cancer Center, University of California – Los Angeles, Los Angeles, CA, UNITED STATES OF AMERICA.*

OP-297

CT-guided percutaneous marking of small pulmonary nodules with [^{99m}Tc]Tc-Macrosalb is very accurate and allows minimally invasive lung-sparing resection: a single-centre quality control

N. Doncic, *C. J. Zech, D. Wild, H. Bachmann, M. Mallaev, N. Tsvetkov, A. Hojski, M. T. L. Takes, D. Lardinois;*
Basel University Hospital, Basel, SWITZERLAND.

OP-298

A truncated 14-amino acid myelin protein zero targeting peptide for fluorescence-guided nerve preserving surgery

N. Berehova, *M. P. van Meerbeek, S. Azargoshasb, L. J. Slof, S. Navaei Lavasani, M. N. van Oosterom, F. W. B. van Leeuwen, T. Buckle;*
Leiden University Medical Center, Leiden, NETHERLANDS.

OP-299

Metabolic 18F FDG PET/CT Guided Intrathoracic Tumor Biopsies: An Analysis of Initial Experience from Central India.

M. Ravina, *R. Ganga, A. Behera, T. Lukose, S. Krishna, S. Dasgupta, R. Kote, A. Rath;*
All India Institute of Medical Sciences, Raipur, Raipur, INDIA.

OP-300

Gamma-Flex, a novel flexible gamma probe for minimal invasive laparoscopic interventions

M. van Oosterom[1], *L. J. Slof*[1], *S. Navaeilavasani*[1], *S. Azargoshasb*[1], *K. Schwenkenbecher*[2], *J. Scheltes*[3], *F. W. B. van Leeuwen*[1];
[1]*Leiden University Medical Center, Leiden, NETHERLANDS,* [2]*Crystal Photonics, Berlin, GERMANY,* [3]*DEAM, Amsterdam, NETHERLANDS.*

OP-301

Performance Evaluation of ^{18}F-PSMA and ^{68}Ga-PSMA in a Novel MicroPET/CT System Dedicated to Radioguided Surgery

A. Moraitis[1], *C. Darr*[2], *T. Kahl*[2], *L. Püllen*[2], *W. Jentzen*[1], *D. Kersting*[1], *B. Hadaschik*[2], *K. Herrmann*[1], *W. P. Fendler*[1], *P. Fragoso Costa*[1];
[1]*Department of Nuclear Medicine at University Hospital Essen, Essen, GERMANY,* [2]*Department of Urology at University Hospital Essen, Essen, GERMANY.*

706

Monday, September 11, 2023, 8:00 AM - 9:30 AM
Hall C

Clinical Oncology Track - TROP Session: Neuroendocrine Tumors - Diagnosis

OP-302

First-in-human Study of an Optimized, potential Kit-type, SSTR Antagonist ^{68}Ga-DATA^{5m}-LM4 in Neuroendocrine Tumors

J. Zhang[1], *L. Greifenstein*[2], *V. Jakobsson*[1], *C. Kramer*[2], *C. Landvogt*[2], *C. Mueller*[2], *R. P. Baum*[2];
[1]*National University of Singapore, Singapore, SINGAPORE,* [2]*Curanosticum Wiesbaden-Frankfurt, Center for Advanced Radiomolecular Precision Oncology, Wiesbaden, GERMANY.*

OP-303

A Prospective Evaluation of [^{18}F]AlF-NOTA-LM3 in Patients with Well-differentiated Neuroendocrine Tumors: Head-to-head Comparison with^{68}GaDOTATATE

M. Liu, *W. Zhu, Y. Zhang, C. Ren, H. Zhang, Z. Huang, L. Huo;*
Peking Union Medical College Hospital, Beijing, CHINA.

OP-304

Superiority of ^{68}Ga-DOTATATE PET/CT compared to ^{18}F-FDG PET/CT, MRI of the spine, and whole-body diagnostic CT and MRI in the detection ofspinal bone metastases associated with pheochromocytoma and paraganglioma

A. Jha[1], *M. Patel*[1], *A. Ling*[1], *R. Shah*[1], *C. C. Chen*[1], *C. Millo*[1], *M. A. Nazari*[1], *N. Sinaii*[1], *K. Charles*[1], *M. J. Kuo*[1], *T. Prodanov*[1], *B. Saboury*[1], *S. Talvacchio*[1], *A. Derkyi*[1], *J. del Rivero*[1], *G. O'Sullivan Coyne*[1], *A. P. Chen*[1], *N. Nilubol*[1], *P. Herscovitch*[1], *F. I. Lin*[1], *D. Taïeb*[1], *A. C. Civelek*[2], *J. A. Carrasquillo*[1], *K. Pacak*[1];
[1]*National Institutes of Health, Bethesda, MD, UNITED STATES OF AMERICA,* [2]*Johns Hopkins Medicine, Baltimore, MD, UNITED STATES OF AMERICA.*

OP-305

Prognostic Value of C-X-C motif Chemokine Receptor 4-directed Molecular Imaging in Patients with Advanced Adrenocortical Carcinoma

W. Schlötelburg[1], *P. E. Hartrampf*[1], *A. Kosmala*[1], *S. E. Serfling*[1], *A. Schirbel*[1], *A. K. Buck*[1], *M. Fassnacht*[2], *S. Hahner*[2], *R. A. Werner*[1,3];
[1]*Department of Nuclear Medicine, University Hospital of Würzburg, GERMANY,* [2]*Division of Endocrinology and Diabetes, Department of Medicine I, University Hospital of Würzburg, GERMANY,* [3]*The Russel H. Morgan Department of Radiology and Radiological Science, Johns Hopkins Unversity School of Medicie, MD, UNITED STATES OF AMERICA.*

OP-306

"Novel ^{99m}Tc-labelled somatostatin antagonists in the diagnostic algorithm of neuroendocrine neoplasms" - results of a multicenter phase I clinical trial - TECANT

M. Opalinska[1], *I. Virgolini*[2], *L. Lezaic*[3], *G. di Santo*[2], *C. Decristoforo*[2], *P. Kolenc*[3], *R. Mikolajczak*[4], *A. Studen*[5], *P. Garnuszek*[4], *U. Simoncic*[5], *M. Trofimiuk-Muldner*[1], *C. Rangger*[2], *B. Glowa*[6], *K. Skorkiewicz*[6], *M. Fani*[7], *A. Sowa-Staszczak*[1], *B. Janota*[4], *M. Kroselj*[3], *S. Rep*[3], *A. Hoermann*[2], *A. Hubalewska-Dydejczyk*[1];
[1]*Chair and Department of Endocrinology, Jagiellonian Medical College, Krakow, POLAND,* [2]*Department of Nuclear Medicine, Medical University Innsbruck, Innsbruck, AUSTRIA,* [3]*Department of Nuclear Medicine , University Medical Centre Ljubljana, Ljubljana, SLOVENIA,* [4]*National Centre for Nuclear Research Radioisotope Centre POLATOM, Otwock, POLAND,* [5]*Faculty of Mathematics and Physics, University of Ljubljana, Ljubljana, SLOVENIA,* [6]*Nuclear Medicine Unit, University Hospital in Krakow, Krakow, POLAND,* [7]*Universitätsspital Basel, Basel, SWITZERLAND.*

OP-307

Comparison of [^{68}Ga]Ga-DOTANOC and [^{68}Ga]Ga-DATA^{5m}-LM4 PET/CT in the same patient group with neuroendocrine tumors.

R. V[1], *S. Ballal*[1], *M. Yadav*[1], *F. Roesch*[2], *P. Sheokand*[1], *M. Martin*[2], *M. Tripathi*[1], *R. Sahoo*[1], *C. Bal*[1];
[1]*AIIMS, Delhi, INDIA,* [2]*Johannes Gutenberg university of Mainz, Mainz, GERMANY.*

OP-308

Prognostic value of the post-treatment ^{177}Lu-DOTATOC scintigraphy in NET patients undergoing PRRT.

S. Leyser[1,2], *H. Lanzafame*[1,2], *D. Kersting*[1,2], *R. Seifert*[1,2], *F. Zarrad*[1], *H. Lahner*[3], *N. Unger*[3], *W. P. Fendler*[1,2], *K. Herrmann*[1,2], *M. M. Weber*[1,4];
[1]*Department of Nuclear Medicine, West German Cancer Center, University Hospital Essen, Essen, GERMANY,* [2]*German Cancer Consortium (DKTK), Partner site University Hospital Essen, Essen, GERMANY,* [3]*Department of Endocrinology West German Cancer Center, University Hospital Essen, Essen, GERMANY,* [4]*German Cancer Consortium (DKTK), Partner site University Hospital Essen, Essen, Germany, Essen, GERMANY.*

OP-309

Optimized segmentation of neuroendocrine tumor lesions on somatostatin receptor PET/CT imaging for therapy response assessment

A. Chaban[1], *J. Brosch-Lenz*[1], *Y. Song*[1], *V. Dinkel*[1], *L. Bodei*[2], *W. Weber*[1];
[1]*Klinikum rechts der Isar, der Technischen Universität München, Munich, GERMANY,* [2]*Memorial Sloan Kettering Cancer Center, New York, NY, UNITED STATES OF AMERICA.*

OP-310

Diagnostic performance of functional imaging with ^{68}Ga-DOTATATE PET/CT, ^{18}F-FDG PET/CT, and ^{18}F-FDG PET/CT, and anatomic imaging with whole-body CT and/or MRI in the detection ofSDHD-related pheochromocytoma and paraganglioma - A comparative prospective study

A. Jha, *M. Patel, A. Ling, C. C. Chen, C. Millo, K. Charles, M. Kuo, T. Prodanov, M. A. Nazari, S. Talvacchio, A. Derkyi, J. del Rivero, A. P. Chen, N. Nilubol, P. Herscovitch, F. I. Lin, D. Taïeb, J. A. Carrasquillo, A. C. Civelek, K. Pacak;
National Institutes of Health, Bethesda, MD, UNITED STATES OF AMERICA.*

707

Monday, September 11, 2023, 8:00 AM - 9:30 AM
Hall F1

Paediatrics Committee - TROP Session: Neuroblastoma & Non-PET Paediatric Studies

OP-311

Prognostic and predictive value of imaging features in neuroblastoma using pre-treatment 123I-MIBG SPECT/CT: is there a place for radiomics?

M. Luporsi[1], *H. Brisse*[2], *C. Nioche*[3], *N. Jehanno*[1], *H. Fokem-Fosso*[3], *I. Buvat*[3], *G. Schleiermacher*[4], *F. Orlhac*[3];
[1]*Department of nuclear medicine, Institut Curie, PSL Research University, Institut Curie, Inserm , LITO-U1288, Paris, FRANCE,* [2]*Institut Curie, Inserm , LITO-U1288, Department of radiology, Institut Curie, PSL Research University, Paris, FRANCE,* [3]*Institut Curie, Inserm , LITO-U1288, Orsay, FRANCE,* [4]*SiREDO Integrated Pediatric, adolescents and young adults Oncology Center, Laboratory of translational research in pediatric oncology INSERM-U830, Institut Curie, Paris, FRANCE.*

OP-312

Comprehensive Analysis of 18F-MFBG Biodistribution and Variability in Pediatric Neuroblastoma Patients

P. Wang[1,2], *H. Zhang*[1], *Y. Zhang*[1], *T. Li*[1], *H. Jing*[1], *F. Li*[1], *J. Zhang*[2];
[1]*Department of Nuclear Medicine, Peking Union Medical College Hospital, Beijing, CHINA,* [2]*Department of Diagnostic Radiology, National University of Singapore, Singapore, SINGAPORE.*

OP-313

The ^{18}F-FDG PET/MRI radiomics nomogram for differentiating high-risk and non-high-risk patients of the International Neuroblastoma Risk Group Staging System

J. Liang;
杭州通用医学影像诊断中心,杭州, *CHINA.*

OP-314

First clinical experience with [^{64}Cu]Cu-NOTA-ch14.18/CHO to visualize GD2 by PET in several pediatric tumor entities - Biodistribution and preliminary dosimetry

N. Trautwein[1,2], *J. Schwenck*[1,2,3], *C. Seitz*[4,5], *S. von Beschwitz*[1], *G. Reischl*[2], *S. Scheuermann*[4,5], *P. Lang*[4], *J. Schaefer*[6], *B. Pichler*[2,3], *C. la Fougère*[1,3], *H. Dittmann*[1];
[1]*1Department of Nuclear Medicine and Clinical Molecular Imaging, Tuebingen, GERMANY,* [2]*2Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, Tuebingen, GERMANY,* [3]*3Cluster of Excellence iFIT (EXC 2180) "Image-Guided and Functionally Instructed Tumor Therapies", Tuebingen, GERMANY,* [4]*4Department of General Pediatrics, Hematology and Oncology, University Children's Hospital Tuebingen, Tuebingen, GERMANY,* [5]*5Cluster of Excellence iFIT (EXC 2180) "Image-Guided and Functionally Instructed Tumor Therapies", Tuebingen, GERMANY,* [6]*6Department of Diagnostic and Interventional Radiology, Tuebingen, GERMANY.*

OP-315

Reaching the target dose with one single [^{131}I]-mIBG treatment in high-risk neuroblastoma. The determinant impact of the primary tumour

F. Fiz[1], *A. Cirone*[1], *S. Righi*[1], *M. Massollo*[1], *L. Amoroso*[2], *G. Bottoni*[1], *M. Conte*[2], *M. Gambaro*[1], *F. Massone*[1], *G. Semino Bruzzone*[1], *S. Orengo*[1], *S. Sorrentino*[2], *A. Garaventa*[2], *A. Piccardo*[1];
[1]*Ospedale Galliera, Genova, ITALY,* [2]*IRCCS Istituto Giannina Gaslini, Genova, ITALY.*

OP-316

Utility and Optimal Scan Time of Diagnostic and Post-therapeutic Whole-Body Scan in Children and Young Adult Patients Administered with Iodine-131

P. Kumar, *C. Bal, N. A. Damle;
All India Institute of Medical Sciences, New Delhi, INDIA.*

OP-317

SPECT/CT in the diagnosis of Ectopic Gastric Mucosa-Meckel's Diverticulum

Z. Koç[1], *P. Özcan*[1], *F. Tuncel*[2], *C. İsbir*[3], *Y. Usta*[4];
[1]*Mersin University Hospital Nuclear Medicine Dpt., Mersin, TÜRKIYE,* [2]*Mersin University Hospital Pathology Dpt., Mersin, TÜRKIYE,* [3]*Mersin University Hospital Pediatric Surgery Dpt., Mersin, TÜRKIYE,* [4]*Mersin University Hospital Pediatric Gastroenterology Dpt., Mersin, TÜRKIYE.*

OP-318

Re-evaluating the milk scan protocol, perplexing or potentially prognostic?

K. Hlongwa[1], *A. Brink*[1], *S. M. Peters*[2], *S. More*[1];
[1]*Red Cross War Memorial Children's Hospital and University of Cape Town, Cape Town, SOUTH AFRICA,* [2]*Groote Schuur Hospital and School of Public Health and Family Medicine, University of Cape Town, Cape Town, SOUTH AFRICA.*

OP-319

Predictive Value of Diuretic Renogram for Progressive Hydronephrosis in Perinatally Detected Unilateral Hydronephrosis

C. Lin[1], *P. Chuang*[2], *I. Tsai*[3], *M. Cheng*[4];
[1]*National Taiwan University Hospital, Taipei City, TAIWAN,* [2]*Department of Nuclear Medicine, National Taiwan University Hospital Yunlin Branch, Douliu City, TAIWAN,* [3]*PEDIATRICS National Taiwan University Children Hospital and National Taiwan University College of Medicine, Taipei City, TAIWAN,* [4]*Nuclear Medicine National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei City, TAIWAN.*

708

Monday, September 11, 2023, 08:00 - 09:30
Hall F2

Special Symposium 2 - Inflammation & Infection Committee: Usefulness of PET in the Evaluation of Inflammatory Rheumatisms

OP-320

Clinical spectrum and imaging of inflammatory rheumatisms: a clinician's perspective

K. van der Geest;
UniversityMedical Center Groningen, Department of Rheumatology and Clinical Immunology, Groningen, NETHERLANDS.

OP-321

[18F]FDG PET/CT in inflammatory rheumatic disorders in elderly (PMR vs EORA vs SpA)

F. Besson;
Hôpitaux Universitaires Paris-Saclay, AP-HP, CHU Bicêtre, Department of Nuclear Medicine and Molecular Imaging, Paris, FRANCE.

OP-322a

[18F]FDG PET/CT in rheumatoid arthritis and other rheumatic disorders

P. Guglielmo;
Instituto Oncologico Veneto, Castelfranco Veneto, ITALY.

OP-322b

Beyond [18F]FDG in inflammatory rheumatisms

C. van der Laken;
Amsterdam UMC, Department of Rheumatology, Amsterdam, NETHERLANDS.

709

Monday, September 11, 2023, 8:00 AM - 9:30 AM
Hall G2

e-Poster Presentations Session 5 - Physics Committee: SPECT/CT, PET/CT, PET/MR Quantitative Imaging

EPS-084
ThyroPIX - Mobile Compton camera based on Timepix3 technology for monitoring of thyroid gland cancer treatment
E. Trojanova[1], *D. Doubravova*[1], *R. Kaderabek*[2], *V. Poriz*[3], *T. Kracmerova*[4];
[1]*ADVACAM s.r.o, Prague, CZECH REPUBLIC,* [2]*Radalytica as.s, Prague, CZECH REPUBLIC,* [3]*Radalytica a.s., Prague, CZECH REPUBLIC,* [4]*Fakultní nemocnice v Motole, Prague, CZECH REPUBLIC.*

EPS-085
Quantification of amyloid load from [^{18}F] florbetaben PET scans agrees with histopathology, visual read, and clinical progression
G. Kolinger[1], *L. Tiraboschi*[1], *F. Padovano*[2], *D. Braca*[2], *M. Spitilli*[2], *G. Lucidi Pressanti*[3], *S. Bullich*[1], *R. Mazza*[2];
[1]*Life Molecular Imaging GmbH, Berlin, GERMANY,* [2]*Nuclear Medicine Unit, "G. Mazzini" Hospital, Teramo, ITALY,* [3]*Services Department, "G. Mazzini" Hospital, Teramo, ITALY.*

EPS-086
2-layer Hemispheric PET featuring different materials on each layer
K. Scheiff, *A. Pashazadeh, C. Hoeschen;*
Otto-von-Guericke-University Magdeburg, Magdeburg, GERMANY.

EPS-087
Survey of Patient Journeys throughout Nuclear Medicine Services
A. Brink[1], *K. Pathmaraj*[2], *M. Marengo*[3], *B. Arends*[4], *Z. Jawa*[5], *R. Jaimovich*[6], *T. Pascual*[7], *S. Rubow*[8], *L. Torres*[9], *S. Vinjamuri*[10], *E. Woodrow*[11], *M. Dondi*[1], *D. Paez*[1];
[1]*International Atomic Energy Agency, Vienna, AUSTRIA,* [2]*Austin Health, Melbourne, AUSTRALIA,* [3]*University of Bologna, Bologna, ITALY,* [4]*Catharina Ziekenhuis, Eindovhen, NETHERLANDS,* [5]*SQUH, Muscat, OMAN,* [6]*Universidada Catolica de Chile, Santiago, CHILE,* [7]*PNRI, Manila, PHILIPPINES,* [8]*University of Stellenbosch, Stellenbosch, SOUTH AFRICA,* [9]*CENTIS, Havana, CUBA,* [10]*Liverpool University Hospital, Liverpool, UNITED KINGDOM,* [11]*Singapore General Hospital, Singapore, SINGAPORE.*

EPS-088
Development of phantom analysis software package for Japanese Society of Nuclear Medicine PET imaging site qualification program
K. Matsumoto[1], *H. Daisaki*[2], *S. Yoshida*[3], *K. Nishida*[3], *N. Tamaki*[1];
[1]*Kyoto College Of Medical Science, Kyoto, JAPAN,* [2]*Gunma Prefectural College of Health Sciences, Maebashi, JAPAN,* [3]*Nihon Medi-Physics Co.,Ltd., Tokyo, JAPAN.*

EPS-089
Insertion of Synthetic Lesions for the Clinical Assessment of AI-based reconstruction algorithms
Q. Maronnier[1], *A. Latgé*[1], *K. Su*[2], *F. Courbon*[1], *O. Caselles*[1];
[1]*Oncopole Claudius Regaud, Toulouse, FRANCE,* [2]*GE Healthcare, Waukesha, WI, UNITED STATES OF AMERICA.*

EPS-090
Anatomy-based correction of kidney PVE on ^{177}Lu SPECT images
J. Salvadori[1], *O. Allegrini*[1], *I. Namer*[1,2];
[1]*Institut de cancérologie Strasbourg Europe (ICANS), Strasbourg, FRANCE,* [2]*ICUBE UMR 7357, Strasbourg, FRANCE.*

EPS-091
The optimum earliest total-body 68Ga-FAPI-04 PET scan timing: An evidence-based single-centre study
Z. Zheng, *H. Gao, Y. Lin, H. Yu, W. Mao, R. Yang, Y. He, X. Chen, H. Wu, P. Hu, H. Shi;*
Zhongshan Hospital, Fudan University, Shanghai, CHINA.

EPS-092
Comparison of a 3D printed wall-less phantom with a conventional NEMA phantom for establishing threshold-based segmentation methods
A. Zounek[1], *A. Zatcepin*[1,2], *A. Delker*[1], *F. Gildehaus*[1], *A. Bollenbacher*[1], *G. Böning*[1], *P. Bartenstein*[1,2], *N. L. Albert*[1,3,4], *S. Ziegler*[1], *L. Kaiser*[1];
[1]*Department of Nuclear Medicine, University Hospital, LMU Munich, Munich, GERMANY,* [2]*German Center for Neurodegenerative Diseases (DZNE), Munich, GERMANY,* [3]*German Cancer Consortium (DKTK), Partner Site Munich, German Cancer Research Center (DKFZ), Munich, GERMANY,* [4]*Bavarian Cancer Research Center (BZKF), Erlangen, GERMANY.*

EPS-093
Discrepancies in commercial Y-90 vial's activity assessments: Monte Carlo simulations provide a possible explanation
L. Auditore[1,2], *D. Pistone*[1,2], *A. Italiano*[3,4], *E. Amato*[1,2], *S. Gnesin*[5];
[1]*Department of Biomedical and Dental Sciences and of Morphofunctional Imaging (BIOMORF), University of Messina, Italy, Messina, ITALY,* [2]*INFN, National Institute for Nuclear Physics, Section of Catania, Italy, Catania, ITALY,* [3]*Istituto Nazionale di Fisica Nucleare (INFN) - Sezione di Catania, Catania, ITALY,* [4]*Department of Mathematical and Computer Science, Physical Sciences and Earth Sciences (MIFT), University of Messina, Italy, Messina, ITALY,* [5]*Institute of Radiation Physics, Lausanne University Hospital and University of Lausanne, Lausanne, SWITZERLAND.*

EPS-094
Characterization of an innovative small animal PET scanner based on a proprietary acquisition method
F. M. Ribeiro[1], *P. M. C. C. Encarnação*[1], *P. M. M. Correia*[1], *A. L. M. Silva*[1], *A. X. Pinto*[1], *R. G. Oliveira*[1], *A. C. M. Magalhães*[1], *J. Sereno*[2], *A. Abrunhosa*[2], *I. F. Castro*[3], *J. F. C. A. Veloso*[1];
[1]*Institute for Nanostructures, Nanomodelling and Nanofabrication (i3N), Department of Physics, University of Aveiro, Aveiro, PORTUGAL,* [2]*Institute for Nuclear Sciences Applied to Health (ICNAS), University of Coimbra, Coimbra, PORTUGAL,* [3]*Radiation Imaging Technologies Lda. (RI-TE), University of Aveiro Incubator, PCI - Creative Science Park, Ílhavo, PORTUGAL.*

EPS-095
Triple and dual PET quantification of a Small-Animal Multi-Pinhole PET/SPECT/CT System
P. Echegoyen, *T. Cuenca Bandín, M. Ecay, E. Prieto, M. Collantes, F. Pareja, J. Simón Martínez, I. Peñuelas, J. Martí-Climent;*
Clínica Universidad de Navarra, Pamplona, SPAIN.

EPS-096
ComBat harmonization in different PET imaging scenarios
M. Gandia-Ferrero[1], *I. Torres-Espallardo*[2,1], *S. Prado-Wohlwend*[2], *B. Martínez-Sanchis*[2], *E. Muñoz*[3], *C. Morera*[3], *P. Bello-Arques*[2], *M. Vázquez-Martínez*[2], *S. Ginés-Cárdenas*[1], *Á. Almendros-Riaza*[1], *L. Martí-Bonmatí*[2,1];
[1]*Health Research Institute La Fe, Valencia, SPAIN,* [2]*La Fe University and Polytechnic Hospital, Valencia, SPAIN,* [3]*Oncovision, Valencia, SPAIN.*

EPS-097
Elimination of not yet Reported Artifacts in Myocardial Perfusion Imaging Studies on Semiconductor Cardiac Gamma Camera by Covering Radiopharmaceutical Injection Site with a Shield
A. Owczarek[1], *P. Cichocki*[1], *Z. Adamczewski*[1], *A. Plachcinska*[2];
[1]*Nuclear Medicine Department, Medical University of Lodz, Lodz, POLAND,* [2]*Department of Quality Control and Radiological Protection, Medical University of Lodz, Lodz, POLAND.*

EPS-098
Match/mismatch between aortic Na[^{18}F]F uptake on PET and macrocalcifications on CT
G. van Praagh[1], *M. Davidse*[2], *J. M. Wolterink*[2], *R. H. J. A. Slart*[1];
[1]*University Medical Center Groningen, Groningen, NETHERLANDS,* [2]*University of Twente, Enschede, NETHERLANDS.*

EPS-099
Metabolic connectivity changes of patients with post-COVID-19 condition: a reorganization of the olfactory cognitive pathway?
M. Doyen[1,2], *T. Horowitz*[3], *A. Bruyere*[4], *F. Goehringer*[4], *A. Verger*[1,2], *E. Guedj*[3];
[1]*Department of Nuclear Medicine and Nancyclotep Imaging Platform, CHRU Nancy, F-54000 Nancy, FRANCE,* [2]*Université de Lorraine, IADI, INSERM U1254, F-54000 Nancy, FRANCE,* [3]*Nuclear Medicine Department, Aix-Marseille University, APHM, CNRS, Centrale Marseille, Institut Fresnel, Timone Hospital, CERIMED, Marseille, France, Marseille, FRANCE,* [4]*Department of Infectious Diseases, CHRU Nancy, 54000, Nancy, FRANCE.*

EPS-100
Impact of ^{68}Ga-specific PET Reconstruction on Image Quality of Patient Data
P. Gavriilidis[1,2,3], *A. Marinus*[4,1], *M. Koole*[3], *T. W. Deller*[5], *F. P. Jansen*[5], *F. M. Mottaghy*[6,1,2], *R. Wierts*[1,2];
[1]*Maastricht University Medical Center, Maastricht, NETHERLANDS,* [2]*Maastricht University, Maastricht, NETHERLANDS,* [3]*Katholieke Universiteit Leuven, Leuven, BELGIUM,* [4]*Eindhoven University of Technology, Eindhoven, NETHERLANDS,* [5]*GE HealthCare, Waukesha, WI, UNITED STATES OF AMERICA,* [6]*RWTH University Hospital, Aachen, GERMANY.*

EPS-101
Clinical evaluation of a deep learning-based CT-free attenuation and scatter correction
S. Xue[1], *H. Zhou*[1], *R. Guo*[2], *M. Viscione*[1], *A. Rominger*[1], *B. Li*[2], *K. Shi*[1];
[1]*University of Bern, Bern, SWITZERLAND,* [2]*Shanghai Jiao Tong University School of Medicine, Shanghai, CHINA.*

EPS-102
Influence of coils and attenuation correction methods on the performance and image quality of a preclinical PET/MR insert
C. Kuntner[1], *J. Friske*[1], *A. Stessl*[2], *M. Haas*[3], *L. Breyer*[1], *T. Wanek*[1], *M. Hacker*[1], *T. Helbich*[1], *I. Rausch*[1];
[1]*Medical University of Vienna, Vienna, AUSTRIA,* [2]*University of Applied Science, Wiener Neustadt, AUSTRIA,* [3]*Bruker BioSpin Preclinical Imaging Division, Ettlingen, GERMANY.*

EPS-103
Impact of patient size on image quality of OSEM3D and BSREM reconstruction in [^{68}Ga]Ga-DOTA-TATE PET/MR
C. P. W. Cox, *T. Brabander, F. A. Verburg, M. Segbers;*
Erasmus MC, Rotterdam, NETHERLANDS.

EPS-104
Impact of 2.5-dimensional Deep Learning for Zero-TE MR-based Attenuation Correction on Chest FDG PET/MRI: Comparison with Conventional and 2-dimensional Deep Learning Approach
M. Tachibana[1], *M. Nogami*[2,3], *H. Matsuo*[1], *M. Nishio*[1], *J. Inukai-Inoue*[1], *F. Zeng*[1], *T. Kurimoto*[4], *K. Kubo*[2], *T. Murakami*[1,2];
[1]*Kobe University Graduate School of Medicine, Kobe, JAPAN,* [2]*Department of Radiology, Kobe University Hospital, Kobe, JAPAN,* [3]*Division of Medical Imaging, Biomedical Imaging Research Center, University of Fukui, Fukui, JAPAN,* [4]*GE Healthcare, Hino, JAPAN.*

710

Monday, September 11, 2023, 8:00 AM - 9:30 AM
Hall K

Technologists Oral Presentations 1: All about PET-CT!

OP-323
Double acquisition protocol for the study of washout in PET/CT parathyroids examination with 18F-Choline
M. Anelli[1], *M. Nicoletto*[2], *A. Zambelli*[3], *A. Di Nicola*[1];
[1]*Azienda Sanitaria Locale di Pescara, Pescara, ITALY,* [2]*Policlinico di Abano Terme, Abano Terme (PD), ITALY,* [3]*Azienda Ospedaliera Universitaria di Padova, Padova, ITALY.*

OP-324
Reduction of scan time in ^{18}F-FMM PET/CT-scans in the diagnosis of Alzheimer's disease
J. Terzic[1,2], *J. K. Fuglsang*[2], *R. Ismail*[3];
[1]*Vejle Hospital, Vejle, DENMARK,* [2]*Aalborg University, Aalborg, DENMARK,* [3]*Odense University Hospital, Odense, DENMARK.*

OP-325

Optimization of TOF-BPL reconstruction using clinical images in [18F]flutemetamol amyloid PET

S. Fukuda[1], *K. Miwa*[2], *K. Wagatsuma*[1,3], *Y. Yakushiji*[1], *T. Yamao*[2], *Y. Kamitaka*[3], *T. Hasegawa*[1];
[1]*Kitasato University Graduate School of Medical Sciences, Kanagawa, JAPAN,* [2]*Fukushima Medical University, Fukushima, JAPAN,* [3]*Tokyo Metropolitan Institution of Gerontology, Tokyo, JAPAN.*

OP-326

Influence of the number of iterations on image quality and semiquantitative accuracy in [18F]FDG PET imaging using a Long Axial Field-of-View PET/CT system

M. van der Vegt, *R. A. J. O. Dierckx, A. W. J. M. Glaudemans, J. van Sluis;*
University Medical Centrum Groningen, Groningen, NETHERLANDS.

OP-327

Comparison of the quadratic scheme suggested by EANM guidelines and manufacturer-recommended dose factor for Fluorine-18 FDG imaging on PET-CT system with SiPM detectors: evaluation on image quality

A. Hurtado de Mendoza, *M. Yaryes, C. Soza-Ried, H. Amaral;*
Positronmed, Santiago, CHILE.

OP-328

The Impact of a New Breathing Movement Correction Method On FDG Uptake and Volume Determination of Body Lesions

M. Schiavini[1], *F. Buffoni*[1], *M. Bardo*[1], *M. Giavarini*[2], *D. Capolongo*[1], *R. Leo*[1], *M. Rognoni*[1], *C. Sdraiati*[1], *L. Sembele*[3], *M. Castellani*[1];
[1]*IRCCS Fondazione "Cà Granda" Osp. Maggiore Policlinico di MILANO, Milan, ITALY,* [2]*UNIMI, Milan, ITALY,* [3]*Latvian Maritime Medical Center, Riga, LATVIA.*

OP-330

Occupational Radiation exposure from PET/CT during patient positioning

R. Siyanbola, *M. Coelho, P. Fragoso Costa, A. Moraitis, K. Herrmann, H. Hautzel;*
Department of Nuclear Medicine, University Hospital Essen, University Duisburg - Essen, Essen, GERMANY.

OP-331

Eye lens exposure of nuclear medicine technologists during PET/CT procedures: compliance with dose limits and eye lens vs whole-body dosimetry

M. Ryser, *S. Figueiredo, S. Medici, J. O. Prior, N. Cherbuin;*
CHUV, Lausanne, SWITZERLAND.

711

Monday, September 11, 2023, 8:00 AM - 9:30 AM

Hall G1

Theranostics Track - TROP Session: What's New in Prostate Cancer?

OP-332

Radioligand Therapy with [177Lu]Lu-PSMA I&T in the Elderly - Safety, Efficacy and Prognosticators of Survival

S. Weber[1], *A. Seitz*[2], *H. Kübler*[2], *A. K. Buck*[1], *R. A. Werner*[1,3], *P. E. Hartrampf*[1];
[1]*University Hospital Wuerzburg, Department of Nuclear Medicine, Wuerzburg, GERMANY,* [2]*University Hospital Wuerzburg, Department of Urology and Paediatric Urology, Wuerzburg, GERMANY,* [3]*Johns Hopkins University School of Medicine, Baltimore, MD, UNITED STATES OF AMERICA.*

OP-333

Evaluation of Nephrotoxicity of Extended Lu177-PSMA in Patients with Metastatic Castration-Resistant Prostate Cancer

E. Topal[1], *B. Kovan*[1], *D. Has Simsek*[1], *C. Civan*[1], *M. Sanli*[2], *M. Basaran*[3], *Y. Sanli*[1];
[1]*Istanbul University, Istanbul Medical Faculty, Department of Nuclear Medicine, Istanbul, TÜRKIYE,* [2]*Istanbul University, Istanbul Medical Faculty, Department of Urology, Istanbul, TÜRKIYE,* [3]*Istanbul University, Oncology Institute, Department of Medical Oncology, Istanbul, TÜRKIYE.*

OP-334

Safety and Efficacy of Extended 177Lu-PSMA Therapy: Multi-Center Retrospective Analysis

T. Telli[1,2,3], *R. Seifert*[1,2,3], *C. Lapa*[4], *T. Hekimsoy*[5], *W. Weber*[5], *C. Pfob*[4], *K. Herrmann*[1,2,3], *K. Rahbar*[6], *M. Eiber*[5], *W. Fendler*[1,2,3];
[1]*Department of Nuclear Medicine, University Hospital Essen, Essen, GERMANY,* [2]*German Cancer Consortium (DKTK), University Hospital Essen, Essen, GERMANY,* [3]*West German Cancer Center, University Hospital Essen, Essen, GERMANY,* [4]*Department of Nuclear Medicine, University Hospital Augsburg, Augsburg, GERMANY,* [5]*Department of Nuclear Medicine, University Hospital of Munich Technical University, Munich, GERMANY,* [6]*Department of Nuclear Medicine, University Hospital Münster, Münster, GERMANY.*

OP-335

AcTION: A phase 1 study of [225Ac]Ac-PSMA-617 in men with PSMA-positive prostate cancer with or without prior [177Lu]Lu-PSMA-617 radioligand therapy

M. Sathekge[1], *M. Crumbaker*[2], *A. M. Joshua*[2], *F. Bruchertseifer*[3], *T. Kreisl*[4], *S. Emineni*[5], *J. Wehbe*[6], *M. Korn*[4], *A. Morgenstern*[*3,7], *L. Emmett*[*2,7];
[1]*University of Pretoria and Steve Biko Academic Hospital, Pretoria, SOUTH AFRICA,* [2]*St Vincent's Hospital, Sydney, AUSTRALIA,* [3]*European Commission, Joint Research Centre, Karlsruhe, GERMANY,* [4]*Novartis Pharmaceuticals Corporation, East Hanover, NJ, UNITED STATES OF AMERICA,* [5]*Novartis India, Hyderbad, Telangana, INDIA,* [6]*Novartis Institutes for BioMedical Research, Basel, SWITZERLAND,* [7]**Co-senior author, GERMANY, AUSTRALIA.*

OP-336

Prediction of resistance to PSMA-617 Lu-177 by assessment of circulating tumor DNA biomarkers

O. Sartor[1], *E. Ledet*[2], *M. Huang*[1], *J. Schwartz*[2], *A. Lieberman*[2], *B. Lewis*[2], *J. Layton*[2], *A. Jang*[2], *O. Pocha*[2], *S. Lanka*[2], *M. Hawkins*[2], *K. Harris*[2];
[1]*Mayo Clinic, Rochester, MN, UNITED STATES OF AMERICA,* [2]*Tulane University, New Orleans, LA, UNITED STATES OF AMERICA.*

OP-337

Implementation of PSMA-PET/CT improves treatment outcomes after salvage radiotherapy for recurrent or persistent prostate cancer after surgery

C. Zamboglou[1,2], *P. Staus*[3], *M. Wolkewitz*[3], *N. S. Schmidt Hegemann*[4], *T. Wiegel*[5], *L. Emmett*[6], *S. Fanti*[7], *A. L. Grosu*[2], *S. Koerber*[8], *S. G. C. Kroeze*[9], *F. Ceci*[10], *J. C. Peeken*[11], *S. Hayoz*[12], *D. M. Aebersold*[13], *A. Vrachimis*[1], *P. Ghadjar*[14];
[1]*German Oncology Center, Limassol, CYPRUS,* [2]*Department of Radiation Oncology, University of Freiburg - Medical Center, Freiburg, GERMANY,* [3]*Institute of Medical Biometry and Statistics, Division Methods in Clinical Epidemiology, Faculty of Medicine and Medical Center, University of Freiburg, Freiburg, Germany, Freiburg, GERMANY,* [4]*Department of Radiation Oncology, University of Munich, Munich, GERMANY,* [5]*Department of Radiation Oncology, University of Ulm, Ulm, GERMANY,* [6]*St VIncent's Public Hospital Sydney, University of New South Wales, Sydney, AUSTRALIA,* [7]*Department of Nuclear Medicine, University of Bologna, Bologna, ITALY,* [8]*Department of Radiation Oncology, University of Heidelberg, Heidelberg, GERMANY,* [9]*Department of Radiation Oncology, University of Zuerich, Zuerich, SWITZERLAND,* [10]*European Institute of Oncology, Milano, ITALY,* [11]*Department of Radiation Oncology, Technical University of Munich, Munich, GERMANY,* [12]*Swiss Group for Clinical Cancer Research (SAKK), Bern, SWITZERLAND,* [13]*Department of Radiation Oncology, University of Bern, Bern, SWITZERLAND,* [14]*Department of Radiation Oncology, Charite Berlin, Berlin, GERMANY.*

OP-338

LuTectomy: phase 1/2 study evaluating dosimetry, safety and potential benefit of pre-surgery [177Lu] Lu-PSMA-617 radioligand therapy in patients with high-risk localised prostate cancer

M. Hofman[1], *R. Eapen*[1], *J. P. Buteau*[1], *P. Jackson*[1], *C. Mitchell*[1], *S. Oon*[1], *O. Alghazo*[2], *L. McIntosh*[1], *N. Dhiantravan*[3], *J. O'Brien*[1], *A. McVey*[1], *S. Sandhu*[1], *A. A. Azad*[1], *S. G. Williams*[1], *G. Sharma*[1], *B. Emmerson*[1], *M. B. Haskali*[1], *M. Bressel*[1], *D. Moon*[1], *N. Lawrentschuk*[1], *P. Neeson*[1], *D. G. Murphy*[1];
[1]*Peter MacCallum Cancer Centre, Melbourne, AUSTRALIA,* [2]*Flinders University, Adelaide, AUSTRALIA,* [3]*Royal Brisbane & Women's Hospital, Brisbane, AUSTRALIA.*

OP-339

Lutetium-177-PSMA-617 in oligo-metastatic hormone sensitive prostate cancer (Bullseye)

B. Privé[1], *C. H. J. Muselaers*[1], *D. Meijer*[2], *W. A. Van Gemert*[1], *B. Timmermans*[1], *M. J. R. Janssen*[1], *M. A. Jonker*[1], *M. de Groot*[1], *I. M. van Oort*[1], *N. Mehra*[1], *W. R. Gerritsen*[1], *E. Alevroudis*[3], *A. Vrachimis*[3], *J. A. Gietema*[4], *M. Gotthardt*[1], *A. N. Vis*[2], *I. J. de Jong*[4], *A. J. Witjes*[1], *W. Noordzij*[4], *D. E. Oprea-Lager*[2], *J. Nagarajah*[1];
[1]*Radboudumc, Nijmegen, NETHERLANDS,* [2]*Amsterdam University Medical Centers, Amsterdam, NETHERLANDS,* [3]*German Oncology Center, Limassol, CYPRUS,* [4]*University Medical Center Groningen, Groningen, NETHERLANDS.*

OP-340

Association of baseline quantitative [68Ga]Ga-PSMA-11 PET imaging parameters with clinical outcomes in patients with mCRPC receiving [177Lu] Lu-PSMA-617: a VISION sub-study

P. H. Kuo[1], *M. Morris*[2], *A. T. Kendi*[3], *K. Rahbar*[4], *X. X. Wei*[5], *B. Fang*[6], *A. J. Armstrong*[7], *J. Hesterman*[8], *K. Chi*[9], *J. de Bono*[10], *K. Fizazi*[11], *B. Krause*[12], *O. Sartor*[3], *S. T. Tagawa*[13], *S. Ghebremariam*[14], *M. Brackman*[15], *C. Wong*[16], *A. M. Catafau*[17], *T. Benson*[18], *K. Herrmann*[19];
[1]*University of Arizona, Tucson, AZ, UNITED STATES OF AMERICA,* [2]*Memorial Sloan Kettering Centter, New York City, NY, UNITED STATES OF AMERICA,* [3]*Mayo Clinic, Rochester, MN, UNITED STATES OF AMERICA,* [4]*University Hospital Münster, Münster, GERMANY,* [5]*Dana-Farber Cancer Institute, Boston, MA, UNITED STATES OF AMERICA,* [6]*Astera Cancer Care, East Brunswick, NJ, UNITED STATES OF AMERICA,* [7]*Duke Cancer Institute Center for Prostate and Urologic Cancers, Durham, NC, UNITED STATES OF AMERICA,* [8]*Invicro, Needham, MA, UNITED STATES OF AMERICA,* [9]*British Columbia Cancer Agency, Vancouver Centre, Vancouver, BC, UNITED STATES OF AMERICA,* [10]*The Institute of Cancer Research and Royal Marsden Hospital, London, UNITED KINGDOM,* [11]*Gustave Roussy Institute, University of Paris Saclay, Villejuif, FRANCE,* [12]*Rostock University Medical Center, Rostock, GERMANY,* [13]*Weill Cornell Medicine, New York City, NY, UNITED STATES OF AMERICA,* [14]*Novartis Pharmaceuticals Corporation, East Hanover, NJ, UNITED STATES OF AMERICA,* [15]*Novartis Pharmaceuticals Corporation, Indianapolis, IN, UNITED STATES OF AMERICA,* [16]*Novartis Pharmaceuticals Corporation, Cambridge, MA, UNITED STATES OF AMERICA,* [17]*Novartis Pharmaceuticals Corporation, Geneva, SWITZERLAND,* [18]*Novartis Pharmaceuticals Corporation, St George, UT, UNITED STATES OF AMERICA,* [19]*University Hospital Essen, Essen, GERMANY.*

801

Monday, September 11, 2023, 09:45 - 11:15

Hall A

CME 6 - Dosimetry Committee: Understanding Radiobiology for Dosimetry-Guided Molecular Radiotherapy

OP-341

General Aspects of Radiobiology Applied to Molecular Radiotherapy

J. Pouget;
Cancer Research Institute/INSERM, Montpellier, FRANCE.

OP-342

Radiobiological Aspects Applied to Different Molecular Radiotherapies

D. Taieb;
La Timone University Hospital, Department of Nuclear Medicine, Marseille, FRANCE.

OP-343

Relevance of the Absorbed Dose, Fractionation, and Time Interval Between Cycles

L. Strigari;
Universityof Bologna, Department of Medical and Surgical Sciences, Bologna, ITALY.

OP-344
Particular Aspects of the Radiobiology of Alpha and Beta Emitters
J. Nonnekens;
Erasmus Medical Center, Department of Radiology and Nuclear Medicine, Rotterdam, NETHERLANDS.

802

Monday, September 11, 2023, 09:45 - 11:15
Hall D (Arena)

Round Table 1 - Translational Molecular Imaging & Therapy + Oncology & Theranostics + Radiopharmaceutical Sciences Committee: Dialogue with the Treating Physician

OP-345
Dialogue with the Treating Physician - Immunoocologist
A. Digklia;
Centre hospitalier universitaire Vaudois, Department of Oncology, Lausanne, SWITZERLAND.

OP-346
Dialogue with the Treating Physician - Cardiologist
C. Kamani;
Leeds Teaching Hospitals NHS Trust, Cardiorespiratory Department, Leeds, UNITED KINGDOM.

OP-347
Dialogue with the Treating Physician - Urologist
T. Maurer;
Universitätsklinikum Hamburg-Eppendorf, Martini-Klinik, Department of Urology, Hamburg, GERMANY.

OP-348
Dialogue with the Treating Physician - Dermatologist
E. Guenova-Hoetzenecker;
CHUV, Department of Dermatology, Lausanne, SWITZERLAND.

OP-349
Dialogue with the Treating Physician - Nuclear Medicine Physician
E. Lopci;
RCCS – Humanitas Research Hospital, Nuclear Medicine, Department of diagnostic imaging, Rozzano, ITALY.

OP-350
Dialogue with the Treating Physician - Radiopharmacist
P. Laverman;
Radboud University Medical Center, Department of Radiology and Nuclear Medicine, Nijmegen, NETHERLANDS.

803

Monday, September 11, 2023, 09:45 - 11:15
Hall E1

LIPS Session 6 - Neuroimaging + Cardiovascular + Inflammation & Infection Committee: Molecular Imaging to Solve the Problem of Long COVID

OP-351
The lung impairment in long COVID
D. Albano;
NuclearMedicine, University of Brescia and Spedali Civili Brescia, Brescia, ITALY.

OP-352
The vascular impairment in long COVID
M. Sollini;
Department of Biomedical Sciences, Humanitas University, Milan, ITALY.

OP-353
The brain impairment in long COVID
E. Guedj;
Aix Marseille Universite, APHM, CNRS, Centrale Marseille, Institut Fresnel, Timone Hospital, CERIMED, Nuclear Medicine Department, Marseille, FRANCE.

804

Monday, September 11, 2023, 9:45 AM - 11:15 AM
Hall E2

M2M Track - TROP Session: TME and Therapy: Direct Targeting and Secondary Effects

OP-355
Optimisation of FAP-targeted radionuclide therapy through molecular evolution of OncoFAP derivatives and combination with immunocytokines
A. Galbiati[1], *M. Bocci*[1], *E. Gilardoni*[1], *J. Mock*[1], *D. Neri*[2], *S. Cazzamalli*[1];
[1]*Philochem AG, Otelfingen, SWITZERLAND,* [2]*Philogen, Siena, ITALY.*

OP-356
Tumor-targeted Interleukin-2 Boosts the Anti-cancer Activity of FAP-directed Radioligand Therapeutics
P. Backhaus[1,2], *P. Dorten*[2], *A. Galbiati*[3], *E. Gilardoni*[3], *F. Gierse*[2], *M. Bocci*[3], *A. Zana*[3], *J. Mock*[3], *M. Claesener*[1], *J. Cufe*[1], *F. Büther*[1], *K. Schäfers*[2], *S. Hermann*[2], *D. Neri*[4,5], *M. Schäfers*[1], *S. Cazzamalli*[3];
[1]*University Hospital Münster, Münster, GERMANY,* [2]*European Institute for Molecular Imaging, University of Münster, Münster, GERMANY,* [3]*Philochem AG, R&D department, Otelfingen, SWITZERLAND,* [4]*Swiss Federal Institute of Technology, Department of Chemistry and Applied Biosciences, Zurich, SWITZERLAND,* [5]*Philogen S.p.A, Siena, ITALY.*

OP-357
FAP directed target modules for UniCAR T cell therapy and radionuclide-based tumour theranostics
C. Neuber, *L. Loureiro, L. Hoffmann, M. Kubeil, C. Arndt, A. Feldmann, M. Bachmann;*
Helmholtz-Zentrum Dresden-Rossendorf, Dresden, GERMANY.

OP-358
Evaluation of Therapeutic and Immunological Action of CAIX-Targeted Lutetium-177 Radionuclide Therapy Combined with Immune Checkpoint Inhibition
S. Kleinendorst[1], *M. Konijnenberg*[1], *G. Franssen*[1], *J. Molkenboer-Kuenen*[1], *S. Wenker*[1], *D. Boreel*[1], *D. Kroon*[1], *M. Gloudemans*[1], *K. Twumasi-Boateng*[2], *M. Wheatcroft*[2], *E. Oosterwijk*[3], *S. Heskamp*[1];
[1]*Department of Medical Imaging, Radboud University Medical Center, Nijmegen, NETHERLANDS,* [2]*Telix Pharmaceuticals Ltd., Melbourne, AUSTRALIA,* [3]*Department of Urology, Radboud University Medical Center, Nijmegen, NETHERLANDS.*

OP-359
RAYZ-15170, a novel small-molecule binder to carbonic anhydrase IX (CA9) for targeted radiopharmaceutical therapy of clear cell renal cell carcinoma and other CA9 expressing tumors
N. Smith, *J. Tran, A. Lai, Y. Bravo, A. Cieniewicz, P. Mondala, R. Clift, T. Lo, G. Chen, G. Li, K. Lidberg, L. Nyiranshuti, S. Richardson, A. Hudson;*
RayzeBio, Inc., San Diego, CA, UNITED STATES OF AMERICA.

OP-360
[^{225}Ac]Ac-DPI-4452, a new peptide radioligand targeting Carbonic Anhydrase IX, displays strong anti-tumoral activity in colorectal cancer and clear cell renal cell carcinoma mouse models
N. Wiedemann, *A. Attinger, E. Da Costa Branquinho, U. Andersson;*
Debiopharm International SA, Lausanne, SWITZERLAND.

OP-361
Extracellular Matrix-Targeted Radionuclide Therapy Remodels Tumor Microenvironment Landscape and Enhances Immunotherapy in Triple-Negative Breast Cancer
L. Li, *Z. Zeng, F. Liu, X. Ma, B. Jia, Z. Yang;*
Peking University Cancer Hospital & Institute, Beijing, CHINA.

OP-362
Profiling the influencing factors of radiopharmaceutical therapy: spatial transcriptomics and computational modeling in microenvironment
J. Hong[1], *S. Bae*[2], *L. Cavinato*[3], *M. Ryhiner*[1], *A. Rominger*[1], *H. Choi*[2], *K. Shi*[1];
[1]*University of Bern/Inselspital, Bern, SWITZERLAND,* [2]*Seoul National University Hospital, Seoul, KOREA, REPUBLIC OF,* [3]*Politecnico di Milano, Milan, ITALY.*

805

Monday, September 11, 2023, 9:45 AM - 11:15 AM
Hall B

Cutting Edge Science Track - TROP Session: Image Reconstruction and Data Corrections

OP-363
Fast Penalized Maximum Likelihood Method for Positron Lifetime Image Reconstruction Using Adaptive Time Framing
J. Qi, *B. Huang;*
UC Davis, Davis, CA, UNITED STATES OF AMERICA.

OP-364
Direct versus indirect parametric whole body [^{18}F] FDG Patlak imaging using a LAFOV PET/CT system
J. van Sluis[1], *L. Providência*[1], *J. H. van Snick*[1], *A. W. J. M. Glaudemans*[1], *R. H. J. A. Slart*[1], *R. A. J. O. Dierckx*[1], *C. Tsoumpas*[1], *R. Boellaard*[1,2];
[1]*University Medical Center Groningen, Groningen, NETHERLANDS,* [2]*Amsterdam University Medical Centers, Amsterdam, NETHERLANDS.*

OP-365
O-15 water in acceptance angle comparison high sensitivity vs ultra-high sensitivity
H. Merisaari[1], *N. Ono*[2], *T. Tolvanen*[3,4], *V. Saunavaara*[3,4], *J. Knuuti*[3], *L. Nummenmaa*[3], *P. Nuutila*[3], *H. Iida*[3];
[1]*Department of Radiology, University of Turku, Turku, FINLAND,* [2]*Department of Information Science, Nara Institute of Science and Technology, Turku, FINLAND,* [3]*Turku PET Centre, University of Turku and Turku University Hospital, Turku, FINLAND,* [4]*Department of Medical Physics, Turku University Hospital, Turku, FINLAND.*

OP-366
Impact of different collimator response models on quantitative ^{177}Lu-SPECT reconstructions
W. Claeys[1], *W. Deckers*[2], *V. Nuttens*[3], *C. Deroose*[1,2], *K. Goffin*[1,2], *K. Baete*[1,2], *M. Koole*[1];
[1]*KU Leuven, Leuven, BELGIUM,* [2]*UZ Leuven, Leuven, BELGIUM,* [3]*OLV Aalst, Aalst, BELGIUM.*

OP-367
Towards the clinical implementation of quantitative^{177}Lu SPECT/CT with a ring-shaped CZT-based camera: comparison of OSEM and Q.Clear reconstruction algorithms
R. Danieli[1], *M. Stella*[2], *J. Leube*[3], *J. Tran Gia*[3], *H. Levillain*[1], *C. Marin*[1], *B. Vanderlinden*[1], *N. Reynaert*[1], *P. Flamen*[1];
[1]*Institut Jules Bordet, Brussels, BELGIUM,* [2]*GE HealthCare, Diegem, BELGIUM,* [3]*University Hospital Würzburg, Würzburg, GERMANY.*

OP-368
Positron-Range Correction for an On-Chip PET Scanner using Deep Learning
C. Clement[1], *G. Birindelli*[1], *F. Pagano*[2,3], *M. Pizzichemi*[2,3], *M. Kruithof-De Julio*[1], *S. Ziegler*[4], *A. Rominger*[1], *E. Auffray*[2], *K. Shi*[1];
[1]*Inselspital Bern, Bern, SWITZERLAND,* [2]*CERN, Geneva, SWITZERLAND,* [3]*University of Milano-Bicocca, Milan, ITALY,* [4]*University Hospital Munich, Munich, GERMANY.*

OP-369
Implementation and performance evaluation of artificial intelligence based SPECT attenuation correction on clinical SPECT images
M. Szolikova[1], *A. Kovacs*[1], *B. Husztik*[1], *N. Meszaros*[1], *F. Nagy*[2], *I. Garai*[2], *S. Barna*[2];
[1]*Mediso Ltd., Budapest, HUNGARY,* [2]*ScanoMed Nuclear Medicine Centers, Debrecen, HUNGARY.*

OP-370
Deep-Learning-based Partial Volume Correction in SPECT
T. Kaprélian, *A. Extebeste, D. Sarrut;*
Université de Lyon, CREATIS; CNRS UMR5220; Inserm U1044; INSA-Lyon; Université Lyon 1; Centre Léon Bérard, France., Lyon, FRANCE.

OP-371
Deep-learning based partial volume correction for ^{177}Lu SPECT/CT imaging based on a large Monte Carlo simulated dataset
J. Leube[1], *J. Gustafsson*[2], *M. Lassmann*[1], *M. Salas Ramirez*[1], *J. Tran-Gia*[1];
[1]*University Hospital Würzburg, Würzburg, GERMANY,* [2]*Lund University, Lund, SWEDEN.*

806

Monday, September 11, 2023, 9:45 AM - 11:15 AM
Hall C

Clinical Oncology Track - Featured Session: FAP Imaging

OP-372
FAP Imaging
J. Calais; *UCLA, Los Angeles, UNITED STATES OF AMERICA.*

OP-373
Dual-phase ^{68}Ga-FAPI-04 PET/CT: the pancreatic FAPI uptake characteristics and differentiation of pancreatic diseases
H. Wu, *C. Li, Y. Tian, Z. Xiao, Y. Jiang, Y. He;*
Zhongnan Hospital of Wuhan University, Wuhan, Hubei Province, CHINA.

OP-374
^{68}Ga-labeled Fibroblast Activation Protein Inhibitor PET/CT in the clinical diagnosis and management of breast cancer: Comparison with [^{18}F]FDG PET/CT
W. Guo[1], *W. Xu*[1], *H. Fu*[1], *Y. Pang*[1], *L. Zhao*[1], *L. Sun*[1], *H. Chen*[2];
[1]*The first affiliated hospital of Xiamen University, Xiamen, CHINA,* [2]*The first affiliated hospital of Xiamen University, Xiamen city, CHINA.*

OP-375
Role of PET/CT using [68Ga]Ga-DOTA-FAPI-04 in the Detection of Lesions and Staging of Various Malignancies, Excluding Gastrointestinal Tract Malignancies with Non-FDG Avid Lesions.
G. Beydagi[1], *N. Alan-Selcuk*[1], *K. Akcay*[1], *E. Demirci*[1], *O. Sonmez*[1], *M. Ocak*[2], *T. Toklu*[1], *S. Celik*[3], *B. Oven*[3], *L. Kabasakal*[4,1];
[1]*Yeditepe University, Department of Nuclear Medicine, Istanbul, TÜRKIYE,* [2]*Istanbul University, Faculty of Pharmacy, Department of Pharmaceutical Technology, Istanbul, TÜRKIYE,* [3]*Yeditepe University, Department of Medical Oncology, Istanbul, TÜRKIYE,* [4]*Istanbul Unıversity-Cerrahpasa, Department of Nuclear Medicine, Istanbul, TÜRKIYE.*

OP-376
Impact of ^{68}Ga-FAPI PET/CTimaging in the diagnosis and management of primary and recurrent epithelial ovarian cancer
K. Xu, *J. Chen, C. Li, Y. Tian, L. Li, Y. Jiang, Z. Xiao, D. Xing, B. Wen, Y. He;*
Zhongnan Hospital of Wuhan University, Wuhan, China, CHINA.

OP-377
Fibroblast activation protein and glycolysis in lymphoma diagnosis: comparison of^{68}Ga-FAPI PET/CT and ^{18}F-FDG PET/CT
X. Chen, *S. Wang, Y. Lai, G. Wang, M. Wei, X. Jin, J. Ding, Y. Zhang, Y. Shi, F. Wang, H. Zhu, Z. Yang, X. Wang;*
Peking University Cancer Hospital & Institute, Beijing, CHINA.

OP-378
[68Ga]GaFAPI-RGD PET/CT in the evaluation of renal carcinoma: comparison with [18F]FDG/[68Ga]Ga-PSMA PET/CT
R. Lin[1], *J. Zang*[1], *C. Wang*[1], *S. Chen*[1], *J. Zhang*[1], *Y. Yang*[1], *F. Xu*[1], *J. Zhang*[2], *X. Chen*[2], *W. Miao*[1];
[1]*Department of Nuclear Medicine, the First Affiliated Hospital, Fujian Medical University, Fuzhou, Fujian Province, CHINA,* [2]*National University of Singapore, Singapore, SINGAPORE.*

OP-379
Diagnostic Accuracy of ^{68}Ga-FAPI and ^{18}F-FDG PET/CT for Localizing Primary Tumor in the Head and Neck Cancer of Unknown Primary
B. Gu, *X. Du, Z. Yang, S. Song, Z. Yang;*
Fudan University Shanghai Cancer Center, Shanghai, CHINA.

OP-380
Head-to-head comparison of^{68}Ga-FAPI46 PET/CT,^{18}F-FDG PET/CT, and contrast-enhanced CT in patient with various solid tumors
M. Watanabe, *H. Grafe, N. Hirmas, R. Hamacher, H. Lanzafame, K. M. Pabst, M. Nader, J. T. Siveke, W. P. Fendler, K. Herrmann, M. Weber;*
Essen University Hospital, Essen, GERMANY.

807

Monday, September 11, 2023, 9:45 AM - 11:15 AM
Hall F1

Cardiovascular Committee - TROP Session: Clinical Perfusion Imaging with PET

OP-381
Cardiac one stop shop: Performance of a Rapid Diagnostic Outpatient Clinic using Rubidium-82 PET-CT Imaging.
J. Boer, *M. Ros, P. Bot;*
Spaarne Gasthuis, Haarlem, NETHERLANDS.

OP-382
Prognostic value of coronary flow capacity by rubidium-82 PET/CT in patients with suspected CAD and normal myocardial perfusion imaging
A. D'Antonio[1], *E. Zampella*[1], *R. Assante*[1], *T. Mannarino*[1], *V. Gaudieri*[1], *P. Buongiorno*[1], *M. Falzarano*[1], *R. Lepre*[1], *F. Reina*[1], *M. Panico*[2], *P. Arumugam*[3], *A. Cuocolo*[1], *W. Acampa*[1];
[1]*Department of Advanced Biomedical Sciences, University of Naples "Federico II", Naples, ITALY,* [2]*Institute of Biostructure and Bioimaging, CNR, Naples, ITALY,* [3]*Department of Nuclear Medicine, Central Manchester Foundation Trust, Manchester, UNITED KINGDOM.*

OP-383
Quantitative relationship between coronary artery calcium and myocardial blood flow by hybrid rubidium-82 PET/CT imaging in heart transplanted patients
T. Mannarino[1], *R. Assante*[1], *E. Zampella*[1], *A. D'Antonio*[1], *F. Cacciatore*[2], *C. Amarelli*[3], *M. Falzarano*[1], *F. Reina*[1], *R. Lepre*[1], *I. Mattucci*[3], *R. Chiappetti*[2], *V. Gaudieri*[1], *P. Buongiorno*[1], *M. Panico*[1], *C. Maiello*[3], *A. Cuocolo*[1], *W. Acampa*[1];
[1]*Department of Advanced Biomedical Sciences, University of Naples Federico II, Naples, ITALY,* [2]*Department of Translational Medical Sciences, University of Naples "Federico II", Naples, ITALY,* [3]*Department of Cardiac Surgery and Transplantation, Monaldi, Azienda Ospedaliera dei Colli, Naples, Naples, ITALY.*

OP-384
MPI - from Rb to [^{15}O]water with a dedicated cyclotron
M. Lonsdale, *S. Fuglsang, M. Krakauer, A. Larsen, I. Rasmussen, U. Talleruphuus, P. Hovind;*
Bispebjerg Hospital, Copenhagen, DENMARK.

OP-385
^{82}Rb and [^{15}O]H_2O Myocardial perfusion PET imaging - a prospective head to head comparison
L. Marner[1], *M. Krakauer*[1], *A. Ismail*[1], *U. Talleruphuus*[1], *A. C. Henriksen*[1], *M. N. Lonsdale*[1], *I. L. Rasmussen*[1], *S. Fuglsang*[1], *E. Prescott*[2], *P. Hovind*[1], *L. Marner*[1];
[1]*Copenhagen University Hospital Bispebjerg, Department of Clinical Physiology and Nuclear Medicine, Copenhagen NV, DENMARK,* [2]*Copenhagen University Hospital Bispebjerg, Department of Cardiology, Copenhagen NV, DENMARK.*

OP-386
Splenic switch-off as marker of adenosine response in myocardial perfusion imaging with O-15-H2O PET
M. Jochumsen[1,2], *L. C. Gormsen*[1,2], *L. P. Tolbod*[1,2], *J. Brorson*[1,2];
[1]*Dept of Nuclear Medicine and PET-Centre, Aarhus University Hospital, Aarhus, DENMARK,* [2]*Department of Clinical Medicine, Aarhus University, Aarhus, DENMARK.*

OP-387
RV to LV Myocardial Blood Flow Ratio With ^{15}O-water PET as a Risk Marker for Cardiac Events in Patients With Left Ventricular Hypertrophy
P. Svanström, *J. Sigfridsson, H. J. Harms, T. Kero, K. Eggers, N. Regula, M. Lubberink, J. Sörensen;*
Uppsala University, Uppsala, SWEDEN.

OP-388
Evaluation of DOTA as a marker of myocardial blood flow by comparison of ^{68}Ga-DOTA to^{15}O-water-PET
M. Lubberink[1], *S. Kvernby*[1], *C. Rischpler*[2], *K. Azarbar*[1], *J. Sörensen*[1], *I. Velikyan*[1], *T. Kero*[1];
[1]*Uppsala University, Uppsala, SWEDEN,* [2]*Klinikum Stuttgart, Stuttgart, GERMANY.*

OP-389
The Second Phase-3 Multi-Center Trial of^{18}F-Flurpiridaz PET Myocardial Perfusion Imaging for Coronary Artery Disease Evaluation
J. Knuuti[1], *D. Agostini*[2], *T. Bateman*[3], *J. J. Bax*[4], *R. Beanlands*[5], *D. Berman*[6], *S. Dorbala*[7], *E. V. Garcia*[8], *J. Feldman*[9], *G. V. Heller*[10], *P. Martinez-Clark*[11], *M. Pelletier-Galarneau*[12], *B. Shepple*[13], *N. Tamaki*[14], *F. Tranquart*[15], *J. E. Udelson*[16], *J. Maddahi*[17];
[1]*Turku University Hospital, Turku, FINLAND,* [2]*University Hospital Caen, Caen, FRANCE,* [3]*Mid-America Heart, Kansas City, KS, UNITED STATES OF AMERICA,* [4]*Leiden University Medical Center, Leiden, NETHERLANDS,* [5]*Ottawa Heart Institute, Ottawa, ON, CANADA,* [6]*Cedars Sinai Medical Center, Los Angeles, CA, UNITED STATES OF AMERICA,* [7]*Brigham and Women's Hospital, Boston, MA, UNITED STATES OF AMERICA,* [8]*Emory University, Atlanta, GA, UNITED STATES OF AMERICA,* [9]*Memorial City and Katy Cardiology, Katy, TX, UNITED STATES OF AMERICA,* [10]*Morristown Medical Center, Morristown, NJ, UNITED STATES OF AMERICA,* [11]*North Miami Beach, Miami, FL, UNITED STATES OF AMERICA,* [12]*Montreal Heart Institute, Montreal, QC, CANADA,* [13]*University of Tennessee Medical Center, Tennessee, TN, UNITED STATES OF AMERICA,* [14]*Kyoto Prefectural University of Medicine, Kyoto, JAPAN,* [15]*GE Healthcare, Chalfont St Giles, UNITED KINGDOM,* [16]*Tufts Medical Center, Boston, MA, UNITED STATES OF AMERICA,* [17]*David Geffen School of Medicine at University of California, Los Angeles, CA, UNITED STATES OF AMERICA.*

808

Monday, September 11, 2023, 9:45 AM - 11:15 AM
Hall F2

Thyroid Committee- Featured Session: Iodine-131 Therapy and Beyond in Differentiated Thyroid Cancer

OP-390

An Overview on Nuclear Medicine Therapy of Differentiated Thyroid Cancer

M Kreissl;
UniversityHospital Magdeburg, Division of Nuclear Medicine, Department of Radiology and Nuclear Medicine, Magdeburg, GERMANY.

OP-391

Radioactive Iodine Therapy for Low-risk Papillary Thyroid Cancer: Long-term Recurrence Risk Reduction in a Matched Cohort Study

S. Bilgic[1], *R. C. Meral*[2], *M. S. Sağer*[3], *K. Sönmezoğlu*[3];
[1]*Sirnak State Hospital, Sirnak, TÜRKIYE,* [2]*University of Michigan, Ann Arbor, MI, UNITED STATES OF AMERICA,* [3]*Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Nuclear Medicine, Istanbul, TÜRKIYE.*

OP-392

Comparison of 1.1 gbq and 2.2 gbq ^{131}I activities in patients with low-risk differentiated thyroid cancer requiring postoperative iodine-131 therapy.

A. Campenni[1], *R. Ruggeri*[1], *M. Garo*[2], *A. Raffa*[1], *M. Siracusa*[1], *G. Restuccia*[1], *A. Rappazzo*[1], *H. Rosarno*[1], *A. Nicocia*[1], *D. Cardile*[1], *P. Petranović Ovčariček*[3], *S. Baldari*[1], *L. Giovanella*[4];
[1]*Ospedale Gaetano Martino, Messina, ITALY,* [2]*Mathsly Research, Roma, ITALY,* [3]*University Hospital Center Sestre Milosrdnice, 10 000 Zagreb, CROATIA,* [4]*Clinic for Nuclear Medicine and Competence Centre for Thyroid Diseases, Imaging Institute of Southern Switzerland, Ente Ospedaliero Cantonale, 6500 Bellinzona, SWITZERLAND.*

OP-393

Integrating ^{131}I SPECT-based RPT dosimetry into stereotactic external beam treatment planning for patients with metastatic radioiodine-refractory thyroid cancer, preliminary clinical trial results

I. Marsh[1], *H. Quon*[1], *P. Santhanam*[1], *P. Ladenson*[1], *B. He*[2], *D. Kaplin*[1], *K. Lowe*[1], *H. Wang*[1], *G. Sgouros*[1], *R. F. Hobbs*[1];
[1]*Johns Hopkins University, Baltimore, MD, UNITED STATES OF AMERICA,* [2]*RAPID LLC, Baltimore, MD, UNITED STATES OF AMERICA.*

OP-394

Is radio iodine therapy really as bad as it is made out to be? A look at secondary neoplasms using the SEER database.

B. Schemmer;
Uniklinik Bonn, Bonn, GERMANY.

OP-395

Radioguided Occult Lesion Localization (ROLL) in patients with persistence/recurrence of differentiated thyroid cancer: a 10-years single-centre experience

C. Manni[1], *G. Follacchio*[1], *G. Gesuelli*[2], *R. Scibè*[2], *G. Ferrara*[3], *M. Capponi*[4], *G. Ciccioli*[4], *F. Capoccetti*[1];
[1]*Nuclear Medicine Unit, Macerata Hospital, Italy, Macerata, ITALY,* [2]*Surgery Unit, Macerata Hospital, Italy, Macerata, ITALY,* [3]*Anatomic Pathology and Cytopathology Unit, Istituto Nazionale Tumori di Napoli, IRCCS "G. Pascale", Naples, ITALY,* [4]*Radiology Unit, Macerata Hospital, Italy, Macerata, ITALY.*

OP-396

High Ki-67 LI is an Important Factor for Good Early Outcomes After Radioiodine Therapy in Patients with Intermediate to High-Risk Papillary Thyroid Cancer

X. Luo, *W. Ouyang;*
Department of Nuclear Medicine, Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong Province, CHINA.

OP-397

Redifferentiation Therapy for RAI-Refractory Differentiated Thyroid Cancers Based on Tumor Genomic Assay

D. Shen[1,2], *H. Chan*[1], *F. Tsai*[1], *Y. Chiu*[1], *T. Liang*[1], *Y. She*[1], *S. Li*[1];
[1]*Kaohsiung Veterans General Hospital, Kaohsiung, TAIWAN,* [2]*Tri-Service General Hospital, Taipei, TAIWAN.*

OP-398

Radioligand Therapy with ^{177}Lu-EB-FAPI for the Treatment of Metastatic Radioiodine Refractory Thyroid Cancer: First-in-Human Dose-Escalation Clinical Trial

H. Fu, *J. Huang, W. Guo, L. Sun, H. Wu, H. Chen;*
The First Affiliated Hospital of Xiamen University, Xiamen, CHINA.

809

Monday, September 11, 2023, 9:45 AM - 11:15 AM
Hall G2

e-Poster Presentations Session 6 - Oncology & Theranostics Committee: Prostate Cancer

EPS-105

The Probability of Prostate Cancer Metastases within different Prostate-Specific Antigen ranges using Primary Staging Prostate-Specific Membrane Antigen PET/CT in Patients with Newly Diagnosed Prostate Cancer

W. Luining[1], *M. J. Hagens*[2], *D. Meijer*[1], *S. Srbljin*[3], *J. C. C. Koppes*[1], *R. J. J. Knol*[4], *P. J. van Leeuwen*[2], *A. N. Vis*[1], *D. E. Oprea-Lager*[1];
[1]*Amsterdam UMC, Amsterdam, NETHERLANDS,* [2]*Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital (NCI-AVL), Amsterdam, NETHERLANDS,* [3]*Zaans Medisch Centrum, Zaandam, NETHERLANDS,* [4]*Northwest Clinics, Alkmaar, NETHERLANDS.*

EPS-106

A systematic review and meta-analysis of the diagnostic test accuracy of PSMA PET for tumor staging in newly diagnosed prostate cancer patients, compared to histopathology

F. Gossili[1,2], *A. W. Mogensen*[1,2], *T. C. Konnerup*[3], *K. Bouchelouche*[4], *I. L. Alberts*[5], *A. Afshar-Oromieh*[5], *H. D. Zacho*[1,2];
[1]*Department of Nuclear Medicine and Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, DENMARK,* [2]*Department of Clinical Medicine, Aalborg University, Aalborg, DENMARK,* [3]*Unit of Clinical Biostatistics, Aalborg University Hospital, Aalborg, DENMARK,* [4]*Department of Nuclear Medicine & PET-Centre, Aarhus University Hospital, Aarhus, DENMARK,* [5]*Department of Nuclear Medicine. Inselspital, Bern University Hospital, University of Bern, Bern, SWITZERLAND.*

EPS-107

A multi-center European study to explore the detection of oligometastatic disease by PSMA-PET/CT in intermediate to high-risk Prostate Cancer

G. Zuccotti[1], *F. Mattana*[1], *A. Barone*[1], *L. Muraglia*[1], *R. Mei*[2], *A. Farolfi*[2], *P. Rajwa*[3], *M. Miszczyk*[4], *V. Kasivisvanathan*[5], *F. Zattoni*[6], *G. Gandaglia*[7], *A. Briganti*[7], *S. Shariat*[3], *P. Castellucci*[2], *S. Fanti*[2], *F. Ceci*[1];
[1]*Division of Nuclear Medicine, IEO European Institute of Oncology IRCCS, Milano, ITALY,* [2]*Service of Nuclear Medicine, Sant'Orsola-Malpighi University Hospital IRCCS, Bologna, ITALY,* [3]*Department of Urology, University of Vienna, Vienna, AUSTRIA,* [4]*Department of Nuclear Medicine, Narodowy Instytute Onkologii, Gliwice, POLAND,* [5]*Department of Urology, Imperial College of London, London, UNITED KINGDOM,* [6]*Department of Urology, University of Padova, Padova, ITALY,* [7]*Department of Urology, San Raffaele Hospital, Milano, ITALY.*

EPS-108

Role of AL^{18}F-labeled prostate specific membrane antigen (PSMA-BCH) PET/CT in detecting extracapsular extension of localized prostate cancer.

Z. Jie[1], *Y. Zhi*[2], *L. Chen*[2];
[1]*Shanxi Cancer Hospital, Taiyuan, CHINA,* [2]*Peking University Cancer Hospital and Institute, Bejing, CHINA.*

EPS-109

Exploring the Correlation between Multiparameters Detected in Primary Prostate Cancer using 18F-PSMA-1007 PET/MRI and thier Potential for Predicting Lymph Node and Bone Metastatses

S. Cheewadhanaraks[1], *K. Sereeborwornthanasak*[2], *C. Chotipanich*[1], *D. Siripongsatian*[1], *C. Promteangtrong*[1], *A. Kunawudhi*[1], *P. Kiatkittikul*[1], *A. Jantarato*[1], *N. Boonsingma*[1], *N. Boonkawin*[1];
[1]*National Cyclotron and PET Centre, Chulabhorn Hospital, Bangkok, THAILAND,* [2]*Bhumibol Adulyadej Hospital, Bangkok, THAILAND.*

EPS-110

The Updated Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE V2.0) Framework for Standardized Reporting of PSMA-PET

R. Seifert[1], *L. Emmett*[2], *K. Herrmann*[1], *B. Hadaschik*[1], *J. Calais*[3], *S. Fanti*[4], *T. A. Hope*[5], *M. S. Hofman*[6], *M. Eiber*[7], *W. P. Fendler*[1];
[1]*University Hospital Essen, Essen, GERMANY,* [2]*St Vincent's Hospital, Sydney, AUSTRALIA,* [3]*David Geffen School of Medicine at UCLA, Los Angeles, CA, UNITED STATES OF AMERICA,* [4]*IRCCS AOU di Bologna, Bologna, ITALY,* [5]*University of California, San Francisco, San Francisco, CA, UNITED STATES OF AMERICA,* [6]*University of Melbourne, Melbourne, AUSTRALIA,* [7]*Technical University of Munich, Munich, GERMANY.*

EPS-111

PRIMARY scores on PSMA PET/CT and MpMRI: Role in initial evaluation of prostate cancer.

S. Kumar, *Y. Mathur, H. Singh, B. Mittal, R. Kumar;*
PGIMER, Chandigarh, INDIA.

EPS-112

European Association of Urology Biochemical Recurrence (EAU BCR) Risk Groups after radical prostatectomy in the era of PSMA PET/CT

C. Artigas, *C. Leplat, Q. Shagera, T. Jabbour, R. Diamand, P. Flamen;*
Institut Jules Bordet, Université Libre de Bruxelles, Brussels, BELGIUM.

EPS-113

Multispectral fluorescence imaging as a means to separate healthy from diseased lymphatics during radioguided robotic surgery

F. van Leeuwen[1], *A. Berrens*[2], *M. van Oosterom*[1], *P. van Leeuwen*[2], *I. Slof*[1], *t. buckle*[1], *h. van der Poel*[2];
[1]*Leiden University Medical Center, Leiden, NETHERLANDS,* [2]*NETHERLANDS cancer institute, Amsterdam, NETHERLANDS.*

EPS-114

Significance of interim ^{18}F-PSMA-1007 PET/CT for early prediction of ^{177}Lu-PSMA-I&T treatment effect in metastatic castration-resistant prostate cancer patients

S. Cheung, *S. Chen, Y. Wong, Y. Yip, C. Ho;*
Hong Kong Sanatorium & Hospital, Hong Kong, HONG KONG.

EPS-115

Absorbed dose prediction for subsequent therapy cycles from 1st cycle of ^{177}Lu-PSMA-617 therapy of mCRPC patients

J. Brosch-Lenz[1], *N. Colpo*[2], *I. Bloise*[1], *X. Hou*[1], *W. R. Parulekar*[3], *C. Dellar*[3], *F. Saad*[4], *K. Chi*[2], *D. Wilson*[2], *F. Bénard*[2], *A. Rahmim*[1], *C. Uribe*[2];
[1]*BC Cancer Research Institute, Vancouver, BC, CANADA,* [2]*BC Cancer, Vancouver, BC, CANADA,* [3]*Canadian Cancer Trials Group, Queen's University Kingston, Kingston, ON, CANADA,* [4]*Prostate cancer research, Montreal Cancer Institute / CRCHUM, Montreal, QC, CANADA.*

EPS-116
Pre-treatment^{68}Ga-PSMA PET/CT Parameters Could Predict Response to^{177}Lu-PSMA Treatment and Overall Survival in Metastatic Castration Resistant Prostate Carcinoma Patients Treated with^{177}Lu-PSMA

*E. Özkan[1], **B. Demir**[1], M. Ozturk[1], M. Araz[1], C. Soydal[1], B. Dursun[2], Y. Urun[2], N. O. Kucuk[1];*
[1]Ankara University School of Medicine Department of Nuclear Medicine, Ankara, TÜRKIYE, [2]Ankara University School of Medicine Department of Medical Oncology, Ankara, TÜRKIYE.

EPS-117
Changes in PSA levels after two cycles of radioligand therapy appear superior to changes in PSMA PET for outcome prediction

***P. Hartrampf**[1], T. Hüttmann[1], A. K. Seitz[2], H. Kübler[2], T. Higuchi[1], S. E. Serfling[1], W. Schlötelburg[1], K. Michalski[1], A. K. Buck[1], R. A. Werner[1];*
[1]Klinik und Poliklinik für Nuklearmedizin, Würzburg, GERMANY, [2]Klinik und Poliklinik für Urologie, Würzburg, GERMANY.

EPS-118
Analysing the Tumour Transcriptome of Prostate Cancer to Predict Efficacy of Lu-PSMA Therapy

***A. Handke**[1], C. Kesch[1], W. Fendler[1], T. Telli[1], Y. Liu[2], A. Hakansson[2], E. Davicioni[2], J. Hughes[2], H. Song[3], K. Lückerath[1], K. Herrmann[1], B. Hadaschik[1], R. Seifert[1];*
[1]Universitätsklinikum Essen, Essen, GERMANY, [2]Decipher Bioscience, Vancouver, BC, CANADA, [3]Stanford University, Stanford, CA, UNITED STATES OF AMERICA.

EPS-119
Initial clinical study results of ^{68}Ga/^{177}Lu-NYM032, a new generation of PSMA-targeting theranostic radiopharmaceuticals, in patients with metastatic prostate cancer

***H. He**[1], Y. Wang[1], Y. Mi[1], C. Yan[2], P. Fang[2], W. Eng[2], H. Fu[1], C. Yu[1];*
[1]Affiliated Hospital of Jiangnan University, Wuxi, CHINA, [2]Norroy bioscience Co. Ltd., Wuxi, CHINA.

EPS-120
Detection Rate of ^{64}Cu-SAR-Bombesin-PET/CT in Men with Biochemically Recurrent Prostate Cancer and Negative or Equivocal ^{68}Ga-PSMA-11-PET/CT

***S. Li**[1], A. Nguyen[1,2], W. Counter[1], N. John[1], J. De Leon[3], G. Hruby[4,3,5], A. M. Joshua[6,7,8], P. Stricker[9,5,10], K. Wong[1], V. Liu[1], E. Lengyelova[11], S. Agrawal[1,6,7], L. Emmett[1,7,2];*
[1]Department of Theranostics and Nuclear Medicine, St Vincent's Hospital, Sydney, AUSTRALIA, [2]St Vincent's Clinical School, University of New South Wales, Sydney, AUSTRALIA, [3]Genesis Cancer Care, Sydney, AUSTRALIA, [4]Department of Radiation Oncology, Royal North Shore Hospital, Sydney, AUSTRALIA, [5]Faculty of Medicine, University of Sydney, Sydney, AUSTRALIA, [6]The Kinghorn Cancer Care Centre, St Vincent's Hospital, Sydney, AUSTRALIA, [7]Garvan Institute of Medical Research, Sydney, AUSTRALIA, [8]St. Vincent's Clinical School, University of New South Wales, Sydney, AUSTRALIA, [9]Department of Urology, St Vincent's Hospital, Sydney, AUSTRALIA, [10]Faculty of Medicine, University of New South Wales, Sydney, AUSTRALIA, [11]Clarity Pharmaceuticals, Sydney, AUSTRALIA.

EPS-121
Impact of ^{68}Ga-PSMA-11 PET/CT on salvage radiation treatment concept in males with early biochemical relapse of prostate cancer after radical prostatectomy

***M. Dyankova**[1,2], T. Stoeva[1], Z. Dancheva[1], S. Chausheva[1], T. Yordanova[1], B. Chaushev[1], A. Klisarova[1];*
[1]Medical University Varna "Prof. Dr. Paraskev Stoyanov", Department of Imaging Diagnostics, Interventional Radiology and Radiotherapy, Varna, BULGARIA, [2]St. Marina University Hospital, Department of Nuclear Medicine, Varna, BULGARIA.

EPS-122
Effects of novel androgen receptor signaling inhibitors on PSMA PET signal intensity in patients with castrate-resistant prostate cancer: a prospective exploratory serial imaging study

***I. Sonni**[1,2], A. Gafita[1,3], R. M. Alano[1], S. Lira[1], L. Unterrainer[1,4], J. Shen[1], A. Drakaki[1], T. Grogan[1], M. B. Rettig[1], J. Czernin[1], J. Calais[1];*
[1]University of California, Los Angeles, Los Angeles, CA, UNITED STATES OF AMERICA, [2]Università Magna Graecia, Catanzaro, ITALY, [3]Johns Hopkins University, Baltimore, MD, UNITED STATES OF AMERICA, [4]Ludwig-Maximilians-University, Munich, GERMANY.

EPS-123
Comparison of SUV and tumour net uptake rate values using dynamic whole-body ^{68}Ga-PSMA-11 PET/CT in patients with metastatic castrate-resistant prostate cancer

***N. Payan**[1], J. M. Vrigneaud[1,2], A. Cochet[1,2];*
[1]George François Leclerc Centre, Department of Nuclear Medicine, Dijon, FRANCE, [2]ICMUB Laboratory, UMR CNRS 6302, University of Burgundy, Dijon, FRANCE.

EPS-124
Predictive ^{18}F-rhPSMA 7.3 PET parameters for outcome assesssment of ^{177}Lu-PSMA RLT

***K. Hansen**, C. Fütterer, T. Langbein, M. Heck, W. A. Weber, M. Eiber, I. Rauscher;*
Klinikum rechts der Isar, Munich, GERMANY.

EPS-125
Associations between antihormonal-treatment status and ^{68}Ga-PSMA-HBED-CC PET biodistribution

***K. Kluge**[1], D. Haberl[1], H. Einspieler[1], D. Muin[1], L. Shiyam Sundar[2], S. Gutschmayer[2], L. Kenner[3], A. Haug[1], M. Hacker[1];*
[1]Medical University of Vienna - Dept. of Nuclear Medicine, Vienna, AUSTRIA, [2]Medical University of Vienna - Dept. of Medical Physics, Vienna, AUSTRIA, [3]Medical University of Vienna - Dept. of Pathology, Vienna, AUSTRIA.

810
Monday, September 11, 2023, 09:45 - 11:15
Hall K

CTE 4 - Technologists Committee: Prostate Cancer Theranostics

OP-399
Prostate Cancer Theranostics – What's its Role and Why we Need it?

***P. Sandach**;*
Universitätsklinikum, Nuclear Medicine Department, Essen, GERMANY.

OP-400
The utility of Theranostics in Various Stages of Prostate Cancer

***R. Madru**;*
Skånes Universitetssjukhus, Lund, SWEDEN.

OP-401a
The role of Nuclear Medicine Technologist in Theranostics

***A. Santos**;*
NuclearMedicine Department, CUF Descobertas Hospital, Lisbon, PORTUGAL.

OP-401b
The role of Nuclear Medicine Technologist in Theranostics in the USA

D. Beyder;
Barnes-Jewish Hospital, Mallinckrodt Institute of Radiology, Missouri, UNITED STATES OF AMERICA.

811
Monday, September 11, 2023, 09:45 - 11:15
Hall G1

Special Symposium 3 - EANM / EJNMMI: You, the EANM and the EJNMMI

OP-402
Setting a world stage for the EANM Journal: a voyage through 50 volumes

***A. Chiti**;*
Professor in Diagnostic Imaging and Radiotherapy Faculty of Medicine and Surgery, Vita-Salute San Raffaele University
Director, Department of Nuclear Medicine, IRCCS Ospedale San Raffaele
Editor in Chief, European Journal of Nuclear Medicine and Molecular Imaging, Milan, ITALY.

OP-403
Ethics and metrics of scientific publication: what you should know

***I. Carriò**;*
Autonomous University of Barcelona, Barcelona, SPAIN.

901
Monday, September 11, 2023, 11:30 - 13:00
Hall A

Plenary 3: Radiotheranostics: What´s New?

OP-406
PRRT in Neuroendocrine Tumours as a Paradigm for Progress in Radiopharmaceuticals: Where are we and where will we be?

***J. Strosberg**;*
Moffitt Cancer Center Tampa, Florida, UNITED STATES OF AMERICA.

OP-407
2023: PSMA State of the Art

***M. Hofman**;*
Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, AUSTRALIA

OP-408
PSMA 2.0

***S. Heskamp**;*
Radboud University Nijmegen Medical Centre, Nijmegen, NETHERLANDS.

OP-409
CXCR4: Ready for Prime Time!

***A. Buck**;*
Universitätsklinikum Würzburg, Würzburg, GERMANY.

OP-410
Targeting the Tumour Microenvironment: Next Breakthrough?!

***K. Lückerath**;*
UniversityHospital Essen, Essen, GERMANY.

OP-411
Dark Horses of Theranostics

***L. Unterrainer**;*
Department of Nuclear Medicine, LMU Munich, Munich , GERMANY, Department of Nuclear Medicine, UCLA, UNITED STATES OF AMERICA.

1001
Monday, September 11, 2023, 15:00 - 16:30
Hall A

CME 7 - Thyroid + Dosimetry Committee: New NM Guidelines of Benign Thyroid Disease

OP-414
Radioiodine Therapy of Hyperthyroidism: An Overview on the New EANM GL

***A. Campennì**;*
UniversityHospital "Gaetano Martino", Messina. Department of Biomedical and Dental Sciences and Morpho-Functional Imaging, Nuclear Medicine Unit, Messina, ITALY.

OP-415
Radioiodine Therapy in Hyperthyroid Pediatric Patients

***F. Verburg** ;*
Department of Radiology and Nuclear Medicine, Erasmus Medical Center, Dr. Molewaterplein 40, 3015 CE, Rotterdam, NETHERLANDS.

OP-416
Radioiodine Therapy in Non-Toxic Benign Thyroid Disorders: Who, When, How

***B. Katica**;*
Department of Nuclear Medicine, University Medical Centre Ljubljana and Faculty of Medicine, University of Ljubljana, Ljubljana, SLOVENIA.

OP-417
Adverse Effects of Radioiodine Therapy: A Real Point of View

***P. Petranović Ovčariček**;*
UniversityHospital Center Sestre Milosrdnice, Department of Oncology and Nuclear Medicine Hospital/Institute; School of Medicine, University of Zagreb, Zagreb, CROATIA.

1002

Monday, September 11, 2023, 15:00 - 16:30
Hall D (Arena)

Award Session: EANM Sanjiv Sam Gambhir Award - Compete and Win!

1003

Monday, September 11, 2023, 15:00 - 16:30
Hall E1

LIPS Session 7 - Inflammation & Infection Committee: Tips and Tricks in the Study of Prosthesis Infection

OP-424
Tips and Tricks in Orthopedic Prosthesis
E. Noriega-Álvarez *;*
General University Hospital of Ciudad Real, Department of Nuclear Medicine, Ciudad Real, SPAIN.

OP-425
Tips and Tricks in Heart Valve Prosthesis
L. Leccisotti*;*
Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Nuclear Medicine Unit, Rome, ITALY.

OP-426
Tips and Tricks in Vascular Prosthesis
A. Glaudemans*;*
UniversityMedical Center Groningen, Department of Nuclear Medicine and Molecular Imaging, Groningen, NETHERLANDS.

1004

Monday, September 11, 2023, 3:00 PM - 4:30 PM
Hall E2

M2M Track - TROP Session: New Roads Towards FAP-directed Theranostics

OP-427
Clinical Evaluation of ^{68}Ga-FAPI-RGD for Imaging of Fibroblast Activation Protein and Integrin $\alpha_v\beta_3$ in Various Cancer Types
Y. Pang*, l. zhao, w. xu, j. cai, l. sun, h. chen;*
Department of Nuclear Medicine & Minnan PET Center, Xiamen Cancer Center, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China, xiamen, CHINA.

OP-428
Quantitative SPECT/CT Imaging of the Radiation Dosimetry of ^{99m}Tc-Labeled FAPI Tracer in Healthy Subjects, and Compared with ^{68}Ga-PET/CT in Gastrointestinal Tumor
C. ZHOU*, G. Li, F. Kang, J. Wang;*
Department of Nuclear Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, China, CHINA.

OP-429
Preclinical evaluation of a novel ^{18}F-labeled probe for fibroblast activation protein-targeted imaging and side by side comparison with FAPI-04
F. Elvas*, N. Filippi, Y. Van Rymenant, S. Grintsevich, L. Cianni, I. De Meester, P. Van der Veken;*
University of Antwerp, Wilrijk, BELGIUM.

OP-430
Enhancing the tumor-to-background ratio of FAP-positive PET/CT scans with the novel ^{61}Cu-Kalios derivatives: synthesis, in vitro and in vivo characterization
J. Millul*[1], T. Basaco Bernabeu[1], R. H. Gaonkar[1], F. De Rose[2], L. Jaafar-Thiel[2], R. Mansi[1], M. Fani[1];*
[1]University Hospital Basel, Basel, SWITZERLAND, [2]Nuclidium AG, Basel, SWITZERLAND.

OP-431
Effects of Linker and Attachment Position on Binding Affinity, Tumor Uptake and Tumor-to-background Contrast of ^{68}Ga-labeled Pyridine-based Fibroblast Activation Protein Inhibitors
A. Verena*, H. Kuo, H. Merkens, N. Colpo, P. Ng, F. Bénard, K. Lin;*
BC Cancer Research Centre, Vancouver, BC, CANADA.

OP-432
Preclinical side by side comparison of two [^{177}Lu] Lu-labeled FAP-based inhibitors: A promising therapeutic approach for targeted radionuclide therapy of stromal tumors
T. Läppchen*[1], A. Bilinska[1], E. Pilatis[1], E. Menéndez[1], S. Imlimthan[1], E. S. Moon[2], F. Rösch[2], A. Rominger[1], E. Gourni[1];*
[1]Department of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, SWITZERLAND, [2]Department of Chemistry – TRIGA site, Johannes Gutenberg - University Mainz, 55128 Mainz, GERMANY.

OP-433
Novel Co-culture Model of Pancreatic Cancer to Accurately Predict the Efficacy of Fibroblast Activation Protein Targeted Radionuclide Therapy using [^{161}Tb]Tb-FAP-2286 and [^{177}Lu]Lu-FAP-2286
C. D. van der Heide*[1], A. Lak[1], R. McMorrow[1,2,3], L. Mezzanotte[1,2], S. U. Dalm[1];*
[1]Department of Radiology & Nuclear Medicine, Erasmus MC, Rotterdam, NETHERLANDS, [2]Department of Molecular Genetics, Erasmus MC, Rotterdam, NETHERLANDS, [3]Percuros B.V, Leiden, NETHERLANDS.

OP-434
Radioligand Therapy in GBM: Fibroblast Activation Protein (FAP) Promises
P. Jeanjean*[1,2], S. Kwock[1,2], T. Cloughesy[1], J. Calais[1,2], J. Czernin[1,2], G. Carlucci[1,2], D. Nathanson[1,2], C. Mona[1,2], E. Besserer-Offroy[1,2];*
[1]Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California - Los Angeles, Los Angeles, CA, UNITED STATES OF AMERICA, [2]Ahmanson Translational Theranostics Division, David Geffen School of Medicine, University of California - Los Angeles, Los Angeles, CA, UNITED STATES OF AMERICA.

OP-435
Targeted Covalent Radiopharmaceutical (TCR) Could be a Promising Modality for Delivering Radionuclides to Tumour
X. Cui*[1], Z. Liu[2,1];*
[1]Changping Lab, Beijing, CHINA, [2]Peking University, Beijing, CHINA.

1005

Monday, September 11, 2023, 3:00 PM - 4:30 PM
Hall B

Cutting Edge Science Track - TROP Session: Clinical Dosimetry I - ^{177}Lu / ^{225}Ac and ^{161}Tb RLT

OP-436
Bone Marrow Dosimetry in Radioligand Therapy using AI-Enabled Whole Body Spongiosa Segmentation and Complementary Marrow/Lesion Maps from ^{99m}Tc-Sulfur Colloid SPECT/CT and [^{68}Ga] Ga-PSMA-11 PET/CT
A. Peterson*[1,2], S. J. Wilderman[1], J. Blakkisrud[1,3], K. Wong[1], K. A. Frey[1], Y. K. Dewaraja[1];*
[1]University of Michigan, Ann Arbor, MI, UNITED STATES OF AMERICA, [2]Wayne State University, Detroit, MI, UNITED STATES OF AMERICA, [3]Oslo University Hospital, Oslo, NORWAY.

OP-437
Radiation absorbed dose in patients with metastatic castration-resistant prostate cancer treated with [^{161}Tb]Tb-PSMA-I&T: first results of the VIOLET phase I/II study
B. Emmerson*[1], L. McIntosh[1], J. P. Buteau[1,2], P. Jackson[1,2], L. Kostos[2,3], T. Akhurst[1,2], R. Alipour[1,2], A. Cardin[1,2], A. S. Ravi Kumar[1,2], R. Kashyap[1], R. Ravi[1], G. Kong[1,2], J. Saghebi[1], S. Sandhu[2,3], B. Tran[2,3], M. B. Haskali[2,4], C. Martin[5], P. Opar[6], E. Medhurst[1,2], A. Azad[2,3], M. S. Hofman[1,2];*
[1]Prostate Cancer Theranostics and Imaging Centre of Excellence; Molecular Imaging and Therapeutic Nuclear Medicine, Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, AUSTRALIA, [2]Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, AUSTRALIA, [3]Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, AUSTRALIA, [4]Radiopharmaceutical Production and Research Laboratory, Peter MacCallum Cancer Centre, Melbourne, AUSTRALIA, [5]Parkville Cancer Clinical Trials Unit, Peter MacCallum Cancer Centre, Melbourne, AUSTRALIA, [6]Centre of Biostatistics and Clinical Trials, Peter MacCallum Cancer Centre, Melbourne, AUSTRALIA.

OP-438
Evaluation of a Phantom-Independent Dual-Energy Quantitative Computed Tomography (PI-DEQCT) Method for Selecting Bone-Site Specific S-Values in Bone Marrow Dosimetry in Molecular Radiotherapy
J. Pereira-Cubillo*[1], E. Mora-Ramirez[2], M. Salas-Ramirez[3];*
[1]University of Costa Rica, Escuela de Física, San José, COSTA RICA, [2]University of Costa Rica, Escuela de Física, CICANUM, San José, COSTA RICA, [3]University Hospital of Würzburg, Department of Nuclear Medicine, Würzburg, GERMANY.

OP-439
Hematological Toxicity Correlates with Monte Carlo-derived Absorbed Dose to the Red Marrow in Patients Treated with [^{177}Lu]Lu-DOTA-TATE
J. Blakkisrud*[1,2], G. Kingkiner[1], A. B. Peterson[1,3], S. J. Wilderman[1], K. Wong[1], K. A. Frey[1], Y. K. Dewaraja[1];*
[1]University of Michigan, Ann Arbor, MI, UNITED STATES OF AMERICA, [2]Oslo University Hospital, Oslo, NORWAY, [3]Wayne State University, Detroit, MI, UNITED STATES OF AMERICA.

OP-440
Dosimetry estimates of ^{177}Lu-PNT2002 in oligorecurrent prostate cancer: preliminary dosimetry results from a randomized phase 2 trial (LUNAR)
Z. Ells*[1], L. Unterrainer[1,2], D. Sennung[1], R. Alano[1], K. Booker[1], C. Felix[1], A. Daley[1], A. Farolfi[1,3], J. Czernin[1], M. Dahlbom[1], A. Kishan[1], J. Calais[1];*
[1]University of California - Los Angeles, Los Angeles, CA, UNITED STATES OF AMERICA, [2]Ludwig Maximilian University of Munich, Munich, GERMANY, [3]Universita di Bologna, Bologna, ITALY.

OP-441
Modelling the effect of daughter migration on dosimetry estimates for actinium-225 in targeted alpha therapy
S. Tronchin*[1], J. C. Forster[1,2], K. Hickson[2,3], E. Bezak[1,4];*
[1]Department of Physics, The University of Adelaide, Adelaide, AUSTRALIA, [2]Medical Physics & Radiation Safety, South Australia Medical Imaging, Adelaide, AUSTRALIA, [3]Allied Health & Human Performance, University of South Australia, Adelaide, AUSTRALIA, [4]Cancer Research Institute, University of South Australia, Adelaide, AUSTRALIA.

OP-442
Image Quantification and Quality Assessment of Dual-Isotope ^{99m}Tc and ^{177}Lu SPECT for Bone Marrow Dosimetry: a Simulation Study
C. Miller*, X. Hou, J. Brosch-Lenz, A. Rahmim, C. Uribe;*
BC Cancer Research Institute, Vancouver, BC, CANADA.

OP-443
Uncertainty analysis for Lu-177-PSMA in clinical routine
V. Nuttens*[1], M. Koole[2], O. De Winter[1], P. De Bondt[1];*
[1]OLVZ, Aalst, BELGIUM, [2]KU Leuven, Leuven, BELGIUM.

OP-444
Tumour dosimetry after ^{177}Lu-RPT with a ring-shaped CZT-based camera requires inclusion criteria based on volume and activity concentration
R. Danieli*[1], C. Marin[1], M. Stella[2], B. Vanderlinden[1], H. Levillain[1],*
N. Reynaert[1], P. Flamen[1];
[1]Institut Jules Bordet, Brussels, BELGIUM, [2]GE HealthCare, Diegem, BELGIUM.

1006

Monday, September 11, 2023, 3:00 PM - 4:30 PM
Hall C

Clinical Oncology Track - Featured Session: Melanoma

OP-445
Pitfalls in Melanoma Imaging

OP-446
Predictive value of baseline quantitative parameters of 2-[^{18}F]FDG-PET/CT for brain metastases in melanoma patients

F. Kalantari[1,2], *L. Hehenwarter*[1], *G. Rendl*[1], *G. Schweighofer-Zwink*[1], *W. Hitzl*[3], *P. Koelblinger*[4], *C. Pirich*[1], *M. Beheshti*[1];
[1]*Division of Molecular Imaging & Theranostics, Department of Nuclear Medicine, University Hospital, Paracelsus Medical University Salzburg, Salzburg, AUSTRIA,* [2]*Iran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF,* [3]*Biostatistics and Publication of Clinical Trial Studies, Research and Innovation Management (RIM), Paracelsus Medical University Salzburg, Salzburg, AUSTRIA,* [4]*Department of Dermatology, University Hospital, Paracelsus Medical University Salzburg, Salzburg, AUSTRIA.*

OP-447
Lymphoid organs' glucose metabolism and its role in predicting the outcomes of patients with malignant melanoma treated with immunotherapy

L. Evangelista[1], *A. Bianchi*[2], *A. Annovazzi*[3], *R. Sciuto*[3], *S. Di Treglia*[3], *A. G. Nappi*[4], *C. Ferrari*[4], *G. Rubini*[4], *S. Panareo*[5], *L. Urso*[6], *M. Bartolomei*[6], *D. Arico*[7], *M. Bombaci*[7], *D. Caponnetto*[7], *S. Gusella*[8], *A. Spimpolo*[8], *C. Carriere*[9], *M. Balma*[2], *A. Buschiazzo*[2], *R. Gallicchio*[10], *G. Storto*[10], *M. L. De Rimini*[11];
[1]*Nuclear Medicine Unit, University of Padua, Padova, ITALY,* [2]*Nuclear Medicine Unit, SC Medicina Nucleare ASO S.Croce e Carle Cuneo, Cuneo, ITALY,* [3]*Nuclear Medicine Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy, Rome, ITALY,* [4]*Section of Nuclear Medicine, Interdisciplinary Department of Medicine, University of Bari "Aldo Moro", Bari, Italy, Bari, ITALY,* [5]*Nuclear Medicine Unit, Oncology and Haematology Department, University Hospital of Modena, Italy, Modena, ITALY,* [6]*Nuclear Medicine Unit, Oncology and Specialistic Department, University Hospital of Ferrara, Italy, Ferrara, ITALY,* [7]*Servizio di Medicina Nucleare, Humanitas Istituto Clinico Catanese, Misterbianco (CT), Italia., Catania, ITALY,* [8]*Nuclear Medicine Department,Central Hospital Bolzano (SABES-ASDAA), Bolzano-Bozen, Italy, Bolzano, ITALY,* [9]*Dermatology Department, Central Hospital Bolzano (SABES-ASDAA), Bolzano-Bozen, Italy., Bolzano, ITALY,* [10]*Nuclear Medicine Unit, IRCCS CROB Referral Cancer Center of Basilicata, Rionero in Vulture (PZ), Italia, Rionero in Vulture, ITALY,* [11]*Nuclear Medicine Unit - Department of Health Service-AORN Ospedali dei Colli, Naples, Italy, Naples, ITALY.*

OP-448
First-in-human PET imaging and evaluation of melanin-targeted ^{18}F-DMPY2 in malignant melanoma patients.

Y. Yang[1], *M. Zhou*[1], *N. Chen*[1], *J. Su*[2], *X. Chen*[2], *S. Hu*[1];
[1]*Department of Nuclear medicine, Xiangya Hospital, Central South University, Changsha City, Hunan Province, CHINA,* [2]*Department of Dermatology, Xiangya Hospital, Central South University, Changsha City, Hunan Province, CHINA.*

OP-449
The prognostic value of [^{18}F]FDG PET/CT based response monitoring in metastatic melanoma patients undergoing immunotherapy: comparison of different metabolic criteria

C. Sachpekidis[1], *V. Weru*[1], *A. Kopp-Schneider*[1], *J. C. Hassel*[2], *A. Dimitrakopoulou-Strauss*[1];
[1]*German Cancer Research Center (DKFZ), Heidelberg, GERMANY,* [2]*National Center for Tumor Diseases (NCT), University Hospital Heidelberg, Heidelberg, GERMANY.*

OP-450
Early monitoring of immunotherapy using ^{18}F-FDG-PET-CT in patients with stage IV melanoma treated with PD-1 inhibitors

D. Hochmuth[1], *C. Sachpekidis*[1], *J. Hassel*[2], *L. Pan*[1], *A. Dimitrakopoulou-Strauss*[1];
[1]*German Cancer Research Center, CCU Nuclear Medicine, Heidelberg, GERMANY,* [2]*Department of Dermatology, University Hospital Heidelberg and NCT Heidelberg, Heidelberg, GERMANY.*

OP-451
FDG PET/CT Biomarker Dissemination Features In Metastatic Melanoma Patients Treated With Immunotherapy: Association With Survival

H. Saadani[1,2], *E. A. Aalbersberg*[1], *M. T. Kayembe*[1], *J. B. A. G. Haanen*[1], *O. S. Hoekstra*[2], *R. Boellaard*[2], *M. P. M. Stokkel*[1];
[1]*NETHERLANDS Cancer Institute, Amsterdam, NETHERLANDS,* [2]*Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, NETHERLANDS.*

OP-452
Correlation of thyroid FDG uptake on 18F-FDG PET/CT with response to immunotherapy in metastatic melanoma patients

K. Zevnik[1,2], *N. Hribernik*[1,2], *K. Strašek*[3], *A. Studen*[3,4], *A. Doma*[1,2], *K. Škalič*[1], *M. Reberšek*[1,2];
[1]*Oncology Institute Ljubljana, Ljubljana, SLOVENIA,* [2]*Faculty of Medicine, University of Ljubljana, Ljubljana, SLOVENIA,* [3]*Faculty of Mathematics and Physics University of Ljubljana, Ljubljana, SLOVENIA,* [4]*Experimental Particle Physics Department, Jožef Stefan Institute, Ljubljana, SLOVENIA.*

OP-453
Prediction of Additional Regional Lymph Node Metastases in Cutaneous Melanoma Patients With Positive Sentinel Lymph Node Biopsy

L. Radosavcev[1], *M. Rajovic*[2], *M. Radulovic*[1], *N. Petrov*[3], *L. Kandolf Sekulovic*[4];
[1]*Institute of Nuclear Medicine, Military Medical Academy, Belgrade, SERBIA,* [2]*Clinic for Plastic and Reconstructive Surgery , Military Medical Academy, Belgrade, SERBIA,* [3]*Institute of Pathology and Forensic Medicine , Military Medical Academy, Belgrade, SERBIA,* [4]*Department of Dermatology and Venerology, Military Medical Academy, Belgrade, SERBIA.*

1007

Monday, September 11, 2023, 3:00 PM - 4:30 PM
Hall F1

Neuroimaging Committee - TROP Session: Imaging Neurotransmission in Movement Disorders

OP-454
Effects Of Medications On Dopamine Transporter Imaging Using ^{123}I-FP-CIT SPECT In Routine Practice

Y. Piatkova[1], *M. Doyen*[1], *S. Frismand*[2], *L. Hopes*[2], *L. Imbert*[1], *A. Verger*[1];
[1]*Université de Lorraine, Department of Nuclear Medicine and Nancyclotep Imaging Platform, CHRU Nancy, Nancy, FRANCE,* [2]*Université de Lorraine, Department of Neurology, CHRU Nancy, Nancy, FRANCE.*

OP-455
Disease-tailored z-score cut-offs for striatal binding ratio of DaT SPECT for the diagnosis of Dementia with Lewy Bodies (DLB): a multicenter study

F. Lanfranchi[1,2], *D. Arnaldi*[2,3], *V. Garibotto*[4], *C. Boccalini*[4], *L. Bonanni*[5], *M. V. Mattoli*[6], *V. Costa*[2,3], *S. Raffa*[1,2], *S. Chiola*[1,2], *F. Massa*[2,3], *M. Losa*[2,3], *M. Pardini*[2,3], *G. Frisoni*[7], *N. Nicastro*[8], *G. Sambuceti*[1,2], *M. Bauckneht*[1,2], *S. Morbelli*[1,2];
[1]*Nuclear Medicine Unit, Department of Health Sciences (DISSAL), University of Genoa, Genoa, ITALY,* [2]*IRCCS Ospedale Policlinico San Martino, Genoa, ITALY,* [3]*Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINOGMI), University of Genoa, Genoa, ITALY,* [4]*Division of Nuclear Medicine and Molecular Imaging, University Hospitals and NIMTLab, Geneva University, Geneva, SWITZERLAND,* [5]*Department of Neuroscience, Imaging and Clinical Sciences, University G. d'Annunzio, Chieti-Pescara, ITALY,* [6]*Nuclear Medicine Unit, Presidio Ospedaliero Santo Spirito, Pescara, ITALY,* [7]*Laboratory of Neuroimaging of Aging (LANVIE), University of Geneva, Geneva, SWITZERLAND,* [8]*Division of Neurorehabilitation, Department of Clinical Neurosciences, Geneva University Hospitals, Geneva, SWITZERLAND.*

OP-456
Dopamine dysregulation in depression: a 123I-FP-CIT SPET study

D. Pizzuto[1], *E. Perrone*[1,2], *F. Cocciolillo*[1], *F. Pesaresi*[3,4], *L. Di Benedetto*[3,4], *A. D'Onofrio*[3,4], *G. Camardese*[3,4], *D. Di Giuda*[1,2];
[1]*Nuclear Medicine Unit, Diagnostic Imaging, Radiation Oncology and Hematology Department, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, ITALY,* [2]*Nuclear Medicine Institute, University Department of Radiological and Hematological Sciences, Università Cattolica del Sacro Cuore, Rome, ITALY,* [3]*Institute of Psychiatry and Psychology, Department of Geriatrics, Neuroscience and Orthopedics, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, ITALY,* [4]*Department of Psychiatry, Università Cattolica del Sacro Cuore, Rome, ITALY.*

OP-457
Comparison of ^{123}I-FP-CIT SPECT and ^{18}F-FE-PE2I PET in patients with parkinsonism and persistent diagnostic uncertainty

M. Dhadamus[1,2], *A. Delva*[3], *W. Vandenberghe*[3], *K. Van Laere*[1,2];
[1]*Division of Nuclear Medicine, University Hospitals Leuven, Leuven, BELGIUM,* [2]*Nuclear Medicine and Molecular Imaging, KU Leuven, Leuven, BELGIUM,* [3]*Neurology, University Hospitals Leuven, Leuven, BELGIUM.*

OP-458
Within-subject comparison of ^{11}C-PE2I and ^{18}F-FE-PE2I PET for dopamine transporter availability and relative blood flow measures

M. Jonasson, *L. Appel, S. Roslin, G. Antoni, D. Nyholm, T. Danfors, M. Lubberink;*
Uppsala University, Uppsala, SWEDEN.

OP-459
Relationship between cerebral blood flow and dopamine transporter availability in healthy individuals

M. Jonasson, *L. Appel, S. Roslin, D. Nyholm, T. Danfors, M. Lubberink;*
Uppsala University, Uppsala, SWEDEN.

OP-460
FDG-PET related pattern expression and survival in Parkinson's disease

G. Martí-Andrés[1], *V. Betech*[2], *E. Prieto*[2], *C. Espinoza-Vinces*[2], *M. Riverol*[2], *M. Luquin*[2], *J. Arbizu*[2];
[1]*Hospital Universitario de Navarra, Pamplona, SPAIN,* [2]*Clínica Universidad de Navarra, Pamplona, SPAIN.*

OP-461
Identification of Synaptic Alterations in Idiopathic REM Sleep Behavior Disorder: A Preliminary Study using ^{18}F-SynVesT-1 PET/CT Imaging

J. Li[1], *J. Huang*[2], *J. Guo*[2], *S. Hu*[1];
[1]*1.Department of Nuclear Medicine (PET Center), Xiangya Hospital Central South University, Changsha, CHINA,* [2]*1.Department of Neurology, Xiangya Hospital Central South University, Changsha, CHINA.*

OP-462
Neurobiological dysfunctional substrates for the self-medication hypothesis in adult individuals with ADHD and cocaine use disorder: an18F-FDG PET study

A. Martini[1], *G. Carli*[2], *M. Bruscoli*[3], *L. Presotto*[4], *C. Mazzeo*[1], *S. Sestini*[1], *D. Perani*[5];
[1]*Unit of Nuclear Medicine, Department of Diagnostic Imaging, N.O.P. - S. Stefano, U.S.L. Toscana Centro, Prato, ITALY,* [2]*Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, Groningen, NETHERLANDS,* [3]*UFC Farmacotossicodipendenze, Department of Drug Addiction, N.O.P. - S. Stefano, U.S.L. Toscana Centro, Prato, ITALY,* [4]*Department of Physics G. Occhialini, Università degli Studi di Milano Bicocca, Milano, ITALY,* [5]*In vivo human molecular and structural neuroimaging Unit, Division of Neuroscience, IRCCS San Raffaele Scientific Institute; NuclearMedicine Unit, San Raffaele Hospital, Milano, ITALY.*

1008

Monday, September 11, 2023, 15:00 - 16:30
Hall F2

Joint Symposium 3 - Translational Molecular Imaging & Therapy Committee + Oncology & Theranostics + Physics / EAU: Metastases Directed Prostate Cancer Surgery - Translational Challenges and Possibilities

OP-463
Surgical removal of nodal metastases in prostate cancer, what is the clinical value?

E. Mazzone;
Dept. of Urology, San Raffaele Scientific Institute, URI - Urological Research Institute, Milan, ITALY.

OP-464
Translation and implementation of (radio)tracers for nodal management of prostate cancer
T. Buckle;
Leiden University Medical center, Radiology, Leiden, NETHERLANDS.

OP-465
An engineers overview of radioguided surgery modalities that support targeted nodal dissections in the pelvis
T. Wendler;
Technical University Munich, CAMP, Munich, GERMANY.

OP-466
State of the art in PSMA-guided surgery
S. Knipper;
Vivantes Klinikum am Urban, Urology, Berlin, GERMANY.

1009

Monday, September 11, 2023, 3:00 PM - 4:30 PM
Hall G2

e-Poster Presentations Session 7 - Cardiovascular Committee: Cardiovascular Imaging e-Posters

EPS-126
Positron Range Correction for ^{82}Rb myocardial PET: Validation in a healthy cohort
M. Lassen[1,2], *H. Kertesz*[3], *I. Rausch*[4], *A. Kjaer*[1,2], *V. Panin*[5], *D. Bharkhada*[5], *R. DeKemp*[6], *T. Beyer*[4], *P. Hasbak*[1];
[1]Department of Clinical Physiology and Nuclear Medicine, University Hospital Copenhagen – Rigshospitalet, Copenhagen, DENMARK, [2]Cluster for Molecular Imaging, Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, DENMARK, [3]Image X Institute, Faculty of Medicine and Health, The University of Sydney, Sydney, AUSTRALIA, [4]QIMP Team, Center for Medical Physics and Biomedical Engineering, Medical University of Vienna, Vienna, AUSTRIA, [5]Siemens Medical Solutions UNITED STATES OF AMERICA, Inc, Knoxville, TN, UNITED STATES OF AMERICA, [6]National Cardiac PET Centre, University of Ottawa Heart Institute, Ottawa, ON, CANADA.

EPS-127
Metabolic pretest calculator to improve cardiac FDG PET/CT imaging
S. Hartikainen[1], *T. Tompuri*[1], *T. M. Laitinen*[1], *T. Laitinen*[1,2];
[1]Kuopio University Hospital, Kuopio, FINLAND, [2]University of Eastern Finland, Kuopio, FINLAND.

EPS-128
Diagnostic accuracy of global parameters obtained during dynamic PET/CT with 13N-Ammonia and vasodilator stress in patients with triple-vessel stenotic lesion of coronary arteries and stable form of CAD
A. Shakhova, *E. Golukova, I. Aslanidis, I. Shurupova, N. Surkova, M. Rumyantseva, I. Ekaeva;
A.N. Bakulev Scientific Center for Cardiovascular Surgery of the Ministry of Health of the Russian Federation, Moscow, RUSSIAN FEDERATION., Moscow, RUSSIAN FEDERATION.*

EPS-129
Does global value of myocardial flow reserve using 13N-ammonia positron emission tomography independently predict identification of multivessel coronary artery disease
A. Shakhova, *E. Golukhova, I. Aslanidis, I. Shurupova, N. Surkova, M. Rumyantseva, I. Ekaeva;
A.N. Bakulev Scientific Center for Cardiovascular Surgery of the Ministry of Health of the Russian Federation, Moscow, RUSSIAN FEDERATION.*

EPS-130
Defining a Significant Change with serial assessment of myocardial perfusion metrics, obtained during dynamic Positron Emission Tomography with 13 N-Ammonia in patients with CAD
A. Shakhova, *E. Golukhova, I. Aslanidis, I. Shurupova, M. Rumyantseva, N. Surkova, I. Ekaeva;
A.N. Bakulev Scientific Center for Cardiovascular Surgery of the Ministry of Health of the Russian Federation, Moscow, RUSSIAN FEDERATION.*

EPS-131
Relationship between myocardial flow reserve measured by a dynamic cadmium-zinc-telluride camera and increase rate in myocardial uptake of radionuclide during exercise
T. Niimi[1], *K. Hirayama*[1], *S. Yoshida*[2];
[1]Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital, Nagoya, JAPAN, [2]Nagoya University, Nagoya, JAPAN.

EPS-132
Stress-only versus rest-stress SPECT MPI in the detection and diagnosis of myocardial ischemia and infarction by machine learning
F. Wang[1], *H. Yuan*[1], *L. Jiang*[1,2];
[1]PET Center, Department of Nuclear Medicine, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, CHINA, [2]Guangdong Provincial Key Laboratory of Artificial Intelligence in Medical Image Analysis and Application, Guangzhou, CHINA.

EPS-133
A Meta-Analysis of Bone Tracer Scintigraphy in the Diagnosis of Cardiac Amyloid ATTR and AI, Comparing HMDP with DPD and PYP Sensitivity and Specificity in Biopsy Proven Cases
A. ALDEHLAUI[1,2], *C. Fowler*[2];
[1]King Abdullah Medical City, Makkah, SAUDI ARABIA, [2]King's College London, London, UNITED KINGDOM.

EPS-134
CT-free attenuation correction for cardiac-dedicated CZT SPECT: preliminary results of the CASCTEC study
M. Hesse, *B. El Jari, F. Dupont, O. Gheysens, R. Lhommel, V. Roelants;
Cliniques Universitaires Saint-Luc, Brussels, BELGIUM.*

EPS-135
The effect of Ursodeoxycholic Acid on early hepatic clearance of 99mTc-sestamibi in patients undergoing myocardial perfusion scintigraphy
E. Hosseinzadeh, *M. Ghodsirad, H. Garavand;
Nuclear medicine department, shohadaye tajrish hospital, Shahidbeheshti university, Tehran, IRAN, ISLAMIC REPUBLIC OF.*

EPS-136
The Role Of Myocardial Perfusion Scintigraphy In Asymptomatic Patients With 50-70% Coronary Artery Stenosis In Coronary Ct
A. Doumas[1], *D. Boundas*[2], *E. Giannoula*[1], *P. Exadaktylou*[1], *A. Tsangaridi*[1], *N. Papadopoulos*[1], *G. Gerasimou*[1], *E. Papanastasiou*[1], *I. Iakovou*[1];
[1]Aristotle University, Thessaloniki, GREECE, [2]Private Nuclear Medicine Centre, Ippokratis, Thessaloniki, GREECE.

EPS-137
Artefacts and False Positive Results of Myocardial Perfusion SPECT with CZT D-SPECT Camera
M. Esnault[1], *D. Legallois*[2], *D. Agostini*[2], *P. Richard*[3], *M. Alain*[2];
[1]Caen University, Caen, FRANCE, [2]Caen University Hospital, Caen, FRANCE, [3]Hospital Privé Saint Martin, Caen, FRANCE.

EPS-138
Impact of Initial Myocardial Perfusion Imaging versus Coronary Angiography on Costs and Outcomes in Patients with Coronary Artery Disease in China
L. Yang, *Y. Hu, S. Li;
First Hospital of Shanxi Medical University, Taiyuan, CHINA.*

EPS-139
The value of gated blood pool SPECT in assessment of stress-induced changes of the right ventricular contractile function.
V. Shipulin, *S. Andreev, V. M. Shipulin, S. Polikarpov, K. Zavadovsky;
Cardiology Research Institute, branch of the Federal State Budgetary Scientific Institution «Tomsk National Research Medical Center of the Russian Academy of Sciences», Tomsk, RUSSIAN FEDERATION.*

EPS-140
Simultaneous PET/MRI myocardial perfusion measurements using Gd-DOTA CMR and 68Ga-DOTA-PET
S. Kvernby[1], *T. Kero*[1], *K. Azarbar*[1], *C. Rischpler*[2], *J. Sörensen*[1], *I. Velikyan*[1], *M. Lubberink*[1];
[1]Uppsala University, Uppsala, SWEDEN, [2]Klinikum Stuttgart, Stuttgart, GERMANY.

EPS-141
Detection of mental stress induced myocardial ischemia with myocardial perfusion imaging in patients with anxiety and/or depression after coronary revascularization
W. Dong, *J. Jiao, N. Nan, T. Mou, H. Mi, X. Song;
Beijing Anzhen Hospital, Beijing, CHINA.*

EPS-142
Radionuclide Assessment of Myocardial Mitochondrial Dysfunction in Patients with Multivessel Coronary Artery Disease
K. Zavadovsky[1], *A. Kalinovsky*[2], *M. Gulya*[1], *K. Kopyeva*[1], *N. Kamenshikov*[1];
[1]Cardiology Research Institute, branch of the Federal State Budgetary Scientific Institution "Tomsk National Research Medical Center of the Russian Academy of Sciences", Tomsk, RUSSIAN FEDERATION, [2]Siberian State Medical University, Tomsk, RUSSIAN FEDERATION.

EPS-143
Multidisciplinary approach for the early detection of amyloid in patients who undergo carpal tunnel syndrome or lumbar stenosis surgery. Results of an ongoing study.
N. Orta[1,2], *T. Ripoll*[3,2,4], *S. Rubí*[1,2,4], *J. Pons*[1,2], *E. Fortuny*[1,2], *M. Bosch*[1,2,4], *C. Nadal*[1], *I. Torralba*[1], *G. Salvà*[1,4], *N. Mora*[1,4], *S. Lirola*[1], *R. Marí*[5], *J. Femenias*[1], *M. Llabrés*[1], *A. Álvarez*[1], *B. Barceló*[1,2,4], *V. Daza-Cajigal*[1,2], *A. Pérez*[1,2], *D. Heine*[1,2], *A. Sharma*[1], *A. Piñar*[1], *M. Villar*[1], *C. Peña*[1,2];
[1]Hospital Universitari Son Espases, Palma, SPAIN, [2]IdISBa, Palma, SPAIN, [3]Hospital Universitari Son Llàtzer, Palma, SPAIN, [4]Department of Medicine, University of the Balearic Islands, Palma, SPAIN, [5]Hospital Sant Joan de Déu, Palma-Inca, SPAIN.

EPS-144
A 3-month of physical exercise reduces stress-related neurobiological activity in obese women: a prospective 18F-FDG PET/CT study
K. Pahk, *H. Kwon, S. Kim;
Korea University College of Medicine, Seoul, KOREA, REPUBLIC OF.*

EPS-145
Prognostic Value of 18F-FDG PET/CT Brain metabolism and Brain Network in Patients with Heart Failure
Y. Bai, *M. Yun, X. Zhang;
Beijing Anzhen Hospital, Capital Medical University, Beijing, CHINA.*

EPS-146
Characterization of brain structure and metabolism in heart failure patients with reduced or preserved ejection fraction: a simultaneous PET/MR study
C. Zheng[1], *Y. Cui*[1], *Q. Ge*[2], *Y. Yang*[3], *X. Li*[4], *J. Lu*[1];
[1]Department of Radiology and Nuclear Medicine, Xuanwu Hospital, Capital Medical University, Beijing, CHINA, [2]Central Research Institute, United Imaging Healthcare, Shanghai, CHINA, [3]Beijing United Imaging Research Institute of Intelligent Imaging, Beijing, CHINA, [4]Division of Nuclear Medicine Department of Biomedical Imaging and Image-guided Therapy. Vienna General Hospital Medical University of Vienna, Vienna, AUSTRIA.

1010

Monday, September 11, 2023, 3:00 PM - 4:30 PM
Hall K

Technologists' e-Poster Presentations Session - Technologists Committee: Techs' e-Posters

TEPS-001
Description of an imaging protocol in patients with glioblastoma treated with [^{177}Lu]Lu-DOTA-TATE.
E. Córdoba Cañete[1], *M. Caballero Vivancos*[1], *N. González Corredera*[1], *E. Triviño Ibañez*[1], *R. Sánchez Sánchez*[2];
[1]Hospital Universitario Virgen de las Nieves, Granada, SPAIN, [2]Hospital Universitario Virgen de las Nieves, Maracena, SPAIN.

TEPS-002

[^{18}F]AlF-complexation of pamidronic acid, a NOTA-conjugated bisphosphonate, as a potential tracer for PET bone imaging

H. Hassan[1], *M. Othman*[2], *H. Abdul Razak*[3], *Z. Zakaria*[4], *F. Ahmad Saad*[1];
[1]Universiti Putra Malaysia, Serdang, MALAYSIA, [2]Universiti Teknologi MARA, Bandar Puncak Alam, MALAYSIA, [3]University of Exeter, Devon EX1 2LU, UNITED KINGDOM, [4]Universiti Malaysia Sabah, Kota Kinabalu, MALAYSIA.

TEPS-003

Evaluation of Variation method to Improve the Sensitivity of Immunoradiometric Assay

W. Kwon, *J. Kim;*
Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, KOREA, REPUBLIC OF.

TEPS-004

Comprehensive management of paediatrics in nuclear medicine: sharing the experience of technologists in a leading cancer center

M. GOLVET, *M. Luporsi, N. Jehanno, S. Lasalle, N. Sanchez Bertomeu;*
Department of nuclear medicine, Institut Curie, Paris, FRANCE.

TEPS-005

Ultra-fast Gallium-68 is it possible in the era of digital PET/CT imaging

Z. Alqallaf[1], *L. Ghadhanfer*[2], *A. Sadeq*[1], *H. Alfake*[1], *F. Marafi*[1];
[1]Jaber Al Ahmed Center For Nuclear Medicine & Molecular Imaging, Sabah Medical area, KUWAIT, [2]Faculty of Allied Health Kuwait university, Jabriya, KUWAIT.

TEPS-006

The Effect of Using Radiopharmaceutical Multidose Injector for 18F FDG on the Received Effective Doses of Radiographers

D. Sercic, *J. Peric, U. Cotar;*
Institute of Oncology Ljubljana, Ljubljana, SLOVENIA.

TEPS-007

Decontamination of Lu-177-PSMA and Tc-99m-Pertechnetate Spills from Laboratory Floor: Comparing Four Cleansing Agents

S. Rajala[1], *I. Rantala*[1], *L. Elg*[2], *A. Honkanen*[2], *J. Lehto*[2], *E. Hippeläinen*[2], *V. Ahtiainen*[1,3], *M. Ladev*[1], *M. Eskola*[1], *S. Keskimäki*[4], *K. Kiviluoto*[4], *J. Tervonen*[4], *M. Salomaa*[1], *V. Reijonen*[1];
[1]HUS Comprehensive Cancer Center, Helsinki, FINLAND, [2]HUS Diagnostic Center, Helsinki, FINLAND, [3]University of Helsinki, Helsinki, FINLAND, [4]HUS Pharmacy, Helsinki, FINLAND.

TEPS-008

Development of a specialized image reconstruction technique for dedicated breast positron emission tomography

K. Hanaoka[1], *S. Watanabe*[1], *D. Ishikawa-Morimoto*[1], *Y. Yamakawa*[2], *T. Kobayashi*[2], *A. Ohtani*[2], *S. Kumakawa*[2], *T. Ito*[3], *Y. Komoike*[3], *H. Kaida*[1], *K. Ishii*[1];
[1]Institute of Advanced Clinical Medicine, KINDAI University, Osaka-sayama, JAPAN, [2]Shimadzu Corporation, Kyoto, JAPAN, [3]Division of Breast and Endocrine Surgery, KINDAI University, Osaka-sayama, JAPAN.

TEPS-009

Impact of Image Space PSF Correction on Quantitative Values and SNR of Clinical PET Images in SiPM-based PET/CT with List-Mode Acquisition

Y. Shirakawa, *K. Ebine, M. Kawada, J. Suyama;*
Kyorin University Hospital, Tokyo, JAPAN.

TEPS-010

Comparison between MIRD-based and Monte Carlo simulation-based patient-specific dosimetry in177Lu-DOTATATE

N. Miyaji[1], *K. Miwa*[1], *K. Yamashita*[2], *T. Yamao*[1], *K. Hasegawa*[1], *N. Oriuchi*[3], *T. Terauchi*[2];
[1]Fukushima Medical University, Fukushima, JAPAN, [2]Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, JAPAN, [3]Advanced Clinical Research Center, Fukushima Medical University, Fukushima, JAPAN.

TEPS-011

[18F]fluorocholine PET is more resource-effective than conventional [99mTc]sestamibi scintigraphy in patients with primary hyperparathyroidism

S. Rep[1,2], *I. Slodnjak*[1], *K. Sirca*[3], *K. Zaletel*[1,4], *M. Hocevar*[3], *L. Lezaic*[1,4];
[1]Department for Nuclear Medicine, University Medical Centre Ljubljana, Ljubljana, SLOVENIA, [2]University of Ljubljana, Faculty of Health Sciences, Medical Imaging and Radiotherapy Department, Ljubljana, SLOVENIA, [3]Department of Oncological Surgery, Institute of Oncology Ljubljana, Ljubljana, SLOVENIA, [4]University of Ljubljana, Faculty of Medicine, Ljubljana, SLOVENIA.

TEPS-012

Does ^{18}F-FDG-PET require withdrawal of Glucagon-like peptide 1 (GLP-1) analogs in diabetic patients?

B. Olsson[1], *U. Bitzén*[1], *S. Garpered*[1], *S. Leide-Svegborn*[2], *A. Stenvall*[2];
[1]Clinical Physiology and Nuclear Medicine, Malmö/Lund, SWEDEN, [2]Radiation Physics, Malmö/Lund, SWEDEN.

TEPS-013

^{99m}Tc-Colloid residuals dependency on the syringe and needles

D. Teixeira Macarico[1], *C. Laurins*[1], *L. Hogg*[2], *R. Williamson*[1], *J. Dennis*[1], *A. Nicol*[1];
[1]Nuclear Medicine Department, Queen Elizabeth University Hospital, Department of Clinical Physics and Bioengineering, NHS Greater Glasgow and Clyde, Glasgow, UNITED KINGDOM, [2]Medical Physics, Royal Alexandra Hospital, Department of Clinical Physics and Bioengineering, NHS Greater Glasgow and Clyde, Glasgow, UNITED KINGDOM.

TEPS-014

Usefulness of ^{99m}Tc-MIBI Myocardial SPECT/CT Subtraction Protocol with CZT Gamma Camera

K. Nam, *H. Cho, J. Lee, W. Lee;*
Seoul National University Bundang Hospital, Seoul, KOREA, REPUBLIC OF.

TEPS-015

Validation of Diagnostic Accuracy for Primary Aldosteronism with Quantitative Adrenal SPECT: Comparison with Adrenal Venous Sampling

T. Sato[1], *N. Matsutomo*[2], *T. Yamamoto*[2], *M. Fukami*[2], *T. Kono*[3];
[1]Chiba Aoba Municipal Hospital, Chiba, JAPAN, [2]Kyorin University, Tokyo, JAPAN, [3]Chiba University, Chiba, JAPAN.

TEPS-016

Image characteristics of ^{99m}Tc myocardial perfusion SPECT/CT using a new multi-focal collimator: comparison with conventional SPECT with LEHR collimator

K. Takami[1], *M. Onoguchi*[1], *T. Shibutani*[1], *A. H. Vija*[2], *F. Massanes*[2], *T. Shimizu*[2], *H. Yoneyama*[3], *T. Konishi*[3], *K. Nakajima*[4];
[1]Department of Quantum Medical Technology, Graduate School of Medical Sciences, Kanazawa University, Kanazawa Japan, Kanazawa, JAPAN, [2]Siemens Medical Solutions UNITED STATES OF AMERICA, Inc., Hoffman Estates, IL, UNITED STATES OF AMERICA, [3]Department of Radiological Technology, Kanazawa University Hospital, Kanazawa Japan, Kanazawa, JAPAN, [4]Department of Functional imaging and Artificial Intelligence, Kanazawa University, Kanazawa Japan, Kanazawa, JAPAN.

TEPS-017

The effect of data-driven respiratory gating on myocardial SPECT

T. Shibutani[1], *M. Onoguchi*[1], *A. H. Vija*[2], *F. Massanes*[2], *T. Shimizu*[2], *H. Yoneyama*[3], *T. Konishi*[3], *K. Nakajima*[4];
[1]Department of Quantum Medical Technology, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Ishikawa, JAPAN, [2]Siemens Medical Solutions UNITED STATES OF AMERICA, Inc., Hoffman Estates, IL, UNITED STATES OF AMERICA, [3]Department of Radiological Technology, Kanazawa University Hospital, Kanazawa, Ishikawa, JAPAN, [4]Department of Functional Imaging and Artificial Intelligence, Kanazawa University, Kanazawa, Ishikawa, JAPAN.

TEPS-018

High dose adenosine overcomes the effect of caffeine intake in Rubidium PET perfusion

B. Ribeiro, *S. Townrow, C. Pacheco, C. Lopez Martinez, E. Reyes, L. Menezes;*
Barts Health NHS Trust, London, UNITED KINGDOM.

TEPS-019

Dose reduction for nuclear medicine technicians through implementation of automated dispensing and infusion devices: a retrospective study

E. Hendrikse, *W. Huisman, J. Medema, P. H. Elsinga, A. T. M. Willemsen;*
University Medical Center Groningen, Groningen, NETHERLANDS.

TEPS-020

A comparative study regarding deep inhalation breath-hold and free-breathing total-body PET/CT with half-dose [18F]-FDG

J. Jia, *K. Yuan, M. Liu, Y. Cui, S. Tang, C. Zhou, W. Zhang;*
Sun Yat-Sen University Cancer Center, Department of Nuclear Medicine, Guangzhou, Guangdong, China., Guangzhou, CHINA.

TEPS-021

Developments in Radiochemical Processing of Solid Targets for Radiopharmaceuticals Production

G. Sciacca[1], *P. Martini*[2], *S. Cisternino*[1], *L. Mou*[1], *G. Balajan*[1], *J. Amico*[3], *J. Esposito*[1], *G. Gorgoni*[3], ***E. Cazzola***[3];
[1]INFN-LNL, Legnaro, ITALY, [2]University of Ferrara, Ferrara, ITALY, [3]Sacro Cuore Don Calabria Hospital, Negrar di Valpolicella, ITALY.

1011

Monday, September 11, 2023, 3:00 PM - 4:30 PM
Hall G1

Case Report Session 1 - TROP Session: Learning from Single Cases in Theranostics

OP-467

Feasibility of ^{177}Lu-PSMA-617 radioligand therapy in a patient with recurrent high-grade glioma

A. Holzgreve[1], *A. Delker*[1], *V. Wenter*[1], *M. J. Zacherl*[1], *N. Thon*[2], *P. Harter*[3], *M. Brendel*[1], *L. M. Unterrainer*[1], *M. Niyazi*[4], *P. Bartenstein*[1], *L. von Baumgarten*[2], *N. L. Albert*[1];
[1]Department of Nuclear Medicine, University Hospital, LMU Munich, Munich, GERMANY, [2]Department of Neurosurgery, University Hospital, LMU Munich, Munich, GERMANY, [3]Center for Neuropathology and Prion Research, LMU Munich, Munich, GERMANY, [4]Department of Radiation Oncology, University Hospital, LMU Munich, Munich, GERMANY.

OP-468

First-In-Human CXCR4 & FAP Instillation Theranostics in Muscle invasive bladder cancer patients predicted not to respond to Neoadjuvant chemotherapy within the Bladder BRIDGister.

R. Wirtz[1,2,3], *L. Kastner*[4], *P. C. Voß*[5], *F. Friedersdorff*[6], *D. Barski*[7], *T. Otto*[8], *M. Waldner*[9], *E. Veltrup*[1], *F. Linden*[1], *M. Schwandt*[1], *R. Hake*[3], *S. Eidt*[1], *J. Roggisch*[10], *C. Rieger*[4], *S. Koch*[11,12], *T. H. Ecke*[13], *A. Heidenreich*[14], *L. Greifenstein*[15], *R. P. Baum*[2,15];
[1]STRATIFYER Molecular Pathology GmbH, Cologne, GERMANY, [2]ICPO Foundation, Ravensburg, GERMANY, [3]Institute of Pathology at the St. Elisabeth Hospital, Cologne, GERMANY, [4]Dpt. of Urology, University Clinic Cologne, Cologne, GERMANY, [5]Dpt. of Urology, Charité - Universitätsmedizin Berlin, Berlin, GERMANY, [6]Dpt. of Urology, Evangelisches Krankenhaus Königin Elisabeth Herzberge, Berlin, GERMANY, [7]Dpt. of Urology, Rheinlandklinikum, Neuss, GERMANY, [8]Dpt. of Urology, Rheinlandklinikum, Cologne, GERMANY, [9]Dpt. of Urology St. Elisabeth Hospital, Cologne, GERMANY, [10]Institute of Pathology, HELIOS Hospital, Cologne, GERMANY, [11]Brandenburg Medical School, DE-14770 Brandenburg, Berlin, GERMANY, [12]Institute of Pathology, HELIOS Hospital, Bad Saarow, GERMANY, [13]Department of Urology, HELIOS Hospital, Berlin, GERMANY, [14]Dpt. of Urology, University Clinic Cologne, Cologne, GERMANY, [15]CURANOSTICUM Wiesbaden-Frankfurt, Wiesbaden, GERMANY.

OP-469

Dual-tracer PET/CT imaging in response assessment to peptide receptor radionuclide therapy - a case report

I. Próspero, *G. Ferreira, J. C. Ferro, D. Barbosa, D. G. Silva, S. Fontão de Castro, J. P. Teixeira, H. Duarte, I. Lucena Sampaio;*
Instituto Português de Oncologia do Porto, Porto, PORTUGAL.

OP-470

Bone-Marrow dosimetry with 177Lu-DOTATATE treatment in a hemodialysis patient.

S. CHAIB[1,2], *P. Tylski*[1], *C. Lachachi*[1], *T. Keniza*[1], *E. Levigoureux*[1,2];
[1]Hospices Civils de Lyon, Lyon, FRANCE, [2]Claude Bernard Lyon 1 University, Lyon Neuroscience Research Center, CNRS, INSERM, Lyon, FRANCE.

OP-471
Evaluation of the potential use of [^{18}F]F-Al-NOTA-Octreotide as a theranostic probe for PRRT with [^{177}Lu]Lu-DOTA-TATE compared to [^{111}In]In-DTPA-Pentetreotide
B. A. M. Lima, *R. C. M. Felix, D. A. Bulzico, P. B. Pujatti;*
Brazilian National Cancer Institute, Rio de Janeiro, BRAZIL.

OP-472
Peptide receptor radionuclide therapy (PRRT) with [177Lu]Lu-DOTA-TATE in the treatment of malignant insulinoma: a case report of remarkable clinical and imaging response
D. Barbosa, *H. Duarte, A. Paula Santos, J. Ferro, I. Próspero, D. Silva, S. Gil-Santos, R. Calheiros, S. Fontão de Castro, G. Ferreira, J. P. Teixeira, I. Lucena Sampaio;*
Portuguese Institute of Oncology, Oporto, PORTUGAL.

OP-473
Peptide receptor radionuclide therapy as neoadjuvant treatment in pancreatic neuroendocrine tumours
I. Próspero, *G. Ferreira, J. C. Ferro, D. Barbosa, D. G. Silva, S. Fontão de Castro, J. P. Teixeira, H. Duarte, I. Lucena Sampaio;*
Instituto Português de Oncologia do Porto, Porto, PORTUGAL.

OP-474
Safety and Efficacy in a Recurrent Squamous Cell Carcinoma of the Foot treated with Sequential Applications of 188Re-resin
L. Vetrone[1], *P. Castellucci*[2], *C. Baraldi*[3], *S. Vichi*[4], *F. Zagni*[5], *B. Piraccini*[3], *L. Strigari*[5], *S. Fanti*[1,6];
[1]Nuclear medicine, Alma Mater Studiorum University of Bologna, BOLOGNA, ITALY, [2]Nuclear Medicine, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, BOLOGNA, ITALY, [3]Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, BOLOGNA, ITALY, [4]Clinical Engineering Department, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, BOLOGNA, ITALY, [5]Medical Physics Department, IRCCS Azienda Ospedaliero-Universitaria di Bologna, BOLOGNA, ITALY, [6]Nuclear Medicine, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY.

1101
Monday, September 11, 2023, 16:45 - 18:15
Hall A

CME 8 - Oncology & Theranostics Committee: Assessing Response to Peptide Receptor Radionuclide Therapy in Patients with Neuroendocrine Tumors

OP-475
PRRT Combinations in On-Going Trials
I. Virgolini;
Department of Nuclear Medicine, Medical University Innsbruck, Innsbruck, AUSTRIA.

OP-476
RECIST and Beyond: How Can Radiological Assessment Be Improved?
L. Solnes;
The Russell H Morgan Department of Radiology and Radiological Science, Johns Hopkins School of Medicine, Baltimore, UNITED STATES OF AMERICA.

OP-477
Functional Nuclear Medicine Parameters (Predictive and/or Prognostic)
V. Ambrosini;
NuclearMedicine, Alma Mater Studiorum, University of Bologna, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY.

OP-478
How to Structure Pts' Follow-Up After PRRT: Guidelines and Beyond
J. Strosberg;
Moffitt Cancer Center Tampa, Tampa, UNITED STATES OF AMERICA.

1102
Monday, September 11, 2023, 17:15 - 18:15
Hall D (Arena)

Debate 3 - Physics Committee: AI in Nuclear Medicine: Fear or Embrace?

OP-479
Embrace Artificial Intelligence
M. Sollini;
Department of Nuclear Medicine, IRCCS Humanitas Research Hospital, Milan, ITALY.

OP-480
Beware of Artificial Intelligence
G. Gaglio;
Professor of Sociology, Research Group in Law, Economics and Management (GREDEG), Côte d Azur University, Nice, FRANCE.

1103
Monday, September 11, 2023, 16:45 - 18:15
Hall E1

LIPS Session 8 - Cardiovascular Committee: Stiff to Sweet - Infiltration and Inflammation

OP-481
Infiltrative cardiac disease: Harder muscle, softer interpretation
S. Ben Haim;
UniversityHospital Hadassah, Jerusalem, Department of Nuclear Medicine, Jerusalem, ISRAEL.

OP-482
Inflammatory cardiac diseases. The sweeter it gets, the hottest it is.
F. Caobelli;
Universitätsklinik für Nuklearmedizin Inselspital Bern, Bern, SWITZERLAND.

OP-483
Quantification: The cherry on top?
M. Burniston;
Head of Nuclear Medicine Physics Barts Health NHS Trust, London, UNITED KINGDOM.

1104
Monday, September 11, 2023, 4:45 PM - 6:15 PM
Hall E2

M2M Track - TROP Session: Efficient Radiolabelling: Key for Clinical Translation

OP-487
Functionalized rigidified pentadentate chelators useful for the [Al^{18}f]$^{2+}$labeling of biomolecules
L. Tei[1], *J. Martinelli*[1], *L. Russelli*[2], *G. Multhoff*[3], *C. D'Alessandria*[2];
[1]Department of Science and Technological Innovation, University of Piemonte Orientale, Alessandria, ITALY, [2]Department of Nuclear Medicine, Technical University Munich, Munich, GERMANY, [3]Department of Radiation Oncology, TranslaTUM, Technical University Munich, Munich, GERMANY.

OP-488
Development of a kit formulation of Technetium-99m labeled holmium microspheres as scout dose for radioembolization treatment planning.
M. Boswinkel[1], *P. Laverman*[1], *T. Weisheit*[2], *R. Drescher*[2], *J. F. W. Nijsen*[1];
[1]Department of Medical Imaging, Radboud University Medical Center, Nijmegen, NETHERLANDS, [2]Clinic of Nuclear Medicine, University Hospital Jena, Jena, GERMANY.

OP-489
Large-scale, GMP-compliant production and quality control of Al[^{18}F]F-NOTA-Octreotide
V. Kramer[1,2], *A. Bispo*[3], *C. Gomez*[3], *D. Zouain*[3], *L. Cantuarias*[1], *C. Soza-Ried*[1,2], *N. Emmanuel*[4], *G. Decoux*[4], *C. Goncalves Gameiro*[4];
[1]Positronpharma, Santiago de Chile, CHILE, [2]Nuclear Medicine & PET/CT Center Positronmed, Santiago de Chile, CHILE, [3]R2IBF, Rio de Janeiro, BRAZIL, [4]Ion Beam Applications, Louvain-la-Neuve, BELGIUM.

OP-490
Fully Automated Radiosynthesis of [^{89}Zr]Zr-Crefmirlimab Berdoxam for Clinical Multi-Centre PET Imaging of CD8^{+} T-Cell Trafficking
C. Wichmann[1], *Z. Cao*[1], *A. McDonald*[1], *N. Guo*[1], *S. Poniger*[2], *F. Scott*[1], *F. Jia*[3], *K. Brady*[3], *W. Le*[3], *A. Scott*[1];
[1]Olivia Newton John Cancer Research Institute, Heidelberg, AUSTRALIA, [2]iPhase Technologies Pty Ltd, Rowville, AUSTRALIA, [3]ImaginAb Inc., Inglewood, CA, UNITED STATES OF AMERICA.

OP-491
Radiopharmaceutical production of [^{61}Cu]Cu-NODAGA-LM3 injection solution
M. Alejandre Lafont[1], *T. Basaco Bernabeu*[1], *M. Blagoev*[2], *A. Johayem*[2], *F. De Rose*[3], *C. Porcelli*[3], *L. Jaafar-Thiel*[3], *M. Fani*[1];
[1]Division of Radiopharmaceutical Chemistry, University Hospital Basel, Basel, SWITZERLAND, [2]Department of Nuclear Medicine, University Hospital of Zürich, Zürich, SWITZERLAND, [3]Nuclidium AG, Basel, SWITZERLAND.

OP-492
Development of an ACE2-Targeting Radiotracer for PET Imaging of the SARS-CoV-2 Entry Receptor
C. Müller[1], *D. Beyer*[1], *J. Wang*[2], *C. Vaccarin*[1], *Y. He*[2], *L. Mu*[2], *J. W. Bode*[2], *R. Schibli*[1];
[1]Paul Scherrer Institute, Villigen-PSI, SWITZERLAND, [2]ETH Zurich, Zurich, SWITZERLAND.

OP-493
One-pot combinatorial 18F fluorination: Innovative high-throughput radiolabelling for acceleration of tracer development
S. Xiao[1], *M. Kominia*[1], *A. Domling*[2], *B. Cornelissen*[1], *P. Elsinga*[1];
[1]University Medical Center Groningen, Groningen, NETHERLANDS, [2]Palacky University, Department of Innovative Chemistry, Olomouc-Holice, CZECH REPUBLIC.

OP-494
To Have and To Hold: The exceptional attraction of ^{225}Ac and Macropa
A. Amor Coarasa[1,2], *M. Friebe*[1], *S. Ponnala*[1], *P. K. Singh*[1], *S. DiMagno*[1], *J. W. Babich*[1];
[1]Ratio Therapeutics Inc, Boston, MA, UNITED STATES OF AMERICA, [2]Albert Einstein College of Medicine, Bronx, NY, UNITED STATES OF AMERICA.

1105
Monday, September 11, 2023, 4:45 PM - 6:15 PM
Hall B

Cutting Edge Science Track - TROP Session: Current Issues of Radiation Protection

OP-495
Radiation Protection of Undertakers (Transport/ Embalming of the Body) and Crematorium Staff in Case of a Patient Death Shortly After Radionuclide Therapy
C. Michel, *H. Caplin, D. Célier, E. Blanchardon, A. Mathieu, A. Isambert;*
Institute for Radiation Protection and Nuclear Safety (IRSN), Fontenay-aux-Roses, FRANCE.

OP-496
Justification of the radiation dose to a pregnant carer and comforter
E. Morris[1,2], *F. Sansum*[2], *M. Easty*[2], *L. Biassoni*[2], *M. Burniston*[1];
[1]Barts Health NHS Trust, London, UNITED KINGDOM, [2]Great Ormond Street Hospital for Children, London, UNITED KINGDOM.

OP-497
Investigating the contamination risk during ^{177}Lu-PSMA and ^{225}Ac-PSMA therapies of advanced prostate cancer patients
J. Brosch-Lenz, *S. Nekolla, L. Tischendorf, J. Allmann, W. Weber, M. Eiber;*
Klinikum rechts der Isar, der Technischen Universität München, Munich, GERMANY.

OP-498

Assessment of Occupational Radiation Exposure During Administration of [^{177}Lu]Lu-DOTA-TATE Using Active and Passive Dosimetry

M. Riveira-Martin[1], *L. Struelens*[2], *J. Muñoz Iglesias*[3], *W. Schoonjans*[2], *J. M. Nogueiras Alonso*[4], *O. Tabuenca*[3], *F. J. Salvador Gomez*[5], *A. Lopez Medina*[5];
[1]*Galicia Sur Health Research Institute, Vigo, SPAIN,* [2]*Belgian Nuclear Research Centre (SCK CEN), Mol, BELGIUM,* [3]*Meixoeiro Hospital, University Hospital of Vigo, Nuclear Medicine Department (SERGAS), Vigo, SPAIN,* [4]*Meixoeiro Hospital, University Hospital of Vigo, Nuclear Medicine Department (GALARIA), Vigo, SPAIN,* [5]*Meixoeiro Hospital, University Hospital of Vigo, Medical Physics and RP Department (GALARIA), Vigo, SPAIN.*

OP-499

Tracer validation for non [^{18}F]FDG PET pharmaceuticals in automatic injector

M. Hammar[1], *R. Solem*[2], *F. Mörnsjö Centofanti*[2], *E. Evetovic*[2], *A. Akbari*[1], *K. Benner*[2], *B. Olsson*[1], *E. Höljer*[2], *J. Oddstig*[2];
[1]*Skane University Hospital, Malmö, SWEDEN,* [2]*Skane University Hospital, Lund, SWEDEN.*

OP-500

Implementation of CT tin filter in PET-CT: dose savings and image quality evaluation for tissues and dose levels relevant to PET-CT

P. Holdgaard[1], *N. A. Bebbington*[2], *K. B. Christensen*[1], *L. L. Østergård*[1];
[1]*Lillebælt University Hospital, Vejle, DENMARK,* [2]*Siemens Healthcare A/S, Aarhus, DENMARK.*

OP-501

Ultra-low Dose CT With and Without Tin Filter for PET Attenuation Correction: Dose Savings and Quantification

N. Bebbington[1], *K. B. Christensen*[2], *L. L. Østergård*[2], *P. C. Holdgaard*[2];
[1]*Siemens Healthcare A/S, Aarhus, DENMARK,* [2]*Department of Nuclear Medicine, Lillebælt University Hospital, Vejle, DENMARK.*

OP-502

How Low Can You Go With Ultra-low-dose Tin Filter CT in PET-CT? Evaluation of Dose and Artifacts in a Whole-body Patient Phantom

N. Bebbington[1], *K. B. Christensen*[2], *P. C. Holdgaard*[2], *L. L. Østergård*[2];
[1]*Siemens Healthcare A/S, Aarhus, DENMARK,* [2]*Department of Nuclear Medicine, Lillebælt University Hospital, Vejle, DENMARK.*

OP-503

Ultra-low-dose CT for Long Axial Field of View PET/CT: A Phantom Study

S. Mostafapour[1], *M. Greuter*[2], *P. van Snick*[1], *J. van Sluis*[1], *A. A. Lammertsma*[1], *C. Tsoumpas*[1];
[1]*Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, Groningen, NETHERLANDS,* [2]*Department of Radiology, University Medical Center Groningen, Groningen, NETHERLANDS.*

1106

Monday, September 11, 2023, 4:45 PM - 6:15 PM
Hall C

Clinical Oncology Track - TROP Session: Prostate Cancer Biochemical Recurrence

OP-504

Final Analysis of a Prospective, Single-center, Phase II/III Imaging Trial of^{68}Ga-RM2 PET/MRI in Patients with Biochemical Recurrence of Prostate Cancer

H. Duan, *F. Moradi, G. A. Davidzon, T. Liang, H. Song, A. Loening, S. Vasanawala, S. Srinivas, J. D. Brooks, S. L. Hancock, A. Iagaru;*
Stanford University, Stanford, CA, UNITED STATES OF AMERICA.

OP-505

Prospective Single-Centre Phase II Clinical Trial On The Diagnostic Accuracy of Fully Hybrid [68Ga] Ga-PSMA-11 PET/MRI and [68Ga]Ga-RM2 PET/MRI in Patients with Biochemically Recurrent Prostate Cancer

S. Ghezzo[1,2], *P. Mapelli*[1,2], *A. Samanes Gajate*[2], *A. Palmisano*[3], *V. Cucchiara*[4,5], *G. Brembilla*[1,3], *C. Bezzi*[1,2], *N. Suardi*[6], *P. Scifo*[2], *A. Briganti*[1,4,5], *F. De Cobelli*[1,3], *A. Chiti*[1,2], *A. Esposito*[1,3], *M. Picchio*[1,2];
[1]*Vita-Salute San Raffaele University, Milan, ITALY,* [2]*Department of Nuclear Medicine, IRCCS San Raffaele Scientific Institute, Milan, ITALY,* [3]*Department of Radiology, IRCCS San Raffaele Scientific Institute, Milan, ITALY,* [4]*Department of Urology, IRCCS San Raffaele Scientific Institute, Milan, ITALY,* [5]*Division of Experimental Oncology, URI, Urological Research Institute, Milan, ITALY,* [6]*IRCCS Ospedale San Martino, Genova, ITALY.*

OP-506

Higher Preoperative Maximum Standardised Uptake Values (SUV_{max}) are Associated with Higher Biochemical Recurrence Rates After Robot-Assisted Radical Prostatectomy for ^{68}Ga-PSMA-11 and ^{18}F-DCFPyL PET/CT

K. De Bie[1], *H. Veerman*[1], *Y. J. L. Bodar*[1], *D. Meijer*[1], *P. J. van Leeuwen*[2], *H. G. van der Poel*[2], *M. Donswijk*[2], *A. N. Vis*[1];
[1]*Amderdam UMC, Amsterdam, NETHERLANDS,* [2]*Nederlands Kanker Instituut, Amsterdam, NETHERLANDS.*

OP-507

Staging with [68Ga]Ga-PSMA-11 PET/CT in patients with intermediate and high-risk prostate cancer prior surgery. Is there any association between semiquantitative parameters and biochemical recurrence?

J. Rosales[1], *J. Bastidas*[1], *A. Bronte*[1], *V. Betech-Antar*[1], *F. Minguez*[1], *M. Romera*[1], *F. Pareja*[1], *E. Guillen*[2], *S. Menendez-Sanchez*[1], *C. Beorlegui*[3], *J. Arbizu*[1], *J. Peréz Gracia*[4], *M. Rodriguez-Fraile*[1];
[1]*Nuclear Medicine Department, University Clinic Of Navarra, Pamplona, SPAIN,* [2]*Nuclear Medicine Department, University Clinic Of Navarra, Madrid, SPAIN,* [3]*Planning Evaluation and Knowledge Management Health Department, Government of Navarra, Pamplona, SPAIN,* [4]*Oncology Department, University Clinic Of Navarra, Pamplona, SPAIN.*

OP-508

From CHAARTED low- and high-volume disease to PSMA PET imaging volume in mHSPC patients: an international multicenter retrospective study

L. Unterrainer[1,2], *T. A. Hope*[3], *H. Ndlovu*[4], *F. Barbato*[5], *W. P. Fendler*[5,6], *K. Herrmann*[5,6], *M. Sathekge*[4], *J. Czernin*[1], *J. Calais*[1];
[1]*UCLA, Los Angeles, CA, UNITED STATES OF AMERICA,* [2]*LMU Munich, Munich, GERMANY,* [3]*UCSF, San Francisco, CA, UNITED STATES OF AMERICA,* [4]*University of Pretoria, Pretoria, SOUTH AFRICA,* [5]*University Hospital Essen, Essen, GERMANY,* [6]*German Cancer Consortium (DKTK)-University Hospital Essen, Essen, GERMANY.*

OP-509

Head-to-head comparison of ^{68}Ga-PSMA-11 PET with ^{99}mTc-MDP bone scan for detection of bone disease in prostate cancer patients with biochemical progression during ADT: a single center prospective study

A. Gafita, *R. Alano, M. Rettig, J. Shen, W. Armstrong, T. R. Grogan, S. Liu, M. R. Benz, J. Czernin, J. Calais;*
University of California, Los Angeles, Los Angeles, CA, UNITED STATES OF AMERICA.

OP-510

Factors Affecting Diagnostic Performance of Ga-68 PSMA PET/MRI in Biochemical Recurrent Prostate Cancer and Nomogram Model

S. Küçükali, *U. Aydos, E. Balcı, Ü. Akdemir, L. Atay;*
Gazi University, Faculty of medicine, Ankara, TÜRKIYE.

OP-511

The diagnostic performance of ^{68}Ga-PSMA-11 PET/CT versus multiparametric MRI for detecting intra-prostatic radiorecurrent prostate cancer

A. Light[1], *S. Lazic*[2], *M. Bayne*[3], *M. J. Connor*[1], *H. Tam*[2], *H. U. Ahmed*[1], *T. T. Shah*[1], *T. D. Barwick*[2];
[1]*Imperial Prostate, Imperial College London, London, UNITED KINGDOM,* [2]*Department of Radiology, Charing Cross Hospital, Imperial College Healthcare NHS Trust, London, UNITED KINGDOM,* [3]*Imperial Urology, Charing Cross Hospital, Imperial College Healthcare NHS Trust, London, UNITED KINGDOM.*

OP-512

The imaging characteristics of theranostic ^{99m}Tc/^{188}Re-PSMA-GCK01 is equivalent to dedicated diagnostic ^{99m}Tc-HYNIC-iPSMA in prostate cancer

E. Mamlins[1], *J. Cardinale*[1,2], *M. Krotov*[1], *E. Winter*[2], *H. Rathke*[2,3], *U. Haberkorn*[2], *C. Kratochwil*[2], *F. Giesel*[1];
[1]*Department of Nuclear Medicine, Medical Faculty and University Hospital Duesseldorf, Heinrich-Heine-University Duesseldorf, Duesseldorf, GERMANY,* [2]*Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, GERMANY,* [3]*Department of Nuclear Medicine, Inselspital Bern, Bern, SWITZERLAND.*

1107

Monday, September 11, 2023, 4:45 PM - 6:15 PM
Hall F1

Inflammation & Infection Committee - TROP Session: Vasculitis and Endocarditis: Current and New Evidence

OP-513

99mTc-white blood cell scintigraphy performance in thoracic aortic vascular graft infection: be careful in early post-operative period

B. Mahida[1,2], *M. Para*[2,3], *C. Regis*[1,4], *L. Deconinck*[5], *K. Ben Ali*[1,2], *X. Duval*[3,6], *B. IUNG*[3,7], *F. Rouzet*[1,2];
[1]*Nuclear medicine department, Bichat Hospital, AP-HP, Paris, FRANCE,* [2]*Université Paris Cité, Paris, FRANCE,* [3]*Department of Cardiovascular Surgery and Transplantation, Bichat Hospital, AP-HP, Paris, FRANCE,* [4]*Department of Medical Imaging, Institut de cardiologie de Montréal, Université de Montréal, Montréal, QC, CANADA,* [5]*Infectious Disease Department, Bichat Hospital, AP-HP, Paris, FRANCE,* [6]*Clinical Investigation Center, Bichat Hospital, AP-HP, Paris, FRANCE,* [7]*Cardiology Department, Bichat Hospital, AP-HP, Paris, FRANCE.*

OP-514

Fast-Track Pathway for Early Diagnosis and Management of Giant Cell Arteritis At University College London Hospital: Positive Impact of FDG PET-CT for Detection of Active Vasculitis

A. Alduraibi[1,2], *D. Ludwiga*[3], *S. Vöö*[4], *V. Morrisa*[3];
[1]*Department of Radiology, College of Medicine, Qassim University, qassim, SAUDI ARABIA,* [2]*University College London Hospitals Nhs Foundation Trust, London, UNITED KINGDOM,* [3]*Department of Rheumatology, University College London Hospital, University College London Hospitals NHS Foundation Trust (UCLH) and bInstitute of Nuclear Medicine, UCLH, London, UNITED KINGDOM,* [4]*Institute of Nuclear Medicine, University College London Hospital, London, UNITED KINGDOM.*

OP-515

[^{18}F]FDG-PET/CT as a Prognostic Inflammatory Imaging Marker in Giant Cell Arteritis

P. Nienhuis, *Y. Van Sleen, E. Brouwer, R. H. J. A. Slart;*
University Medical Center Groningen, Groningen, NETHERLANDS.

OP-516

18F-FDG-PET/CT imaging on the LAFOV-PET/CT in patients with suspected large vessel vasculitis: reference values and diagnostic performance.

L. Knappe, *C. Bregenzer, N. Gözlügöl, C. Mingels, A. Rominger, F. Caobelli;*
Department of Nuclear Medicine, Inselspital Bern, Bern, SWITZERLAND.

OP-517

C-X-C Motif Chemokine Receptor 4-directed PET/CT in Newly Diagnosed Giant Cell Arteritis - Initial Results from a Phase II Trial

M. Fröhlich[1], *S. E. Serfling*[2], *K. V. Guggenberger*[3], *T. Higuchi*[2], *M. Gernert*[1], *S. Samnick*[2], *M. Schmalzing*[1], *A. K. Buck*[2], *T. A. Bley*[3], *R. A. Werner*[2];
[1]*Medical Department II, Rheumatology, University Hospital Würzburg, Würzburg, GERMANY,* [2]*Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, Germany, Würzburg, GERMANY,* [3]*Institute of Diagnostic and Interventional Radiology, University Hospital Würzburg, Würzburg, GERMANY.*

OP-518

[68Ga]Ga-FAPI-46 PET/CT in patients with Large Vessel Vasculitis and comparison with age gender-matched controls.

J. Rosales[1], *J. Hoppner*[2], *U. Haberkorn*[2], *W. Merkt*[2], *P. Kvacskay*[2], *M. Röhrich*[2];
[1]*University Clinic Of Navarra, Pamplona, SPAIN,* [2]*University Hospital of Heidelberg, Heidelberg, GERMANY.*

OP-519

Improved [18F] FDG PET/CT diagnostic accuracy for infective endocarditis: cardiac motion correction using different gating strategies

D. ten Hove[1,2], *B. Sinha*[1,2], *P. J. H. Van Snick*[1,2], *R. H. J. A. Slart*[1,2], *A. W. J. M. Glaudemans*[1,2];
[1]*Rijksuniversiteit Groningen, Groningen, NETHERLANDS,* [2]*University Medical Center Groningen, Groningen, NETHERLANDS.*

OP-520

Impact and diagnostic performance of dedicated cardiac [18F]-FDG digital PET/CT in infective endocarditis

S. Notohamiprodjo[1], *K. Scheidhauer*[1], *M. Eiber*[1], *I. Yakushev*[1], *S. Kleiner*[1], *J. Kraus-Deuringer*[1], *H. W. A. Krebs-Fleischmann*[1], *A. G. Villagran Asiares*[1], *S. G. Nekolla*[1], *R. Eggerstedt*[2], *B. Eglseder*[3], *W. A. Weber*[1];
[1]*Technical University of Munich, Munich, GERMANY,* [2]*German Heart Centre Munich, Munich, GERMANY,* [3]*Krankenhaus GmbH Landkreis Weilheim-Schongau, Weilheim, GERMANY.*

OP-521

New semiquantitative parameters to improve diagnostic accuracy of FDG-PET/CT in suspected endocarditis

C. Bregenzer, *L. Knappe, C. Mingels, N. Gözlügöl, A. Rominger, F. Caobelli;*
Department of Nuclear Medicine, Inselspital, University Hospital Bern, University of Bern, Bern, SWITZERLAND.

1108

Monday, September 11, 2023, 4:45 PM - 6:15 PM
Hall F2

Thyroid Committee - TROP Session: Iodine-131 Therapy in Differentiated Thyroid Cancer: Present and Future Perspective

OP-522

Efficacy of 131I therapy and its influencing factors in children and adolescents with differentiated thyroid cancer lung metastases: comparative analysis with youth using propensity score matching

X. Zhang[1], *H. Feng*[2];
[1]*Department of Nuclear Medicine, Zhujiang Hospital Southern Medical University, Guangzhou,Guangdong Province, CHINA,*
[2]*Department of Nuclear Medicine, Zhujiang Hospital Southern Medical University, 广州市, CHINA.*

OP-523

Prognostic factors in children with differentiated thyroid cancer

S. Zakavi[1], *F. Nesari Javan*[1], *E. Askari*[1], *S. Shafiee*[1], *V. Roshanravan*[1], *A. Aghaei*[1], *N. Ayati*[2];
[1]*Nuclear Medicine Research Center, Mashhad University of Medical Sciences, Mashhad, IRAN, ISLAMIC REPUBLIC OF,* [2]*Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, AUSTRALIA.*

OP-524

Impact of micro-extrathyroidal extension and bilateral topography of malignancy on clinical initial stating and early outcome of differentiated thyroid cancer (<4cm) patients.

A. Campenni'[1], *R. Ruggeri*[1], *M. Siracusa*[1], *D. Cardile*[1], *S. Russo*[1], *A. Nicocia*[1], *A. Rappazzo*[1], *V. Davì*[1], *A. Alibrandi*[1], *S. Baldari*[1], *L. Giovanella*[2];
[1]*Ospedale Gaetano Martino, Messina, ITALY,* [2]*Ente Ospedaliero Cantonale, 6500 Bellinzona, SWITZERLAND.*

OP-525

Postoperative Thyroglobulin as a Yard-stick for Radioiodine Therapy: Decision Tree Analysis in a European Multicenter Series of 1317 Patients with Differentiated Thyroid Cancer

L. Giovanella[1], *L. Milan*[1], *W. Roll*[2], *M. Weber*[3], *S. Schenke*[4], *M. Kreissl*[4], *A. Vrachimis*[5], *K. Pabst*[6], *T. Murat*[7], *P. Petranović Ovčariček*[8], *B. Riemann*[9], *L. Ceriani*[1], *A. Campenni*[10], *R. Goerges*[6];
[1]*Imaging Institute of Southern Switzerland, Bellinzona, SWITZERLAND,* [2]*University Hospital Muenster, Muenster, GERMANY,* [3]*University Hospital of Essen, Essen, GERMANY,* [4]*University Hospital Magdeburg, Magdeburg, GERMANY,* [5]*German Oncology Center, Limassol, CYPRUS,* [6]*University Hospital Essen, Essen, GERMANY,* [7]*Hacettepe University, Ankara, TÜRKIYE,* [8]*University Hospital Center "Sestre milosrdnice", Zagreb, CROATIA,* [9]*University Hospital Münster, Münster, GERMANY,* [10]*Ospedale Universitario di Messina, Messina, ITALY.*

OP-526

Diffuse Sclerosing Variant of Papillary Thyroid Carcinoma is Related to A Poor Outcome: A Comparison Study Using Propensity Score Matching

L. Yang, *M. Zhao, L. Xiao, L. Li, P. Dong;*
Department of Nuclear Medicine, West China Hospital, Sichuan University, Chengdu, CHINA.

OP-527

Radiomics approaches for predicting non-iodine-avid status of lung metastases in patients with differentiated thyroid cancer based on CT: a prospective observational study

X. Gao;
Department of Radiology, Zhejiang Cancer Hospital, Hangzhou, CHINA.

OP-528

Could Coprococcus catus be used as a biomarker for the treatment response of I-131 in thyroid cancer patients?

A. Fernandes[1], *R. Soares*[2], *P. Barata Coelho*[3];
[1]*Centro Hospitalar e Universitário São João, Porto, PORTUGAL,* [2]*Faculdade de Medicina da Universidade do Porto, Porto, PORTUGAL,* [3]*Universidade Fernando Pessoa, Porto, PORTUGAL.*

OP-529

Determination of whole-body effective half-life of I-131 on differentiated thyroid cancer patients with a cloud-based remote dose meter

L. Kääriä[1,2], *M. Lapela*[3,2], *M. Seppänen*[4,2], *J. Ruohola*[3,2], *A. Ålgars*[5,2], *T. Noponen*[6,2];
[1]*Department of Nuclear Medicine, Turku University Hospital and Wellbeing services county of Southwest Finland, Turku, FINLAND,* [2]*University of Turku, Turku, FINLAND,* [3]*Department of Oncology, Turku University Hospital and Wellbeing services county of Southwest Finland, Turku, FINLAND,* [4]*Department of Clinical Physiology, Nuclear Medicine and Turku PET Centre, Turku University Hospital and Wellbeing services county of Southwest Finland, Turku, FINLAND,* [5]*Deparment of Oncology, Turku University Hospital and Wellbeing services county of Southwest Finland, Turku, FINLAND,* [6]*Department of Clinical Physiology, Nuclear Medicine, Turku PET Centre and Medical Physics, Turku University Hospital and Wellbeing services county of Southwest Finland, Turku, FINLAND.*

OP-530

Preliminary results from a clinical trial combining 131I and external beam radiotherapy for treatment of metastatic radioiodine-refractory thyroid cancer

R. Hobbs, *I. Marsh, H. Quon, P. Santhanam, P. Ladenson, B. He, D. Kaplin, K. Lowe, H. Wang, G. Sgouros;*
Johns Hopkins, Baltimore, MD, UNITED STATES OF AMERICA.

1109

Monday, September 11, 2023, 4:45 PM - 6:15 PM
Hall G2

e-Poster Presentations Session 8 - Neuroimaging Committee: E-Poster Neurology: It's in the Brain!

EPS-147

Improving the quantification of tau pathology in Alzheimer's Disease: A data-driven analysis using 18F-PI2620 PET.

G. Bischof[1,2], *M. Kanekiyo*[3], *M. Irrizari*[3], *A. Stephens*[4], *T. van Eimeren*[1], *A. Drzezga*[1,2,5];
[1]*University Hospital Cologne, Cologne, GERMANY,* [2]*Molecular Organization of the Brain, Institute for Neuroscience and Medicine (INM2), Juelich, GERMANY,* [3]*Eisai Inc., Nutley, NJ, UNITED STATES OF AMERICA,* [4]*Life Molecular Imaging, Berlin, GERMANY,* [5]*German Center for Dementia Research (DZNE), Bonn, GERMANY.*

EPS-148

Single Tracer ATN Assessment With Dynamic 18F-PI-2620 Recordings

J. Gnörich[1], *M. Zaganjori*[1], *M. Groß*[1], *M. Scheifele*[1], *A. Bronte*[2], *R. Perneczky*[3], *K. Bürger*[4], *J. Levin*[5], *O. Sabri*[6], *P. Bartenstein*[1], *H. Barthel*[6], *N. Franzmeier*[4], *M. Brendel*[1];
[1]*LMU Munich, Department of Nuclear Medicine, Munich, GERMANY,* [2]*Universidad de Navarra, Pamplona, SPAIN,* [3]*LMU Munich, Department of Psychiatry and Psychotherapy, Munich, GERMANY,* [4]*Institute for Stroke and Dementia Research, LMU Munich, Munich, GERMANY,* [5]*LMU Munich, Department of Neurology, Munich, GERMANY,* [6]*Department of Nuclear Medicine, Leipzig, GERMANY.*

EPS-149

Early-phase [18F]FBB PET vs [18F]FDG PET in atypical dementia: preliminary data from a multicentric study (AMY-ITA).

D. Cecchin[1], *A. Chincarini*[2], *S. Mozzetta*[3], *C. Gagliani*[3], *A. Osele*[3], *S. Morbelli*[4], *S. Sestini*[5], *F. Dore*[6], *M. Dottorini*[7], *L. Ruffini*[8], *G. Trifirò*[9], *M. Farsad*[10], *L. Turk*[3], *A. Cagnin*[3];
[1]*Nuclear Medicine University Hospital Padova, Padova, ITALY,* [2]*Istituto Nazionale di Fisica Nucleare (INFN), Genova, ITALY,* [3]*University of Padova, Padova, ITALY,* [4]*University of Genoa, Genoa, ITALY,* [5]*Hospital of Prato, Prato, ITALY,* [6]*Azienda sanitaria universitaria Giuliano Isontina, Trieste, ITALY,* [7]*Azienda Ospedaliera di Perugia, Perugia, ITALY,* [8]*Azienda Ospedaliero Universitaria di Parma, Parma, ITALY,* [9]*ICS Maugeri, Pavia, ITALY,* [10]*Ospedale di Bolzano, Bolzano, ITALY.*

EPS-150

Clinical outcomes up to 9 years after [18F] flutemetamol amyloid-PET in a symptomatic memory clinic population

L. Collij[1,2], *G. Farrar*[3], *M. Zwan*[1], *E. M. van de Giessen*[1], *R. Ossenkoppele*[1,2], *F. Barkhof*[1,4], *A. Rozemuller*[1], *Y. Pijnenburg*[1], *W. M. Van der Flier*[1], *F. Bouwman*[1];
[1]*Amsterdam UMC, location VUmc, Amsterdam, NETHERLANDS,* [2]*Lund University, Lund, SWEDEN,* [3]*GE Healthcare, Amersham, UNITED KINGDOM,* [4]*University College London, London, UNITED KINGDOM.*

EPS-151

Gender influences the expression of metabotropic glutamate receptor 5 in the brain of cognitively impaired individuals: a PET/MR study

W. Jie[1], *Y. Guan*[2], *F. Xie*[2];
[1]*Fudan University, shanghai, CHINA,* [2]*Department of Nuclear Medicine & PET Center, Huashan Hospital, Fudan University, Shanghai, CHINA.*

EPS-152

Prevalence of Limbic-predominant Age-related TDP-43 Encephalopathy (LATE) in Tertiary Care Cognitive Disorder Clinics

E. Park, *C. J. Cliatt-Brown, Y. Anzai, S. Minoshima;*
University of Utah, Salt Lake City, UT, UNITED STATES OF AMERICA.

EPS-153

Application of principal component analysis on amyloid-PET and clinical data to predict conversion from mild cognitive impairment to Alzheimer's disease

E. Perrone[1,2], *F. Cocciolillo*[2], *S. Taralli*[2], *D. Quaranta*[3], *D. Santoni*[4], *M. Mazzei*[4], *C. Marra*[5], *M. L. Calcagni*[1,2];
[1]*Nuclear Medicine Institute, University Department of Radiological and Hematological Sciences, Università Cattolica del Sacro Cuore, Rome, ITALY,* [2]*Nuclear Medicine Unit, Diagnostic Imaging, Radiation Oncology and Hematology Department, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, ITALY,* [3]*Neurology Unit, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, ITALY,* [4]*Institute for System Analysis and Computer Science "Antonio Ruberti", National Research Council of Italy, Rome, ITALY,* [5]*Memory Clinic, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, ITALY.*

EPS-154
Clinical utility of Amyloid Brain PET in patients with Mild Cognitive Impairment
M. Pudis[1], *L. Rodríguez-Bel[1], M. Suarez-Piñera[1], C. Martínez-Ramos[1], J. Gascón-Bayarri[2], J. Campdelacreu-Fumado[2], S. Bondia-Bescós[1], B. Hervás-Sanz[1], J. Diaz-Moreno[1], M. Cortés-Romera[1];*
[1]Nuclear Medicine - PET (IDI), Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, SPAIN, [2]Neurology Department, Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, SPAIN.

EPS-155
Unilateral Nasal Septal Deviation Mediates Contralateral Loss of Striatal Dopamine Transporter Uptake in Patients with Parkinson's Disease
J. Wang[1,2], *J. Ge[1], F. Liu[3], M. Tian[2], J. Wang[3], C. Zuo[1];*
[1]Department of Nuclear Medicine/PET center, Huashan Hospital, Fudan University, Shanghai, CHINA, [2]Human Phenome Institute, Fudan University, Shanghai, CHINA, [3]Department of Neurology, Huashan Hospital, Fudan University, Shanghai, CHINA.

EPS-156
Dopamine D_1 receptor availability in Gilles de la Tourette syndrome measured by [11C]SCH23390 PET
M. Rullmann[1], *D. Gkotsoulias[2], S. Schmitt[3], C. Fremer[3], C. Klages[3], K. Hartung[3], A. Bujanow[2], F. Zientek[1], K. Messerschmidt[1], M. Patt[1], O. Sabri[1], K. Müller-Vahl[3], H. Möller[2], H. Barthel[1];*
[1]Department of Nuclear Medicine, University of Leipzig, Leipzig, GERMANY, [2]Max Planck Institute for Human Cognitive and Brain Sciences, Leipzig, GERMANY, [3]Clinic of Psychiatry, Social Psychiatry and Psychotherapy, Hannover Medical School, Hannover, GERMANY.

EPS-157
Multiparametric ^{11}C-MET PET/MR for predicting survival of postsurgical glioma patients
Y. Xu, *C. Li, F. Liu, F. Hu, W. Ruan, X. Lan;*
Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, CHINA.

EPS-158
A Feasibility Study of Ga68-PSMA PET/CT in Differentiating Brain Metastases from Radiation Necrosis
F. Lattuada[1], *S. Wagemaker[2], L. de Wit-van der Veen[2], D. Brandsma[2], M. Stokkel[2];*
[1]Post Graduate School of Nuclear Medicine, University of Milano-Bicocca, Milano, ITALY, [2]NKI-AVL, Amsterdam, NETHERLANDS.

EPS-159
Feasibility and initial experience of chemokine receptor-4 receptor-4 (CXCR4) expression using 68Ga-Pentixafor and O-2-18F-fluoroethyl-l-tyrosine (18F-FET) PET-MR image fusion in low- and high-grade gliomas
H. Dadgar[1,2], *N. Norouzbeigi[1], M. Assadi[3], B. Al-balooshi[4], A. Al-Ibraheem[5], Y. Omar[6], H. Muhsin Al-Alawi[7], S. Usmani[8], M. Ricci[9], A. Cimini[10], H. Arabi[11], H. Zaidi[11,12,13];*
[1]Nuclear Medicine and Molecular imaging research center, Mashad, IRAN, ISLAMIC REPUBLIC OF, [2]Cancer Research Center, RAZAVI Hospital, Imam Reza International University, Mashhad, Iran, Mashhad, IRAN, ISLAMIC REPUBLIC OF, [3]The Persian Gulf Nuclear Medicine Research Center, Department of Molecular imagingand Radionuclide Therapy, Bushehr Medical University Hospital,Bushehr University of Medical Sciences, IRAN, Bushehr, IRAN, ISLAMIC REPUBLIC OF, [4]Dubai Nuclear Medicine & amp; Molecular imaging center-Dubai Academic Health corporation-DAHC, UAE, Dubai, UNITED ARAB EMIRATES, [5]Department of Nuclear Medicine, King Hussein Cancer Center, Amman, Jordan-Devision of Nuclear Medicine/Department of Radiology and Nuclear Medicine, University of Jordan, Amman, Jordan, Amman, JORDAN, [6]PET-CT department at Misr Radiology Center, Heliopolis, Egypt, Heliopolis, EGYPT, [7]Nuclear Medicine department, Amir Al-momineen Specialty Hospital, Al-Najaf Governorate, Iraq Middle Euphrates Cancer Hospital, Al-Najaf Governorate, Iraq, Mashad, IRAQ, [8]Department of Nuclear Medicine Sultan Qaboos Comprehensive Cancer Care and Research Center (SQCCCRC), Seeb, Oman, Seeb, OMAN, [9]Nuclear Medicine Unit, Cardarelli Hospital, Campobasso, Italy, Campobasso, ITALY, [10]Nuclear Medicine Unit, St. Salvatore Hospital, 67100 L'Aquila, Italy, L'Aquila, ITALY, [11]Division of Nuclear Medicine and Molecular Imaging, Department of Medical Imaging, Geneva University Hospital, CH-1211 Geneva 4, Switzerland, Geneva, SWITZERLAND, [12]Geneva Neuroscience Center, Geneva University, CH-1205 Geneva, Switzerland, Geneva, SWITZERLAND, [13]Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, 9700 RB Groningen, NETHERLANDS, Groningen, NETHERLANDS.

EPS-160
Histopathological validation of 18F-FACBC uptake in high- and low-grade glioma
B. Vindstad[1], *L. K. Pedersen[2], E. M. Berntsen[1,3], O. Solheim[3,1], I. Reinertsen[4,1], H. Johansen[3], A. J. Skjulsvik[1,3], L. Eikenes[1], A. Karlberg[1,3];*
[1]Norwegian University of Science and Technology, Trondheim, NORWAY, [2]University Hospital of North Norway, Tromsø, NORWAY, [3]St. Olavs Hospital, Trondheim, NORWAY, [4]SINTEF Digital, Trondheim, NORWAY.

EPS-161
Prognostic Role of Preoperative [^{11}C]Methionine PET in IDH-Wildtype Astrocytomas
G. Ninatti[1], *M. Sollini[2,3], B. Bono[2], L. Antunovic[4], F. Gelardi[2], C. Landoni[1,5], F. Pessina[2,3], M. Rodari[3], A. Chiti[6,4];*
[1]University of Milano Bicocca, Monza, ITALY, [2]Humanitas University, Pieve Emanuele, ITALY, [3]IRCCS Humanitas Research Hospital, Rozzano, ITALY, [4]IRCCS San Raffaele Scientific Institute, Milan, ITALY, [5]IRCCS-San Gerardo, Monza, ITALY, [6]Vita-Salute San Raffaele University, Milan, ITALY.

EPS-162
^{99m}Tc-ECD SPECT Predicts Neurological Recovery in Cardiac Arrest Survivors
P. Chuang[1], *Y. Chen[2], Y. Huang[2], C. Wang[3], W. Chang[4], Y. Wu[5], M. Cheng[2];*
[1]Department of Nuclear Medicine, National Taiwan University Hospital Yunlin Branch, Douliu City, TAIWAN, [2]Department of Nuclear Medicine, National Taiwan University Hospital, Taipei City, TAIWAN, [3]Department of Emergency Medicine, National Taiwan University Hospital Yunlin Branch, Douliu City, TAIWAN, [4]Department of Emergency Medicine and Cardiology, National Taiwan University Hospital, Taipei City, TAIWAN, [5]Department of Nuclear Medicine and Cardiology, Far Eastern Memorial Hospital, New Taipei City, TAIWAN.

EPS-163
Cerebral perfusion imaging with [^{15}O]H_2O and an image derived input function from an additional scan of the heart
L. Marner[1], *M. E. Larsen[1,2], A. O. Kellberg[1], A. C. Henriksen[1], S. Fuglsang[1], M. N. Lonsdale[1], L. Marner[3];*
[1]Copenhagen University Hospital Bispebjerg, Department of Clinical Physiology and Nuclear Medicine, Copenhagen NV, DENMARK, [2]Copenhagen University Hospital Rigshospitalet, Department of Anestesiology, Copenhagen, DENMARK, [3]Copenhagen University Hospital Bispebjerg, Department of Clinical Physiology and Nuclear Medicine, Copenhagen, DENMARK.

EPS-164
Hypermetabolism in the Cerebellum is Related to M1 Microglial Activation in Temporal Lobe Epilepsy
Y. Tang, *L. Xiao, J. Yang, J. Hou, B. Chen, S. Hu;*
Xiangya Hospital Central South University, Changsha, CHINA.

EPS-165
Brain Networks Involved in Cancer Treatment Response:Insights from 18F-FDG PET Scans
M. Namías[1], *M. Perovnik[2], D. T. Huff[3], C. Tinetti[1,4], M. Azar[4], R. Jeraj[5,6];*
[1]Fundación Centro Diagnóstico Nuclear, Buenos Aires, ARGENTINA, [2]University Medical Center Ljubljana, Ljubljana, SLOVENIA, [3]University of Wisconsin-Madison, Madison, WI, UNITED STATES OF AMERICA, [4]Instituto de Oncología "Ángel H. Roffo", Buenos Aires, ARGENTINA, [5]University of Wisconsin School of Medicine and Public Health, Madison, WI, UNITED STATES OF AMERICA, [6]Faculty of Mathematics and Physics, University of Ljubljana, Ljubljana, SLOVENIA.

EPS-166
Correlation between neovascularization and macrophage inflammation in carotid atherosclerotic plaques evaluated by hybrid ^{18}F-FDG PET/MR:a fused image-based histological validation study
Y. Zhang[1,2], *B. Cui[1,2], H. Yang[1,2], Y. Ma[3], J. Lu[1,2];*
[1]Department of Radiology and Nuclear Medicine, Xuanwu Hospital Capital Medical University, Beijing, CHINA, [2]Beijing Key Laboratory of Magnetic Resonance Imaging and Brain Informatics, Beijing, CHINA, [3]Department of Neurosurgery, Xuanwu Hospital Capital Medical University, Beijing, CHINA.

EPS-167
Brain-dedicated PET system shows non-inferiority compared to conventional PET-CT
P. Nespral[1], *P. Bascuñana[1], G. Cuesta Domingo[1], A. Canora[1], A. Delgado-Cano[1], J. Matías-Guiu[2], J. Carreras-Delgado[1], M. Cabrera-Martín[1];*
[1]Department of Nuclear Medicine, Instituto de Investigación Sanitaria San Carlos (IdISSC). Hospital Clínico San Carlos, Universidad Complutense, Madrid, SPAIN, [2]Department of Neurology. Instituto de Investigación Sanitaria San Carlos (IdISSC). Hospital Clínico San Carlos, Universidad Complutense, Madrid, SPAIN.

1110

Monday, September 11, 2023, 16:45 - 18:15
Hall K

CTE 5 - Technologists Committee: Cardiac Inflammatory Disease

OP-531
Nuclear Medicine's input in Cardiac Inflammation – clinical overview
P. Erba;
Università di Pisa, Department of Translational Research on New Technologies in Medicine and Surgery, Bergamo, ITALY.

OP-532
The importance of patient preparation
V. Mautone;
Instituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST IRCCS, Meldola, ITALY.

OP-533a
Nuclear Medicine's input in Cardiac Amyloidosis
O. Gheysens;
UCLouvain Louvain-la-Neuve Belgium, Nuclear Medicine Department, Brussels, BELGIUM.

OP-533b
Multimodality in cardiac Imaging: who are the imagers?
S. Pereira;
King's College London and Guy's and St Thomas' Hospital NHS Foundation Trust, Clinical PET Centre, London, UNITED KINGDOM.

1111

Monday, September 11, 2023, 4:45 PM - 6:15 PM
Hall G1

Case Report Session 2 - TROP Session: Successful Molecular Targeting in Oncology

OP-534
Triple Imaging in a Patient with Symptomatic Multiple Myeloma at Staging: Which Is More Informative?
M. Di Franco[1], *D. Bezzi[1], A. Cattabriga[2], S. Brocchi[2], C. Mosconi[2,3], E. Zamagni[4], M. Talarico[4], C. Gaudiano[2], L. Vetrone[1], R. Mei[5], S. Fanti[1,5], C. Nanni[5];*
[1]Nuclear medicine, Alma Mater Studiorum University of Bologna, Bologna, ITALY, [2]Department of Radiology, IRCCS Azienda Ospedaliero Universitaria Di Bologna, Bologna, ITALY, [3]DIMEC, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, [4]Istituto di Ematologia "Seràgnoli", IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, [5]Nuclear Medicine, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY.

OP-535
Anthracosis: a potential pitfall in 18F-FCH PET/CT and 18F-PSMA-1007 PET/CT interpretation
A. Cimini[1], *M. Ricci*[2], *A. Marzullo*[1], *M. Menichini*[1], *F. Di Stasio*[1], *M. Di Pietro*[1], *H. Arabi*[3], *H. Dadgar*[4], *G. L. Gravina*[5]; [1]*Nuclear Medicine Unit, St. Salvatore Hospital, L'Aquila, ITALY,* [2]*Nuclear Medicine Unit, Cardarelli Hospital, Campobasso, ITALY,* [3]*Division of Nuclear Medicine and Molecular Imaging, Department of Medical Imaging, Geneva University Hospital, Geneva, SWITZERLAND,* [4]*Cancer Research Center, RAZAVI Hospital, Imam Reza International University, Mashhad, IRAN, ISLAMIC REPUBLIC OF,* [5]*Department of Applied Clinical Sciences and Biotechnologies Division of Radiotherapy, University of L'Aquila, L'Aquila, ITALY.*

OP-536
Epididymal metastasis of prostate adenocarcinoma in [68Ga]Ga-PSMA-11
B. Martins, *T. Timóteo, C. Loewenthal; Hospital da Luz, Lisboa, PORTUGAL.*

OP-537
PET/CT with 18F-FDG and 68Ga-DOTATOC: a case of negative findings in a Solitary Fibrous Tumor.
L. Jonghi-Lavarini[1], *F. Bono*[2], *A. Tuoro*[3], *C. Crivellaro*[4], *L. Guerra*[4,1], *C. Landoni*[4,5,6]; [1]*University Milano-Bicocca, Milan, ITALY,* [2]*Department of Pathology, IRCCS San Gerardo dei Tintori Hospital, Monza, ITALY,* [3]*Thoracic Surgery Department, IRCCS San Gerardo dei Tintori Hospital, Monza, ITALY,* [4]*Department of Nuclear Medicine, IRCCS San Gerardo dei Tintori Hospital, Monza, ITALY,* [5]*University of Milano–Bicocca, Milan, ITALY,* [6]*Tecnomed Foundation, Monza, ITALY.*

OP-538
Flip-flop phenomenon on dual SSTR PET and amino acid PET in a case of pre-treated atypical meningioma CNS WHO grade 2
A. Holzgreve[1], *S. Quach*[2], *P. Harter*[3], *R. Forbrig*[4], *C. Schichor*[2], *J. Tonn*[2], *M. Niyazi*[5], *P. Bartenstein*[1], *L. von Baumgarten*[2], *N. L. Albert*[1]; [1]*Department of Nuclear Medicine, University Hospital, LMU Munich, Munich, GERMANY,* [2]*Department of Neurosurgery, University Hospital, LMU Munich, Munich, GERMANY,* [3]*Center for Neuropathology and Prion Research, LMU Munich, Munich, GERMANY,* [4]*Institute of Neuroradiology, University Hospital, LMU Munich, Munich, GERMANY,* [5]*Department of Radiation Oncology, University Hospital, LMU Munich, Munich, GERMANY.*

OP-539
"Not always a zebra" - Clear Cell Renal Cell Carcinoma Metastasis detected in [68Ga]Ga-DOTA-NOC PET/CT
J. C. Ferro, *J. P. Teixeira, I. Próspero, D. Barbosa, D. G. Silva, S. Fontão de Castro, G. Ferreira, L. Violante, F. Lopes, H. Duarte, I. Lucena e Sampaio; Instituto Português de Oncologia do Porto Francisco Gentil, Oporto, PORTUGAL.*

OP-540
Brain [18F]FET PET/CT in acute myeloid leukemia
G. Crosta[1], *A. Castello*[2], *S. Pacella*[2], *V. Longari*[2], *L. Florimonte*[2], *M. Castellani*[2]; [1]*University of Milan, Milan, ITALY,* [2]*Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, ITALY.*

OP-541
Two Cases of Diffuse Mild-Moderate 18F-Fluoroestradiol Lung Uptake in Women with Metastatic Estrogen Receptor Positive Breast Cancer
E. Phillips, *P. Karak; Hartford Hospital, Hartford, CT, UNITED STATES OF AMERICA.*

OP-542
The ultimate indication for surgical probe use: a case of an ectopic intraesophageal parathyroid adenoma.
A. Doumas[1], *I. Pliakos*[2], *T. Papavramidis*[2], *P. Exadaktylou*[1], *D. Boundas*[3], *E. Giannoula*[1], *A. Tsangaridi*[1], *G. Gerasimou*[1], *E. Papanastasiou*[1], *N. Papadopoulos*[1], *I. Iakovou*[1]; [1]*Aristotle University, Thessaloniki, GREECE,* [2]*1st Surgery Clinic of Aristotle University of Thessaloniki, University Hospital AXEPA, Thessaloniki, GREECE,* [3]*Private Nuclear Medicine Centre, Ippokratis, Thessaloniki, GREECE.*

1201

Tuesday, September 12, 2023, 08:00 - 09:30
Hall A

CME 9 - Bone & Joint + Physics Committee: Current Bone SPECT/CT (including 360 CZT)

OP-543
360 CZT Bone SPECT/CT How to report it and Case Examples
D. Little; *Royal United Hospital, Radiology Department, Bath, UNITED KINGDOM.*

OP-544
CT findings in SPECT/CT – Bone and Incidental
I. Bruno; *Regional General Hospital "F. Miulli", Bari, ITALY.*

OP-545
Extent of scan in SPECT/CT Whole Body vs Single and Multiple Fields of View
S. Redman; *Royal United Hospital, Radiology Department, Bath, UNITED KINGDOM.*

OP-546
SUV in Bone SPECT/CT
B. Geist; *Medical University of Vienna, Department of Biomedical Imaging and Image-guided Therapy, Vienna, AUSTRIA.*

1202

Tuesday, September 12, 2023, 08:00 - 09:30
Hall D (Arena)

Round Table 2 - Radiation Protection Committee: Establishing and Running a Theranostics Center in a Clinical Setting

OP-547
Why theranostics and future challenges, the clinical perspective
K. Herrmann; *UniversityHospital Essen, Department of Nuclear Medicine, Essen, GERMANY.*

OP-548
Staff, infrastructure and instrumentation, and related regulatory issues
A. Sundlöv; *Swedish Medical Products Agency, Uppsala, SWEDEN.*

OP-549
Patient management and radiation protection considerations of staff, patients, carers, and the public
N. Cherbuin; *Centre Hospitalier Universitaire Vaudois, Institut de Radiophysique, Lausanne, SWITZERLAND.*

OP-550
New theranostic agents and future challenges
S. Heskamp; *Department of Medical Imaging, Nuclear Medicine, Radboud University Medical Center Nijmegen, Nijmegen, NETHERLANDS.*

1203

Tuesday, September 12, 2023, 08:00 - 09:30
Hall E1

LIPS Session 9 - Paediatrics Committee: Paediatric Nephro-Urology - Beyond Hydro-Nephrosis

OP-551
Renal scintigraphy in kidney abnormalities other than hydronephrosis
A. Santos; *Hospital Garcia de Orta, Nuclear Medicine Department, E.P.E. , Almada, PORTUGAL.*

OP-552
MAG3 or DMSA in congenital renal malformation
J. Rogasch; *Charité-Universitätsmedizin Berlin, Department of Nuclear Medicine, Berlin, GERMANY.*

OP-553
DMSA, MAG3, sonography and functional MRI: contribution in complex ectopic, duplex and horseshoe kidneys
P. Zucchetta; *Padova University Hospital, Department of Medicine, Nuclear Medicine Unit, Padova, ITALY.*

1204

Tuesday, September 12, 2023, 8:00 AM - 9:30 AM
Hall E2

M2M Track - TROP Session: Imaging the Brain from all Angles

OP-555
First imaging of PARP1 in the living human brain - a translational PET study with [11C]AZ3391
M. Schou[1,2], *A. Pike*[3], *A. Jucaite*[1,2], *P. Johnström*[1,2], *M. Cortes Gonzalez*[2], *A. Högnäsbacka*[2], *K. Dahl*[1,2], *A. Ghosh*[4], *J. Johannes*[4], *A. Staniszewska*[3], *E. Leo*[3], *P. Hamerlik*[3], *B. Davies*[3], *S. Cosulich*[3], *J. Swales*[3], *R. Lawrence*[3], *M. Squatrito*[3], *N. Mueller*[5], *V. Sousa*[2], *J. Bartek*[2], *G. Straglíotto*[2], *P. Stenkrona*[2], *L. Farde*[2], *C. Halldin*[2], *Z. Cselényi*[1,2]; [1]*AstraZeneca, Stockholm, SWEDEN,* [2]*Karolinska Institutet, Stockholm, SWEDEN,* [3]*AstraZeneca, Cambridge, UNITED KINGDOM,* [4]*AstraZeneca, Waltham, MA, UNITED STATES OF AMERICA,* [5]*AstraZeneca, Gaithersburg, MD, UNITED STATES OF AMERICA.*

OP-557
Development of a PET imaging agent for the detection of amyotrophic lateral sclerosis
B. Guérin[1], *S. Ait-Mohand*[1], *V. Dumulon-Perreault*[2], *J. Rousseau*[1], *O. Sarrhini*[2], *S. Tremblay*[1], *M. Maier*[3], *M. Salzmann*[3]; [1]*Universite de Sherbrooke, Sherbrooke, QC, CANADA,* [2]*CRCHUS/CIUSSSE CHUS, Sherbrooke, QC, CANADA,* [3]*Neurimmune AD, Zurich, SWITZERLAND.*

OP-558
In vivo performance of different 18F-labelled cannabinoid receptor 2 radioligands
D. Guendel[1], *W. Deuther-Conrad*[1], *L. Ueberham*[2], *R. Teodoro*[1,3], *G. Bormans*[4], *M. Toussaint*[1], *E. Hey-Hawkins*[2], *K. Kopka*[5,6], *P. Brust*[1,7], *R. Moldovan*[1]; [1]*Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Department Neuroradiopharmaceuticals, Leipzig, GERMANY,* [2]*Leipzig University, Faculty of Chemistry and Mineralogy, Institute of Inorganic Chemistry, Leipzig, GERMANY,* [3]*Life Molecular Imaging GmbH, Berlin, GERMANY,* [4]*Laboratory for Radiopharmacy, KU Leuven, Leuven, BELGIUM,* [5]*Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Reserach, Dresden, GERMANY,* [6]*Faculty of Chemistry and Food Chemistry, School of Science, Technische Universität Dresden, Dresden, GERMANY,* [7]*University Medical Center Schleswig-Holstein, The Lübeck Institute of Experimental Dermatology, Lübeck, GERMANY.*

OP-559
18F-FDS PET imaging as a quantitative marker to investigate the magnitude and dynamics of enhanced of blood-brain barrier permeability induced by regadenoson
B. Hosten, *S. Goutal, S. Leterrier, A. Winkeler, L. Breuil, M. Goislard, C. Truillet, N. Tournier; Université Paris-Saclay, INSERM, CNRS, CEA, Biomaps, Orsay, FRANCE.*

OP-560

The 5-HT1A receptor modulates motor/exploratory activity, object recognition and DAT binding in the dorsal and ventral striatum of the rat

S. Nikolaus[1], *M. Beu*[1], *J. Henke*[1], *C. Antke*[1], *B. Fazari*[2], *E. Mamlins*[1], *F. L. Giesel*[1];
[1]*University Hospital Düsseldorf, Düsseldorf, GERMANY,*
[2]*Heinrich-Heine University, Düsseldorf, GERMANY.*

OP-561

Brain mitochondrial function and cerebral glucose utilization in non-human primate of Parkinson disease model with α-synuclein propagation via the olfactory system: a ^{18}F-BCPP-EF and ^{18}F-FDG PET imaging study

H. Onoe[1], *M. Sawamura*[2], *T. Hirato*[2], *H. Tsukada*[3], *T. Nakako*[4], *T. Nakayama*[4], *K. Ikeda*[4], *C. Chen*[5], *K. Isa*[5], *M. Nakamura*[5], *T. Isa*[5], *R. Takahashi*[2];
[1]*Human Brain Research Center, Kyoto University Graduate School of Medicine, Kyoto, JAPAN,* [2]*Department of Neurology, Kyoto University Graduate School of Medicine, Kyoto, JAPAN,* [3]*Central Research Laboratory, Hamamatsu Photonics K.K., Hamakita, JAPAN,* [4]*Sumitomo Pharma Co., Ltd., Osaka, JAPAN,* [5]*Department of Physiology and Neurobiology, Kyoto University Graduate School of Medicine, Kyoto, JAPAN.*

OP-562

Discovery of Novel PET tracer [^{18}F] F-diarylbisthiazoles for α-Synucleinopathies Imaging

B. Hooshyar Yousefi[1], *B. Uzuegbunam*[2], *S. Bagheri*[3], *G. B. Kotipalli*[3], *W. Paslawski*[4], *J. Li*[5], *E. Nasiri*[6], *F. Geibl*[6], *M. Henrich*[6], *P. Svenningsson*[4], *H. Ågren*[5], *M. Luster*[7], *W. Weber*[8], *T. Arzberger*[9], *D. Librizzi*[10];
[1]*Nuclear Medicine Department, Radiopharmacy section, Philipps University Marburg, Marburg, GERMANY,* [2]*Nuclear Medicine Department, Radiopharmacy section, Philipps University, Munich, GERMANY,* [3]*Nuclear Medicine Department, Radiopharmacy section, Philipps University, Marburg, GERMANY,* [4]*Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, SWEDEN,* [5]*Department of Physics and Astronomy, Uppsala University, Uppsala, SWEDEN,* [6]*Department of Neurology, Philipps University Marburg, Marburg, GERMANY,* [7]*Nuclear Medicine Department, Philipps University, Marburg, GERMANY,* [8]*Department of Nuclear Medicine, Technical University of Munich, Munich, GERMANY,* [9]*Neurobiobank Munich, Ludwig-Maximilians-University of Munich, Munich, GERMANY,* [10]*Nuclear Medicine Department, Philipps University Marburg, Marburg, GERMANY.*

OP-563

In vivo quantification of [^{11}C]BIO-1819578, a novel radioligand for O-GlcNAcase, in non-human primates using Positron Emission Tomography

M. Bolin[1], *S. Nag*[1], *P. Datta*[1], *R. Arakawa*[1], *Y. Khani Meynaq*[1], *E. Lin*[2], *N. Genung*[2], *H. Hering*[2], *K. Guckian*[2], *L. Martarello*[2], *M. Kaliszczak*[2], *L. Farde*[1], *P. Stenkrona*[1], *C. Halldin*[1], *A. Forsberg Morén*[1];
[1]*Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet, & Stockholm Health Care Services, Region Stockholm, Stockholm, SWEDEN,* [2]*BIOGEN MA Inc., 225 Binney St., Cambridge, MA, UNITED STATES OF AMERICA.*

1205

Tuesday, September 12, 2023, 8:00 AM - 9:30 AM
Hall B

Cutting Edge Science Track - TROP Session: Total Body PET Methods

OP-564

Application of the long axial field-of-view PET/CT with direct and indirect Patlak parametric imaging

L. Pan, *C. Sachpekidis, A. Dimitrakopoulou-Strauss;*
German Cancer Research Center, Heidelberg, GERMANY.

OP-565

Kinetic modeling and parametric imaging of 18F-PSMA-11: an evaluation based on total-body dynamic PET scan

H. Yuan, *L. Jiang;*
Guangdong Provincial People's Hospital, Guangzhou, CHINA.

OP-566

Multi-tracer image-derived input function validation using a long axial field of view PET scanner

X. Palard-Novello[1,2], *D. Visser*[2], *N. Tolboom*[3], *C. Smith*[2], *G. Zwezerijnen*[2], *E. van der Giessen*[2], *M. den Hollander*[2], *F. Barkhof*[2], *B. Windhorst*[2], *B. N. M. van Berckel*[2], *R. Boellaard*[2], *M. Yacub*[2];
[1]*Centre Eugène Marquis, Rennes, FRANCE,* [2]*Amsterdam Universitair Medische Centra, Amsterdam, NETHERLANDS,* [3]*Universitair Medisch Centrum Utrecht, Utrecht, NETHERLANDS.*

OP-567

The ENHANCE-PET Framework: An initiative to engage the imaging community in Advancements in Total-Body PET Analysis

L. Shiyam Sundar[1], *B. A. Spencer*[2], *J. Callahan*[3], *S. R. Cherry*[2], *R. D. Badawi*[2], *I. Buvat*[4], *D. Lewis*[5], *D. Ferrara*[1], *S. Gutschmayer*[1], *R. Hicks*[3], *M. Lassen*[6], *J. Mannheim*[7], *O. Muzik*[8], *M. Pires*[1], *J. Yu*[1], *T. Beyer*[1];
[1]*Medical University of Vienna, Vienna, AUSTRIA,* [2]*University of California-Davis, Davis, CA, UNITED STATES OF AMERICA,* [3]*Melbourne Theranostics Innovation Center, Melbourne, AUSTRALIA,* [4]*Institut Curie, Paris, FRANCE,* [5]*CRUK Glasgow, Glasgow, UNITED KINGDOM,* [6]*Rigshospitalet Copenhagen, Copenhagen, DENMARK,* [7]*Uniklinikum Tuebingen, Tuebingen, GERMANY,* [8]*Wayne State University, Detroit, MI, UNITED STATES OF AMERICA.*

OP-568

Walk-Through Flat-Panel Total Body PET: System Design and Comparison of Body Motion with a standard PET-CT

F. Muller[1], *J. Maebe*[1], *N. Withofs*[2], *S. Vandenberghe*[1];
[1]*Medical Image and Signal Processing, Faculty of Engineering and Architecture, Ghent University, Ghent, BELGIUM,* [2]*Division of Nuclear Medicine and Oncological Imaging, Department of Medical Physics, CHU of Liege, Quartier Hôpital, Liège, BELGIUM.*

OP-569

TOF Data Compression Strategies for 3D Fourier-Based Analytical Reconstruction of Long Axial Field of View (LAFOV) scanners data

V. Panin;
Siemens Medical Solutions United States Of America, Knoxville, TN, UNITED STATES OF AMERICA.

OP-570

Comparison of the standard and ultra-high sensitivity modes on a long axial FOV PET/CT system

M. Roya, *J. van Sluis, J. H. van Snick, A. W. J. M. Glaudemans, C. Tsoumpas;*
University Medical Center Groningen, Groningen, NETHERLANDS.

OP-571

Sub-minute acquisition with deep-learning reconstruction in the diagnosis of colorectal cancers using total-body 18F-FDG PET/CT

E. Liu, *Z. Lyu, L. Jiang;*
Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, CHINA.

OP-572

Diagnostic image quality and quantitative PET parameters of low-dose ^{18}F-FDG-PET/CT in a total-body PET/CT scanner: How low can we go?

E. Calderón[1], *F. P. Schmidt*[1,2], *W. Lan*[1], *H. Dittmann*[1], *C. la Fougère*[1,3], *L. S. Kiefer*[1];
[1]*Department of Nuclear Medicine and Clinical Molecular Imaging, University Hospital Tübingen, Tübingen, GERMANY,* [2]*Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, Eberhard-Karls University Tübingen, Tübingen, GERMANY,* [3]*Cluster of Excellence iFIT (EXC 2180) "Image Guided and Functionally Instructed Tumor Therapies", University of Tübingen, Tübingen, GERMANY.*

1206

Tuesday, September 12, 2023, 8:00 AM - 9:30 AM
Hall C

Clinical Oncology Track - TROP Session: Gynaecological Malignancies

OP-573

Molecular imaging predicts response absence to T-DM1 in advanced HER2-positive breast cancer: final results from a prospective phase II ZEPHIR trial

M. Mileva[1], *E. G. de Vries*[2], *T. Guiot*[3], *Z. Wimana*[4], *A. Deleu*[1], *C. Schröder*[5,6], *Y. Lefebvre*[1], *M. Paesmans*[7], *S. Stroobants*[8], *M. Huizing*[9], *P. Aftimos*[10], *J. Tol*[11], *W. Van der Graaf*[12], *W. Oyen*[13,14,15], *D. Vugts*[16], *C. Menke-van der Houven van Oordt*[12], *A. Brouwers*[17], *M. Piccart-Gebhart*[10], *P. Flamen*[1], *G. Gebhart*[1];
[1]*Department of Nuclear Medicine, Institut Jules Bordet, Hôpital Universitaire de Bruxelles (H.U.B), Université Libre de Bruxelles (ULB), Brussels, BELGIUM,* [2]*Department of Medical Oncology, University of Groningen, University Medical Center Groningen, Groningen, NETHERLANDS,* [3]*Department of Medical Physics, Institut Jules Bordet, Hôpital Universitaire de Bruxelles (H.U.B), Université Libre de Bruxelles (ULB), Brussels, BELGIUM,* [4]*Department of Radiopharmacy, Institut Jules Bordet, Hôpital Universitaire de Bruxelles (H.U.B), Université Libre de Bruxelles (ULB), Brussels, BELGIUM,* [5]*Department of Medical Oncology, University of Groningen, University Medical Center Groningen, Groningen, NETHERLANDS,* [6]*Department of Medical Oncology, Antoni van Leeuwenhoek-NETHERLANDS Cancer Institute, Amsterdam, NETHERLANDS,* [7]*Data center, Institut Jules Bordet, Hôpital Universitaire de Bruxelles (H.U.B), Université Libre de Bruxelles (ULB), Brussels, BELGIUM,* [8]*Department of Nuclear Medicine, Antwerp University Hospital, Edegem, Antwerp, BELGIUM,* [9]*Department of Medical Oncology, Antwerp University Hospital, Edegem, Antwerp, BELGIUM,* [10]*Department of Medical Oncology, Institut Jules Bordet, Hôpital Universitaire de Bruxelles (H.U.B), Université Libre de Bruxelles (ULB), Brussels, BELGIUM,* [11]*Department of Internal Medicine, Jeroen Bosch Ziekenhuis, Den Bosch, NETHERLANDS, Den Bosch, NETHERLANDS,* [12]*Department of Medical Oncology, Amsterdam UMC location VUMC, Cancer Centre Amsterdam, Amsterdam, NETHERLANDS,* [13]*Humanitas Clinical and Research Center, Humanitas University, Milan, ITALY,* [14]*Department of Radiology and Nuclear Medicine, Rijnstate Hospital, Arnhem, NETHERLANDS,* [15]*Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, NETHERLANDS,* [16]*Department of Radiology and Nuclear Medicine, Amsterdam UMC, Vrije Universiteit, Cancer Center Amsterdam, Amsterdam, NETHERLANDS,* [17]*Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Groningen, NETHERLANDS.*

OP-574

First Clinical experience with^{68}Ga-Nitroimidazole imaging in cancer of the cervixuteri

K. Mokoala[1,2], *I. O. Lawal*[3,1], *L. C. Maserumule*[1,2], *K. N. Hlongwa*[4], *H. Ndlovu*[1], *J. D. Reed*[1], *J. Jeong*[5], *J. Mahapane*[1], *C. Davis*[1,2], *C. van de Wiele*[6], *A. Maes*[7], *M. Vorster*[8], *M. M. Sathekge*[1,2];
[1]*University of Pretoria, Pretoria, SOUTH AFRICA,* [2]*Nuclear Medicine Research Infrastructure (NuMeRI), Pretoria, SOUTH AFRICA,* [3]*Emory University, Atlanta, GA, UNITED STATES OF AMERICA,* [4]*University of Cape Town, Cape Town, SOUTH AFRICA,* [5]*Seoul National University College of Medicine, Seoul, KOREA, REPUBLIC OF,* [6]*Katholieke University Leuven, Leuven, BELGIUM,* [7]*University of Ghent, Ghent, BELGIUM,* [8]*University of Kwazulu Natal, Durban, SOUTH AFRICA.*

OP-575

2-[^{18}F]FDG-PET/CT in the early prediction of histopathological response in breast carcinoma: results of the German multi-center Gepar-PET study

B. Krause[1], *W. Mohnike*[2], *S. Dresel*[3], *H. Rudolf*[4], *F. H. H. Müller*[5], *J. Farahati*[6], *H. Palmedo*[7], *S. M. Schwarzenböck*[1], *M. Untch*[8], *J. Kurth*[1], *K. Mohnike*[2];
[1]*Department of Nuclear Medicine, University Medical Center Rostock, Rostock, GERMANY,* [2]*Center for Nuclear Medicine, DTZ Berlin, Berlin, GERMANY,* [3]*Department of Nuclear Medicine, Helios Clinics Berlin-Buch, Berlin, GERMANY,* [4]*Institute for Biostatistics and Informatics in Medicine and Ageing Research, University Medical Center Rostock, Rostock, GERMANY,* [5]*Radiologie und Nuklearmedizin Ludwigshafen, Ludwigshafen, GERMANY,* [6]*Department of Nuclear Medicine, Ev. Krankenhaus BETHESDA zu Duisburg, Duisburg, GERMANY,* [7]*Institute of Nuclear Medicine and Radiology, Kaiserpassage, PET/CT Center Johanniter Hospital, Bonn, GERMANY,* [8]*Department of Gynecology and Obstetrics, Helios Clinics Berlin-Buch, Berlin, GERMANY.*

E-POSTER PRESENTATION SESSIONS | FINAL PROGRAMME

OP-576

Evaluation of a Dual Integrin αvβ3 and Gastrin-Releasing Peptide Receptor Targeting PET tracer [^{68}Ga]Ga-RM26-RGD in Breast Cancer Patients

R. Wang[1,2,3], *X. Wen*[4], *P. Xu*[5], *X. Zhang*[4], *Z. Guo*[4], *Z. Zhu*[1,2,3], *X. Chen*[6,7,8], *J. Zhang*[6,7,8];
[1]*Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, CHINA,* [2]*State Key Laboratory of Complex Severe and Rare Diseases, Beijing, CHINA,* [3]*Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Beijing, CHINA,* [4]*State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics & Center for Molecular Imaging and Translational Medicine, School of Public Health, Xiamen University, Xiamen, CHINA,* [5]*Institute of Clinical Pharmacy & Pharmacology, Jining First People's Hospital, Jining Medical University, Jining, CHINA,* [6]*Departments of Diagnostic Radiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, SINGAPORE,* [7]*Nanomedicine Translational Research Program, NUS Center for Nanomedicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, SINGAPORE,* [8]*Clinical Imaging Research Centre, Centre for Translational Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, SINGAPORE.*

OP-577

Tumor and metastatic lymph nodes metabolic activity on ^{18}F-FDG PET/CT to predict progression-free survival in locally advanced cervical cancer

J. Song;
Zhejiang Cancer Hospital, Hangzhou, CHINA.

OP-578

HER2-specific Affibody Molecule [^{99m}Tc]Tc-ZHER2:41071: phase I clinical trial

V. Tolmachev[1], *O. Bragina*[2], *M. Larkina*[3], *A. Rybina*[2], *R. Zelchan*[2], *M. Oroujeni*[1], *A. Loftenius*[4], *A. Orlova*[5], *J. Sörensen*[6], *F. Frejd*[1], *V. Chernov*[2];
[1]*Department of Immunology, Genetics and Pathology (IGP), Uppsala University, Uppsala, SWEDEN,* [2]*Cancer Research Institute, Tomsk National Research Medical Center, Tomsk, RUSSIAN FEDERATION,* [3]*Research Centrum for Oncotheranostics, Research School of Chemistry and Applied Biomedical Sciences, Tomsk Polytechnic University, Tomsk, RUSSIAN FEDERATION,* [4]*Affibody AB, Solna, SWEDEN,* [5]*Department of Medicinal Chemistry, Uppsala University, Uppsala, SWEDEN,* [6]*Radiology and Nuclear Medicine, Department of Surgical Sciences, Uppsala University, Uppsala, SWEDEN.*

OP-579

HER2-targeting [^{68}Ga]Ga-ABY-025 PET Predicts Early Metabolic Response in Metastatic Breast Cancer

A. Alhuseinalkhudhur[1,2], *H. Lindman*[2], *P. Liss*[3], *T. Sundin*[4], *F. Y. Frejd*[2,5], *J. Hartman*[6,7], *V. Iyer*[1], *J. Feldwisch*[5], *M. Lubberink*[1,8], *C. Rönnlund*[6,7], *V. Tolmachev*[2], *I. Velikyan*[1], ***J. Sörensen***[1];
[1]*Nuclear Medicine and PET, Department of Surgical Sciences, Uppsala University, Uppsala, SWEDEN,* [2]*Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, SWEDEN,* [3]*Radiology, Department of Surgical Sciences, Uppsala University, Uppsala, SWEDEN,* [4]*Clinical Research and Development Unit, Uppsala University Hospital, Uppsala, SWEDEN,* [5]*Affibody AB, Solna, SWEDEN,* [6]*Department of Oncology-Pathology, Karolinska Institute, Stockholm, SWEDEN,* [7]*Department of Clinical Pathology and Cancer Diagnostics, Karolinska University Hospital, Stockholm, SWEDEN,* [8]*Medical Physics, Uppsala University Hospital, Uppsala, SWEDEN.*

OP-580

^{68}Ga-NeoB PET for Glioma and Breast Cancer: First Results from a Prospective Observational Trial

D. Kersting[1], *L. Lazaridis*[2], *F. Barbato*[1], *S. Kebir*[2], *S. Kümmel*[3], *A. Welt*[4], *L. Umutlu*[5], *A. Milosevic*[5], *M. Nader*[1], *P. Fragoso Costa*[1], *T. Schmidt*[2], *C. Oster*[2], *C. Deuschl*[5], *U. Sure*[1], *M. Stuschke*[6], *C. Kleinschnitz*[2], *B. Scheffler*[7], *H. Hautzel*[1], *M. Schuler*[4], *M. Glas*[2], *W. P. Fendler*[1], *K. Herrmann*[1];
[1]*Department of Nuclear Medicine, University Hospital Essen, University of Duisburg-Essen, Essen, GERMANY,* [2]*Department of Neurology and Center for Translational Neuro- and Behavorial Sciences (C-TNBS), Division of Clinical Neurooncology, University Medicine Essen, University of Duisburg-Essen, Essen, GERMANY,* [3]*Breast Unit Kliniken Essen-Mitte, Essen, GERMANY,* [4]*Department of Medical Oncology, University Hospital Essen, University of Duisburg-Essen, Essen, GERMANY,* [5]*Institute of Diagnostic, Interventional Radiology and Neuroradiology, University Hospital Essen, University of Duisburg-Essen, Essen, GERMANY,* [6]*Department of Radiotherapy, University Hospital Essen, University of Duisburg-Essen, Essen, GERMANY,* [7]*DKFZ-Division Translational Neurooncology at the West German Cancer Center (WTZ), DKTK Partner Site, University Medicine Essen, University Duisburg-Essen, Essen, GERMANY.*

OP-581

Prognostic Value Of [^{18}F]-FDG PET/CT In Patients With Metastatic Breast Cancer Treated With Cyclin-Dependent Inhibitors

D. Maccora[1], *A. Annovazzi*[1], *S. Rea*[1], *L. Pizzuti*[2], *G. Ferretti*[3], *P. Vici*[4], *F. Cappuzzo*[2], *R. Sciuto*[1];
[1]*Nuclear Medicine Unit, IRCCS Regina Elena National Cancer Institute, Rome, ITALY,* [2]*Division of Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Rome, ITALY,* [3]*Division of Medical Oncology 1, IRCCS Regina Elena National Cancer Institute, Rome, ITALY,* [4]*Phase IV Clinical Trial Unit, IRCCS Regina Elena National Cancer Institute, Rome, ITALY.*

1207

Tuesday, September 12, 2023, 8:00 AM - 9:30 AM
Hall F1

Neuroimaging Committee - Featured Session

OP-582

Breadth of Tracers and Approaches in Neuro-Oncology

I. Law, *University of Copenhagen, Faculty of Health and Medical Sciences Consultant Department of Clinical Physiology and Nuclear Medicine, Rigshospitalet, Copenhagen, DENMARK.*

OP-583

Fibroblast activation protein staining in tissue samples of high-grade gliomas

N. Tolboom, *S. Sabunchi, A. Muhlebner, P. A. J. T. Robe, T. J. Snijders;
University Medical Centre Utrecht, Utrecht, NETHERLANDS.*

OP-584

Postoperative ^{68}Ga-DOTATATE-/PET-CT imaging is prognostic for progression-free survival survival in meningioma WHO grade 1:A prospective single center study

N. Teske, *A. Biczok, S. Quach, F. J. Dekorsy, R. Forbrig, R. Bodensohn, M. Niyazi, J. Tonn, N. L. Albert, C. Schichor, M. Ueberschaer;
Munich University Hospital, LMU Munich, Munich, GERMANY.*

OP-585

^{18}F-DOPA PET imaging in re-irradiation with proton therapy of recurrent glioblastoma.

D. Donner[1], *D. Amelio*[2], *D. Scartoni*[2], *L. Picori*[1], *S. Agostini*[1], *F. Magnani*[1], *A. Palermo*[1], *M. Cianchetti*[2], *F. Chierichetti*[1];
[1]*Nuclear Medicine Unit, Azienda Provinciale per i Servizi Sanitari, Trento, ITALY,* [2]*Centro di Protonterapia, Azienda Provinciale per i Servizi Sanitari, Trento, ITALY.*

OP-586

Amino-acid PET for monitoring temozolomide adjuvant therapy after a Stupp protocol in gliomas

T. Zaragori[1,2], *S. Ahrari*[1,2], *A. Zinsz*[2], *A. Mortada*[2], *L. Taillandier*[3,4], *M. Blonski*[3,4], *F. Rech*[5,4], *L. Imbert*[1,2], *A. Verger*[1,2];
[1]*Université de Lorraine, IADI, INSERM, UMR 1254, Vandoeuvre-lès-Nancy, FRANCE,* [2]*Department of Nuclear Medicine & Nancyclotep Imaging Platform, CHRU-Nancy, Université de Lorraine, Vandoeuvre-lès-Nancy, FRANCE,* [3]*Department of Neuro-Oncology, CHRU-Nancy, Université de Lorraine, Nancy, France, Vandoeuvre-lès-Nancy, FRANCE,* [4]*Centre de Recherche en Automatique de Nancy CRAN UMR 7039, CNRS, Université de Lorraine, Vandoeuvre-lès-Nancy, FRANCE,* [5]*Department of Neurosurgery, CHRU-Nancy, Université de Lorraine, Vandoeuvre-lès-Nancy, FRANCE.*

OP-587

Predictive values of preoperative [^{68}Ga]Ga-PSMA-11 PET/CT in patients with suspected brain tumours of glial origin.

K. Pelka[1,2], *K. Koczyk*[3], *L. Koperski*[4], *T. Dziedzic*[3], *A. Nowak*[3], *L. Królicki*[1], *P. Kunert*[3], *J. Kunikowska*[1];
[1]*Nuclear Medicine Department, Medical University of Warsaw, Warsaw, POLAND,* [2]*Laboratory of Centre for Preclinical Research, Department of Research Methodology, Medical University of Warsaw, Warsaw, POLAND,* [3]*Department of Neurosurgery, Medical University of Warsaw, Warsaw, POLAND,* [4]*Department of Pathology, Medical University of Warsaw, Warsaw, POLAND.*

OP-588

Tumoral TSPO-radioligand uptake on PET prior to radiotherapy is associated with overall survival in glioblastoma patients

A. Holzgreve[1], *D. V. Nelwan*[1], *D. F. Fleischmann*[2], *S. Quach*[3], *K. von Rohr*[1], *L. Kaiser*[1], *N. Teske*[3], *L. M. Unterrainer*[1], *L. M. Bartos*[1], *V. C. Ruf*[4], *M. Brendel*[1], *M. J. Riemenschneider*[5], *C. Wetzel*[6], *J. Herms*[4], *R. Rupprecht*[6], *N. Thon*[3], *J. Tonn*[3], *C. Belka*[2], *P. Bartenstein*[1], *L. von Baumgarten*[3], *M. Niyazi*[2], *M. Unterrainer*[1], *N. L. Albert*[1];
[1]*Department of Nuclear Medicine, University Hospital, LMU Munich, Munich, GERMANY,* [2]*Department of Radiation Oncology, University Hospital, LMU Munich, Munich, GERMANY,* [3]*Department of Neurosurgery, University Hospital, LMU Munich, Munich, GERMANY,* [4]*Center for Neuropathology and Prion Research, LMU Munich, Munich, GERMANY,* [5]*Department of Neuropathology, Regensburg University Hospital, Regensburg, GERMANY,* [6]*Department of Psychiatry and Psychotherapy, University of Regensburg, Regensburg, GERMANY.*

OP-589

Imaging PD-L1 in the brain - journey from the lab to the clinic

G. Kramer-Marek[1,2], *D. Dar*[1], *M. Rodak*[2], *C. Da Pieve*[1], *M. Niedbala*[3], *G. Sharma*[1], *I. Gorczewska*[2], *P. Bzowski*[2], *A. d'Amico*[2], *E. Chmielik*[2], *B. Bobek-Bilewicz*[2], *E. Nowicka*[2], *R. Tarnawski*[2], *W. Kaspera*[3];
[1]*The Institute of Cancer Research, London, UNITED KINGDOM,* [2]*Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice, POLAND,* [3]*Medical University of Silesia, Katowice, POLAND.*

OP-590

Profiling Functional Clusters of Short Chain Fatty Acids Metabolism in Primary Brain Gliomas for Phenotype Prediction

M. Inglese[1,2], *T. Boccato*[1], *M. Ferrante*[1], *S. Islam*[2], *M. Williams*[2], *A. D. Waldman*[3], *K. O'Neill*[4], *E. O. Aboagye*[2], *N. Toschi*[1,5];
[1]*University of Rome "Tor Vergata", Rome, ITALY,* [2]*Imperial College London, London, UNITED KINGDOM,* [3]*University of Edinburgh, Edinburgh, UNITED KINGDOM,* [4]*Imperial College Healthcare NHS Trust, London, UNITED KINGDOM,* [5]*Athinoula A. Martinos Center for Biomedical Imaging, Boston, MA, UNITED STATES OF AMERICA.*

1208

Tuesday, September 12, 2023, 08:00 - 09:30
Hall F2

Joint Symposium 4 - Dosimetry Committee / ESTRO: Dosimetry in Different Modalities - Where We Are and Where We Want To Be

OP-591

Dosimetry for EBRT and Brachytherapy

E. Gershkevitsh;
North Estonia Medical Centre, Tallinn, ESTONIA.

OP-592

Dosimetry for Selective Internal Radiotherapy

C. Hindorf;
Karolinska University Hospital, Solna, SWEDEN.

OP-593

Dosimetry for Molecular Radiotherapy

J. Gear;
Royal Marsden NHSFT and Institute of Cancer Research, Joint Department of Physics, Sutton, UNITED KINGDOM.

OP-594

Comparisons and future perspectives

M. Cremonesi;
Istituto Europeo Di Oncologia, Department of Medical Imaging and Radiation Sciences, Milan, ITALY.

1209

Tuesday, September 12, 2023, 8:00 AM - 9:30 AM
Hall G2

e-Poster Presentations Session 9 - Physics Committee: Artificial Intelligence and Radiomics

EPS-168
Development of deep learning model for generalized utilization to restore short-scanning PET images using three radiopharmaceuticals
Y. Jeong[1], *S. Cheon*[1], *H. Park*[2], *K. Jeon*[2];
[1]*Dong-A University Hospital, Busan, KOREA, REPUBLIC OF,* [2]*National Institute for Mathematical Science, Daejeon, KOREA, REPUBLIC OF.*

EPS-169
Deep-learning based classification of dual-phase 18F-FP-CIT PET images for the diagnosis of Parkinsonism
D. Kim[1], *K. Choo*[1], *D. Kim*[2], *H. Lim*[2], *M. Yun*[2];
[1]*Yonsei University, Seoul, KOREA, REPUBLIC OF,* [2]*Yonsei University College of Medicine, Seoul, KOREA, REPUBLIC OF.*

EPS-170
Feasibility of transfer learning in decoding hibernating myocardium from rest myocardial perfusion images
B. Khangembam, *J. Jaleel, A. Roy, P. Gupta, C. Patel;*
All India Institute of Medical Sciences, New Delhi, INDIA.

EPS-171
Synthetic Attenuation Correction Maps for SPECT Imaging using Deep Learning: A Study on Myocardial Perfusion Imaging
M. Namías[1], *M. A. Prieto Canalejo*[2], *A. Palau San Pedro*[1], *R. Geronazzo*[1], *D. M. Minsky*[3], *L. E. Juarez Orozco*[4];
[1]*Fundación Centro Diagnóstico Nuclear, Buenos Aires, ARGENTINA,* [2]*Universidad Tecnológica Nacional, Facultad Regional Buenos Aires, Buenos Aires, ARGENTINA,* [3]*Comisión Nacional de Energía Atómica, San Martín, ARGENTINA,* [4]*University Medical Center Utrecht, Utrecht, NETHERLANDS.*

EPS-172
Human vs Machine: Comparison of manual and deep learning semantic segmentation algorithm generated tumour volumes on [177Lu]Lu-PSMA-617 post therapy SPECT/CT images
R. Karri, *P. Jackson, L. McInstosh, J. P. Buteau, G. Kong, T. Akhurst, A. S. Ravi Kumar, D. G. Murphy, S. Sandhu, M. S. Hofman;*
Peter MacCallum Cancer Centre, Melbourne, AUSTRALIA.

EPS-173
Primary tumour type impacts 3D U-Net for [18F]FDG PET lesion segmentation performance in cases of lung cancer, melanoma, and lymphoma
M. Sobral[1,2], *M. Oliveira*[1,3], *C. Constantino*[1], *F. Oliveira*[1], *N. Matela*[4], *D. C Costa*[1];
[1]*Champalimaud Foundation, Lisboa, PORTUGAL,* [2]*Departamento de Física, Faculdade de Ciências, Universidade de Lisboa, Lisboa, PORTUGAL,* [3]*Escola Superior de Biotecnologia, Universidade Católica Portuguesa, Porto, PORTUGAL,* [4]*Instituto de Biofísica e Engenharia Biomédica, Faculdade de Ciências, Universidade de Lisboa, Lisboa, PORTUGAL.*

EPS-174
A systemic analysis of [18F]FDG PET/CT data for early detection of cachexia in lung cancer patients
D. Ferrara[1], *A. Frille*[2], *E. Abenavoli*[3], *T. Beyer*[1], *S. Duke*[4], *S. Gruenert*[5], *M. Hacker*[5], *S. Hesse*[2], *L. Hofmann*[2], *S. Holm*[4], *M. Rullmann*[2], *R. Sciagrà*[3], *L. Shiyam Sundar*[1], *A. Tönjes*[2], *H. Wirtz*[2], *J. Yu*[1,5], *O. Sabri*[2];
[1]*QIMP Team, Medical University of Vienna, Vienna, AUSTRIA,* [2]*University Hospital of Leipzig, Leipzig, GERMANY,* [3]*Division of Nuclear Medicine, Azienda Ospedaliero Universitaria Careggi, Florence, ITALY,* [4]*University of Copenhagen, Copenhagen, DENMARK,* [5]*Division of Nuclear Medicine, Medical University of Vienna, Vienna, AUSTRIA.*

EPS-175
Comparison of a deep learning model to denoise low dose 18F-FDG PET images trained using synthetic image versus acquired low dose images
L. Sibille, *R. Chamberlain;*
Subtle Medical, Menlo Park, CA, UNITED STATES OF AMERICA.

EPS-176
Multi-tracer Deep Learning-based Time-of-Flight (DL-ToF) Image Enhancement of non-TOF PET Scans
A. Mehranian[1], *S. Wollenweber*[2], *K. Bradley*[3], *M. Walker*[4], *K. Su*[2], *R. Johnsen*[2], *F. Jansen*[2], *D. McGowan*[4,5];
[1]*GE HealthCare, Oxford, UNITED KINGDOM,* [2]*GE HealthCare, Waukesha, WI, UNITED STATES OF AMERICA,* [3]*Wales Research and Diagnostic PET Imaging Centre, University Hospital of Wales, Cardiff, UNITED KINGDOM,* [4]*Oxford University Hospitals NHS FT, Oxford, UNITED KINGDOM,* [5]*Department of Oncology, University of Oxford, Oxford, UNITED KINGDOM.*

EPS-177
Deep learning based missing data retrieval of small animal PET using a conditional GAN (Pix2Pix)
Z. Karimi[1], *A. Ghafari*[2], *M. Farahani*[2], *P. Sheikhzadeh*[3], *M. Ay*[2];
[1]*Faculty of Physics, University of Isfahan, Isfahan, IRAN, ISLAMIC REPUBLIC OF,* [2]*Research Center for Molecular and Cellular Imaging (RCMCI), Advanced Medical Technologies and Equipment Institute (AMTEI), Tehran University of Medical Sciences (TUMS), Tehran, IRAN, ISLAMIC REPUBLIC OF,* [3]*Department of Nuclear Medicine, Imam Khomeini Hospital Complex, Tehran, IRAN, ISLAMIC REPUBLIC OF.*

EPS-178
Enhanced characterization of functionally significant coronary lesions using machine learning techniques with radiomics-based analysis
G. Kalykakis[1,2], *F. V. Driest*[3], *A. Broersen*[4], *D. Terentes-Printzios*[5], *A. Antonopoulos*[5], *N. Anousakis Vlachichristou*[1], *R. Liga*[6], *D. Visvikis*[7], *A. Scholte*[8], *J. Knuuti*[9], *D. Neglia*[10], *C. D. Anagnostopoulos*[1];
[1]*Biomedical Research Foundation Academy of Athens, Athens, GREECE,* [2]*Ionio University, Corfu, GREECE,* [3]*Leiden University Medical Center, Department of Cardiology, Leiden, NETHERLANDS,* [4]*University Medical Center, Division of Image Processing, Leiden, NETHERLANDS,* [5]*Hippocration General Hospital of Athens, Athens, GREECE,* [6]*University of Pisa, Pisa, ITALY,* [7]*University of Bretagne Occidentale, Brest, FRANCE,* [8]*Leiden University Medical Center, Leiden, NETHERLANDS,* [9]*Turku University Hospital, Turku, FINLAND,* [10]*Institute of Clinical Physiology, Pisa, ITALY.*

EPS-179
Volume dependence and repeatability of ^{99m}Tc SPECT radiomic parameters
A. Gemmell[1,2,3], *C. Brown*[1,2], *S. Ray*[3], *S. Small*[1,2];
[1]*Nuclear Medicine, Gartnavel General Hospital, Glasgow, UNITED KINGDOM,* [2]*Department of Clinical Physics & Bioengineering, Glasgow, UNITED KINGDOM,* [3]*School of Mathematics & Statistics, University of Glasgow, Glasgow, UNITED KINGDOM.*

EPS-180
The biological counterpart of radiomics in pancreatic cancer: a preliminary simulation study
L. Cavinato[1], *J. Hong*[2], *S. Reinhard*[2], *M. Wartenberg*[2], *F. Ieva*[1,3], *K. Shi*[2];
[1]*Politecnico di Milano, Milano, ITALY,* [2]*University of Bern, Bern, SWITZERLAND,* [3]*Human Technopole, Milan, ITALY.*

EPS-181
A machine learning approach based on rest myocardial perfusion image radiomics to detect the presence of hibernating myocardium: a single institutional experience on 239 patients with 371 perfusion defects
C. Patel, *B. Khangembam, J. Jaleel, A. Roy, P. Gupta;*
All India Institute of Medical Sciences, New Delhi, INDIA.

EPS-182
Clinical Evaluation of ^{18}F-FDG PET Radiomics Stability to Respiratory Motion Using a Data-Driven Respiratory Gating Algorithm
K. Lue[1], *K. Kan*[2,3], *Y. Chen*[2,4], *S. Liu*[1,2], *I. Shih*[5], *H. Lin*[6,7];
[1]*Tzu Chi University of Science and Technology, Hualien, TAIWAN,* [2]*Hualien Tzu Chi Hospital, Hualien, TAIWAN,* [3]*Fu Jen Catholic University Hospital, New Taipei City, TAIWAN,* [4]*Tzu Chi University, Hualien, TAIWAN,* [5]*GE HealthCare, Taipei, TAIWAN,* [6]*Chang Gung University, Taoyuan, TAIWAN,* [7]*Keelung Chang Gung Memorial Hospital, Keelung, TAIWAN.*

EPS-183
Does fdg pet-based radiomics have an added value for prediction of overall survival in non-small cell lung cancer?
G. Giovacchini[1], *E. Giovannini*[1], *F. Tutino*[1], *A. Milano*[1], *L. Florimonte*[2], *E. Bonatto*[3], *C. Bareggi*[2], *L. Dellavedova*[4], *A. Castello*[5], *C. Aschele*[1], *M. Castellani*[2], *A. Ciarmiello*[1];
[1]*S. Andrea Hospital, La Spezia, ITALY,* [2]*Fondazione IRCCS Ca' Granda, Milano, ITALY,* [3]*University of Milan, Milano, ITALY,* [4]*ASST Ovest Milanese, Legnano, ITALY,* [5]*IRCCS Ca' Granda, Milano, ITALY.*

EPS-184
Improving Outcome Prediction in Multicentric Data: Novel harmonization and clustering Techniques for Radiomic Feature Analysis
N. Abdallah[1], *J. Marion*[2], *C. Tauber*[1], *T. Carlier*[3], *P. Chauvet*[2], *M. Hatt*[4];
[1]*Imaging & Brain, INSERM, Tours, FRANCE,* [2]*LARIS, Angers, FRANCE,* [3]*CRCINA, INSERM, CNRS, Université d'Angers, Université de Nantes, Nantes, FRANCE,* [4]*LaTIM, INSERM, Brest, FRANCE.*

EPS-185
[18F]FDG-PET/CT Tumor Spread and Dissemination Measured from the Spleen in Lymphoma: How Predictive of the Outcome?
K. Girum[1], *A. Cottereau*[2], *J. Clerc*[2], *L. Vercellino*[3], *O. Casasnovas*[4], *F. Morschhauser*[5], *C. Thieblemont*[6], *I. Buvat*[1];
[1]*LITO laboratory, U1288 Inserm, Institut Curie, University Paris-Saclay, Orsay, FRANCE,* [2]*Department of Nuclear Medicine, Cochin Hospital, AP-HP, Paris Descartes University, Paris, FRANCE,* [3]*Department of Nuclear Medicine, Saint-Louis Hospital, AP-HP, Paris, FRANCE,* [4]*Department of Hematology, University Hospital of Dijon, Dijon, FRANCE,* [5]*Department of Hematology, Claude Huriez hospital, University Lille, EA 7365, Research Group on Injectable Forms and Associated Technologies, Lille, FRANCE,* [6]*Department of Hematology, Saint Louis Hospital, AP-HP, Paris, FRANCE.*

EPS-187
Quantitative Analysis of Dual Time Point in FDG PET/CT images
N. Reshtebar[1], *S. Hosseini*[1], *A. Rahmim*[2], *p. Sheikhzadeh*[3];
[1]*Sharif University of Technology, Tehran, IRAN, ISLAMIC REPUBLIC OF,* [2]*University of British Columbia, Vancouver, BC, CANADA,* [3]*Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF.*

EPS-188
Predicting overall survival in non-Hodgkin lymphoma patients using baseline ^{18}F-FDG PET radiomic features
T. Husevåg, *A. M. Løndalen, J. Blakkisrud, C. Stokke;*
Oslo University Hospital, Oslo, NORWAY.

1210

Tuesday, September 12, 2023, 08:00 - 09:30
Hall K

CTE 6 - Technologists Committee: Extravasation Incidents Management

OP-595
Extravasation incidents – theoretical principles and examples in Conventional Nuclear Medicine
M. Cruz;
Centro Hospitalar de Lisboa Ocidental, EPE - Hospital de Santa Cruz, Nuclear Medicine, Carnaxide, PORTUGAL.

OP-596
Extravasation incidents with PET agents and contrast media
J. Elliott;
Canterbury Christ Church University, School of Allied and Public Health Professions (Diagnostic Radiography), Canterbury, UNITED KINGDOM.

OP-597
Extravasation in radionuclide therapy – a step by step guide
N. Ahmadi Bidakhvidi;
UZ Leuven, Nuclear Medicine and Molecular Imaging, Leuven, BELGIUM.

1211

Tuesday, September 12, 2023, 08:00 - 09:30
Hall G1

Special Symposium 4 - Lung scintigraphy for pulmonary embolism diagnosis and long term management

OP-598
Clinical challenge of acute pulmonary embolism diagnosis
H. Robert-Ebadi;
Division of angiology and hemostasis, Geneva, SWITZERLAND.

OP-599
Clinical challenge of long-term management after an acute pulmonary embolism
G. Le Gal;
Universityof Ottawa, Department of Medicine, Ottawa, CANADA.

OP-600
Role and interpretation of lung scintigraphy for the diagnosis and follow up of pulmonary embolism
P. Le Roux;
UniversityHospital of Brest, Department of Nuclear Medicine - UMR U1304 -GETBO, Brest, FRANCE.

1301

Tuesday, September 12, 2023, 09:45 - 11:15
Hall A

CME 10 - Radiation Protection + Paediatrics Committee + Women´s Empowerment Task Force: Radiation Protection in Motherhood and Childhood - What is so Special?

OP-602
Radiobiological aspects to consider during pregnancy, neonates and small children
U. Eberlein;
Universityof Würzburg, Department of Nuclear Medicine, Würzburg, GERMANY.

OP-603
Dilemmas of the pregnant or breastfeeding radiation worker, patient and carer
S. Leide-Svegborn;
Department of Radiation Physic, Skåne University Hospital Malmö, Lund University, Lund, SWEDEN.

OP-604a
Common diseases during childhood and the role of Nuclear Medicine
P. Zucchetta;
Universityof Padua, Nuclear Medicine Unit, Padua, ITALY.

OP-604b
Family management in therapeutics and diagnostics of children
L. Cunha;
IsoPor-Azores, Department of Nuclear Medicine and Molecular Imaging, Azores, PORTUGAL.

1302

Tuesday, September 12, 2023, 09:45 - 11:15
Hall D (Arena)

Debate 4 - Physics + Oncology & Theranostics Committee: Whole Body Parametric Imaging

OP-605
Whole-body parametric imaging is ready for clinic
A. Tavares;
University/BHF Centre for Cardiovascular Science, University of Edinburgh, The Queen's Medical Research Institute, Edinburgh, UNITED KINGDOM.

OP-606
Whole-body parametric imaging is not ready for clinic
D. Visvikis;
National Institute of Health and Medical Research (INSERM), Medical Image Processing Lab, Brest, FRANCE.

1303

Tuesday, September 12, 2023, 09:45 - 11:15
Hall E1

LIPS Session 10 - Neuroimaging Committee: The Sunrise of Alpha-Synuclein in vivo Brain Imaging

OP-611
The Need of an Alpha-Synuclein Biomarker
R. Smith;
Lund University, Memory Clinic at Skåne University Hospital, Lund, SWEDEN.

OP-612
Alpha-Synuclein in Parkinson's Disease
D. Van Weehaeghe;
UZ Gent, Gent BELGIUM.

OP-613a
Alpha-Synuclein in Lewy Body Dementia
N. Tolboom;
UniversityMedical Centre Utrecht, Department of Radiology, Utrecht, NETHERLANDS.

OP-613b
Alpha-Synuclein in Multi System Atrophy
H. Barthel;
Leipzig University Medical Centre, Department of Nuclear Medicine, Leipzig, GERMANY.

1304

Tuesday, September 12, 2023, 9:45 AM - 11:15 AM
Hall E2

M2M Track - TROP Session: Emerging Theranostic Concepts

OP-614
Radio-theragnostics targeting CXCR4 based on the endogenous ligand EPI-X4 for oncological applications
R. Gaonkar[1], *J. Millul*[1], *R. Mansi*[1], *M. Harms*[2], *J. Münch*[2], *M. Fani*[1];
[1]University Hospital Basel, Basel, SWITZERLAND, [2]Institute of Molecular Virology, Ulm University Medical Center, Ulm, GERMANY.

OP-615
Next Generation Theranostics Based on the Tetrazine Ligation
U. Battisti[1,2], *V. Shalgunov*[1], *C. B. M. Poulie*[1], *L. Hvass*[3], *M. Muller*[2], *A. S. Clausen*[3], *E. Hansson*[4], *E. H. K. Aneheim*[5], *M. El Fakiri*[6], *M. Eder*[6], *S. Lindegren*[5], *A. Kjaer*[3], *H. J. Jensen*[7], *A. T. I. Jensen*[1], *M. M. Herth*[1,2];
[1]Tetrakit Technologies, Copenhagen, DENMARK, [2]Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, DENMARK, [3]Department of Clinical Physiology and Nuclear Medicine & Cluster for Molecular Imaging, Copenhagen University Hospital – Rigshospitalet & Department of Biomedical Sciences, University of Copenhagen, Copenhagen, DENMARK, [4]Atley solution, Gothenburg, SWEDEN, [5]Sahlgrenska Academy, University of Gothenburg, Gothenburg, SWEDEN, [6]Faculty of Medicine, Albert-Ludwigs-Universität Freiburg, Freiburg, GERMANY, [7]PET and Cyclotron Unit, Copenhagen University Hospital, Copenhagen, DENMARK.

OP-616
CD83 as a Theranostic Target for Acute Myeloid Leukemia
K. Ott[1], *A. J. Robertson*[1], *J. P. Gallant*[1], *K. K. Walton*[2], *B. C. Betts*[2], *A. M. LeBeau*[1];
[1]The University of Wisconsin-Madison, Madison, WI, UNITED STATES OF AMERICA, [2]The University of Minnesota, Minneapolis, MN, UNITED STATES OF AMERICA.

OP-617
Development of [^{18}F]F-[^{nat}Lu]Lu-/[^{19}F]F-[^{177}Lu]Lu-DOTA-rhCCK-84, a Radiohybrid-Based Minigastrin Analogue With High Tumour and low Kidney Accumulation: A Viable Clinical Option for Imaging and Radioligand Therapy of Medullary Thyroid Carcinoma?
T. Günther[1], *N. Holzleitner*[1], *I. Maniyankerikalam*[1], *L. Greifenstein*[2], *R. Beck*[1], *D. Di Carlo*[1], *R. P. Baum*[2], *H. Wester*[1];
[1]Technical University of Munich, Garching, GERMANY, [2]CURANOSTICUM Wiesbaden-Frankfurt, Wiesbaden, GERMANY.

OP-618
Construction and preclinical evaluation of a $^{124/125}$IIabeled specific antibody targeting CD147 in pan-cancer
X. Ma, *T. Liu, H. Zhu, Z. Yang;*
Peking University Cancer Hospital, Beijing, CHINA.

OP-619
CD47-targeted nanobody theranostics
W. Wei;
Shanghai Jiao Tong University, Shanghai, CHINA.

OP-620
Preclinical Evaluation of [^{18}F]F-[^{nat}Lu]Lu-/[^{19}F]F-[^{177}Lu]Lu DOTA-rhCCK-18, a Radiohybrid-Based Minigastrin Analog With High Target Affinity and Tumor Accumulation: First Steps Towards Clinical Translation
N. Holzleitner[1], *T. Günther*[1], *L. Greifenstein*[2], *N. Urtz-Urban*[1], *D. Di Carlo*[1], *C. Lapa*[3], *R. Baum*[2], *H. Wester*[1];
[1]Technical University Munich, Munich, GERMANY, [2]Center for Advanced Radiomolecular Precision Oncology, Wiesbaden, GERMANY, [3]University of Augsburg, Augsburg, GERMANY.

OP-621
In vitro and in vivo evaluation of BCY18469, a novel EphA2-targeting Bicycle® for radiotheranostic applications
M. El Fakiri[1,2,3], *G. E. Mudd*[4], *J. Mitschke*[5,1], *P. Huxley*[4], *K. McDonnell*[4], *A. R. Regupathy*[4], *N. Klemm*[5], *L. Domogalla*[2,1], *A. C. Eder*[1,2], *T. Reinheckel*[5,1], *M. Eder*[1,2];
[1]German Cancer Consortium (DKTK), Partner Site Freiburg, and German Cancer Research Center (DKFZ), Freiburg, GERMANY, [2]Department of Nuclear Medicine, University Medical Center Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, GERMANY, [3]Faculty of Biology, University of Freiburg, Freiburg, GERMANY, [4]BicycleTx Limited, Cambridge, UNITED KINGDOM, [5]Institute of Molecular Medicine and Cell Research, University of Freiburg, Freiburg, GERMANY.

OP-622
Theranostic role of^{89}Zr/^{177}Lu-labeled aflibercept in triple-negative breast cancer
L. Kang, *Q. Yang, Z. Chen, Y. Qiu, W. Huang, L. Song;*
Peking University First Hospital, Beijing, CHINA.

1305

Tuesday, September 12, 2023, 9:45 AM - 11:15 AM
Hall B

Cutting Edge Science Track - TROP Session: Quantitative SPECT/CT Imaging

OP-623
Comparison of lesion detectability in Whole-Body Bone Scan images: A Monte Carlo study of CdZnTe- and NaI(Tl)-based Gamma Cameras
R. Madru[1], *N. Karindotter-Borgendahl*[2], *M. Dahlbeck*[2], *M. Ljungberg*[3];
[1]Skane University Hospital, Lund, SWEDEN, [2]Skane Sjukhus Nordost, Kristianstad, SWEDEN, [3]Lund University, Lund, SWEDEN.

OP-624
CZT swiveling-detectors ring SPECT enables 3D dynamic acquisitions
M. Hesse, *F. Dupont, R. Lhommel;*
Cliniques Universitaires Saint-Luc, Brussels, BELGIUM.

OP-625
SPECT image reconstruction from sparse projection data using deep learning model trained by randomly generated training phantom
R. Yano[1], *Y. Okura*[2], *M. Yamamoto*[2];
[1]*Graduate School of Medical Technology and Health Welfare Sciences, Hiroshima International University, Higashihiroshima, JAPAN,* [2]*Department of Clinical Radiology Faculty of Health Sciences, Hiroshima International University, Higashihiroshima, JAPAN.*

OP-626
Assessing the Efficacy of the Relative Difference Prior for SPECT Dosimetry
L. Polson;
University of British Columbia, Vancouver, BC, CANADA.

OP-627
Head-to-head comparison of SPECT and MRI based holmium-166 dosimetry
L. E. L. Westlund Gotby[1], *Y. X. Mak*[2], *N. J. M. Klaassen*[1], *J. Roosen*[1], *M. W. M. van Wijk*[1], *M. W. Konijnenberg*[1,3], *M. Abayazid*[2], *J. F. W. Nijsen*[1];
[1]*Department of Medical Imaging, Radboud University Medical Center, Nijmegen, NETHERLANDS,* [2]*Robotics and Mechatronics, University of Twente, Enschede, NETHERLANDS,* [3]*Department of Radiology and Nuclear Medicine, Erasmus Medical Center, Rotterdam, NETHERLANDS.*

OP-628
Holmium-166 SPECT/CT imaging for dosimetry: a multi-center optimization study in the Netherlands
L. E. L. Westlund Gotby[1], *M. Stella*[2], *C. D. E. van Speybroeck*[1], *D. Lobeek*[1], *D. M. V. de Vries-Huizing*[3], *B. J. de Wit-van de Veen*[3], *E. J. Rijkhorst*[4], *R. Wierts*[5], *M. K. Stam*[6], *F. H. P. van Velden*[6], *P. Dibbets-Schneider*[6], *R. van Rooij*[2];
[1]*Department of Medical Imaging, Radboud University Medical Center, Nijmegen, NETHERLANDS,* [2]*Department of Radiology and Nuclear Medicine, University Medical Center Utrecht, Utrecht, NETHERLANDS,* [3]*Department of Nuclear Medicine, NETHERLANDS Cancer Institute, Amsterdam, NETHERLANDS,* [4]*Department of Medical Physics and Technology, NETHERLANDS Cancer Institute, Amsterdam, NETHERLANDS,* [5]*Department of Radiology and Nuclear Medicine, Maastricht University Medical Center, Maastricht, NETHERLANDS,* [6]*Department of Radiology, Leiden University Medical Center, Leiden, NETHERLANDS.*

OP-629
Quantitative ^{177}Lu SPECT/CT imaging with a ring-shaped CZT-based camera: 208 vs 113 keV photopeak
R. Danieli[1], *M. Stella*[2], *C. Marin*[1], *J. Tran Gia*[3], *J. Leube*[3], *C. Uribe-Munoz*[4], *M. Hesse*[5], *H. Levillain*[1], *B. Vanderlinden*[1], *N. Reynaert*[1], *P. Flamen*[1];
[1]*Institut Jules Bordet, Bruxelles, BELGIUM,* [2]*GE HealthCare, Diegem, BELGIUM,* [3]*University Hospital Würzburg, Würzburg, GERMANY,* [4]*University of British Columbia, Vancouver, BC, CANADA,* [5]*Cliniques Universitaires Saint-Luc, Bruxelles, BELGIUM.*

OP-630
Hyperthyroidism Etiological Diagnosis: a Multilabel Classification using Convolutional Neural Networks on Thyroid Scans
M. Abdi[1], *Q. Naili*[1], *M. Habbeche*[1], *M. Bourouba*[2], *S. Berrani*[3];
[1]*Centre d'imagerie scintigraphique Blida, Blida, ALGERIA,* [2]*Clinique Fatema Al Azhar, Alger, ALGERIA,* [3]*National Polytechnic School of Algiers (Ecole Nationale Polytechnique), Algiers, ALGERIA.*

OP-631
Fundamental study on brain SPECT denoising using deep image prior
T. Zeniya[1], *A. Yabe*[1], *Y. Aita*[1], *K. Matsubara*[2], *K. Koshino*[3], *H. Watabe*[4], *T. Yuasa*[5];
[1]*Hirosaki University, Hirosaki, JAPAN,* [2]*Akita Prefectural University, Yurihonjo, JAPAN,* [3]*Hokkaido Information University, Ebetsu, JAPAN,* [4]*Tohoku University, Sendai, JAPAN,* [5]*Yamagata University, Yonezawa, JAPAN.*

1306

Tuesday, September 12, 2023, 9:45 AM - 11:15 AM
Hall C

Clinical Oncology Track - TROP Session: Lung

OP-632
Residual total metabolic tumor volume, assessed on post-therapeutic 18F-FDG PET/CT, is a game-changer in the early monitoring of patients with metastatic non-small cell lung cancer treated with immunotherapy.
P. Tricarico;
Centre Antoine Lacassagne, Nice, FRANCE.

OP-633
Predictive value of primary tumor metabolic heterogeneity of ^{18}F-FDG PET/CT for lung cancer progression
X. Li[1,2], *M. Hou*[3], *X. Wang*[1,2], *C. Cui*[1,2], *Z. Wu*[1,2];
[1]*Department of Nuclear Medicine, First Hospital of Shanxi Medical University, Taiyuan, Shanxi, CHINA,* [2]*Collaborative Innovation Center for Molecular Imaging of Precision Medicine Shanxi Medical University, Taiyuan, Shanxi, CHINA,* [3]*Department of Respiratory, First Hospital of Shanxi Medical University, Taiyuan, Shanxi, CHINA.*

OP-634
Prognostic role of pre-operative 18F-FDG PET/CT in surgically treated patients with early-stage non-small-cell lung cancer
S. Taralli[1], *F. Vocaturo*[1,2], *E. Perrone*[1,2], *P. C. Pafundi*[3], *S. Ricciardi*[4], *G. Cardillo*[4], *M. L. Calcagni*[1,2];
[1]*Nuclear Medicine Unit, Diagnostic Imaging, Radiation Oncology and Hematology Department, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, ITALY,* [2]*Nuclear Medicine Institute, University Department of Radiological and Hematological Sciences, Università Cattolica del Sacro Cuore, Rome, ITALY,* [3]*Epidemiology and Biostatistics Research Core Facility, GEMELLI GENERATOR, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, ITALY,* [4]*Thoracic Surgery Unit, San Camillo Forlanini Hospital, Rome, ITALY.*

OP-635
The variability and diagnostic value of respiratory-gated 4D PET/CT based radiomics features in lung lesions compared to ungated PET/CT
S. Huang[1], *C. Cao*[2], *L. Guo*[1], *C. Li*[1], *W. Mu*[2,3], *Y. Liang*[1,4];
[1]*National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, CHINA,* [2]*School of Engineering Medicine, Beihang University, Beijing, CHINA,* [3]*Key Laboratory of Big Data-Based Precision Medicine, Ministry of Industry and Information Technology of the People's Republic of China, Beijing, CHINA,* [4]*National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, CHINA.*

OP-636
Improved imaging of small lung nodules using LAFOV [^{18}F]FDG-PET and data-driven motion compensation method
C. Bregenzer[1], *C. Mingels*[1], *M. Viscione*[1], *H. Sari*[1,2], *K. Shi*[1], *A. Rominger*[1], *T. Pyka*[1];
[1]*Department of Nuclear Medicine, Inselspital, University Hospital Bern, University of Bern, Bern, SWITZERLAND,* [2]*Advanced Clinical Imaging Technology, Siemens Healthcare AG, Lausanne, SWITZERLAND.*

OP-637
Predicting survival of metastatic non-small cell lung cancer (NSCLC) patients treated by anti-PD-1 by combining clinical and radiomic features
J. Auriac[1], *N. Captier*[1], *E. Woff*[1,2], *M. Luporsi*[1,3], *C. Nioche*[1], *N. Girard*[4], *I. Buvat*[1], *F. Orlhac*[1];
[1]*Institut Curie, Inserm, Université Paris-Saclay, U1288-LITO, Orsay, FRANCE,* [2]*Université libre de Bruxelles, Jules Bordet Institut, Department of Nuclear Medicine, Bruxelles, BELGIUM,* [3]*Institut Curie, Department of Nuclear Medicine, Paris, FRANCE,* [4]*Institut du Thorax Curie-Montsouris, Paris, FRANCE.*

OP-638
Variables Derived From 18F-FDG PET/CT In Predicting Patterns Of Recurrence In Patients With Non-Small Cell Lung Cancer (Stage I-III)
G. Jimenez Londoño[1], *A. M. Garcia Vicente*[2], *J. J. Bosque*[3], *J. Perez-Beteta*[3], *M. Amo-Salas*[4], *A. F. Honguero-Martinez*[5], *E. Noriega Alvarez*[1], *C. Lucas Lucas*[1], *V. M. Perez-Garcia*[3], *A. M. Soriano Castrejon*[2];
[1]*Department of Nuclear Medicine, Hospital General Universitario de Ciudad Real, Ciudad Real, SPAIN,* [2]*Department of Nuclear Medicine, Complejo Hospitalario Universitario de Toledo, Toledo, SPAIN,* [3]*Department of Mathematics, Mathematical Oncology Laboratory (MOLAB), Universidad de Castilla-La Mancha, Ciudad Real, SPAIN,* [4]*Department of Mathematics, Universidad de Castilla-La Mancha, Ciudad Real, SPAIN,* [5]*Department of Surgery, Hospital General Universitario de Albacete, Albacete, SPAIN.*

OP-639
18F-FDG PET/CT and Coefficient of Variation of Primary Tumors and Metastatic Lymph Nodes To Assess the Heterogeneity of Glycolytic Phenotype in Patients With Advanced NSCLC
S. Pellegrino[1], *R. Fonti*[1], *C. Vallone*[1], *A. Catapano*[1], *R. Morra*[2], *S. De Placido*[2], *S. Del Vecchio*[1];
[1]*Department of Advanced Biomedical Sciences, University Federico II, Naples, ITALY,* [2]*Department of Clinical Medicine and Surgery, University Federico II, Naples, ITALY.*

OP-640
Use of 18F-FDG PET Imaging after Curative Treatment of Non-Small Cell Lung Cancer Patients: A Nationwide Cohort Study
K. Guldbrandsen[1], *L. Sopina*[2], *T. R. Rasmussen*[3], *B. M. Fischer*[1];
[1]*Dept. of Clinical Physiology, Nuclear Medicine & PET, Copenhagen University Hospital, Rigshospitalet, Copenhagen, DENMARK,* [2]*Danish Centre for Health Economics, DaCHE, Dept. of Public Health, University of Southern Denmark, Odense, DENMARK,* [3]*Department of Respiratory Diseases and Allergy, Aarhus University Hospital, Aarhus, DENMARK.*

1307

Tuesday, September 12, 2023, 9:45 AM - 11:15 AM
Hall F1

Cardiovascular Committee - TROP Session: Plaque, Fibrosis and Cardio-Oncology

OP-641
Value of Na[18F]F and 2-[18F]FDG PET/CT imaging in early stages of aortic valve degeneration assessment after transcatheter aortic valve (TAVI) implantation
M. Opalinska[1], *D. Sorysz*[2], *A. Sowa-Staszczak*[1], *A. Grochowska*[3], *A. Dziewierz*[2], *K. Malinowski*[4], *N. Maruszak*[2], *M. Bagieński*[5], *S. Bartus*[2], *D. Dudek*[6];
[1]*Department of Endocrinology, Jagiellonian University Medical College, Krakow, POLAND,* [2]*2nd Department of Cardiology, Institute of Cardiology, Jagiellonian University Medical College, Krakow, POLAND,* [3]*Department of Radiology, University Hospital, Krakow, POLAND,* [4]*Department of Bioinformatics and Telemedicine, Jagiellonian University Medical College, Krakow, POLAND,* [5]*Intensive Cardiac Care Unit, University Hospital, Krakow, POLAND,* [6]*Center for Digital Medicine and Robotics, Jagiellonian University Medical College, Krakow, POLAND.*

OP-642
The relationship between arterial calcification and hypoxia of the arterial wall detected by [^{18}F]F-Fluoromisonidazole Positron Emission Tomography
J. Bellinge[1,2], *I. Barry*[3], *R. Francis*[1,2], *F. Picazo-Pineda*[3], *N. Altaf*[3], *C. Schultz*[1,3];
[1]*University of Western Australia, Perth, AUSTRALIA,* [2]*Sir Charles Gairdner Hospital, Perth, AUSTRALIA,* [3]*Royal Perth Hospital, Perth, AUSTRALIA.*

OP-643
Morphological and component features of advanced carotid plaque on MRI in correlation with inflammation on PET: a hybrid ^{18}F-FDG PET/MRI study
F. Yu, *Y. Zhang, J. Lu;*
Xuanwu Hospital, Capital Medical University, Beijing, CHINA.

OP-644
Comparison between Cardiac ^{18}F-FAPI PET/CT and MRI for Assessment of Myocardial Fibrosis in Hypertrophic Cardiomyopathy
L. Wang[1], *Y. Wang*[2], *Y. Zhang*[1], *Z. Dong*[3], *J. Wang*[3], *X. Xi*[1], *B. Chen*[1], *S. Zhao*[3], *M. Yang*[1];
[1]*Beijing Chaoyang Hospital, Beijing, CHINA,* [2]*Beijing Tsinghua Changgung Hospital, Beijing, CHINA,* [3]*Fuwai Hospital, Beijing, CHINA.*

OP-645
Coronary microvascular dysfunction: main characteristics and prognostic value
K. Kopeva, *E. Grakova, A. Maltseva, A. Mochula, A. Gusakova, A. Smorgon, K. Zavadovsky;*
Cardiology Research Institute, branch of the Federal State Budgetary Scientific Institution «Tomsk National Research Medical Center of the Russian Academy of Sciences», Tomsk, RUSSIAN FEDERATION.

OP-646
Comparative analysis of multi-modality cardiac imaging for prediction of cardiovascular outcomes in patients undergoing coronary artery bypass grafting
M. Gao[1], *W. Wen*[2], *J. Meng*[2], *M. Yun*[2], *H. Li*[1], *Y. Yu*[1], *X. Zhang*[2];
[1]*Department of Cardiac Surgery, Beijing Anzhen Hospital, Capital Medical University, Beijing, CHINA,* [2]*Department of Nuclear Medicine, Molecular Imaging Lab, Beijing Anzhen Hospital, Capital Medical University, Beijing, CHINA.*

OP-647
Coronary artery calcium score and epicardial adipose tissue from unenhanced whole-body PET-CT imaging in oncological patients with and without standard modifiable cardiovascular risk factors
C. Vallone[1], *C. Nappi*[1], *R. Lepre*[1], *L. Basile*[1], *A. Ponsiglione*[1], *C. Ferraioli*[1], *R. Green*[1], *V. Cantoni*[1], *C. Mainolfi*[1], *M. Imbriaco*[1], *M. Petretta*[2], *A. Cuocolo*[1];
[1]*Department of Advanced Biomedical Sciences, University of Naples Federico II, Naples, ITALY,* [2]*IRCCS Synlab SDN, Naples, ITALY.*

OP-648
Immune checkpoint inhibitor treatment may induce abated reactive arterial inflammation in lung cancer patients with history of sysmatic therapy: trained immunity before immunotherapy?
R. Calabretta, *L. Beer, H. Prosch, D. Kifjak, P. Binder, S. Grünert, W. Langsteger, M. Mitterhauser, X. Li, M. Hacker;*
Medical University of Vienna, Vienna, AUSTRIA.

OP-649
Leg-muscle perfusion preserve on 99mTc-MIBI stress-rest scintigraphy : the novel use of radionuclide imaging in peripheral arterial disease
G. Parida, *T. Singhal, P. Singh, P. Kumar, R. Emerson, K. Bishnoi, A. Rehaman, S. Patro, K. Agrawal;*
All India Institute Of Medical Sciences, Bhubaneswar, INDIA.

1308

Tuesday, September 12, 2023, 9:45 AM - 11:15 AM
Hall F2

Thyroid Committee - TROP Session: ^{18}F-FDG and Novel Tracers in the Diagnostic Management of Patients with Thyroid Cancers

OP-650
Investigating the role of F18-FDG PET/CT and Ga68 DOTATOC PET/CT in the evaluation of differentiated thyroid cancer patients with increased serum thyroglobulin and negative I-131 whole body scan
A. Aghaee, *K. Aryana, M. Esmatinia, V. Roshan Ravan;*
Nuclear Medicine Research Center,Mashhad University Of Medical Sciences, Mashhad, IRAN, ISLAMIC REPUBLIC OF.

OP-651
Exploring the role of new angiogenic tracer, ^{68}Ga DOTAGA- IAC and comparison of its diagnostic performance with ^{18}F-FDG PET/CT in patients with radioiodine refractory differentiated thyroid carcinoma
S. Ananth Kumar, *A. Sood, J. Shukla, R. Kumar, P. Aggarwal, B. Rai Mittal;*
Postgraduate Institute Of Medical Education and Research, Chandigarh, Chandigarh, INDIA.

OP-652
Lactate dehydrogenase A is associated with glucose metabolism, radioiodine avidity and prognosis in differentiated thyroid cancer
T. Tian, *H. Dai, R. Huang;*
West China Hospital, Sichuan University, Chengdu, CHINA.

OP-653
The Complementary Role of PSMA Expression and [^{18}F]FDG PET/CT in Predicting Thyroid Cancer Outcome — from Black and White to Shades of Grey, in the Era of Precision Oncology
C. Pini[1], *M. Sollini*[2,3], *M. Kirienko*[4], *L. Di Tommaso*[2,5], *F. Gelardi*[2,3], *S. Ariano*[2,6], *C. Landoni*[1,7], *A. G. Lania*[2,6], *G. Mazziotti*[2,6], *G. Mercante*[2,8], *A. Chiti*[2,3];
[1]*School of Medicine and Surgery, University of Milano-Bicocca, Monza, ITALY,* [2]*Department of Biomedical Sciences - Humanitas University, Pieve Emanuele, ITALY,* [3]*Nuclear Medicine – IRCCS Humanitas Research Hospital, Rozzano, ITALY,* [4]*Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, ITALY,* [5]*Pathology - IRCCS Humanitas Research Hospital, Rozzano, ITALY,* [6]*Endocrinology - IRCCS Humanitas Research Hospital, Rozzano, ITALY,* [7]*Nuclear Medicine Department, IRCCS Monza, San Gerardo Hospital, Monza, ITALY,* [8]*Otorhinolaryngology, IRCCS Humanitas Research Hospital, Rozzano, ITALY.*

OP-654
Prospective study on the usefulness of 18FDOPA PET-CT in the management of medullary thyroid cancer patients with higt residual calcitonin rate after surgery
M. Terroir Cassou Mounat[1], *A. Lusque*[1], *E. Hindié*[2], *D. Taieb*[3], *L. Vija*[1], *J. Sarini*[1], *F. Courbon*[1], *A. Decotte*[4], *S. Grunenwald*[5], *S. Zerdoud*[1];
[1]*IUCT Oncopole, toulouse, FRANCE,* [2]*University Hospital of Bordeaux, Bordeaux, FRANCE,* [3]*La Timone University Hospital, Marseille, FRANCE,* [4]*University Hospital Rangueil-Larrey, toulouse, FRANCE,* [5]*Centre Hospitalier Universitaire de Toulouse, toulouse, FRANCE.*

OP-655
CCK$_2$-receptor targeted PET/CT in patients with medullary thyroid cancer using [^{68}Ga]Ga-DOTA-CCK-66 - First clinical experience
O. Viering[1], *T. Günther*[2], *N. Holzleitner*[2], *H. Wester*[2], *A. Dierks*[1], *M. Kircher*[1], *G. Wienand*[1], *C. H. Pfob*[1], *R. A. Bundschuh*[1], *C. Lapa*[1];
[1]*Nuclear Medicine, faculty of medicine, University of Augsburg, Augsburg, GERMANY,* [2]*Chair of Pharmaceutical Radiochemistry, Technische Universität München, Munich, GERMANY.*

OP-656
PET/CT imaging of differentiated and medullary thyroid carcinoma using the novel SSTR-targeting peptide [^{18}F]SiTATE - first clinical experiences
S. Kunte[1], *V. Wenter*[1], *G. T. Sheikh*[1], *M. Unterrainer*[1], *S. Lindner*[1], *J. Toms*[1], *K. Jurkschat*[2], *C. Wängler*[3], *B. Wängler*[3], *R. Schirrmacher*[4], *J. Rübenthaler*[1], *C. J. Auernhammer*[1], *C. Spitzweg*[1], *P. Bartenstein*[1], *A. Holzgreve*[1], *L. M. Unterrainer*[1];
[1]*LMU, Munich, GERMANY,* [2]*Technische Universität Dortmund, Dortmund, GERMANY,* [3]*Medizinische Fakultät Mannheim der Universität Heidelberg, Mannheim, GERMANY,* [4]*University of Alberta, Edmonton, Edmonton, AL, CANADA.*

OP-657
Clinical Impact of Ga68-DOTATATE PET/CT Imaging in Medullary Thyroid Carcinoma, a retrospective single center study
A. Abdelrahman, *R. Akinlusi, S. Gavane;*
Icahn School of Medicine at Mount Sinai, New York, NY, UNITED STATES OF AMERICA.

OP-658
18f tetrafluoroborate-pet in evaluation of thyroid cancer patients: preliminary results
K. Saglam, *O. Sahin, E. Karayel, H. Pehlivanoglu, R. Uslu Besli, A. Aygun, S. Asa, K. Sonmezoglu;*
Istanbul Univercity-Cerrahpasa Cerrahpasa Medical Faculty, Istanbul, TÜRKIYE.

1309

Tuesday, September 12, 2023, 9:45 AM - 11:15 AM
Hall G2

e-Poster Presentations Session 10 - Oncology & Theranostics Committee: Haematological and Abdominal Malignancies / localised Treatments

EPS-189
Role of 68Ga-DOTATATE PET/CT Quantitative Parameters in the Differential Diagnosis of Adrenal Lesions
D. Denizmen[1], *D. Has Simsek*[1], *E. G. Isık*[1], *H. Hacısahinogulları*[2], *S. Kuyumcu*[1];
[1]*Istanbul University Istanbul Faculty of Medicine Nuclear Medicine Department, Istanbul, TÜRKIYE,* [2]*Istanbul University Istanbul Faculty of Medicine Endocrinology and Metabolic Diseases Department, Istanbul, TÜRKIYE.*

EPS-190
Role of ^{68}Ga-PSMA-11 PET/CT in staging metastatic renal cell cancer: A pilot study
P. Aggarwal, *H. Singh, C. K. Das, R. S. Mavuduru, A. Lal, N. Kakkar, R. Kumar, U. Gorsi, B. R. Mittal;*
Post Graduate Institute of Medical Education and Research, Chandigarh, INDIA.

EPS-191
Incremental value of ^{68}Ga-FAPI-04 to dual-tracer PET/CT for the evaluation of hepatobiliary masses with indeterminate CT/MR findings
I. Ho[1,2], *S. Chen*[2], *K. Cheng*[2], *K. Wu*[2], *C. Ho*[2];
[1]*The Chinese University of Hong Kong, Hong Kong, HONG KONG,* [2]*Hong Kong Sanatorium & Hospital, Hong Kong, HONG KONG.*

EPS-192
Utility of CT-free attenuation and scatter correction in dual-tracer PET/CT for Evaluation of Gastric Cancer
S. Xue[1], *Y. Miao*[2], *M. Viscione*[1], *H. Wang*[2], *A. Rominger*[1], *R. Guo*[2], *B. Li*[2], *K. Shi*[1];
[1]*University of Bern, Bern, SWITZERLAND,* [2]*Shanghai Jiao Tong University School of Medicine, Shanghai, CHINA.*

EPS-193
^{68}Ga-NY104 PET/CT in patients with recurrent/metastatic clear cell renal cell carcinoma suspicion: a comparative study with ^{18}F-FDG
W. Zhu, *X. Li, Y. Zhang, L. Huo;*
Peking Union Medical College Hospital, Beijing, CHINA.

EPS-194
First-in-human validation of enzymolysis clearance strategy for decreasing renal radioactivity using modified 68Ga-HER2 Affibody
M. Zhang, *T. Xing, J. Wang, T. Ma, G. Li, Z. Quan, W. Yang, F. Kang, J. Wang;*
Department of Nuclear Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, CHINA.

EPS-195

Biodistribution of Monoclonal Antibodies: Defining New Baselines for ^{89}Zr-Immuno-PET-Derived Target Engagement In Vivo.

H. J. Sebus[1,2], *J. E. Wijngaarden*[3,2], *I. H. C. Miedema*[1,2], *J. J. Eertink*[1,2], *I. Bahce*[4], *A. J. De Langen*[4,5], *E. F. Smit*[6], *M. Cleveland*[7], *D. J. Vugts*[3], *G. J. C. Zwezerijnen*[3,2], *M. C. Huisman*[3,2], *C. W. Menke - van der Houven van Oordt*[1,2];
[1]*Amsterdam UMC location Vrije Universiteit Amsterdam, Medical Oncology, De Boelelaan 1117, Amsterdam, NETHERLANDS,* [2]*Cancer Center Amsterdam, Imaging & Biomarkers, Amsterdam, NETHERLANDS,* [3]*Amsterdam UMC location Vrije Universiteit Amsterdam, Department of Radiology and Nuclear Medicine, Boelelaan 1117, Amsterdam, NETHERLANDS,* [4]*Department of Pulmonary Diseases, Cancer Center Amsterdam, Amsterdam University Medical Centers, Amsterdam, NETHERLANDS,* [5]*Department of Thoracic Oncology, NKI-AvL, Amsterdam, NETHERLANDS,* [6]*Department of Pulmonology, Leiden University Medical Center, Leiden, NETHERLANDS,* [7]*Bioimaging, Platform Technology and Science, GlaxoSmithKline, Stevenage, UNITED KINGDOM.*

EPS-196

Smouldering multiple myeloma: progression to symptomatic disease predicted by 18F-FDG PET-CT

C. Caldarella[1], *S. Taralli*[1], *F. Cocciolillo*[1], *T. Za*[2], *V. De Stefano*[2,3], *M. L. Calcagni*[1,4];
[1]*Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, UOC di Medicina Nucleare, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, ITALY,* [2]*Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, UOC Servizio e Day Hospital di Ematologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, ITALY,* [3]*Dipartimento di Scienze Radiologiche ed Ematologiche, Istituto di Ematologia, Università Cattolica del Sacro Cuore, Rome, ITALY,* [4]*Dipartimento di Scienze Radiologiche ed Ematologiche, Istituto di Medicina Nucleare, Università Cattolica del Sacro Cuore, Rome, ITALY.*

EPS-197

A novel prognostic index for diffuse large B-cell lymphoma combined baseline metabolic tumour volume with clinical and pathological risk factors

T. Yuan, *X. Chen, Y. Zhang, M. Wei, H. Zhu, Z. Yang, X. Wang;*
Peking University Cancer Hospital & Institute, Beijing, CHINA.

EPS-198

Lung dose prediction in radioembolization: ^{166}Ho-microspheres scout for ^{166}Ho-microspheres treatment vs. ^{99m}Tc-MAA scout for ^{90}Y-microspheres treatment

M. Wagemans, *R. van Rooij, A. J. A. T. Braat, M. L. J. Smits, R. C. G. Bruijnen, H. W. A. M. de Jong, M. G. E. H. Lam;*
Department of Radiology and Nuclear Medicine, UMC Utrecht,
Utrecht, NETHERLANDS.

EPS-199

Comparison of response evaluation criteria in diffuse large B-cell lymphoma: Lugano versus RECIL, and PERCIST

P. Tang, *R. Tian, M. Su;*
Department of Nuclear Medicine, West China Hospital, Sichuan University, Chengdu, CHINA.

EPS-200

Voxel-Based Dosimetry with Integrated Y-90 PET/MRI Following TARE with Glass Microspheres and Dose-Response Relationships - Preliminary Results

B. Demir[1], *E. C. Celebioglu*[2], *C. Soydal*[1], *N. O. Kucuk*[1], *D. Kuru Oz*[2], *M. S. Bilgic*[2], *K. M. Kir*[1];
[1]*Ankara University School of Medicine Department of Nuclear Medicine, Ankara, TÜRKIYE,* [2]*Ankara University School of Medicine Department of Radiology, Ankara, TÜRKIYE.*

EPS-201

Dose Distribution Pattern of Fractionally Administered Transarterial Radioembolization Holmium Microspheres in Non-Tumorous Human Liver Tissue

A. van den Brekel[1], *T. J. Snoeijink*[1], *J. Roosen*[1], *S. J. S. Ruiter*[2], *V. E. de Meijer*[2], *J. F. W. Nijsen*[1];
[1]*Department of Medical Imaging, Radboud University Medical Center, Nijmegen, NETHERLANDS,* [2]*Department of HPB Surgery and Liver Transplantation, University of Groningen, University Medical Center Groningen, Groningen, NETHERLANDS.*

EPS-202

Can Circulating Angiogenic Factors Predict ^{90}Y Microsphere Treatment Outcomes ?

M. Mavi[1], *B. Volkan Salanci*[2], *I. Lay*[3], *F. G. Eldem*[4], *B. Peynircioğlu*[4], *S. Yalçın*[5], *Ö. Uğur*[2], *M. F. Bozkurt*[2];
[1]*Karaman Training and Research Hopital Nuclear Medicine Department, Karaman, TÜRKIYE,* [2]*Hacettepe University Nuclear Medicine Department, Ankara, TÜRKIYE,* [3]*Hacettepe University Medical Biochemistry Department, Ankara, TÜRKIYE,* [4]*Hacettepe University Interventional Radiology Department, Ankara, TÜRKIYE,* [5]*Hacettepe University Medical Oncology Department, Ankara, TÜRKIYE.*

EPS-203

Improvement of minimally invasive parathyroidectomy through the introduction of radioguided surgical approach.

A. Alomar, *I. Blanco, I. Saura, J. Cruz, A. Barrera, P. Salvador, E. Anda, N. Rudic, F. Lozada, M. Ribelles, A. Camarero, E. Goñi;*
Hospital Universitario de Navarra (HUN), Pamplona, SPAIN.

EPS-204

^{188}Re-N-DEDC lipiodol trans-arterial radionuclide therapy (TART) in HCC patients: Modification in lung Shunt fraction (LSF) criteria and clinical implication on therapeutic dose estimation using scout dose of ^{188}Re-N DEDC lipiodol

N. Kumar, *P. Gupta, S. A. Shamim, S. Gamanagatti, S. Shalimar, C. Bal;*
All India Institute of Medical Sciences, New Delhi, INDIA.

EPS-205

A controlled administration device for MRI-guided holmium-166 transarterial radioembolisation: MR-safe and fractional microsphere administration

M. W. M. van Wijk[1], *G. van Wolfswinkel*[2], *J. Roosen*[1], *M. J. Arntz*[1], *M. J. R. Janssen*[1], *J. F. W. Nijsen*[1];
[1]*Department of Medical Imaging, Radboud university medical center, Nijmegen, NETHERLANDS,* [2]*R&D TIO, Quirem Medical B.V. - a Terumo company, Deventer, NETHERLANDS.*

EPS-206

NOBLE (Nobody Left Behind) Registry: Initial Experience of [^{99m}Tc]Tc-HYNICiPSMA Imaging in the Detection of Prostate Cancer

S. Martina[1], *P. Tually*[2], *V. Garcia Quinto*[3], *Y. Omar*[4], *R. Yudistiro*[5], *M. Sathekge*[6], *G. Currie*[7], *P. Galette*[1], *N. Patel*[1], *T. Brown*[1], *G. Bolland*[8], *R. Lo bue*[8], *C. Hayward*[1];
[1]*Telix Pharmaceuticals, Melbourne, AUSTRALIA,* [2]*TeleMed Nuclear Imaging, Kalgoorlee, AUSTRALIA,* [3]*Hospital Galenia, Cancun, MEXICO,* [4]*Misr Rediology Center, Cairo, EGYPT,* [5]*Siloam International Hospitals, Tangerang, INDONESIA,* [6]*University of Pretoria, Pretoria, SOUTH AFRICA,* [7]*Charles Sturt Univeristy, Wagga Wagga, AUSTRALIA,* [8]*Oncidium Foundation, Brussels, BELGIUM.*

EPS-207

BPH-related False Positive of [^{68}Ga]Ga-PSMA PET/CT in the Diagnosis of Prostate Cancer: the Achilles' Heel of Biopsy-free Radical Prostatectomy?

Y. Tang, *L. Xiao, J. Yang, J. Hou, B. Chen, S. Hu;*
Xiangya Hospital Central South University, Changsha, CHINA.

EPS-208

FDG-PET/CT for lymph node staging prior to radical cystectomy

M. Markus[1], *V. Pihl*[2], *F. Liedberg*[2], *E. Trägårdh*[1];
[1]*Clinical Physiology and Nuclear Medicine, Malmö, SWEDEN,* [2]*Department of Urology, Malmö, SWEDEN.*

EPS-209

One-day dual-tracer PET/CT protocol with [68Ga]-DOTA-FAPI-04 for negative orequivocal [18F]FDG

H. Li, *Z. Xiao, C. Li, Y. Tian, N. Lu, J. Chen, D. Xing, Y. He;*
Zhongnan Hospital of Wuhan University, Wuhan, CHINA.

1310

Tuesday, September 12, 2023, 9:45 AM - 11:15 AM
Hall K

Technologists Oral Presentations 3: NM Technologists: Competencies and Training

OP-659

Technologists´ interests and barriers toward healthcare research.

C. H. Led[1], *C. Baun*[1,2], *M. G. Hildebrandt*[1,2];
[1]*Department of Nuclear Medicine, Odense C, DENMARK,* [2]*Department of Clinical Research, University of Southern Denmark, Odense, DENMARK.*

OP-660

Framework for Online Radiographer Clinical Education (FORCE): results of students' evaluation of the Nuclear Medicine strand

P. Costa[1], *J. Lemos*[1], *R. Strudwick*[2], *P. Bezzina*[3], *N. Dalen*[4], *J. T. Huhtanen*[5], *M. Jaronen*[6], *T. Saila*[6], *C. Kamp*[7], *L. Rainford*[8], *K. Matthews*[8];
[1]*Nuclear Medicine Department, School of Health - Polytechnic Institute of Porto (ESS\|P.Porto), Porto, PORTUGAL,* [2]*School of Health and Sports Sciences - University of Suffolk, Suffolk, UNITED KINGDOM,* [3]*Faculty of Health Sciences - University of Malt, Msida, MALTA,* [4]*Department of Health and Functioning - Western Norway University of Applied Sciences, Bergen, NORWAY,* [5]*Health and Well-being, Rehabilitation, Oral Health Care and Diagnostic Services - Turku University of Applied Sciences, Turku, FINLAND,* [6]*Social Services and Health Care - Tampere University of Applied Sciences, Tampere, FINLAND,* [7]*University of Applied Sciences FH Campus Wien, Wien, AUSTRIA,* [8]*School of Medicine - University College Dublin, Dublin, IRELAND.*

OP-661

The evolution of our PSMA PET imaging service

L. Thomas;
St Vincent's Hospital Melbourne, Melbourne, AUSTRALIA.

OP-662

Comparison of calculated Left Ventricular Ejection Fraction (LVEF) from F-18 FDG dual-gated PET/CT, single-gated PET/MRI, and cardiac MRI

P. Toompong, *A. Jantarato, D. Siripongsatian, P. Panperee, C. Promteangtrong, A. Kunawudh, P. Kiatkittikul, P. Lerdsirisuk, S. Sombon, C. Chotipsnich;*
National Cyclotron and PET Centre, Bangkok, THAILAND.

OP-663

A. Resende Geao, *A. Santos, P. Colarinha;*
Hospital Cuf Descobertas, Lisboa, PORTUGAL.

OP-664

Short and long-term outcomes prediction using baseline FDG PET imaging in mCRPC patients treated with ^{177}Lu-PSMA radioligand therapy

Q. Shagera, *C. Broeckaert, T. Guiot, E. Barraco, S. Albeaini, L. Taraji, I. Karfis, P. Flamen, C. Artigas;*
Jules Bordet Institute, Université Libre de Bruxelles (ULB), Brussels, BELGIUM.

OP-665

Comparison of non-specific bone uptake of [^{18}F] AIF-PSMA-11 in prostate cancer patients acquired at different time intervals.

I. Cordero[1,2], *K. Suanes*[1,2], *P. Duarte*[1], *O. Alonso*[1,2];
[1]*Centro Uruguayo de Imagenología Molecular, Montevideo, URUGUAY,* [2]*Unidad Académica de Medicina Nuclear e Imagenología Molecular, Facultad de Medicina, Universidad de la República, Montevideo, URUGUAY.*

OP-666

The relentless pursuit for the best compromise between image quality and dose reduction - a single center experience with pediatric patients undergoing 18F-FDG PET/CT with long axial field of view scanner

A. Cardoso, *A. Mendes, C. Bregenzer, K. Krieger, H. Sari, K. Zeimpekis, N. Gözlügöl, A. Rominger, A. Afshar-Oromieh;*
Department of Nuclear Medicine, Inselspital, University Hospital Bern, University of Bern, Bern, SWITZERLAND.

OP-667

Measuring GFR Using ^{51}Cr-EDTA: a Clinical Case Requiring Gamma Ray Spectra Analysis

P. Geleijnse, *S. Jentjens, K. Goffin, W. Deckers, K. Baete;*
Nuclear Medicine, University Hospitals Leuven, Leuven, BELGIUM.

1311

Tuesday, September 12, 2023, 9:45 AM - 11:15 AM
Hall G1

Theranostics Track - TROP Session: What's New in Neuroendocrine Tumors?

OP-668
Primary tumor resection followed by PRRT in the treatment of patients with metastatic neuroendocrine ileal cancer: preliminary data from a retrospective single center study.
F. Mattana[1], *G. A. Zuccotti*[1], *A. Barone*[1], *E. Pisa*[2], *N. Fazio*[3], *U. Fumagalli Romario*[4], *C. M. Grana*[1], *F. Ceci*[1,5], *E. Bertani*[4];
[1]*IEO European Institute of Oncology, Nuclear Medicine, Milano, ITALY,* [2]*IEO European Institute of Oncology, Pathology, Milano, ITALY,* [3]*IEO European Institute of Oncology, Division of Gastrointestinal Medical Oncology, Milano, ITALY,* [4]*IEO European Institute of Oncology, Division of Digestive Surgery, Milano, ITALY,* [5]*Department of Oncology and Hemato-Oncology, University of Milan, ITALY.*

OP-669
First results from IEO 676 clinical study of PRRT in neuroendocrine tumors: is there still space for Y-90-DOTATOC?
C. Grana, *A. Barone, S. Papi, P. Rocca, S. Fracassi, M. Ferrari, F. Botta, F. Mattana, F. Ceci, C. Fodor, F. Spada, I. Clerici, N. Fazio, M. Rubino;*
European Institute of Oncology, IRCCS, Milano, ITALY.

OP-670
Intra-arterial PRRT, a Prospective Clinical Study in NET Patients with Hepatic Metastases
S. Ebbers[1], *M. W. Barentsz*[1], *D. M. V. de Vries-Huizing*[2], *M. W. J. Versleijen*[2], *L. G. Klompenhouwer*[2], *M. E. T. Tesselaar*[2], *M. P. M. Stokkel*[2], *T. Brabander*[3], *H. Hofland*[3], *A. Moelker*[3], *A. J. A. T. Braat*[1], *M. G. E. H. Lam*[1];
[1]*University Medical Center Utrecht, Utrecht, NETHERLANDS,* [2]*Netherlands Cancer Institute, Amsterdam, NETHERLANDS,* [3]*Erasmus Medical Center, Rotterdam, NETHERLANDS.*

OP-671
Diagnostic Performance of [^{18}F]F-meta-fluorobenzylguanidine ([^{18}F]MFBG) PET/CT in Patients with Pheochromocytoma and Paraganglioma
P. Wang[1], *F. Li*[1], *J. Zhang*[2], *H. Jing*[1], *Y. Zhang*[1];
[1]*Peking Union Medical College Hospital, Beijing, CHINA,* [2]*National University of Singapore, Singapore, SINGAPORE.*

OP-672
^{225}Ac-DOTATATE Dosimetry Results from Part 1 of the ACTION-1 Trial
M. Morris[1], *G. Ulaner*[2], *T. Delie*[1], *S. Kotiah*[3], *D. Ferreira*[4], *K. Ma*[1], *J. Rearden*[4], *J. Li*[4], *S. Moran*[4], *E. Sneeden*[4], *B. He*[5], *M. Ghaly*[5], *E. Frey*[6], *A. Scott*[1], *C. Huffman*[1], *G. Sgouros*[6];
[1]*Advanced Molecular Imaging and Therapy, Glen Burnie, MD, UNITED STATES OF AMERICA,* [2]*Hoag Family Cancer Institute, Newport Beach, CA, UNITED STATES OF AMERICA,* [3]*Mercy Medical Center, Baltimore, MD, UNITED STATES OF AMERICA,* [4]*RayzeBio, San Diego, CA, UNITED STATES OF AMERICA,* [5]*5Radiopharmaceutical Imaging and Dosimetry, LLC (Rapid), Baltimore, MD, UNITED STATES OF AMERICA,* [6]*The Russell H. Morgan Department of Radiology and Radiological Science, School of Medicine, Johns Hopkins University, Baltimore, MD, UNITED STATES OF AMERICA.*

OP-673
Early results of^{212}Pb-VMT-α-NET Targeted Alpha Therapy in Metastatic Gastro-entero-pancreatic Neuroendocrine Tumors: First in Human Clinical Experience on Safety and Efficacy
D. Malik[1], *I. Sen*[1], *P. Thakral*[1], *S. Das*[1], *M. Schultz*[2];
[1]*Fortis Memorial research institute (FMRI), Gurugram, INDIA,* [2]*University of Iowa, Iowa, IA, UNITED STATES OF AMERICA.*

OP-674
The increase of LutaThera Therapy posology due to dosimetry could be give a better progression free survival (PFS) in GEPNets patients?
M. Cuomo[1,2], *G. Argiroffi*[2], *A. Lorenzoni*[2], *G. Aliberti*[2], *M. Bagnalasta*[2], *F. Scalorbi*[2], *M. Kirienko*[2], *C. Chiesa*[2], *E. Seregni*[2], *M. Maccauro*[2];
[1]*University of the study of Milan, Milan, ITALY,* [2]*Istituto Nazionale Tumori Milano, Milan, ITALY.*

OP-675
Personalized, dosimetry-based PRRT therapy in patients with neuroendocrine tumors using [177Lu] Lu-DOTA-TATE or [177Lu]Lu/[90Y]Y-DOTA-TATE mixture - the initial results of DUONEN multicenter study
M. Opalinska[1], *G. Kaminski*[2], *M. Dedecjus*[3], *A. Kowalska*[4], *M. Kolodziej*[2], *M. Saracyn*[2], *D. Gasior-Perczak*[4], *W. Lenda-Tracz*[5], *A. Sowa-Staszczak*[1], *A. Borkowska*[6], *A. Budzynska*[7], *A. Kubik*[7], *W. Chalewska*[3], *K. Kacperski*[7], *P. Szubstarska*[7], *P. Garnuszek*[8], *R. Mikolajczak*[8], *A. Hubalewska-Dydejczyk*[1];
[1]*Chair and Department of Endocrinology, Jagiellonian University Medical College, Krakow, POLAND,* [2]*Department of Endocrinology and Isotope Therapy, Military Institute of Medicine - National Research Institute, Warsaw, POLAND,* [3]*Department of Endocrine Oncology and Nuclear Medicine, National Institute of Oncology, Warsaw, POLAND,* [4]*Collegium Medicum, Jan Kochanowski University in Kielce, Kielce, POLAND,* [5]*Department of Endocrinology, Oncological Endocrinology and Nuclear Medicine, University Hospital, Krakow, POLAND,* [6]*Faculty of Health Sciences, Jagiellonian University Medical College, Krakow, POLAND,* [7]*Department of Nuclear Medicine, Military Institute of Medicine - National Research Institute, Warsaw, POLAND,* [8]*Radioisotope Center POLATOM, National Centre for Nuclear Research, Otwock, POLAND.*

OP-676
Quantitative somatostatin receptor image assessment for survival prediction: a full-body, longitudinal, individual lesion analysis of neuroendocrine tumors in patients treated with peptide receptor radiation therapy
V. Santoro-Fernandes[1], *B. Schott*[1], *A. Deatsch*[1], *Q. Keigley*[2], *T. Francken*[1], *R. Meeker*[1], *R. Lyer*[3], *F. Christos*[3], *S. Perlman*[2,4], *R. Jeraj*[1,4];
[1]*Department of Medical Physics, School of Medicine and Public Health, University of Wisconsin, Madison, WI, UNITED STATES OF AMERICA,* [2]*Section of Nuclear Medicine and Molecular Imaging, Department of Radiology, School of Medicine and Public Health, University of Wisconsin, Madison, WI, UNITED STATES OF AMERICA,* [3]*Division of GI Medicine, Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, UNITED STATES OF AMERICA,* [4]*Carbone Cancer Centre, University of Wisconsin, Madison, WI, UNITED STATES OF AMERICA.*

1401

Tuesday, September 12, 2023, 11:30 - 13:00
Hall A

Plenary 4: Diagnostic Imaging: Proven Beyond Doubt?

OP-677
AI technology: FDG PET imaging and lymphomas: a proven certainty
J. Zijlstra;
Amsterdam UMC, Amsterdam, NETHERLANDS.

OP-678
PET imaging in every oncological guideline: what is still missing?
S. Carrilho Vaz;
Champalimaud Foundation, Lisbon, PORTUGAL.

OP-679
Impact without a cure: prospective evidence for diagnostic neuroimaging
A. Drzezga;
UniversityHospital of Cologne, Cologne, GERMANY.

OP-680
Cardiac imaging: prospective studies and the EURECA registry
D. Neglia;
Fondazione CNR/Regione Toscana G. Monasterio, Pisa, ITALY.

OP-681
Cost effectiveness molecular imaging studies
M. Gauthé;
SCINTEP, Grenoble, FRANCE.

OP-682
Real world data: an answer to all questions?
J. Kleesiek;
Institute for AI in Medicine (IKIM), Essen, GERMANY.

1501

Tuesday, September 12, 2023, 15:00 - 16:30
Hall A

CME 11 - Paediatrics Committee: Pediatric Lymphoma and Update on FDG

OP-685
Clinical background on pediatric lymphoma and what do clinicians expect from nuclear medicine
A. Attarbaschi;
St Anna's Kinderspital, Department of Hematology, Vienna, AUSTRIA.

OP-686
Role of Molecular Imaging (FDG PET-CT) in the evaluation pediatric lymphoma patients
P. Ozgen Kiratli;
Hacettepe University Hospital Department of Nuclear Medicine, Ankara, TÜRKIYE.

OP-687
Response to therapy assessment via FDG PET-CT
L. Kurch;
Universityof Leipzig Hospital, Department of Nuclear Medicine, Leipzig, GERMANY.

1502

Tuesday, September 12, 2023, 15:00 - 16:30
Hall D (Arena)

Challenge the Expert 4 - Neuroimaging Committee: Amyloid vs. Tau PET: Which is First in suspected Alzheimer Patients? Germany versus Italy

OP-688
Tau PET first in the AD flow-chart - Germany
H. Barthel;
Department of Nuclear Medicine, University of Leipzig, Leipzig, GERMANY.

OP-689
Challengers case - Germany
K. Messerschmidt;
Department of Nuclear Medicine, Leipzig University Hospital Centre, Leipzig, GERMANY.

OP-690
Challengers case - Germany
J. Gnörich;
Department of Nuclear Medicine, Ludwig Maximillian University Munich, Munich, GERMANY.

OP-691a
Amyloid PET first in the AD flow-chart - Italy
S. Morbelli;
Department of Nuclear Medicine, University of Genoa, Genoa, ITALY.

OP-691b
Challengers case - Italy
G. Polverari;
PET/CT Center, AFFIDEA-IRMET S.P.A., Turin, ITALY.

OP-691c
Challengers case - Italy
A. Martini;
NuclearMedicine Unit, Department of Diagnostic Imaging, N.O.P. - S. Stefano, U.S.L. Toscana Centro, Prato, ITALY.

1503

Tuesday, September 12, 2023, 15:00 - 16:30
Hall E1

LIPS Session 11 - Bone & Joint Committee: Pitfalls and Common Bony Findings in PET-CT/MRI using Novel Tracers

OP-692
PSMA PET/CT - atypical bony patterns using different radioligands - tips on assessment of bone metastases
A. Maurer;
UniversityHospital Zurich, Nuclear Medicine, Zurich, SWITZERLAND.

OP-693
FAPI PET/CT - what should be considered in interpretation of bony lesion?
K. Pabst;
UniversityHospital Essen, Nuclear Medicine, Essen, GERMANY.

OP-694
PET/MRI - Pitfalls and normal variations in assessment of bone metastases
S. Wan;
Institute of Nuclear Medicine, University College London, London, UNITED KINGDOM.

1504

Tuesday, September 12, 2023, 3:00 PM - 4:30 PM
Hall E2

M2M Track - TROP Session: Imaging the Components of the TME

OP-697
STING-targeted PET Tracer for Early Assessment of CRC Tumor Immunogenicity after Chemotherapy
D. Xu[1,2,3], *X. Lu*[1,3], *F. Yang*[2,3], *D. Li*[3,2];
[1]*Center for Interventional Medicine, the Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, CHINA,* [2]*Department of Nuclear Medicine, the Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, CHINA,* [3]*Guangdong Provincial Engineering Research Center of Molecular Imaging, the Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, CHINA.*

OP-698
Targeting PD-1 on Chronically Activated T cells with Radioimmunotherapy as a Novel Therapeutic Strategy for Multiple Sclerosis.
C. Frank[1], *H. E. Salapa*[2,3,4], *K. J. H. Allen*[1], *M. C. Levin*[2,3,4], *W. Dawicki*[5], *E. Dadachova*[1];
[1]*College of Pharmacy and Nutrition, University of Saskatchewan, Saskatoon, SK, CANADA,* [2]*Office of Saskatchewan Multiple Sclerosis Clinical Research Chair, CMSNRC (Cameco MS Neuroscience Research Center), College of Medicine, University of Saskatchewan, Saskatoon, SK, CANADA,* [3]*Department of Medicine, Neurology Division, University of Saskatchewan, Saskatoon, SK, CANADA,* [4]*Department of Anatomy, Physiology and Pharmacology, College of Medicine, University of Saskatchewan, Saskatoon, SK, CANADA,* [5]*Department of Biochemistry, Microbiology and Immunology, College of Medicine, University of Saskatchewan, Saskatoon, SK, CANADA.*

OP-699
The synthesis of a novel molecular imaging probe^{68}Ga-DOTA-PDL1P and applicationin malignant melanoma
Z. Yang;
Fudan University Shanghai Cancer Center, Shanghai, CHINA.

OP-700
A Novel PET Tracer ^{68}Ga-NOTA-XH05 Targeting LAG-3 for Evaluating the Efficacy of Immunotherapy in Tumors
P. Yuan[1,2], *Y. Long*[1,2], *N. Wei*[1,2], *Y. Gai*[1,2], *Y. Zhang*[1,2], *R. An*[1,2], *X. Lan*[1,2];
[1]*Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, CHINA,* [2]*Hubei Key Laboratory of Molecular Imaging, Wuhan, CHINA.*

OP-701
Preclinical evaluation of a small-molecule carbonic anhydrase IX targeting PET tracer in clear cell renal cell carcinoma
W. Zhu, *X. Li, Y. Zhang, L. Huo;*
Peking Union Medical College Hospital, Beijing, CHINA.

OP-702
A Radiohapten Capture System for In Vivo CAR T Cell Tracking in Ovarian Cancer
L. Gajecki, *L. Eibler, K. Kurtz, S. Lovibond, D. Veach, S. Larson, D. Scheinberg, S. Krebs;*
Memorial Sloan Kettering, New York, NY, UNITED STATES OF AMERICA.

OP-703
Discovery and development of high-affinity macrocyclic peptide for PET imaging of human Granzyme-B
T. Nayak[1], *J. Schubert*[1], *Z. Zhou*[1], *I. Bennacef*[1], *X. Meng*[1], *M. Stenslik*[1], *K. Getty*[1], *J. Patteson*[1], *H. Zokian*[2], *J. Lee*[2], *E. DiNunzio*[2], *H. Wan*[2], *F. Orvieto*[3], *V. Piacenti*[3], *A. Saldanha*[2], *A. Walji*[1], *E. Hostetler*[1];
[1]*MSD, West Point, PA, UNITED STATES OF AMERICA,* [2]*MSD, Kenilworth, NJ, UNITED STATES OF AMERICA,* [3]*IRBM S.p.A, Rome, ITALY.*

OP-704
Evaluation of Affinity Matured Affibody Molecules for Imaging of Immune Check-Point Protein B7-H3
M. Oroujeni[1], *E. Bezverkhniaia*[2], *T. Xu*[1], *Y. Liu*[1], *E. Plotnikov*[2], *E. Ryer*[3], *I. Karlberg*[3], *A. Orlova*[1], *F. Frejd*[1], *V. Tolmachev*[1];
[1]*Uppsala University, Uppsala, SWEDEN,* [2]*Tomsk Polytechnic University, Tomsk, RUSSIAN FEDERATION,* [3]*Affibody AB, Stockholm, SWEDEN.*

OP-705
A ^{68}Ga labelled CD25 targeted cyclopeptide probe for activated T cell imaging
F. Liu[1], *S. Wang*[2], *P. Wang*[1], *Z. Yang*[1];
[1]*Peking University Cancer Hospital & Institute, Beijing, CHINA,* [2]*Peking University Health Science Cente, Beijing, CHINA.*

1505

Tuesday, September 12, 2023, 3:00 PM - 4:30 PM
Hall B

Cutting Edge Science Track - TROP Session: AI Methods and Applications

OP-706
Primary prostate characterization in PSMA-11 PET on real quantum computers
L. Papp, *C. P. Spielvogel, M. Hacker, W. Drexler, S. Moradi;*
Medical University of Vienna, Vienna, AUSTRIA.

OP-707
Image-based PSMA PET/MRI deep learning model for automatic prostate cancer grading
E. Solari[1], *S. Schachoff*[1], *I. Rauscher*[1], *M. Eiber*[1], *W. Weber*[1], *N. Navab*[2], *S. G. Nekolla*[1];
[1]*Klinikum rechts der Isar, Technical University Munich, München, GERMANY,* [2]*School of Informatics, Technical University Munich, München, GERMANY.*

OP-708
Increased sensitivity for AI-based detection of lymph node metastases on [18F]-PSMA-1007 PET-CT when adding synthetic data to the training data
E. Tragardh[1,2], *J. Ulén*[3], *O. Enqvist*[3,4], *L. Edenbrandt*[5], *M. Larsson*[3];
[1]*Skåne University Hospital, Malmö, SWEDEN,* [2]*Lund University, Malmö, SWEDEN,* [3]*Eigenvision AB, Malmö, SWEDEN,* [4]*Chalmers University of Technology, Gothenburg, SWEDEN,* [5]*Sahlgrenska Academy, Gothenburg, SWEDEN.*

OP-709
Deep learning-based PET Image harmonization improves robustness and discriminative power of quantitative imaging markers in multi-institutional studies
D. Haberl[1], *C. P. Spielvogel*[1], *D. Iommi*[1], *I. Buvat*[2], *A. R. Haug*[1], *L. Papp*[3];
[1]*Department of Biomedical Imaging and Image-Guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, AUSTRIA,* [2]*LITO laboratory, U1288 Inserm, Institut Curie, University Paris-Saclay, Orsay, FRANCE,* [3]*Center for Medical Physics and Biomedical Engineering, Medical University of Vienna, Vienna, AUSTRIA.*

OP-710
[^{11}C] CFT PET to [^{123}I] FP-CIT SPECT Domain Adaptation:A CycleGAN harmonization approach
L. Lopes[1,2], *S. Xu*[1], *J. Lu*[3], *T. Pyka*[1], *K. Krieger*[1], *R. Fahmi*[4], *B. Spottiswoode*[4], *A. Soliman*[4], *R. Buchert*[5], *M. Brendel*[6], *J. Hong*[1,2], *C. Clement*[1,2], *C. Bassetti*[7], *A. Rominger*[1], *P. Wu*[3], *K. Shi*[1];
[1]*Department of Nuclear Medicine, Inselspital, University of Bern, Bern, SWITZERLAND,* [2]*Graduate School for Cellular and Biomedical Sciences, University of Bern, Bern, SWITZERLAND,* [3]*Department of Nuclear Medicine & PET Center, Huashan Hospital, Fudan University, Shanghai, CHINA,* [4]*Siemens Medical Solutions United States Of America, Inc., Knoxville, TN, UNITED STATES OF AMERICA,* [5]*Department of Diagnostic and Interventional Radiology and Nuclear Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, GERMANY,* [6]*Department of Nuclear Medicine, University Hospital, LMU Munich, Munich, GERMANY,* [7]*Department of Neurology, University of Bern, Bern, SWITZERLAND.*

OP-711
Estimating the Tumor Localization Performance via Class-Activation Map Explanations of a Slice Classification Neural Network Without Pixel-Level Supervision
S. Ahamed[1,2], *C. F. Uribe*[1,3], *A. Rahmim*[1,2];
[1]*University of British Columbia, Vancouver, BC, CANADA,* [2]*BC Cancer Research Institute, Vancouver, BC, CANADA,* [3]*BC Cancer, Vancouver, BC, CANADA.*

OP-712
Early experiences with the use of triplet networks for histological subtype classification in Non-Small Cell Lung Cancer
F. Gelardi[1,2], *F. Aksu*[1], *A. Chiti*[1,2], *P. Soda*[3,4];
[1]*Department of Biomedical Sciences, Humanitas University, Pieve Emanuele (MI), ITALY,* [2]*Department of Nuclear Medicine, IRCCS Humanitas Research Hospital, Rozzano (MI), ITALY,* [3]*Research Unit of Computer Systems and Bioinformatics, Campus Bio-Medico University of Rome, Rome, ITALY,* [4]*Department of Radiation Sciences, Radiation Physics, Biomedical Engineering, Umea University, Umea, SWEDEN.*

OP-713
Development and Multicenter Validation of an Artificial Intelligence System for the Detection of Cardiac Amyloidosis in ^{99m}Tc Scintigraphy
C. Spielvogel[1], *D. Haberl*[1], *J. Ning*[2], *R. Calabretta*[1], *T. Traub-Weidinger*[1], *R. H. Davies*[3], *I. Pierce*[4], *K. Patel*[4], *K. Kluge*[1], *T. Nakuz*[1], *A. Goellner*[1], *D. Amareller*[1], *M. Weber*[1], *M. Zhao*[5], *X. Ma*[6], *X. Li*[1], *A. R. Haug*[1], *L. Menezes*[4], *T. A. Treibel*[3], *M. Hacker*[1], *C. Nitsche*[7], *CS and DH are first authors with equal contribution;*
[1]*Department of Biomedical Imaging and Image-Guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, AUSTRIA,* [2]*Christian Doppler Laboratory for Applied Metabolomics, Medical University of Vienna, AUSTRIA,* [3]*Institute of Cardiovascular Science, University College London, London, UNITED KINGDOM,* [4]*Department of Cardiology, Bart's Heart Centre, St Bartholomew's Hospital, West Smithfield, London, UNITED KINGDOM,* [5]*Department of Nuclear Medicine, First Xiangya Hospital, Central South University, Changsha, CHINA,* [6]*Department of Nuclear Medicine, Second Xiangya Hospital, Central South University, Changsha, CHINA,* [7]*Department of Medicine II, Division of Cardiology, Medical University of Vienna, Vienna, AUSTRIA.*

OP-714
Deep learning-based image classification in differentiating lymphoma pulmonary involvement and other hypermetabolic pulmonary diseases on ^{18}F-FDG PET/CT
R. Cheng[1], *Y. Peng*[1], *M. Quan*[2], *B. Li*[1], *N. Wen*[2], *J. Hu*[1];
[1]*Department of Nuclear Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, CHINA,* [2]*Department of Radiology, Ruijin Hospital Shanghai Jiao Tong University School of Medicine, Shanghai, CHINA.*

1506

Tuesday, September 12, 2023, 3:00 PM - 4:30 PM
Hall C

Clinical Oncology Track - TROP Session: Prostate Cancer Treatment

OP-715
Can pre-therapy ^{68}Ga-PSMA-11 PET SUVs predict absorbed doses across multiple cycles of ^{177}Lu-PSMA-617 therapy of mCRPC patients?
J. Brosch-Lenz[1], *N. Colpo*[2], *I. Bloise*[1], *X. Hou*[1], *W. R. Parulekar*[3], *C. Dellar*[3], *F. Saad*[4], *K. Chi*[2], *D. Wilson*[2], *F. Bénard*[2], *A. Rahmim*[1], *C. Uribe*[2];
[1]*BC Cancer Research Institute, Vancouver, BC, CANADA,* [2]*BC Cancer, Vancouver, BC, CANADA,* [3]*Canadian Cancer Trials Group, Queen's University Kingston, Kingston, ON, CANADA,* [4]*Prostate cancer research, Montreal Cancer Institute / CRCHUM, Montreal, QC, CANADA.*

OP-716
Safety and efficacy of PSMA-targeted radionuclide therapy with ^{177}Lu-ITG-PSMA-1 in metastatic castration resistant prostate cancer patients: Update on the prospective, multicentre, Swiss registry study
A. Chirindel[1], *A. Bauman*[1], *M. Fani*[1], *F. Forrer*[2], *A. Afshar-Oromieh*[3], *M. del Sol Pérez Lago*[4], *J. Blautzik*[5], *N. Schaefer*[6], *E. Nitzsche*[7], *D. Wild*[1], *G. Nicolas*[1];
[1]*University Hospital Basel, Basel, SWITZERLAND,* [2]*Kantonsspital St. Gallen, St Gallen, SWITZERLAND,* [3]*Inselspital, Berne, SWITZERLAND,* [4]*Luzerner Kantonsspital, Lucerne, SWITZERLAND,* [5]*Hirslanden Klinik St. Anna, Lucerne, SWITZERLAND,* [6]*University Hospital Lausanne, CHUV, Lausanne, SWITZERLAND,* [7]*Kantonsspital Aarau, Aarau, SWITZERLAND.*

OP-717
Systematic evaluation of response and adverse events in mCRPC patients treated with different combinations of ^{225}Ac/^{177}Lu-PSMA-therapy
G. Sheikh[1], *M. J. Zacherl*[1], *A. Holzgreve*[1], *S. C. Kunte*[1], *V. Wenter*[1], *M. Unterrainer*[2], *W. Kunz*[3], *J. Casuscelli*[4], *C. Stief*[4], *P. Bartenstein*[1], *L. M. Unterrainer*[1];
[1]*Department of Nuclear Medicine, LMU Klinikum, Munich, GERMANY,* [2]*Die Radiologie, Munich, GERMANY,* [3]*Department of Radiology, LMU Klinikum, Munich, GERMANY,* [4]*Department of Urology, LMU Klinikum, Munich, GERMANY.*

OP-718
ProstACT GLOBAL: A Phase 3 Study of 177Lu-DOTA-rosopatamab (TLX591) With and Without the Best Standard of Care for Patients With PSMA Expressing Metastatic Castration-resistant Prostate Cancer Progressing Despite Prior Treatment with a Novel Androgen Axis Drug
S. Martina[1], *C. Hawkins*[1], *N. Patel*[1], *J. Gibson*[1], *T. Brown*[1], *N. Lenzo*[2], *C. Hayward*[1];
[1]*Telix Pharmaceuticals, Melbourne, AUSTRALIA,* [2]*Genesis Care, Alexandria NSW 2015, AUSTRALIA.*

OP-719
[^{225}Ac]Ac-PSMA-617 mutational landscape in circulating tumor DNA (ctDNA): early clinical outcome prediction in metastatic castration-resistant prostate cancer
M. Amghar[1], *T. Rausch*[2], *T. Hielscher*[1], *H. Ozgur*[2], *M. Roscher*[1], *U. Bauder-Wüst*[1], *M. Schick*[1], *Y. Remde*[1], *G. Bakos*[1], *M. Schäfer*[1], *F. Bruchertseifer*[3], *A. Morgenstern*[3], *V. Beneš*[2], *C. Kratochwil*[4], *M. Benešová-Schäfer*[1];
[1]*DKFZ, Heidelberg, GERMANY,* [2]*EMBL, Heidelberg, GERMANY,* [3]*European Commission, Joint Research Centre (JRC), Karlsruhe, GERMANY,* [4]*Department of Nuclear Medicine, University Hospital, Heidelberg, GERMANY.*

OP-720
Evaluation of labelingparameters of PSMA-617 with ^{213}Bi for targeted alpha-radionuclide therapy of metastatic castration-resistant prostate cancer
H. khoshhosn, *M. Davarpanah, H. Khoshhosn*, A. Gravand, Y. Tavakoli, N. Soltani, M. Harati, B. Kalantari, F.Johri;*
Pars Isotope company, Tehran, IRAN, ISLAMIC REPUBLIC OF.

OP-721
Safety, Dosimetry and Response of ^{177}Lu-LNC1003 in Patients with Metastatic Castration Resistant Prostate Cancer
J. Zang[1], *G. Wang*[2], *T. Zhao*[3], *Y. Yang*[1], *W. Miao*[1], *Z. Zhu*[2], *J. Zhang*[3], *X. Chen*[3];
[1]*Department of Nuclear Medicine, the First Affiliated Hospital, Fujian Medical University, Fuzhou, CHINA,* [2]*Department of Nuclear Medicine, Peking Union Medical College (PUMC) Hospital, Chinese Academy of Medical Science and PUMC, Beijing, CHINA,* [3]*Departments of Diagnostic Radiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, SINGAPORE.*

OP-722
Extension of a ^{68}Ga-PSMA PET-based nomogram for outcome prediction of ^{177}Lu-PSMA radioligand therapy for the use of ^{18}F-rhPSMA-7.3
I. Rauscher[1], *K. Hansen*[1], *A. Gafita*[1], *W. A. Weber*[1], *M. Eiber*[2];
[1]*Department of Nuclear Medicine, Technical University of Munich, Klinikum rechts der Isar, Munich, GERMANY,* [2]*Technical University of Munich, Klinikum rechts der Isar, Munich, GERMANY.*

OP-723
^{177}Lu-PSMA-617 therapy in advanced mCRPC patients: preliminary results of the phase 2 prospective trial IRST-185.03
I. Marini, *M. Sansovini, G. Paganelli, I. Grassi, F. Matteucci, S. Nicolini, U. De Giorgi, E. F. Giunta, F. Foca, M. Monti, M. Celli, P. Caroli, V. Di Iorio, A. Sarnelli, C. Lolli, G. Schepisi, N. Brighi, S. Severi;*
IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, ITALY.

1507

Tuesday, September 12, 2023, 3:00 PM - 4:30 PM
Hall F1

Cardiovascular Committee - TROP Session: Perfusion

OP-724
Prognostic role of coronary microvascular dysfunction in non-obstructive coronary artery disease
K. Kopeva, *A. Maltseva, E. Grakova, A. Mochula, K. Zavadovsky;*
Cardiology Research Institute, branch of the Federal State Budgetary Scientific Institution «Tomsk National Research Medical Center of the Russian Academy of Sciences», Tomsk, RUSSIAN FEDERATION.

OP-725
Impact of coronary flow reserve on the mortality and major adverse cardiac and cerebrovascular event in hemodialysis patients, regardless of diabetes
S. Ohshima;
Nagoya Kyoritsu Hospital, Nagoya, JAPAN.

OP-726
Relationship between monocyte to high density lipoprotein cholesterol ratio and myocardial perfusion imaging findings
M. Sadic;
Division of Nuclear Medicine, Department of Radiology, University of Washington, Seattle, WA, UNITED STATES OF AMERICA.

OP-727
Analysis of related factors of persistent or recurrent chest pain in patients with coronary artery disease after PCI based on gated myocardial perfusion imaging
Z. Yang[1,2], *J. Wang*[1,2], *Y. Wang*[1,2];
[1]*Department of Nuclear Medicine, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu Province, CHINA,* [2]*Institute of Clinical Translation of Nuclear Medicine and Molecular Imaging, Soochow University, Changzhou, Jiangsu Province, CHINA.*

OP-728
Association between myocardial perfusion and peripheral endothelial function in patients with coronary artery disease
N. Vartiainen, *J. E. K. Hartikainen, T. M. Laitinen, H. Mussalo, P. Kuikka, T. P. Laitinen;*
Kuopio University Hospital, Kuopio, FINLAND.

OP-729
Relative stress perfusion deficit is an independent predictor of significant stenosis in a heterogenous population of patients examined with [^{15}O]H_2O PET
P. Mark[1], *E. Prescott*[2], *L. Marner*[1], *P. Hovind*[1], *M. Krakauer*[1];
[1]*Department of Clinical Physiology and Nuclear Medicine, Copenhagen University Hospital - Bispebjerg Frederiksberg Hospital, Bispebjerg Bakke 23, 2400 Copenhagen, DENMARK,* [2]*Department of Cardiology, Copenhagen University Hospital - Bispebjerg Frederiksberg Hospital, Bispebjerg Bakke 23, 2400 Copenhagen, DENMARK.*

OP-730
Cardiac ^{15}O-water PET/CT predicts progression of Cardiac Dysfunction in Patients with Type 2 Diabetes and Diabetic Foot Ulcers
N. Christensen[1,2,3], *L. P. Tolbod*[1,2], *K. Bouchelouche*[1,2], *M. A. Madsen*[1], *C. S. Buhl*[3], *J. Sørensen*[1];
[1]*Department of Nuclear Medicine & PET, Aarhus University Hospital, Aarhus N, DENMARK,* [2]*Aarhus University, Aarhus C, DENMARK,* [3]*Steno Diabetes Center Aarhus, Aarhus University Hospital, Aarhus N, DENMARK.*

OP-731
Prevalence, characteristics and effect of cardiac motion in ^{13}N-ammonia PET/CT dynamic acquisitions
O. Mendoza-Ibanez[1], *T. S. Martinez Lucio*[1], *F. van der Zant*[2], *C. Hayden*[3], *R. J. J. Knol*[2], *R. H. J. A. Slart*[1], *S. V. Lazarenko*[2];
[1]*University Medical Center Groningen, Groningen, NETHERLANDS,* [2]*Northwest Clinics Alkmaar, Alkmaar, NETHERLANDS,* [3]*Siemens Medical Solutions, Inc. United States Of America, TN, UNITED STATES OF AMERICA.*

OP-732
Role of motion correction tools in the estimation of microvascular coronary function by ^{13}N-ammonia hybrid-positron emission tomography
O. Mendoza-Ibanez[1], *R. J. J. Knol*[2], *R. H. J. A. Slart*[1], *C. Hayden*[3], *T. S. Martinez Lucio*[1], *S. V. Lazarenko*[2];
[1]*University Medical Center Groningen, Groningen, NETHERLANDS,* [2]*Northwest Hospital Group Alkmaar, Alkmaar, NETHERLANDS,* [3]*Siemens Medical Solutions United States Of America, Tenesse, TN, UNITED STATES OF AMERICA.*

1508

Tuesday, September 12, 2023, 15:00 - 16:30
Hall F2

Joint Symposium 5 - Oncology & Theranostics Committee / ESMO: Prostate Cancer Theranostics: Where Do We Go?

OP-733
Biology and Treatment Landscape in advanced Prostate Cancer and unmet Medical Needs
E. Castro;
12 de Octubre University Hospital, Department of Medical Oncology, Madrid, SPAIN.

OP-734
Potential combination partners for PSMA radioligand therapy
B. Krause;
UniversityMedical Center, University of Rostock, Department of Nuclear Medicine, Rostock, GERMANY.

OP-735
Moving PSMA RLT to earlier lines
B. Privé;
Erasmus Medical Center, Department of Radiation oncology, Rotterdam, NETHERLANDS.

OP-736
The future role of radiotherapy of prostate cancer

1509

Tuesday, September 12, 2023, 3:00 PM - 4:30 PM
Hall G2

e-Poster Presentations Session 11 - Translational Molecular Imaging & Therapy Committee + Radiopharmaceutical Sciences Committee: Novel Therapeutic Approaches

EPS-210
In Vitro Evaluation of Radiation-induced DNA Damage and Repair within Targeted Radionuclide Therapies in Comparison to External Radiation
R. Winter, *U. Bauder-Wüst, M. Schäfer, M. Roscher, R. Lopez Perez, M. Benešová-Schäfer;*
German Cancer Research Center, Heidelberg, GERMANY.

EPS-211
Three-dimensional spheroids as in vitro preclinical model for radiobiology studies: the example of radium-223 in prostate cancer spheroids
A. Pires Lourenço[1,2,3], *I. A. Marques*[4,2,5], *D. Cancelinha*[4,6], *G. Costa*[7], *A. M. Abrantes*[4,2,3], *M. F. Botelho*[4,2,3];
[1]Institute of Biophysics, Coimbra Institute for Clinical and Biomedical Research (iCBR) area of CIMAGO, Faculty of Medicine, University of Coimbra, Coimbra, PORTUGAL, [2]Center for Innovative Biomedicine and Biotechnology (CIBB), University of Coimbra, Coimbra, PORTUGAL, [3]Clinical Academic Center of Coimbra (CACC), Coimbra, PORTUGAL, [4]Univ Coimbra, Coimbra Institute for Clinical and Biomedical Research (iCBR) area of Environment Genetics and Oncobiology (CIMAGO), Institute of Biophysics, Faculty of Medicine, Coimbra, PORTUGAL, [5]Faculty of Pharmacy, University of Coimbra, Coimbra, PORTUGAL, [6]Faculty of Science and Technology, University of Coimbra, Coimbra, PORTUGAL, [7]Department of Nuclear Medicine, Centro Hospitalar e Universitário de Coimbra (CHUC), Coimbra, PORTUGAL.

EPS-212
Comparison of biological effects produced by radioactively labeled antibodies in human cancer cells and fungal cells
J. Bonet, *M. E. Malo, K. J. Allen, C. Frank, R. Jiao, E. Dadachova;*
University of Saskatchewan, Saskatoon, SK, CANADA.

EPS-213
HDACi Treatment Increases SSTR2 mRNA and Protein Expression in Tumor-Bearing Animals: What is the Effect on Radiolabeled DOTATATE uptake?
M. J. Klomp, *L. van den Brink, P. M. van Koetsveld, C. M. A. de Ridder, D. C. Stuurman, L. J. Hofland, S. U. Dalm;*
Erasmus MC, Rotterdam, NETHERLANDS.

EPS-214
Preclinical efficacy of novel anti-oxMIF/HSG bispecific antibody for pretargeted radioimmunotherapy
A. Puchol Tarazona, *I. Mirkina, M. Thiele, A. Schinagl;*
OncoOne Research & Development GmbH, Vienna, AUSTRIA.

EPS-215
Combined Treatment with ^{177}Lu-DOTATOC and Histone Deacetylase Inhibitor s on SSTR2 Expression and Uptake in in vivo
H. Bakr[1,2], *A. Al-Awar*[1], *E. Forssell-Aronsson*[1,2];
[1]Department of Medical Radiation Sciences, Institute of Clinical Sciences, Sahlgrenska Center for Cancer Research, Sahlgrenska Academy, University of Gothenburg, Gothenburg, SWEDEN, [2]Department of Medical Physics and Biomedical Engineering, Sahlgrenska University Hospital, Gothenburg, SWEDEN.

EPS-216
Effective treatment of SSTR2 positive small cell lung cancer using^{211}At-containing targeted α-particle therapy agent which promotes endogenous anti-tumor immune response.
F. Yu, *S. Qin, J. Zhang, M. Yang;*
Department of Nuclear Medicine, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, CHINA.

EPS-217
DOTAGA-modified DB15 mimics for theranostic use in prostate cancer
P. Kanellopoulos[1], *A. Mattsson*[1], *A. Abouzayed*[1], *K. Obeid*[1], *B. A. Nock*[2], *V. Tolmachev*[1], *T. Maina*[3], *A. Orlova*[1];
[1]Uppsala University, Uppsala, SWEDEN, [2]INRASTES, NCSR "Demokritos", Athens, GREECE, [3]INRASTES, NSCR "Demokritos", Athens, GREECE.

EPS-218
Development and preclinical evaluation of biodistribution and dosimetry of ^{177}Lu-labelled PSMA targeting therapeutic with optimized linker for treatment of disseminated prostate cancer
A. Orlova[1], *A. Abouzayed*[1], *K. Seitova*[2], *F. Lundmark*[1], *V. Bodenko*[2], *M. Oroujeni*[1], *V. Tolmachev*[1], *U. Rosenström*[1];
[1]Uppsala University, Uppsala, SWEDEN, [2]Tomsk Polytechnic University, Tomsk, RUSSIAN FEDERATION.

EPS-219
Theranostic approach in CD30 positive cancers with a radiolabeled antibody conjugated to the radiosensitizing antitubulin monomethyl auristatin E payload
C. Petitot[1], *J. Frenay*[2], *A. M. M. Dias*[1], *A. Oudot*[1], *A. Helbling*[1], *M. Moreau*[3], *M. Monterrat*[1], *M. Guillemin*[1], *N. Ranjit*[1], *A. Cochet*[4], *P. S. Bellaye*[5], *B. Collin*[6];
[1]Pirp - Service de Médecine Nucléaire, Centre Georges-François Leclerc, Dijon, FRANCE, [2]Icb - Umr Cnrs 6303 / Pirp - Service de Médecine Nucléaire, Centre Georges-François Leclerc, Dijon, FRANCE, [3]Icmub - Umr Cnrs 6302, Dijon, FRANCE, [4]Icmub - Umr Cnrs 6302 / Pirp - Service de Médecine Nucléaire, Centre Georges-François Leclerc / Chu François Mitterrand, Dijon, FRANCE, [5]Pirp - Service de Médecine Nucléaire, Centre Georges-François Leclerc / Lnc - Umr Inserm 1231, Dijon, FRANCE, [6]Icmub - Umr Cnrs 6302 / Pirp - Service de Médecine Nucléaire, Centre Georges-François Leclerc, Dijon, FRANCE.

EPS-220
Testing the potential therapeutic use of [^{188}Re]Re-maSSS/maSES-PEG2-RM26 as part of a theranostic pair with their [^{99m}Tc]Tc-labeled counterparts
P. Kanellopoulos, *Q. Yu, A. Abouzayed, E. Bezverkhniaia, V. Tolmachev, A. Orlova;*
Uppsala University, Uppsala, SWEDEN.

EPS-221
Alpha-emitter radium-223 mediates tumor eradication via STING-dependent pyroptosis
F. Yu, *M. Yang, S. Qin, J. Zhang;*
Department of Nuclear Medicine, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, CHINA.

EPS-222
Fractionated therapy of the PSMA-targeted radioligand^{212}Pb-AB001 significantly delays tumor growth
A. Kjoel Tornes[1,2], *V. Y. Stenberg*[1,2], *A. Repetto-Llamazares*[1], *R. H. Larsen*[3,1], *A. Juzeniene*[2];
[1]ArtBio AS, Oslo, NORWAY, [2]Department of Radiation Biology, Oslo University Hospital, Oslo, NORWAY, [3]Sciencons AS, Oslo, NORWAY.

EPS-223
Biodistribution Study and Pre-clinical Radiopharmaceutical Therapy with a CXCR4-targetted Compound on a Human CXCR4 Positive Multiple Myeloma Orthotopic Model
I. Bloise, *H. Kuo, N. Colpo, H. Merkens, P. Ng, D. Kwon, L. Escano, F. Kuchenbauer, K. Lin, F. Benard;*
BC Cancer, Vancouver, BC, CANADA.

EPS-224
Design and evaluation of a new generation of long-acting SSTR2 antagonists for enhanced radionuclide therapy of NETs
M. Handula[1], *S. Beekman*[1], *Y. Seimbille*[1,2];
[1]Erasmus MC, Rotterdam, NETHERLANDS, [2]TRIUMF, Vancouver, BC, CANADA.

EPS-225
DOTA-MGS5, a novel cholecystokinin-2 receptor-targeting peptide analogue for use in targeted therapy, preclinical evaluation for clinical translation
T. Zavvar[1], *A. A. Hoermann*[1], *M. Klingler*[1], *J. Hagenbuchner*[2], *L. Joosten*[3], *G. Franssen*[3], *P. Laverman*[3], *M. W. Konijnenberg*[4], *I. Skvortsova*[5], *L. Gruber*[6], *E. von Guggenberg*[1];
[1]Department of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, AUSTRIA, [2]Department of Pediatrics II, Medical University of Innsbruck, Innsbruck, AUSTRIA, [3]Department of Medical Imaging, Radboud University Medical Center, Nijmegen, NETHERLANDS, [4]Department of Radiology and Nuclear Medicine, Erasmus Medical Center, Rotterdam, NETHERLANDS, [5]Department of Therapeutic Radiology and Oncology, Medical University of Innsbruck, Innsbruck, AUSTRIA, [6]Department of Radiology, Medical University Innsbruck, Innsbruck, AUSTRIA.

EPS-227
Preclinical evaluation of a radiotheranostic single-domain antibody against Fibroblast Activation Protein alpha
Y. Dekempeneer[1], *S. Massa*[1], *F. Santens*[1], *L. Navarro*[1], *M. Berdal*[1], *M. M. Lucero*[1], *A. Pombo Antunes*[1], *J. A. Van Ginderachter*[2,3], *T. Lahoutte*[1,4,3], *N. Devoogdt*[1,3], *M. D'Huyvetter*[1,3];
[1]PRECIRIX NV/SA, Brussels, BELGIUM, [2]VIB Center for Inflammation Research, Brussels, BELGIUM, [3]Vrije Universiteit Brussel, Brussels, BELGIUM, [4]UZ Brussel, Brussels, BELGIUM.

EPS-228
Auger electron therapy of prostate cancer: a preclinical evaluation of ^{58m}Co-DOTA-PSMA-617
C. Baun[1,2,3], *J. H. Dam*[1], *J. D. Ewald*[4,2], *B. W. Kristensen*[4], *V. S. Laursen*[1,2], *M. G. Hildebrandt*[1,2,3], *B. B. Olsen*[1], *H. Thisgaard*[1,2];
[1]Department of Nuclear Medicine, Odense University Hospital, Odense C, DENMARK, [2]Department of Clinical Research, University of Southern Denmark, Odense, DENMARK, [3]Center for Personalized Response Monitoring in Oncology (PREMIO), Odense University Hospital, Odense, DENMARK, [4]Department of Pathology, Odense University Hospital, Odense C, DENMARK.

EPS-229
Polymeric Micelles as Drug Delivery System for PARP Inhibitor-Based Chemo-Radiotherapy Combination Against Triple-Negative Breast Cancer
L. Schäfer[1], *A. Wang*[2], *Q. Peña*[2], *E. Henrard*[1], *T. Lammers*[2], *E. M. Buhl*[3], *M. Frings*[4], *C. Bolm*[4], *A. Morgenroth*[1], *F. M. Mottaghy*[1,5];
[1]Department of Nuclear Medicine, RWTH Aachen University Hospital, 52074 Aachen, GERMANY, [2]Institute for Experimental Molecular Imaging, RWTH Aachen University Hospital, 52074 Aachen, GERMANY, [3]Electron Microscopy Facility, Institute of Pathology, RWTH Aachen University Hospital, 52074 Aachen, GERMANY, [4]Institute of Organic Chemistry, RWTH Aachen University, 52074 Aachen, GERMANY, [5]Department of Radiology and Nuclear Medicine, Maastricht University Medical Center, 6229 ER Maastricht, NETHERLANDS.

EPS-230
Successful treatment of human high-risk neuroblastoma using ^{177}Lu-octreotide combined with Lorlatinib in a mouse model
E. Forssell-Aronsson[1,2], *A. Romiani*[1], *D. Pettersson*[1], *K. Simonsson*[1], *H. Bakr*[1,2], *D. Lind*[1], *A. Kovacs*[1,2], *R. Palmer*[1], *B. Hallberg*[1], *K. Helou*[1], *J. Spetz*[1];
[1]University of Gothenburg, Gothenburg, SWEDEN, [2]Sahlgrenska University Hospital, Gothenburg, SWEDEN.

1510

Tuesday, September 12, 2023, 15:00 - 16:30
Hall K

CTE 7 - Technologists & Thyroid Committee: Molecular Thyroid Imaging - Qualitative and Quantitative Approaches

OP-737
Best practice on thyroid imaging: What's to know?!
M. Punda;
UniversityClinical Hospital Center "Sestre Milosrdnice", Department of Oncology and Nuclear Medicine, Zagreb, CROATIA.

OP-738
MIBI-Imaging of the thyroid and parathyroid: How to get most out of it.
M. Jessop;
Brighton and Sussex University Hospitals, Department of Nuclear Medicine, Brighton, UNITED KINGDOM.

OP-739
Imaging of thyroid cancer: From I-131 to FAPi.
J. Nagarajah;
Radboud UMC, Department of Nuclear Medicine, Nijmegen, NETHERLANDS.

OP-740
Update on new developments in thyroid ultrasound
T. Wendler;
Technical University of Munich, TUM School of Computation, Information and Technology, Munich, GERMANY.

1511

Tuesday, September 12, 2023, 15:00 - 16:30
Hall G1

EU Policy Symposium 1 - Policy & Regulatory Affairs Committee: Supply & Shortages of Radiopharmaceuticals

OP-742
Supply & Shortages of Radiopharmaceuticals

1601

Tuesday, September 12, 2023, 16:45 - 18:15
Hall A

CME 12 - Physics + Oncology & Theranostics + Translational Molecular Imaging & Therapy + Technologists Committee: Long Axial Field-of-View PET Scanners - A Copernical Revolution

OP-749
Hybrid Total Body PET scanners
I. Tsoumpas;
UMCG, Nuclear Medicine, Groningen, NETHERLANDS.

OP-750
Clinical Perspectives of Total Body PET/CT
A. Dimitrakopoulou-Strauss;
DKFZ, Nuclear Medicine, Heidelberg, GERMANY.

OP-751
Parametric Imaging with dynamic PET for oncological applications
J. van Sluis;
UMCG, Nuclear Medicine, Groningen, NETHERLANDS.

OP-752
Non Oncological applications
R. Boellaard;
Amsterdam UMC, Radiology and nuclear medicine, Amsterdam, NETHERLANDS.

1602

Tuesday, September 12, 2023, 16:45 - 18:15
Hall D (Arena)

Debate 5 - Bone & Joint + Cardiovascular Committee: NaF PET in cardiology and MSK: pro or cons?

OP-753
NaF PET in cardiology: pro
P. Høilund-Carlsen;
Odense University Hospital, Clinical Physiology and Nuclear Medicine Department, Odense, DENMARK.

OP-754
NaF PET in cardiology: cons
F. Hyafil;
Hopital européen Georges Pompidou, Nuclear medicine Department, Paris, FRANCE.

OP-755
NaF PET in musculoskeletal imaging: pro
H. Zacho;
Kræftforsknings-Center, Aalborg Universitetshospital og, Aalborg, DENMARK.

OP-756
NaF PET in musculoskeletal imaging: cons
D. Mak; *Guys and St Thomas' NHS, Nuclear medicine Department, London, UNITED KINGDOM.*

1603

Tuesday, September 12, 2023, 16:45 - 18:15
Hall E1

LIPS Session 12 - Neuroimaging + Inflammation & Infection Committee: The Role of FDG PET in the Diagnosis of Auto-Immune Encephalitis

OP-760
Interpretation of auto-immune encephalitis with brain FDG PET
A. Verger;
CHRU Nancy, Nuclear Medicine, Nancy, FRANCE.

OP-761
The role of the whole-body FDG PET in autoimmune encephalitis
I. Apostolova;
Department of Diagnostic and Interventional Radiology and Nuclear Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, GERMANY.

OP-762
The complementary PET/MRI modalities in autoimmune encephalitis
D. Cecchin;
Department of Medicine, Nuclear Medicine Unit, University-Hospital of Padova, Padova, ITALY.

1604

Tuesday, September 12, 2023, 4:45 PM - 6:15 PM
Hall E2

M2M Track - TROP Session: Understanding and Improving RLT

OP-764
Novel DNA polymerase theta inhibitors induce efficient X-ray and proton therapy sensitisation in vitro and in vivo
J. Barlow[1], *A. Cicconi*[1], *M. Ranzani*[1], *G. Rodriguez-Berriguete*[2], *R. Prevo*[2], *M. Boursier*[1], *A. Galbiati*[1], *L. Geo*[1], *D. Grande*[1], *R. A. Heald*[1], *J. Majithiya*[1], *D. Piscitello*[1], *E. Rajendra*[1], *M. Stockley*[1], *P. Mariniello*[3], *G. Sawakuchi*[3], *G. Smith*[1], *G. S. Higgins*[2], *H. Robinson*[1];
[1]*Artios Pharma, Cambridge, UNITED KINGDOM,* [2]*University of Oxford, Oxford, UNITED KINGDOM,* [3]*University of Texas MD anderson Cancer Center, Houston, TX, UNITED STATES OF AMERICA.*

OP-765
Dissecting signaling network response to radiolabeled minigastrin analog reveals radiosensitizing targets in CCKBR-positive cancers
M. Grzmil[1], *Y. Qin*[1], *A. Blanc*[1], *T. Chiorazzo*[1], *P. Berger*[2], *S. Frank*[3], *R. Schibli*[1,4], *M. Behe*[1];
[1]*Center for Radiopharmaceutical Sciences, Paul Scherrer Institute, Villigen PSI, SWITZERLAND,* [2]*Laboratory of Nanoscale Biology, Paul Scherrer Institute, Villigen PSI, SWITZERLAND,* [3]*Division of Neuropathology, Institute of Pathology, University of Basel, Basel, SWITZERLAND,* [4]*Department of Chemistry and Applied Biosciences, ETH Zürich, Zürich, SWITZERLAND.*

OP-766
p53 Stabilisation Potentiates ^{177}Lu-DOTATATE Treatment in Neuroblastoma
H. Berglund[1], *S. Lundsten Salomonsson*[2], *T. Mohajershojai*[1], *D. P. Lane*[1,3,4], *M. Nestor*[1];
[1]*Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, SWEDEN,* [2]*Ridgeview Instruments AB, Uppsala, SWEDEN,* [3]*Department of Microbiology, Tumour and Cell Biology, Karolinska Institute, Stockholm, SWEDEN,* [4]*p53Lab, Agency for Science Technology and Research (A*STAR), Singapore, SINGAPORE.*

OP-767
Substantial Reduction of the Activity Retention in the Kidneys of Radiohybrid-Based Minigastrin Analogues by Modifying the Charge Distribution Within the Linker Section
N. Holzleitner[1], *T. Günther*[1], *S. Fischer*[1], *R. Beck*[1], *C. Lapa*[2], *H. Wester*[1];
[1]*Technical University Munich, Munich, GERMANY,* [2]*University of Augsburg, Augsburg, GERMANY.*

OP-768
Internalising radioimmunoconjugates to target KRAS in pancreatic cancer cells for simultaneous radionuclide therapy and radiosensitisation
K. Vallis[1], *J. Lourenco*[1], *N. Sereesongsaeng*[2], *O. Tietz*[3], *T. Rabbitts*[2];
[1]*University of Oxford, Oxford, UNITED KINGDOM,* [2]*Institute of Cancer Research, London, UNITED KINGDOM,* [3]*Macquarie University, Sydney, AUSTRALIA.*

OP-769
Human hematopoietic stem cells show SSTR2 expression and specific binding of radioligands providing a potential explanation for the hematotoxicity of ^{177}Lu-DOTA-JR11
S. Kossatz[1], *Y. Min*[1], *N. T. Nguyen*[1], *J. Rivière*[1], *M. van der Garde*[1], *S. Ghosh*[2], *L. Bartos*[3], *M. Brendel*[3], *F. Bassermann*[1], *K. Götze*[1], *A. Azhdarinia*[4], *W. A. Weber*[1];
[1]*Klinikum rechts der Isar at Technical University Munich, Munich, GERMANY,* [2]*University of Texas Health Science Center at Houston, Houston, VT, UNITED STATES OF AMERICA,* [3]*University Hospital of Munich, LMU Munich, Munich, GERMANY,* [4]*University of Texas Health Science Center at Houston, Munich, GERMANY.*

OP-770
Reducing the Effective Specific Activity of [^{225}Ac]-PSMA-617 to Minimize Salivary Gland and Renal Toxicity
T. Esposito, *T. Kalidindi, R. Payne, Z. Faudemer, K. Jones, N. Pillarsetty;*
Memorial Sloan Kettering Cancer Center, New York City, NY, UNITED STATES OF AMERICA.

OP-771
Improvement of the pharmacokinetic properties of PSMA-617 by introducing sarcosine moieties
N. M. Geis[1,2,3], *N. Steinacker*[1,2], *L. Domogalla*[1,2], *P. T. Meyer*[1,2], *M. Eder*[1,2], *A. Eder*[1,2];
[1]*Department of Nuclear Medicine, University Medical Center Freiburg, Freiburg im Breisgau, GERMANY,* [2]*Division of Radiopharmaceutical Development, German Cancer Consortium, Freiburg im Breisgau, GERMANY,* [3]*Faculty of Biology, University of Freiburg, Freiburg im Breisgau, GERMANY.*

OP-772
Preclinical toxicity study of [^{211}At]PSMA5 in mice and for the FIH clinical trial of targeted alpha therapy against refractory prostate cancer
T. Watabe[1], *K. Kaneda-Nakashima*[1], *Y. Kadonaga*[1], *K. Ooe*[1], *T. Sampunta*[1], *X. Yin*[2], *H. Haba*[2], *Y. Kon*[1], *A. Toyoshima*[1], *J. Cardinale*[3], *F. L. Giesel*[3], *K. Fukase*[1], *N. Tomiyama*[1], *Y. Shirakami*[1];
[1]*Osaka University, Suita, JAPAN,* [2]*RIKEN, Wako, JAPAN,* [3]*University Hospital Duesseldorf, Duesseldorf, GERMANY.*

1605

Tuesday, September 12, 2023, 4:45 PM - 6:15 PM
Hall B

Cutting Edge Science Track - TROP Session: Data Analysis

OP-773
Using timestamps in fast time-of-flight positron emission tomography detectors to encode the depth of interaction of 511 keV gamma-photons in scintillators
V. Nadig[1], *K. Herweg*[1], *K. Weindel*[1], *D. Schug*[1,2], *H. Radermacher*[1], *F. Mueller*[1], *B. Weissler*[1,2], *V. Schulz*[1,2], *S. Gundacker*[1];
[1]*RWTH Aachen University, Aachen, GERMANY,* [2]*Hyperion Hybrid Imaging Systems GmbH, Aachen, GERMANY.*

OP-774
Brain PET Quantitative and Qualitative Interpretation Using Sparse Detector Ring Configuration PET System
R. Fahmi[1], *J. Cabello*[1], *G. Platsch*[2], *B. Spottiswoode*[1];
[1]*Siemens Healthineers, Knoxville, TN, UNITED STATES OF AMERICA,* [2]*Siemens Healthineers, Erlangen, GERMANY.*

OP-775
PUMA: PET Unification for Multi-Tracer Applications in Multiplexed PET Imaging
S. Gutschmayer[1], *B. A. Spencer*[2], *Y. G. Abdelhafez*[2], *R. D. Badawi*[2], *S. R. Cherry*[2], *T. Beyer*[1], *L. Shiyam Sundar*[1];
[1]*Quantitative Imaging and Medical Physics (QIMP) Team, Medical University of Vienna, Vienna, AUSTRIA,* [2]*Department of Biomedical Engineering and Radiology, University of California-Davis, Davis, CA, UNITED STATES OF AMERICA.*

OP-776
Comparison of Standardized Uptake Values of [18F] FDG-PET/CT imaging of healthy volunteers: a multi-country PET/CT study
D. Ferrara[1], *R. Badawi*[2], *T. Beyer*[1], *Z. Chen*[3], *S. Cherry*[4], *B. Geist*[5], *S. Gutschmayer*[1], *M. Hacker*[5], *S. Kinuya*[3], *L. Shiyam Sundar*[1], *B. Spencer*[4], *S. Takeda*[6], *J. Taki*[6], *H. Wakabayashi*[3];
[1]*QIMP Team, Medical University of Vienna, Vienna, AUSTRIA,* [2]*Department of Radiology, UC Davis, Sacramento, CA, UNITED STATES OF AMERICA,* [3]*Department of Nuclear Medicine, Kanazawa University Hospital, Kanazawa, Ishikawa, JAPAN,* [4]*Department of Biomedical Engineering, UC Davis, Davis, CA, UNITED STATES OF AMERICA,* [5]*Division of Nuclear Medicine, Medical University of Vienna, Vienna, AUSTRIA,* [6]*PET Center, Kanazawa Advanced Medical Center, Kanazawa, Ishikawa, JAPAN.*

OP-777
Non-rigid anatomical standardization of whole-body PET/CT identifies variation of FDG distribution with age and sex: an AI-assisted study
K. Hirata[1,2,3], *S. Watanabe*[1,2], *J. Takenaka*[1,2], *N. Wakabayashi*[1,2], *R. Kimura*[1,4], *T. Nagai*[5], *T. Ogawa*[6], *K. Kudo*[1,3,4];
[1]*Department of Diagnostic Imaging, Graduate School of Medicine, Hokkaido University, Sapporo, JAPAN,* [2]*Department of Nuclear Medicine, Hokkaido University Hospital, Sapporo, JAPAN,* [3]*Global Center for Biomedical Science and Engineering, Faculty of Medicine, Sapporo, JAPAN,* [4]*Department of Diagnostic and Interventional Radiology, Hokkaido University Hospital, Sapporo, JAPAN,* [5]*Department of Cardiovascular Medicine, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, JAPAN,* [6]*Faculty of Information Science and Technology, Hokkaido University, Sapporo, JAPAN.*

OP-778
Noise and Sharpness estimation in Positron Emission Tomography (PET) images using radiomics and deep learning
P. Gurunath Bharathi, *F. Moradi, M. Khalighi;*
Stanford Medicine, Palo Alto, CA, UNITED STATES OF AMERICA.

OP-779
Evaluation of potential dose reduction in O-15 water PET by simulation of low count data and sinogram denoising
M. Voskamp[1,2], *F. Büther*[3], *M. Mamach*[4,2], *J. Lücke*[5,6], *S. Salwig*[5], *H. Mousavi*[5], *F. M. Bengel*[1], *T. Lenarz*[7,2], *G. Berding*[1,2];
[1]*Department of Nuclear Medicine, Hannover Medical School, Hannover, GERMANY,* [2]*Cluster of Excellence "Hearing4all", Hannover, GERMANY,* [3]*Department of Nuclear Medicine, University Hospital, Münster, GERMANY,* [4]*Department of Medical Physics and Radiation Protection, Hannover Medical School, Hannover, GERMANY,* [5]*Department of Medical Physics and Acoustics, Carl von Ossietzky University Oldenburg, Oldenburg, GERMANY,* [6]*Cluster of Excellence "Hearing4all", Oldenburg, GERMANY,* [7]*Department of Otolaryngology, Hannover Medical School, Hannover, GERMANY.*

OP-780
Intra-arterial super-selective delivery of Yttrium-90 for the treatment of recurrent Glioblastoma: feasibility and safety results in virtual patients' cohort
G. Paolani[1], *S. Strolin*[1], *S. Minosse*[2], *M. Santoro*[1], *N. Pucci*[2], *L. Oddo*[3], *Y. Toumia*[3], *E. Guida*[4], *F. Di Giuliano*[4], *R. Floris*[4], *F. Garaci*[4], *S. Dolci*[4], *G. Paradossi*[3], *F. Domenici*[3], *V. Da Ros*[4], *L. Strigari*[1];
[1]*Department of Medical Physics, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY,* [2]*UOC Diagnostica per Immagini, University Hospital of Rome "Tor Vergata", Rome, ITALY,* [3]*Department of Chemical Science and Technologies, University of Rome "Tor Vergata", Rome, ITALY,* [4]*Department of Biomedicine and Prevention, University Hospital of Rome "Tor Vergata", Rome, ITALY.*

OP-781
Variational autoencoder for detecting coronary artery disease in myocardial perfusion SPECT
K. Okuda[1], *K. Nakajima*[2], *T. Hara*[3], *H. Yoneyama*[2], *S. Kinuya*[2];
[1]*Hirosaki University, Hirosaki, JAPAN,* [2]*Kanazawa University, Kanazawa, JAPAN,* [3]*Gifu University, Gifu, JAPAN.*

1606

Tuesday, September 12, 2023, 4:45 PM - 6:15 PM
Hall C

Clinical Oncology Track - TROP Session: Head and Neck Imaging

OP-782
Dual time-point imaging of FAPI-04 in head and neck squamous cell carcinoma
J. Yaqun, *L. Chongjiao, H. Yong;*
Department of Nuclear Medicine, Zhongnan Hospital of Wuhan University, Wuhan, CHINA.

OP-783
Effectiveness of HAN-MI-RADS (Head and Neck Molecular Imaging-Reporting and Data System) criterion in head and neck squamous cell carcinoma post concurrent chemoradiotherapy
M. Gupta[1], *A. Jajodia*[2], *P. Ahlawat*[3], *M. Gairola*[3], *M. Agarwal*[4], *S. Goyal*[5], *P. Choudhury*[1];
[1]*Department of Nuclear Medicine, Rajiv Gandhi Cancer Institute and Research Centre, Delhi, INDIA,* [2]*Department of Radiology, Juravinski Hospital, McMaster University, ON, CANADA,* [3]*Department of Radiotherapy, Rajiv Gandhi Cancer Institute and Research Centre, Delhi, INDIA,* [4]*Department of Surgical Oncology, Rajiv Gandhi Cancer Institute and Research Centre, Delhi, INDIA,* [5]*Department of Medical Oncology, Rajiv Gandhi Cancer Institute and Research Centre, Delhi, INDIA.*

OP-784
[^{18}F]FDG PET/CT in the Therapy Response Evaluation of Head and Neck Carcinoma. How to approach it?
V. Carrero-Vásquez[1], *B. Hervas-Sanz*[1], *L. Rodríguez-Bel*[1], *G. Reynes-Llompart*[2], *R. Martin-Vaello*[2], *A. Lozano-Borbalas*[3], *O. Bermejo-Segu*[4], *P. Perlaza-Jiménez*[1], *C. Martínez-Ramos*[1], *M. Cortés-Romera*[1];
[1]*Nuclear Medicine Department, Bellvitge University Hospital, Barcelona, SPAIN,* [2]*Radiophysics Department, Bellvitge University Hospital, Barcelona, SPAIN,* [3]*Radiation Oncology Department, Bellvitge University Hospital, Barcelona, SPAIN,* [4]*Plastic Surgery Department, Bellvitge University Hospital, Barcelona, SPAIN.*

OP-785
C-X-C motif chemokine receptor 4-directed PET/CT in newly diagnosed Head and Neck Squamous Cell Carcinoma - Initial Experience
S. Serfling, *R. Werner, S. Andreas, H. Takahiro, A. K. Buck, A. Kosmala, R. Hagen, S. Hackenberg, A. Scherzag, E. Gerhard-Hartmann, Y. Zhi;*
University Hospital Würzburg, Würzburg, GERMANY.

OP-786
Targeted imaging of αvβ6-integrin in patients of Head and Neck Squamous Cell Carcinoma and Pancreatic Ductal Adenocarcinoma with ^{68}Ga-Trivehexin PET/CT scan and correlation with immunohistochemistry- a pilot study
S. Das, *I. B. Sen, D. Malik, P. Thakral;*
Fortis Memorial Research Institute, Gurugram, INDIA.

OP-787
Role of pet biomarkers (suvmax, tlg and mtv) in the response to treatment in patients with nasopharyngeal carcinoma and its evolution.
S. Lopez Puche, *F. Gómez-Caminero López, P. García-Talavera San Miguel, L. Diaz Gonzalez, E. Casillas Sagrado, J. Badell Martinez, S. Rama Alonso, E. Campaña Diaz, P. Tamayo Alonso;*
Hospital Universitario de Salamanca, Salamanca, SPAIN.

OP-788
Evaluation of relationship between Total Tumor Metabolic Volume and tumour tissue modified viral Human papilloma virus DNA levels at initial staging in HPV driven oropharyngeal squamous cell carcinoma.
R. Kulkarni, *M. Posner, S. Roof, N. Ghesani;*
Mount Sinai Hospital, New York, NY, UNITED STATES OF AMERICA.

OP-789
A prospective Comparison of ^{68}Ga-FAPI and ^{18}F-FDG PET/MR in the Diagnosis of Residual Tumor Tissue for Head and Neck Squamous Cell Carcinoma Patients after Neoadjuvant Treatment
X. Zhong[1], *Y. Luo*[2], *M. Su*[3], *X. Peng*[2], *W. Zhang*[4];
[1]*Nuclear Medicine Department and Biomedical Big Data Center, West China Hospital of Sichuan University, Chengdu, CHINA,* [2]*Cancer Center, West China Hospital of Sichuan University, Chengdu, CHINA,* [3]*Nuclear Medicine Department, West China Hospital of Sichuan University, Chengdu, CHINA,* [4]*Biomedical Big Data Center, West China Hospital of Sichuan University, Chengdu, CHINA.*

OP-790
Preclinical and clinical evaluation of^{68}Ga-FAPI-LM3 for PET imaging in nasopharyngeal carcinoma
L. Zhao, *H. Chen, Q. Lin;*
the First Affiliated Hospital of Xiamen University, Xiamen, CHINA.

1607

Tuesday, September 12, 2023, 4:45 PM - 6:15 PM
Hall F1

Neuroimaging Committee - TROP Session: New PET Tracers for Brain Imaging

OP-791
Potentially incremental role of ^{18}F-DPA714 PET to conventional MRI in the detection and therapeutic monitoring of autoimmune encephalomyelitis
M. Zhang[1], *H. Meng*[2], *S. Chen*[2], *B. Li*[1];
[1]*Department of Nuclear Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, CHINA,* [2]*Department of Neurology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, CHINA.*

OP-792
Activated Microglia Detected by TSPO PET in Anti-N-Methyl-D-Aspartate Receptor (NMDAR) Encephalitis: Distinct Pattern of Disease
J. Ge, *J. Wang, P. Wu, Y. Guan, C. Zuo;*
Huashan Hospital, Shanghai, CHINA.

OP-793
Safety, biodistribution, and dosimetry of [18F]OP-801, a novel neuroinflammation PET biomarker, in healthy individuals
F. Moradi[1], *M. Jovin*[1], *N. Malik*[1], *J. H. Park*[1], *V. Ferri*[1], *M. L. James*[1], *J. L. Cleland*[2], *S. Maricich*[2];
[1]*Stanford University, Stanford, CA, UNITED STATES OF AMERICA,* [2]*Ashvattha Therapeutics, Redwood City, CA, UNITED STATES OF AMERICA.*

OP-794
Dopaminergic Damage Pattern Predicts Phenoconversion Time in Isolated Rapid Eye Movement Sleep Behaviour Disorder
J. Ge, *Q. Xu, H. Lin, Y. Guan, C. Zuo, P. Wu, H. Yu;*
Huashan Hospital, Shanghai, CHINA.

OP-795
[^{18}F]F-SynVesT-1 and [^{18}F]F-FDG PET imaging in the pre-surgical evaluation of MRI-negative children with focal cortical dysplasia
L. Xiao, *Y. Tang, J. Yang, S. Hu;*
Department of Nuclear Medicine, Xiangya Hospital, Central South University, Changsha, CHINA.

OP-796
Mapping Sudden sensorineural hearing loss-related brain activation: a preliminary study by Using [18 F] SynVesT-1 and PET Imaging.
J. Zhong[1], *S. Hu*[1], *E. Zhou*[2];
[1]*Department of Nuclear Medicine, XiangYa Hospital, Central South University, Changsha, CHINA,* [2]*2Department of Otolaryngology Head and Neck Surgery, Hunan Provincial People's Hospital (First Affiliated Hospital of Hunan Normal University), Changsha, CHINA.*

OP-797
Lower synaptic density and its association with cognitive dysfunction in patients with obsessive-compulsive disorder
J. Hou, *Q. Xiao, L. Xiao, S. Hu;*
Xiangya Hospital, Central South University, Changsha, CHINA.

OP-798
A1 adenosine receptor availability and perfusion in the human brain during acute normobaric hypoxia measured with [F-18]CPFPX PET/MRI
H. Weis[1,2], *M. Michno*[3], *J. Schmitz*[4], *A. Foerges*[3], *S. Beer*[3], *B. Neumaier*[5], *A. Drzezga*[1], *D. Aeschbach*[4], *A. Bauer*[3], *J. Tank*[4], *E. Elmenhorst*[6], *D. Elmenhorst*[3];
[1]*Department of Nuclear Medicine, University Cologne, Germany, Cologne, GERMANY,* [2]*Institute of Aerospace Medicine, German Aerospace Center, Cologne, Germany, GERMANY,* [3]*Institute of Neuroscience and Medicine (INM-2), Forschungszentrum Jülich, Jülich, GERMANY,* [4]*Institute of Aerospace Medicine, German Aerospace Center, Cologne, GERMANY,* [5]*Institute of Neuroscience and Medicine (INM-5), Forschungszentrum Jülich, Jülich, GERMANY,* [6]*Institute of Aerospace Medicine, German Aerospace Center, Cologne, Cologne, GERMANY.*

OP-799
mGluR5 and glutamate involvement in Autism spectrum disorder (ASD) adult patients : a multimodal imaging study
A. Dupont[1,2], *N. Arlicot*[1,2,3], *L. Barantin*[4], *J. Vercouillie*[4], *C. Tauber*[5],
V. Gissot[6], *F. Bonnet-Brilhault*[7,2], *M. Santiago-Ribeiro*[8,2,3];
[1]*Radiopharmacie, CHRU Tours, Tours, FRANCE,* [2]*Inserm U 1253, Tours, FRANCE,* [3]*Inserm CIC 1415, Tours, FRANCE,* [4]*Inserm U 1253, Tours, FRANCE,* [5]*Inserm U1253, Tours, FRANCE,* [6]*CIC1415, Chru Tours, Tours, FRANCE,* [7]*Centre Universitaire de Pédopsychiatrie, Chru Tours, Tours, FRANCE,* [8]*Médecine nucléaire, Chru Tours, Tours, FRANCE.*

1608

Tuesday, September 12, 2023, 4:45 PM - 6:15 PM
Hall F2

Thyroid Committee - TROP Session: Nuclear Medicine Imaging in Thyroid and Parathyroid Disorders

OP-800
The Risk of Malignancy of Thyroid PET-Avidomas on ^{18}F-FDG PET/CT using the Bethesda System for Reporting Thyroid Cytopathology
H. Coerts[1], *F. J. van Kemenade*[1], *F. A. Verburg*[1], *B. de Keizer*[2], *J. L. F. Raithel*[1], *T. M. van Ginhoven*[1];
[1]*Erasmus Medical Center, Rotterdam, NETHERLANDS,* [2]*University Medical Center Utrecht, Utrecht, NETHERLANDS.*

OP-801
Iodine-123 diagnostic imaging in the early follow-up of differentiated thyroid cancer patients: wich is the best acquisition timing ?
A. Campenni'[1], *R. Ruggeri*[1], *M. Siracusa*[1], *A. Rappazzo*[1], *V. Davì*[1], *A. Nicocia*[1], *D. Cardile*[1], *S. Baldari*[1], *L. Giovanella*[2];
[1]*Ospedale Gaetano Martino, Messina, ITALY,* [2]*Ente Ospedaliero Cantonale, 6500, Bellinzona, SWITZERLAND.*

OP-802
Prospective comparison of F-18-TFB and I-124 PET/CT in metastatic thyroid cancer
P. Backhaus[1,2], *K. Pentlow*[2], *A. L. Ho*[2,3], *A. Mauguen*[2], *J. A. Fagin*[2], *N. V. K. Pillarsetty*[2], *S. K. Lyashchenko*[2], *E. Burnazi*[3], *R. A. Ghossein*[2], *S. Chhabra*[2], *M. Abusamra*[2], *S. M. Larson*[2], *H. Schöder*[2], *J. O'Donoghue*[2], *W. Weber*[4], *R. K. Grewal*[2];
[1]*University Hospital Münster, Münster, GERMANY,* [2]*Memorial Sloan Kettering Cancer Center, New York City, NY, UNITED STATES OF AMERICA,* [3]*Weill Cornell Medical College, New York City, NY, UNITED STATES OF AMERICA,* [4]*Technical University Munich, München, GERMANY.*

OP-803
Diagnostic value of [99mTc] Tc-HYNIC-TOC scintigraphy in the management of differentiated thyroid cancer with elevated thyroglobulin and negative radioiodine whole-body scan
A. Aghaee, *E. Askari, S. Shafiei, K. Aryana;*
Nuclear Medicine Research Center,Mashhad University Of Medical Sciences, Mashhad, IRAN, ISLAMIC REPUBLIC OF.

OP-804
Dual time ^{18}F-Fluorocholine PET/CT in patients with primary hyperparathyroidism
L. Vija[1], *A. Latgé*[1], *M. Sinigaglia*[1], *C. Renaud*[2], *S. Grunenwald*[2], *P. Pascal*[1], *S. Kanoun*[1], *S. Zerdoud*[1], *S. Brillouet*[1], *M. Terroir Cassou-Mounat*[1], *T. Cassou Mounat*[1], *L. O. Dierickx*[1], *F. Courbon*[1];
[1]*Institut Claudius Regaud-Oncopole, Toulouse Cedex 9, FRANCE,* [2]*CHU Toulouse, Toulouse Cedex 9, FRANCE.*

OP-805
^{18}F-fluorocholine (FCH) PET/CT performance to detect hyperfunctioning parathyroid glands in patients with no definite kidney disease and whose PTH serum level and/or calcemia are within the normal range. 786 PET/CTs in one centre.
J. Talbot[1], *C. Aveline*[2], *J. Zhang-Ying*[2], *O. Belissant-Benesty*[2], *J. Ohnona*[2], *S. Périé*[3], *S. Gaujoux*[4], *I. Wagner*[2], *M. Bennis*[5], *F. Ménégaux*[4], *S. Christin-Maître*[5], *J. Haymann*[1], *B. Baujat*[6], *S. Balogova*[7], *F. Montravers*[2];
[1]*APRAMEN, Hopital Tenon, Paris, FRANCE,* [2]*Hopital Tenon, Paris, FRANCE,* [3]*CH privé Ambroise Paré Hartmann, Neuilly sur seine, FRANCE,* [4]*GH Pitié-Salpétrière, Paris, FRANCE,* [5]*Hôpital St Antoine, Paris, FRANCE,* [6]*Hôpital Tenon, Paris, FRANCE,* [7]*Comenius University, Bratislava, SLOVAKIA.*

OP-806
First-line FCH PET/CT versus MIBI SPECT/CT in the surgical management of primary hyperparathyroidism: the multicentre APACH2 phase III trial
E. Quak[1], *A. Lasne-Cardon*[1], *M. Cavarec*[2], *B. Lireux*[1], *V. Bastit*[1], *N. Roudaut*[2], *P. Salaun*[2], *N. Keromnes*[2], *G. Potard*[2], *P. Vaduva*[3], *A. Esvant*[3], *F. Jegoux*[3], *O. Crouy-Chanel*[3], *A. Devillers*[4], *C. Guery*[4], *C. Lasnon*[1], *R. Ciappuccini*[1], *M. Sali-Dauda*[1], *B. Legrand*[1], *A. Estienne*[1], *J. Grellard*[1], *S. Bardet*[1], *B. Clarisse*[1];
[1]*Francois Baclesse Cancer Centre, Caen, FRANCE,* [2]*University Hospital of Brest, Brest, FRANCE,* [3]*University Hospital of Rennes, Rennes, FRANCE,* [4]*Eugene Marquis Cancer Institute, Rennes, FRANCE.*

OP-807
PET/CT with [^{11}C]-methionine in the diagnosis of tertiary hyperparathyroidism
M. Kolodziej[1], *M. Saracyn*[1], *A. Lubas*[2], *M. Dziuk*[3], *A. Mazurek*[3], *J. Smoszna*[2], *O. Kaminska*[3], *S. Niemczyk*[2], *G. Kaminski*[1];
[1]*Department of Endocrinology and Isotope Therapy, Military Institute of Medicine - National Research Institute, Warszawa, POLAND,* [2]*Department of Internal Medicine, Nephrology and Dialysis, Military Institute of Medicine - National Research Institute, Warszawa, POLAND,* [3]*Department of Nuclear Medicine, Military Institute of Medicine - National Research Institute, Warszawa, POLAND.*

OP-808
Performance of multiphase iodine contrast enhanced CZT SPECT-CT in the detection of parathyroid adenomas
M. Ochoa Figueroa, *F. Askling, T. Lööw, P. Norberg, M. Ressner, J. Dahl, V. Sanchez-Rodriguez;*
Universitetssjukhuset i Linköping, Linköping, SWEDEN.

1609

Tuesday, September 12, 2023, 4:45 PM - 6:15 PM
Hall G2

e-Poster Presentations Session 12 - Dosimetry Committee: Dosimetry Simphony

EPS-231
Estimation of absorbed tumour doses in patients treated with Yttrium-90 radioembolization in the prospective TRACE trial
B. Lambert[1], *Y. D'Asseler*[2], *E. Dhondt*[2], *L. Hermie*[2], *L. Huyck*[2], *H. Van Vlierberghe*[3], *L. Defreyne*[3];
[1]*AZ Maria Middelares en AZ Jan Palfijn Gent, Gent, BELGIUM,* [2]*Ghent University Hospital, Gent, BELGIUM,* [3]*Ghent University, Gent, BELGIUM.*

EPS-232
A Dosimetric Study of Liver and Tumors for Patients Undergoing HO-166 Microspheres Radioembolization
L. Miseo[1], *G. Iaccarino*[1], *M. D'Andrea*[1], *S. Ungania*[1], *A. Soriani*[1], *F. Murtas*[1], *M. Pacilio*[2], *D. Maccora*[3], *R. Sciuto*[3], *G. E. Vallati*[4], *B. Cassano*[1];
[1]*Laboratory of Medical Physics and Expert Systems, IRCCS Regina Elena National Cancer Institute, Rome, ITALY,* [2]*Medical Physics Division, Azienda Ospedaliera-Universitaria Policlinico Umberto I, Rome, ITALY,* [3]*Nuclear Medicine Unit, IRCCS Regina Elena National Cancer Institute, Rome, ITALY,* [4]*Interventional Radiology Unit, IRCCS Regina Elena National Cancer Institute, Rome, ITALY.*

EPS-233
Quantification accuracy evaluation of Yttrium-90 PET for post-therapeutic voxelised dosimetry on three generations PET/CT scanners: a phantom study
G. Croes, *J. van Sluis, A. Willemsen, W. Noordzij, O. Ivashchenko;*
UMCG, Groningen, NETHERLANDS.

EPS-234
Overestimation in 90Y-PET/CT based mean lung doses following 90Y-radioembolization
S. Kappadath, *B. P. Lopez, E. C. Henry, B. M. Kelley, A. Mahvash;*
UT MD Anderson Cancer Center, Houston, TX, UNITED STATES OF AMERICA.

EPS-235
A Model to Describe the DNA Damage Response in Blood Cells During Radioiodine Therapy
S. Schumann[1], *H. Scherthan*[2], *S. Schoof*[2], *P. Hartrampf*[1], *A. K. Buck*[1], *M. Port*[2], *M. Lassmann*[1], *U. Eberlein*[1];
[1]*Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, GERMANY,* [2]*Bundeswehr Institute of Radiobiology affiliated to the University of Ulm, Munich, GERMANY.*

EPS-236
Validation of a Monte Carlo Simulation Model for Quantification of DNA Double-Strand Breaks in Lymphocyte Nuclei by Ex Vivo Internal Irradiation with Radionuclides
M. Salas Ramirez[1], *L. Maigne*[2], *G. Fois*[2], *H. Scherthan*[3], *M. Lassmann*[1], *U. Eberlein*[1];
[1]*University Hospital Würzburg, Department of Nuclear Medicine, Würzburg, GERMANY,* [2]*Physics Laboratory of Clermont, University of Clermont Auvergne, Clermont, FRANCE,* [3]*Bundeswehr Institute of Radiobiology affiliated to the University of Ulm, Munich, GERMANY.*

EPS-237
Dose-dependent relative biological effectiveness of ^{225}Ac compared to ^{177}Lu during [^{225}Ac]Ac-PSMA and [^{177}Lu]Lu-PSMA radionuclide therapy
M. Rumiantcev[1], *W. Li*[2], *S. Lindner*[1], *G. Liubchenko*[1], *S. Resch*[1], *P. Bartenstein*[1], *S. Ziegler*[1], *G. Böning*[1], *A. Delker*[1];
[1]*Department of Nuclear Medicine, LMU Hospital, Munich, GERMANY,* [2]*Federal Office for Radiation Protection, Oberschleißheim, GERMANY.*

EPS-238
PET Quantification Performance of the Oversize-Volume-of-Interest Approach in the Context of Tumour Dosimetry in Radionuclide Therapy Planning
N. Hammersen, *W. Jentzen, F. Stawitzki, K. Herrmann, D. Kersting, P. Fragoso Costa, A. Moraitis;*
Department of Nuclear Medicine at University Hospital Essen, Essen, GERMANY.

EPS-239
Investigating various parameters on the labeling efficiency of ^{67}Ga-phytate and its absorbed dose estimation in humans based on mouse data
z. bayat[1], *N. Vahidfar*[2], *E. Saeedzadeh*[1], *M. Sadeghi*[3], *S. Farzanefar*[2];
[1]*Radiation Medical Engineering, Science and Research branch, Islamic Azad University, Tehran, Iran, ISLAMIC REPUBLIC OF,* [2]*Department of Nuclear Medicine, Vali-Asr Hospital, Tehran University of Medical Sciences, Tehran, Iran, ISLAMIC REPUBLIC OF,* [3]*Medical Physics Department, School of Medicine, Iran University of Medical Sciences, Tehran, Iran, ISLAMIC REPUBLIC OF.*

EPS-240
Head-to-head comparison of ^{177}Lu-DOTATATE dosimetry between high-speed 360° CZT-SPECT/CT and conventional SPECT/CT systems
L. Imbert, *C. Boursier, V. Roch, E. Chevalier, P. Marie;*
CHU Nancy Hopital Brabois Adultes, Vandoeuvre Les Nancy, FRANCE.

EPS-241
Validation of Lu-177 PSMA dosimetry from 113keV energy peak using digital 3D SPECT/CT imaging system
H. Gröhn, *M. Hakulinen, K. T. Tapani, T. M. Laitinen;*
Kuopio University Hospital, Kuopio, FINLAND.

EPS-242
Semiautomatic Segmentation for Tumour Dosimetry in PSMA Radiopharmaceutical Therapy using a Novel Digital Twins Framework
R. Fedrigo[1,2], *L. Polson*[1,2], *C. Li*[1,2], *S. Harsini*[1], *I. Bloise*[1], *J. Brosch-Lenz*[1], *B. Saboury*[3], *F. Bénard*[1,2,4], *A. Rahmim*[1,2,4], *C. Uribe*[1,2,4];
[1]*BC Cancer Research Institute, Vancouver, BC, CANADA,* [2]*University of British Columbia, Vancouver, BC, CANADA,* [3]*National Institutes of Health (NIH), Bethesda, MD, UNITED STATES OF AMERICA,* [4]*BC Cancer, Vancouver, BC, CANADA.*

EPS-243
Does urinary excretion rate change over the courses of 177Lu-PSMA therapies ?
L. Ferrer[1,2], *M. CHABIRON*[3], *C. Rousseau*[1,2], *N. Varmenot*[1,2];
[1]*ICO René Gauducheau, St Herblain cedex, FRANCE,* [2]*Nantes Université, Univ Angers, INSERM, CNRS, CRCI2NA, Nantes, FRANCE,* [3]*Nantes Université, Nantes, FRANCE.*

EPS-244
Outcome-Driven Assessment of Single-Time-Point Dosimetry for PSMA-Directed Radiopharmaceutical Therapy
J. Hu, *S. Xue, C. Vinicius Gomes Ferreira, L. Mercolli, A. Afshar-Oromieh, A. Rominger, K. Shi;*
University of Bern, Department of Nuclear Medicine, 3008 Bern, SWITZERLAND.

EPS-245
Comparison of the Images Taken at the 1st and 4th Hours After ^{99m}TC-MAA Injection in ^{90}Y TARE Treatment Planning
B. Kovan[1], *E. Işık*[1], *Y. Şanlı*[1], *S. Kuyumcu*[1], *B. Demir*[2];
[1]*Istanbul Faculty of Medicine, Nuclear Medicine Department, Istanbul, TÜRKIYE,* [2]*Istanbul University, Faculty of Science, Istanbul, TÜRKIYE.*

EPS-246
Evaluation of a portable high-resolution gamma camera for personalized dosimetry during radioiodine treatment ofthyroid diseases
T. Bossis[1,2], *M. Verdier*[1,2], *L. Pinot*[1], *F. Bouvet*[1], *T. Beaumont*[3], *D. Broggio*[3], *S. Lamart*[3], *O. Caselles*[4], *S. Zerdoud*[4], *L. Ménard*[1,2];
[1]*IJCLab - CNRS/IN2P3, Université Paris-Saclay, Orsay, FRANCE,* [2]*IJCLab - CNRS/IN2P3, Université Paris Cité, Orsay, FRANCE,* [3]*Internal Dose Assessment Laboratory, IRSN, Fontenay-aux-Roses, FRANCE,* [4]*Institut Claudius Regaud, IUCTO, Toulouse, FRANCE.*

EPS-247
3D Whole-Body SPECT images for dosimetry of ^{177}Lu-PSMA treatment using a 360° CZT gamma camera
L. Vergnaud[1], *A. Giraudet*[2], *E. Paquet*[2], *T. Baudier*[1], *J. Badel*[1], *D. Sarrut*[1];
[1]*Centre Léon Bérard / CREATIS, Lyon, FRANCE,* [2]*Centre Léon Bérard, Lyon, FRANCE.*

EPS-248
Comparison of Model Implementations in SAAM II and MATLAB/SimBiology: a PBPK model for PRRT with [^{177}Lu]Lu-DOTATATE
V. Vasic[1,2], *J. Gustafsson*[3], *E. Yousefzadeh-Nowshahr*[1,2], *A. Beer*[1], *K. Sjögreen Gleisner*[3], *G. Glatting*[1,2];
[1]*Department of Nuclear Medicine, Ulm University Medical Centre, Ulm, GERMANY,* [2]*Medical Radiation Physics, Department of Nuclear Medicine, Ulm University, Ulm, Germany, Ulm, GERMANY,* [3]*Medical Radiation Physics, Lund University, Lund, Sweden, Lund, SWEDEN.*

EPS-249
Current Practice in Reporting Internal Dosimetry for [177Lu]Lu-DOTA-TATE Therapy: Literature Review
O. Ivashchenko[1], *J. O'Doherty*[2], *T. Perez*[3], *J. Tran-Gia*[4], *E. Hippeläinen*[5], *M. Sandström*[6], *C. Stokke*[7], *G. Glatting*[8], *M. Cremonesi*[9];
[1]*University Medical Center Groningen, Groningen, NETHERLANDS,* [2]*Siemens Medical Solutions, Malvern, PA, UNITED STATES OF AMERICA,* [3]*University Hospital of Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, SPAIN,* [4]*University Hospital Würzburg, Würzburg, GERMANY,* [5]*University of Helsinki and Helsinki University Hospital, Helsinki, FINLAND,* [6]*Uppsala University, Uppsala, SWEDEN,* [7]*Oslo University Hospital, Oslo, NORWAY,* [8]*Ulm University Hospital, Ulm, GERMANY,* [9]*European Institute of Oncology IRCCS, Milan, ITALY.*

EPS-250
Clinical dosimetry in [^{177}Lu]Lu-PSMA therapy: kidney mean absorbed dose difference between subsequent cycles
E. Owers, *E. Rijkhorst, M. Dotinga, L. J. de Wit-van der Veen, D. M. V. de Vries - Huizing;*
Antoni van Leeuwenhoek, Amsterdam, NETHERLANDS.

EPS-251
Implementation of an ^{18}F PET / ^{177}Lu SPECT Phantom Study for Personalized Theranostics in PSMA Radiopharmaceutical Therapies
R. Fedrigo[1,2], *J. Tran-Gia*[3], *J. Brosch-Lenz*[1], *P. Petric*[4], *L. Fougner*[1], *K. Sabo*[4], *R. Ralea*[5], *S. Harsini*[1], *I. Bloise*[1], *J. Beauregard*[6], *F. Bénard*[1,2,4], *A. Rahmim*[1,2,4], *C. Uribe*[1,2,4];
[1]*BC Cancer Research Institute, Vancouver, BC, CANADA,* [2]*University of British Columbia, Vancouver, BC, CANADA,* [3]*University of Würzburg, Würzburg, GERMANY,* [4]*BC Cancer, Vancouver, BC, CANADA,* [5]*Vancouver General Hospital, Vancouver, BC, CANADA,* [6]*Laval University, Laval, QC, CANADA.*

1610

Tuesday, September 12, 2023, 16:45 - 18:15
Hall K

CTE 8 - Technologists Committee: Gynaecological Studies

OP-809
Gynaecological studies: where NM is and its importance
K. Dendl;
Heidelberg University Hospital, Department of Nuclear Medicine, Heidelberg, GERMANY.

OP-810
Radiotracers used in gynaecological studies
N. Hartman;
Swansea University, Head of nuclear medicine, Singleton Hospital, Swansea, UNITED KINGDOM.

OP-811
The role of the Technologists in Gynaecological studies: protocols and patient care
G. Paixão;
Hospital Garcia de Orta, Departamento de Medicina Nuclear Hospital Garcia de Orta, Almada, PORTUGAL.

1611

Tuesday, September 12, 2023, 16:45 - 18:15
Hall G1

EU Policy Symposium 2 - Policy & Regulatory Affairs Committee: Regulatory Challenges of Radiopharmaceuticals

OP-813
Regulatory Challenges of Radiopharmaceuticals

1701

Wednesday, September 13, 2023, 08:00 - 09:30
Hall A

CME 13 - Translational Molecular Imaging & Therapy + Oncology & Theranostics + Radiopharmaceutical Sciences Committee: Diagnostic Imaging and Theranostics in Breast Cancer - Old Targets, New Tracers

OP-819
Targeting HER2 from Preclinical to the Clinics
M. Keyaerts;
Department of Nuclear Medicine, Faculty of Medicine and Pharmacy, University Hospital Brussels, Free University Brussels, Jessa Hospital, Hasselt, BELGIUM.

OP-820
Estrogen Receptor-Targeted Imaging: Appropriate Use Criteria (AUC) and Interpretation
G. Ulaner;
Hoag Family Cancer Institute, New Port Beach, UNITED STATES OF AMERICA.

OP-821
Clinical Targets Beyond the Classical Approaches
P. Backhaus;
Department of Nuclear Medicine, University Hospital Munster, Münster, GERMANY.

1702

Wednesday, September 13, 2023, 08:00 - 09:30
Hall D (Arena)

Debate 6 - Oncology & Theranostics Committee / EHA: Staging Lymphoma - Ann Arbour Outdated and Replaced by MTV?

OP-822
Staging Lymphoma: Ann Arbour outdated and replaced by Metabolic Tumor Volume? - Pro
A. Cottereau;
Department of Nuclear Medicine, Cochin Hospital, Assitance Publique Hôpitaux de Paris, Université de Paris, Paris, FRANCE.

OP-823
Staging Lymphoma: Ann Arbour outdated and replaced by Metabolic Tumor Volume? - Contra
B. von Tresckow;
Department of Hematology and Stem Cell Transplantation, University of Duisburg-Essen and German Cancer Consortium (DKTK)-University Hospital Essen, Essen, GERMANY.

1703

Wednesday, September 13, 2023, 08:00 - 09:30
Hall E1

LIPS Session 13 - Dosimetry Committee: Case Reading - Dosimetry in SIRT

OP-827
Dosimetry in whole liver and whole lobe targeting
E. Garin;
Cancer Centre Eugene Marquis, Department of Nuclear Medicine, Rennes, FRANCE.

OP-828
Dosimetry in specific tumour and oligosegmental targeting
A. Harteveld;
Erasmus Medical Center, Department of Radiology and Nuclear Medicine, Rotterdam, NETHERLANDS.

OP-829
Dosimetry of off-target accumulation
C. Chiesa;
Department of Nuclear Medicine, Foundation IRCCS Istituto Nazionale Tumori, Milan, ITALY.

1704

Wednesday, September 13, 2023, 8:00 AM - 9:30 AM
Hall E2

Dosimetry Committee - TROP Session: Clinical Disimetry II - Tutti Frutti

OP-831
An Update on Normal Tissue Absorbed Doses for Patients Treated with [^{177}Lu]Lu-lilotomab satetraxetan; Results From Two Studies
J. Blakkisrud[1,2], *A. Løndalen*[1], *R. Midthun*[1], *C. Stokke*[1,3];
[1]Oslo University Hospital, Oslo, NORWAY, [2]University of Michigan, Ann Arbor, MI, UNITED STATES OF AMERICA, [3]University of Oslo, Oslo, NORWAY.

OP-832
Absorbed Doses to Kidneys and Tumours for Alpha-Emitter Peptide Receptor Radionuclide Therapies Estimated with [^{177}Lu]Lu-DOTATATE SPECT Images and Biokinetic Models
M. Kvassheim[1,2], *J. Blakkisrud*[1,3], *M. E. Revheim*[4,2,5], *A. J. Tulipan*[4,6], *C. Stokke*[1,7];
[1]Department of Physics and Computational Radiology, Division of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, NORWAY, [2]Faculty of Medicine, University of Oslo, Oslo, NORWAY, [3]University of Michigan, Ann Arbor, MI, UNITED STATES OF AMERICA, [4]Department of Nuclear Medicine, Division of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, NORWAY, [5]The Intervention Centre, Oslo University Hospital, Oslo, NORWAY, [6]Nuclear Medicine/PET center, Department of Radiology, Haukeland University Hospital, Bergen, NORWAY, [7]Department of Physics, University of Oslo, Oslo, NORWAY.

OP-833
Comparison of Commercial Software Solutions for ^{177}Lu Labelled Radiopharmaceutical Therapies
S. Beykan, *M. Lassmann, S. Schlögl;*
University Hospital Würzburg, Würzburg, GERMANY.

OP-834
Determination of the treatment coverage of theragnostic ^{124}I-8H9 antibody to treat diffuse pontine glioma by convective enhance delivery
A. França Velo[1], *A. Giantini Larsen*[2,3], *J. Humm*[1], *P. Zanzonico*[1], *M. Souweidane*[3], *N. Pandit-Taskar*[4];
[1]Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY, UNITED STATES OF AMERICA, [2]Department of Neurosurgery, Memorial Sloan Kettering Cancer Center, New York, NY, UNITED STATES OF AMERICA, [3]Department of Neurological Surgery, Weill Medical College of Cornell University, New York, NY, UNITED STATES OF AMERICA, [4]Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, UNITED STATES OF AMERICA.

OP-835
Accuracy of single-time-point dosimetry using a population-based model selection and Bayesian fitting method
B. Patrianesha[1], *A. Jundi*[1], *M. Naqiyyun*[2], *D. Hardiansyah*[1];
[1]Medical Physics and Biophysics Research Group, Physics Department, Faculty of Mathematics and Natura, Depok, INDONESIA, [2]Nuclear Medicine Department, MRCCC Siloam Hospital, Jakarta, INDONESIA.

OP-836
AI-Generated Synthetic Intermediate Projections could enable SPECT-based bone marrow dosimetry with reduced acquisition time
K. Smits[1], *F. Westerbergh*[1], *J. Hemmingsson*[1], *J. Svensson*[2], *T. Rydén*[3], *P. Bernhardt*[1,3];
[1]Department of Medical Radiation Sciences, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, Gothenburg, SWEDEN, [2]Department of Oncology, Institution of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, Gothenburg, SWEDEN, [3]Department of Medical Physics and Biomedical Engineering (MFT), Sahlgrenska University Hospital, Gothenburg, SWEDEN.

OP-837
RPT-TEC assessment of normal organ toxicity avoidance thresholds for alpha-emitter radiopharmaceutical therapy - an appeal for data.
J. Hesterman[1], *R. Hobbs*[2], *G. Sgouros*[2],
Radiopharmaceutical Therapy Normal Tissue Effectsin the Clinic (RPT-TEC);
[1]Ratio Therapeutics, Boston, MA, UNITED STATES OF AMERICA, [2]Johns Hopkins University, Baltimore, MD, UNITED STATES OF AMERICA.

OP-838
Impact Of Small Patient Motion During SPECT/CT Scans Onto Activity Quantification Of ^{177}Lu-PSMA Based on A Phantom Simulation
S. Resch[1], *X. Shen*[1], *M. Reymann*[2], *F. Basi Massanes*[3], *P. Bartenstein*[1], *G. Platsch*[2], *A. Vija*[3], *G. Böning*[1], *A. Delker*[1];
[1]LMU Klinikum Großhadern, München, GERMANY, [2]Siemens Healthcare GmbH, Molecular Imaging, Forchheim, GERMANY, [3]Siemens Medical Solutions UNITED STATES OF AMERICA Inc., Molecular Imaging, Hoffman Estates, IL, UNITED STATES OF AMERICA.

OP-839
Comparison of transmission-dependent and energy-window based scatter correction methods for quantitative SPECT imaging for ^{225}Ac
G. Liubchenko, *M. Rumiantcev, S. Resch, M. Zacherl, F. Gildehaus, P. Bartenstein, S. Ziegler, G. Böning, A. Delker;*
LMU Klinikum Munich, Munich, GERMANY.

1705

Wednesday, September 13, 2023, 8:00 AM - 9:30 AM
Hall B

Cutting Edge Science Track - Featured Session: Dynamic Imaging

OP-840
State of the Art in Quantitative Dynamic Imaging
G. Wang;
Department of Radiology, University of California Davis Health, Scacramento, UNITED STATES OF AMERICA

OP-841
Prediction of bone turnover in chronic kidney disease with hemodialysis patients using K_i-Patlak dynamic ^{18}F-NaF PET/CT imaging
K. Khamwan[1], *V. Sanoesan*[1], *J. Phannajit*[1], *T. Sawatnatee*[2], *B. Phromphao*[2], *C. Sukprakhun*[1], *P. Susantitaphong*[1], *K. Kingpetch*[1];
[1]Chulalongkorn University, Bangkok, THAILAND, [2]King Chulalongkorn Memorial Hospital, Bangkok, THAILAND.

OP-842
Automated and reproducible processing and kinetic modelling of whole-body [15O]H2O PET/CT data
S. Palonen[1], *J. Tuisku*[2], *H. Kärpijoki*[2], *S. Nesterov*[2], *V. Oikonen*[2], *R. Klén*[2], *L. Nummenmaa*[2], *J. Knuuti*[1];
[1]Turku PET centre, Turku University, Turku, FINLAND, [2]Turku PET centre, Turku, FINLAND.

OP-843
Shortening Dynamic [^{11}C]PK11195 PET Protocol for Parametric Imaging Using Supervised Clustering to Improve Clinical Feasibility
D. B. A. Mantovani[1], *M. S. Pitombeira*[1], *P. N. Schuck*[2], *C. Buchpiguel*[1], *D. de Paula Faria*[1], *A. Marques da Silva*[1];
[1]University of Sao Paulo, Sao Paulo, BRAZIL, [2]Weill Cornell Medical College, New York, NY, UNITED STATES OF AMERICA.

OP-844
Feasibility of Dynamic Total-Body Pre-therapy PET for Predicting Radiopharmaceutical Therapy (RPT) Dosimetry: a simulation study
J. Hong[1], *M. Kassar*[2], *A. Rominger*[1], *K. Shi*[1];
[1]University of Bern/Inselspital, Bern, SWITZERLAND, [2]Technical University Munich, Munich, GERMANY.

OP-845
Voxel-wise parametric imaging of 4D PET data :evaluation of new software solution for [^{18}F]-FDG PET kinetic modeling at the whole FOV level.
F. Besson[1,2], *E. Marchal*[1], *S. Faure*[3];
[1]CEA / Inserm / CNRS / Université Paris Saclay, BioMaps, Orsay, FRANCE, [2]Department of Nuclear Medicine-Molecular Imaging, Hôpitaux Universitaires Paris Saclay, AP-HP, Le Kremlin-Bicêtre, FRANCE, [3]Laboratoire de Mathématique d'Orsay, CNRS, Université Paris Saclay, Orsay, FRANCE.

OP-846
Incorporating prior knowledge with physics-informed neural networks to predict arterial input functions from dynamic PET images
M. Ferrante[1], *M. Inglese*[1], *L. Brusaferri*[2], *A. C. Whitehead*[3], *M. L. Loggia*[4], *N. Toschi*[1];
[1]University of Rome Tor Vergata, Roma, ITALY, [2]Department of Radiology, Athinoula A. Martinos Center for Biomedical Imaging, Boston, MA, UNITED STATES OF AMERICA, [3]Institute of Nuclear Medicine, University College London, (UNITED KINGDOM), London, UNITED KINGDOM, [4]2)Department of Radiology, Athinoula A. Martinos Center for Biomedical Imaging, Boston, MA, UNITED STATES OF AMERICA.

OP-847
Impact of AI-based Image Denoising on Quantitative Kinetic Analysis in Dynamic PET imaging
B. Liu[1], *G. Hu*[2], *X. Wang*[2], *L. Huo*[2], *H. Ding*[1], *H. Zhang*[1];
[1]Tsinghua University, Beijing, CHINA, [2]Peking Union Medical College Hospital, Beijing, CHINA.

OP-848
Myocardial Dynamic Positron Emission Tomography Later Time Frames Prediction Using Deep Learning
M. Mokri[1], *M. Safari*[2], *L. Archambault*[2], *S. Kaviani*[1], *D. Juneau*[3], *C. Cohalan*[3], *J. Carrier*[1,3];
[1]Université de Montréal, Montreal, QC, CANADA, [2]Université Laval, Quebec City, QC, CANADA, [3]Centre hospitalier de l'Université de Montréal, Montreal, QC, CANADA.

1706

Wednesday, September 13, 2023, 8:00 AM - 9:30 AM
Hall C

Clinical Oncology Track - TROP Session: Localised Treatments

OP-849
Is there any factor that influences the quality of the I125 placement in non palpable breast lesions?
O. Ajuria Illarramendi, *A. Martinez Lorca, U. Vera Schmulling, P. Azpeitia Hernandez, M. Gutierrez Guerrero, P. Paredes Rodriguez, T. Navarro Martinez, M. Orduña Diez;*
Hospital universitario ramon y cajal, Madrid, SPAIN.

OP-850
Investigation on Dose-Toxicity and Dose-Response Relationship in Neuroendocrine Liver Metastases treated with Holmium-166 Radioembolization
K. Ramdhani, *J. J. Verduin, S. C. Ebbers, M. L. J. Smits, R. C. G. Bruijnen, M. G. E. H. Lam, A. J. A. T. Braat;*
University Medical Center Utrecht, Utrecht, NETHERLANDS.

OP-851

Radioembolization of HCC Patients for Curative Intent with Personalized Yttrium-90 Dosimetry (RAPY90D)

S. Kappadath, *E. C. Henry, B. P. Lopez, A. Mahvash;*
UT MD Anderson Cancer Center, Houston, TX, UNITED STATES OF AMERICA.

OP-852

166Holmium-SIRT after PRRT (HEPAR PLuS) versus PRRT-only in Patients with Metastatic Neuroendocrine Tumors: a Propensity-score Matched Analysis

A. Braat[1], *T. Walter*[2], *D. de Vries-Huizing*[3], *J. Theysohn*[4], *S. Barton*[5], *E. Ekkelenkamp*[6], *B. Lachachi*[2], *R. de Jong*[6], *L. van Golen*[3], *H. Lanzafame*[4], *L. Milot*[2], *H. Lahner*[4], *W. Veldhuis*[1], *M. Tesselaar*[3], *M. Lam*[1];
[1]*University Medical Center Utrecht, Utrecht, NETHERLANDS,* [2]*Hospices Civils de Lyon, Lyon, FRANCE,* [3]*NKI-AVL, Amsterdam, NETHERLANDS,* [4]*University Hospital Essen, Essen, GERMANY,* [5]*Barton Biostatistics Ltd, London, UNITED KINGDOM,* [6]*Medical Affairs Interventional Oncology Terumo Europe NV, Leuven, BELGIUM.*

OP-853

Intratumoral Holmium-166 Microsphere Brachytherapy in Patients with Pancreatic Ductal Adenocarcinoma: The Sloth Project

C. Y. Willink, *S. F. M. Jenniskens, M. W. J. Stommel, M. J. R. Janssen, J. J. Fütterer, K. J. H. M. van Laarhoven, J. F. W. Nijsen;*
Radboudumc, Nijmegen, NETHERLANDS.

OP-854

A phase II trial to evaluate the accuracy of an intra-operative radio-guided approach with a beta probe for 68Ga-DOTATOC in patients affected by GEP-NET of the ileum.

F. Mattana[1], *E. Bertani*[2], *F. Collamati*[3], *R. Mirabelli*[3], *A. M. Bonomi*[2], *A. Barone*[1], *L. L. Travaini*[1], *M. Ferrari*[4], *E. Pisa*[5], *N. Fusco*[5], *U. Fumagalli Romario*[2], *F. Ceci*[1,6];
[1]*IEO European Institute of Oncology, Nuclear Medicine, Milano, ITALY,* [2]*IEO European Institute of Oncology, Division of Digestive Surgery, Milano, ITALY,* [3]*INFN National Institute of Nuclear Physics, Nuclear Physics, Rome, ITALY,* [4]*IEO European Institute of Oncology, Medical Physics, Milano, ITALY,* [5]*IEO European Institute of Oncology, Pathology, Milano, ITALY,* [6]*Department of Oncology and Hemato-Oncology, University of Milan, ITALY.*

OP-855

Prediction of acute radiation-induced lung toxicity after SBRT using dose-volume parameters from functional mapping on Gallium-68 lung perfusion PET/CT

P. Le Roux, *D. Bourhis, F. Pinot, M. Hamya, G. Goasduff, F. Blanc, S. Hennebicq, M. Mauguen, K. Kerleguer, U. Schick, M. Consigny, O. Pradier, G. Le Gal, P. Salaun, V. Bourbonne, F. Lucia;*
Brest University Hospital, Brest, FRANCE.

OP-856

Intra-arterial Administration of PRRT in Patients with Advanced Meningioma

A. Amerein[1], *A. Rinscheid*[2], *A. Gäble*[1], *A. Krebold*[1], *O. Viering*[1], *A. Berlis*[3], *C. Maurer*[3], *C. Lapa*[1], *C. Pfob*[1], *R. Bundschuh*[1];
[1]*Nuclear Medicine, faculty of medicine, University of Augsburg, Augsburg, GERMANY,* [2]*Medical Physics, University Hospital Augsburg, Augsburg, GERMANY,* [3]*Neuroradiology, faculty of medicine, University of Augsburg, Augsburg, GERMANY.*

OP-857

Preliminary Clinical data in the Phase 1/2a Dose Escalation Trial of 186RNL (Rhenium-186 nanoliposome) (186Re) Obisbemeda in Leptomeningeal Metastases (LM): the ReSPECT-LM Trial

W. Phillips[1], *A. Bao*[2], *N. LaFrance*[3], *M. Hedrick*[3], *M. Moore*[3], *T. Patel*[4], *J. Floyd*[1], *M. Youssef*[4], *J. Michalek*[1], *A. Brenner*[1];
[1]*The University of Texas Health Science Center at San Antonio, San Antonio, TX, UNITED STATES OF AMERICA,* [2]*Case Western Reserve University, San Antonio, TX, UNITED STATES OF AMERICA,* [3]*Plus Therapeutics, Inc, Austin, TX, UNITED STATES OF AMERICA,* [4]*UT Southwestern Medical Center, Dallas, TX, UNITED STATES OF AMERICA.*

1707

Wednesday, September 13, 2023, 8:00 AM - 9:30 AM
Hall F1

Cardiovascular Committee - TROP Session: Heart Failure, Sarcoidosis and Amyloidosis

OP-858

Current practices and access to cardiac bone scans for the detection of transthyretin cardiac amyloidosis based on the results of a large national electronic survey

F. Hyafil[1,2], *W. Amara*[3], *T. Bardin*[4], *B. Bouquillon*[5], *G. Canali*[6], *M. Dubois*[6], *P. Fournier*[7], *S. Guignard*[8], *C. Labeyrie*[9], *D. Legallois*[10], *S. Oghina*[11], *N. Piriou*[12], *P. Sabouret*[13], *C. Sauvage*[5], *O. Toulza*[14], *R. Tresorier*[15], *M. Walle*[16], *T. Damy*[17];
[1]*AP-HP, Paris, FRANCE,* [2]*APHP, European Hospital Georges-Pompidou, Department of Nuclear Medicine, Paris, FRANCE,* [3]*GHI Le Raincy-Montfermeil, Department of Cardiology, Montfermeil, FRANCE,* [4]*University Hospital Strasbourg, Department of Internal Medicine, Strasbourg, FRANCE,* [5]*Carely, Lille, FRANCE,* [6]*Pfizer, Paris, FRANCE,* [7]*University Hospital Toulouse, Department of Cardiology, Toulouse, FRANCE,* [8]*University Hospital Henri Mondor, UPEC, Department of Rheumatology, Créteil, FRANCE,* [9]*University Hospital Bicêtre, Referral Center for Familial Amyloid Neuropathy and other Rare Peripheral Neuropathies, Department of Neurology, Paris, FRANCE,* [10]*University Hospital of Caen-Normandy, Department of Cardiology, Caen, FRANCE,* [11]*APHP (Assistance Publique-Hôpitaux de Paris), Department of Cardiology, French Referral Centre for Cardiac Amyloidosis, Cardiogen Network, Henri Mondor University Hospital, Paris, FRANCE,* [12]*University Hospital of Nantes, Department of Cardiology, Thorax Institute, Nantes, FRANCE,* [13]*Cardiovascular Prevention Institute, Paris, FRANCE,* [14]*University Hospital of Toulouse, Department of Geriatrics, Toulouse, France, Toulouse, FRANCE,* [15]*University Hospital of Clermont Ferrand, Department of Cardiology, Clermond Ferrand, FRANCE,* [16]*Edouard Herriot Hospital, HCL, Department of Upper Limb Orthopedic Surgery, Lyon, FRANCE,* [17]*APHP (Assistance Publique-Hôpitaux de Paris), Department of Cardiology, French Referral Centre for Cardiac Amyloidosis, Cardiogen Network, Henri Mondor University Hospital, Créteil, FRANCE.*

OP-859

SPECT/CT SUV based metrics: a promising diagnostic tool in patients with suspected transthyretin cardiac amyloidosis.

S. Koukouraki[1,2], *N. Kapsoritakis*[1,2], *O. Bourogianni*[1,2], *M. Stathaki*[1,2], *I. Zaganas*[3,4], *A. Patrianakos*[3,5], *A. Plevritaki*[1,5], *D. Corela*[6], *M. Marketou*[7], *E. Foukarakis*[6];
[1]*Medical School, University of Crete, Heraklion-Crete, GREECE,* [2]*Nuclear Medicine department, Medical School, University of Crete, Heraklion, crete, GREECE,* [3]*Medical School, University of Crete, HERAKLION, CRETE, GREECE,* [4]*Neurology Department, Medical School, University of Crete, Heraklion, crete, GREECE,* [5]*Cardiology Department , Medical School University of Crete, Heraklion, crete, GREECE,* [6]*Cardiology Department Venizeleion Hospital, Heraklion-Crete, GREECE,* [7]*Cardiology Department, Medical School, University of Crete, Heraklion-Crete, GREECE.*

OP-860

99mTc-hydroxydiphosphonate Uptake in Soft Tissue Reflects Amyloid Load in Subcutaneous Abdominal Fat Tissue and Harbors Prognostic Value in Wild Type Transthyretin Amyloidosis Patients

H. Tingen[1], *D. Groothof*[1], *A. Tubben*[1], *E. J. Houwerzijl*[1], *F. L. H. Muntinghe*[1], *P. van der Meer*[1], *B. P. C. Hazenberg*[1], *H. L. A. Nienhuis*[1], *R. H. J. A. Slart*[1,2];
[1]*University Medical Center Groningen, Groningen, NETHERLANDS,* [2]*University Twente, Enschede, NETHERLANDS.*

OP-861

Agreement of 68Ga-DOTANOC PET/CT with 18F-FDG PET/CT and Cardiac MR in sarcoid patients with suspected cardiac involvement: A tertiary care center experience

R. Solanki, *A. Sood, S. Kumar, B. R. Mittal;*
Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, INDIA.

OP-862

Cardiac Viability Imaging With 15O-H2O/18F-FDG Positron Emission Tomography Does Not Predict Left Ventricular Ejection Fraction Improvement After Revascularization in Patients With Chronic Ischemic Heart Failure

M. Gram Kjærulff[1], *K. Pryds*[2], *R. Nielsen*[2], *S. Madsen*[1], *T. V. Luong*[1], *L. P. Tolbod*[1], *L. C. Gormsen*[1];
[1]*Department of Nuclear Medicine & PET Centre, Aarhus University Hospital, Aarhus, DENMARK,* [2]*Department of Cardiology, Aarhus University Hospital, Aarhus, DENMARK.*

OP-863

Epicardial adipose tissue is differently associated with myocardial remodeling and perfusion in heart failure with reduced and preserved ejection fraction

Y. Cui, *C. Zheng, S. Gu, J. Lu;*
Department of Radiology and Nuclear Medicine, Xuanwu Hospital, Capital Medical University, Beijing, CHINA.

OP-864

Relationship between left ventricular mechanical dyssynchrony with cardiac resynchronization therapy response in chronic heart failure patients with CRT-D

T. Atabekov, *A. Mishkina, R. Batalov, S. Sazonova, S. Krivolapov, V. Saushkin, M. Khlynin, Y. Varlamova, K. Zavadovsky, S. Popov;*
Cardiology Research Institute, branch of the Federal State Budgetary Scientific Institution "Tomsk National Research Medical Center of the Russian Academy of Sciences", Tomsk, RUSSIAN FEDERATION.

OP-865

The prognostic value of mechanical and electrical dyssynchrony and hibernating myocardium in patients with ischemic heart failure: a comparative study of medical and revascularization therapy

L. Shan[1], *X. Zhang*[2];
[1]*Department of Cardiology, Beijing Anzhen Hospital, Beijing, CHINA,* [2]*Department of Nuclear Medicine, Molecular Imaging Lab, Beijing Anzhen Hospital, Beijing, CHINA.*

OP-866

C-X-C Motif Chemokine Receptor 4-directed Molecular Imaging of the Cardiac Lymphatic System after Acute Myocardial Infarction - Initial Results from the Phase II LOMI Trial

A. Kosmala[1], *A. Dörrler*[1], *N. Hasenauer*[1], *N. Kraus*[2], *S. E. Serfling*[1], *P. E. Hartrampf*[1], *A. K. Buck*[1,3], *T. Higuchi*[1,3,4], *T. Reiter*[2], *R. A. Werner*[1,3,5];
[1]*Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, GERMANY,* [2]*Department of Internal Medicine I, Cardiology, University Hospital Würzburg, Würzburg, GERMANY,* [3]*Comprehensive Heart Failure Center, University Hospital Würzburg, Würzburg, GERMANY,* [4]*Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, JAPAN,* [5]*The Russell H Morgan Department of Radiology and Radiological Sciences, Johns Hopkins School of Medicine, Baltimore, MD, UNITED STATES OF AMERICA.*

1708

Wednesday, September 13, 2023, 08:00 - 09:30
Hall F2

Joint Symposium 6 - Neuroimaging Committee / EAN: Progress in Multimodal Imaging of Parkinson's Disease

OP-867

Novel MR Techniques to Image Parkinson's Disease

E. van de Giessen;
Amsterdam UMC, Radiology and Nuclear Medicine, Amsterdam, NETHERLANDS.

OP-868

Transcranial Sonography to Image Parkinson's Disease

R. Yilmaz;
Ankara University Faculty of Medicine, Ibni Sina Hospital, Ankara, TÜRKIYE.

OP-869
Novel PET Tracers to Image Parkinson's Disease
S. Jakobsen Mo;
Umeå University, Department of Radiation Sciences, Umeå, SWEDEN.

1709

Wednesday, September 13, 2023, 8:00 AM - 9:30 AM
Hall G2

e-Poster Presentations Session 13 - Oncology & Theranostics Committee: Head and Neck Tumours, Lung, Melanoma and Others

EPS-252
Predictors for Disease Free and Progression Free Survival in Metabolic Responders and Non-responders on follow-up FDG PET/CT after Chemoradiation in Nasopharyngeal Cancers
M. Zaman[1], *N. Fatima*[2], *R. Tahseen*[3], *A. Ahmed*[1], *A. Zaman*[4], *S. Zaman*[5], *U. Zaman*[6];
[1]*Dept of Radiology, Aga Khan University Hospital, Karachi, PAKISTAN,* [2]*Dept of Radiology, Aga Khan University Hospital, KARACHI, PAKISTAN,* [3]*Dept of Radiation Oncology, Aga Khan University Hospital, Karachi, PAKISTAN,* [4]*Dept of Medicine, Sunny Downstate Medical Centre, NY, New York, NY, UNITED STATES OF AMERICA,* [5]*Dept of Medicine, Dr Ruth Pfau Hospital, Karachi, PAKISTAN,* [6]*Dept ogf Hem Oncology, Oklahoma University, Okla, Oklahoma, OK, UNITED STATES OF AMERICA.*

EPS-253
Performance of hybrid [^{18}F]FDG PET-MRI for staging of head and neck cancer
E. Droogers, *I. J. Pruis, A. W. A. van der Eerden, A. A. Harteveld, R. Valkema, S. E. M. Veldhuijzen van Zanten; Erasmus Medical Center, Rotterdam, NETHERLANDS.*

EPS-254
The Validity of F-18-FDG PET/CT in the Management of the Patients with Laryngeal Carcinoma After Therapy
J. Petrovic, *J. Milovanovic, A. Jotic, D. Sobic Saranovic; Center for Nuclear Medicine, University Clinical Center of Serbia, Faculty of Medicine, University of Belgrade, Belgrade, SERBIA.*

EPS-255
PET/CT-guided GTV delineation during radiotherapy planning and prognosis evaluation in recurrent oral cavity squamous cell carcinoma
Y. Tian, *Y. Zhang, C. Li, Y. He; Zhongnan Hospital of Wuhan University, Wuhan, CHINA.*

EPS-256
Detection of Perineural Tumour Spread in Head and Neck Cancers by 18F-FDG PET/CT
A. Ormanci, *M. Tuncel; Hacettepe University Faculty of Medicine, Department of Nuclear Medicine, Ankara, TÜRKIYE.*

EPS-257
18F-FDG PET CT andTumour Tissue Modified Viral (TTMV) -Human papilloma virus DNA : Role in Recurrent HPV driven oropharyngeal squamous cell carcinoma.
R. Kulkarni, *M. Posner, S. Roof, M. Ghesani, N. Ghesani; Mount SInai Hospital, New York, NY, UNITED STATES OF AMERICA.*

EPS-258
Convolutional Neural Network for Prediction of Early Disease Progression in Patients with Advanced Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma Receiving Tyrosine Kinase Inhibitor Therapy Based on 18F-FDG PET Images
K. Lue[1], *Y. Chen*[2,3], *L. Yong*[1], *X. Wong*[1], *S. Liu*[1,2], *H. Lin*[4,5];
[1]*Tzu Chi University of Science and Technology, Hualien, TAIWAN,* [2]*Hualien Tzu Chi Hospital, Hualien, TAIWAN,* [3]*Tzu Chi University, Hualien, TAIWAN,* [4]*Chang Gung University, Taoyuan, TAIWAN,* [5]*Keelung Chang Gung Memorial Hospital, Keelung, TAIWAN.*

EPS-259
Role Of Novel Geometric Variables Derived From 18F-FDG PET/CT As Predictive Factors In Patients With Non-Small Cell Lung Cancer
G. Jimenez Londoño[1], *A. M. Garcia Vicente*[2], *J. J. Bosque*[3], *J. Perez-Beteta*[3], *M. Amo-Salas*[4], *A. F. Honguero-Martinez*[5], *E. Noriega Alvarez*[1], *C. Lucas Lucas*[1], *V. M. Perez-Garcia*[3], *A. M. Soriano Castrejon*[2];
[1]*Department of Nuclear Medicine, Hospital General Universitario de Ciudad Real, Ciudad Real, SPAIN,* [2]*Department of Nuclear Medicine, Complejo Hospitalario Universitario de Toledo, Toledo, SPAIN,* [3]*Department of Mathematics, Mathematical Oncology Laboratory (MOLAB), Universidad de Castilla-La Mancha, Ciudad Real, SPAIN,* [4]*Department of Mathematics, Universidad de Castilla-La Mancha, Ciudad Real, SPAIN,* [5]*Department of Surgery, Hospital General Universitario de Albacete, Albacete, SPAIN.*

EPS-260
Correlation between 18F-FDG-PET parameters and outcome od Durvalumab treatment in unresectable locally advanced Non Small Cell Lung Cancer (NSCLC, stage IIIa-b-c)
K. Beshiri[1], *F. G. Dall'Olio*[1], *M. Aldea*[1], *C. Genova*[2], *F. Barlesi*[1], *A. Botticella*[1], *A. Levy*[1], *C. Le Pechoux*[1], *P. Lavaud*[1], *M. Frelaut*[1], *P. Abdayem*[1], *J. Remon Masip*[1], *D. Planchard*[1], *B. Besse*[1], *S. Ponce-Aix*[1], *F. Selhane*[1], *D. Deandreis*[1], *M. Bauckneht*[2], *C. Garcia*[1];
[1]*Institute Gustave Roussy, Villejuif, FRANCE,* [2]*IRCCS Ospedale Policlinico San Martino, Genova, ITALY.*

EPS-262
Usefulness of imaging parameters by FDG-PET/CT and conventional CT in early T-stage lung adenocarcinoma patients who underwent surgery
S. Tsukamoto, *S. Koyasu, M. Hamaji, H. Date, Y. Nakamoto; Kyoto University, Kyoto, JAPAN.*

EPS-263
Prognostic Value of Total Body Metabolic Tumour Volume in Patients with Advanced SCLC Treated by Chemotherapy and Immunotherapy.
A. CABARET[1], *C. GARCIA*[1], *F. DALL-OLIO*[1], *E. AUCLIN*[2], *B. BESSE*[1], *P. LAVAUD*[1];
[1]*Institut Gustave Roussy, Villejuif, FRANCE,* [2]*Hopital George Pompidou, Paris, FRANCE.*

EPS-264
Lymph Node Ultrasound Prior to Sentinel Lymph Node Biopsy in 414 Patients with Melanoma: Usefulness in the Era of Adjuvant Systemic Therapy
G. Horvatic Herceg[1], *S. Kusacic-Kuna*[2], *M. Ciglar-Hlasc*[2], *D. Herceg*[3], *L. Simetic*[3], *D. Mijatovic*[4];
[1]*University Hospital Zagreb, Zagreb, CROATIA,* [2]*Department of nuclear medicine and radiation protection, University Hospital Zagreb, Zagreb, CROATIA,* [3]*Clinic of oncology, University Hospital Zagreb, Zagreb, CROATIA,* [4]*Clinic of surgery, University Hospital Zagreb, Zagreb, CROATIA.*

EPS-265
Could lymphadenectomy be avoided in a selection of patients diagnosed with cutaneous melanoma with metastatic sentinel lymph node biopsy?
B. Hervás-Sanz[1], *M. T. Bajén-Lázaro*[1], *J. G. Reyes-Junca*[1], *A. M. Benítez-Segura*[1], *I. E. Sánchez-Rodríguez*[1], *S. Maymó-Garrido*[2], *J. L. Díaz-Moreno*[1], *M. A. Crespí-Busquets*[2], *M. Pudis*[1], *S. Bondia-Bescós*[1], *R. M. Penín-Mosquera*[3], *J. Marcoval-Caus*[4], *J. O. Bermejo-Segú*[5], *J. J. Martín-Liberal*[6], *I. Linares-Galiana*[7], *M. Cortés-Romera*[1];
[1]*Nuclear Medicine-PET (IDI) Department, Bellvitge University Hospital-IDIBELL, L'Hospitalet de Llobregat, SPAIN,* [2]*Radiopharmaceutical Department, Bellvitge University Hospital-IDIBELL, L'Hospitalet de Llobregat, SPAIN,* [3]*Anatomical Pathology Department, Bellvitge University Hospital-IDIBELL, L'Hospitalet de Llobregat, SPAIN,* [4]*Dermatology Department, Bellvitge University Hospital-IDIBELL, L'Hospitalet de Llobregat, SPAIN,* [5]*Plastic Surgery Department, Bellvitge University Hospital-IDIBELL, L'Hospitalet de Llobregat, SPAIN,* [6]*Medical Oncology Department, Institut Català d'Oncologia, L'Hospitalet de Llobregat, SPAIN,* [7]*Radiation Oncology Department, Institut Català d'Oncologia, L'Hospitalet de Llobregat, SPAIN.*

EPS-266
Can physiologic colonic [18F]FDG uptake in PET/CT imaging predict response to immunotherapy in metastatic melanoma?
C. Sachpekidis[1], *C. K. Stein-Thoeringer*[2], *A. Kopp-Schneider*[1], *V. Weru*[1], *A. Dimitrakopoulou-Strauss*[1], *J. C. Hassel*[3];
[1]*German Cancer Research Center (DKFZ), Heidelberg, GERMANY,* [2]*Laboratory of Translational Microbiome Science, Internal Medicine I, University Clinic Tuebingen, Tuebingen, GERMANY,* [3]*Department of Dermatology and National Center for Tumor Diseases (NCT), University Hospital Heidelberg, Heidelberg, GERMANY.*

EPS-267
The role of 18F-FDG PET/CT in changing the therapeutic plan in cutaneous melanoma patients at different clinical stages and time points of the disease.
Z. Dancheva, *T. Stoeva, M. Dyankova, S. Chausheva, T. Yordanova, B. Chaushev, A. Klisarova; Medical University, "Prf. Dr. Paraskev Stoyanov", Varna, BULGARIA.*

EPS-268
Prognostic Value of Restaging FDG-PET/CT for Detecting Recurrence in Patients with Malignant Cutaneous Melanoma
M. Contreras Ameduri[1], *E. Noriega-Álvarez*[1], *M. Sicilia Pozo*[1], *C. Lucas Lucas*[1], *A. Padilla Bermejo*[1], *M. Cruz Montijano*[2], *L. García Zoghby*[2], *F. Pena Pardo*[1], *M. Talavera Rubio*[1], *A. García Vicente*[2], *Á. Soriano Castrejón*[2], *V. García Poblete*[1];
[1]*Servicio de Medicina Nuclear, Hospital General Universitario de Ciudad Real, Ciudad Real, SPAIN,* [2]*Servicio de Medicina Nuclear, Hospital Universitario de Toledo, Toledo, SPAIN.*

EPS-269
Survival and risk factors analysis for locoregional and distant metastases in patients with sentinel lymph node-negative cutaneous melanoma
A. Leiva Montejo, *A. Blesa Jimenez, A. De Agrela Serrao, C. Ruiz Corbalán, D. Cáceres Silva, J. Contreras Gutierrez, J. Navarro Fernández, A. Hernandez Martinez, T. Rodriguez Lorcano, L. Frutos Esteban, L. Mohamed Salem, M. Castellon Sánchez; Hospital Virgen de la Arrixaca, Murcia, SPAIN.*

EPS-270
A steerable modality for simultaneous radio- and fluorescence-guidance during robotic surgery
M. van Oosterom[1,2], *L. J. Slof*[1], *S. I. van Leeuwen*[1], *S. Azargoshasb*[1], *A. Berrens*[2], *K. Houwing*[1], *H. G. van der Poel*[2], *F. W. B. van Leeuwen*[1];
[1]*Leiden University Medical Center, Leiden, NETHERLANDS,* [2]*NETHERLANDS Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, NETHERLANDS.*

EPS-271
Feasibility of [99mTc] Tc-FAPI-SPECT Imaging for Detection of Primary Tumors, Lymph Node, and Distant Metastasis in Various Cancers
S. Rezaei, *E. Gharepapagh, S. Dabiri Oskue; Department of Nuclear Medicine, Medical School, Tabriz University of Medical Sciences, Tabriz, IRAN, ISLAMIC REPUBLIC OF.*

EPS-272
The Role of [18F]FDG PET/CT for predicting histology and prognosis in patients with thymic lesions
A. Castello[1], *P. Mendogni*[2], *M. Cattaneo*[2], *L. Rosso*[2], *G. A. Croci*[3], *S. Pacella*[1], *L. Florimonte*[1], *F. Lococo*[4], *S. Margaritora*[4], *S. Ferrero*[3], *M. Nosotti*[2], *M. Castellani*[1];
[1]*Department of Nuclear Medicine, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milan, ITALY,* [2]*Thoracic Surgery, Fondazione IRCCS Ca' Granda, Ospedale Maggiore PoliCnico, Milan, ITALY,* [3]*Division of Pathology, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milan, ITALY,* [4]*Department of Thoracic Surgery, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, ITALY.*

1710a

Wednesday, September 13, 2023, 08:00 - 09:00
Hall K

Mini Course 1 - Technologists Committee: Radiotherapy Planning Using PET/CT and PET/MR

OP-871
Hybrid imaging in radiotherapy and the role of technologists
B. Bak;
Radiotherapy Department II, Greater Poland Cancer Centre, Poznan, POLAND.

OP-872
PET/CT based radiotherapy planning
V. Mautone;
Instituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST IRCCS U.o.s Medicina Nucleare Diagnostica, Meldola (FC), ITALY.

OP-873
PET/MRI based radiotherapy planning
D. Sipos;
Somogy County Kaposi Mór Teaching Hospital, Dr. József Baka Center, Department of Radiation Oncology, Kaposvár, HUNGARY.

1710b

Wednesday, September 13, 2023, 09:05 - 10:05
Hall K

Mini Course 2 - Technologists Committee: AI in the Technologists Practice

OP-875
Improving PET imaging based on artificial intelligence
M. De Summa;
Medipass S.p.a. c/o Fondazione Policlinico Universitario A. Gemelli IRCCS, PET-CT, Radiopharmacy and AI Research Laboratory, Rome, ITALY.

OP-876
AI in the Technologists Practice.
C. Votta;
Fondazione Policlinico Universitario A. Gemelli IRCCS, Deparmtnet of Diagnostic Imaging, Oncological, Radiotherapy and Hematology, Rome, ITALY.

1710c

Wednesday, September 13, 2023, 10:15 - 11:15
Hall K

Mini Course 3 - Technologists Committee: Phantoms Management

OP-940
The use of phantoms in QC & QA
K. Matuszewski;
Greater Poland Cancer Centre, Medical Physics Dep, Poznan, POLAND.

OP-941
Gamma Camera & PET-CT vs PET-MRI phantoms management
D. Sørensen;
Department of Nuclear Medicine, Odense University Hospital, Odense, DENMARK.

OP-942
Phantoms in practice & Computer-based phantom models
C. Abreu;
Royal Marsden NHS Foundation Trust, London , UNITED KINGDOM.

1711

Wednesday, September 13, 2023, 8:00 AM - 9:30 AM
Hall G1

Case Report Session 3 - TROP Session: Every Day a Discovery with FAP and Novel Targets

OP-878
FAPi imaging identified occurrence of fibrosis may indicate rapid progression of liver failure induced by immune checkpoint inhibitor
X. Jia[1], *R. Tao*[1], *Y. Yang*[1], *Y. Wang*[1], *X. Li*[1], *B. Jia*[2], *R. Gao*[1];
[1]The first hospital of Xi'an jiaotong university, Xi'an, CHINA, [2]Medical Isotopes Research Center and Department of Radiation Medicine, School of Basic Medical Sciences, Peking University, Beijing, CHINA.

OP-879
Is This a Real [68Ga]Ga-FAPI Scan? The Strange Case of [68Ga]Ga-FAPI-avid Liver
E. Fortunati[1], *G. Cuzzani*[1], *S. Telo*[2], *C. Nanni*[3], *P. Castellucci*[3], *A. Farolfi*[3], *L. Zanoni*[3], *T. Galasso*[4], *M. Ferrari*[4], *F. Natali*[4], *G. Bandelli*[4], *P. Candoli*[4], *S. Fanti*[1,3];
[1]Nuclear Medicine, Alma Mater Studiorum University of Bologna, Bologna, ITALY, [2]Nuclear Medicine Unit, AUSL Romagna, Cesena, ITALY, [3]Nuclear Medicine, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, [4]Interventional Pulmunology Unit, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY.

OP-880
Role of 68Ga FAPI-04 PET/CT in detecting cardiac sarcoidosis in a patient mimicking malignancy and its comparison with 18F-FDG PET/CT
S. Patel, *P. Sundaram, P. Sundaram, F. Saju;*
Amrita Institute of Medical Sciences & Research Center, Kochi, INDIA.

OP-881
An Example of How [68Ga]Ga-FAPI PET/CT can Potentially Help Changing The Therapeutic Process of Patients with Sarcoma
G. Cuzzani[1], *E. Fortunati*[1], *M. Focaccia*[2], *S. Telo*[3], *A. Farolfi*[4], *C. Nanni*[4], *P. Castellucci*[4], *T. Frisoni*[2], *B. Spazzoli*[2], *C. Plenteda*[5], *D. M. Donati*[2], *S. Fanti*[1,4];
[1]Nuclear medicine, Alma Mater Studiorum University of Bologna, Bologna, ITALY, [2]Orthopaedic Oncology Unit, IRCCS Istituto Ortopedico Rizzoli, Bologna, ITALY, [3]Nuclear Medicine Department, AUSL Romagna, Romagna, ITALY, [4]Nuclear Medicine IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, [5]Hematology and Bone Marrow Transplant Center Unit, Parma University Hospital, Parma, ITALY.

OP-882
[68Ga]Ga-FAPI PET/CT: a Valid Aid in Breast Cancer Not Only for Malignancies Reporting
G. Cuzzani[1], *E. Fortunati*[1], *S. Telo*[2], *C. Nanni*[3], *P. Castellucci*[3], *A. Farolfi*[3], *S. Zanotti*[4], *S. Grendele*[5], *D. Rosini*[4], *M. Taffurelli*[4], *S. Fanti*[1,3];
[1]Nuclear medicine, Alma Mater Studiorum University of Bologna, Bologna, ITALY, [2]Nuclear Medicine Department, AUSL Romagna, Romagna, ITALY, [3]Nuclear Medicine, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, [4]Breast Surgery, Department of Oncology and Hematological Diseases, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, [5]Breast Surgery, Department of Functional Oncology, AULSS 7 Pedemontana, Santorso Hospital, Vicenza, ITALY.

OP-883
Comparative PET/CT imaging in a patient with metastatic clear cell renal cell carcinoma: 68Ga-NY104 versus 68Ga-PSMA versus 18F-FDG
W. Zhu, *X. Li, Y. Zhang, Y. Li, L. Huo;*
Peking Union Medical College Hospital, Beijing, CHINA.

OP-884
[99mTc]Tc-HYNIC-TOC as an alternative to [123I] mIBG for Neuroblastoma Staging, a Comparative Case Series
K. Hlongwa, *A. Brink, O. Kolade, A. Alnabulsi, S. More;*
Red Cross War Memorial Children's Hospital and University of Cape Town, Cape Town, SOUTH AFRICA.

OP-885
[18F]F-SynVesT-1 PET In a Rare Case of Paraneoplastic Neurological Syndrome Associated With Isolated Anti-amphiphysin Antibodies
Y. Tang, *L. Xiao, J. Yang, S. Hu;*
Xiangya Hospital Central South University, Changsha, CHINA.

1801

Wednesday, September 13, 2023, 09:45 - 11:15
Hall A

CME 14 - Neuroimaging + Paediatric Committee: Modern Imaging of Paediatric Epilepsy

OP-886
Clinical Point of View on Paediatric Epilepsy with a Focus on [18F]FDG PET/MR
L De Palma;
Ospedale Pediatrico Bambino Gesù, Dipartimento di Neuroscienze e Neuroriabilitazione, Rome, ITALY.

OP-887
Cortical Morphology and MR Post Processing in Paediatric Epilepsy
A. Hammers;
Kings College, London, UNITED KINGDOM.

OP-888
How Imaging Helps the Surgeon in Paediatric Epilepsy
K. Goffin;
UZ Leuven, Leuven, BELGIUM.

OP-889
Are We Really Ready to Go with New PET Tracers in Paediatric Epilepsy?
D. Van Weehaeghe;
UZ Gent, Gent BELGIUM.

1802

Wednesday, September 13, 2023, 09:45 - 11:15
Hall D (Arena)

Round Table 3 - Women´s Empowerment Task Force: Women in Science - Special Focus on Nuclear Medicine

OP-890
Women in Nuclear Medicine: the past and the present
O. Israel;
Nuclear Medicine, Rambam Health Care Campus, Haifa, ISRAEL.

OP-891a
The challenges of Women Technologists in Nuclear Medicine
A. Santos;
Department of Nuclear Medicine, Hospital Cuf Descobertas, Lisbon, PORTUGAL.

OP-891b
Women in Nuclear Medicine: the present and the future
L. de Geus-Oei;
Department of Radiology, Leiden University Medical Center (LUMC), Leiden, NETHERLANDS.

OP-891c
Radiochemist and to be a woman: what are the main challenges?
E. Eppard;
Institute of Nuclear Chemistry, Johannes Gutenberg-University, Mainz, GERMANY.

OP-891d
Physicist, Woman, Nuclear Medicine: how to conjugate them?
C. Stokke;
Department of Physics and Computational Radiology, Division of Radiology and Nuclear Medicine, Oslo, NORWAY.

1803

Wednesday, September 13, 2023, 09:45 - 11:15
Hall E1

LIPS Session 14 - Translational Molecular Imaging & Therapy + Physics + Radiation Protection + Oncology & Theranostics + Ethics Committee: Beta Emitters for Radioguided Surgery - Challenges and Opportunities

OP-892
Developments in instrumentation and probes
K. Shi;
Department of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, SWITZERLAND.

OP-893
Radiation protection in beta RGS nuts and bolts
E. Ciarrocchi;
Department of Physics "E. Fermi", University of Pisa, Pisa, ITALY.

OP-894
Protocols and clinical relevance of beta RGS
C. Darr;
Department of Urology, University Hospital Essen, Essen, GERMANY.

1804

Wednesday, September 13, 2023, 9:45 AM - 11:15 AM
Hall E2

M2M Track - TROP Session: New Therapeutic Radiopharmaceuticals

OP-895
Radiometal modification of JMV6659 for theranostic approach of NTS1 targeting
S. Bodin[1,2], *S. Previti*[3], *S. Fernandez*[4], *D. Vimont*[2], *F. Masmejean*[2], *E. Rémond*[3], *A. Khatib*[5], *P. Garrigue*[4,6], *B. Guillet*[4,6], *E. Hindié*[7,2], *F. Cavelier*[3], *C. Morgat*[1,2];
[1]*Radiopharmacy, Nuclear Medicine, Bordeaux Hospital University Center, Bordeaux, FRANCE,* [2]*IMT, INCIA UMR-5287 CNRS, University of Bordeaux, Bordeaux, FRANCE,* [3]*Univ. Montpellier, CNRS, Institut des Biomolécules Max Mousseron, IBMM, UMR-5247, Montpellier, FRANCE,* [4]*Aix Marseille Univ, CNRS, CERIMED, Marseille, FRANCE,* [5]*RyTME, Bordeaux Institute of Oncology (BRIC), UMR 1312 Inserm, University of Bordeaux, Bordeaux, FRANCE,* [6]*Radiopharmacy, La Timone University Hospital, CERIMED, Aix-Marseille University, Marseille, FRANCE,* [7]*Nuclear Medicine, Bordeaux Hospital University Center, Bordeaux, FRANCE.*

OP-896
Prostate Specific Membrane Antigen in Human and Mouse Tissue
T. Kalidindi, *T. Esposito, D. Adilbay, P. Demetrio De Souza Franca, R. payne, N. Pillarsetty;*
Memorial Sloan Kettering Cancer Center, New York, NY, UNITED STATES OF AMERICA.

OP-897
DARPin platform for the development of powerful targeting agents for radioligand therapy
C. Lizak[1], *A. Bosshart*[1], *S. Wullschleger*[1], *M. Behe*[2], *A. Blanc*[2], *S. Imobersteg*[2], *A. Constantinescu*[1], *J. Blunschi*[1], *L. Abduli*[1], *S. Schütz*[1], *J. Wolter*[1], *Z. Ziauddin Siddiqui*[1], *M. Matzner*[1], *A. Auge*[1], *N. Fic*[1], *W. Ali Abobaker Hassan*[1], *T. Chiorazzo*[2], *C. Reichen*[1], *A. Croset*[1], *A. Villa*[1], *P. Legenne*[1], *A. Goubier*[1], *R. Schibli*[2], *D. Steiner*[1];
[1]*Molecular Partners AG, Schlieren, SWITZERLAND,* [2]*Paul Scherrer Institute, Villigen, SWITZERLAND.*

OP-898
[198Au]Au Labeled Gold Nanoparticle Depot ([198Au]Au-NPD) Inhibits the Growth of a 4T1 Murine Mammary Carcinoma Tumor on Immunocompetent BALB/c Mice without Normal Tissue Toxicity and Causes an Abscopal Effect on a Distant Non-irradiated Tumor
Z. Cai[1], *C. J. Georgiou*[1], *M. Kondo*[1], *C. Chan*[1], *R. Liu*[1], *M. Moran*[2], *A. Armstrong*[2], *R. M. Reilly*[1,3,4];
[1]*Department of Pharmaceutical Sciences, Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON, CANADA,* [2]*McMaster Nuclear Reactor, McMaster University, Hamilton, ON, CANADA,* [3]*Department of Medical Imaging, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, CANADA,* [4]*Joint Department of Medical Imaging and Princess Margaret Cancer Centre, University Health Network, Totonto, ON, CANADA.*

OP-899
Radioactive immuno-imaging and radioimmunotherapy of 131I-labeled human single-chain variable fragment antibodies against anaplastic thyroid cancer in tumor-bearing nude mice
Q. Liu[1], *H. Pang*[2];
[1]*the Second Affiliated Hospital of Chengdu Medical College, China National Nuclear Corporation 416 Ho, Chengdu, Sichuan, CHINA,* [2]*The First Affiliated Hospital of Chongqing Medical University, Chongqing, P.R. China, Chongqing, Sichuan, CHINA.*

OP-900
Preparation of 47SC-labeled DOTA-RGD4 tetramer and preliminary preclinical study on its application in iodine-refractory differentiated thyroid carcinoma
X. Jiang;
Second Affiliated Hospital of Chengdu Medical College (China National Nuclear Corporation 416 Hospital), chengdu, CHINA.

OP-901
PSMA-Targeted Single Domain Antibody Fragment NB7: Preliminary Evaluation as a Scaffold for Targeted α-particle Therapy of Prostate Cancer
T. Huynh[1], *Y. Feng*[1], *R. Meshaw*[1], *X. Zhao*[1], *L. Rosenfeld*[2], *N. Papo*[2], *M. Zalutsky*[1];
[1]*Duke University, Durham, NC, UNITED STATES OF AMERICA,* [2]*Ben-Gurion University of the Negev, Beer-Sheva, ISRAEL.*

OP-902
177Lu-labeled aflibercept for theranostic application in renalcancer models
L. Kang, *Z. Chen, Q. Yang, Y. Qiu, W. Huang, L. Song, X. Sun;*
Peking University First Hospital, Beijing, CHINA.

OP-903
Development of cobalt-55 labelled neurotensin antagonist NOTA-SR142948 for cobalt-58m NTSR1 targeted radionuclide therapy
W. Lin[1], *G. O. Fonseca Cabrera*[2], *E. Aluicio Sarduy*[1], *T. E. Barnhart*[1], *Z. Li*[2], *Z. Wu*[2], *J. W. Engle*[1];
[1]*University of Wisconsin Madison, Madison, WI, UNITED STATES OF AMERICA,* [2]*University of North Carolina at Chapel Hill, Chapel Hill, NC, UNITED STATES OF AMERICA.*

1805

Wednesday, September 13, 2023, 9:45 AM - 11:15 AM
Hall B

Cutting Edge Science Track - TROP Session: Clinical Dosimetry III - Time & Co.

OP-904
Single-time-point [68Ga]Ga-DOTATATE-PET/CT for model-based prediction of the time-integrated activity of [177Lu]Lu-DOTATATE during therapy
V. Vasic[1,2], *J. Gustafsson*[3], *E. Yousefzadeh-Nowshahr*[1,2], *A. Beer*[1], *K. Sjögreen Gleisner*[3], *G. Glatting*[1,2];
[1]*Department of Nuclear Medicine, Ulm University Medical Centre, Ulm, GERMANY,* [2]*Medical Radiation Physics, Department of Nuclear Medicine, Ulm University, Ulm, Germany, Ulm, GERMANY,* [3]*Medical Radiation Physics, Lund University, Lund, Sweden, Lund, SWEDEN.*

OP-905
Accuracy of predicted kidney's absorbed doses in [177Lu]Lu-PSMA-617 therapy using single-time-point data and non-linear mixed effect modelling
D. Hardiansyah[1], *E. Yousefzadeh-Nowshahr*[2], *F. Kind*[3], *A. J. Beer*[2], *J. Ruf*[3], *G. Glatting*[2], *M. Mix*[3];
[1]*Universitas Indonesia, Depok, INDONESIA,* [2]*Ulm University, Ulm, GERMANY,* [3]*University of Freiburg, Freiburg, GERMANY.*

OP-906
Accuracy and Uncertainty Analysis of Reduced Time Point Imaging Effect on Time-Integrated Activity for [177Lu]Lu-DOTA-TATE PRRT in Clinical Patients and Realistic Simulations
A. Peterson[1,2], *D. M. Mirando*[3], *Y. K. Dewaraja*[1];
[1]*University of Michigan, Ann Arbor, MI, UNITED STATES OF AMERICA,* [2]*Wayne State University, Detroit, MI, UNITED STATES OF AMERICA,* [3]*MIM Software Inc, Beachwood, OH, UNITED STATES OF AMERICA.*

OP-907
Non-Uniqueness of Multiexponential Time-Activity Curves in Few-Timepoint Theranostic Workflows Can Increase Dosimetric Error
D. Balfour, *J. Sage, J. Willaime, D. Boukerroui;*
Mirada Medical Ltd., Oxford, UNITED KINGDOM.

OP-908
Estimating Biochemical PSA Dynamics after Radioligand Therapy with [177Lu]Lu-PSMA-I&T Using a Population Pharmacokinetic/Pharmacodynamic Model
H. Siebinga[1,2], *B. J. de Wit - van der Veen*[1], *D. M. V. de Vries - Huizing*[1], *J. J. M. A. Hendrikx*[1,2], *A. D. R. Huitema*[2,3,4];
[1]*Department of Nuclear Medicine, NETHERLANDS Cancer Institute, Amsterdam, NETHERLANDS,* [2]*Department of Pharmacy and Pharmacology, NETHERLANDS Cancer Institute, Amsterdam, NETHERLANDS,* [3]*Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht University, Utrecht, NETHERLANDS,* [4]*Department of Pharmacology, Princess Máxima Center for Pediatric Oncology, Utrecht, NETHERLANDS.*

OP-909
Population-based model selection for iodine kinetics in benign thyroid disease
D. Hardiansyah[1], *A. Riana*[1], *H. Hänscheid*[2], *M. Lassmann*[2], *G. Glatting*[3];
[1]*Universitas Indonesia, Depok, INDONESIA,* [2]*University Hospital Würzburg, Würzburg, GERMANY,* [3]*Ulm University, Ulm, GERMANY.*

OP-910
131I Thyroid lesion dosimetry with quantitative imaging
E. Richetta, *C. Cutaia, A. Codegone, V. Garbaccio, R. Pellerito, M. Stasi;*
Ordine Mauriziano Hospital, Turin, ITALY.

OP-911
Evaluation of images from patients treated with 224Ra-CaCO3-microparticles for peritoneal metastases - can 224Ra be quantified using SPECT/CT?
S. Grønningsæter[1], *L. G. Mikalsen*[1,2], *J. Blakkisrud*[1], *M. Revheim*[1,3], *S. Westrøm*[4], *S. Selboe*[1], *Ø. Bruland*[5,6], *S. Larsen*[7], *C. Stokke*[1,8];
[1]*Division of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, NORWAY,* [2]*Department of Life Sciences and Health, Oslo Metropolitan University, Oslo, NORWAY,* [3]*Faculty of Medicine, University of Oslo, Oslo, NORWAY,* [4]*Oncoinvent AS, Oslo, NORWAY,* [5]*Department of Oncology, Oslo University Hospital, Oslo, NORWAY,* [6]*Institute of Clinical Medicine, Oslo University Hospital, Oslo, NORWAY,* [7]*Department of Gastroenterological Surgey, Oslo University Hospital, Oslo, NORWAY,* [8]*Department of Physics, University of Oslo, Oslo, NORWAY.*

OP-912
90Y Voxel S-Values updated Monte Carlo database including Internal Bremsstrahlung and new analytical model extending the evaluation to any voxel size
D. Pistone[1,2], *L. Auditore*[1,2], *A. Italiano*[2,3], *E. Amato*[1,2,4];
[1]*Department of Biomedical and Dental Sciences and of Morphofunctional Imaging (BIOMORF), University of Messina, Messina, ITALY,* [2]*INFN, National Institute for Nuclear Physics, Section of Catania, Catania, ITALY,* [3]*Department of Mathematical and Computer Science, Physical Sciences and Earth Sciences (MIFT), University of Messina, Messina, ITALY,* [4]*Health Physics Unit, University Hospital "Gaetano Martino", Messina, ITALY.*

1806

Wednesday, September 13, 2023, 9:45 AM - 11:15 AM
Hall C

Clinical Oncology Track - TROP Session: Radiomics

OP-913
Texture Analysis of 68Ga-DOTATOC PET/CT Images For the Prediction of Outcome in Patients With Neuroendocrine Tumors
S. Pellegrino[1], *R. Fonti*[1], *R. Bologna*[1], *M. Panico*[1], *R. Morra*[2], *G. Palmieri*[2], *M. Giuliano*[2], *S. De Placido*[2], *S. Del Vecchio*[1];
[1]*Department of Advanced Biomedical Sciences, University Federico II, Naples, ITALY,* [2]*Department of Clinical Medicine and Surgery, University Federico II, Naples, ITALY.*

OP-914
Association Between Absorbed Dose Heterogeneity and Metabolic Response in HCC Patients Undergoing Transarterial Radioembolization with Y-90 Resin Microspheres
N. Coskun[1], *M. Kartal*[2], *A. Erdogan*[2], *E. Ozdemir*[1];
[1]*Ankara Bilkent City Hospital, Ankara Yildirim Beyazit University, Ankara, TÜRKIYE,* [2]*Ankara Bilkent City Hospital, Ankara, TÜRKIYE.*

OP-915
Development of clinical-radiomic model on baseline FDG-PET images in non-small-cell-lung cancer patients, referred to radical lung surgery
L. Travaini, *G. Zuccotti, F. Botta, S. Netti, M. Casiraghi, M. Ferrari, A. Gaeta, P. Rocca, F. Mattana, S. Fracassi, A. Barone, G. Buonsanti, G. Petralia, L. Spaggiari, F. Ceci;*
EUROPEAN INSTITUTE OF ONCOLOGY, Milano, ITALY.

OP-916
Texture Analysis of 18F-FDG PET/CT Images for the Prediction of Outcome in Patients with Multiple Myeloma
S. Pellegrino[1], *D. Origlia*[1], *C. Vallone*[1], *R. Della Pepa*[2], *S. Del Vecchio*[1], *R. Fonti*[1];
[1]*Department of Advanced Biomedical Sciences, University Federico II, Naples, ITALY,* [2]*Department of Clinical Medicine and Surgery, University Federico II, Naples, ITALY.*

OP-917
Inter-institutional validation of a [18F]-FDG PET radiomic signature to predict the location of tumor recurrence after re-irradiation in head and neck cancer in an independent cohort
A. Beddok[1,2], *K. Grogg*[2], *L. Rozenblum*[3,2], *C. Nioche*[1], *F. Orlhac*[1], *H. Shih*[4], *T. Marin*[2], *I. Buvat*[1], *G. El Fakhri*[2];
[1]*Institut Curie, PSL Research University, University Paris Saclay, Inserm LITO, Paris, FRANCE,* [2]*Gordon Center for Medical Imaging, Massachusetts General Hospital, Harvard Medical School, Boston, MA, UNITED STATES OF AMERICA,* [3]*Department of Nuclear Medicine, AP – HP Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Sorbonne Université, Paris, FRANCE,* [4]*Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, UNITED STATES OF AMERICA.*

OP-918
Multi-imaging adaptive radiotherapy for locally advanced head and neck cancer: preliminary results from the RadiomicART study
F. Gelardi[1,2], *C. Franzese*[1,3], *M. Teriaca*[3], *M. Badalamenti*[3], *M. Roghi*[3], *D. Dei*[1,3], *C. Giannitto*[4], *M. Rodari*[2], *M. Scorsetti*[1,3];
[1]*Department of Biomedical Sciences, Humanitas University, Pieve Emanuele (MI), ITALY,* [2]*Department of Nuclear Medicine, IRCCS Humanitas Research Hospital, Rozzano (MI), ITALY,* [3]*Department of Radiation Oncology, IRCCS Humanitas Research Hospital, Rozzano (MI), ITALY,* [4]*Department of Diagnostic Imaging, IRCCS Humanitas Research Hospital, Rozzano (MI), ITALY.*

OP-919
Application of an artificial intelligence-based tool in [18F]FDG PET/CT for the assessment of bone marrow involvement in multiple myeloma
C. Sachpekidis[1], *O. Enqvist*[2], *J. Ulén*[3], *A. Kopp-Schneider*[1], *L. Pan*[1], *A. Jauch*[4], *M. Hajiyianni*[5], *L. John*[5], *N. Weinhold*[5], *S. Sauer*[5], *H. Goldschmidt*[5], *L. Edenbrandt*[6], *A. Dimitrakopoulou-Strauss*[1];
[1]*German Cancer Research Center (DKFZ), Heidelberg, GERMANY,* [2]*Department of Electrical Engineering, Chalmers University of Technology, Department of Electrical Engineering, Chalmers Uni, SWEDEN,* [3]*Eigenvision AB, Eigenvision AB, SWEDEN,* [4]*Institute of Human Genetics, University of Heidelberg, Heidelberg, GERMANY,* [5]*Department of Internal Medicine V, University Hospital Heidelberg and National Center for Tumor Diseases (NCT), Heidelberg, GERMANY,* [6]*Department of Clinical Physiology, Region Västra Götaland, Sahlgrenska University Hospital, Department of Clinical Physiology, Region Västra G, SWEDEN.*

OP-920
Development and validation of 18F-PSMA PET/CT-based radiomics model to predict biochemical recurrence-free survival following radical prostatectomy
T. Li, *K. Zhao, X. Su;*
The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, CHINA.

OP-921
Radiomic analysis of pre-surgery FDG-PET images in early-stage Non-Small Lung Cancer patients can improve outcome stratification
L. Travaini, *G. Zuccotti, M. Ferrari, M. Casiraghi, F. Botta, M. Colandrea, F. Mattana, C. Zanini, L. Gilardi, M. Calabrese, F. Bellerba, L. Spaggiari, G. Petralia, F. Ceci;*
European Institute Of Oncology, Milano, ITALY.

1807

Wednesday, September 13, 2023, 9:45 AM - 11:15 AM
Hall F1

Inflammation & Infection Committee - TROP Session: COVID-19: Isn't it over yet?

OP-922
Noninvasive imaging of inflammatory processes by macrophage-directed PET-tracers during a SARS-CoV-2-infection in cynomolgus macaques (Macaca fascicularis)
M. Stammes[1], *G. Koopman*[1], *T. Wagner*[2], *B. Traenkle*[2], *P. Kaiser*[2], *A. Maurer*[3], *J. Schwenck*[3], *U. Rothbauer*[3], *M. Kneiling*[3], *D. Sonanini*[3];
[1]*BPRC, Rijswijk, NETHERLANDS,* [2]*University of Tübingen, Reutlingen, GERMANY,*
[3]*Eberhard Karls University, Tübingen, GERMANY.*

OP-923
Role of 18F-FDG PET/CTin detecting residual or recurrent diseaseafter surgery in patients with rhino-orbito-cerebral mucormycosis: a pilot study
A. Phulia[1], *I. Singh*[1], *R. Kumar*[2];
[1]*Maulana Azad Medical College, New Delhi, INDIA,* [2]*All India Institute of Medical Sciences, New Delhi, INDIA.*

OP-924
Covid-19. Before and after in the diagnosis of pulmonary embolism in nuclear medicine. Our experience.
C. Ruiz Corbalán, *A. Leiva Montejo, A. De Agrela Serrao, D. Cáceres Silva, M. Castellón Sanchez, L. Mohamed Salem, J. Navarro Fernadez, T. Rodriguez Locarno, A. Hernandez Martinez, L. Frutos Esteban, J. Contreras Gutierrez; Arrixaca, Murcia, SPAIN.*

OP-925
Results of V/Q SPECT in the evaluation of pulmonary Long COVID - a two-year analysis of the pandemic
J. Lepej[1,2], *I. Marin*[1,2], *K. Lepejová*[3], *I. Kuglová*[1], *A. Obušeková*[1], *I. Polčová*[1], *O. Zahornacký*[4], *M. Duránik*[5];
[1]*Institut of Nuclear and Molecular Medicine, Košice, SLOVAKIA,* [2]*Clinic of Nuclear Medicine UPJŠ LF and INMM, Košice, SLOVAKIA,* [3]*Department of Clinical Biochemistry, Haematology and Immunology - Cumulus s.r.o., Košice, SLOVAKIA,* [4]*Clinic of Infectious Diseases and Travel Medicine, UPJŠ and UNLP, Košice, SLOVAKIA,* [5]*Faculty of Medicine University P.J. Šafarik, Košice, SLOVAKIA.*

OP-926
Incidental Acute COVID-19 Infection during Radioligand Therapy
A. Mishra, *R. P. Baum, C. Müller, C. Landvogt; Curanosticum, Wiesbaden, GERMANY.*

OP-927
FDG PET CT in the Neurological manifestations of COVID-19
N. Seniaray[1], *R. Verma*[1], *R. Ranjan*[2], *E. Belho*[1], *H. Mahajan*[1];
[1]*Mahajan Imaging & labs, New Delhi, INDIA,* [2]*Department of Neurology, Sir Ganga Ram Hospital, New Delhi, INDIA.*

OP-928
Neuroinflammation in post-COVID individuals with and without persistent complaints 2 years after infection: a [18F]DPA-714 PET study
D. Visser[1,2], *S. S. V. Golla*[1,2], *S. C. J. Verfaillie*[3], *A. Verveen*[3], *D. W. Koch*[3], *R. M. Rikken*[1,2], *E. van de Giessen*[1,2], *M. E. den Hollander*[1], *J. Horn*[2,4], *C. M. van Heugten*[5], *M. D. de Jong*[6,7], *C. C. van den Wijngaard*[8], *T. van der Maaden*[8], *Y. M. G. van Os*[9], *M. Prins*[6,10], *J. M. A. Visser-Meilij*[11], *P. Schober*[12], *R. C. Schuit*[1,2], *A. D. Windhorst*[1,2], *S. Biere-rafi*[13], *B. Appelman*[6,14], *M. van Vugt*[6,15], *F. Barkhof*[1,16], *B. N. M. Berckel*[1,2], *R. Boellaard*[1,2], *H. Knoop*[3], *N. Tolboom*[17];
[1]*Department of Radiology & Nuclear Medicine, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, NETHERLANDS,* [2]*Amsterdam Neuroscience, Brain Imaging, Amsterdam, NETHERLANDS,* [3]*Department of Medical Psychology, University of Amsterdam, Amsterdam UMC, Amsterdam, NETHERLANDS,* [4]*Amsterdam UMC location University of Amsterdam, Intensive Care, Meibergdreef 9, Amsterdam, NETHERLANDS,* [5]*Department of Psychiatry and Neuropsychology, Maastricht University Faculty of Health Medicine and Life Sciences & department of Neuropsychology and Psychopharmacology, Faculty of Psychology and Neuroscience Maastricht University, Maastricht, NETHERLANDS,* [6]*Amsterdam Institute for Infection and Immunity, Infectious Diseases, Amsterdam, NETHERLANDS,* [7]*Amsterdam UMC location University of Amsterdam, Medical Microbiology & Infection Prevention, Meibergdreef 9, Amsterdam, NETHERLANDS,* [8]*National Institute for Public Health and the Environment (RIVM), Center for Infectious Disease Control, Bilthoven, NETHERLANDS,* [9]*Occupational Health Office, Department of Human Resources, University Medical Center Utrecht, Utrecht, NETHERLANDS,* [10]*Amsterdam UMC location University of Amsterdam, Infectious Diseases, Meibergdreef 9, Amsterdam, NETHERLANDS,* [11]*Department of Rehabilitation, Physical Therapy Science and Sports, University Medical Centre Utrecht, Utrecht, NETHERLANDS,* [12]*Department of Anaesthesiology, Location VUMC, Amsterdam UMC, Amsterdam, NETHERLANDS,* [13]*C-support, 's-Hertogenbosch, NETHERLANDS,* [14]*Amsterdam UMC location University of Amsterdam, Center for Experimental and Molecular Medicine, Meibergdreef 9, Amsterdam, NETHERLANDS,* [15]*Amsterdam UMC location University of Amsterdam, Division of Infectious Diseases, Tropical Medicine, Department of Medicine, Meibergdreef 9, Amsterdam, NETHERLANDS,* [16]*Institute of Neurology and Healthcare Engineering, University College London, London, UNITED KINGDOM,* [17]*Department of Radiology & Nuclear Medicine, University Medical Centre Utrecht, Utrecht, NETHERLANDS.*

OP-929
Little recovery of brain metabolic impairment in patient with persistent long COVID: a [18F]FDG PET study
T. Horowitz, *P. Dudouet, E. Kaphan, T. Radulesco, S. Gonzalez, S. Cammilleri, A. Menard, E. Guedj;*
APHM, Marseille, FRANCE.

OP-930
Extracerebral findings from [18F]DPA-714 PET/CT using a long axial field of view PET scanner in post-COVID
D. Visser[1,2], *X. Palard-Novello*[1,2,3], *M. Yaqub*[1,2], *E. van der Giessen*[1,2], *M. den Hollander*[1,2], *A. D. Windhorst*[1,2], *S. C. J. Verfaillie*[4], *F. Barkhof*[1,2,5], *H. Knoop*[4], *B. N. M. van Berckel*[1,2], *S. S. V. Golla*[1,2], *N. Tolboom*[6], *R. Boellaard*[1,2];
[1]*Department of Radiology & Nuclear Medicine, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, NETHERLANDS,* [2]*Amsterdam Neuroscience, Brain Imaging, Amsterdam, NETHERLANDS,* [3]*Centre Eugène Marquis, Rennes, FRANCE,* [4]*Department of Medical Psychology, University of Amsterdam, Amsterdam UMC, Amsterdam, NETHERLANDS,* [5]*Queen Square Institute of Neurology and Centre for Medical Image Computing, University College, London, UNITED KINGDOM,* [6]*Department of Radiology & Nuclear Medicine, University Medical Centre Utrecht, Utrecht, NETHERLANDS.*

1808

Wednesday, September 13, 2023, 9:45 AM - 11:15 AM
Hall F2

Bone & Joint Committee - Featured Session: Unconventional Bone & Joint: FAPI and Beyond

OP-931
Unconventional Bone & Joint
S. Annunziata;
Department of Radiology, Radiotherapy and Hematology, Fondazione Policlinico Universitario A.Gemelli IRCCS, Rome , ITALY.

OP-932
68Ga-FAPI PET/CT novel diagnostic tool in sarcoma.
H. Lanzafame[1,2], *R. Hamacher*[2,3], *I. A. Mavroeidi*[2,3], *K. M. Pabst*[1,2], *N. Hirmas*[1], *L. Kessler*[1,2], *T. Bartel*[1,2], *S. Leyser*[1,2], *F. Barbato*[1,2], *M. Schuler*[2,3], *S. Bauer*[2], *J. T. Siveke*[2,3,4], *K. Herrmann*[1,2], *W. P. Fendler*[1];
[1]Department of Nuclear Medicine, West German Cancer Center, University Hospital Essen, Essen, GERMANY, [2]German Cancer Consortium (DKTK), Partner site University Hospital Essen, Essen, GERMANY, [3]Department of Medical Oncology, West German Cancer Center, University Hospital Essen, Essen, GERMANY, [4]Bridge Institute of Experimental Tumor Therapy, West German Cancer Center, University Hospital Essen, Essen, GERMANY.

OP-933
Head-to-head Comparison of [68Ga]Ga-FAPI04 and [18F]-FDG PET/CT Imaging in Recurrent/Metastatic Solitary Fibrous Tumor Patients
R. Wang[1,2,3], *J. Wang*[1,2,3], *G. Wang*[1,2,3], *L. Li*[1,2,3], *Z. Zhu*[1,2,3], *X. Chen*[4,5,6], *J. Zhang*[4,5,6];
[1]Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, CHINA, [2]State Key Laboratory of Complex Severe and Rare Diseases, Beijing, CHINA, [3]Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Beijing, CHINA, [4]Departments of Diagnostic Radiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, SINGAPORE, [5]Nanomedicine Translational Research Program, NUS Center for Nanomedicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, SINGAPORE, [6]Clinical Imaging Research Centre, Centre for Translational Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, SINGAPORE.

OP-934
Prognostic value of fluorodeoxyglucose positron emission tomography derived metabolic parameters and textural features in soft tissue and bone sarcomas
N. Aydin, *G. Mütevelizade, G. Gümüşer, E. Sayıt Bilgin; Celal Bayar University, Manisa, TÜRKIYE.*

OP-935
Assessing bone metabolism in chronic kidney disease-mineral bone disease (CKD-MBD) using 18F-NaF PET/CT Imaging
M. Usmani[1], *N. Ahmed*[2], *F. Marafi*[3], *G. Gnanasegaran*[4], *T. Van den Wyngaert*[5];
[1]Sultan Qaboos Comprehensive Cancer Care and Research center (SQCCCRC), Muscat, OMAN, [2]Jack Brignall PET/CT Centre, Castle Hill Hospital, Cottingham, UNITED KINGDOM, [3]Jaber Al-Ahmad Molecular Imaging Center, Kuwait, kuwait, KUWAIT, [4]Royal Free Hospital NHS Trust, London, UNITED KINGDOM, [5]Antwerp University Hospital, Antwerp, BELGIUM.

OP-936
99mTc-HDP-SPECT/CT in axial pain: comparison with magnetic resonance imaging and impact on image guided therapeutic intervention.
M. ROMERA[1], *Á. Bronte*[1], *V. Betech-Antar*[1], *F. Mínguez*[1], *S. Menéndez-Sánchez*[1], *J. Bastidas*[1], *E. Guillén*[2], *L. Sancho*[2], *L. García-Belaustegui*[2], *J. Arbizu*[1], *M. García Velloso*[1], *M. Rodríguez*[1], *A. Arcadi*[1], *V. Rodrigo*[1], *N. Varela*[1], *F. Pareja*[1], *J. Rosales*[1];
[1]Clínica Universidad de Navarra, Navarra, SPAIN, [2]Clínica Universidad de Navarra, Madrid, SPAIN.

OP-937
The value of Tc-99m-DPD bone scintigraphies in patients with alkaptonuria. A promising imaging tool for disease monitoring?
D. Schmitt[1], *S. vom Dahl*[2], *K. Mattes-György*[1], *E. Novruzov*[1], *M. Dabir*[1], *S. David*[2], *K. Jan Philipp*[1], *T. Lüdde*[2], *M. Busch*[2], *E. Mamlins*[1], *F. Giesel*[1];
[1]Department of Nuclear Medicine, Medical Faculty and University Hospital Duesseldorf, Heinrich-Heine-University Duesseldorf, Duesseldorf, GERMANY, [2]Clinic for Gastroenterology, Hepatology and Infectious Diseases, Medical Faculty and University Hospital Duesseldorf, Heinrich-Heine-University Duesseldorf, Duesseldorf, GERMANY.

OP-938
^{99m}Tc-NTP15-5, proteoglycan tracer: Phase I trial (CARSPECT)
M. Chanchou[1], *P. Auzeloux*[1], *N. Sas*[1], *T. Billoux*[1], *S. Levesque*[1], *E. Thivat*[1], *E. Jouberton*[1], *E. Miot-Noirault*[2], *M. Galmier*[2], *M. Couderc*[3], *S. Mathieu*[3], *X. Durando*[1], *F. Cachin*[1];
[1]Centre Jean Perrin/UMR1240 INSERM (IMoST)/UCA, Clermont-Ferrand, FRANCE, [2]UMR1240 INSERM (IMoST)/UCA, Clermont-Ferrand, FRANCE, [3]CHU/UCA, Clermont-Ferrand, FRANCE.

OP-939
Comparison and Clinical Significance of Hybrid Imaging and Planar Bone Scintigraphy in Patients With Oncological Lesions
P. Korol[1], *O. Shcherbina*[1], *M. Tkachenko*[2];
[1]Shupik National University Healthcare of Ukraine, Kyiv, UKRAINE, [2]Bogomolets National Medical University of Ukraine, Kyiv, UKRAINE.

1809

Wednesday, September 13, 2023, 9:45 AM - 11:15 AM
Hall G2

e-Poster Presentations Session 14 - Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy - New Imaging Agents

EPS-273
Molecular PET/CT mapping of rhACE2 distribution and quantification in organs: a helper for SARS-CoV-2 targeting therapy
Z. Wang[1,2], *C. Zhao*[3], *C. Li*[4], *Q. Liu*[5], *H. Zhu*[6,5], *Y. Liu*[1];
[1]School of Basic Medical Science, Southwest Medical University, Luzhou, CHINA, [2]Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Key Laboratory for Research Evaluation of Radiopharmaceuticals (National Medical Products Administration), Department of Nuclear Medicine, Peking University Cance, Beijing, CHINA, [3]Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Biochemistry and Molecular Biology, Peking University Cancer Hospital and Institute, Beijing, Beijing, CHINA, [4]Department of Nuclear Medicine,First Affiliated Hospital of Hebei North University, Zhangjiakou, CHINA, [5]Institute of Biomedical Engineering, Peking University Shenzhen Graduate School, Shenzhen, CHINA, [6]Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Product Administration), Department of Nuclear Medicine, Peking University Ca, Beijing, CHINA.

EPS-274
Evaluating a suite of anti-FAP nanobody constructs as PET imaging agents.
J. Gallant, *Z. T. Rosenkrans, K. L. Ott, N. Y. Luo, A. S. Thickens, R. Hernandez, A. M. LeBeau; University of Wisconsin, School of Medicine and Public Health, Madison, WI, UNITED STATES OF AMERICA.*

EPS-275
Close but no cigar? In vitro properties of small molecule PD-L1 ligands assessed by real-time radioligand binding in comparison to peptides and antibodies.
C. Donat[1], *F. Krutzek*[1], *K. Zarschler*[1], *K. Kopka*[1,2,3], *S. Stadlbauer*[1,2];
[1]Helmholtz Centre Dresden-Rossendorf, Dresden, GERMANY, [2]Technical University Dresden, Dresden, GERMANY, [3]National Center for Tumor Diseases, Dresden, GERMANY.

EPS-276
AlI18F-DX600-BCH
J. Ding[1], *Q. Zhang*[1], *J. Jiang*[1], *N. Zhou*[1], *Z. Yu*[1], *Z. Wang*[1], *X. Meng*[1], *T. Liu*[1], *F. Wang*[1], *z. Lu*[1], *X. Yang*[2], *Z. Yang*[1], *P. Du*[1], *Z. Hua*[1];
[1]Peking University Cancer Hospital & Institute, Beijing, CHINA, [2]Peking University First Hospital, Beijing, CHINA.

EPS-277
Development of a dual-modality imaging probe targeting SSTR2 via a trifunctional chelate
D. Chapeau, *S. Beekman, Y. Seimbille; ErasmusMC, Rotterdam, NETHERLANDS.*

EPS-278
Conjugation of different chelators to a HER2 targeting single domain antibody for Ga-68 and Lu-177 radiolabelling
B. Altunay, *L. Obradović, F. M. Mottaghy, A. T. J. Vogg; University Hospital RWTH Aachen, Aachen, GERMANY.*

EPS-279
More than sweet: TRAP-based Sugar Trimers for Functional Liver Imaging with 68Ga
M. A. Zierke[1], *C. Rangger*[1], *K. Samadikhah*[2], *A. Schmid*[2], *R. Haubner*[1];
[1]Nuclear Medicine, Innsbruck, AUSTRIA, [2]Werner Siemens Imaging Center, Tübingen, GERMANY.

EPS-280
Novel Dual-Modality Imaging Agents Targeting the CCK2 Receptor by Chelator Scaffolding
G. GARIGLIO[1], *K. Bendová*[2], *M. Hermann*[3], *M. Petrik*[2], *E. von Guggenberg*[1], *D. Putzer*[4], *C. Decristoforo*[1];
[1]Department of Nuclear Medicine, Medical University Innsbruck, Innsbruck, AUSTRIA, [2]Faculty of Medicine and Dentistry, Palacky University Olomouc, Institute of Molecular and Translational Medicine, Olomouc, CZECH REPUBLIC, [3]Department of Anesthesiology and Critical Care Medicine, Medical University of Innsbruck, Innsbruck, AUSTRIA, [4]Department of Radiology, Medical University Innsbruck, Innsbruck, AUSTRIA.

EPS-281
Construction and immnoPET imaging of an iodine-labeled specific antibody for targeting MMP2 detection in pan-cancer
X. Ma, *T. Liu, H. Zhu, Z. Yang; Peking university, Beijing, CHINA.*

EPS-282
Novel fluorinated Osimertinib analogue for medical nuclear imaging of EGFRm-positive non-small cell lung cancer
Y. Brief, *H. Grievink, G. Abourbeh, E. Mishani, O. Shamni; Cyclotron & Radiochemistry unit, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, ISRAEL.*

EPS-283
FAPI-functionalised melanin nanoparticles for PET/MRI/PA imaging of glioma
L. Wen, *H. Wang, S. Yang, X. Long, C. Zheng, D. Jiang; Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, CHINA.*

EPS-284
Preclinical PET imaging with 89Zr-labelled oxMIF-specific antibody delineates subcutaneous tumours in colorectal murine models
F. Bachmann, *A. Puchol Tarazona, I. Mirkina, M. Thiele, A. Schinagl; OncoOne Research & Development GmbH, Vienna, AUSTRIA.*

EPS-285
Preparation and preclinical evaluation of anti ROR1 labeled with 64Cu as a Radioimmunoconjugate for ROR1+ breast cancer Imaging
B. Alirezapour[1], *H. Rabbani*[2];
[1]Nuclear Science and technology research Institute (NSTRI), Tehran, IRAN, ISLAMIC REPUBLIC OF, [2]Antigen and Antibody Engineering Department, Monoclonal Antibody Research Center, Avicenna Research Institute, ACECR, Tehran, IRAN, ISLAMIC REPUBLIC OF.

EPS-286
Radiosynthesis and preclinical evaluation of [Zr89] mAb1 and [Zr89]mAb2 as PET tracers for B7:H3-positive tumors
B. Fernandes[1], *F. Basuli*[2], *C. P. Olkowski*[1], *D. Nambiar*[1], *S. Adler*[3], *G. L. Griffiths*[3], *F. I. Lin*[1], *P. Choyke*[1];
[1]*Molecular Imaging Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, UNITED STATES OF AMERICA,* [2]*Chemistry and Synthesis Center, National Heart, Lung, and Blood Institute, National Institutes of Health, Rockville, MD, UNITED STATES OF AMERICA,* [3]*Clinical Research Directorate, Frederick National Laboratory for Cancer Research Frederick, Frederick, MD, UNITED STATES OF AMERICA.*

EPS-287
A Zirconium Coordination Platform for Positron Emission Tomography Traceable Cargo Delivery
H. Hong, *X. Jiao, X. Li, Y. Cong, J. Hu, Y. Jiang;*
Nanjing University, Nanjing, CHINA.

EPS-288
Organotrifluoroborate sugar conjugates for a guided boron neutron capture therapy: radioisotopic exchange reactions for PET imaging
A. Erhard[1], *L. Confalonieri*[2], *D. Imperio*[2], *M. Balcerzyk*[1], *L. Panza*[2];
[1]*Centro Nacional de Aceleradores, Sevilla, SPAIN,* [2]*University of Eastern Piedmont Amedeo Avogadro, Novara, ITALY.*

EPS-289
Preclinical characterization of novel radiolabeled and fluorescent-labeled Fibroblast Activation Protein (FAP)-targeting ligands using gamma counting, SPECT imaging and Cryo-Fluorescence Tomography (CFT)
J. Hesterman[1], *A. Novicki*[1], *K. Orcutt*[1], *S. DiMagno*[1], *S. Hillier*[1], *S. Patel*[1], *A. Amor*[1], *B. Burke*[2], *S. Archibald*[3], *J. Wright*[3], *J. Domarkas*[3], *J. Heimann*[2], *V. Yost*[2], *E. White*[4], *C. Stokes*[4], *M. Silva*[4], *A. Cordova*[4], *S. Toddes*[4], *J. Babich*[1], *J. Hoppin*[1];
[1]*Ratio Therapeutics, Boston, MA, UNITED STATES OF AMERICA,* [2]*Invicro, Needham, MA, UNITED STATES OF AMERICA,* [3]*University of Hull, Hull, UNITED KINGDOM,* [4]*Emit Imaging, Baltimore, MD, UNITED STATES OF AMERICA.*

EPS-290
68Ga-NOTA-ACN376 imaging as a non-invasive approach to diagnose CLDN18.2-positive tumors
c. yan[1,2], *Z. Hua*[3], *Z. Hua*[3], *Z. Hua*[3];
[1]*Beijing cancer hospital, Beijing, CHINA,* [2]*Guizhou University Medicine College, Guizhou, CHINA,* [3]*Beijing Cancer Hospital, Beijing, CHINA.*

EPS-291
61Cu-PSMA PET in prostate cancer: development and selection of the first radioligand for clinical translation
T. Basaco Bernabeu[1], *R. Mansi*[1], *L. Del Pozo*[1], *S. Zanger*[1], *M. Blagoev*[2], *R. H. Gaonkar*[1], *L. McDougall*[1], *A. Johayem*[2], *L. Jaafar-Thiel*[3], *M. Fani*[1];
[1]*Division of Radiopharmaceutical Chemistry, University Hospital Basel, Basel, SWITZERLAND,* [2]*Department of Nuclear Medicine, University Hospital of Zürich, Zürich, SWITZERLAND,* [3]*Nuclidium AG, Basel, SWITZERLAND.*

EPS-292
Preclinical 68Ga-EMP100 PET Imaging to quantify c-Met Expression in non-small cell lung cancer (NSCLC)
A. Prignon[1,2], *T. Rusu*[2,1], *R. Anita*[2], *C. Portal*[3], *J. Cadranel*[2];
[1]*Sorbonne University, UMS28, LIMP, Paris, FRANCE,* [2]*THERANOSCAN Clinical Research Group of the Pneumology and Thoracic Oncology Department Tenon Hospital AP-HP, Paris, FRANCE,* [3]*Edinburgh Molecular Imaging, Edinburgh, UNITED KINGDOM.*

EPS-293
Early detection of CD38using a novel 68Ga-labeled peptidein lymphoma murine models
L. Kang[1], *Q. Yang*[1], *X. Li*[2], *L. Song*[1], *W. Huang*[1], *X. Sun*[1], *Z. Wang*[2];
[1]*Peking University First Hospital, Beijing, CHINA,* [2]*National Center for Nanoscience and Technology, Beijing, CHINA.*

1811

Wednesday, September 13, 2023, 9:45 AM - 11:15 AM
Hall G1

Case Report Session 4 - TROP Session: FDG PET and Conventional Imaging: Still Surprising!

OP-943
Pre- and post-CAR-T therapy FDG PET/CT images and limitations of the Deauville Criteria: A Pictorial Essay
S. Kwon[1], *S. Ha*[1], *J. Min*[2], *J. O*[1], *Catholic University Lymphoma Group (CULG);*
[1]*Seoul St Mary's Hospital, Seoul, KOREA, REPUBLIC OF,* [2]*The Catholic University of Korea, Seoul, KOREA, REPUBLIC OF.*

OP-944
Dramatic treatment response images of a metastatic lung adenocarcinoma case with Osimertinib treatment on 18F-FDG PET/CT
B. Ince, *A. Namazova, M. Bodur, S. Asa, L. Uslu-Besli, S. Sager, H. Sayman, K. Sonmezoglu;*
Istanbul University-Cerrahpasa, Istanbul, TÜRKIYE.

OP-945
Imaging Plasmacytoid Dendritic Cell Neoplasm with FDG PET/CT: Atypical Presentation of a Rare Disease in a Child
M. Ben Nasr, *O. Ben Hamida, R. Belayouni, C. Mhiri, I. Slim, I. Meddeb, A. Mhiri;*
Salah Azaiez Institute of Tunis, Tunis, TUNISIA.

OP-946
Utility of 18F-FDG PET/CT in Rhabdomyosarcoma of Prostate
S. Jain[1], *H. Goyal*[2];
[1]*All India Institute of Medical Sciences, Bhopal, INDIA,* [2]*Jipmer, Puducherry, INDIA.*

OP-947
When Histopathology is Wrong and Bone Scintigraphy is Right - an Exemplary Case of a Rare Genetic Metabolic Disease (Familial Expansile Osteolysis) Repeatedly Mistaken for Fibrous Dysplasia and Paget's Disease
D. Filipan[1], *E. Koumakis*[2,3], *V. Cormier-Daire*[4], *T. Funck-Brentano*[5], *F. Paycha*[6];
[1]*University Department of Oncology and Nuclear Medicine, Sestre Milosrdnice University Hospital Centre, Zagreb, CROATIA,* [2]*Centre de Référence des Maladies Osseuses Constitutionnelles, Service de Rhumatologie, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Paris, FRANCE,* [3]*INSERM UMR 1163, Institut Imagine, Hôpital Necker, Paris, FRANCE,* [4]*Service de Génétique Clinique Hôpital Necker-Enfants Malades, Assistance Publique-Hôpitaux de Paris, Paris, FRANCE,* [5]*Service de Rhumatologie & BIOSCAR UMR 1132, INSERM, Université Paris Cité, Paris, FRANCE,* [6]*Service de Médecine Nucléaire, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, Paris, FRANCE.*

OP-948
Delayed Onset Angiosarcoma Arising from a Femur Infarct Pictured by [99mTc]bisphosphonates SPECT/CT and [18F]FDG-PET/CT: Caution with Tumour Necrosis and Haemorrhage Phenomena in Molecular Imaging analysis!
D. Filipan[1], *N. Saleh*[2], *R. Kaci*[3], *F. Paycha*[2];
[1]*University Department of Oncology and Nuclear Medicine, Sestre Milosrdnice University Hospital Centre, Zagreb, CROATIA,* [2]*Service de Médecine Nucléaire, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, Paris, FRANCE,* [3]*Service d'Anatomie et de Cytologie Pathologiques, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, Paris, FRANCE.*

OP-949
Facial asymmetry unmasked by bone scintigraphy
L. Sobral Torres, *A. OLiveira, P. Soeiro;*
Centro Hospital Universitário de São João, Porto, PORTUGAL.

OP-950
Unexpected Finding of Myeloma in Myocardial Perfusion Imaging Study with 99mTc-sestamibi
P. Cichocki[1], *A. Płachcińska*[2], *Z. Adamczewski*[1];
[1]*Nuclear Medicine Department, Medical University of Lodz, Lodz, POLAND,* [2]*Department of Quality Control and Radiation Protection, Medical University of Lodz, Lodz, POLAND.*

OP-951
Ga-68 DOTATOC PET/CT and I-123 MIBG scan in a refractory case of pediatric neuroblastoma: imaging biomarkers with complete mismatch and implications for patient management
L. Vija[1], *A. Latgé*[1], *M. Gambart*[1], *L. Guillon*[2], *S. Brillouet*[1], *D. Vallot*[1], *L. Dierickx*[1], *S. Zerdoud*[1], *F. Courbon*[1];
[1]*Institut Claudius Regaud-Oncopole, Toulouse Cedex 9, FRANCE,* [2]*CHU Toulouse, Toulouse Cedex 9, FRANCE.*

1901

Wednesday, September 13, 2023, 11:25 - 11:45
Hall A

Closing Session

OP-952
Closing Session
V. Garibotto;
University Hospitals and University of Geneva, Geneva, SWITZERLAND.

e-Posters

EP-01

e-Poster Area

A: Preclinical Studies -> A1 Medical Preclinical -> A11 In Vitro Studies

EP-0001
An exploratory study on the mechanism of pralatrexate killing gemcitabine-resistant pancreatic cancer cells
W. Weng, *J. Hong, D. Jiang, B. Chen, S. Zheng;*
The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, CHINA.

EP-0002
Androgen-induced cell cycle arrest in prostate carcinoma cells as a potential risk for pseudoprogression during diagnosis with prostate-specific membrane antigen (PSMA) radiopharmaceuticals and treatment failure with PSMA radioligands. An in vitro study.
B. Meller[1], *P. Thelen*[2], *V. Unterkircher*[3], *J. Bucerius*[1], *L. Trojan*[2], *C. O. Sahlmann*[1], *F. Bremmer*[3];
[1]*University Medical Center Göttingen, Clinic of Nuclear Medicine, Göttingen, GERMANY,* [2]*University Medical Center Göttingen, Clinic of Urology, Göttingen, GERMANY,* [3]*University Medical Center Göttingen, Institute of Pathology, Göttingen, GERMANY.*

EP-0003
Synthesis and in vitro evaluation of a small molecule 99mTc-G2C-CBM as potential PD-L1 imaging agent
Z. Chen[1,2,3], *D. Zhu*[1,4], *C. Lu*[1,2,3];
[1]*Jiangsu Institute of Nuclear Medicine, Wuxi, CHINA,* [2]*NHC Key Laboratory of Nuclear Medicine, Wuxi, CHINA,* [3]*Jiangsu Key Laboratory of Molecular Nuclear Medicine, Wuxi, CHINA,* [4]*Department of Radiopharmaceuticals, School of Pharmacy, Nanjing Medical University, Nanjing, CHINA.*

EP-0004
Robustness of radiomic features in dopamine transporter imaging with single photon emission tomography
V. Laskov[1,2], *P. Choniawko*[1,2], *D. Rotbauer*[2];
[1]*University Hospital Kralovske Vinohrady, Department of Radiology and Nuclear medicine, Prague, CZECH REPUBLIC,* [2]*Third Faculty of Medicine, Charles University, Prague, CZECH REPUBLIC.*

EP-0005
Sinomenine Hydrochloride enhances Trametinib-induced iodide-handling gene expression and radioiodine uptake
J. Zhang, *A. Yang;*
The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, CHINA.

EP-0006
"In house" radiolabeling of anti-PD-L1 monoclonal antibodies with 111-Indium for in vivo imaging
F. Silva[1], *R. Lopes*[1], *A. S. Capacho*[1], *M. Fortunato*[1,2], *S. Vaz*[1], *F. Oliveira*[1], *C. João*[1], *D. Costa*[1];
[1]*Champalimaud Foundation, Lisbon, PORTUGAL,* [2]*Nova School of Science and Technology, Lisbon, PORTUGAL.*

EP-0007
The high affinity angiotensin AT2 receptor agonist, C21, inhibits proliferation and induces cell death in prostate cancer cells by an AT2 receptor-independent mechanism
Y. Zhao, *M. Marx, U. Lützen, M. Zuhayra;*
Department of Nuclear Medicine, Molecular Imaging, Diagnostics and Therapy, UKSH, Kiel, GERMANY.

EP-0008
Microleakage evaluation of new composite resins for posterior teeth: bioactive resins vs bulk fill resins
A. Pires Lourenço[1,2,3], *C. M. Marto*[2,3,4], *A. Coelho*[2,3,4], *M. V. Pinto*[4], *P. Neves*[4], *I. Amaro*[2,3,4], *J. Sousa*[4], *M. Marques Ferreira*[2,3,5], *E. Carrilho*[2,3,4], *M. Laranjo*[1,2,3], *A. M. Abrantes*[1,2,3], *M. F. Botelho*[1,2,3], *A. B. Paula*[2,3,4];
[1]*Univ Coimbra, Coimbra Institute for Clinical and Biomedical Research (iCBR) area of Environment Genetics and Oncobiology (CIMAGO), Institute of Biophysics, Faculty of Medicine, Coimbra, PORTUGAL,* [2]*Univ Coimbra, Center for Innovative Biomedicine and Biotechnology (CIBB), Coimbra, PORTUGAL,* [3]*Clinical Academic Center of Coimbra (CACC), Coimbra, PORTUGAL,* [4]*Univ Coimbra, Coimbra Institute for Clinical and Biomedical Research (iCBR) area of Environment Genetics and Oncobiology (CIMAGO); Institute of Integrated Clinical Practice and Laboratory for Evidence-Based Sciences and Precision Dentistry, Faculty of Med, Coimbra, PORTUGAL,* [5]*Univ Coimbra, Coimbra Institute for Clinical and Biomedical Research (iCBR) area of Environment Genetics and Oncobiology (CIMAGO); Institute of Endodontics and Laboratory for Evidence-Based Sciences and Precision Dentistry, Faculty of Medicine, Coimbra, PORTUGAL.*

EP-0009
[99mTc][Tc-HYNIC-scFvD2B] vs [99mTc][Tc(CO)3(scFvD2B-HisTag)] for the imaging SPECT of prostate cancer: preliminary in vitro studies
C. Gobbi[1], *L. Melendez-Alafort*[2], *B. Spolaore*[3], *N. Salvarese*[1], *D. Carpanese*[2], *V. Rossi*[2], *A. Rosato*[2,4], *G. Fracasso*[5], *C. Bolzati*[1];
[1]*Institute of Condensed Matter Chemistry and Energy Technologies - National Research Council, Padua, ITALY,* [2]*Istituto Oncologico Veneto IOV-IRCSS, Padua, ITALY,* [3]*Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Padua, ITALY,* [4]*Department of Surgery, Oncology and Gastroenterology, University of Padua, Padova, ITALY,* [5]*Department of Biomedical Sciences, University of Padua, Padua, ITALY.*

EP-0010
161Tb-PSMA-I&T and177Lu- PSMA-I&T treatment in T23 and ST4787 prostate cancer cell lines - a model representative of177Lu-PSMA-resistant prostate cancer phenotype
M. Kirienko, *E. Jachetti, R. Sulsenti, C. Pascali, A. Bogni, M. Colombo, E. Seregni;*
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, ITALY.

EP-0011
αvβ3 integrin-selective RGDechi peptides labelled with [99mTc][Tc(N)(PNP)]- and [99mTc][Tc-HYNIC]-systems: an in vitro comparison
C. Bolzati[1], *C. Gobbi*[1], *N. Salvarese*[1], *A. Giorgio*[2], *D. Carpanese*[3], *V. Rossi*[3], *L. Melendez-Alafort*[3], *A. Rosato*[3,4], *M. Saviano*[5], *A. Del Gatto*[2], *L. Zaccaro*[2];
[1]*Institute of Condensed Matter Chemistry and Energy Technologies, ICMATE-CNR, PADOVA, ITALY,* [2]*Institute of Biostructures and Bioimaging, IBB-CNR, Napoli, ITALY,* [3]*Istituto Oncologico Veneto, IOV-IRCCS, PADOVA, ITALY,* [4]*Department of Surgery, Oncology and Gastroenterology, University of Padua, DiSCOG-UniPD, Padova, ITALY,* [5]*Institute of Crystallography, IC-CNR, Bari, ITALY.*

EP-0012
Let's label biomolecules in mild conditions with the [99mTc][Tc(N)(PNP)]-system: the PNP3OH experience
C. Bolzati[1], *N. Salvarese*[1], *B. Spolaore*[2], *C. Gobbi*[1], *A. Vittadini*[1], *D. Forrer*[1], *S. Ghiani*[3], *A. Maiocchi*[4];
[1]*Institute of Condensed Matter Chemistry and Energy Technologies, ICMATE-CNR, PADOVA, ITALY,* [2]*Department of Pharmaceutical and Pharmacological Sciences, University of Padua, PADOVA, ITALY,* [3]*Bracco Research Centre, Bracco Imaging SpA, Torino, ITALY,* [4]*Bracco SpA, Milano, ITALY.*

EP-0013
To study uptake of 18F-AVT-011 in different cell lines expressing p-glycoprotein.
R. Thakur[1], *M. Kumar*[1], *P. chaudhari*[2], *P. Kumar*[1];
[1]*National Institute of mental health and neurosciences, Bangalore, INDIA,* [2]*Advanced Centre for Treatment, Research and Education, Mumbai, INDIA.*

EP-0014
Dual-radionuclide detection for radiopharmaceutical studies
J. Campeiro, *C. D. van der Heide, J. de Swart, S. U. Dalm; Erasmus Medical Center, Rotterdam, NETHERLANDS.*

EP-02

e-Poster Area

A: Preclinical Studies -> A1 Medical Preclinical -> A12 Preclinical Cardiology and Neurology

EP-0015
Age Related Changes of Cellular Contributions in FDG Uptake Correlate with Metabolic Connectivity
J. Gnörich, *L. Bartos, A. Zatcepin, R. Schäfer, S. Kunte, P. Beumers, P. Bartenstein, N. Albert, S. Ziegler, M. Brendel; LMU Munich, Munich, GERMANY.*

EP-0016
Inhibition of PFKFB3 counteracts atherosclerosis via NLRP3/Casepase1/IL-1β pathway in macrophages
M. Zhao[1], *X. Wang*[2], *W. Wu*[1], *Y. Bai*[2], *X. Li*[3];
[1]*The Third Xiangya Hospital of Central South University, Changsha, CHINA,* [2]*Xiangya Hospital of Central South University, Changsha, CHINA,* [3]*Division of Nuclear Medicine, Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, AUSTRIA.*

EP-0017
In vivo [18F]SMBT-1 imaging of reactive astrocytes in mouse models of Alzheimer's disease - temporospatial relationship with amyloid, tau and microgliosis
R. Ni[1], *Y. Kong*[2], *C. Maschio*[1], *B. Yao*[3], *J. Xiao*[2], *Q. Huang*[2], *Y. Guan*[2];
[1]*University of Zurich, Zurich, SWITZERLAND,* [2]*PET Center, Huashan Hospital, Fudan University, Shanghai, CHINA,* [3]*Radiopharmacy and Molecular Imaging Center, School of Pharmacy, Fudan University, Shanghai, CHINA.*

EP-0018
A comparison of the biodistribution and the patient dose estimation of [18F]FEPP and [18F]FEAO, potential radiotracers for PET myocardial perfusion imaging
K. Gotowicz[1,2], *U. Karczmarczyk*[3], *S. Krajewski*[1], *E. Witkowska-Patena*[4], *L. Steczek*[1], *J. Towpik*[1], *P. Kozanecki*[1], *M. Mazur*[2], *M. Dziuk*[4,5], *J. Włostowska*[1], *C. Kozanecki*[1], *P. Garnuszek*[3];
[1]*Synektik SA, Research & Development Centre, Warsaw, POLAND,* [2]*Department of Chemistry, University of Warsaw, Warsaw, POLAND,* [3]*National Centre for Nuclear Researach, Radioisotope Centre POLATOM, Warsaw, POLAND,* [4]*Military Institute of Medicine - National Research Institute, Nuclear Medicine Department, Warsaw, POLAND,* [5]*Affidea Poland, Warsaw, POLAND.*

EP-0019
Early brain [18F]FDG PET imaging predicts the long-term behavioral impact of exposure to sublethal doses of organophosphates: a longitudinal study in mice exposed to NIMP, a sarin surrogate
A. Soyer[1], *A. Champault*[2], *S. Leterrier*[1], *C. Corvo*[1], *L. Breuil*[1], *B. Hosten*[1], *W. Saba*[1], *C. Leroy*[1], *A. Winkeler*[1], *G. Dal Bo*[2], *K. Thibault*[2], *N. Tournier*[1];
[1]*Laboratoire d'Imagerie Biomédicale Multimodale (BioMaps), CEA, CNRS, Inserm, Service Hospitalier Frédéric Joliot, Université Paris-Saclay, Orsay, FRANCE,* [2]*Institut de Recherche Biomédicale des Armées (IRBA), Bretigny-sur-Orge, FRANCE.*

EP-0020
Comparison of intravenous and oral administration of [18F]MC225: a feasibility study in rats
G. Salvi de Souza[1,2], *J. W. Sijbesma*[1], *J. Doorduin*[1], *A. M. Marques da Silva*[3,4], *C. R. Furini*[2,5], *A. A. Lammertsma*[1], *C. Tsoumpas*[1], *G. Luurtsema*[1];
[1]*Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Groningen, NETHERLANDS,* [2]*School of Medicine, PUCRS, Porto Alegre, BRAZIL,* [3]*Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, BRAZIL,* [4]*Medical Imaging & Data Analytics, San Diego, CA, UNITED STATES OF AMERICA,* [5]*Laboratory of Cognition and Memory Neurobiology, Brain Institute, PUCRS, Porto Alegre, BRAZIL.*

EP-0021
Short-term synaptic remodeling in a rat model of alcohol binge drinking assessed using [11C]UCB-J PET imaging
C. CORVO[1], *C. Leroy*[2], *S. Letterier*[2], *S. Goutal*[2], *F. Caille*[2], *A. Soyer*[2], *M. Goislard*[2], *S. Amargier*[2], *N. Tournier*[2], *W. Saba*[2];
[1]*Université Paris-Saclay, Inserm, CNRS, CEA, Laboratoire d'Imagerie Biomédicale Multimodale (BioMaps), ORSAY, FRANCE,* [2]*Université Paris-Saclay, Inserm, CNRS, CEA, Laboratoire d'Imagerie Biomédicale Multimodale (BioMaps), Orsay, FRANCE.*

EP-0022
Sex differences in [18F]-FDG uptake and behavioral impairment following repetitive mild traumatic brain injury (rmTBI)
R. Moraga-Amaro, *M. Bankstahl, J. P. Bankstahl;*
Hannover Medical School, Hannover, GERMANY.

EP-0023
Longitudinal [18F]-FDG PET Characterization of Alzheimer's Disease P301S Transgenic Mice
L. García-Varela[1,2,3], *A. Custodia*[4,3], *L. Barro Rico*[1,3], *N. Gomez Lado*[1,3], *J. Codesido*[2,3,5], *A. Cuartero*[5], *A. Fernández-Ferreiro*[5], *D. Romaus Sanjurjo*[4,3], *A. Ouro*[4,3], *T. Sobrino*[4,3], *P. Aguiar*[1,2,3];
[1]*Molecular Imaging and Pharmacokinetic Modelling Group, CIMUS, USC, Santiago de Compostela, SPAIN,* [2]*Nuclear Medicine and Molecular Imaging Group, University Clinical Hospital, IDIS, Santiago de Compostela, SPAIN,* [3]*Centro de Investigación Biomédica en Red en Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos III, Madrid, SPAIN,* [4]*NeuroAging Group (NEURAL), Clinical Neurosciences Research Laboratory (LINC), IDIS, Santiago de Compostela, SPAIN,* [5]*Pharmacology Group, University Clinical Hospital of Santiago de Compostela, IDIS, Santiago de Compostela, SPAIN.*

EP-0024
Applicability of early phase imaging with 18F-PI-2620 and 18F-Florbetaben in mouse models with Tau and Amyloid pathology
A. Englert, *L. Slemann, S. Hummel, L. Hörmann, L. Kunze, C. Palleis, K. Wind-Mark, S. Lindner, P. Bartenstein, S. Ziegler, N. Albert, J. Levin, M. Brendel, J. Gnörich;*
LMU Klinikum Campus Großhadern, Munich, GERMANY.

EP-0025
Brain Metabolic Effects of Coca-paste Acute Systemic Administration in Rats
R. Ferrando[1,2], *L. Reyes*[2], *J. Prieto*[3], *A. Paolino*[2], *A. Abin-Carriquiry*[4], *P. Oliver*[2], *E. Savio*[2], *M. Scorza*[3];
[1]*University of the Republic, Montevideo, URUGUAY,* [2]*Uruguayan Centre for Molecular Imaging (CUDIM), Montevideo, URUGUAY,* [3]*Departamento de Neurofarmacología Experimental, Instituto de Investigaciones Biológicas Clemente Estable., Montevideo, URUGUAY,* [4]*Departamento de Neuroquímica, Instituto de Investigaciones Biológicas Clemente Estable., Montevideo, URUGUAY.*

EP-03

e-Poster Area

A: Preclinical Studies -> A1 Medical Preclinical -> A13 Preclinical Oncology

EP-0026
A study on the volume of preclinical xenograft tumours assessed by ultrasound imaging and MRI compared to calliper measurements
J. Strand[1], *C. Ceberg*[2], *M. Safi*[1], *S. Strand*[2], *F. Szczepankiewicz*[2], *D. Roth*[2];
[1]*Clinical Sciences, Oncology, Lund University, Lund, SWEDEN,* [2]*Medical Radiation Physics, Clinical Sciences, Lund University, Lund, SWEDEN.*

EP-0027
Construction and Preclinical Evaluation of a 68Ga-Labeled Single-chain Fragment Variable Targeting PD-L2 in Lung Cancer
Y. Yao, *N. Li;*
Peking university cancer hospital, Beijing, CHINA.

EP-0028
Preparation and evaluation of Evans blue modified aptamer probe targeting to EpCAM
M. Zhang, *J. Ye, Z. Xie, W. Yang, F. Kang, J. Wang;*
Department of Nuclear Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, CHINA.

EP-0029
Evaluation of a Long-circulating PSMA-targeting Peptide in a Xenograft Model of Bone Metastatic Prostate Cancer.
W. Lo, *Y. Huang, M. Chen, A. Lu, S. Wang, L. Chen, S. Farn;*
Institute of Nuclear Energy Research, Taoyuan, TAIWAN.

EP-0030
Goat milk-derived extracellular vesicle engineered for multimodal imaging of cancer stem cells
Y. Gao, *Y. Zhang, X. Lan, R. An;*
Wuhan Union Hospital, Wuhan, CHINA.

EP-0031
Porphyrin-modified strategy contributes to aptamers' tumor targeting
S. Yang, *X. Lan, D. Jiang;*
Wuhan Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China, Wuhan, CHINA.

EP-0032
Tumours inducing cachexia driven by Fn14 show enhanced 18F-FDG uptake in mice versus tumours that do not induce cancer cachexia: a quantitative PET analysis
I. Burvenich[1,2], *L. Osellame*[1,2,3], *A. Rigopoulos*[1], *N. Hoogenraad*[3], *A. M. Scott*[1,2,4];
[1]*Olivia Newton-John Cancer Research Institute, Heidelberg, AUSTRALIA,* [2]*School of Cancer Medicine, La Trobe University, Bundoora, AUSTRALIA,* [3]*Department of Biochemistry and Genetics, La Trobe Institute for Molecular Science, La Trobe University, Bundoora, AUSTRALIA,* [4]*Department of Molecular Imaging and Therapy, Austin Health, Heidelberg, AUSTRALIA.*

EP-0033
89Zr-anti-murine CD103 PET imaging for non-invasive assessment of immune checkpoint inhibitor therapy
X. Fan, *N. P. Holland, A. Plat, H. W. Nijman, P. H. Elsinga, M. d. Bruyn;*
University of Groningen, Groningen, NETHERLANDS.

EP-0034
In vivo testing of a novel anti-B4GALNT1 nanobody as a potential theragnostic tool for osteosarcoma tumors.
M. Collantes[1], *N. Mendoza*[2], *J. Simón*[3], *F. Pareja*[3], *M. Ecay*[1], *G. Quincoces*[3], *M. García-Moure*[4], *A. J. Schuhmacher*[2], *I. Peñuelas*[3];
[1]*Translational Molecular Imaging Unit (UNIMTRA), Nuclear Medicine Department, Clínica Universidad de Navarra, Pamplona, SPAIN,* [2]*Instituto de Investigación Sanitaria Aragón, Zaragoza, SPAIN,* [3]*Radiopharmacy Unit, Department of Nuclear Medicine, Clínica Universidad de Navarra, Pamplona, SPAIN,* [4]*Solid TumorsProgram, CIMA-Universidad de Navarra, Pamplona, SPAIN.*

EP-0035
Development of neurotensin analogues stabilized by Lys8-Lys9 reduction and linker modifications
C. Morgat[1,2], *S. Previti*[3], *S. Bodin*[1,2], *L. Balasse*[4], *E. Rémond*[3], *P. Garrigue*[4], *F. Debordeaux*[1], *B. Guillet*[4], *F. Lamare*[2], *D. Vimont*[2], *E. Hindié*[1,2], *F. Cavelier*[3];
[1]*Nuclear Medicine Department - University Hospital of Bordeaux, Bordeaux, FRANCE,* [2]*University of Bordeaux, CNRS, EPHE, INCIA, UMR 5287, Bordeaux, FRANCE,* [3]*Institut des Biomolecules Max Mousseron, IBMM, UMR 5247, CNRS, Université de Montpellier, ENSCM, Montpellier, FRANCE,* [4]*CERIMED, Aix-Marseille University, Marseille, FRANCE.*

EP-0036
In vivo evaluation of luteinizing hormone-releasing hormone antagonists in triple negative breast tumor-bearing model by using SPECT/CT imaging
M. Weng, *S. Farn;*
Institute of Nuclear Energy Research, Taoyuan City, TAIWAN.

EP-0037
Enhancing PSMA-RLT efficacy with STING agonist in syngeneic models of prostate cancer
B. Louis[1,2], *M. Taddio*[1,2], *K. Rashid*[1,2], *E. Abt*[1,2], *E. Rosser*[1,2], *T. Le*[1,2], *K. Lueckerath*[3,4], *C. Radu*[1,2], *J. Czernin*[1,2], *C. Mona*[1,2];
[1]*University of California at Los Angeles, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, Ahmanson Translational Theranostics Division, Los Angeles, CA, UNITED STATES OF AMERICA,* [2]*Jonsson Comprehensive Cancer Center, Los Angeles, CA, UNITED STATES OF AMERICA,* [3]*Department of Nuclear Medicine, University Hospital Essen, Essen, GERMANY,* [4]*German Cancer Consortium–University Hospital Essen, Essen, GERMANY.*

EP-0038
[18F](2S,4R)4-Fluoroglutamine illustrates ability to distinguish KRAS mutation in pancreatic carcinoma
S. Liu, *F. Liu, X. Xu;*
Peking University Cancer Hospital, Beijing, CHINA.

EP-0039
A novel 18F labeled TKI-PET tracer for targeting EGFR mutation
S. Liu, *F. Liu, Z. Yang;*
Peking University Cancer Hospital, Beijing, CHINA.

EP-0040
Lenvatinib strengthened I-131-trastuzumab radioimmunotherapy in HER2 positive tumor model
I. Lim, *S. Cho;*
Korea Cancer Center Hospital, Seoul, KOREA, REPUBLIC OF.

EP-0041
GRPR-antagonists based on AU-RM26-M1 and their [111In]In-radioligands: Preclinical evaluation for prostate cancer imaging
A. Abouzayed[1], *K. Obeid*[1], *P. Kanellopoulos*[1], *A. Mattsson*[1], *B. A. Nock*[2], *V. Tolmachev*[1], *T. Maina*[2], *A. Orlova*[1];
[1]*Uppsala University, Uppsala, SWEDEN,* [2]*Molecular Radiopharmacy, NCSR Demokritos, Athens, GREECE.*

EP-0042
Using [89Zr]Zr-Oxine ex-vivo labelled macrophages and [89Zr]Zr-DFO-anti-F4/80 to investigate the effect of moderate-dose external beam radiation therapy on macrophage polarisation
V. De Santis[1], *A. Banu*[1], *S. Langdon*[1], *J. Cheng*[1], *M. Cleveland*[2], *M. Ma*[1], *S. Terry*[1];
[1]*King's College London, London, UNITED KINGDOM,* [2]*Glaxosmithkline, Stevenage, UNITED KINGDOM.*

EP-0043
[68Ga]Ga-Bedaquiline - A Potential Diagnostic Radiotracer for Overexpressed Mitochondrial ATP Synthase Composing Proteins in Lung Carcinoma
A. Chakraborty[1], *M. Tawate*[1], *A. Mitra*[2], *S. Sahu*[1], *S. Lad*[1], *S. Rakshit*[1], *G. Dhotre*[3], *M. K. Ray*[1], *A. Damle*[1], *U. Pandey*[2], *S. Kulkarni*[1];
[1]*Bhabha Atomic Research Centre, Mumbai, INDIA,* [2]*Board of Radiation & Isotope Technology, Mumbai, INDIA,* [3]*Tata Institute of Fundamental Research, Mumbai, INDIA.*

EP-0044
Preclinical Evaluation of an Anti-Nectin-4 ImmunoPET Reagent in Tumor Bearing Mice
y. Ren[1], *Z. Yang*[2];
[1]*Guizhou University, Guiyang, CHINA,* [2]*Peking University Cancer Hospital and Institute, Beijing, CHINA.*

EP-0045
Preclinical evaluation of 64Cu-DOTHA2-FAPI for PET Imaging of head and neck cancer
I. Ben-Salem[1], *E. Croteau*[1], *V. Dumulon-Perreault*[2], *N. Saidi*[1], *O. Sarrhini*[1], *S. Ait-Mohand*[1], *O. Bélissant*[1], *E. Turcotte*[1], *A. Oweida*[1], *B. Guérin*[1], *E. Rousseau*[1];
[1]*Département de médecine nucléaire et radiobiologie, Université de Sherbrooke, Sherbrooke, QC, CANADA,* [2]*Centre d'Imagerie Moléculaire de Sherbrooke (CIMS), Centre de Recherche du CHUS (CRCHUS), Sherbrooke, QC, CANADA.*

EP-0046
Evaluation of 89Zr-DFO-C23 in immuno-PET imaging of A549 xenograft models with high TIM3 expression
J. Tao[1], *Z. Zeng*[2], *H. Zhu*[3];
[1]*Peking University Cancer Hospital, Beijing, Beijing, CHINA,* [2]*Peking University Cancer Hospital, Beijing, CHINA,* [3]*Peking University Cancer Hospital and Institute, Beijing, CHINA.*

EP-0047
Preparation and Application of Bioorganic Nanoparticle Enhanced PDL1 Targeted Small Molecule Probe
C. He, *L. Xia;*
Beijing Institute of Cancer Prevention and Treatment, Beijing, CHINA.

EP-0048
Preclinical evaluation of novel PSMA-targeting ligands labelled with gallium-68
Z. Novy[1], *K. Hajduova*[1], *M. Petrik*[1], *K. Bendova*[1], *M. Benesova*[2], *M. Hajduch*[1];
[1]*Faculty of Medicine and Dentistry, Olomouc, CZECH REPUBLIC,* [2]*German Cancer Research Center, Heidelberg, GERMANY.*

EP-0049
Design of novel small molecules targeting Fibroblast activating protein and preclinical exploration of 47Sc labeling
Y. Xia;
Second Affiliated Hospital of Chengdu Medical College (China National Nuclear Corporation 416 Hospital, Chengdu, CHINA.

EP-0050
Lead Optimisation Strategy for the Development Of New Grpr Radioantagonists
P. Paraïso[1], *C. van Deurzen*[2], *Y. Seimbille*[1,3];
[1]*Department of Radiology and Nuclear Medicine, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, NETHERLANDS,* [2]*Department of Pathology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, NETHERLANDS,* [3]*Life Sciences Division, TRIUMF, Vancouver, BC, CANADA.*

EP-0051
Normal organs uptake values in F 18- FDG PET/CT in relation to serum blood glucose
R. Mostafa[1], *H. Askar*[2], *M. Helbawi*[2], *H. Mahmoud*[2];
[1]*Nuclear Medicine Unit, Department of Radiation Oncology and Nuclear Medicine, South Egypt Cancer Institute, Assiut University, Assiut, EGYPT,* [2]*Department of Clinical Oncology and Nuclear Medicine, Faculty of Medicine, Assiut University, Assiut, Assiut, EGYPT.*

EP-0052
Synthesis and preliminary assessment of 68Ga/177Lu-TATE-EB-01 for the theranostic in neuroendocrine tumor
X. Wen[1], *P. Xu*[2], *J. Liu*[1], *J. Zhang*[3], *Z. Guo*[1], *X. Chen*[3];
[1]*State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics & Center for Molecular Imaging and Translational Medicine, School of Public Health, Xiamen University, Xiamen, CHINA,* [2]*Institute of Clinical Pharmacy & Pharmacology, Jining First People's Hospital, Jining Medical University, Jining, CHINA,* [3]*Department of Diagnostic Radiology, Yong Loo Lin School of Medicine and Faculty of Engineering, National University of Singapore, Singapore, SINGAPORE.*

EP-0053
[18F]FDG-PET/CT and MRI to assess treatment response to anti-PD1 in an orthotopic mouse renal cancer model.
O. Bejuy, *H. Poinot, D. Colin, A. Pommier, V. Garibotto; University Of Geneva, Geneva, SWITZERLAND.*

EP-04

e-Poster Area

A: Preclinical Studies -> A1 Medical Preclinical -> A14 Preclinical Therapy

EP-0054
FAP-targeted cancer theranostics
W. Wei;
Shanghai Jiao Tong University, Shanghai, CHINA.

EP-0055
Development ofINER-PP-F11N as the Radionuclide Theragnostics Agent against Cholecystokinin B Receptor-overexpressed Tumors
M. Chang, *C. CHEN, P. CHIANG, C. PENG;*
Institute of Nuclear Energy Research, Taipei, TAIWAN.

EP-0056
Local Infusion of 177Lu-Labeled Gold Nanoparticles Combined with anti-PD1 Checkpoint Immunotherapy Prolongs Survival of C57BL/6 Mice Bearing Orthotopic GL261 Murine Gliomas
C. Georgiou[1], *Z. Cai*[1], *J. T. Rutka*[2], *M. Winnik*[1], *R. M. Reilly*[1];
[1]*University of Toronto, Toronto, ON, CANADA,* [2]*The Hospital for Sick Children, Toronto, ON, CANADA.*

EP-0057
Compositedegradablepolymer microspheresloaded with 177Lufor Transarterial Radioembolization therapy of Rat hepatocellular carcinoma
L. Xiao, *H. Cai, L. Li;*
Department of Nuclear Medicine, West China Hospital, Sichuan University, Chengdu, CHINA.

EP-0058
Nucleic acid nanospheres for PET imaging and antioxidant therapy of hepatic ischemia-reperfusion injury
H. Wang, *X. Lan, D. Jiang;*
Wuhan Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, CHINA.

EP-0059
Continuous enzymatic hypoxia relief with NIR-II moderate photothermal assistance for enhanced Yttrium-90 microspheres oncotherapy
J. Li, *X. Su;*
The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, CHINA.

EP-0060
Prostate-specific membrane antigen-targeted endogenous radiotherapy of triple-negative breast cancer
A. Heesch[1], *J. Maurer*[2,3], *A. Florea*[1], *A. Morgenroth*[1], *F. M. Mottaghy*[1,4];
[1]*Department of Nuclear Medicine, University Hospital RWTH Aachen, Aachen, GERMANY,* [2]*Department of Obstetrics and Gynecology, University Hospital RWTH Aachen, Aachen, GERMANY,* [3]*Center for Integrated Oncology (CIO), Aachen, Bonn, Cologne, Düsseldorf (ABCD), GERMANY,* [4]*Department of Radiology and Nuclear Medicine, Maastricht University Medical Center (MUMC+), Maastricht, NETHERLANDS.*

EP-0061
Impact of injection velocity during transarterial radioembolization, an in vitro analysis
T. Snoeijink[1], *J. L. van der Hoek*[2], *H. Mirgolbabaee*[2], *E. Groot Jebbink*[2], *J. F. W. Nijsen*[1];
[1]*Radboud University Medical Centre, Nijmegen, NETHERLANDS,* [2]*University of Twente, Enschede, NETHERLANDS.*

EP-0062
Sn-117m Homogeneous Colloid is a Disease-Modifying Device in the Treatment of Osteoarthritis
C. Doerr[1], *A. Bendele*[2], *J. Simon*[3], *N. Stevenson*[4], *G. Gonzales*[1];
[1]*Serene, LLC, The Woodlands, TX, UNITED STATES OF AMERICA,* [2]*Inotiv, Boulder, CO, UNITED STATES OF AMERICA,* [3]*Isotherapeutics Group, LLC, Angleton, TX, UNITED STATES OF AMERICA,* [4]*Exubrion Therapeutics, Buford, GA, UNITED STATES OF AMERICA.*

EP-0063
Therapeutic potential of a Claudin 18.2 targeted alpha therapeutic [225Ac]-FPI-2474 in a pre-clinical gastric cancer tumor model
S. Almasi, *T. Kostelnik, V. Subramony, N. Robinson, W. Turnbull, B. L. Thériault, C. P. Leamon, J. Valliant;*
Fusion pharmaceuticals, Hamilton, ON, CANADA.

EP-0064
Development and evaluation of fluorescent SSTR2-antagonists for intraoperative image-guided surgery of NETs
M. Handula[1], *S. Beekman*[1], *Y. Seimbille*[1,2];
[1]*Erasmus MC, Rotterdam, NETHERLANDS,* [2]*TRIUMF, Vancouver, BC, CANADA.*

EP-0065
Preclinical studies for optimal implementation of GRPR radiotracers in clinical studies
T. S.T. Damiana[1], *P. Paraïso*[1], *C. de Ridder*[2], *D. Stuurman*[1], *L. van den Brink*[1], *Y. Seimbille*[1], *S. U. Dalm*[1];
[1]*Department of Radiology & Nuclear Medicine, Erasmus Medical Center, Rotterdam, NETHERLANDS,* [2]*Department of Experimental Urology, Erasmus Medical Center, Rotterdam, NETHERLANDS.*

EP-0066
Restoration of impaired portal glucose sensing by targeted manipulation of GLP-1r density in a translational model of insulin resistance
C. Malbert[1], *R. Allouche*[2], *M. Horowitz*[3], *K. L. Jones*[3];
[1]*INRAE - Aniscan, Saint-Gilles, FRANCE,* [2]*Paltech, Paris, FRANCE,* [3]*Adelaide Medical School, The University of Adelaide, Adelaide, AUSTRALIA.*

EP-0067
Long-term characterization of a radiolabeled hydrogel after intrastriatal injection in rats to improve post-stroke brain repair
N. Hugues[1], *C. Pin-Barre*[2], *O. Nachar*[1], *V. Nail*[1], *L. Balasse*[1], *B. Guillet*[1], *T. Trimaille*[3], *J. Laurin*[4], *P. Garrigue*[1];
[1]*Centre Européen de Recherche en Imagerie Médicale (CERIMED), Marseille, FRANCE,* [2]*Syncrosome, Marseille, FRANCE,* [3]*Institut de Chimie Radicalaire (ICR), Marseille, FRANCE,* [4]*Insitut de Neurobiologie de la Méditerranée (INMED), Marseille, FRANCE.*

EP-0068
miRNAs as Early Biomarkers of GEPNET Disease Progression. Evaluation of Feasibility and Preliminary Results
F. SCALORBI, *M. Gariboldi, L. Roz, G. Centonze, F. Facchinetti, G. Calareso, E. Garanzini, V. Lagano, G. Argiroffi, S. Pusceddu, M. Maccauro, E. Seregni, M. Milione;*
Istituto Nazionale Tumori Milano, MILAN, ITALY.

EP-0069
Implementation of a human brain tumour model in large animals, to translate holmium-166 microbrachytherapy towards the clinic.
N. Klaassen[1], *M. Boswinkel*[1], *N. C. Morsink*[2], *S. A. van Nimwegen*[2], *J. F. W. Nijsen*[1];
[1]*Department of Medical Imaging, Radboud University Medical Center, Nijmegen, NETHERLANDS,* [2]*Utrecht University, Department of Clinical Sciences of Companion Animals, Faculty of Veterinary Medicine, Utrecht, NETHERLANDS.*

EP-0070
Targeted Alpha Therapy Using Terbium-149 with Somatostatin Analogues: Comparison of [149Tb] Tb-DOTA-LM3 and [149Tb]Tb-DOTATATE
S. D. Busslinger[1], *A. K. Mapanao*[1], *C. Favaretto*[1,2], *P. V. Grundler*[1], *U. Köster*[3], *K. Johnston*[4], *R. Schibli*[1,5], *N. P. van der Meulen*[1], *C. Müller*[1,5];
[1]*Paul Scherrer Institut, Villigen-PSI, SWITZERLAND,* [2]*University Hospital Basel, Basel, SWITZERLAND,* [3]*Institut Laue-Langevin, Grenoble, FRANCE,* [4]*ISOLDE/CERN, Geneva, SWITZERLAND,* [5]*ETH Zurich, Zurich, SWITZERLAND.*

EP-0071
Radiation dosimetric and biodistribution comparison of the PSMA agonists 177Lu-PSMA I&T, 99mTc-Hynic PSMA and 99Tc-PSMA I&T to the 177Lu-RM2 antagonist
G. Limouris[1,2], *M. Paphiti*[3], *A. Zafeirakis*[2];
[1]*Nuclear Medicine, Medical School, National and Kapodistrian University of Athens, Athens, GREECE,* [2]*Nucl Med Dept, Army Share Fund Hospital of Athens, Athens, GREECE,* [3]*Cyclotron Section, Pharmazac SA, Athens, GREECE.*

EP-05

e-Poster Area

A: Preclinical Studies -> A1 Medical Preclinical -> A15 Other Medical Preclinical

EP-0072
WAY100635 and altanserin differentially modulate nigrostriatal and mesolimbic D2 receptor binding
S. Nikolaus[1], *H. J. Wittsack*[1], *M. Beu*[1], *C. Antke*[1], *B. Fazari*[2], *H. Hautzel*[3], *E. Mamlins*[1], *H. Müller*[1], *G. Antoch*[1], *F. L. Giesel*[1];
[1]*University Hospital Düsseldorf, Düsseldorf, GERMANY,* [2]*Heinrich-Heine University, Düsseldorf, GERMANY,* [3]*University Hospital Essen, Düsseldorf, GERMANY.*

EP-0073
5-HT1A and 5-HT2A receptor agonists and antagonists modulate behavior and regional DAT binding in the rat brain
S. Nikolaus, *M. Beu;*
University Hospital Düsseldorf, Düsseldorf, GERMANY.

EP-0074
Somatostatin receptor imaging in mice with different positive rate of SSTR2
Q. Xie, *X. Meng, Z. Yang, J. Yu;*
Peking University Cancer Hospital & Institute, Beijing, CHINA.

EP-0075
Assessment of macrophage inflammatory activity on visceral adipose tissue in high-fat diet-induced obese mice by 18F-FDG PET/CT
K. Pahk, *H. Kwon, S. Kim;*
Korea University College of Medicine, Seoul, KOREA, REPUBLIC OF.

EP-0076
IPCEF1 serves as a novel biomarker and correlates with immune infiltration in PTC
X. Jia, *R. Gao, J. zhang, H. Xu, Y. Yang, A. Yang;*
The first hospital of Xi'an jiaotong university, Xi'an, CHINA.

EP-0077
Pilot study: non-invasive imaging of CD8+ T-cell infiltration during the development of type 1 diabetes in non-obese diabetic mice
S. Tokgöz[1], *C. Frielink*[1], *P. J. Wierstra*[1], *I. M. Hagemans*[2], *M. Verdoes*[2], *S. Heskamp*[1], *M. Gotthardt*[1], *M. Boss*[1];
[1]*Department of Medical Imaging, Radboud University Medical Center, Nijmegen, NETHERLANDS,* [2]*Department of Tumor Immunology, Radboud University Medical Center, Nijmegen, NETHERLANDS.*

EP-0078
68Ga-siderophores for Klebsiella pneumoniae detection by positron emission tomography
K. Bendová[1], *M. Zappeová*[1], *P. Mlynárčik*[2], *Z. Nový*[1], *M. Popper*[1], *M. Hajdúch*[1];
[1]*Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University, Olomouc, CZECH REPUBLIC,* [2]*Department of Microbiology, Faculty of Medicine and Dentistry, Palacký University, Olomouc, CZECH REPUBLIC.*

EP-0079
Renal-clearable gambogic acid nanoparticles for PET imaging-guided acute kidney injury treatment
N. Liu, *X. Su;*
PET Center, Department of Nuclear Medicine, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, CHINA.

EP-0080
A longitudinal PET study of an open blast induced TBI model in NHP (Cynomolgus macaques) by [11C] PBR28 and [18F]FlumazenilA longitudinal PET study of an open blast induced TBI model in NHP (Cynomolgus macaques) by [11C]PBR28 and [18F] Flumazenil
P. Padmanabhan[1], *K. K. Ghosh*[1], *C. Yang*[2], *Z. Wang*[1], *K. Ng*[3], *B. Ogden*[4], *J. Lu*[3], *C. Halldin*[1], *B. Gulyás*[1];
[1]*LKC School of Medicine, NTU, Singapore, SINGAPORE,* [2]*Singapore General Hospital, Singapore, SINGAPORE,* [3]*DSO National Laboratories, Singapore, SINGAPORE,* [4]*SingHealth Experimental Medicine Centre, Singapore, SINGAPORE.*

EP-0081
GPT-MI: An automated GPT-based pipeline to meta-analyse the field of molecular imaging
P. Jané[1], *X. Xu*[2], *V. Taelman*[2], *E. Jané*[3], *K. Gariani*[1], *R. Dumont*[2], *M. Gómez*[4], *M. Walter*[2];
[1]*Hôpitaux Universitaires de Genève, Geneva, SWITZERLAND,* [2]*University of Lucerne, Lucerne, SWITZERLAND,* [3]*Universidad Politécnica de Madrid, Madrid, SPAIN,* [4]*Hospital Universitario Ramón y Cajal, Madrid, SPAIN.*

EP-0082
Pilot PET study of molecular processes disturbing the electrode nerve interface in a guinea pig model of cochlear implantation
P. Deutsch[1,2], *M. Mamach*[3,2], *J. Schweiger*[4,2], *J. Bankstahl*[1], *F. M. Bengel*[1], *T. Lenarz*[4,2], *V. Scheper*[4,2], *G. Berding*[1,2];
[1]*Department of Nuclear Medicine, Hannover Medical School, Hannover, GERMANY,* [2]*Cluster of Excellence Hearing4all, German Research Foundation, GERMANY,* [3]*Department of Radiation Protection and Medical Physics, Hannover Medical School, Hannover, GERMANY,* [4]*Department of Otolaryngology, Hannover Medical School, Hannover, GERMANY.*

EP-0083
Evaluating the Relevance of Non-invasive Measurement of Protein Synthesis by Gallium-68-DOTA-puromycin PET/MRI for Imaging of Mycobacterial Infection - a Preclinical Report
J. Kleynhans[1,2], *S. Eigner*[3], *M. M. Sathekge*[4,2], *T. Ebenhan*[2,4];
[1]*Radiopharmaceutical Research, Catholic University of Leuven, Leuven, BELGIUM,* [2]*Nuclear Medicine Research Infrastructure NPC, Pretoria, SOUTH AFRICA,* [3]*Nuclear Physics Institute, Academy of Science of the Czech Republic, Rez near Prague, CZECH REPUBLIC,* [4]*Nuclear Medicine and Steve Biko Academic Hospital, University of Pretoria, Pretoria, SOUTH AFRICA.*

EP-06

e-Poster Area

B: Imaging Clinical Studies -> B10 Other Imaging Clinical Studies -> B101 Other Clinical Studies

EP-0084
Performance of 68Ga-FAPI PET/CT in evaluation of Erdheim-Chester disease: compared with 18F-FDG PET/CT
J. Ma;
Peking Union Medical College Hospital, Beijing, CHINA.

EP-0085
Effects of Aromatase inhibitors on bone mineral density and trabecular bone score in patients with breast cancer
V. Dabbagh[1], *F. Homaee Shandiz*[2], *A. Taghizadeh Kermani*[3], *F. Nesari Javan*[1];
[1]*Nuclear Medicine Research Center, Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad, IRAN, ISLAMIC REPUBLIC OF,* [2]*Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad, IRAN, ISLAMIC REPUBLIC OF,* [3]*Omid Hospital, Mashhad University of Medical Sciences, Mashhad, IRAN, ISLAMIC REPUBLIC OF.*

EP-0086
Bone SPECT-CT in the study of facet arthropathy
B. Martins, *A. Duarte, M. Correia, A. Figueiredo, S. Matos, N. Canto, D. Calado, C. Loewenthal;*
Hospital da Luz, Lisboa, PORTUGAL.

EP-0087
Usefulness of bone scan in the management of Paget's disease
N. Ben Fekih[1], *W. El Ajmi*[2], *S. Cherif*[3], *A. Sellem*[2], *H. Hammami*[2];
[1]*faculty of medicine monastir, Tunis, TUNISIA,* [2]*Military Hospital of Tunis, Tunis, TUNISIA,* [3]*faculty of medicine Tunis, Tunis, TUNISIA.*

EP-0088
Is there any added value of a DXA scan of the distal forearm to lumbar and hip DXA values in predicting osteoporotic bone fractures?
M. ROMERA[1], *Á. Bronte*[1], *V. Betech-Antar*[1], *F. Mínguez*[1], *J. Rosales*[1], *S. Menéndez-Sánchez*[1], *J. Bastidas*[1], *E. Guillén*[2], *L. Sancho*[2], *L. García-Belaustegui*[2], *J. Arbizu*[1], *M. García Velloso*[1], *F. Pareja*[1], *M. Rodríguez*[1];
[1]*Clínica Universidad de Navarra, Pamplona, SPAIN,* [2]*Clínica Universidad de Navarra, Madrid, SPAIN.*

EP-0089
Optimization of SPECT/CT reconstruction parameters for intrapancreatic accessory spleen imaging
D. Sfiligoj Planjsek, *S. Rep, A. Cuderman, J. Jamsek, L. Lezaic;*
UMC Ljubljana, Ljubljana, SLOVENIA.

EP-0090
Identifying immunotherapy progressors by 18F-FLT PET/CT in solid tumours: a pilot study
P. Aravind[1], *M. Lythgoe*[1], *J. Evans*[2], *L. Tookman*[2], *W. E. Park*[2], *N. Sarwar*[2], *A. Sita-Lumsden*[3], *D. J. Pinato*[2], *T. D. Barwick*[1,2], *E. O. Aboagye*[1], *R. Sharma*[1,2];
[1]*Imperial College London, London, UNITED KINGDOM,* [2]*Imperial College Hospital NHS TRUST, London, UNITED KINGDOM,* [3]*Guys and St Thomas' NHS Foundation Trust, London, UNITED KINGDOM.*

EP-07

e-Poster Area

B: Imaging Clinical Studies -> B1 Oncological Imaging Clinical Study -> B11 Central Nervous System

EP-0091
Unraveling the Relationship Between Glioma Tumor Residuals from Incongruent 18F-FET PET/MR Imaging and Tumor Proliferation Utilizing Multiparametric MRI Radiomics Analysis
X. Li[1,2], *Y. Cheng*[3], *X. Han*[1], *H. Yang*[1], *B. Cui*[1,2], *J. Li*[1,2], *G. Xu*[3], *Q. Lin*[3], *X. Xiao*[3], *J. Tang*[3], *J. Lu*[1,2];
[1]*Department of Radiology and Nuclear Medicine, Xuanwu Hospital, Capital Medical University, Beijing, CHINA,* [2]*Beijing Key Laboratory of Magnetic Resonance Imaging and Brain Informatics, Capital Medical University, Beijing, CHINA,* [3]*Department of Neurosurgery, Xuanwu Hospital, Capital Medical University, Beijing, CHINA.*

EP-0092
[18F]FDG-PET Radiomics Improves Outcome Prognostication in Patients With Primary CNS Lymphoma
S. Chen[1], *O. Yildirim*[2], *A. Mauguen*[2], *C. Grommes*[2], *H. Schöder*[2], *M. E. Mayerhoefer*[2], *S. Krebs*[2];
[1]*Weill Cornell Medical College, New York, NY, UNITED STATES OF AMERICA,* [2]*Memorial Sloan Kettering Cancer Center, New York, NY, UNITED STATES OF AMERICA.*

EP-07

e-Poster Area

B: Imaging Clinical Studies -> B1 Oncological Imaging Clinical Study -> B12 Head and Neck

EP-0093
Somatostatin Receptor-Directed Theranostics in Paragangliomas of the Head and Neck
S. Serfling[1], *Y. Zhi*[2], *E. Gerhard-Hartmann*[3], *A. Weich*[4], *T. Higuchi*[5], *S. Hackenberg*[6], *R. Hagen*[2], *H. Remde*[7], *A. Scherzad*[1], *M. Fassnacht*[8], *R. A. Werner*[1];
[1]*Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, GERMANY,* [2]*Department of Otorhinolaryngology, Plastic, Aesthetic and Reconstructive Head and Neck Surgery, University Hospital Würzburg, Würzburg, GERMANY,* [3]*Institute of Pathology and Comprehensive Cancer Center Mainfranken, Würzburg, GERMANY,* [4]*ENETS Center of Excellence, University Hospital Würzburg, Würzburg, GERMANY,* [5]*University Hospital Würzburg, Würzburg, GERMANY,* [6]*RWTH Aachen University, Aachen, GERMANY,* [7]*Internal Medicine II, Gastroenterology, University Hospital Würzburg, Würzburg, GERMANY,* [8]*8 Internal Medicine I, Endocrinology, University Hospital Würzburg, Würzburg, GERMANY.*

EP-0094
Prediction of Nodal Metastasis by FDG PET/CT in Untreated Laryngeal Carcinoma; Comparison to MRI
A. Al ibraheem, *A. S. Abdlkadir, H. KHCC Group, D. Al-adhami;*
King Hussein Cancer Center, Amman, JORDAN.

EP-0095
Diagnostic utility of Semiquantitative parameters on FDG PET/CT for lymph node metastases in patients with laryngeal Squamous Carcinoma
A. Al ibraheem, *A. Abdlkadir, D. Al-Adhami, King Hussein Cancer Center Head and neck cancer Group, H. KHCC Group;*
King Hussein Cancer Center, Amman, JORDAN.

EP-0096
Role of F-18-FDG PET/CT in staging and assessment of treatment response to neoadjuvant chemotherapy in patients with extra-ocular retinoblastoma (EORB) - a single centre initial experience
S. G Ravindra, *S. Garg, A. Khurana, J. Pathak, N. Lomi, R. Seth, R. Kumar, C. S. Bal;*
All India Institute of Medical Sciences, New Delhi, INDIA.

EP-0097
The impact of the COVID 19 pandemic on nasopharyngeal carcinoma extent at FDG PET/MR staging:the NPCOVIPET study
Y. Xu;
Hangzhou Universal Medical Imaging Diagnostic Center, Hangzhou, CHINA.

EP-0098
Use of 18F-FDG PET/MR as an initial staging procedure for nasopharyngeal carcinoma
Y. Xu;
Hangzhou Universal Medical Imaging Diagnostic Center, Hangzhou, CHINA.

EP-0099
A diagnostic model of nasopharyngeal carcinoma based on PET/MRI radiomics and semi-quantitative parameters
J. Liang;
杭州通用医学影像诊断中心, 杭州, *CHINA.*

EP-0100
Detection of metastatic lymph nodes with multiparametric PET/MR in head and neck imaging
A. Harteveld, *E. H. M. Kemper, N. D. Sijtsema, P. A. Wielopolski, D. H. J. Poot, M. Segbers, F. A. Verburg; Erasmus MC, Rotterdam, NETHERLANDS.*

EP-0101
Clinical Value of [18F]FDG PET-CT In the Study of Head and Neck Carcinoma of Unknown Origin.
V. Carrero-Vásquez, *L. Rodríguez-Bel, C. Martinez-Ramos, P. Notta, L. Gracia-Sánchez, I. Sanchez-Rodriguez, A. Palomar-Muñoz, M. Cortés-Romera; Nuclear Medicine Department, Bellvitge University Hospital, Barcelona, SPAIN.*

EP-0102
Pretreatment PET-derived GLCM & TLG model predicts therapy outcome in patients with Head & Neck S.C.C.
M. Elahmadawy[1], *A. Ashraf*[1], *H. Moustafa*[2], *M. Kotb*[1];
[1]*Nuclear Medicine Unit, National Cancer Institute (NCI) , Cairo University, Cairo, EGYPT,* [2]*Nuclear Medicine Unit, Kasr Al-Ainy (NEMROCK Center), Cairo University, Cairo, EGYPT.*

EP-0103
Application value of 18F-FDG PET/MRI in scanning for cephalic and cervical lymph node metastasis of nasopharyngeal carcinoma
J. Liang;
Hangzhou Universal Medical Imaging Diagnostic Center, Hangzhou, CHINA.

EP-0104
Application value of 18F-FDG PET/MRI in monitoring the staging and treatment effectiveness of nasopharyngeal carcinoma
J. Liang;
Hangzhou Universal Medical Imaging Diagnostic Center, Hangzhou, CHINA.

EP-0105
Deciphering Organ-Specific Interactions in Cancer-Associated Cachexia in Head and Neck Squamous Cell Carcinoma Using FDG PET/CT Imaging
J. Yu[1], *D. Ferrara*[2], *S. Gutschmayer*[2], *M. Moreira Pires*[2], *L. Shiyam Sundar*[2], *C. Spielvogel*[1], *D. Haberl*[1], *T. Beyer*[2], *M. Hacker*[1];
[1]*Medical University of Vienna, Vienna, AUSTRIA,* [2]*QIMP Team, Medical University of Vienna, Vienna, AUSTRIA.*

EP-08

e-Poster Area

B: Imaging Clinical Studies -> B1 Oncological Imaging Clinical Study -> B13 Breast

EP-0106
Comparison of 1 day protocol and 2 day protocol of lymphoscintigraphy by subareolar injection in the detection of sentinel lymph nodes in breast cancer patients.
J. Seok;
Chung-Ang University, College of Medicine, Seoul, KOREA, REPUBLIC OF.

EP-0107
The comparative study of the validation for Tc-99m Tin-colloid and Tc-99m Phytate in sentinel node detection in breast cancer patients.
J. Seok;
Chung-Ang University, College of Medicine, Seoul, KOREA, REPUBLIC OF.

EP-0108
Prediction of HER2 expression status in breast cancer based on 18F-FDG PET-CT radiomics
D. Han[1,2], *X. Duan*[1], *N. Yu*[2];
[1]*the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, CHINA,* [2]*Affiliated Hospital of Shaanxi University of Chinese Medicine, Xianyang, CHINA.*

EP-0109
Detection of internal mammary lymph node chain infiltration in breast cancer patients by 18F-FDG-PET/MRI. Impact on patient management
M. Kauak Kuschel, *J. García Garzón, A. Compte, E. Valls, P. Bassa, M. Minoves, E. Llinares, L. Mont, E. Riera, M. Blanch Labrador; CETIR ASCIRES, Barcelona, SPAIN.*

EP-0110
A pilot study of the use of positron emission tomography to evaluate early oestrogen receptor changes in patients with advanced and/or relapsed breast cancer administered endocrine therapy and CDK4/6 inhibitor combination therapy
I. Kuji[1], *K. Matsuura*[2], *A. Osaki*[2], *T. Yamane*[1], *H. Ishiguro*[2], *T. Saeki*[2];
[1]*Department of Nuclear Medicine, Saitama Medical University International Medical Center, Hidaka, Saitama, JAPAN,* [2]*Department of Breast Oncology, Saitama Medical University International Medical Center, Hidaka, Saitama, JAPAN.*

EP-0111
Is subcutaneous/cutaneous uptake on [18F] FDG PET/CT a prognostic marker for breast cancer patients undergoing surgery?
Y. Kitano[1], *K. Miyake*[2], *T. Nobashi*[1], *T. Ishimori*[3], *R. Nakamoto*[1], *S. Koyasu*[1], *M. Kataoka*[1], *K. Kawaguchi*[4], *Y. Takeuchi*[5], *M. Toi*[6], *Y. Nakamoto*[1];
[1]*Diagnostic Imaging and Nuclear Medicine, Kyoto University Hospital, Kyoto, JAPAN,* [2]*Department of Advanced Imaging in Medical Magnetic Resonance, Kyoto University Hospital, Kyoto, JAPAN,* [3]*Diagnostic Radiology, Medical Research Institute Kitano Hospital, PIIF Tazuke Kofukai, Osaka, JAPAN,* [4]*Department of Breast Surgery, Graduate School of Medicine, Kyoto University, Kyoto, JAPAN,* [5]*Clinical Bio Resource Center, Kyoto University Hospital, Kyoto, JAPAN,* [6]*Breast Surgery, Tokyo Metropolitan Cancer and Infectious Disease Center, Komagome Hospital, Tokyo, JAPAN.*

EP-0112
[18F]FDG-PET/MRI in Breast Cancer
G. Argalia[1], *F. M. Fringuelli*[1], *G. Biscontini*[1], *A. Palucci*[1], *C. Romagnolo*[1], *C. Cottignoli*[1], *P. Ercolani*[2], *B. F. Simonetti*[2], *S. Borgoforte Gradassi*[2], *L. Burroni*[1];
[1]*Nuclear Medicine, Department of Radiological Sciences, University Hospital of Marche, Ancona, ITALY,* [2]*Radiology, Department of Radiological Sciences, University Hospital of Marche, Ancona, ITALY.*

EP-0113
Automated Lesion Detection for 18F-Fluoroestradiol PET/CT Images Demonstrates Lesion Heterogeneity in Patients with ER+ Metastatic Breast Cancer
M. Battle[1], *K. Wangerin*[2], *R. Miller*[1], *S. S. Houshmandi*[3], *D. T. Huff*[3], *A. J. Weisman*[3], *T. G. Perk*[3], *G. A. Ulaner*[4];
[1]*GE HealthCare, Little Chalfont, UNITED KINGDOM,* [2]*GE HealthCare, Marlborough, MA, UNITED STATES OF AMERICA,* [3]*AIQ Solutions, Madison, WI, UNITED STATES OF AMERICA,* [4]*Hoag Family Cancer Institute, Long Beach, CA, UNITED STATES OF AMERICA.*

EP-0114
Potential role of 18F-FDG PET/CT in the initial staging of breast cancer.
R. Sanchez Sanchez[1], *A. González Jimenez*[2], *T. Aroui Luquin*[1], *A. Piñero Donis*[1], *J. Villa Palacios*[1];
[1]*Hospital Virgen de las Nieves, Granada, SPAIN,* [2]*Hospital Universitario de Jaén, Granada, SPAIN.*

EP-0115
Standardized Uptake Values of Breast Cancer in Sub-millimetre 18F-FDG-PET/CT: Direct Correlation with Histopathology
L. Maris[1,2], *M. Göker*[3], *K. De Man*[4], *B. Van den Broeck*[4], *R. Van Holen*[2], *V. Keereman*[1,2], *K. Van de Vijver*[5,6], *C. Vanhove*[1,7];
[1]*Department of Electronics and Information Systems, Ghent University, Ghent, BELGIUM,* [2]*XEOS Medical, Ghent, BELGIUM,* [3]*Department of Gynaecology, Ghent University Hospital, Ghent, BELGIUM,* [4]*Department of Medical Imaging, Nuclear Medicine, Ghent University Hospital, Ghent, BELGIUM,* [5]*Department of Pathology, Ghent University Hospital, Ghent, BELGIUM,* [6]*Department of Diagnostic Sciences and Cancer Research Institute Ghent (CRIG), Ghent University, Ghent, BELGIUM,* [7]*INFINITY Lab, Ghent University, Ghent, BELGIUM.*

EP-0116
The Role Of F-18 FDG PET/CT In The Prediction of Residual Cancer Burden After Neoadjuvant Chemotherapy In Locally Advanced Breast Cancer
E. KAYA[1], *O. VURAL TOPUZ*[1], *B. E. AKKAS*[1], *M. KAYA*[1], *T. SOYLEMEZ AKKURT*[2], *E. ACAR*[1];
[1]*University of Health Sciences, Başakşehir Cam and Sakura City Hospital, Department of Nuclear Medicine, Istanbul, Türkiye., Istanbul, TÜRKIYE,* [2]*University of Health Sciences, Başakşehir Cam and Sakura City Hospital, Department of Pathology, Istanbul, Türkiye., Istanbul, TÜRKIYE.*

EP-0117
Therapeutic impact of [18F]FDG PET/CT for initial staging in patients with clinical stage I and IIA, HER2-positive and triple negative breast cancer
C. François[1], *A. Mailliez*[2], *S. Chrétien*[2], *L. Ceugnart*[3], *A. Oudoux*[1], *O. Cougnenc*[4], *A. Olivier*[1];
[1]*Department of Nuclear Medicine, Centre Oscar Lambret, Lille, FRANCE,* [2]*Department of Medical Oncology, Centre Oscar Lambret, Lille, FRANCE,* [3]*Department of Radiology, Centre Oscar Lambret, Lille, FRANCE,* [4]*Department of Clinical Pharmacy, Centre Oscar Lambret, Lille, FRANCE.*

EP-0118
The Role of Primary Tumor PET/MR Quantitative Values in Predicting Pathological Complete Response after Neoadjuvant Treatment in Breast Cancer
Y. Ünlüer Ates, *U. Aydos, E. Balcı, L. Atay; Gazi University Medicine Faculty, Nuclear Medicine, Ankara, TÜRKIYE.*

EP-0119
Can Tumor Heterogeneity in TNBC Obtained With FDG PET/CT Predict Survival? a Novel Method: Heterogenity index3
G. B. Babacan[1], *M. Öner Tamam*[1], *S. Saraçoğlu*[1], *M. N. Acar*[1], *M. C. Şahin*[1], *G. Kulduk*[2], *H. Özçevik*[3];
[1]*University of Health Sciences, Prof. Dr. Cemil Tascioglu City Hospital, Department of Nuclear Medicine, Istanbul, TÜRKIYE,* [2]*University of Health Sciences, Prof. Dr. Cemil Tascioglu City Hospital, Department of Pathology, Istanbul, TÜRKIYE,* [3]*University of Health Sciences, Hamidiye Faculty of Medicine, Department of Nuclear Medicine, Istanbul, TÜRKIYE.*

EP-0120
The Role Of 68ga Dotatate Pet/Ct In Breast Cancer Imaging; A Prospective Study Compared With 18f Fdg Pet/Ct
C. Sezgin, *T. Coşkun, Y. Parlak, G. Mutevelizade, E. Sayıt, G. Gümüşer; Celal Bayar University, Manisa, TÜRKIYE.*

EP-0121
FAPI-04 uptake in healthy breast glandular tissue
Y. Zhang, *M. Su; Department of Nuclear Medicine, West China Hospital, Sichuan University, Chengdu, CHINA.*

EP-0122
Role of semi quantitative 18F-FDG PET/CT parameters in prediction of the hormone status and progression free survival of advanced stage breast carcinoma patients
S. Sarswat, *A. Singhal, K. J. Das; AIIMS DELHI, Delhi, INDIA.*

EP-0123
The Detection Value of 18F-FDG PET/MR for Breast Cancer Liver Metastasis
X. Chenjie;
Hangzhou Universal Medical Imaging Diagnostic Center, hangzhou, CHINA.

EP-0124
Dose Reduction for 89Zr ImmunoPET Imaging Using LAFOV PET/CT: An Analysis Based on Count-Reduced Images
P. Mohr, *J. van Sluis, L. Providência, A. A. Lammertsma, A. H. Brouwers, C. Tsoumpas;*
University Medical Center Groningen, Groningen, NETHERLANDS.

EP-0125
Prone FDG PET/CT in breast cancer restaging (Response to treatment evaluation)
M. Agolti, *L. Solari;*
Centro de Medicina Nuclear Clinica Modelo, Parana, ARGENTINA.

EP-0126
Comparison of whole-body PET/CT and dedicated breast PET with F-18 Fluoroestradiol for breast cancer detection in patients with newly diagnosed ER-positive breast cancer
K. Miyake[1], *M. Takada*[2], *Y. Shimizu*[1], *S. Yuge*[1], *Y. Kitano*[1], *T. Ishimori*[3], *M. Kataoka*[1], *M. Kawashima*[2], *K. Kawaguchi*[2], *T. Oishi*[1], *K. Itagaki*[2], *Y. Yamada*[2], *Y. Takeuchi*[2], *M. Toi*[4], *Y. Nakamoto*[1];
[1]*Kyoto University Graduate School of Medicine, Kyoto, JAPAN,* [2]*Kyoto University Hospital, Kyoto, JAPAN,* [3]*Kitano Hospital, Osaka, JAPAN,* [4]*Komagome Hospital, Tokyo, JAPAN.*

EP-0127
18F-FDG PET/CT for monitoring treatment response in bone-dominant metastatic breast cancer patients.
P. Portilla Merino, *C. Escabias del Pozo, Y. Abadi Sedraoui, E. López Llobet, L. Giraldo Gonzalez, S. Rizkallal Monzon, D. Monachello Araujo, C. Lancha Hernandéz, S. Rodado Marina, M. Coronado Poggio, J. Cordero García, L. Domínguez Gadea;*
Hospital Universitario La Paz, Madrid, SPAIN.

EP-0128
Metabolic Parameters of FDG PET/CT to Predict Disease Progression in Breast Cancer Type
J. Park[1], *J. Choi*[1], *Z. Kim*[1], *C. Lim*[1], *J. Yoon*[2], *C. Lim*[3], *S. Park*[3], *J. Moon*[1], *S. Seo*[4], *S. Woo*[5], *J. Choi*[6];
[1]*Soonchunhyang University Bucheon Hospital, Bucehon, KOREA, REPUBLIC OF,* [2]*Ajou University Medical Center, Suwon, KOREA, REPUBLIC OF,* [3]*Soonchunhyang University Seoul Hospital, Seoul, KOREA, REPUBLIC OF,* [4]*Pai Chai University, Daejeon, KOREA, REPUBLIC OF,* [5]*Korea Institutes of Radiological and Medical Sciences, Seoul, KOREA, REPUBLIC OF,* [6]*Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, KOREA, REPUBLIC OF.*

EP-0129
Comparative Analysis of Immunohistochemistry Markers for Breast Carcinoma (ER, PR And HER 2 NEU) With Respect to Bone Metastasis
N. Kumar Gupta, *V. K Dhingra, S. Jha, A. S.;*
AIIMS Rishikesh, Rishikesh, INDIA.

EP-0130
Depth of response using total tumor volume with [18F]-Fluorodeoxyglucose PET/CT for monitoring therapy response to Cyclin Dependent 4/6 Kinase Inhibitors
O. Garcia-Perez, *P. Cabrera Galeana, I. Soldevilla Gallardo, E. Bargallo, D. Gutierrez-Cruz, A. Franco-Ardila;*
Instituto Nacional de Cancerologia, Mexico city, MEXICO.

EP-0131
Does Body Mass Index correlate with risk of recurrence in patients with breast cancer undergoing [^{18}F]FDG PET/CT ?
N. Quartuccio, *S. Ialuna, S. Pulizzi, D. D'Oppido, M. Antoni, A. M. Moreci;*
Nuclear Medicine Unit, A.O.O.R. Villa Sofia Cervello, Palermo, ITALY.

EP-09

e-Poster Area

B: Imaging Clinical Studies -> B1 Oncological Imaging Clinical Study -> B14 Lung (including Mesothelioma)

EP-0132
PERCIST and Beyond : revisiting 18FDG PET/CT response patterns to ICPIs for non-small cell lung cancer considering atypical response, and their long-term prognostic value.
M. Masse[1], *D. Chardin*[1,2], *P. Tricarico*[1], *N. Martin*[1], *J. Darcourt*[1], *J. Otto*[1], *O. Humbert*[1,2];
[1]*Centre Antoine Lacassagne, Nice, FRANCE,* [2]*TIRO-UMR E 4320, UCA/CEA, Nice, FRANCE.*

EP-0133
Comparison of Diagnostic Performance Between 68Ga-FAPI-04 and 18F-FDG PET/CT in Patients with Non-Small Cell Lung Cancer
C. Li[1], *Y. Tian*[1], *Z. Xiao*[1], *J. Chen*[1], *L. Li*[1], *N. Lu*[1], *H. Li*[1], *J. Zhong*[1], *D. Zeng*[1], *B. Wen*[1], *Q. Chen*[2], *Y. He*[1];
[1]*Department of Nuclear Medicine, Zhongnan Hospital of Wuhan University, Wuhan, CHINA,* [2]*Department of Pathology, Zhongnan Hospital of Wuhan University, Wuhan, CHINA.*

EP-0134
First-in-human PET imaging of KRAS p.G12C mutation status in NSCLC and CRC patients using 18F-AMG510
J. Ye, *X. Li, M. Zhang, W. Yang, F. Kang, J. Wang;*
Xijing Hospital, Xi'an, CHINA.

EP-0135
Qualitative Analysis of Pericardial Metastasis in Oncologic F-18 FDG PET/CT
H. Lee;
Dongnam Institute of Radiological and Medical Sciences, Busan, KOREA, REPUBLIC OF.

EP-0136
Comparison of FDG PET/CT and PET/MR Imaging for Primary Staging of Newly Diagnosed Lung Cancer
E. Erbil, *U. Aydos, Ü. Akdemir, N. Karabacak, L. Atay;*
Gazi University Faculty of Medicine, Ankara, TÜRKIYE.

EP-0137
Added diagnostic sensitivity of MTV and TLG in the assessment of left adrenal gland metastasis in lung cancer with [18F]FDG PET/CT
H. Hautzel[1], *F. Özkan*[2], *C. Laschinsky*[1], *D. Kersting*[1], *M. Opitz*[3], *D. Theegarten*[4], *K. Darwiche*[2], *K. Herrmann*[1];
[1]*Department of Nuclear Medicine, University Hospital Essen, University Duisburg - Essen, Essen, GERMANY,* [2]*Department of Pneumology, Section of Interventional Pneumology, Ruhrlandklinik Essen, Universitätsmedizin Essen, Essen, GERMANY,* [3]*Institute of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, University Duisburg - Essen, Essen, GERMANY,* [4]*Institute of Pathology, University Hospital Essen, University Duisburg - Essen, Essen, GERMANY.*

EP-0138
Value of 18F-FDGPET/CT in the Differential Diagnosis of Tuberculous Pulmonary Cavity and Lung Cancer Cavity
M. Zhao[1,2], *L. Ma*[1];
[1]*Shandong Cancer Hospital of China, Ji Nan, CHINA,* [2]*Department of Nuclear Medicine, Zibo Central Hospital, Shandong Province, Zibo City, CHINA.*

EP-0139
Contribution of 18F-FDG PET-CT in initial staging of non-small cell lung cancers
H. Noamen[1,2], *H. Charfi*[2], *I. Jardak*[1], *R. Sfar*[2], *I. Touil*[2], *K. Chatti*[2], *K. Chtourou*[1], *F. Guermazi*[1];
[1]*University hospital of Habib Bourguiba, Sfax, TUNISIA,* [2]*University of Monastir, Monastir, TUNISIA.*

EP-0140
Prediction of mediastinal node involvement in non-small lung cancer by baseline 18 F-FDG PET/CT metabolic parameters
H. Noamen[1,2], *H. Charfi*[2], *I. Jardak*[1], *R. Sfar*[2], *I. Touil*[2], *K. Chatti*[2], *K. Chtourou*[1], *F. Guermazi*[1];
[1]*University hospital of Habib Bourguiba, Sfax, TUNISIA,* [2]*University of Monastir, Monastir, TUNISIA.*

EP-0141
PET attenuation correction of chest FDG PET/MRI: Deep learning-based denoising and pseudo-CT generation using fast zero-TE MRI and unpaired PET/CT data
M. Nogami[1,2], *H. Matsuo*[3], *M. Nishio*[3], *M. Tachibana*[3], *J. Inukai-Inoue*[3], *F. Zeng*[3], *K. Kubo*[1], *T. Kurimoto*[4], *T. Murakami*[3,1];
[1]*Kobe University Hospital, Kobe, JAPAN,* [2]*University of Fukui, Fukui, JAPAN,* [3]*Kobe University Graduate School of Medicine, Kobe, JAPAN,* [4]*GE Healthcare, Hino, JAPAN.*

EP-0142
Prediction of 131I Uptake in Lung Metastases of Differentiated Thyroid Cancer UsingDeep Learning before Radioiodine Therapy: a Pilot Study
H. Song;
Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, CHINA.

EP-0143
The value of 18F-FDG PET/CT radiologic features and radiomics features predicting the bronchogenic carcinomas with ALK rearrangement fused gene
Y. Xu;
Hangzhou Universal Medical Imaging Diagnostic Center, Hangzhou, CHINA.

EP-0144
The value of PET/MRI radiomics features in predicting synchronous brain metastases in non-small cell lung cancer
J. Liang;
杭州通用医学影像诊断中心, 杭州, *CHINA.*

EP-0145
The Application of Three-dimensional Ventilation/Perfusion single photon emission tomography/computed tomography in Asthma and COPD
H. Xie, *L. Li;*
West China Hospital of Sichuan University, Chengdu, CHINA.

EP-0146
68Ga-SSO-120 versus 18F-FDG PET in the Initial Staging of Small-Cell Lung Cancer Patients
D. Kersting[1], *P. Sandach*[1], *M. Sraieb*[1], *M. Wiesweg*[2], *M. Metzenmacher*[2], *K. Darwiche*[3], *F. Oezkan*[3], *S. Bölükbas*[4], *M. Stuschke*[5], *L. Umutlu*[6], *M. Nader*[1], *R. Hamacher*[2], *W. P. Fendler*[1], *J. Wienker*[3], *W. Eberhardt*[2], *M. Schuler*[2], *K. Herrmann*[1], *H. Hautzel*[1];
[1]*Department of Nuclear Medicine, University Hospital Essen, University of Duisburg-Essen, Essen, GERMANY,* [2]*Department of Medical Oncology, University Hospital Essen, University of Duisburg-Essen, Essen, GERMANY,* [3]*Department of Pulmonology, Section of Interventional Pulmonology, University Medicine Essen - Ruhrlandklinik, University of Duisburg-Essen, Essen, GERMANY,* [4]*Department of Thoracic Surgery and Thoracic Endoscopy, University Medicine Essen - Ruhrlandklinik, University of Duisburg-Essen, Essen, Germany, Essen, GERMANY,* [5]*Department of Radiotherapy, University Hospital Essen, University of Duisburg-Essen, Essen, GERMANY,* [6]*Institute of Diagnostic, Interventional Radiology and Neuroradiology, University Hospital Essen, University of Duisburg-Essen, Essen, GERMANY.*

EP-0147
Ongoing Trial on the Role of the Promising Oncological PET/CT Tracer [68Ga]Ga-FAPI-46 for Staging Suspected/Confirmed Lung Cancer: Preliminary Results on Patients who Underwent Radical Surgery
E. Fortunati[1], *L. Zanoni*[2], *G. Cuzzani*[1], *C. Nanni*[2], *F. Lodi*[2], *F. Antonacci*[3], *P. Solli*[3], *F. Giunchi*[4], *A. Degiovanni*[4], *M. Ferrari*[5], *F. Natali*[5], *T. Galasso*[5], *G. Bandelli*[5], *P. Candoli*[5], *A. D'Errico*[4], *S. Fanti*[1,2];
[1]*Nuclear Medicine, Alma Mater Studiorum University of Bologna, Bologna, ITALY,* [2]*Nuclear Medicine, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY,* [3]*Division of Thoracic Surgery, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY,* [4]*Pathology, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY,* [5]*Interventional Pulmunology Unit, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY.*

EP-0148
Can [18F] FDG PET/CT parameters Predict Pathological Response in Locally Advanced NSCLC? Findinds from NADIM Study
R. Jimeno Pernett[1], *J. Mucientes Rasilla*[1], *J. Gonzalez Larriba*[2], *A. Martinez Martí*[3], *E. Nadal*[4], *N. Viñolas*[5], *J. Bosch Barrera*[6], *A. Insa Mallá*[7], *J. Casal Rubio*[8], *M. Cobo Dols*[9], *R. Bernabe Caro*[10], *M. Mitjavila Casanovas*[1], *V. Calvo de Juan*[1], *M. Provencio Pulla*[1];
[1]*Hospital Universitario Puerta De Hierro, Madrid, SPAIN,* [2]*Hospital Univeristario Clínico San Carlos, Madrid, SPAIN,* [3]*Hospital Universitario Vall d'Hebrón, Barcelona, SPAIN,* [4]*ICO Hospitalet, Barcelona, SPAIN,* [5]*Hospital Clínic Barcelona, Barcelona, SPAIN,* [6]*Instituto Catalán de Oncología Médica de Girona, Barcelona, SPAIN,* [7]*Hospital Clínico Universitario de Valencia, Valencia, SPAIN,* [8]*Hospital Álvaro Cunqueiro, Vigo, SPAIN,* [9]*Hospital Carlos Haya, Málaga, SPAIN,* [10]*Hospital Virgen del Rocío, Sevilla, SPAIN.*

EP-0149
Relationship between [18]FDG myocardial uptake and subsequent evolution towards cachexia and outcome in lung cancer patients. Assessment from the retrospective LuCaPET database.
E. Abenavoli[1], *A. Grosso*[2], *T. Beyer*[3], *S. Duke*[4], *D. Ferrara*[3], *A. Frille*[5], *S. Gruenert*[6], *M. Hacker*[6], *S. Hesse*[5], *L. Hofmann*[7], *S. Holm*[4], *O. Sabri*[7], *L. Sundar*[3], *J. Yu*[3], *R. Sciagrà*[1];
[1]*Department of Nuclear Medicine, Azienda Ospedaliero-Universitaria Careggi, Florence, ITALY,* [2]*Department of Pneumology, Azienda Ospedaliero-Universitaria Careggi, Florence, ITALY,* [3]*QIMP Team, Medical University of Vienna, Vienna, AUSTRIA,* [4]*University of Copenhagen, Copenhagen, DENMARK,* [5]*University Hospital of Leipzig, Leipgz, GERMANY,* [6]*Division of Nuclear Medicine, Medical University of Vienna, Vienna, AUSTRIA,* [7]*University Hospital of Leipzig, Leipgz, AUSTRIA.*

EP-10

e-Poster Area

B: Imaging Clinical Studies -> B1 Oncological Imaging Clinical Study -> B15 Gastro-Intestinal (including Liver and Non-Endocrine Pancreas)

EP-0150
Diagnostic and prognostic value of TOF-18F-FDG PET/CT in patients with malignant pancreatic tumors
S. Stanzel, *T. Nazerani-Zemann, R. M. Aigner;*
Division of Nuclear Medicine, Graz, AUSTRIA.

EP-0151
Diagnostic and prognostic value of time-of-flight 18F-FDG PET/CT in staging of patients with pancreatic ductal adenocarcinoma using TrueX and Q.Clear reconstruction
S. Stanzel, *T. Nazerani-Zemann, R. M. Aigner;*
Medical University of Graz, Department of Nuclear Medicine, Division of Nuclear Medicine, Graz, AUSTRIA.

EP-0152
Evaluation of Liver Lesions with Diffusion Weighted Imaging PET/MRI in Transarterial Radioembolization Treatment Patients
A. Kibar, *F. Aghazada, L. Uslu-Besli, O. E. Sahin, S. Asa, S. Sager, K. Sonmezoglu;*
Istanbul University-Cerrahpasa, Cerrahpasa Faculty of Medicine, Department of Nuclear Medicine, Istanbul, TÜRKIYE.

EP-0153
Comparison of Tc-99m Mebrofenin Scintigraphy with Other Parameters in Prediction of Patient Status in Y-90 Patients
A. Kibar, *S. Asa, F. Aghazada, N. Yeyin, M. Abuqbeitah, K. Sahin, C. Guneren, K. Saglam, B. Ince, S. Sager, K. Sonmezoglu;*
Istanbul University-Cerrahpasa, Cerrahpasa Faculty of Medicine, Department of Nuclear Medicine, Istanbul, TÜRKIYE.

EP-0154
Dual-tracer PET/CT protocol with [18F]FDG and [68Ga]Ga-FAPI-46 outperforms single-tracer PET/CT with [18F]FDG in gastrointestinal and head and neck cancer, due to higher tumour to background ratio and larger gross and functional tumour volume.
K. Roth[1], *S. Wegen*[2], *J. Weindler*[1], *C. Voltin*[1], *L. van Heek*[1], *K. Schomäcker*[1], *T. Fischer*[1], *S. Marnitz*[2], *C. Kobe*[1], *A. Drzezga*[1];
[1]*Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, Cologne, Germany, Cologne, GERMANY,* [2]*Department of Radiation Oncology, Cyberknife and Radiotherapy, Faculty of Medicine and University Hospital Cologne, Cologne, Germany, Cologne, GERMANY.*

EP-0155
Surveillance 18F-FDG PET/CT in predicting the prognosis of esophageal cancer patients
S. Chan, *C. Tseng, S. Liu;*
Hualien Tzu Chi Hospital, Hualien, TAIWAN.

EP-0156
A dose optimization study using Visual Grading Regression in [68Ga]-FAPI-46 PET imaging of patients with pancreatic lesions
T. Nilsson[1], *P. Rasinski*[1,2], *S. af Burén*[1,2], *Ö. Smedby*[3], *A. Blomgren*[1], *M. Löhr*[2,4], *E. Sparrelid*[5], *T. Tran*[6,7], *R. Axelsson*[1,8], *M. Holstensson*[1,2];
[1]*Department of Medical Radiation Physics and Nuclear Medicine, Karolinska University Hospital, Huddinge, SWEDEN,* [2]*Department of Clinical Science, Intervention and Technology (CLINTEC), Karolinska Institutet, Stockholm, SWEDEN,* [3]*Department of Biomedical Engineering and Health Systems, KTH Royal Institute of Technology, Stockholm, SWEDEN,* [4]*Department of Upper Gastrointestinal Diseases, Karolinska University Hospital, Huddinge, SWEDEN,* [5]*Division of Surgery and Oncology, Department of Clinical Science, Intervention and Technology (CLINTEC), Karolinska Institutet, Stockholm, SWEDEN,* [6]*Department of Oncology-Pathology, Karolinska Institutet, Stockholm, SWEDEN,* [7]*Department of Radiopharmacy, Karolinska University Hospital, Stockholm, SWEDEN,* [8]*Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, SWEDEN.*

EP-0157
The prognostic value of metabolic parameters and heterogeneity index of PET/CT in patients with advanced gastric adenocarcinoma
Y. Tian, *T. Zhao, W. Cai, Y. Dong, X. Ma, P. Ma, Q. Zhao;*
General Hospital of Ningxia Medical University, Yinchuan, CHINA.

EP-0158
Incremental value of 18F-FDG PET-CECT over conventional imaging in evaluation of Gall Bladder Carcinoma.
P. Singh, *T. Singhal, P. Kumar, G. Parida, R. Emerson, K. Bishnoi, A. Rehman, K. Kandula, K. Agrawal, S. Patro;*
AIIMS Bhubaneswar, Bhubaneswar, INDIA.

EP-0159
Prognostic value of negative FDG PET/CT in curatively treated colorectal carcinomas with rising CEA levels during surveillance
A. Suresh[1], *V. Rangarajan*[2], *N. Purandare*[2], *A. Agrawal*[2], *S. Shah*[2], *A. Puranik*[2], *A. Saklani*[2];
[1]*Tata Memorial Centre, Varanasi, INDIA,* [2]*Tata Memorial Centre, Mumbai, INDIA.*

EP-0160
Comparison of 18F-FAPI-04 and 18F-FDG PET/CT in detecting the primary tumor and metastatic lesions in patients with initial pancreatic ductal adenocarcinoma
L. Lin, *G. Wang, X. Su;*
Department of Nuclear Medicine, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, CHINA.

EP-0161
Comparison of Diagnostic Efficacy of 18FAl-NOTA-FAPI-04 and 18F-FDG PET/CT for recurrence and/ormetastasis in patients with gastric cancer
K. Zheng, *Y. Zhang, H. Ye, A. Xie;*
Hunan Cancer Hospital (the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University), Changsha, CHINA.

EP-0162
Prognostic value of semiquantitative [18F]F-FDG PET/MRI parameters in patients with a newly diagnosed Pancreatic Adenocarcinoma
G. Mango[1], *P. Bartoletti*[2], *S. Serafini*[3], *R. Guastella*[4], *C. Berto*[5], *S. Da Pozzo*[6], *M. Sitara*[2], *G. Fichera*[7], *C. Giraudo*[2], *L. Evangelista*[2];
[1]*Nuclear Medicine, Department of Advanced Biomedical Sciences, University of Naples Federico II, Naples, ITALY,* [2]*Nuclear Medicine Unit, Department of Medicine DIMED, University of Padua, Padua, ITALY,* [3]*General Surgery Padua University Hospital, Padua, ITALY,* [4]*Hepato-Pancreato-Biliary Surgery and Liver Transplantation Unit, Padua University Hospital, Padua, ITALY,* [5]*Radiology Unit, Department of Medicine DIMED, University of Padua, Padua, ITALY,* [6]*Radiology Unit, Azienda Ospedaliera di Padua, Padua, ITALY,* [7]*Pediatric Radiology Unit, Padua University Hospital, Padua, ITALY.*

EP-0163
Head-to-head comparison of 18F-FDG and 68Ga-DOTA-FAPI PET/CT for staging and therapeutic evaluation of esophageal cancer
W. Hou, *R. Tian;*
West China Hospital, Sichuan University, Chengdu, CHINA.

EP-0164
Comparison of 3D Voxel-Based Yttrium-90 Dosimetry Quantification of using Y90 PET/CT Versus Y90 SPECT/CT
N. Kokabi[1,2], *M. Xing*[3], *D. Brandon*[2], *H. Dabbous*[2], *J. R. Galt*[4], *I. Sethi*[2], *S. Kappadath*[5], *A. Villalobos*[1], *D. M. Schuster*[2];
[1]*University of North Carolina School of Medicine, Chapel Hill, NC, UNITED STATES OF AMERICA,* [2]*Emory University School of Medicine, Atlanta, GA, UNITED STATES OF AMERICA,* [3]*University of North Carolina School of Public Health, Chapel Hill, NC, UNITED STATES OF AMERICA,* [4]*Emory University School of Medicine, AtaInta, GA, UNITED STATES OF AMERICA,* [5]*MD Anderson Cancer Center, Houston, TX, UNITED STATES OF AMERICA.*

EP-0165
2-[18F]FDG PET/CT derived semi-quantitative parameters in predicting response to chemoradiation in oesophageal squamous cell carcinoma
L. Lemos[1], *I. Lopo*[1], *P. Lapa*[1,2], *G. Costa*[1,2];
[1]*Nuclear Medicine Department, Centro Hospitalar e Universitário de Coimbra, Coimbra, PORTUGAL,* [2]*Faculdade de Medicina, Universidade de Coimbra, Coimbra, PORTUGAL.*

EP-0166
Role of whole-body FDG PET/CT in the detection of peritoneal metastases in cases of gastroesophageal junction adenocarcinoma
S. Thakur, *N. Purandare, V. Rangarajan, A. Agrawal, S. Shah, A. Puranik, C. Pramesh, G. Karimundackal, K. Prabhash, S. Jinwani, D. Niyogi, R. Kumar;*
Tata Memorial Hospital, Mumbai, INDIA.

EP-0167
18F-AlF-NOTA-FAPI PET/CT in the evaluation of gastric, liver, and pancreatic cancer and comparison with 18F-FDG PET/CT
w. xu, *J. Cai, Y. Pang, L. Sun, H. Chen;*
Department of Nuclear Medicine & Minnan PET Center, Xiamen Cancer Center, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China, xiamen, CHINA.

EP-0168
Diagnostic Efficiency of F-18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Malignant Biliary Obstruction
Z. Koç[1], *P. Özcan*[1], *E. Reyhan*[2], *M. Yaldız*[3], *E. Üçbilek*[4];
[1]*Mersin University Hospital Nuclear Medicine Dpt., Mersin, TÜRKIYE,* [2]*Mersin University Hospital Surgical Oncology Dpt., Mersin, TÜRKIYE,* [3]*Mersin University Hospital Pathology Dpt., Mersin, TÜRKIYE,* [4]*Mersin University Hospital Gastroenterology Dpt., Mersin, TÜRKIYE.*

EP-0169
Caracterization of pancreatic lessions by PETMR and evaluation of the diagnostic efficacy of this technique correlated to anatomopathological findings
C. A. Field Galán, *L. Delgado Niño, I. Plaza de las Heras, R. de Teresa Herrera, P. Recarte Ortega, L. García Cañamaque;*
HM Hospitales Madrid, Madrid, SPAIN.

EP-0170
Diagnostic Value of Integrated PET/MR in Postoperative Recurrence of Liver Cancer
X. Chenjie;
Hangzhou Universal Medical Imaging Diagnostic Center, hangzhou, CHINA.

EP-0171
Prospective Intra-individual comparison of 68Ga-FAPI and 18F-FDG PET/CT in the diagnosis and staging of gastric malignancies
M. Jayanthi, *S. BATCHU, A. Sekaran, G. VENKAT RAO, N. Duvvur;*
AIG Hospitals, Hyderabad, INDIA.

EP-0172
The value of 18F-FDG PET/MR radiomics features in predicting regenerative nodules (RN), dysplastic nodules (DN) and small hepatocellular carcinoma nodules (sHCC) in cirrhosis
Y. Xu;
Hangzhou Universal Medical Imaging Diagnostic Center, Hangzhou, CHINA.

EP-0173
The Detection Value of 18F-FDG PET/MR for Small Hepatocellular Carcinoma
X. Chenjie;
Hangzhou Universal Medical Imaging Diagnostic Center, hangzhou, CHINA.

EP-0174
Application value of 18F-FDG PET/MR in postoperative metastasis and restating of gastric cancer
S. Yun;
Hangzhou Panoramic Medical Imaging Diagnostic Center, Hangzhou, CHINA.

EP-0175
Comparative analysis of early and late-phase of [18F]F-Fluorocholine PET/CT adquisition in the assessment of hepatocellular carcinoma
D. Rivas-Navas, *J. Fernández-Fernández, E. Triviño-Ibáñez, J. Villa-Palacios, A. Rodríguez-Fernández;*
Hospital Universitario Virgen de las Nieves, Granada, SPAIN.

EP-0176
Impact of [18F]F-Fluorocholine PET/CT in the management and prognosis of hepatocellular carcinoma.
D. Rivas-Navas, *J. Fernández-Fernández, E. Triviño-Ibáñez, J. Villa-Palacios, A. Rodríguez-Fernández;*
Hospital Universitario Virgen de las Nieves, Granada, SPAIN.

EP-0177
The prediction value of metabolic parameters of 18F-FDG PET/CT for risk stratification of hypermetabolic gastrointestinal stromal tumors
L. Zhang, *W. Cao, Y. Ding, Y. Liu, Y. Deng, H. Chen;*
Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, CHINA.

EP-0178
Prospective study of the diagnostic value of 68Ga-FAPI-04 PET/CT for gallbladder cancer: comparison with 18F-FDG
L. Liu, *Y. Huang, Q. Liu, D. Xu;*
The Second Affiliated Hospital of Chengdu Medical College (China National Nuclear Corporation 416 Hospital), Chengdu, CHINA.

EP-0179
Impact Of FDG PET CT On Management Of Patients With Treatment Naive HCC Intended For Local Surgical/Ablative Or Embolisational Therapies
M. SARMA, *B. S T, W. Jose;*
Amrita Institute of Medical Sciences and Research, Cochin, INDIA.

EP-0180
Diagnostic role of FAPi PET/CT in the detection of peritoneal metastases in cases of stomach and gastroesophageal junction adenocarcinoma
S. Thakur, *V. Shukla, M. Manikandan, S. Arvind;*
Mahamana Pandit Madan Mohan Malviya Cancer Centre, Varanasi, INDIA.

EP-0181
Role of 99mTc-Mebrofenin SPECT/CT in preoperative determination of global and segmental liver function
A. Bakos[1], *T. Czékus*[1], *I. Farkas*[1], *L. Libor*[2], *Z. Mikó*[1], *S. Nagy*[1], *R. Német*[1], *L. Pávics*[1], *G. Sipka*[1], *S. Urbán*[1], *M. Bukva*[3], *Z. Besenyi*[1];
[1]*University of Szeged Nuclear Medicine Department, Szeged, HUNGARY,* [2]*University of Szeged Department of Surgery, Szeged, HUNGARY,* [3]*University of Szeged Department of Immunology, Szeged, HUNGARY.*

EP-0182
Diagnostic Performance of [18F]PSMA-1007 PET/CT on Hepatocellular Carcinoma: a Prospective Clinical Study
K. Michalski[1], *F. Reiter*[2], *A. Kosmala*[1], *P. E. Hartrampf*[1], *S. E. Serfling*[1], *T. A. Bley*[3], *A. Geier*[2], *A. K. Buck*[1], *R. A. Werner*[1], *A. Weich*[2];
[1]*University hospital Würzburg - Department of Nuclear Medicine, Würzburg, GERMANY,* [2]*University hospital Würzburg - Internal Medicine II, Würzburg, GERMANY,* [3]*University hospital Würzburg - Department of Diagnostic and Interventional Radiology, Würzburg, GERMANY.*

EP-0183
Gallium-68 Prostate-Specific Membrane Antigen (68Ga-PSMA) PET Metabolic Metrics in Patients with Hepatocellular carcinoma with and without Hepatis B Infection
N. Nyakale[1,2], *L. M. Harry*[2], *C. Aldous*[3], *A. Maes*[4], *C. van de Wiele*[5], *M. M. Sathekge*[6,7];
[1]*Department of Nuclear Medicine, Sefako Makgatho Health Sciences University and Dr George Mukhari Academic Hospital, Pretoria, SOUTH AFRICA,* [2]*Department of Nuclear Medicine, University of Kwa-Zulu Natal, Durban, SOUTH AFRICA,* [3]*Department of Genetics, College of Health Sciences, University of KwaZulu Natal, Durban, South Africa., Durban, SOUTH AFRICA,* [4]*Katholieke University Leuven, Kortrijk, BELGIUM,* [5]*Ghent University, Ghent, BELGIUM,* [6]*Department of Nuclear Medicine, University of Pretoria and Steve Biko Academic Hospital, Pretoria, SOUTH AFRICA,* [7]*Nuclear Medicine Research Infrastructure (NuMeRI), Pretoria, SOUTH AFRICA.*

EP-0184
Prognostic Value of F18-FDG PET-CT in Patients With Localized Oesophageal Cancer Treated With Neoadjuvant Chemoradiation: The Use of Hopkins Criteria for Treatment Response Assessment
N. Bin Essa, *A. Alderaibi, M. Hawkins, J. Bomanji, S. Vöö;*
University College of London Hospital, London, UNITED KINGDOM.

EP-0185
The Evaluation Of Relationship Between F18 Fdg Pet/Ct Parameters And Sarcopenia İn Esophagus Can
M. ACAR TAYYAR[1], *M. ÖNER TAMAM*[1], *G. B. BABACAN*[1], *M. ŞAHİN*[1], *H. ÖZÇEVİK*[2], *N. GÜRDAL*[3];
[1]*University of Health Sciences, Prof. Dr. Cemil Tascioğlu City Hospital of Nuclear Medicine, Istanbul, TÜRKIYE,* [2]*University of Health Sciences, Hamidiye Faculty of Nuclear Medicine, Istanbul, TÜRKIYE,* [3]*University of Health Sciences, Prof. Dr. Cemil Tascioğlu City Hospital of Radiation Oncology, Istanbul, TÜRKIYE.*

EP-0186
[18F]F-FAPI-74 PET for initial clinical staging in patients with pancreatic cancer : a prospective pilot study
J. Gil[1,2], *W. Yun*[3], *H. Choi*[1,2], *J. Paeng*[1,2], *K. Kang*[1,2], *J. Jang*[3], *G. Cheon*[1,2];
[1]*Department of Nuclear Medicine, Seoul National University Hospital, Seoul, KOREA, REPUBLIC OF,* [2]*Department of Nuclear Medicine, College of Medicine, Seoul National University, Seoul, KOREA, REPUBLIC OF,* [3]*Department of Surgery, Seoul National University Hospital, Seoul, KOREA, REPUBLIC OF.*

EP-0187
The prognostic value of 18F FDG PET/CT intra-tumoural metabolic heterogeneity in patients with esophageal squamous cell carcinoma treated with Concurrent Chemoradiotherapy or Definitive Chemoradiotherapy(dCRT)
Z. Zhu, *X. Ma, Q. Xie, X. Yao;*
The University of Science and Technology of China, Hefei, CHINA.

EP-0188
Diagnostic Performances Of [18f]F-Fdg Pet, Mri And Pet/Mri In Patients With Newly Diagnosed Pancreatic Adenocarcinoma
P. Bartoletti[1], *G. Mango*[2], *S. Serafini*[3], *R. Guastella*[4], *C. Berto*[5], *S. Da Pozzo*[6], *M. Sitara*[1], *G. Fichera*[7], *C. Giraudo*[1], *L. Evangelista*[1];
[1]*Nuclear Medicine Unit, Department of Medicine DIMED, University of Padua, Padova, ITALY,* [2]*2Department of Advanced Biomedical Sciences, University of Naples Federico II, Naples, ITALY,* [3]*General Surgery, Padua University Hospital, Padova, ITALY,* [4]*General Surgery Universita' degli Studi di Padova, Padova, ITALY,* [5]*Radiology Unit, Department of Medicine DIMED, University of Padua, Padova, ITALY,* [6]*Radiology Unit, Azienda Ospedaliera di Padua, Padova, ITALY,* [7]*Pediatric Radiology Unit, Padua University Hospital, Padova, ITALY.*

EP-0189
Exploratory data on prostate-specific membrane antigen and vessels encapsulating tumour clusters in hepatocellular carcinomas: are two sides of the same coin?
R. Zanca[1,2], *R. Akpinar*[3], *L. Di Tommaso*[1,3], *F. Gelardi*[1,2], *M. Rodari*[2], *M. Sollini*[1,2];
[1]*Department of Biomedical Sciences, Humanitas University, Milan, ITALY,* [2]*Nuclear Medicine, IRCCS Humanitas Research Hospital, Rozzano, Milan, ITALY,* [3]*Pathology Unit, IRCCS Humanitas Research Hospital, Rozzano, Milan, ITALY.*

EP-0190
Ga-68 PSMA PET/CT Imaging Findings of Cholangiocellular Carcinoma
T. Kissa, *Z. C. Balaban Genc, X. Niftaliyeva, N. Filizoglu, S. Kesim, K. Öksüzoğlu, F. Çağlıyan, S. Özgüven, F. Dede, T. Ones, H. T. Turoglu, T. Y. Erdil;*
Marmara University Pendik Research and Training Hospital, Istanbul, TÜRKIYE.

EP-11

e-Poster Area

B: Imaging Clinical Studies -> B1 Oncological Imaging Clinical Study -> B16 Neuroendocrine (Pancreatic and Others)

EP-0191
68Ga-DOTA-TATE in Cervicothoracic, Coeliac and Sacral Ganglia: sites of physiological uptake in the Era of total-body PET/CT
E. Triumbari[1], *Y. Abdelhafez*[2], *D. Morland*[3], *B. A. Spencer*[2], *A. Calabrò*[4], *F. Sen*[2], *R. D. Badawi*[2], *M. Guindani*[5], *L. Nardo*[2];
[1]*Nuclear Medicine Unit, TracerGlab, Rome, ITALY,* [2]*Department of Radiology, UC Davis, Sacramento, CA, UNITED STATES OF AMERICA,* [3]*Service de médecine nucléaire, Institut Godinot, Reims, FRANCE,* [4]*Nuclear Medicine Department, University of Brescia and ASST Spedali Civili di Brescia, Brescia, ITALY,* [5]*Department of Biostatistics, University of California, Los Angeles, Los Angeles, CA, UNITED STATES OF AMERICA.*

EP-0192
The quantification for the treatment response evaluation of Metastatic Gastroenteropancreatic Neuroendocrine Tumors in Ga-68 DOTATATE PET/CT
Z. Koç[1], *P. Özcan*[1], *E. Sezer*[2], *T. Kara*[3];
[1]*Mersin University Hospital Nuclear Medicine Dpt., Mersin, TÜRKIYE,* [2]*Mersin University Hospital Oncology Dpt., Mersin, TÜRKIYE,* [3]*Mersin University Hospital Pathology Dpt., Mersin, TÜRKIYE.*

EP-0193
The additional value of SPECT/CT imaging to planar imaging in neuroendocrine tumors
A. Tsaroucha, *N. Kapsoritakis, O. Bourogianni, G. Lamprakopoulos, M. Stathaki, E. Papadaki, S. Koukouraki;*
University Hospital of Heraklion, Heraklion,Crete, GREECE.

EP-0194
18F-AlF-NOTA-Octreotide PET/CT: Krenning´s score and tumor burden influence by tumor volume and total lesion activity
M. González Martínez[1], *A. Piana Bezaury*[1], *I. Pérez Díaz*[2], *M. Olarte Casas*[1];
[1]*PET/CT unit, UNAM, Mexico City, MEXICO,*
[2]*UNAM, Mexico City, MEXICO.*

EP-0195
Referral Patterns and Image Results of 2,249 [64Cu]Cu-DOTATATE PET/CT in a European Neuroendocrine Tumor Society Center of Excellence
M. Loft[1,2], *E. A. Carlsen*[1,2], *C. B. Johnbeck*[1,2], *U. Knigge*[2,3], *M. Andreassen*[2,3], *S. W. Langer*[2,4,5], *H. H. Johannesen*[1,2], *J. Mortensen*[1,2,5], *L. H. Enevoldsen*[1,2], *P. Oturai*[1,2], *A. Kjaer*[1,2];
[1]*Department of Clinical Physiology and Nuclear Medicine & Cluster for Molecular Imaging, Copenhagen University Hospital – Rigshospitalet & Department of Biomedical Sciences, University of Copenhagen, Copenhagen, DENMARK,* [2]*European Neuroendocrine Tumor Society Center of Excellence at Copenhagen University Hospital – Rigshospitalet, Copenhagen, DENMARK,* [3]*Departments of Clinical Endocrinology and Surgical Gastroenterology, Copenhagen University Hospital – Rigshospitalet, Copenhagen, DENMARK,* [4]*Department of Oncology, Copenhagen University Hospital – Rigshospitalet, Copenhagen, DENMARK,* [5]*Department of Clinical Medicine, University of Copenhagen, Copenhagen, DENMARK.*

EP-0196
Impact on clinical management when using [18F] AlF-NOTA-octreotide instead of [68Ga]Ga-DOTA-SSA PET/CT in neuroendocrine tumor patients: preliminary results
H. Leupe[1], *E. Pauwels*[1], *T. Vandamme*[2,3], *B. Van den Broeck*[4], *W. Lybaert*[3], *J. Dekervel*[5], *J. Jaekers*[6], *F. Cleeren*[7], *J. Hofland*[8], *A. Brouwers*[9], *M. Koole*[1], *G. Bormans*[7], *E. Van Cutsem*[5], *K. Geboes*[10], *C. Verslype*[5], *S. Stroobants*[11], *C. M. Deroose*[1];
[1]*Nuclear Medicine, University Hospitals Leuven & Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, KU Leuven, Leuven, BELGIUM,* [2]*Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), University of Antwerp, Antwerp, BELGIUM,* [3]*Oncology, NETwerk Antwerpen-Waasland CoE, Antwerp-Waasland, BELGIUM,* [4]*Nuclear Medicine, Ghent University Hospital, Ghent, BELGIUM,* [5]*Digestive Oncology, University Hospitals Leuven, Leuven, BELGIUM,* [6]*Department of Visceral Surgery, University Hospitals KU Leuven, Leuven, BELGIUM,* [7]*Radiopharmaceutical Research, Department of Pharmacy and Pharmacology, KU Leuven, Leuven, BELGIUM,* [8]*Department of Internal Medicine, Section of Endocrinology, ENETS Centre of Excellence Rotterdam, Erasmus MC Cancer Institute, Rotterdam, NETHERLANDS,* [9]*University of Groningen, University Medical Center Groningen, Department of Nuclear Medicine and Molecular Imaging, Groningen, NETHERLANDS,* [10]*Digestive Oncology, Department of Gastroenterology, Ghent University Hospital, Ghent, BELGIUM,* [11]*Nuclear Medicine, Antwerp University Hospital & Molecular Imaging and radiology, Faculty of Medicine and Health Sciences, University of Antwerp, Wilrijk, BELGIUM.*

EP-0197
Development of a Semi-Automatic Platform for Whole Body Tumor Segmentation and Radiomic Feature Extraction From 68Ga-DOTATATE PET/CT Using TriDFusion (3DF)
S. Krebs, *D. Lafontaine, L. Bodei, M. E. Mayerhoefer, J. Humm, H. Schöder;*
Memorial Sloan Kettering Cancer Center, New York, NY, UNITED STATES OF AMERICA.

EP-0198
The risk factors of pancreatic neuroendocrine tumor predicted by 18F-FDG and 68Ga-DOTANOC PET/CT before surgery.
J. Xu, *S. Song;*
Fudan University Shanghai Cancer Center, Shanghai, CHINA.

EP-0199
The use of18F-DOPA PET/CT for the diagnosis of neuroendocrine tumors suspected or confirmed from unkown origin
A. Rodríguez Pajuelo, *J. Cuenca Cuenca, M. Guerra Gómez, J. Jiménez-Hoyuela García;*
Virgen del Rocio Univsersity Hospital, Seville, SPAIN.

EP-0200
Impact of Tumor-to-Background Ratio on Training of AI for Liver Metastasis Detection in Neuroendocrine Tumors
B. Schemmer;
Uniklinik Bonn, Bonn, GERMANY.

EP-0201
What is the utility of combined 68Ga-DOTATOC and 18F-FDG- PET/CT in the work-up of subjects with neuroendocrine tumors of unknown origin?
I. Bloise, *S. Harsini, F. Benard, D. Wilson, J. M. Loree, P. Martineau;*
BC Cancer, Vancouver, BC, CANADA.

EP-0202
[68Ga]Ga-DOTATOC PET radiomics supports lymph node metastases detection for accurate surgical planning of well-differentiated pancreatic neuroendocrine tumours patients
C. Bezzi[1,2], *P. Mapelli*[1,2], *S. Ghezzo*[1,2], *F. Muffatti*[3], *M. Schiavo Lena*[4], *V. Andreasi*[3], *C. Canevari*[2], *P. Magnani*[2], *S. Partelli*[3], *M. Falconi*[1,3], *A. Chiti*[1,2], *M. Picchio*[1,2];
[1]*Vita-Salute San Raffaele University, Milan, ITALY,* [2]*Nuclear Medicine Department, IRCCS San Raffaele Scientific Institute, Milan, ITALY,* [3]*Pancreatic Surgery Unit, Pancreas Translational & Clinical Research Centre, IRCCS San Raffaele Scientific Institute, Milan, ITALY,* [4]*Pathology Department, IRCCS San Raffaele Scientific Institute, Milan, ITALY.*

EP-0203
Role of 68Ga-DOTANOC PET/CT in the assessment of Appendiceal Neuroendocrine Tumors
R. Goel, *S. A. Shamim, N. Kumar, S. Rastogi, R. Kumar, C. Bal;*
All India Institute of Medical Sciences, NEW DELHI, INDIA.

EP-0204
Clinical impact of [68Ga] Ga-DOTA-TOC PET/CT in the management of neuroendocrine tumors.
J. Villa Palacios, *T. Aroui Luquin, D. Rivas-Navas, P. Guijarro-Caba, M. Muros De Fuentes;*
Hospital Universitario Virgen de las Nieves, Granada, SPAIN.

EP-0205
Utility of different semiquantitative parameters of [68Ga] Ga-DOTA-TOC PET/CT and their correlation with neuroendocrine tumors differentiation grade.
J. Villa Palacios, *T. Aroui-Luquin, D. Rivas-Navas, M. Muros De Fuentes, R. Sanchez Sanchez;*
Hospital Universitario Virgen de las Nieves, Granada, SPAIN.

EP-0206
Quantification of 99mTc-EDDA/HYNIC-TOC SPECT/CT: a feasible alternative to68Ga-DOTA-PET in patients with NET disease
P. Spiridon[1], *A. Lazar*[1], *R. Maaz*[1], *J. Rabah*[1], *M. Mutuleanu*[1,2], *M. Gherghe*[1,2];
[1]*Nuclear Medicine Department, Institute of Oncology "Professor Doctor Alexandru Trestioreanu", Bucharest, ROMANIA,* [2]*Nuclear Medicine Department, University of Medicine and Pharmacy "Carol Davila", Bucharest, ROMANIA.*

EP-0207
Prognostic impact of Gallium-68 DOTANOC PET/CECT in metastatic well differentiated Gastro-entero-pancreatic Neuroendocrine Tumors (GEP NETs).
I. Dev, *V. Rangarajan, A. Puranik, A. Agrawal, N. Purandare, S. Shah, S. Shrikhande, V. Chaudhari, S. Choudhury, S. Ghosh;*
TATA MEMORIAL CENTRE, Mumbai, INDIA.

EP-0208
Role of 68Ga-DOTANOC PET/CT in the assessment of Lung Carcinoids
S. Shamim, *R. Goel, N. Kumar, G. Arora, S. Rastogi, A. Goyal, R. Kumar, C. Bal;*
AIIMS New Delhi, Delhi, INDIA.

EP-0209
Assessment of glucose metabolism in skeletal muscle and adipose tissue with the use of 2-[18F]FDG PET/CT in patients with ectopic adrenocorticotropin secretion
M. Opalinska[1], *J. Kokoszka*[2], *E. Rzepka*[1], *K. Sitarz*[3], *A. Sowa-Staszczak*[1], *A. Gilis-Januszewska*[1], *A. Hubalewska-Dydejczyk*[1];
[1]*Jagiellonian University Medical College, Chair and Department of Endocrinology, Krakow, POLAND,* [2]*Endocrinology, Oncologic Endocrinology and Nuclear Medicine Department, University Hospital in Krakow, Krakow, POLAND,* [3]*University Hospital in Krakow, Krakow, POLAND.*

EP-0210
The evaluation of kidney function using the Somatostatin (SSTR)-targeting radioligands 18F-SiFA-TATE, 68Ga-DOTATATE and 68Ga-DOTATOC in a theranostic setting
M. Tiling[1], *A. Holzgreve*[1], *S. Kunte*[1], *G. Sheikh*[1], *M. Unterrainer*[2,1], *P. Bartenstein*[1], *A. Delker*[1], *L. Unterrainer*[1];
[1]*Department of Nuclear Medicine, University Hospital, LMU Munich, Munich, GERMANY,*
[2]*DIE RADIOLOGIE, Munich, GERMANY.*

EP-0211
Spectrum of hyperuptake findings detected in PET/CT [68Ga]Ga-DOTA-TOC studies. Experience in our center
S. Bondia-Bescós, *J. Vercher-Conejero, J. Martin-Marcuartu, A. Rodriguez-Gasen, J. Suils-Ramón, M. Perlaza-Jiménez, M. Pudis, B. Hervás-Sanz, J. Díaz-Moreno, M. Cortés-Romera;*
Nuclear Medicine-PET (IDI) Department, Bellvitge University Hospital, Barcelona, SPAIN.

EP-0212
68Ga-DOTA peptides PET/CT radiomic parameters useful to differentiate para-physiological uptake in pancreatic uncinate process from pancreatic NET.
F. Linguanti[1], *E. M. Abenavoli*[2], *A. Lombardo*[1], *V. Briganti*[2], *F. Mungai*[3], *L. Antonuzzo*[4], *D. Lavacchi*[4], *L. Vaggelli*[2], *M. Matteini*[2], *R. Sciagrà*[1], *V. Berti*[1];
[1]*Nuclear Medicine Unit, Department of Experimental and Clinical Biomedical Sciences 'Mario Serio', University of Florence, Florence, ITALY,* [2]*Department of Nuclear Medicine, Azienda Ospedaliero-Universitaria Careggi, Largo Brambilla 3, 50134, Florence, ITALY,* [3]*Department of Radiology, Azienda Ospedaliero-Universitaria Careggi, Largo Brambilla 3, 50134, Florence, ITALY,* [4]*Medical Oncology Unit, Careggi University Hospital, Largo Brambilla 3, 50134, Florence, ITALY.*

EP-0213
β-1600 Q.Clear Reconstruction Improves [68Ga]Ga-DOTANOC Digital PET/CT Image Quality
E. Fortunati[1], *N. Bonazzi*[1], *M. Di Franco*[1], *L. Zanoni*[2], *C. Mosconi*[3,4], *S. Civollani*[2], *D. Campana*[3,5], *C. Malizia*[6], *V. Allegri*[2], *S. Fanti*[1,2], *V. Ambrosini*[1,2];
[1]*Nuclear Medicine, Alma Mater Studiorum University of Bologna, Bologna, ITALY,* [2]*Nuclear Medicine, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY,* [3]*DIMEC, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY,* [4]*Radiology, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY,* [5]*Division of Medical Oncology, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY,* [6]*PET Radiopharmacy Unit, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY.*

EP-0214
Comparison of 68Ga-DOTATATE PET/CT and 68Ga-DOTATATE PET/MR in Detection of Neuroendocrine Tumour Liver Metastasis
B. Demir[1], *C. Soydal*[1], *M. Araz*[1], *M. H. Baltacioglu*[1], *D. Kuru Oz*[2], *N. O. Kucuk*[1];
[1]*Ankara University School of Medicine Department of Nuclear Medicine, Ankara, TÜRKIYE,* [2]*Ankara University School of Medicine Department of Radiology, Ankara, TÜRKIYE.*

EP-0215
[68Ga]Ga-DOTANOC and [18F]F-FDG PET/CT Tumour Burden Across 3-Grades Functional Scoring
E. Fortunati[1], *N. Bonazzi*[1], *M. Di Franco*[1], *L. Zanoni*[2], *C. Mosconi*[3,4], *D. Campana*[3,5], *C. Malizia*[6], *E. Andrini*[5], *V. Allegri*[2], *S. Fanti*[1,2], *V. Ambrosini*[1,2];
[1]Nuclear Medicine, Alma Mater Studiorum University of Bologna, Bologna, ITALY, [2]Nuclear Medicine, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, [3]DIMEC, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, [4]Radiology, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, [5]Division of Medical Oncology, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, [6]PET Radiopharmacy Unit, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY.

EP-0216
Correlation Between Dual Tracer Imaging (68 Ga Dotanoc and 18 FDG PET) And Mib Index in WHO Grade 2 NET.
S. Kale, *A. Puranik, N. Purandare, S. Shah, A. Agrawal, V. Rangarajan, S. Shrikhande, V. Ostwal, A. Ramaswamy, M. Bhandare, V. Chaudhari;*
TATA MEMORIAL CENTRE, Mumbai, INDIA.

EP-12

e-Poster Area

B: Imaging Clinical Studies -> B1 Oncological Imaging Clinical Study -> B17 Colorectal

EP-0217
Differentiating subcentimeter lung metastasis in colorectal cancer patients by radiomics and deep learning approaches: a multicenter study
D. Ma;
Department of Colorectal Surgery, Zhejiang Cancer Hospital, Hangzhou, CHINA.

EP-0218
Correlation of 18F-FDG PET/CT Parameters Such As SUVmax, MTV and TLG with Histopathological Characteristics in Colorectal Cancer Patients
B. Ural, *B. Okudan Tekin;*
Ankara Bilkent City Hospital, Ankara, TÜRKIYE.

EP-13

e-Poster Area

B: Imaging Clinical Studies -> B1 Oncological Imaging Clinical Study -> B18a Prostate Staging

EP-0219
PET/CT Imaging 2 Hours After Injection of [18F] PSMA-1007 Can Lead to Higher Staging of Prostate Cancer Than Imaging After 1 Hour
E. Hvittfeldt[1,2], *U. Bitzén*[3], *D. Minarik*[1,4], *J. Oddstig*[1,5], *B. Olsson*[2,1], *E. Trägårdh*[1,2];
[1]Department of Translational Medicine, Wallenberg Centre for Molecular Medicine, Lund University, Malmö, SWEDEN, [2]Department of Clinical Physiology and Nuclear Medicine, Skåne University Hospital, Malmö, SWEDEN, [3]Department of Clinical Physiology and Nuclear Medicine, Skåne University Hospital, Lund, SWEDEN, [4]Department of Medical Physics, Skåne University Hospital, Malmö, SWEDEN, [5]Department of Medical Physics, Skåne University Hospital, Lund, SWEDEN.

EP-0220
99mTc-PSMA-SPECT/CT in primary staging of high risk prostate cancer
K. Liepe[1], *M. Baehr*[1,2], *T. M. Hoang*[3];
[1]Klinikum Frankfurt (Oder), Frankfurt (Oder), GERMANY, [2]Campus Virchow-Klinikum, Charité, Department of Diagnostic and Interventional Radiology, Berlin, GERMANY, [3]Statistician, Düsseldorf, GERMANY.

EP-0221
Clinical Utility of 68Ga-PSMA PET/CT in Initial Staging of Patients with Prostate Cancer and Importance of Intraprostatic SUVmax Values
I. Rogic, *A. Golubic, M. Zuvic, T. Smitran, N. Jukic, D. Huic;*
University Hospital Centre Zagreb, Zagreb, CROATIA.

EP-0222
Head-to-head comparison of 68Ga-PSMA-11 with 68Ga-P137 in patients with suspected prostate cancer
T. Han, *Z. Quan, M. Wang, X. Meng, M. Zhang, J. Ye, G. Li, J. Wang, F. Kang;*
Department of Nuclear Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, CHINA.

EP-0223
Comparison of 18F-Thretide PET/CT and multiparametric MRI for the detection of intermediate and high risk prostate cancer
J. Zang[1], *Y. Yang*[1], *C. Wang*[1], *S. Chen*[1], *W. Miao*[1], *X. Chen*[2], *J. Zhang*[2];
[1]Department of Nuclear Medicine, the First Affiliated Hospital, Fujian Medical University, Fuzhou, CHINA, [2]Departments of Diagnostic Radiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, SINGAPORE.

EP-0224
The Relationship Of Lymp Node Distance And Disease Parameters In Prostate Cancer Ga-68 PSMA PET/CT Imaging
C. Aydin[1], *B. Özdemir Günay*[2], *Ü. Korkmaz*[1], *F. Soyluoğlu*[1];
[1]Trakya University, Edirne, TÜRKIYE, [2]Edirne Sultan Murat I State Hospital, Nuclear Medicine Clinic, Edirne, TÜRKIYE.

EP-0225
The Relationship of Tumor SUVmax Value in 68Ga-PSMA PET/CT with Pathological Grade Group Grading System in Patients with Prostate Cancer
F. Demir, *S. Karaçavuş, H. Gençer, A. Ozdal, Z. Erdogan, I. Ciftci, F. Cevik, N. Ozhan, H. İsci, M. Kaya;*
Kayseri City Training and Research Hospital, Kayseri, TÜRKIYE.

EP-0226
Multimodality Approach with 68Ga-PSMA-11 PET/CT in Staging High-risk Prostate Cancer Patients Candidate to Radical Prostatectomy
G. Rovera[1], *S. Grimaldi*[1], *M. Oderda*[2], *R. Passera*[1], *M. Falco*[1], *S. Dall'Armellina*[1], *P. Gontero*[2], *D. Deandreis*[1];
[1]Nuclear Medicine, Department of Medical Sciences, AOU Città della Salute e della Scienza di Torino, Turin, ITALY, [2]Department of Surgical Sciences, Urology Unit, AOU Città della Salute e della Scienza di Torino, Molinette Hospital, University of Turin, Turin, ITALY.

EP-0227
Location-Based Detection of Low-Uptake Lymph-Node Metastasis of Prostate Cancer in the Pelvis Using PSMA-PET/CT and Artificial Intelligence
B. Schemmer;
Uniklinik Bonn, Bonn, GERMANY.

EP-0228
Value of Ga-68 PSMA PET/CT in ISUP Grade 2 Prostate Cancer Patients
F. Aghazada, *M. Demirbilek, O. Sahin, S. Asa, B. Onal, L. Kabasakal;*
Istanbul University-Cerrahpasa, Cerrahpasa Faculty of Medicine, Istanbul, TÜRKIYE.

EP-0229
Analytical performance validation of aPROMISE platform for prostate cancer tumor burden and index and dominant tumor assessment with 18F-DCFPyL PET/CT.
C. Lucas Lucas[1], *A. M. García Vicente*[2], *L. García Zoghby*[2], *J. Pérez Beteta*[3], *P. Borrelli*[4], *M. Amo Salas*[5], *A. Padilla Bermejo*[1], *M. N. Sicilia Pozo*[1], *M. Contreras Ameduri*[1], *M. Cruz Montijano*[2], *F. J. Pena Pardo*[1], *E. Noriega Álvarez*[1], *M. P. Talavera Rubio*[1], *V. M. Poblete García*[1], *Á. M. Soriano Castrejón*[2];
[1]Nuclear Medicine Department. University General Hospital of Ciudad Real, Ciudad Real, SPAIN, [2]Nuclear Medicine Department. University Hospital of Toledo, Toledo, SPAIN, [3]Mathematical Oncology Laboratory. Castilla-La Mancha University, Ciudad Real, SPAIN, [4]Department of Clinical Physiology, Sahlgrenska University Hospital, Gothenburg, SWEDEN, [5]Mathematics Department. Castilla La-Mancha University, Ciudad Real, SPAIN.

EP-0230
Contribution of 68GA-PSMA-PET/CT to Risk Classification In Prostate Cancer With Gleason Score 6
Ö. Sahin, *E. BEYHAN, Ö. E. FENERCİOĞLU, E. ARSLAN, T. F. ÇERMİK, N. ERGÜL;*
University of Health Sciences, Istanbul Training and Research Hospital, Department of Nuclear Medicine, , Türkiye., Istanbul, TÜRKIYE.

EP-0231
Comparison of 68Ga-FAPI and 18F-PSMA PET/CT in the Evaluation of Ductal Adenocarcinoma of the Prostate
C. Liu, *Q. Xie, T. Liu, Z. Li, C. Guo, Z. Yang;*
Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Beijing, CHINA.

EP-0232
PSMA Immunohistochemistry Staining in Prostate Cancer Primary Lesion and Comparison with [68Ga] Ga-PSMA-PET/CT Findings
Z. Isik[1], *G. Güner*[2], *M. Çağlar Tuncalı*[1], *M. Karcaaltincaba*[3], *B. Akdoğan*[4], *D. Akıncı*[3], *M. Tuncel*[1];
[1]Hacettepe University, Department of Nuclear Medicine, Ankara, TÜRKIYE, [2]Hacettepe University, Department of Pathology, Ankara, TÜRKIYE, [3]Hacettepe University, Department of Radiology, Ankara, TÜRKIYE, [4]Hacettepe University, Department of Urology, Ankara, TÜRKIYE.

EP-0233
Comparison of 68Ga-PSMA PET/MRI with PET and mpMRI in concise evaluation of primary prostate tumor and its prognostic value in detection of locally advanced prostate cancer
L. Uslu-Besli[1], *B. Bakir*[2], *N. Urganci*[3], *&. Gürses*[3], *S. Özel-Yıldız*[4], *C. Demirdag*[5], *K. Sönmezoglu*[1], *H. Sayman*[1];
[1]Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Nuclear Medicine, Istanbul, TÜRKIYE, [2]Istanbul University, Istanbul Medical Faculty, Department of Radiology, Istanbul, TÜRKIYE, [3]Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Pathology, Istanbul, TÜRKIYE, [4]Istanbul University, Istanbul Medical Faculty, Department of Biostatistics, Istanbul, TÜRKIYE, [5]Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Urology, Istanbul, TÜRKIYE.

EP-0234
Preliminary Clinical Study of a Novel Small-molecule PSMA Inhibitor 68Ga-SC691: Biodistribution, Dosimetry and Prospective Comparison with 68Ga-PSMA-11
J. Cao;
416 Hospital, China National Nuclear Corporation, chengdu, CHINA.

EP-0235
PSMA PET/MR with parametric Patlak imaging to increase image contrast, better quantification and shorten examination times in patients with suspected prostate cancer.
M. Gammel, *I. Rauscher, M. Eiber, S. van Marwick, S. Schachoff, R. Tauber, W. A. Weber, S. Nekolla;*
TUM, Munich, GERMANY.

EP-0236
PSMA-PET and PCa: an exploratory analysis beyond the numerical definition of oligometastatic state
F. Mattana[1], *L. Airò Farulla*[1,2], *G. Marvaso*[3], *G. Corrao*[3], *C. Lorubbio*[3,2], *M. G. Vincini*[3], *M. Zaffaroni*[3], *L. Muraglia*[1], *M. Colandrea*[1], *C. Fodor*[3], *F. Ceci*[1,2], *B. A. Jereczek-Fossa*[3,2];
[1]IEO European Institute of Oncology IRCCS, Nuclear Medicine Department, Milan, ITALY, [2]Department of Oncology and Hemato-Oncology, University of Milan, ITALY, [3]IEO European Institute of Oncology IRCCS, Department of Radiation Oncology, Milan, ITALY.

EP-0237

The spleen as a reference organ for PSMA expression evaluation according to PROMISE in Prostate cancer imaging with 18F-PSMA-1007 PET/CT: a critical approach

G. Arsos[1], *A. Georgiou*[2], *D. Katsampoukas*[2], *V. Mpalaris*[2], *S. Georga*[2], *E. Moralidis*[2];
[1]*3rd Department of Nuclear Medicine, Aristotle University of Thessaloniki School of Medicine, Papageorgiou Gen. Hospital, THESSALONIKI, GREECE,* [2]*3rd Department of Nuclear Medicine, Aristotle University of Thessaloniki School of Medicine, Papageorgiou Gen. Hospital, Thessaloniki, GREECE.*

EP-0238

Evaluation of imaging, clinical and pathological factors associated with 2-year biochemical recurrence in surgical patients with intermediate-to high-risk prostate cancer: a focus on 68GaPSMA PET and pelvic 3Tesla mpMRI

M. Celli[1], *R. Gunelli*[2], *F. Ferroni*[1], *G. Feliciani*[1], *A. Sarnelli*[1], *P. Caroli*[1], *I. Marini*[1], *L. Fantini*[1], *V. Rossetti*[1], *U. De Giorgi*[1], *D. Barone*[1], *V. Di Iorio*[1], *F. Matteucci*[1];
[1]*IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, ITALY,* [2]*AUSL della Romagna – Presidio Ospedaliero Morgagni-Pierantoni, Forlì, ITALY.*

EP-0239

PSMA PET/CT and local disease: a retrospective radiomic analysis based on a single center's experience

M. Monteiro[1], *A. M. Ferreira*[1], *A. P. Moreira*[1,2], *R. Silva*[1,2], *G. Costa*[1,3];
[1]*CHUC, Coimbra, PORTUGAL,* [2]*Instituto de Ciências Nucleares Aplicadas à Saúde, Coimbra, PORTUGAL,* [3]*Faculdade de Medicina da Universidade de Coimbra, Coimbra, PORTUGAL.*

EP-0240

PSG Score of Tubarial, Submandibular and Parotid Salivary Glands Utilizing 68Ga-PSMA-PET/CT-Scans of Prostate Cancer Patients

S. Al-Sadoon, *F. Risheq, Z. Risheq, K. Faqeh;*
Nuclear Medicine PET/CT & Bone Density Center, Amman, JORDAN.

EP-14

e-Poster Area

B: Imaging Clinical Studies -> B1 Oncological Imaging Clinical Study -> B18b Prostate BC Recurrence

EP-0241

Therapeutic implications of 18F-PSMA PET/MRI in patients with prostate cancer and biochemical recurrence (PSA < 2 ng/ml) after prostatectomy

J. Garcia, *A. Compte, M. Kauak, P. Bassa, T. Blanch, J. Pastor, E. Riera;*
CETIR ASCIRES Grupo biomédico, Barcelona, SPAIN.

EP-0242

Clinical impact of 18F-DCFPyL PET/CT for clinical decision-making in biochemical recurrence of prostate cancer in our province.

Y. Santaella Guardiola, *J. Rodriguez-Rubio Corona, M. Piñero Fernandez-Reyes, F. Cañete Sanchez, C. Quintana Bolaño, M. Pajares Vinardell;*
Hospital Puerta del Mar, Cadiz, SPAIN.

P-0243

Evaluation of the Success of 18F-PSMA PET/CT in the Detection of Prostate Cancer Recurrence in Patients with Biochemical Recurrence

G. Sutcu[1], *C. Soydal*[1], *M. Araz*[1], *Y. Urun*[2], *E. Suer*[3], *S. Baltaci*[3], *N. O. Kucuk*[1];
[1]*Ankara University Medical School Department of Nuclear Medicine, Ankara, TÜRKIYE,* [2]*Ankara University Medical School Department of Medical Oncology, Ankara, TÜRKIYE,* [3]*Ankara University Medical School Department of Urology, Ankara, TÜRKIYE.*

EP-0244

Flare phenomenon of 99mTc-bone scintigraphy is a determinant of prognosis in patients with metastatic castration-resistant prostate cancer

X. Zhang[1], *K. Nakajima*[2], *H. Horikoshi*[3], *A. Mizokami*[4], *K. Nishimoto*[5], *K. Hashine*[6], *H. Matsuyama*[7], *S. Takahashi*[8], *H. Wakabayashi*[1], *S. Kinuya*[1];
[1]*Department of Nuclear Medicine, Kanazawa University, Kanazawa, Ishikawa, JAPAN,* [2]*Department of Functional Imaging and Artificial Intelligence, Kanazawa University, Kanazawa, Ishikawa, JAPAN,* [3]*Department of Diagnostic Radiology, Gunma Prefectural Cancer Center, Ota, JAPAN,* [4]*Department of Urology, Kanazawa University, Kanazawa, Ishikawa, JAPAN,* [5]*Department of Uro-Oncology, Saitama Medical University International Medical Center, Saitama, JAPAN,* [6]*Department of Urology, National Hospital Organization Shikoku Cancer Center, Matsuyama, JAPAN,* [7]*Department of Urology, Graduate School of Medicine, Yamaguchi University, Ube, JAPAN,* [8]*Department of Urology, Nihon University School of Medicine, Tokyo, JAPAN.*

EP-0245

Efficacy of 18-F-DCFPyL-PET/CT in the first biochemical recurrence of prostate cancer and its impact on therapeutic management

I. Obedkova, *A. Prieto Soriano, L. Santamaria Chico, S. Guzmán Ortiz, K. Velasquez Diaz, P. Soares Meneses, M. Grajeda Gallardo, I. Garrido Solesio, M. Mitjavila Casanovas;*
University Hospital Puerta de Hierro, Majadahonda, SPAIN.

EP-0246

Outcomes of [68Ga]Ga-PSMA-11 PET/CT in biochemical recurrence after brachytherapy

I. Próspero[1], *G. Ferreira*[1], *J. C. Ferro*[1], *D. Barbosa*[1], *D. G. Silva*[1], *P. Leite Silva*[2], *S. Fontão de Castro*[1], *J. P. Teixeira*[1], *H. Duarte*[1], *I. Lucena Sampaio*[1];
[1]*Department of Nuclear Medicine, Instituto Português de Oncologia do Porto, Porto, PORTUGAL,* [2]*Cancer Epidemiology Group-Research Center, Department of Epidemiology, Instituto Português de Oncologia do Porto, Porto, PORTUGAL.*

EP-0247

Impact of [18F]-DCFPyL (PSMA) PET/CT in the diagnostic and therapeutic impact in the biochemical recurrence of prostate cancer.

J. Fernández Fernández, *E. Triviño-Ibáñez, D. Rivas-Navas, J. Villa-Palacios, A. Rodríguez-Fernández;*
Virgen de las Nieves University Hospital, Granada, SPAIN.

EP-0248

Analysis of pathological findings in 18F-DCFPyL PSMA PET in recurrence of prostate cancer according to PSMA-RADS classification and E-PSMA overexpression score. Confirmation of results by pathological anatomy, biochemical response or imaging.

B. Hervás-Sanz[1], *J. J. Robles-Barba*[1], *J. J. Martín-Marcuartu*[1], *S. Bondia-Bescós*[1], *M. Pudis*[1], *J. E. Romero-Herrera*[2], *G. Reynés-Llompart*[3], *F. Ferrer-González*[4], *J. F. Suárez-Novo*[5], *M. Cortés-Romera*[1];
[1]*Nuclear Medicine-PET (IDI) Department, Bellvitge University Hospital-IDIBELL, L'Hospitalet de Llobregat, SPAIN,* [2]*Radiopharmaceutical Department, Bellvitge University Hospital-IDIBELL, L'Hospitalet de Llobregat, SPAIN,* [3]*Radiophysics Department, Bellvitge University Hospital-IDIBELL, L'Hospitalet de Llobregat, SPAIN,* [4]*Radiation Oncology Department, Bellvitge University Hospital-IDIBELL, L'Hospitalet de Llobregat, SPAIN,* [5]*Urology Department, Bellvitge University Hospital-IDIBELL, L'Hospitalet de Llobregat, SPAIN.*

EP-0249

Comparison of Digital Versus Analog 68Ga-PSMA-11 PET/CT Performance in Hormone-sensitive Prostate Cancer Patients with Early Biochemical Recurrence or Persistence

G. Rovera[1], *S. Grimaldi*[1], *S. Dall'Armellina*[1], *R. Passera*[1], *M. Oderda*[2], *P. Gontero*[2], *D. Deandreis*[1];
[1]*Nuclear Medicine, Department of Medical Sciences, AOU Città della Salute e della Scienza di Torino, Turin, ITALY,* [2]*Department of Surgical Sciences, Urology Unit, AOU Città della Salute e della Scienza di Torino, Molinette Hospital, University of Turin, Turin, ITALY.*

EP-0250

Whole Body Tumour Burden On PET/CT With 18F-DCFPyL Obtained By aPROMISE Platform: Associations With Tumour Biology And PSA Kinetics In Patients With Biochemical Relapse Prostate Cancer.

L. García Zoghby[1], *A. García Vicente*[1], *M. Amo-Salas*[2], *P. Borrelli*[3], *C. Lucas Lucas*[4], *A. Padilla Bermejo*[4], *N. Sicilia Pozo*[4], *M. Contreras Ameduri*[4], *M. Cruz Montijano*[1], *F. Pena Pardo*[4], *E. Noriega Álvarez*[4], *M. Talavera Rubio*[4], *V. Poblete García*[4], *Á. Soriano Castrejón*[1];
[1]*University Hospital of Toledo, Toledo, SPAIN,* [2]*Castilla-La Mancha University, Ciudad Real, SPAIN,* [3]*Sahlgrenska University Hospital, Göteborg, SWEDEN,* [4]*General University Hospital of Ciudad Real, Ciudad Real, SPAIN.*

EP-0251

Influence of Gleason, ISUP grade, initial TNM, PSA values and kinetics on detection rate in prostate cancer recurrence by [18F]DCFPyL PSMA PET/CT

J. Martin-Marcuartu[1], *J. Robles Barba*[1], *S. Bondia Bescos*[1], *E. Romero Herrera*[2], *G. Reynes Llompart*[3], *J. Suárez Novo*[4], *F. Ferrer Gonzalez*[5], *S. Ruiz Llama*[6], *M. Cortés Romera*[1];
[1]*Department of MNU-PET/CT (IDI). Hospital Universitari de Bellvitge, Barcelona, SPAIN,* [2]*Department of Radiopharmacy. Hospital Universitari de Bellvitge, Barcelona, SPAIN,* [3]*Department of Radiophysics. ICO Duran i Reynals, Barcelona, SPAIN,* [4]*Department of Urology. Hospital Universitari de Bellvitge, Barcelona, SPAIN,* [5]*Department of Radiotherapy. ICO Duran i Reynals, Barcelona, SPAIN,* [6]*Department of Radiopharmacy. Hospital Germans Trias i Pujol, Barcelona, SPAIN.*

EP-0252

Attitude and Management Change in Those Patients with Extrapelvic Findings in a PET-CT Study with PSMA

R. Bellviure-Meiro[1], *M. Simó Perdigó*[1], *S. Menendez-Sanchez*[2], *C. Franco Monterroso*[1], *I. Navales Mateu*[1], *S. Asadurova*[1], *F. Velázquez*[1], *J. Echeverri Diaz*[1], *N. Calviño*[1], *S. Aguade-Bruix*[1];
[1]*Hospital Universitari Vall d'Hebron, Barcelona, SPAIN,* [2]*Clínica Universidad de Navarra, Pamplona, SPAIN.*

EP-0253

Psma PET/CT Results and Effect on Treatment in Patients with Biochemical Recurrence After Radical Prostatectomy

K. Akçay[1], *N. Selcuk*[1], *G. Beydagi*[1], *T. Toklu*[1], *E. Demirci*[1], *Ö. Sönmez*[1], *D. Karaçam*[1], *M. Yücel*[1], *E. Kaymak*[2], *O. Civi*[3], *L. Kabasakal*[4];
[1]*yeditepe university, istanbul, TÜRKIYE,* [2]*İstanbul Başakşehir Çam Sakura Hospital, istanbul, TÜRKIYE,* [3]*istanbul oncology hospital, istanbul, TÜRKIYE,* [4]*İstanbul University-Cerrahpaşa, istanbul, TÜRKIYE.*

EP-0254

Serum values of prostate-specific antigen (PSA) and grade groups according to the International Society of Urological Pathology (ISUP grading), as determinants of [18F]DCFPyL PET/CT positivity in patients with biochemical recurrence of prostate cancer treated with radical prostatectomy.

A. Peñaherrera Cepeda, *L. Diaz Gonzaga, J. Villanueva Curto, J. Badell Martínez, P. García-Talavera San Miguel, F. Gómez-Caminero López, E. Campaña Diaz, S. Rama Alonso, P. Tamayo Alonso;*
Complejo asistencial universitario de Salamanca, Salamanca, SPAIN.

EP-0255

Usefulness of PET-MR with 18F-DCFPyL in the Diagnosis of Biochemical Recurrence in Prostate Cancer and its Therapeutic Implication

R. De Teresa, *I. Plaza de las Heras, C. Field, L. García Cañamaque;*
GRUPO HM HOSPITALES. UNIVERSIDAD SAN PABLO CEU, Madrid, SPAIN.

EP-0256

To evaluate the efficacy of F-18 PSMA -1007 PET/CT to diagnose biochemically recurrent Adenocarcinoma Prostate

A. Vyas[1], *A. Tiwary Vyas*[2];
[1]*Max Superspeciality Hospital Vaishali, New Delhi, INDIA,* [2]*Janakpuri Superspeciality Hospital, New Delhi, INDIA.*

EP-0257

Prognostic Value of F-18 FDG PET/CT Metabolic Parameters in Prostate Cancer Patients

C. Soydal[1], *M. H. Baltacioglu*[2], *M. Araz*[1], *B. Demir*[1], *N. O. Kucuk*[1];
[1]*Ankara University Medical School, Department of Nuclear Medicine, Ankara, TÜRKIYE,* [2]*Sbu Trabzon Kanuni Training and Research Hospital Department of Nuclear Medicine, Trabzon, TÜRKIYE.*

EP-0258
Role of 68Ga/18F-PSMA PET/CT in the Secondary Staging of Prostate Cancer patients as a guide for clinicians
P. Mammucci, *C. Ferrari, V. Lavelli, C. Battisti, N. C. Merenda, G. Rubini;*
A.O.U. Policlinico di Bari, Bari, ITALY.

EP-15

e-Poster Area

B: Imaging Clinical Studies -> B1 Oncological Imaging Clinical Study -> B18c Prostate Other

EP-0259
Dual time psma pet/ct with diuretics and contrast to detect prostate cancer pelvic metastases: is there a benefit?
T. Tognoli[1], *M. R. F. Camacho*[2], *A. O. Santos*[1], *M. C. L. Lima*[1], *B. J. Amorim*[1], *U. Ferreira*[1], *E. Etchebehere*[1];
[1]*State University of Campinas (UNICAMP), CAMPINAS-SP, BRAZIL,* [2]*MND Campinas, CAMPINAS-SP, BRAZIL.*

EP-0260
Ultrafast & Fast F18-PSMA 1007 PET/CT Acquisition in the Era of Digital PET/CT System; Single Institution Experience
A. Sadeq[1], *Z. Alqallaf*[1], *I. Abdelrahman*[1], *M. Ibrahim*[1], *L. Ghadhanfer*[2], *F. Marafi*[1];
[1]*Jaber AlAhmad center for Molecular Imaging, Shuwaikh medical area, KUWAIT,* [2]*Faculty of Allied health sciences- Kuwait University, Jabriya, KUWAIT.*

EP-0261
Multimodal Radiomics Features of periprostatic adipose tissue from 18F-PSMA-1007 PET/CT to predict Persistent Prostate-Specific Antigen
S. Bian;
the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, CHINA.

EP-0262
Association between blood-derived circulating-tumor DNA and ^{68}Ga-PSMA-HBED-CC PET/CT findings
K. Kluge[1,2], *H. Einspieler*[1], *D. Haberl*[1], *C. Spielvogel*[1,2], *S. Stoiber*[3,2], *M. Hacker*[1], *L. Kenner*[3,2], *A. Haug*[1,2];
[1]*Medical University of Vienna - Dept. of Nuclear Medicine, Vienna, AUSTRIA,* [2]*Medical University of Vienna - Christian Doppler Lab for Applied Metabolomics, Vienna, AUSTRIA,* [3]*Medical University of Vienna - Dept. of Pathology, Vienna, AUSTRIA.*

EP-0263
Evaluation of therapeutic response with 68Ga-prostate-specific membrane antigen (PSMA) PET/CT after androgen deprivation therapy in patients with prostate carcinoma
M. Dyankova[1,2], *T. Stoeva*[1], *Z. Dancheva*[1], *S. Chausheva*[1], *T. Yordanova*[1], *B. Chaushev*[1], *A. Klisarova*[1];
[1]*Medical University Varna "Prof. Dr. Paraskev Stoyanov", Department of Imaging Diagnostics, Interventional Radiology and Radiotherapy, Varna, BULGARIA,* [2]*St. Marina University Hospital, Department of Nuclear Medicine, Varna, BULGARIA.*

EP-0264
Comparing the Diagnostic Efficacy of 99m Tc-PSMA SPECT/CT Scanning After 75 Minutes and 4 Hours of Radiotracer Injection in Men with Prostate Cancer
A. Aghaee[1], *A. Sahebkari*[1], *S. Soltani*[2], *H. Ghorbani*[3], *K. Aryana*[1],
K. Sadri[1];
[1]*nuclear medicine research center,Mashhad university of Medical Sciences, Mashhad, IRAN, ISLAMIC REPUBLIC OF,* [2]*kidney translantation research center,Mashhad university of Medical Sciences, Mashhad, IRAN, ISLAMIC REPUBLIC OF,* [3]*kidney transplantation research center,Mashhad university of Medical Sciences, Mashhad, IRAN, ISLAMIC REPUBLIC OF.*

EP-0265
Comparison of the 18F-PSMA-1007 and 18F-FAPI-42 PET/CT in the evaluation of prostate cancer and correlation between PSMA and FAPI uptake
X. Mu, *M. Li, W. Fu;*
Department of Nuclear medicine, Affiliated hospital of Guilin medical university, Guilin, CHINA.

EP-0266
Evaluating the diagnostic value of early static and delayed imaging of 68Ga-PSMA-11 PET/CT in detection of prostate bed recurrence and regional lymph node metastasis in prostate cancer patients
A. Aghaee, *Z. Bakhshi, V. Roshan Ravan, K. Aryana, N. Norouzbeigi;*
nuclear medicine research center,Mashhad university of Medical Sciences, Mashhad, IRAN, ISLAMIC REPUBLIC OF.

EP-0267
Quantitative MRI parameters adds value in PSMA PET/MR for improving diagnostic specificity of Prostate Cancer with SUVmax<12
W. Ma, *J. Wang, Z. Quan, F. Kang, J. Wang;*
Fourth Military Medical University, Xi'an, CHINA.

EP-0268
68Ga-PSMA-PETCT for the evaluation of pulmonary nodules in patients with prostate cancer
G. Mateva, *P. Bochev, N. Novoselska;*
Acibadem CityClinic Mladost, Sofia, BULGARIA.

EP-0269
Optimizing PSMA Scintigraphy Imaging Protocols for Prostate Cancer in Resource Limited Settings
O. Kolade[1], *A. Ayeni*[1,2], *J. Holness*[3], *A. Brink*[1], *S. More*[1];
[1]*University of Cape Town / Groote Schuur Hospital, Cape Town, SOUTH AFRICA,* [2]*Klerksdorp/Tshepong Hospital Complex, Klerksdorp, SOUTH AFRICA,* [3]*Stellenbosch University, Cape Town, SOUTH AFRICA.*

EP-0270
AI18F-PSMA-617 PET Quantitative Analysis for Prostate Cancer Diagnosis: A Comprehensive Study
B. Liu[1], *G. Hu*[2], *X. Wang*[2], *L. Huo*[2], *H. Ding*[1], *H. Zhang*[1];
[1]*Tsinghua University, Beijing, CHINA,* [2]*Peking Union Medical College Hospital, Beijing, CHINA.*

EP-0271
The Effect of Folate on [68Ga]Ga-PSMA-11 Organ and Tumor Uptake: Predictions Using Physiologically Based Pharmacokinetic Modelling
H. Siebinga[1,2], *J. J. M. A. Hendrikx*[1,2], *A. D. R. Huitema*[2,3,4], *B. J. de Wit - van der Veen*[1];
[1]*Department of Nuclear Medicine, NETHERLANDS Cancer Institute, Amsterdam, NETHERLANDS,* [2]*Department of Pharmacy and Pharmacology, NETHERLANDS Cancer Institute, Amsterdam, NETHERLANDS,* [3]*Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht University, Utrecht, NETHERLANDS,* [4]*Department of Pharmacology, Princess Máxima Center for Pediatric Oncology, Utrecht, NETHERLANDS.*

EP-0272
PSMA PET/CT correlates with biochemical response in patients with prostate cancer undergoing High-Intensity Focused Ultrasound (HIFU) focal therapy
E. Lopci, *G. Lughezzani, V. Fasulo, D. Maffei, A. Saita, P. Colombo, R. Hurle, K. Marzo, L. Leonardi, R. Peschechera, A. Benetti, S. Zandegiacomo, L. Pasini, J. Jandric, R. Zanca, P. Casale, M. Rodari, L. Balzarini, G. Guazzoni, N. Buffi, M. Lazzeri;*
IRCCS - Humanitas Research Hospital, Rozzano MI, ITALY.

EP-0273
Guiding metastases-directed therapy with Prostate-Specific Membrane Antigen (PSMA) PET/CT improves the oncological outcome of oligometastatic prostate cancer patients
F. Lanfranchi[1], *L. Belgioia*[1], *D. Albano*[2], *F. Dondi*[2], *F. Bertagna*[2], *E. Mataj*[3], *F. Linguanti*[4], *E. M. Abenavoli*[5], *L. Vaggelli*[5], *B. Detti*[6], *L. Urso*[7], *N. Ortolan*[7], *A. Malorgio*[8], *M. Bartolomei*[7], *A. Rizzo*[9], *M. Racca*[9], *A. Guarneri*[10], *F. Garrou*[11], *S. Panareo*[12], *P. Ghedini*[12], *S. Morbelli*[1], *G. Sambuceti*[1], *M. Bauckneht*[1];
[1]*Department of Health Sciences, University of Genoa and IRCCS Ospedale Policlinico San Martino, Genoa, ITALY,* [2]*Nuclear Medicine Department, Università degli Studi di Brescia and ASST Spedali Civili di Brescia, Brescia, ITALY,* [3]*Department of Radiation Oncology, Università degli Studi di Brescia and ASST Spedali Civili di Brescia, Brescia, ITALY,* [4]*Nuclear Medicine Unit, Department of Experimental and Clinical Biomedical Sciences "Mario Serio", University of Florence, Florence, ITALY,* [5]*Nuclear Medicine Division, Careggi University Hospital, Florence, ITALY,* [6]*Radiation Oncology Unit, Azienda Ospedaliero-Universitaria Careggi, Florence, ITALY,* [7]*Nuclear Medicine Unit, Oncological Medical and Specialist Department, University Hospital of Ferrara, Ferrara, ITALY,* [8]*Radiotherapy Unit, University Hospital of Ferrara, Ferrara, ITALY,* [9]*Department of Nuclear Medicine, Candiolo Cancer Institute, FPO-IRCCS, Turin, ITALY,* [10]*Department of Radiotherapy, Candiolo Cancer Institute, FPO-IRCCS, Turin, ITALY,* [11]*Nuclear Medicine Unit, Department of Medical Sciences, AOU Città della Salute e della Scienza, University of Turin, Turin, ITALY,* [12]*Nuclear Medicine Unit, Oncology and Haematology Department, University Hospital of Modena, Modena, ITALY.*

EP-0274
Treatment response evaluation with PSMA-PET/CT imaging in patients with metastatic castration-resistant prostate cancer (mCRPC)
F. Kleiburg[1,2], *L. F. De Geus-Oei*[1,2,3], *S. A. C. Luelmo*[2], *R. Spijkerman*[1,2], *F. A. J. Toonen*[4], *F. Smit*[4], *T. van der Hulle*[2], *L. Heijmen*[2];
[1]*University of Twente, Enschede, NETHERLANDS,* [2]*Leiden University Medical Centre, Leiden, NETHERLANDS,* [3]*Delft University of Technology, Delft, NETHERLANDS,* [4]*Alrijne Hospital, Leiderdorp, NETHERLANDS.*

EP-0275
Radium-223 response assessment and outcomes prediction using 68Ga-PSMA PET/CT: RECIP 1.0 vs PPP criteria
Q. Shagera, *P. Flamen, C. Artigas;*
Jules Bordet Institute, Université Libre de Bruxelles (ULB), Brussels, BELGIUM.

EP-0276
[68Ga]PSMA-11 PET/CT response in metastatic prostate cancer following systemic therapy
P. Aravind[1], *T. D. Barwick*[2,1], *S. Dubsash*[1], *M. J. Connor*[2], *H. Tam*[2], *F. A. Mauri*[1], *H. U. Ahmed*[1,2], *E. O. Aboagye*[1];
[1]*Imperial College London, London, UNITED KINGDOM,* [2]*Imperial College Hospital NHS TRUST, London, UNITED KINGDOM.*

EP-0277
The use of clinical, laboratory, and imaging parameters to interpret bone focal uptakes in hormone-sensitive prostate cancer patients imaged with [18F]-PSMA-1007 PET/CT
F. D'Amico[1], *A. Signori*[1], *D. Albano*[2], *M. Riondato*[3], *F. Dondi*[2], *T. Di Raimondo*[1], *L. Sofia*[1], *F. Lanfranchi*[1], *C. Ghersi*[3], *A. Democrito*[3], *G. Fornarini*[4], *C. Marini*[5], *F. Bertagna*[2], *S. Morbelli*[1], *G. Sambuceti*[1], *M. Bauckneht*[1];
[1]*Department of Health Sciences, University of Genoa, Genova, ITALY,* [2]*Nuclear Medicine, University of Brescia and ASST Spedali Civili Brescia, Brescia, ITALY,* [3]*Nuclear Medicine Unit, IRCCS, Ospedale Policlinico San Martino, Genova, ITALY,* [4]*Medical Oncology Unit 1, IRCCS Ospedale Policlinico San Martino, Genova, ITALY,* [5]*CNR, Institute of Molecular Bioimaging and Physiology (IBFM), Genova, ITALY.*

EP-0278
Modified PROMISE Criteria for Standardized Interpretation of Gastrin Releasing Peptide Receptor (GRPR)-targeted PET
H. Duan, *G. A. Davidzon, F. Moradi, T. Liang, H. Song, A. Iagaru;*
Stanford University, Stanford, CA, UNITED STATES OF AMERICA.

EP-0279
Consensus statements on Prostate Specific Membrane Antigen (PSMA)-Targeted Surgery - outcomes from an international multidisciplinary panel
F. van Leeuwen[1], *A. Berrens*[2], *the PSMA-guided surgery panel, H. van der Poel*[2];
[1]*Leiden University Medical Center, Leiden, NETHERLANDS,* [2]*NETHERLANDS cancer institute, Amsterdam, NETHERLANDS.*

E-POSTERS | FINAL PROGRAMME

EP-0280
Evaluation of [18F]DCFPyL excretion in the saliva of patients with prostate cancer
B. Fernandes[1], *J. Roy*[1], *F. Basuli*[2], *Y. McKinney*[1], *B. M. Warner*[3], *E. Mena*[1], *L. Lindenberg*[1], *B. Turkbey*[1], *P. Choyke*[1], *F. I. Lin*[1];
[1]*Molecular Imaging Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, UNITED STATES OF AMERICA,* [2]*Chemistry and Synthesis Center, National Heart, Lung, and Blood Institute, National Institutes of Health, Rockville, MD, UNITED STATES OF AMERICA,* [3]*National Institute of Dental and Craniofacial Research, National Institute of Health, Bethesda, MD, UNITED STATES OF AMERICA.*

EP-0281
Clinical Application of 18F-Thretide PET/CT and Early PET/CT Scan in Prostate Cancer
X. Cheng[1,2], *G. Hou*[1,2], *X. Wang*[1,2], *X. Chen*[3,4,5], *Y. Wang*[1,2], *V. Jakobsson*[3,4,5], *X. Shen*[1,2], *J. Zhang*[3,4,5], *R. Zheng*[1,2];
[1]*Department of Nuclear Medicine (PET-CT Center), National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, CHINA,* [2]*Department of Nuclear Medicine (PET-CT Center), National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Langfang, CHINA,* [3]*Department of Diagnostic Radiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, SINGAPORE,* [4]*Nanomedicine Translational Research Program, NUS Center for Nanomedicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, SINGAPORE,* [5]*Clinical Imaging Research Centre, Centre for Translational Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, SINGAPORE.*

EP-0282
Dual tracer PET/CT with 68Ga-PSMA and 18F-FDG in patients with prostate cancer
Y. Zhang, *M. Su;*
Department of Nuclear Medicine, West China Hospital, Sichuan University, Chengdu, CHINA.

EP-0283
Improvement of Gleason Grading prediction in Prostate Cancer Stratification for Radical Prostatectomy: a Machine Learning-based Theronostic Multi-omics Study
J. Ning[1], *C. P. Spielvogel*[1,2], *D. Haberl*[1], *K. Trachtova*[1], *S. Stoiber*[1], *S. Rasul*[1], *V. Bystry*[1], *E. Gurnhofer*[1], *G. Timelthaler*[1], *L. Papp*[1], *M. Schlederer*[1], *M. Hacker*[1], *A. Haug*[1], *L. Kenner*[1];
[1]*Christian Doppler Lab for Applied Metabolomics, Medical University of Vienna, Vienna, AUSTRIA,* [2]*JN and CPS shared the first authorship, Vienna, AUSTRIA.*

EP-0284
Assessment of Response Evaluation Criteria in PSMA PET/CT (RECIP 1.0) in Metastatic Castration-Resistant Prostate Cancer
A. Gafita[1], *L. Djaileb*[2], *I. Rauscher*[3], *W. P. Fendler*[4], *B. Hadaschik*[4], *J. Czernin*[5], *K. Herrmann*[4], *S. P. Rowe*[1], *J. Calais*[6], *M. Rettig*[6], *M. Eiber*[3], *M. Weber*[4], *M. R. Benz*[6], *A. Farolfi*[7];
[1]*Johns Hopkins University, Baltimore, MD, UNITED STATES OF AMERICA,* [2]*University Grenoble Alpes, Grenoble, FRANCE,* [3]*Technical University Munich, Munich, GERMANY,* [4]*University Hospital Essen, Essen, GERMANY,* [5]*University of California Los Angeles, Los Angeles, CA, UNITED STATES OF AMERICA,* [6]*University of California, Los Angeles, Los Angeles, CA, UNITED STATES OF AMERICA,* [7]*University of Bologna, Bologna, ITALY.*

EP-0285
Association of Blood Count Parameters and Non-metastatic Bone Uptake at [18F]PSMA-1007 PET — Could Osteoporosis Be the Key to Unravel this Conundrum?
G. Ninatti[1], *C. Pini*[1], *R. Camedda*[2], *F. Gelardi*[3], *L. Antunovic*[4], *C. Landoni*[1,5], *P. Mapelli*[4], *M. Picchio*[6,4], *M. Sollini*[3,7], *A. Chiti*[6,4];
[1]*University of Milano Bicocca, Monza, ITALY,* [2]*University of Rome Tor Vergata, Rome, ITALY,* [3]*Humanitas University, Pieve Emanuele, ITALY,* [4]*IRCCS San Raffaele Scientific Institute, Milan, ITALY,* [5]*IRCCS-San Gerardo, Monza, ITALY,* [6]*Vita-Salute San Raffaele University, Milan, ITALY,* [7]*IRCCS Humanitas Research Hospital, Rozzano, ITALY.*

EP-0286
The Impact of 18F-DCFPYL Specific Activity on Organ Uptake
G. Chaussé[1], *S. Plaha*[2];
[1]*McGill University, Montreal, QC, CANADA,* [2]*University of British Columbia, Vancouver, BC, CANADA.*

EP-0287
Can Ga-68 PSMA PET/CT Parameters Predict Progression in Hormone-Sensitive De Novo Metastatic Prostate Cancer
S. Aksu[1], *B. B. Demirel*[1], *S. Gülbahar Ateş*[1], *Ö. Ateş*[2], *G. Uçmak*[1];
[1]*Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Department of Nuclear Medicine, Ankara, TÜRKIYE,* [2]*Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Department of Medical Oncology, Ankara, TÜRKIYE.*

EP-0288
Reducing the frequency of prostate cancer biopsy by F18-rhPSMA7.3 PET/MR
T. Hekimsoy[1], *S. Kleiner*[1], *M. Heck*[2], *K. Schwamborn*[3], *M. Eiber*[1], *W. Weber*[1];
[1]*Department of Nuclear Medicine, Technical University of Munich, Klinikum rechts der Isar, Munich, GERMANY,* [2]*Department of Urology, Technical University of Munich, Klinikum rechts der Isar, Munich, GERMANY,* [3]*Department of Pathology, Technical University of Munich, Klinikum rechts der Isar, Munich, GERMANY.*

EP-16

e-Poster Area

B: Imaging Clinical Studies -> B1 Oncological Imaging Clinical Study -> B19 Thyroid

EP-0289
Prediction of Lymph Node Metastasis in Differentiated Thyroid Cancer Based on Radiomics Models: A Meta-analysis and Systematic Review
J. Mu, *Y. Cao, X. Zhong, W. Diao, Z. Jia;*
West China Hospital, Sichuan University, Chengdu, CHINA.

EP-0290
Contribution of Neck Ultrasonography to Patient Management in Patients with Differentiated Thyroid Carcinoma with Excellent Response to Therapy
I. Hekimsoy[1], *M. Guven*[2], *R. Tokac*[2], *G. Kavukcu*[3], *A. Akgun*[2];
[1]*Department of Radiology, Torbali State Hospital, Izmir, TÜRKIYE,* [2]*Department of Nuclear Medicine, Ege University, Izmir, TÜRKIYE,* [3]*Department of Radiology, Ege University, Izmir, TÜRKIYE.*

EP-0291
Role of Thyroid Scintigraphy with pertechnetate in Congenital Hypothyroidism
A. Marques[1], *J. Carvalho*[2], *F. Abreu*[1];
[1]*Instituto de Medicina Nuclear da Faculdade de Medicina da Universidade de Lisboa, Lisboa, PORTUGAL,* [2]*Centro Hospitalar de Lisboa Ocidental, Lisboa, PORTUGAL.*

EP-0292
Semiquantitative analysis of 99mTc MIBI thyroid scan in patients with amiodarone induced thyrotoxicosis
L. Fischer[1,2], *N. Girotto*[1,2], *T. Bogović Crnčić*[1,2], *M. Ilić Tomaš*[1,2], *S. Grbac-Ivanković*[1,2], *M. Mavrinac*[3];
[1]*Department of Nuclear Medicine, Faculty of Medicine, University of Rijeka, Rijeka, CROATIA,* [2]*Clinical Department of Nuclear Medicine, Clinical Hospital Centre Rijeka, Rijeka, CROATIA,* [3]*Department of Medical Informatics, Faculty of Medicine, University of Rijeka, Rijeka, CROATIA.*

EP-0293
The prevalence of pre-thyroidectomy thyroid function test abnormalities among patients with differentiated thyroid carcinoma: A descriptive study
A. Aghaee, *s. barashki, s. zakavi;*
nuclear medicine research center,Mashhad university of Medical Sciences, Mashhad, IRAN, ISLAMIC REPUBLIC OF.

EP-0294
Prognostic role of minimal extrathyroidal tumor extension (mETE) in the follow-up of patients with papillary carcinoma (PC) unaffected by other risk factors.
A. Marongiu, *S. Nuvoli, S. Vargiu, P. Solinas, A. Spanu, G. Madeddu;*
Unit of Nuclear Medicine, University of Sassari, viale S. Pietro 8 - 0700 Sassari, Italy, Sassari, ITALY.

EP-0295
68Ga FAPI-PET CT in patients with rising calcitonin after treatment of medullary thyroid carcinoma and negative conventional and nuclear imaging - pilot cases.
P. Bochev, *G. Mateva, N. Novoselska;*
Acibadem Cityclinic Mladost UMBAL, Sofia, BULGARIA.

EP-0296
The total volume of lung metastases from thyroid cancer based on infer artificial intelligence can predict abnormal lung function
M. Qi, *R. Huang, S. Huang;*
Department of Nuclear Medicine, West China Hospital of Sichuan University, Chengdu, CHINA.

EP-0297
SOP for cervical ultrasound cine loops on DTC follow-up
P. Seifert, *M. P. Sopuschek, M. Freesmeyer;*
Clinic of Nuclear Medicine, Jena, GERMANY.

EP-0298
[68Ga]Ga-PSMA-11 PET/CT in Thyroid Cancer - Preliminary Results
K. Zajkowska, *M. Wojewódzka-Mirocha, P. Cegła, A. Sackiewicz, P. Ochman, J. Januszkiewicz-Caulier, A. Żyłka, M. Dedecjus;*
Department of Oncological Endocrinology and Nuclear Medicine, Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, POLAND.

EP-0299
Differentiated thyroid carcinoma: correlation between thyroglobulin, basal anti-thyroglobulin antibodies and post-ablative treatment study.
B. Hervás-Sanz, *A. Rodríguez-Gasén, J. Suils-Ramon, M. P. Perlaza-Jiménez, M. Pudis, S. Bondia-Bescós, J. L. Díaz-Moreno, J. L. Vercher-Conejero, M. Cortés-Romera;*
Nuclear Medicine-PET (IDI) Department, Bellvitge University Hospital-IDIBELL, L'Hospitalet de Llobregat, SPAIN.

EP-0300
Does the duplication time of thyroglobulin have any use as a predictor factor on the detection of recurrence and or metastasis in the differentiated thyroid cancer in the 2-[18F]fluoro-2-deoxy-d-glucose PET/CT.
D. Rodriguez Oviedo, *B. Manzarbeitia Arroba, M. Tagliatori Nogueira, M. Alvarez Moreno, C. Galindo, M. De La Rubia Marcos, M. Garcia Alonso, C. Paniagua Correa, C. Sandoval Moreno;*
Hospital Universitario de Getafe, Madrid, SPAIN.

EP-0301
Comparative Study of [68Ga]Ga-DOTA-FAPI-04, [68Ga] Ga-DOTATATE and [18F] -DOPA in Imaging of Medullary Thyroid Carcinoma: A Case Series and 18F-DOPA in Imaging of Medullary Thyroid Carcinoma: A Case Series
G. dos Santos[1,2], *A. Quagliata*[1], *E. Silvera*[1,2], *R. Castro*[1], *A. Banchero*[1], *A. Damian*[1], *I. Cordero*[1], *K. Suanes*[1], *O. Alonso*[1,2], *E. Savio*[1], *P. Duarte*[1], *J. Gambini*[1];
[1]*CUDIM, Uruguayan Center Of Molecular Imaging, Montevideo, URUGUAY,* [2]*Hospital de Clínicas Dr. Manuel Quintelas, Montevideo, URUGUAY.*

EP-0302
Correlation Between Clinical Characteristics And Effective Washout Time In Patients Treated With High Radioiodine Activities
C. Guerrero Calatayud, *A. C. Marin, S. Prado Wohlwend, J. R. Cañón Sánchez, N. I. Orrego Castro, S. Montesinos González, A. M. Yepes Agudelo, P. Bello Arques;*
Hospital La Fe, Valencia, Valencia, SPAIN.

EP-0303
Usefulness of 2-[18F]FDG PET/CT in indeterminate thyroid nodules (Bethesda III and IV) for risk stratification: do we still have to rely on FDG positivity? A retrospective monocentric experience
F. Serani[1], *E. Tabacchi*[2], *L. Calderoni*[1], *G. Cuzzani*[1], *S. Chillotti*[3], *S. Damiani*[4], *S. Fanti*[5];
[1]*Nuclear Medicine, Alma Mater Studiorum -University of Bologna, Bologna, ITALY,* [2]*Nuclear Medicine Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY,* [3]*Pathology Unit, Alma Mater Studiorum -University of Bologna, Bologna, ITALY,* [4]*Pathology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna-ITALY, Bologna, ITALY,* [5]*Nuclear Medicine, Alma Mater Studiorum - University of Bologna, Nuclear Medicine Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY.*

EP-17

e-Poster Area

B: Imaging Clinical Studies -> B1 Oncological Imaging Clinical Study -> B20 Gynaecological

EP-0304
Vulva lesions as characterized by F-18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography
Z. Koç[1], *P. Özcan*[1], *T. İlhan*[2], *S. Gökulu*[2], *Y. Karabulut*[3];
[1]*Mersin University Hospital Nuclear Medicine Dpt., Mersin, TÜRKIYE,* [2]*Mersin University Hospital Gynecologic Oncology Dpt., Mersin, TÜRKIYE,* [3]*Mersin University Hospital Pathology Dpt., Mersin, TÜRKIYE.*

EP-0305
Comparison of the diagnostic efficacy between 68Ga-FAPI PET/CT and 18F-FDG PET/CT in gynecological malignancies: A Systemic Review and Meta-analysis
C. Zhao, *L. Li;*
West China Hospital, Sichuan University, Chengdu, CHINA.

EP-0306
Prognostic value of semiquantitative parameters of18F-FDG PET/CTin the staging of cervical cancer.
L. Rodríguez Díaz, *C. Vigil Díaz, A. Laverde Mächler, J. Maraña González, S. Naranjo Sancho, M. Fernández Llana, M. Domínguez Grande, J. Suárez Fernández, N. Martín Fernández, F. González García;*
Hospital Universitario Central de Asturias, Oviedo, SPAIN.

EP-0307
Development and External Testing of Integrating PET/MR Radiomics and Clinical Characteristics to Predict Lymphovascular Space Invasion in Endometrial Carcinoma: A Dual-Center Study
X. Li[1,2], *T. Song*[1,2], *B. Cui*[1,2], *J. Li*[1,2], *J. Ma*[1,2], *H. Yang*[1,2], *Y. Wang*[3], *H. Sun*[4], *J. Lu*[1,2];
[1]*Department of Radiology and Nuclear Medicine, Xuanwu Hospital, Capital Medical University, Beijing, CHINA,* [2]*Beijing Key Laboratory of Magnetic Resonance Imaging and Brain Informatics, Capital Medical University, Beijing, CHINA,* [3]*GE Healthcare China, Shanghai, CHINA,* [4]*Department of Radiology, Shengjing Hospital of China Medical University, Shenyang, CHINA.*

EP-0308
Potential for time-synchronized PET/MRI with dual tracers of FDG and FES: Utility in the diagnostic capability to distinguish between benign and malignant endometrial lesions
J. Inukai-Inoue[1], *M. Nogami*[2,3], *M. Tachibana*[1], *F. Zeng*[2], *K. Kubo*[2], *T. Kurimoto*[4], *T. Tujikawa*[5], *Y. Yoshida*[6], *H. Okazawa*[3], *T. Murakami*[1,2];
[1]*Department of Radiology, Kobe University Graduate School of Medicine, Kobe, JAPAN,* [2]*Department of Radiology, Kobe University Hospital, Kobe, JAPAN,* [3]*Division of Medical Imaging, Biomedical Imaging Research Center, University of Fukui, Fukui, JAPAN,* [4]*GE Healthcare, Hino, JAPAN,* [5]*Department of Radiology, Faculty of Medical Sciences, University of Fukui, Fukui, JAPAN,* [6]*Department of Obstetrics and Gynecology, Faculty of Medical Sciences, University of Fukui, Fukui, JAPAN.*

EP-0309
Comparing CECT, 18F-FDG PET and 68Ga-FAPI PET derived peritoneal carcinomatosis index (PCI) in primary ovarian cancers.
S. Singh, *K. Verma, A. Singh;*
Globe Healthcare, Lucknow, INDIA.

EP-0310
Investigation of the Effect of Hormonal Therapy on Endometrial FDG Uptake in Postmenopausal Women
R. Nakamoto, *M. Yakami, T. Nobashi, H. Isoda, Y. Nakamoto;*
Kyoto University Hospital, Kyoto, JAPAN.

EP-0311
Treatment response evaluation using FDG-PET/CT predicts survival in women with locally advanced cervical cancer
M. Markus[1], *H. Sartor*[2], *M. Bjurberg*[3], *E. Trägårdh*[1];
[1]*Clinical Physiology and Nuclear Medicine, Malmö, SWEDEN,* [2]*Radiology Diagnostics, Malmö, SWEDEN,* [3]*Department of Hematology, Oncology and Radiation Physics, Malmö, SWEDEN.*

EP-0312
MRI and 18F-FDG PET/CT interrelationship in the postradiotherapy cervical carcinoma early response assessment
S. Lucic[1,2], *M. Spirovski*[1,2], *J. Licina*[1,2], *D. Stojanovic*[2], *A. Peter*[2], *M. A. Lucic*[1,2];
[1]*Medical Faculty, University of Novi Sad, Novi Sad, SERBIA,* [2]*Oncology Institute of Vojvodina, Sremska Kamenica, SERBIA.*

EP-0313
Utility of 18F FDG PET/CT in rare gynaecological malignancies
A. Nair S, *V. Rangarajan, S. Shah, A. Agrawal, N. Purandare, A. Puranik, S. Choudhury;*
Tata Memorial Hospital, Mumbai, INDIA.

EP-0314
Prognostic Role of F-18 FDG PET in Uterine Cervical Cancer Patients: 10 Years Experience
C. Soydal[1], *M. H. Baltacioglu*[2], *M. Araz*[1], *S. Taskin*[3], *N. O. Kucuk*[1], *U. F. Ortac*[3];
[1]*Ankara University Medical School, Department of Nuclear Medicine, Ankara, TÜRKIYE,* [2]*Sbu Trabzon Kanuni Training and Research Hospital Department of Nuclear Medicine, Trabzon, TÜRKIYE,* [3]*Ankara University Medical School, Department of Gynecology and Obstetrics, Ankara, TÜRKIYE.*

EP-0315
Does Peritoneal Metastasis Evaluation with 18F-FDG PET/MRI Contribute to Prognosis Prediction in Patients with Ovarian Cancer
M. Baltacioglu[1], *C. Soydal*[2], *M. Araz*[2], *D. Kuru Oz*[3], *N. O. Kucuk*[2];
[1]*Sbu Trabzon Kanuni Training and Research Hospital Department of Nuclear Medicine, Trabzon, TÜRKIYE,* [2]*Ankara University Medical School Department of Nuclear Medicine, Ankara, TÜRKIYE,* [3]*Ankara University Medical School, Department of Radiology, Ankara, TÜRKIYE.*

EP-0316
Role of Radiomics Applied to Baseline 18F-FDG PET/CT in Locally Advanced Cervical Carcinoma Patients Treated with Combined Chemoradiotherapy
G. Mathoux[1], *L. Monaco*[2], *E. De Bernardi*[1], *G. Di Martino*[3], *C. Crivellaro*[2], *F. Elisei*[2], *M. Musarra*[2], *L. Bazzano*[1], *C. Landoni*[1,2,4], *L. Guerra*[1,2,4], *C. Messa*[1,4];
[1]*Università degli Studi di Milano-Bicocca, Monza, ITALY,* [2]*Nuclear Medicine Department, Fondazione IRCCS San Gerardo dei Tintori, Monza, ITALY,* [3]*UOC Gynaecology, Fondazione IRCCS San Gerardo dei Tintori, Monza, ITALY,* [4]*Tecnomed Foundation, Monza, ITALY.*

EP-0317
Potential of baseline and early response FDG-PET/MRI to predict radiotherapy outcome in uterine cervical squamous cell carcinoma - a pilot study
S. Strandberg[1], *J. Jonsson*[1], *M. Zarei*[1], *K. Aglund*[1], *L. Blomqvist*[2], *K. Söderkvist*[1], *B. Zackrisson*[1];
[1]*Department of Radiation sciences, Umea University, Umea, SWEDEN,* [2]*Department of Molecular Medicine and Surgery, Karolinska Institute, Solna, SWEDEN.*

EP-18

e-Poster Area

B: Imaging Clinical Studies -> B1 Oncological Imaging Clinical Study -> B21 Lymphoma

EP-0318
Metabolic tumour volume in Hodgkin lymphoma - a comparison between manual and AI-based analysis
M. Sadik[1], *S. F. Barrington*[2], *J. Ulén*[3], *O. Enqvist*[4], *E. Trägårdh*[5], *B. Saboury*[6], *A. Lerberg Nielsen*[7], *A. Loft Jakobsen*[8], *J. Loaiza Gongora*[9], *J. López-Urdaneta*[1], *R. Kumar*[10], *L. Edenbrandt*[1];
[1]*Molecular and Clinical Medicine, Gothenburg, SWEDEN,* [2]*Clinical PET Centre, London, UNITED KINGDOM,* [3]*Eigenvision AB, Malmö, SWEDEN,* [4]*Eigenvision AB and Electrical Engineering, Malmö and Gothenburg, SWEDEN,* [5]*Clinical Physiology and Nuclear Medicine, Malmö, SWEDEN,* [6]*Radiology and Imaging Sciences, Bethesda, MD, UNITED STATES OF AMERICA,* [7]*Nuclear Medicine, Odense, DENMARK,* [8]*Clinical Physiology, Copenhagen, DENMARK,* [9]*Diagnostic Imaging, Oslo, NORWAY,* [10]*Nuclear Medicine, Chandigarh, INDIA.*

EP-0319
C-X-C Motif Chemokine Receptor 4-directed PET/CT provides improved Diagnostic Performance relative to [18F]FDG in Newly Diagnosed Patients with Marginal Zone Lymphoma
A. Kosmala[1], *S. E. Serfling*[1], *S. Schneid*[1], *T. Higuchi*[1,2], *A. Weich*[3], *C. Lapa*[4], *P. E. Hartrampf*[1], *M. Raderer*[5], *H. Einsele*[3], *A. K. Buck*[1], *M. S. Topp*[3], *J. Duell*[3], *R. A. Werner*[1,6];
[1]*Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, GERMANY,* [2]*Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, JAPAN,* [3]*Department of Internal Medicine II, University Hospital Würzburg, Würzburg, GERMANY,* [4]*Nuclear Medicine, Faculty of Medicine, University of Augsburg, Augsburg, GERMANY,* [5]*Department of Internal Medicine I, Medical University Vienna, Vienna, AUSTRIA,* [6]*Johns Hopkins School of Medicine, The Russell H Morgan Department of Radiology and Radiological Sciences, Baltimore, MD, UNITED STATES OF AMERICA.*

EP-0320
Development of prediction models for treatment response and prognosis in patients with diffuse large B-cell lymphoma based on 18F-FDG PET radiomics
Y. Zhou;
West China Hospital, Chengdu, CHINA.

EP-0321
Diagnostic performance of whole-body [18F] FDGPET/MRIwith diffusion-weighted imaging for detecting bone marrow involvement in lymphomas
X. Chen, *M. Wei, T. Yuan, B. Yu, N. Zhou, Z. Hua, Z. Yang, X. Wang;*
Peking University Cancer Hospital & Institute, Beijing, CHINA.

EP-0322
A focus on the impact of spleen involvement in total metabolic tumor volume measurements in Diffuse Large B-Cell Lymphoma patients.
L. Rebaud[1,2], *N. Capobianco*[3], *K. Girum*[2], *A. Cottereau*[4], *F. Morschhauser*[5], *B. Spottiswoode*[6], *I. Buvat*[2];
[1]*Siemens Healthcare SAS, Courbevoie, FRANCE,* [2]*LITO laboratory, U1288 Inserm, Institut Curie, University Paris-Saclay, Orsay, FRANCE,* [3]*Siemens Healthcare GmbH, Erlangen, GERMANY,* [4]*Cochin University Hospital, AP-HP, Department of Nuclear Medicine, Paris, FRANCE,* [5]*Service des Maladies du Sang, CHU Lille, Lille, FRANCE,* [6]*Siemens Medical Solutions UNITED STATES OF AMERICA, Inc., Knoxville, TN, UNITED STATES OF AMERICA.*

EP-0323
The Role Of Baseline 18F-FDG PET/CT Metrics And Radiomics Features In Predicting Primary Gastric Lymphoma Diagnosis
A. Calabro', *D. Albano, F. Dondi, P. Bellini, A. Tucci, F. Bertagna;*
ASST Spedali Civili of Brescia, University of Brescia, Brescia, ITALY.

EP-0324
18F-FDG PET/CT radiomics features and MYC protein expression predict progression in Diffuse Large B-cell Lymphoma
C. Cui, *B. Li, X. Mu, Z. Wu;*
SXMU, Tai Yuan, CHINA.

EP-0325
Prognostic value of baseline 18F-FDG PET/CT metabolic tumour volume and total lesion glycolysis in Diffuse Large B Cell Lymphoma patients
A. Doma[1,2], *A. Studen*[3,4], *B. Jezeršek Novaković*[1,2];
[1]*Ljubljana Oncology institute, Ljubljana, SLOVENIA,* [2]*Faculty of Medicine, University of Ljubljana, Ljubljana, SLOVENIA,* [3]*Experimental Particle Physics Department, Jožef Stefan Institute, Ljubljana, SLOVENIA,* [4]*Faculty of Mathematics and Physics, University of Ljubljana, Ljubljana, SLOVENIA.*

EP-0326
PET-Based Volumetric Biomarkers for Risk Stratification in Pediatric Hodgkin's Lymphoma
M. Dunaykin, *M. Yadgarov, G. Shestopalov, K. Chaurasiya, E. Kireeva, Y. Likar;*
Dmitry Rogachev National Medical Research Center Of Pediatric Hematology, Oncology and Immunology, Moscow, RUSSIAN FEDERATION.

EP-0327
Prognostic value of interim FDG PET/CT in Extranodal Natural Killer/T-Cell Lymphoma, nasal type : comparison of Deauville scores, deltaSUVmax and qPET
W. Hou, *R. Tian;*
West China Hospital, Sichuan University, Chengdu, CHINA.

EP-0328
Deep learning-based fully automatic segmentation of whole-body [18F]FDG PET/CT images from lymphoma patients: addition of CT data has poor impact on networks performance
C. S. Constantino[1,2], *F. P. M. Oliveira*[1], *S. Leocádio*[1], *M. Silva*[1], *C. Oliveira*[1], *J. C. Castanheira*[1], *Â. Silva*[1], *S. Vaz*[1], *R. Teixeira*[1], *M. Neves*[1], *P. Lúcio*[1], *C. João*[1], *S. Vinga*[2], *D. C. Costa*[1];
[1]*Champalimaud Clinical Centre, Champalimaud Foundation, Lisbon, PORTUGAL,* [2]*INESC-ID, Instituto Superior Técnico, Universidade de Lisboa, Lisbon, PORTUGAL.*

EP-0329
Assessment of the metabolic volume of the tumor as a marker of response to therapy with CAR-T Cells in patients with B-cell non-Hodgkin lymphoma, our experience.
M. CASALLAS CEPEDA, *J. Montalva Pastor, S. Salcedo, I. Gomez Fernandez, J. Alonso Farto;*
Hospital General Universitario Gregorio Marañón, Madrid, SPAIN.

EP-0330
18F-FDG PET/CT Volumetric and Radiomic Features for lesions/patients' characterization in CAR-T therapy
E. Abenavoli[1], *F. Linguanti*[1], *I. Cutini*[2], *L. Nassi*[3], *B. Puccini*[3], *M. Palazzo*[3], *B. Sordi*[4], *R. Saccardi*[2], *A. Vannucchi*[4], *R. Sciagrà*[1], *V. Berti*[1];
[1]*Nuclear Medicine Unit, Experimental and Clinical Biomedical Sciences Department "Mario Serio", AOU Careggi, Florence, Italy, Florence, ITALY,* [2]*Department of Cellular Therapies and Transfusion Medicine, Careggi University Hospital, Florence, ITALY,* [3]*Hematology Department, Azienda Ospedaliero-Universitaria Careggi, Florence, ITALY,* [4]*Department of Experimental and Clinical Medicine, CRIMM, Center Research and Innovation of Myeloproliferative Neoplasms, Azienda Ospedaliera Universitaria Careggi, University of Florence, Florence, ITALY.*

EP-0331
Is [18F]FDG PET/CT at one month of chimeric antigen receptor T-cell therapy (CAR-T) in lymphomas necessary in the early treatment response assessment?
P. Stefaneli Mormandi, *C. Soldevila-Lozano, A. Caballero-Gonzalez, S. Abouzian Senhaji, P. Torres-Quintana, A. Fernández-León, R. Valverde-Jorge, M. Velasco-Nuño, J. Duch, V. Camacho, A. Flotats;*
Hospital de la Santa Creu i Sant Pau, Barcelona, SPAIN.

EP-0332
Head-to-head comparison between 68Ga-Pentixafor and 18F-FDG PET/CT in diffuse large B cell lymphoma
P. Palanivelu, *H. Goyal, D. Halanaik, P. Ganesan;*
Jawaharlal Institute of Postgraduate Medical Education and Research, Pondicherry, INDIA.

EP-0333
18F-FDG PET/CT features as potent imaging biomarkers of efficacy and toxicity in large-B-cell lymphoma treated with CAR-T cell therapy
D. Leithner[1], *J. R. Flynn*[1], *A. Mauguen*[1], *S. M. Devlin*[1], *T. Fei*[1], *B. S. Imber*[1], *H. Hubbeling*[1], *M. E. Mayerhoefer*[1], *D. Lafontaine*[1], *L. Michaud*[2], *M. Perales*[1], *H. Schöder*[1], *R. Shouval*[1];
[1]*Memorial Sloan Kettering Cancer Center, New York, NY, UNITED STATES OF AMERICA,* [2]*Lausanne University Hospital, Lausanne, SWITZERLAND.*

EP-0334
Effect of chemotherapy-related hepatic steatosis on liver 18F-FDG uptake in lymphoma patients
Y. Wang, *M. Su, L. Li;*
West China Hospital, Sichuan University, Chengdu City, CHINA.

EP-0335
Classical Hodgkin's Lymphoma: does baseline 18F-FDG PET/CT radiomics from the largest and hottest lesions add value to conventional prognostic models?
E. Triumbari[1,2], *D. Morland*[3], *R. Gatta*[4], *A. Collarino*[4], *E. Maiolo*[4], *A. Cuccaro*[4], *M. De Summa*[4], *S. Chiesa*[4], *L. Boldrini*[4], *M. E. Mayerhoefer*[5], *L. Nardo*[6], *S. Hohaus*[4], *S. Annunziata*[4];
[1]*1Department of Radiology, Radiotherapy and Hematology, Fondazione Policlinico Universitario A.Gemelli IRCCS, Rome, ITALY,* [2]*Radiopharmacy Research Core Facility, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, ITALY,* [3]*Service de médecine nucléaire, Institut Godinot and CReSTIC EA 3804, Université de Reims Champagne-Ardenne, Reims, FRANCE,* [4]*Department of Radiology, Radiotherapy and Hematology, Fondazione Policlinico Universitario A.Gemelli IRCCS, Rome, ITALY,* [5]*Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, UNITED STATES OF AMERICA,* [6]*Department of Radiology, UC Davis, Sacramento, CA, UNITED STATES OF AMERICA.*

EP-0336
Comparison of Low dose Vs standard dose 18F-FDG PET/CT in Lymphoma Patients using Conventional PET/CT Scanner
N. Kumar, *J. Yadav, G. Arora, S. A. Shamim;*
All India Institute of Medical Sciences, New Delhi, INDIA.

EP-0337
Do FDG PET metrics have a role for predicting the response to BeGeV therapeutic scheme in refractory Hodgkin lymphoma? A pilot study.
D. Pizzuto[1], *N. Messina*[2,3], *E. Maiolo*[2], *F. D'Alò*[2,3], *S. Hohaus*[2,3], *S. Annunziata*[1];
[1]*Nuclear Medicine Unit, GSteP Radiopharmacy, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, ITALY,* [2]*Hematology Unit, Diagnostic Imaging, Radiation Oncology and Hematology Department, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, ITALY,* [3]*Hematology Institute, University Department of Radiological and Hematological Sciences, Università Cattolica del Sacro Cuore, Rome, ITALY.*

EP-0338
Normalization and 2-bit-quantization of FDG-PET using the Deauville Score for training an deep learning AI for lymphoma staging
B. Schemmer;
Uniklinik Bonn, Bonn, GERMANY.

EP-0339
Total metabolic tumor volume (TMTV) at baseline 18F-FDG PET/CT and Laboratory Prognostic Index (LAB-PI) as outcome predictors in Large B-Cell Lymphoma (LBCL).
L. García Belaústegui, *S. Borwne, L. Sancho Rodríguez, R. Figueroa, F. Minguez, M. Canales, S. Huerga, V. Betech-Antar, E. Pena, C. Grande, M. Garcia-Velloso;*
Clínica Universidad de Navarra, Madrid, SPAIN.

EP-0340
Prognostic Value of Volumetric Parameters with 18F-FDG PET/TC in Follicular Lymphoma
P. Sarandeses[1], *M. Poza*[1], *S. Pedraza*[1], *A. Medina Benito*[2], *A. Peter Seiffert*[2], *A. Jimenez*[1], *D. Vega*[1], *P. Zaragoza*[1], *S. Angiolillo*[1], *X. Guarnizo*[1], *S. Ruiz*[1], *A. Gomez*[1], *E. Martinez*[1], *A. Saviatto*[1], *A. Galiana*[1], *S. Barrio*[1], *M. Tabuenca*[1];
[1]*HOSPITAL UNIVERSITARIO 12 DE OCTUBRE, Madrid, SPAIN,* [2]*Universidad Politécnica Madrid, Madrid, SPAIN.*

EP-19

e-Poster Area

B: Imaging Clinical Studies -> B1 Oncological Imaging Clinical Study -> B22 Other Hemato-Oncology

EP-0341
18F-FDG PET/CT maybe not so helpless in detection leptomeningeal metastasis- a case report
T. Stoeva, *M. Dyankova, S. Chausheva, T. Yordanova, Z. Dancheva, B. Chaushev, A. Klisarova;*
UMHAT "Sveta Marina" EAD- Varna, Varna, BULGARIA.

EP-0342
18F-FDG PET/CT assessment of metabolic activity of the osteolytic lesions in patients with multiple myeloma after treatment for evaluation tumor vitality
T. Stoeva, *Z. Dancheva, M. Dyankova, S. Chausheva, T. Yordanova, B. Chaushev, A. Klisarova;*
UMHAT "Sveta Marina" EAD- Varna, Varna, BULGARIA.

EP-0343
18F-FDG PET/CT in unknown primary suspected of multiple myeloma
T. Stoeva, *Z. Dancheva, M. Dyankova, T. Yordanova, S. Chausheva, B. Chaushev, A. Klisarova;*
UMHAT "Sveta Marina" EAD- Varna, Varna, BULGARIA.

EP-0344
18F-FDG PET/CT assessment of metabolic activity of the osteolytic lesions in newly diagnosed multiple myeloma patients as predictive factor for overall survival
T. Stoeva, *Z. Dancheva, M. Dyankova, T. Yordanova, S. Chausheva, B. Chaushev, A. Klisarova;*
UMHAT "Sveta Marina" EAD- Varna, Varna, BULGARIA.

EP-0345
Impact of the Segmentation Method on the Correlation between Metabolic Tumor Volume and Total Circulating Tumor DNA
C. D. Ramos[1], *G. Duffles*[1], *M. S. Takahashi*[1], *E. Napolitano*[2], *F. Lupinacci*[2], *L. Pereira*[2], *J. Maues*[1], *M. Chauffaille*[1], *I. Lorand-Metze*[1];
[1]*University of Campinas, Campinas, BRAZIL,* [2]*Laboratorio Fleury, Sao Paulo, BRAZIL.*

EP-0346
End of treatment FDG PET CT in patients with Langerhans cell histiocytosis as a predictor of disease recurrence and survival.
P. Bochev[1], *Z. Dancheva*[2];
[1]*Acibadem Cityclinic Mladost UMBAL, Sofia, BULGARIA,* [2]*Medical University "Prof.Dr Paraskev Stoyanov", Varna, BULGARIA.*

EP-0347
Unresolved Challenges in Functional Imaging of Multiple Myeloma: F-18 Fluorocholine PET/CT or F-18 FDG PET/CT? A Single Center Experience
G. KAYA[1], *S. Akın*[2], *Y. Büyükaşık*[3], *M. Tuncel*[1], *M. F. Bozkurt*[1], *P. Özgen Kıratlı*[1];
[1]*Hacettepe University Medical School Department of Nuclear Medicine, Ankara, TÜRKIYE,* [2]*Hacettepe University Medical School Department of Medical Oncology, Ankara, TÜRKIYE,* [3]*Hacettepe University Medical School Department of Hematology, Ankara, TÜRKIYE.*

EP-0348
Prognostic utility of baseline 18F-FDG PET/CT in relapsed and refractory Multiple myeloma patients treated with T-cell redirecting bispecific antibodies.
F. MINGUEZ[1], *V. Betech-Antar[1], L. Tamariz-Amador[1], A. Bronte Viedma[1], J. Rosales[1], J. Bastidas[1], C. von Gall[2], M. Romera[1], P. Echegoyen[1], F. Pareja del Rio[1], T. Cuenca[1], S. Menendez-Sanchez[1], L. García Belaustegui[3], L. Sancho[3], E. Guillen[3], E. Prieto[1], R. Ramos[3], J. Simon[1], M. Panizo[1], S. Huerga[1], J. San-Miguel[1], P. Rodriguez Otero[1], M. García-Velloso[1];*
[1]Clínica Universidad de Navarra, Pamplona, SPAIN, [2]Siemens Healthineers, Molecular Imaging, Knoxville, TN, UNITED STATES OF AMERICA, [3]Clínica Universidad de Navarra, Madrid, SPAIN.

EP-0349
Comparison of C-11 Methionine and F-18 FDG PET/CT findings in evaluation of Multiple Myeloma: First Türkiye Experience
E. Özkan[1], ***B. Demir***[1], *G. Cengiz Seval[2], M. Araz[1], C. Soydal[1], M. Beksac[2], N. O. Kucuk[1];*
[1]Ankara University School of Medicine Department of Nuclear Medicine, Ankara, TÜRKIYE, [2]Ankara University School of Medicine Department of Hemotology, Ankara, TÜRKIYE.

EP-0350
Role of 18F-FDG PET/CT in patients with Castleman disease
R. Goel, *N. Damle, Y. Dharmashaktu, C. Bal, M. Tripathi, R. Kumar, P. Kumar;*
All India Institute of Medical Sciences (AIIMS), New Delhi, INDIA.

EP-0351
Talquetamab, a Novel Anti-Myeloma GPRC5DxCD3 Bispecific Antibody, is Associated with Increased Oropharyngeal FDG Uptake
J. Trak, *T. Mouhieddine, G. Lancman, L. Sanchez, A. Chari, M. Ghesani;*
Mount Sinai Hospital, New York, NY, UNITED STATES OF AMERICA.

EP-0352
A follow up of 30 patients with multiple myeloma confirmed: prognostic role of number of focal lesions and SUV max at diagnosis in 18F-FDG PET/CT
I. López Villar[1], *V. Castillo Morales[1], I. Hernández Pérez[1], A. García Noblejas[2], S. Hernández Muñiz[3], I. Salmerón Beliz[3], J. Alonso Farto[4], D. Zamudio[4], N. Gómez de Leon[3];*
[1]Princesa University Hospital, Nuclear Medicine Service, Madrid, SPAIN, [2]Princesa University Hospital, Hematology Service, Madrid, SPAIN, [3]Princesa University Hospital, Radiology Service, Madrid, SPAIN, [4]Gregorio Marañón University Hospital. Nuclear Medicine Service, Madrid, SPAIN.

EP-0353
[11C]-Methionine as Novel Image Biomarker of Disease Activity in Newly Diagnosed Multiple Myeloma Patients - Comparison with [18F]-FDG
S. Serfling[1], *M. Bittrich[1], A. K. Buck[1], T. Higuchi[1], S. Samnick[1], K. M. Kortüm[1], L. Rasche[1], H. Einsele[1], R. A. Werner[1], S. Knop[2];*
[1]University Hospital Würzburg, Würzburg, GERMANY, [2]Klinikum Nürnberg Nord, Nürnberg, GERMANY.

EP-0354
Multiple Myeloma: a comparison between 18F-FDG-PET/CT and 68Ga-PSMA-PET/CT
D. Bezzi[1], *E. Zamagni[2], S. Fanti[3], L. Vetrone[1], M. Talarico[2], C. Malizia[3], C. Nanni[3];*
[1]Nuclear medicine, Alma Mater Studiorum University of Bologna, Bologna, ITALY, [2]Seràgnoli Institute of Hematology, Bologna University, Bologna, ITALY, [3]Nuclear Medicine Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY.

EP-0355
Sarcopenia and metabolic parameters of [18F]-FDG PET/CT in patients with multiple myeloma. Preliminary results.
A. Palomar-Muñoz[1], *S. Hermosa-García[2,3], I. Sánchez-Rodríguez[1], Y. Benavente[2,3], J. A. Jorge-Novoa[2], V. Carrero-Vásquez[1], B. Hervás-Sanz[1], E. Garamundi-Grimalt[4], G. Bustamante-Ramírez[5], E. Cabezudo-Pérez[6], M. Cortés-Romera[1], D. Casabonne[2,3], the IBERICAT/IMMAGE study collaborators;*
[1]Nuclear Medicine Department, Hospital Universitario Bellvitge, L'Hospitalet de Llobregat (Barcelona), SPAIN, [2]Catalan Institute of Oncology (ICO), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat (Barcelona), SPAIN, [3]Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, SPAIN, [4]Pathological Anatomy Department, Hospital Universitario Bellvitge, L'Hospitalet de Llobregat (Barcelona), SPAIN, [5]Hematology Department, Catalan Institute of Oncology (ICO), L'Hospitalet de Llobregat (Barcelona), SPAIN, [6]Hematology Department, Catalan Institute of Oncology (ICO) Hospital Sant Joan Despí Moisés Broggi, Sant Joan Despí (Barcelona), SPAIN.

EP-0356
[18F]- FDG PET/CT prognostic value in the assessment of multiple myeloma patients treated with CAR-T therapy
M. Tormo-Ratera[1], *I. Zugasti[2], A. Oliver-Caldes[2], V. González-Calle[3], V. Cabañas[4], P. Rodríguez-Otero[5], J. Reguera[6], M. Mateos[7], K. Quintero[1], S. Casanueva-Eliceiry[1], M. Cibeira[8], A. Niñerola-Baizan[1], X. Tomas[9], L. Rosiñol[2], P. Tamayo[10], M. García-Velloso[11], C. Fernández de Larrea[2], X. Setoain[1];*
[1]Department of Nuclear Medicine, Hospital Clínic., Barcelona, SPAIN, [2]Hospital Clínic. Institut d'Investigació Biomèdica August Pi i Sunyer., Barcelona, SPAIN, [3]Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, SPAIN, [4]Hospital Clínico Universitario Virgen de la Arrixaca., IMIB-Arrixaca, SPAIN, [5]Clínica Universidad de Navarra, Centro de Investigación Médica Aplicada (CIMA), Pamplona, SPAIN, [6]Hospital Universitario Virgen del Rocío, Sevilla, SPAIN, [7]Hospital Universitario de Salamanca, Salamanca, SPAIN, [8]Department of Hematology, Hospital Clínic., Barcelona, SPAIN, [9]Department of Radiology, Hospital Clínic., Barcelona, SPAIN, [10]Department of Nuclear Medicine, University Hospital of Salamanca, Salamanca, SPAIN, [11]Nuclear Medicine Department, Clínica Universidad de Navarra, Pamplona, SPAIN.

EP-0357
Prognostic value of 18F-FDG PET/CT biomarkers in patients with diffuse large B-cell lymphoma treated with chimeric antigen receptor T-cell therapy Preliminary results.
J. Cañadas Salazar, *A. Martín Lopez, L. G. Díaz González, C. Montes fuentes, A. Martín García-Sancho, P. Tamayo Alonso;*
Sacyl, Salamanca, SPAIN.

EP-20
e-Poster Area

B: Imaging Clinical Studies -> B1 Oncological Imaging Clinical Study -> B23 Bone and Soft Tissues

EP-0358
Dual time point [18F]FDG PET/CT can differentiate benign from malignant soft tissue tumors and outperforms the diagnostic performance of conventional PET/CT acquisition
P. D'Abadie, *O. Gheysens, R. Lhommel, T. Kirchgesner, A. De Roo, T. Schubert;*
Cliniques universitaires Saint Luc, Brussels, BELGIUM.

EP-0359
Prognostic Value of Pre-Treatment F-18 FDG PET/CT Parameters in Soft-Tissue Sarcomas
I. Ak Sivrikoz, *H. Deveci, E. Çinçin;*
ESOGU School of Medicine Department of Nuclear Medicine, Eskisehir, TÜRKIYE.

EP-0360
Association of 'Hot Kidneys' on Bone Scintigraphy and Serum Ferritin Levels
I. Kuji[1], *K. Watanabe[1], E. Ryuta[1], Y. Matsusaka[1], A. Seto[1], I. Matsunari[2];*
[1]Department of Nuclear Medicine, Saitama Medical University International Medical Center, Hidaka, Saitama, JAPAN, [2]Department of Nuclear Medicine, Saiatama Medical University Hospital, Saitama Medical University, Moroyama, Saitama, JAPAN.

EP-0361
Prognostic value of metabolic parameters of 18F-FDG PET-CT in the staging of adult soft tissue sarcomas
A. Berardinelli[1], *M. Meneses Navas[1], G. Cuesta Domingo[1], P. Nespral Torres[1], P. Romero Fernández[1], P. Dauden Oñate[1], P. Bascuñana[1], A. Crespo[2], M. Cabrera Martín[1];*
[1]Department of Nuclear Medicine, Instituto de Investigación Sanitaria San Carlos (IdISSC), Hospital Clínico San Carlos, Universidad Complutense, Madrid, SPAIN, [2]Department of Radiology, Hospital Clínico San Carlos., Madrid, SPAIN.

EP-0362
Utility of metabolic indices in 18F-FDG-PETCT for prediction of presence, patterns and sites of metastases in patients with osteosarcoma
N. Kundu, *S. Sagar, D. Khan, A. Roy, R. Goel, M. Y S, R. V, R. Kumar;*
AIIMS New Delhi, Delhi, INDIA.

EP-0363
The Relationship Between Staging F-18 FDG PET/CT Parameters and Survival in Patients Diagnosed with Soft Tissue Sarcoma
N. Aydin, *G. Mütevelizade, G. Gümüşer, E. Sayıt Bilgin;*
Celal Bayar University, Manisa, TÜRKIYE.

EP-0364
Additional diagnostic contribution of bone SPECT/CT in foot and ankle pathology
K. Bayardo, *L. F. Portugal, F. Carrera, O. Alonso, R. Ferrando;*
University of the Repubic, Montevideo, URUGUAY.

EP-0365
Assessing the role of 18F-FDG PET-CT in the initial staging of soft tissue sarcomas: bone infiltration and distant metastasis
Y. Abadi Sedraoui, *J. Cordero García, E. Ortiz Cruz, I. Barrientos Ruiz, J. Pozo Kreilinger, C. Lancha Hernández, M. Coronado Poggio, S. Rizkallal Monzón, E. López LLobet, D. Monachello Araujo, L. Giraldo González, P. Portilla Merino, S. Rodado Marina, C. Escabias Del Pozo, L. Domínguez Gadea;*
Hospital Universitario La Paz, Madrid, SPAIN.

EP-0366
Evaluation of F-18 FDG PET-CT based parameters in prediction of histopathological response to neoadjuvant chemotherapy in patients with Osteosarcoma
S. Maitra, *N. Singh;*
P.D. Hinduja National Hospital and MRC, Mumbai, INDIA.

EP-0367
Usefulness of SPECT/CT 99mTc MIBI for the evaluation of lesions suggestive of bone sarcomas.
F. Lemus Ramírez[1], *A. López Méndez[2], D. Arguelles Pérez[1], D. Orendain Novoa[1];*
[1]Instituto Nacional De Rehabilitación Luis Guillermo Ibarra Ibarra, México, MEXICO, [2]J&J, México, MEXICO.

EP-0368
18F-NaF PET/CT in diagnosis and response assessment to Radiofrequency Ablation (RFA) in Osteoid Osteoma patients
S. Shamim, *N. Kumar, J. Pathak, G. Arora, S. Gamanagatti, S. Khan;*
AIIMS New Delhi, Delhi, INDIA.

EP-21
e-Poster Area

B: Imaging Clinical Studies -> B1 Oncological Imaging Clinical Study -> B24 Melanoma

EP-0369
The value of 18F-FDG PET/MR in the metastasis and re-stage of melanoma after operation
F. Wang;
Hangzhou Universal Imaging diagnostic center, Hangzhou, CHINA.

EP-22
e-Poster Area

B: Imaging Clinical Studies -> B1 Oncological Imaging Clinical Study -> B25 Any Other Malignant (including Primary of Unknown Origin)

EP-0370
Utility of 68Ga FAPI 46 PET CT scan in oncology patients with indeterminate 18 FFDG PET CT findings- A single institute study
V. Malasani, *s. dash, d. pendharkar, n. singhal, a. raj, m. mehndiratta, d. parwan, n. n. begum, a. tomar, a. javed; sarvodaya hospital and research center, faridabad, INDIA.*

EP-0371
Comparison of Diagnostic Value between18F-FDG PET/CT and Immunohistochemistry in Lymph Node Metastatic Cancer with Unknown Primary site
Y. Yu, *S. Xu, X. Han;*
the First Affiliated Hospital,Zhengzhou, Zhengzhou, CHINA.

EP-0372
Diagnostic Efficacy of 68Ga-NY104 PET/CT in Patients With Clear Cell Renal Cell Carcinoma
W. Zhu, *X. Li, Y. Zhang, L. Huo;*
Peking Union Medical College Hospital, Beijing, CHINA.

EP-0373
The added values of 18F-FAPI over 18F-FDG in patients with oncologic diseases for evaluation of malignant lesions and management of incidental pathologic uptake
X. Mu, *M. Li, W. Fu;*
Department of Nuclear medicine, Affiliated hospital of Guilin medical university, Guilin, CHINA.

EP-0374
Using dual-time 18F-FAPI PET/CT to distinguishing the nature of lesion and avoid digestive pitfalls
X. Mu;
Department of Nuclear medicine, Affiliated hospital of Guilin medical university, Guilin, CHINA.

EP-0375
Does Brown Adipose Tissue represent a double-edged sword with mixed effects?
W. Jalloul[1], *D. Jalloul[1], R. Tibu[2], I. Grierosu[1,2], T. Ionescu[1], C. Stolniceanu[1,2], V. Ghizdovat[1,2], M. Moscalu[1], C. Stefanescu[1,2];*
[1]University of Medicine and Pharmacy U.M.F „Grigore T. Popa" Iasi, Romania, Iasi, ROMANIA, [2]Nuclear Medicine Laboratory, County Emergency Hospital „Sf. Spiridon", Iasi, ROMANIA.

EP-0376
Prognostic value of volumetric and metabolic 18F-FDG indices in patients with Merkel cell carcinoma: a multicentric retrospective study
M. Ricci[1], *F. Zarrelli[1], B. Carabellese[1], A. Marzullo[2], M. Tudini[3], B. Criscuoli[4], G. A. Follacchio[4], L. Travascio[5], A. D. Di Nicola[5], E. Giovannini[6], F. Calabria[7], M. Leporace[7], A. Bagnato[7], A. Cimini[2];*
[1]Nuclear Medicine Unit, Cardarelli Hospital, Campobasso, ITALY, [2]Nuclear Medicine Unit, St. Salvatore Hospital, L'Aquila, ITALY, [3]Medical Oncology Unit, St. Salvatore Hospital, L'Aquila, ITALY, [4]Nuclear Medicine Unit, Macerata Hospital, Macerata, ITALY, [5]Nuclear Medicine Unit, P.O. Pescara, Pescara, ITALY, [6]Nuclear Medicine Unit, S. Andrea Hospital, La Spezia, ITALY, [7]Department of Nuclear Medicine and Theragnostics, "Mariano Santo" Hospital, Cosenza, ITALY.

EP-0377
68Ga-FAPI-04 PET/CT in Renal Cell Carcinoma: A Preliminary Study
C. Civan[1], *S. Kuyumcu[1], D. Has Simsek[1], O. Sanli[2], Z. Ozkan[1], O. Hurdogan[3], Y. Sanli[1];*
[1]Istanbul Faculty of Medicine, Nuclear Medicine Department, Istanbul, TÜRKIYE, [2]Istanbul Faculty of Medicine, Urology Department, Istanbul, TÜRKIYE, [3]Istanbul Faculty of Medicine, Pathology Department, Istanbul, TÜRKIYE.

EP-0378
68Ga-NY104 PET/CT helps discriminate metastatic clear cell renal cell carcinoma from post-surgical inflammation: compared with18F-FDG
W. Zhu, *X. Li, Y. Zhang, L. Huo;*
Peking Union Medical College Hospital, Beijing, CHINA.

EP-0379
A Rare Case of Adrenal Hemangioma with CT, MRI and Pathology Findings.
B. Karasah Erkek, *A. Akgün, Y. Ertan, M. Harman;*
Ege University, Izmir, TÜRKIYE.

EP-0380
Comparison of 18F-FDG and 68Ga-FAPI PET/CT in the diagnosis of lung metastasis in different malignant tumors
Z. Yang;
Fudan University Shanghai Cancer Center, Shanghai, CHINA.

EP-0381
Bone scan with technetium 99m-methyl diphosphonate, the missing link in the initial staging of muscle-invasive bladder carcinoma
A. Aghaee[1], *S. Soltani[2], H. Ghorbani[2], H. Ghorbani[1], S. Zakavi[1], K. Aryana[1];*
[1]Nuclear Medicine Research Center,Mashhad University of Medical Sciences, Mashhad, IRAN, ISLAMIC REPUBLIC OF, [2]Kidney Transplantation Research Center, Mashhad University of Medical Sciences, Mashhad, IRAN, ISLAMIC REPUBLIC OF.

EP-0382
The Role of Integrin αvβ6-PET/CT for Patients with Different Cancer-Preliminary Clinical Experience
L. Li, *Z. Xiao, D. Zeng, D. Xing, H. Wu, Y. Tian, C. Li, Y. He;*
Department of Nuclear Medicine, Zhongnan Hospital, Wuhan University, Wuhan, CHINA.

EP-0383
Tumor Uptake of a Bi-specific Antibody which Binds to CD137 and FAP is Shown Using 89[Zr]Zr-BI 765179 PET-imaging
M. Stavenga[1,2], *M. C. Huisman[3,2], G. J. C. Zwezerijnen[3,2], J. J. Eertink[1,2], K. Ridler[4,5], Ö. Yalkinoglu[6], H. Maas[4], D. Radonjic[7], J. Pasek[8], D. J. Vugts[3,2], C. W. Menke-van der Houven van Oordt[1,2];*
[1]Amsterdam UMC location Vrije Universiteit Amsterdam, Department of Medical Oncology, Amsterdam, NETHERLANDS, [2]Cancer Center Amsterdam, research program, Amsterdam, NETHERLANDS, [3]Amsterdam UMC location Vrije Universiteit Amsterdam, Department of Radiology and Nuclear Medicine, Amsterdam, NETHERLANDS, [4]Boehringer Ingelheim Pharma GmbH & Co. KG, Department of Translational Medicine & Clinical Pharmacology, Biberach, GERMANY, [5]Invicro, A Konica Minolta Company, London, UNITED KINGDOM, [6]Boehringer Ingelheim International GmbH, Department of Translational Medicine & Clinical Pharmacology, Ingelheim am Rhein, GERMANY, [7]Boehringer Ingelheim International GmbH, TA Oncology Medicine, Ingelheim am Rhein, GERMANY, [8]Boehringer Ingelheim Pharmaceuticals, Early Clinical Operations, Ridgefield, CT, UNITED STATES OF AMERICA.

EP-0385
Diagnostic Accuracy of 18F-Flurodeoxyglucose Positron Emission Tomography-Computed Tomography in the Evaluation of Carcinoma of Unknown Primary Against Computed Tomography; Experience of Single Centre
M. Numair Younis, *U. B. Zahra, A. Shahid;*
Institute of Nuclear Medicine and Oncology-INMOL, Lahore, PAKISTAN.

EP-0386
The utility of PET/CT with 18F-FDG in the localization of unknown primary tumors and its correlation with anatomopathological findings: Experience of the University Hospital of Salamanca.
J. Badell[1], *P. García-Talavera San Miguel[2], F. Gómez-Caminero López[1], A. C. Peñaherrera Cepeda[1], E. Campaña Díaz[1], S. Rama Alonso[1], J. G. Villanueva Curto[1], L. G. Díaz González[1], P. Tamayo Alonso[1];*
[1]Hospital Clinico Universitario de Salamanca, Salamanca, SPAIN.

EP-0387
The relevance of 18FDG-PET/CT in the therapeutic assessment of recurrent leimyosarcoma of the inferior vena cava
K. Ben Ahmed, *M. Maaloul, H. Noomen, F. Chaltout, M. Ouachem, I. Jardak, S. Charfeddine, K. Chtourou, F. Guermazi;*
Nuclear medicine department , Habib bourguiba hospital, Sfax, TUNISIA.

EP-0388
PSMA Theragnostic beyond prostate cancer. A monocentric prospective observational study on the diagnostic performance of PSMA PET/CT in patients with metastatic Renal Clear Cell Carcinoma
F. Serani[1], *A. Farolfi[2], P. Castellucci[2], L. Vetrone[1], R. Mei[2], S. Fanti[3];*
[1]Nuclear Medicine, Alma Mater Studiorum - University of Bologna, Bologna, ITALY, [2]Nuclear Medicine Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, [3]Nuclear Medicine, Alma Mater Studiorum - University of Bologna, Nuclear Medicine Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY.

EP-23
e-Poster Area

B: Imaging Clinical Studies -> B3 Other Oncological Clinical Study -> B31 Radioguided Surgery and Radiation Therapy Planning

EP-0389
Feasibility study about the intra-operative use of a novel PET/CT Specimen Imager in Prostate Cancer and Neuroendocrine Tumors
L. Muraglia[1], *F. Mattana[1], L. Travaini[1], G. Musi[2], E. Bertani[3], G. Renne[4], E. Pisa[4], M. Ferrari[5], U. Fumagalli Romario[3], O. De Cobelli[2], N. Fusco[6], C. Francesco[7];*
[1]Nuclear Medicine Division, European Institute of Oncology IRCCS, Milan, ITALY, [2]Urology Division, European Institute of Oncology IRCCS; Oncology and Hemato-Oncology Department, University of Milan, Milan, ITALY, [3]Digestive Surgery Division, European Institute of Oncology IRCCS, Milan, ITALY, [4]Pathology Division, European Institute of Oncology IRCCS, Milan, ITALY, [5]Medical Physics Unit, European Institute of Oncology IRCCS, Milan, ITALY, [6]Pathology Division, European Institute of Oncology IRCCS; Oncology and Hemato-Oncology Department, University of Milan, Milan, ITALY, [7]Nuclear Medicine Division, European Institute of Oncology IRCCS; Oncology and Hemato-Oncology Department, University of Milan, Milan, ITALY.

EP-0390
Preoperative Radioisotope-guided Localization of Non-palpable Pulmonary Nodules
M. Olajos, *K. Park, Á. Ghimessy, K. Csende, M. Csaba, J. Andi, M. Téglás, L. Agócs, F. Rényi-Vámos, I. Sinkovics;*
National Institute Of Oncology, Budapest, HUNGARY.

EP-0391
Improving radical prostatectomy with intraoperative ex-vivo PSMA-PET/CT imaging
P. Fragoso Costa[1], *C. Darr[2], A. Moraitis[1], T. Kahl[2], J. Engel[2], M. Al-Nader[2], H. Henning[3], J. Köllermann[3], C. Kesch[2], U. Krafft[2], T. Maurer[4,5], D. Köhler[6], S. Klutmann[6], F. Falkenbach[4], J. Kleesiek[7], W. P. Fendler[1], K. Herrmann[1], B. Hadaschik[2];*
[1]Department of Nuclear Medicine, University Hospital Essen, Essen, GERMANY, [2]Department of Urology, University Hospital Essen, Essen, GERMANY, [3]Institute of Pathology, University Hospital Frankfurt, Frankfurt, GERMANY, [4]Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, GERMANY, [5]Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, GERMANY, [6]Department of Diagnostic and Interventional Radiology and Nuclear Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, GERMANY, [7]Institute of Artificial Intelligence in Medicine, University Hospital Essen, Essen, GERMANY.

EP-0393
Preoperative CT-guided radiolabeling of lung nodules with 99mTc-MAA and Video-Assisted or Robotic-Assisted Thorascopic Surgery: experience in our center since 2017.
C. Wakfie Corieh[1,2], *E. Rodríguez Gallo[1,2], J. Sánchez Corral[1,2], N. Mimica Haasz[1,2], F. Moradiellos Díez[1,2], S. Amor Alonso[1,2], A. Maldonado Suarez[1,2];*
[1]Hospital Universitario Quirónsalud Madrid, Madrid, SPAIN, [2]Universidad Europea, Madrid, SPAIN.

EP-0394
x2x2
E. Gromova[1], *A. Smirnova[1], G. Kataeva[2], N. Plakhotina[1];*
[1]LDC MIBS, Saint-Petersburg, RUSSIAN FEDERATION, [2]RRCRST, Saint-Petersburg, RUSSIAN FEDERATION.

EP-0395

Fast SPECT/CT confirmation of the preoperative location with ROLL: analysis of a 2-year single-centre real life experience

I. Lopo[1], *E. Lima*[2], *A. Bitencourt*[2], *L. Santos*[2], *A. Tavares*[2], *P. Lapa*[1,3], *G. Costa*[1,3];
[1]*Centro Hospitalar e Universitário de Coimbra, Coimbra, PORTUGAL,* [2]*A. C. Camargo Cancer Center, São Paulo, BRAZIL,* [3]*Faculdade de Medicina da Universidade de Coimbra, Coimbra, PORTUGAL.*

EP-0396

Intraoperative PET/CT Specimen Imaging for the Evaluation of Surgical Margins and Nodal Metastases in Prostate Cancer Patients Undergoing Robot-assisted PSMA-radioguided Surgery

G. Rovera[1], *S. Grimaldi*[1], *M. Oderda*[2], *L. Delsedime*[3], *D. D'Agate*[2], *F. Lavagno*[2], *A. Marquis*[2], *G. Marra*[2], *L. Molinaro*[3], *P. Gontero*[2], *D. Deandreis*[1];
[1]*Nuclear Medicine, Department of Medical Sciences, AOU Città della Salute e della Scienza di Torino, Turin, ITALY,* [2]*Department of Surgical Sciences, Urology Unit, AOU Città della Salute e della Scienza di Torino, Molinette Hospital, University of Turin, Turin, ITALY,* [3]*Department of Pathology, AOU Città della Salute e della Scienza di Torino, Molinette Hospital, University of Turin, Turin, ITALY.*

EP-0397

DROP-IN robotic SPECT in sentinel lymph node prostate cancer patients

S. Azargoshasb[1], *A. Berrens*[2], *L. J. Slof*[1], *E. M. K. Wit*[2], *P. J van Leeuwen*[2], *H. G. van der Poel*[2], *M. N. van Oosterom*[1], *F. W. B. van Leeuwen*[1];
[1]*Interventional Molecular Imaging Laboratory, Department of Radiology, Leiden University Medical Cent, Leiden, NETHERLANDS,* [2]*Department of Urology, NETHERLANDS Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, NETHERLANDS.*

EP-0398

IMPLEMENTATION OF IODINE-125 (125I) SEEDS MARKING IN NON-PALPABLE MALIGNANT BREAST LESIONS

M. Garcia Aragon, *R. Zambrano Infantino, F. Sebastian Palacid, N. Alvarez Mena, A. Sainz Esteban, M. Alonso Rodríguez, M. Moral Cano, M. Gonzalez Soto, R. Ruano Perez;*
Hospital Universitario Clínico Valladolid, Valladolid, SPAIN.

EP-0399

Minimally invasive radioguided parathyroidectomy: A descriptive report and correlation between variables of interest

M. Sanchez Torrente, *R. Nieto Serrano, A. Martin Garcia, M. Gallego Marquez, J. Venero Chaparro, D. Becerra Garcia;*
Hospital Universitario Clínico San Cecilio, Granada, SPAIN.

EP-0400

Lung nodule radioguided localization results.

M. Guiote Moreno[1], *A. Lopez Cano*[1], *S. Castejón Echevarne*[1], *D. Tercero Garrido*[1], *R. Zurera Pareja*[2], *J. Vallejo Casas*[1];
[1]*Hospital Universitario Reina Sofía, Cordoba, SPAIN,* [2]*IMIBIC, Cordoba, SPAIN.*

EP-0401

Diagnostic Value Of Salivary Gland Scintigraphy In Post-Radiation Xerostomia In Nasopharyngeal Carcinoma Patients: First Tunisian study

H. Rokbani[1], *L. Zaabar*[1,2], *S. Zarraa*[3,2], *L. Kechaou*[3], *M. El bessi*[3], *T. Ben Ghachem*[1,2], *C. Nasr*[4,2], *A. Mhiri*[1,2];
[1]*Nuclear Medicine departement, Salah Azaeiz Institute, tunis, TUNISIA,* [2]*Faculté de Médecine de Tunis, Tunis, TUNISIA,* [3]*Radiotherapy departement, Salah Azaeiz Institute, tunis, TUNISIA,* [4]*Radiotherapy departement, Salah Azaeiz Institute, Tunis, TUNISIA.*

EP-0402

Comparison of Radioactive Seed Localization and Radioguided Occult Lesion Localization in Surgical Success of Nonpalpable Breast Cancer

R. Sahin[1], *M. Baykara Ulusan*[2], *E. S. Ata*[2], *M. B. Cengiz Gökmen*[3], *N. Ergül*[1], *T. Aksoy*[1], *T. F. Çermik*[1], *E. Arslan*[1];
[1]*University of Health Sciences, Istanbul Training and Research Hospital, Department of Nuclear Medicine, Istanbul, TÜRKIYE,* [2]*University of Health Sciences, Istanbul Training and Research Hospital, Department of Radiology, Istanbul, TÜRKIYE,* [3]*University of Health Sciences, Istanbul Training and Research Hospital, Department of Surgery, Istanbul, TÜRKIYE.*

EP-24

e-Poster Area

B: Imaging Clinical Studies -> B3 Other Oncological Clinical Study -> B32 Sentinel Node

EP-0403

SPECT/CT imaging and Sentinel lymphnode biopsy in early breast cancer in 150 patients -KMCH India experience.

K. Kamaleshwaran, *E. Ramkumar;*
Kovai Medical center and Hospital Limited (KMCH), Coimbatore, INDIA.

EP-0404

Unusual lymphatic drainage pathways detected by intradermal lymphoscintigraphy for sentinel lymph node biopsy in breast cancer.

G. Tartaglione[1], *M. Pagan*[1], *F. P. Ieria*[1], *E. Covello*[2], *L. M. Marino Cosentino*[3], *S. Di Filippo*[2], *S. Ghinassi*[3], *R. Marsico*[3], *L. Leone*[3], *M. R. Limiti*[4], *P. L. Bonatti*[2,3];
[1]*Cristo Re Hospital, Nuclear Medicine, Rome, ITALY,* [2]*Santo Spirito Hospital, Breast Unit ASL Roma 1, Rome, ITALY,* [3]*San Filippo Neri Hospital, Breast Unit ASL Roma 1, Rome, ITALY,* [4]*Santo Spirito Hospital, Pathology, Breast Unit ASL Roma 1, Rome, ITALY.*

EP-0405

Sentinel lymph node biopsy and axillary marking after neoadjuvant treatment in node-positive breast cancer patients

P. Guardia Jimena, *A. Santos Bueno, Á. Rebollo Aguirre, E. Sánchez de Mora, A. Jiménez Heffernan;*
Hospital Universitario Juan Ramón Jiménez, Huelva, SPAIN.

EP-0406

Local anaesthetic improves patient experience of breast and melanoma lymphoscintigraphy

K. Jewell, *G. Kong, B. Emmerson, T. Akhurst, K. Moodie;*
Peter MacCallum Cancer Centre, Melbourne, AUSTRALIA.

EP-0407

Detection rates of sentinel lymph node biopsy (SLNB) in gynecological cancer. Our experience.

C. Ruiz Corbalán, *A. De Agrela Serrao, A. Leiva Montejo, D. Cáceres Silva, M. Castellón Sanchez, L. Frutos Esteban, J. Navarro Fernadez, T. Rodriguez Locarno, A. Hernandez Martinez, L. Mohamed Salem, J. Contreras Gutierrez;*
ARRIXACA, Murcia, SPAIN.

EP-0408

Radiation-free bimodal sentinel node procedure combining fluorescence and magnetic guidance and pre-operative resonance imaging in prostate cancer - A first in-human study

B. Michalik[1], *S. Engels*[1], *M. C. Otterbach*[2], *M. N. van Oosterom*[3], *M. Maurer*[2], *F. Wawroschek*[1], *A. Winter*[1];
[1]*University Hospital for Urology, Klinikum Oldenburg, Carl von Ossietzky University Oldenburg, Oldenburg, GERMANY,* [2]*University Institute for Diagnostic and Interventional Radiology, Klinikum Oldenburg, Carl von Ossietzky University Oldenburg, Oldenburg, GERMANY,* [3]*Interventional Molecular Imaging Laboratory, Department of Radiology, Leiden University Medical Center, Leiden, NETHERLANDS.*

EP-0409

Validation of sentinel node biopsy in head and neck tumors at one single center. Our experience.

D. Rivas-Navas, *J. Fernández-Fernández, E. Triviño-Ibáñez, C. Ramos-Font, R. Sánchez-Sánchez;*
Hospital Universitario Virgen de las Nieves, Granada, SPAIN.

EP-0410

Nodal staging in patients with penile cancer. Correlation between [18F]FDG-PET/CT and sentinel node biopsy.

A. Piñeiro Donis, *J. Fernández Fernández, E. Triviño Ibáñez, C. Ramos Font, R. Sánchez Sánchez;*
Hospital Universitario Virgen de las Nieves, Granada, SPAIN.

EP-0411

Investigation into the frequency of systemic tracer uptake when performing sentinel lymph node examinations

A. Carradus[1,2], *M. Bradnam*[1,3], *J. Foster*[1,3], *A. Bolster*[1,2,3];
[1]*Department of Clinical Physics and Bioengineering, NHS Greater Glasgow and Clyde, Glasgow, UNITED KINGDOM,* [2]*Nuclear Medicine, North East Sector Glasgow, NHS Greater Glasgow and Clyde, Glasgow, UNITED KINGDOM,* [3]*College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UNITED KINGDOM.*

EP-0412

Single Institution Study of Sentinel Lymph Node Detection in Cervical Cancer: Validating an Alternative to Pelvic Lymphadenectomy

D. Rombo[1], *D. Fraga*[1], *M. Bernardino*[2], *I. Vitorino*[1], *E. Sousa*[1], *J. Aço*[1], *I. P. Carvalho*[1], *R. Sousa*[1], *A. F. Jorge*[2], *L. Salgado*[1];
[1]*Serviço de Medicina Nuclear, Instituto Português de Oncologia de Lisboa Francisco Gentil E.P.E., Lisboa, PORTUGAL,* [2]*Serviço de Ginecologia, Instituto Português de Oncologia de Lisboa Francisco Gentil E.P.E., Lisboa, PORTUGAL.*

EP-0413

Prospective evaluation of SPECT/CT & intra-operative Gamma probe techniques for identification of sentinel lymph node (SLN) in early stage oral cancer

M. L Narayan[1], *P. Kaul*[2], *P. Singh*[3], *T. Singhal*[3], *M. Negi*[1], *P. K. Garg*[2];
[1]*All India Institute of Medical Sciences (A.I.I.M.S), Rishikesh,India, INDIA,* [2]*SGRR Institute of Medical Sciences and SMI Hospital, Dehradun, Uttarakhand, India, INDIA,* [3]*All India Institute of Medical Sciences (A.I.I.M.S), Bhubneshwar , Orissa, INDIA.*

EP-0414

DROP-INradioguidanceduring robotic sentinel nodeprocedures in bladder cancer

D. Rietbergen[1], *M. N. van Oosterom*[1], *E. van Gennep*[1], *B. van Rhijn*[2], *H. G. van der Poel*[2], *F. W. B. van Leeuwen*[1];
[1]*Leids Universitair Medisch Centrum (LUMC), Leiden, NETHERLANDS,* [2]*NKI, Amsterdam, NETHERLANDS.*

EP-0415

Lymphoscintigraphy patterns in recurrent breast cancer. Can they predict the outcome?

B. Pereira, *P. Soeiro, A. Fernandes, A. Oliveira;*
Centro Hospitalar Universitário de São João, Porto, PORTUGAL.

EP-0416

Lymphoscintigraphy in Breast Cancer. Is there a difference in primary versus recurrent disease?

B. Pereira, *P. Soeiro, P. Dias, A. Oliveira, A. Fernandes;*
Centro Hospitalar Universitário de São João, Porto, PORTUGAL.

EP-0417

Concordance between portable SPECT and conventional scintigraphy for detection of sentinel node in breast cancer

J. Orozco Cortés[1], *Á. Esteban Hurtado*[2], *C. Siscar Gelo*[2], *M. Navas de la Cruz*[2], *L. Casas Calabuig*[2], *Á. Badenes Romero*[3], *T. Mut Dolera*[2], *D. Reyes Ojeda*[1], *D. Balaguer Muñoz*[2], *P. Abreu Sánchez*[2], *P. Carcamo Ibarra*[1], *C. Plancha Mansanet*[2], *E. Caballero Calabuig*[2];
[1]*Hospital Clínico Universitario de Valencia, Valencia, SPAIN,* [2]*Hospital Universitario Doctor Peset Valencia, Valencia, SPAIN,* [3]*Hospital Universitario Joan XXIII Tarragona, Tarragona, SPAIN.*

EP-0418

Is SPECT/CT useful in selective sentinel lymph node biopsy in melanoma in all primary lesion location?

P. Zaragoza Ballester, *X. T. Guarnizo Poma, S. Angiolillo Grau, D. Vega Pérez, P. Sarandeses Fernández, Á. Galiana Morón, A. Saviatto Nardi, E. Martínez Albero, S. Ruiz Solís, M. Marín Ferrer, V. Godino Gulloteu, A. Gómez Grande, M. Tabuenca Mateo;*
Hospital Universitario 12 De Octubre, Madrid, SPAIN.

EP-0419

Selective sentinel lymph node biopsy (SLNB) in early stages oral cavity cancer: a single center study

A. De Agrela Serrao, *C. Ruiz Corbalan, A. M. Leiva Montejo, J. L. Navarro Fernández, M. Castellón Sanchez, T. E. Rodríguez Locarno, L. Frutos Esteban, A. C. Hernández Martínez, L. Mohamed Salem, D. R. Cáceres Silva, J. F. Contreras Gutierrez;*
Hospital Clinico Universitario Virgen de Arrixaca, Murcia, SPAIN.

EP-0420
Sentinel Lymph Node Mapping For Endometrial Cancer: Results of the First Tunisian, Arab and African study.
L. Zaabar[1,2], *H. Bouaziz*[3,2], *S. Sghaier*[4], *G. Sahraoui*[5,2], *M. Slimane*[4,2], *M. Hechiche*[4,2], *K. Mrad*[5,2], *K. Rahal*[4,2], *A. Mhiri*[1,2];
[1]*Salah Azaeiz Institute, Nuclear Medicine departement, Tunis, TUNISIA,* [2]*Faculté de Médecine de Tunis, Tunis, TUNISIA,* [3]*Salah Azaeiz Institute,Surgical Department of Oncology, Tunis, TUNISIA,* [4]*Salah Azaeiz Institute, Surgical Department of Oncology, Tunis, TUNISIA,* [5]*Salah Azaeiz Institute, Pathological Anatomy Department, Tunis, TUNISIA.*

EP-0421
Performance of99mTc-albumin nanocolloid and indocyanine green as tracers in sentinel lymph node detection in cervical and endometrial cancer.
M. Grajeda Gallardo, *A. Prieto Soriano, P. Meneses Soares, K. Velasquez Díaz, I. Garrido Solesio, L. Santamaria Chico, I. Obedkova, S. Guzmán Ortiz, M. Mitjavila Casanovas;
Hospital Universitario Puerta de Hierro, Madrid, SPAIN.*

EP-25

e-Poster Area

B: Imaging Clinical Studies -> B4 Cardiovascular Imaging Clinical Study -> B41 Perfusion

EP-0422
C-reactive protein and myocardial perfusion imaging
C. Sioka, *A. Kekiopoulou, P. Kekiopoulos, A. Bechlioulis, A. Rammos, A. Papadopoulos, J. Al-Boucharali, S. Tsiouris, X. Xourgia, D. Dristiliaris, C. Katsouras;
University Hospital of Ioannina, Ioannina, GREECE.*

EP-0423
Atrial fibrillation is an independent predictor of the extent and severity of myocardial ischemia in myocardial perfusion imaging
C. Sioka, *A. Bechlioulis, P. Zotou, S. Alexiou, A. Kekiopoulou, E. Gkika, P. Kekiopoulos, D. Dristiliaris, A. Rammos, L. Lakkas, K. Naka, L. Michalis, C. Katsouras;
University Hospital of Ioannina, Ioannina, GREECE.*

EP-0424
How did the COVID-19 pandemic affect SPECT myocardial perfusion scans? A single center experience
A. Aghaee, *s. ataei nakhaei, e. askari, h. mohammadzadeh, h. roustaee, f. karamian;
nuclear medicine research center,Mashhad university of Medical Sciences, Mashhad, IRAN, ISLAMIC REPUBLIC OF.*

EP-0425
Stress Myocardial Perfusion Imaging (MPI) for Predicting Major Cardiac Events in Diabetic Women and Men
N. Fatima[1,2], *S. Zaman*[3], *A. Zaman*[4], *J. Bano*[2], *M. u. Zaman*[5,2];
[1]*Dept of Radiology Aga Khan University, Karachi, PAKISTAN,* [2]*Dept of Nuclear Cardiology, Karachi Institute of Heart Diseases (KIHD), Karachi, PAKISTAN,* [3]*Dr Ruth Pfau (CHK), Karachi, PAKISTAN,* [4]*Dept of Medicine, Sunny Downstate Medical Centre, New York, NY, UNITED STATES OF AMERICA,* [5]*Dept of Radiology Aga Khan University, KARACHI, PAKISTAN.*

EP-0426
Prognostic Value of Rest SPECT MPI Derived Left Ventricular Shape Indexes in Patients with Prediabetes
Y. Hu, *Y. Zhao, R. Wang, L. Yang, Y. Li, Y. Wang, X. Diao, S. Li;
Department of Nuclear Medicine, First Hospital of Shanxi Medical University, Taiyuan, CHINA.*

EP-0427
The Correlation Study between MPI and CAG in Risk Stratification of CAD Patients with Different Uric Acid Levels
Y. Chen[1], *X. Liu*[1], *X. Li*[1], *M. Cai*[2], *S. Li*[3];
[1]*Shanxi Medical University, Tai Yuan, CHINA,* [2]*Shanxi provincial People's Hospital & Fifth Clinical College of Shanxi Medical University Medicine, Tai Yuan, CHINA,* [3]*The first hospital of Shanxi Medical University, Tai Yuan, CHINA.*

EP-0428
Prognostic Value of Gated SPECT MPI Varied by Atherosclerotic Cardivascular Disease Risk: A Retrospective Study
Y. Li, *Y. Zhao, R. Wang, Y. Hu, Y. Wang, X. Diao, J. Zhang, S. Li;
First Hospital of Shanxi Medical University, Taiyuan, CHINA.*

EP-0429
Improving multi-pinhole cadmium zinc telluride myocardial perfusion imaging specificity without changing sensibility by using adapted prefilter parameters
F. Vauchot, *A. Bourdon, M. Benkiran, J. Dubois;
CHU Gui de Chauliac, Montpellier, FRANCE.*

EP-0430
Spherization Indexes by Rest SPECT Improves Risk Stratification in Patients with Non-obstructive Coronary Artery Disease
Y. Zhao, *Y. Hu, P. Wu, Y. Li, S. Li;
Department of Nuclear Medicine, First Hospital of Shanxi Medical University, Taiyuan, CHINA.*

EP-0431
Long-term Outcome of Patients after Radionuclide Myocardial Perfusion Imaging
J. Huang[1], *K. Chien*[2], *Y. Wu*[3];
[1]*Department of Nuclear Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, TAIWAN,* [2]*Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, TAIWAN,* [3]*Division of Cardiology, Cardiovascular Medical Center, Far Eastern Memorial Hospital, New Taipei City, TAIWAN.*

EP-0432
Comparison of Myocardial Perfusion Imaging Studies of Patients with Confirmed Coronary Artery Disease Performed on Traditional SPECT Gamma Camera and Dedicated Semiconductor Cardiac Gamma Camera
P. Cichocki[1], *M. Blaszczyk*[1], *A. Aulich*[1], *Z. Adamczewski*[1], *A. Plachcinska*[2];
[1]*Nuclear Medicine Department, Medical University of Lodz, Lodz, POLAND,* [2]*Department of Quality Control and Radiological Protection of the Medical University of Lodz, Lodz, POLAND.*

EP-0433
Coronary Reserve assessement by means of routine standard perfusion SPECT (no first-pass): easy method to evaluate macro-angiopathy and microvascular lesions.
L. Philippe, *C. Prunier-Aesch, Y. El Yaagoubi;
Medecine Nucleaire Tourangelle, Chambray-les-Tours, FRANCE.*

EP-0434
Clinical value of Tc-99m MIBI Myocardial Gated SPECT in children and adolescents presenting with exercise related chest pain
A. Alakbarli[1], *M. A. Karacan*[1], *Y. Ozananar Sevinc*[2], *Y. Ceylan*[3], *A. M. Argon*[1], *Z. Ozcan*[1];
[1]*Ege University Hospital Nuclear Medicine, Izmir, TÜRKIYE,* [2]*Bakircay University Cigli Regional Education Hospital, Izmir, TÜRKIYE,* [3]*Usak University Hospital, Usak, TÜRKIYE.*

EP-0435
Long-term prognostic value of semi-quantitative myocardial perfusion imaging in patients with homozygous familial hypercholesterolemia
J. Jiao, *W. Dong, T. Mou, H. Mi, Y. Zhang;
Department of Nuclear Medicine, Beijing Anzhen Hospital, Capital Medical University, Beijing, CHINA.*

EP-0436
The relationships between apolipoproteins and myocardial blood flow in patients with non-obstructive coronary artery disease
K. Zavadovsky, *A. Maltseva, K. Kopeva, A. Mochula, O. Trubacheva, E. Grakova;
Cardiology Research Institute, branch of the Federal State Budgetary Scientific Institution «Tomsk National Research Medical Center of the Russian Academy of Sciences», Tomsk, RUSSIAN FEDERATION.*

EP-0437
Predictive Factors of Myocardial Perfusion SPECT Positivity using a CZT D SPECT Camera in 3594 Patients Referred For Myocardial Perfusion Imaging In one year.
M. Esnault[1], *D. Legallois*[2], *P. Richard*[3], *D. Agostini*[2], *M. Alain*[2];
[1]*Caen University, Caen, FRANCE,* [2]*Caen University Hospital, Caen, FRANCE,* [3]*Hospital privé Saint Martin, Caen, FRANCE.*

EP-0438
Shorten Acquisition of Dynamic 11C-Acetate Cardiac PET/CT in Quantifying Pharmacokinetic Parameters
T. Gong[1], *F. Shang*[1], *X. Tang*[1], *L. Huo*[2], *S. Liu*[1];
[1]*School of Life Science, Beijing Institute of Technology, Beijing, CHINA,* [2]*Department of Nuclear Medicine, Peking Union Medical College Hospital, Beijing, CHINA.*

EP-0439
Evaluation and related influencing factors of left ventricular systolic dyssynchrony after PCI in patients with acute myocardial infarction by gated myocardial perfusion imaging
J. Wang[1,2], *Y. Wang*[1,2];
[1]*The Third Affiliated Hospital of Soochow University, Changzhou, CHINA,* [2]*Institute of Clinical Translation of Nuclear Medicine and Molecular Imaging, Soochow University, Changzhou, CHINA.*

EP-0440
The Characteristics of Perfusion in Cardiac SPECT/CT of Suspected INOCA and Obstructive Coronary Artery Disease Patients.
M. Kalnina[1,2], *B. Vitola*[3,4], *J. Kedrova*[1], *I. Mintale*[3,5], *A. Erglis*[3,2];
[1]*Department of Radiology, Pauls Stradins Clinical University Hospital, Riga, LATVIA,* [2]*Faculty of Medicine, University of Latvia, Riga, LATVIA,* [3]*Latvian Centre of Cardiology, Pauls Stradins Clinical University Hospital, Riga, LATVIA,* [4]*Faculty of Medicine, Riga Stradins University, Riga, LATVIA,* [5]*University of Latvia, Faculty of Medicine, Riga, LATVIA.*

EP-0441
Comparison of Ejection Fraction Measurements with Novel Multi-pinhole Collimator on Triple-NaI-Detector SPECT and Conventional Dual-NaI-Detector Parallel-hole Collimator Technique
Á. Krizsán[1], *K. Kukuts*[1], *L. Balazs*[2], *J. Kiss*[3], *M. Alamin*[1], *V. Linczerne Bencze*[1], *S. Barna*[1], *I. Garai*[1], *J. Mester*[4], *A. Forgacs*[1];
[1]*ScanoMed Nuclear Medicine Centers, Debrecen, HUNGARY,* [2]*Mediso Ltd., Budapest, HUNGARY,* [3]*Medical Imaging Clinic Radiology, Clinical Center, University of Debrecen, Debrecen, HUNGARY,* [4]Universitäsklinikum *Hamburg-Eppendorf, Hamburg, GERMANY.*

EP-0442
Prognostic Value of Myocardial Blood Flow and Coronary Flow Reserve on Dynamic Myocardial SPECT
M. Havel, *M. Kaminek, A. Klegova, L. Quinn, L. Henzlova, P. Koranda, V. Icova, G. Havlova;
Department of Nuclear Medicine, University Hospital and Faculty of Medicine and Dentistry Palacký University, Olomouc, CZECH REPUBLIC.*

EP-0443
Role of Myocardial Scintigraphy in Evaluating Patients in the Emergency Department
I. Gotuzzo[1], *P. Ferro*[1], *R. Boni*[1], *P. Vai*[1], *R. H. J. A. Slart*[2], *P. A. Erba*[3];
[1]*Nuclear Medicine Department ASST Ospedale Papa Giovanni XXIII, Bergamo, ITALY,* [2]*Medical Imaging Center, University Medical Center Groningen, Groningen, NETHERLANDS,* [3]*Department of Medicine and Surgery, University of Milan Bicocca and Nuclear Medicine Department ASST Ospedale Papa Giovanni XXIII Bergamo, Bergamo, ITALY.*

EP-0444
myocardial injury Assessment of SPECT MPI in fulminant and suspected myocarditis compared with CMR
J. Cui, *S. Wang, Y. Ge;
Henan Provincial People's Hospital Heart Center, Zhengzhou, CHINA.*

EP-0445
Psychology of attendants/caregivers during the myocardial perfusion imaging of patients
C. Sioka, *A. Bechlioulis, P. Giantsouli, Z. Panagiotou, S. Alexiou, P. Kekiopoulos, A. Kekiopoulou, A. Papadopoulos, L. Astrakas, P. Zotou, J. Zika, A. Arseniou, K. Pappas, C. Katsouras, P. Petrikis;
University Hospital of Ioannina, Ioannina, GREECE.*

EP-0446
The effect of Attenuation correction on myocardial blood flow and reserve measured by dynamic SPECT
A. Mochula, *A. Maltseva, A. Cygikalo, O. Mochula, K. Zavadovsky;*
Cardiology Research Institute, Tomsk NRMC, Tomsk, RUSSIAN FEDERATION.

EP-0447
Transient ischemic dilatation and heart rate at stress and rest: Searching for a threshold of significance in patients with normal perfusion.
A. Alomar, *A. Camarero, I. Blanco, N. Rudic, I. Saura, J. Cruz, A. Barrera, M. Ribelles, E. Goñi;*
Hospital Universitario de Navarra (HUN), Pamplona, SPAIN.

EP-0448
The prognostic value of complex CMR and dynamic SPECT assessment in patient with acute myocardial infarction
A. Mochula, *O. Mochula, E. Nalesnik, A. Maltseva, A. Sulejmanova, V. Ryabov, K. Zavadovsky;*
Cardiology Research Institute, Tomsk NRMC, Tomsk, RUSSIAN FEDERATION.

EP-0449
Attenuation correction in SPECT-Myocardial perfusion imaging:It can be corrected, but is it really useful?
S. Abhilash, *S. Jeevan, P. Pradeep, S. Sarath, L. N. Manishi;*
All India Institute of Medical Sciences, Rishikesh, INDIA.

EP-26

e-Poster Area

B: Imaging Clinical Studies -> B4 Cardiovascular Imaging Clinical Study -> B42 Metabolism and Innervation

EP-0450
Automated absolute quantitation of cardiac sympathetic activity using convolutional neural network and 123I-MIBG SPECT/CT
S. Saito[1], *K. Nakajima*[2], *L. Edenbrandt*[3,4], *M. Larsson*[5], *O. Enqvist*[5], *J. Ulén*[5], *S. Kinuya*[1];
[1]Department of Nuclear Medicine, Kanazawa University, Kanazawa, JAPAN, [2]Department of Functional Imaging and Artificial Intelligence, Kanazawa University, Kanazawa, JAPAN, [3]Sahlgrenska University Hospital, Gothenburg, SWEDEN, [4]University of Gothenburg, Gothenburg, SWEDEN, [5]Eigenvision, Malmö, SWEDEN.

EP-0451
Long-term cardiac risk in recovered Covid-19 patients evaluated by 123I-mIBG
A. Liebich[1], *G. Sheikh*[2], *B. Nittbaur*[1], *R. A. Bundschuh*[1], *M. Kircher*[1], *A. Dierks*[1], *P. Raake*[3], *M. Rieger*[3], *T. Higuchi*[4], *C. Lapa*[1], *C. H. Pfob*[1];
[1]Nuclear Medicine, Faculty of Medicine, University of Augsburg, Augsburg, GERMANY, [2]Department of Nuclear Medicine, LMU Munich, Munich, GERMANY, [3]Cardiology, Faculty of Medicine, University of Augsburg, Augsburg, GERMANY, [4]Department of Nuclear Medicine, University Hospital Wuerzburg, Wuerzburg, GERMANY.

EP-0452
The characteristic myocardial accumulation pattern in oncologic FDGPET/CT under long-term fasting is likely indicative of ischemic lesions
Y. Yashima[1], *K. Takanami*[2], *K. Kiso*[2], *A. Masuda*[2], *M. Saito*[2], *Y. Toyama*[2], *Y. Maekawa*[2], *K. Takase*[2], *Y. Taniyama*[1], *T. Kamei*[1];
[1]Department of Surgery,Tohoku University Hospital, 1-1, Seiryo-cho, Aoba-Ku,Sendai, Miyagi, JAPAN, [2]Department of Diagnostic Radiology,Tohoku University Hospital, 1-1, Seiryo-cho, Aoba-Ku,Sendai, Miyagi, JAPAN.

EP-0453
Combined Assessment of PET and CMR for Decision Making in patients with Coronary Artery Disease
X. Han, *L. Wang, S. Song, W. Fang;*
Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, CHINA.

EP-0454
Comparing the heart-to-mediastinum ratio of 123I-mIBG myocardial scintigraphy between a 2D image and a pseudo planar image converted from a 3D image acquired with a conventional and a ring CZT gamma camera
J. Hagerman[1], *D. Minarik*[2], *R. Smith*[3,4], *E. Stormrud*[3,4], *S. Hall*[3,4], *A. Nahimi*[3,4], *O. Hansson*[3,4], *F. Hedeer*[1,5];
[1]Clinical Physiology and Nuclear Medicine, Skåne University Hospital, Lund/Malmö, SWEDEN, [2]Radiation Physics, Skåne University Hospital, Lund/Malmö, SWEDEN, [3]Clinical Memory Research Unit, Lund University, Malmö, SWEDEN, [4]Memory Clinic, Skåne University Hospital, Malmö, SWEDEN, [5]Clinical Physiology and Nuclear Medicine, Department of Clinical Sciences, Lund University, Lund, SWEDEN.

EP-0455
Prognostic Role of 123i-Mibg Cardiac Scintigraphy in Patients With Cardiac Transthyretin Amyloidosis (Attr)
F. Sebastián Palacid, *B. Pérez López, R. Zambrano Infantino, M. García Aragón, N. Álvarez Mena, M. Alonso Rodríguez, J. Gómez Hidalgo, C. Gamazo Laherrán, R. Ruano Pérez;*
Hospital Clínico Universitario Valladolid, Valladolid, SPAIN.

EP-27

e-Poster Area

B: Imaging Clinical Studies -> B4 Cardiovascular Imaging Clinical Study -> B43 Heart Failure (including Sarcoidosis and Amyloidosis)

EP-0456
The proportion of hibernating myocardium in total perfusion defect predicts the reversal of ventricular remodeling and clinical outcomes in patients with HFrEF after CABG
Y. Lu, *X. Zhang;*
Department of Nuclear Medicine, Beijing Anzhen Hospital, Capital Medical University, Beijing, CHINA.

EP-0457
Dynamic SPECT in heart failure with preserved ejection fraction: tips and tricks
K. Kopeva, *A. Maltseva, A. Mochula, V. Shipulin, A. Gusakova, E. Grakova, K. Zavadovsky;*
Cardiology Research Institute, branch of the Federal State Budgetary Scientific Institution «Tomsk National Research Medical Center of the Russian Academy of Sciences», Tomsk, RUSSIAN FEDERATION.

EP-0458
Left ventricle myocardial remodeling and coronary flow reserve in heart failure patients with non-obstructive coronary artery disease
K. Kopeva, *A. Maltseva, A. Smogon, A. Mochula, V. Shipulin, K. Zavadovsky;*
Cardiology Research Institute, branch of the Federal State Budgetary Scientific Institution «Tomsk National Research Medical Center of the Russian Academy of Sciences», Tomsk, RUSSIAN FEDERATION.

EP-0459
Diagnostic Value of Semi-Quantitative Parameters Obtained from [99mTc]Tc-PYP Bone Scintigraphy and SPECT/CT in Cardiac Amyloidosis
K. Kucuker, *A. Aksu, B. Turgut;*
Izmir Katip Celebi University, Ataturk Training and Research Hospital, Nuclear Medicine Department, Izmir, TÜRKIYE.

EP-0460
Prognostic value of right ventricular involvement in Transthyretin Cardiac amyloidosis: a quantitative 99mTc-DPD SPECT/CT study
M. Zhao[1], *R. Calabretta*[2], *P. Binder*[2], *J. Yu*[2], *Z. Jiang*[2], *M. Hacker*[2], *X. Li*[2];
[1]The Thrid Xiangya Hospital of Central South University, Changsha, CHINA, [2]Division of Nuclear Medicine, Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, AUSTRIA.

EP-0461
Evaluation of left ventricular contractile function in patients with large perfusion defects: is gated MPI applicable?
V. Shipulin, *S. Andreev, T. Shelkovnikova, V. M. Shipulin, A. Maslova, K. Zavadovsky;*
Cardiology Research Institute, branch of the Federal State Budgetary Scientific Institution «Tomsk National Research Medical Center of the Russian Academy of Sciences», Tomsk, RUSSIAN FEDERATION.

EP-0462
Prediction value of left ventricular mechanical dyssynchrony indicators associated with super response to cardiac resynchronization therapy
T. Atabekov, *A. Mishkina, R. Batalov, S. Sazonova, S. Krivolapov, V. Saushkin, M. Khlynin, Y. Varlamova, K. Zavadovsky, S. Popov;*
Cardiology Research Institute, branch of the Federal State Budgetary Scientific Institution "Tomsk National Research Medical Center of the Russian Academy of Sciences", Tomsk, RUSSIAN FEDERATION.

EP-0463
Potential utility of SPECT/CT with 99mTc-Tektrotyd for imaging of post myocardial infarction inflammation
J. Ilyushenkova, *S. Sazonova, A. Syrkina, A. Trusov, O. Mochula, A. Mishkina, V. Ryabov;*
RI Cardiology, Tomsk, RUSSIAN FEDERATION.

EP-0464
99mTc-PYP Quantification Through SPECT/CT-Based Parameters in the Assessment of Cardiac Transthyretin Amyloidosis: Feasibility and Correlation with Semiquantitative Planar Indices
A. Lazar[1], *M. Mutuleanu*[1,2], *A. Jercan*[3], *S. Badelita*[3], *D. Coriu*[3,2], *M. Gherghe*[1,2];
[1]Institute of Oncology "Professor Doctor Alexandru Trestioreanu", Bucharest, ROMANIA, [2]University of Medicine and Pharmacy "Carol Davila", Bucharest, ROMANIA, [3]Fundeni Clinical Institute, Bucharest, ROMANIA.

EP-0465
Utility of SPECT/CT in 99mTc-PYP scan in patients with suspected ATTR cardiac amyloidosis
B. Bardessi, *P. Canales, J. Quintana, I. Díaz, C. Waeger, F. Aguila, A. Hiplan, D. Jordan, N. Covarrubias, R. Jaimovich, K. Colorado;*
Pontificia Universidad Catolica de Chile, Santiago de Chile, CHILE.

EP-0466
Potential of glucose metabolic rate obtained from dynamic18F-FDG PET/CT scan in differentiating cardiac sarcoidosis from physiological accumulation
M. Nagao[1], *Y. Shirai*[1], *A. Yamamoto*[1], *K. Kaneko*[1], *A. Sakai*[1], *N. Komura*[2], *S. Sakai*[1];
[1]Tokyo Women's Medical University, Tokyo, JAPAN, [2]Siemens Health Care, Tokyo, JAPAN.

EP-0467
Relationship between the distribution of diphosphonate uptake and changes in cardiac MRI in patients with transthyretin cardiac amyloidosis
L. Santamaría-Chico, *K. Velásquez-Díaz, M. Mitjavila-Casanovas, P. Soares-Meneses, I. Obedkova, M. Grajeda-Gallardo, I. Garrido-Solesio, M. Pastrana-Ledesma, F. de Haro-del Moral;*
Hospital Universitario Puerta de Hierro, Madrid, SPAIN.

EP-0468
Using reprojected planar images from 99mTc-labelled diphosphonate scintigraphy for visual scoring of transthyretin amyloidosis: validating a novel ring-configured cadmium zinc telluride gamma camera
I. Ceric Andelius[1,2], *D. Minarik*[1,2], *R. Fridriksdóttir*[3], *F. Hedeer*[3,4], *A. Stenvall*[1,4], *E. Trägårdh*[2,3], *J. Oddstig*[1,2];
[1]Radiation Physics, Skånes University Hospital, Lund/Malmö, SWEDEN, [2]Department of Translational Medicine and Wallenberg Centre of Molecular Medicine, Lund University, Malmö, SWEDEN, [3]Department of Clinical Physiology and Nuclear Medicine, Lund/Malmö, SWEDEN, [4]Department of Clinical Sciences, Lund University, Lund, SWEDEN.

EP-0469
Different extracardiac uptake, evidenced on 99mTc-HDP scintigraphy, in various types of cardiac amyloidosis
M. Starace[1], *F. Cappelli*[2], *F. Perfetto*[3], *E. Costanzo*[4], *R. Sciagrà*[5], *V. Berti*[1];
[1]*Nuclear Medicine Unit, Department of Experimental and Clinical Biomedical Sciences "Mario Serio", University of Florence, 50134 Florence, Italy., florence, ITALY,* [2]*Tuscan Regional Amyloid Centre, Careggi University Hospital, Florence, Italy, florence, ITALY,* [3]*Tuscan Regional Amyloidosis Centre, Careggi University Hospital, Florence, Italy., florence, ITALY,* [4]*Department of Nuclear Medicine, Azienda Ospedaliero-Universitaria Careggi, Largo Brambilla 3, 50134, Florence, Italy., florence, ITALY,* [5]*Nuclear Medicine Unit, Department of Experimental and Clinical Biomedical Sciences "Mario Serio", University of Florence, 50134 Florence, Italy, florence, ITALY.*

EP-0470
The Relationship of Tc-99m Pyp Scıntıgraphy Parameters wıth Prognosis and Life Expectation ın Cardiac Amiloidosis
Ü. Aksu[1], *E. Akgün*[1], *S. G. Yaran*[1], *M. Ayer*[2], *A. Güler*[3], *G. B. Güler*[3], *A. Türkvatan*[4], *M. Kaya*[1], *B. E. Akkas*[1];
[1]*Başakşehir Çam and Sakura Hospital Clinic of Nuclear Medicine, Istanbul, TÜRKIYE,* [2]*Başakşehir Çam and Sakura Hospital Clinic of Hematology, Istanbul, TÜRKIYE,* [3]*Mehmet Akif Ersoy Thoracic and Cardiovascular Surgery Hospital Clinic of Cardiology, Istanbul, TÜRKIYE,* [4]*Mehmet Akif Ersoy Thoracic and Cardiovascular Surgery Hospital Clinic of Radiology, Istanbul, TÜRKIYE.*

EP-0471
Is there any relation between "Red flags" for cardiac amyloidosis, extracardiac uptake and the type of cardiac amyloidosis?
A. Roteta Unceta Barrenechea[1,2], *F. Asensio Pérez*[3], *G. Martínez Arias*[1], *D. Nogueira Souto*[1], *M. Parra Rina*[1], *T. Escalera Temprado*[1], *Y. Saker Diffalah*[1], *M. Delgado Castro*[1], *G. Guzmán Prudencio*[1], *L. Tardin Cardoso*[1], *P. Razola Alba*[1], *A. Andrés Gracia*[1,2];
[1]*UCMHMNA - Clinic Hospital "Lozano Blesa", Zaragoza, SPAIN,* [2]*IIS-Aragon, Zaragoza, SPAIN,* [3]*Universidad de Zaragoza, Zaragoza, SPAIN.*

EP-0472
Is T-DM1 cardiotoxicity close monitoring relevant in palliative breast cancer patients? A single center experience using equilibrium radionuclide ventriculography (ERNV)
D. Silva, *H. Duarte, P. Leite-Silva, J. F. Ferro, I. Próspero, D. Barbosa, S. F. Castro, G. Ferreira, J. P. Teixeira, I. L. Sampaio; Instituto Português de Oncologia do Porto Francisco Gentil, Porto, PORTUGAL.*

EP-0473
Diagnostic Performance of Cardiac Magnetic Resonance and Cardiac Scintigraphy in patients with clinical suspicion of Transthyretin Cardiac Amyloidosis
M. Pudis[1], *P. C. Notta*[1], *L. Gràcia-Sánchez*[1], *I. E. Sánchez-Rodríguez*[1], *E. Claver-Garrido*[2], *C. Diez-López*[2], *J. González-Costello*[2], *V. Carrero-Vasquez*[1], *C. Martínez-Ramos*[1], *S. Bondia-Bescós*[1], *B. Hervás-Sanz*[1], *J. Diaz-Moreno*[1], *M. Cortés-Romera*[1];
[1]*Nuclear Medicine - PET (IDI), Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, SPAIN,* [2]*Cardiology Department, Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, SPAIN.*

EP-0474
Usefulness of semi-quantitative analysis in cardiac amyloidosis.
J. Venero Chaparro, *M. Gallego Márquez, M. Sánchez Torrente, F. Garí Martínez, D. Guirado Llorente, M. Martínez-Valle Torres;*
Hospital Clínico San Cecilio, Granada, SPAIN.

EP-0475
Ventricular Function Patterns In Ttr Cardiac Amyloidosis: Can We Select Patients For Resynchronization Therapies Using ^{99m}TC-DPD Gspect?
F. Sebastián Palacid, *B. Pérez López, M. García Aragón, R. Zambrano Infantino, N. Álvarez Mena, M. Alonso Rodríguez, J. Gómez Hidalgo, C. Gamazo Laherrán, R. Ruano Pérez;*
Hospital Clínico Universitario Valladolid, Valladolid, SPAIN.

EP-28

e-Poster Area

B: Imaging Clinical Studies -> B4 Cardiovascular Imaging Clinical Study -> B44 Other Cardiovascular Imaging (including Plaque)

EP-0476
The Utility of Right Ventricular Myocardial Strain Ratio Estimated by Ammonia Positron Emission Tomography to Stratify the Risk for Coronary Artery Disease
A. Yamamoto[1], *M. Nagao*[1], *M. Kawakubo*[2], *R. Nakao*[1], *Y. Matsuo*[1], *A. Sakai*[1], *M. Momose*[1], *K. Kaneko*[1], *K. Fukushima*[3], *J. Yamaguchi*[1], *S. Sakai*[1];
[1]*Tokyo Women's Medical University Hospital, Tokyo, JAPAN,* [2]*Kyushu University, Fukuoka, JAPAN,* [3]*Fukushima Medical University, Fukushima, JAPAN.*

EP-0477
The relationships between quantitative CCTA and dynamic CZT SPECT in patients with non-obstructive coronary artery disease
K. Zavadovsky[1], *A. Maltseva*[1], *R. Dorzhieva*[2], *A. Mochula*[1], *K. Kopeva*[1], *E. Grakova*[1];
[1]*Cardiology Research Institute, branch of the Federal State Budgetary Scientific Institution «Tomsk National Research Medical Center of the Russian Academy of Sciences», Tomsk, RUSSIAN FEDERATION,* [2]*Siberian State Medical University of the Ministry of Health of the Russian Federation, Tomsk, RUSSIAN FEDERATION.*

EP-0478
Prognostic value of coronary artery calcifications (CAC) applying a dedicated ECG-gated CT protocol using a hybrid gamma camera in combination with cardiac SPECT performed with a CZT scanner in patients during primary diagnosis of ischemic heart disease.
M. Chojnowska, *A. Giżewska, A. Mazurek, M. Dziuk;*
Military Institute of Medicine - National Research Institute, Warsaw, POLAND.

EP-0479
Myocardial Extracellular Volume Fraction from Late Iodine Enhancement for Risk Stratification in Non-ischemic Heart Failure
J. Deng, *D. Li*;*
Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, CHINA.

EP-0480
First-pass determination of thoracic aortic blood flow rate
V. Saushkin, *Y. Varlamova, N. Ryumshina, A. Vrublevsky, D. Panfilov, B. Kozlov, S. Sazonova;*
Cardiology Research Institute, Tomsk NRMC, Tomsk, RUSSIAN FEDERATION.

EP-0481
Unusual discovery of a lipomatous hypertrophy of interatrial septum causing hot spot on 18 fluorodeoxyglucose positron emission tomography: a case report
T. Ben Ghachem, *M. Somai, I. Yeddes, I. Slim, A. Mhiri;*
Salah Azaiez Institute, Tunis, TUNISIA.

EP-29

e-Poster Area

B: Imaging Clinical Studies -> B5 Neurological Imaging Clinical Study -> B51 Neurodegeneration

EP-0482
Neuroimagen. Enfoque multimodal para la evaluación de pacientes con enfermedad de Alzheimer leve y terapia neuroprotectora.
Y. Peña Quián[1], *L. Pérez*[2], *J. Batista*[1], *L. Torres*[1], *L. Rodríguez*[3], *T. Rodríguez*[2];
[1]*Centro de Isotopos, La Habana, CUBA,* [2]*Center for Molecular Immunology., La Habana, CUBA,* [3]*Hermanos Ameijeiras Hospital, La Habana, CUBA.*

EP-30

e-Poster Area

B: Imaging Clinical Studies -> B6 Endocrinological Imaging Clinical Study -> B61 Endocrinology (including Thyroid Benign)

EP-0483
Screening of risk factors influencing the responsiveness of lung metastatic forci of differentiated thyroid cancer under 131I radiotherapies
W. Muyu[1], *X. Liu*[2], *C. Liu*[3], *S. Qin*[4], *X. Lin*[1], *W. Shi*[5], *Q. Ding*[3], *X. Zhang*[3], *P. Li*[1];
[1]*Department of Nuclear Medicine, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, CHINA,* [2]*Department of General Surgery, Xinqiao Hospital, Army Medical University, Chongqing, CHINA,* [3]*School of Mathematical Sciences, Shanghai Jiao Tong University, Shanghai, CHINA,* [4]*Department of Nuclear Medicine, Shanghai Tenth People's Hospital, Tongji University School of MedicineUniversity, Shanghai, CHINA,* [5]*Department of Nuclear Medicine, Tianjin Medical University General Hospital, Shanghai, CHINA.*

EP-0484
An exploratory study on pathologic molecular characteristics of sestamibi single positron emission computed tomography/computed tomography in predicting primary hyperparathyroidism
J. Yang, *X. Su, J. Zhang, W. Weng, P. Zhou;*
the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, CHINA.

EP-0485
Graves' disease: do TRAb measurement help predicting thyroid radioiodine uptake?
I. Casimiro, *G. Costa, R. Silva;*
Centro Hospitalar e Universitário de Coimbra, Coimbra, PORTUGAL.

EP-0486
Does the hypothalamus-pituitary-adrenal axis play a role in the difference in treatment response to GLP-1 receptor agonists in type 2 diabetes?
S. Tokgöz[1], *T. J. P. Jansen*[1], *R. Meijer*[2], *C. Frielink*[1], *C. J. Tack*[2], *B. E. de Galan*[2,3], *M. Gotthardt*[1], *M. Boss*[1];
[1]*Department of Medical Imaging, Radboud University Medical Center, Nijmegen, NETHERLANDS,* [2]*Department of Internal Medicine, Radboud University Medical Center, Nijmegen, NETHERLANDS,* [3]*Department of Internal Medicine, Maastricht University Medical Center, CARIM School for cardiovascular diseases, Maastricht, NETHERLANDS.*

EP-0487
68Ga-NODAGA-exendin4 PET-CT Imaging of Pancreatic Beta Cells: Preliminary Data in Type 1 Diabetic Patients and in Obese People
L. Ruffini[1], *M. Scarlattei*[1], *G. Ladisa*[1], *S. Migliari*[1], *G. Baldari*[1], *V. Spigoni*[2], *R. Aldigeri*[2], *G. Cinquegrani*[2], *A. Dei Cas*[2], *R. Bonadonna*[2];
[1]*Nuclear Medicine Division, University Hospital of Parma, Parma, ITALY,* [2]*Dept of Medicine & Surgery, University of Parma, Parma, ITALY.*

EP-0488
Role of 68Ga DOTANOC PET/CT In Localisation of Culprit Ectopic ACTH Secreting Tumors
R. Kumar, *S. Sagar, D. Khan, R. Khadgawat;*
All India Institute of Medical Sciences, New Delhi, INDIA.

EP-0489
Short 4D 18F-Fluorocholine PET/CT for hyperparathyroidism: A new tool for hyper-functional parathyroid finding ?
A. CALLAUD[1], *M. Bailly*[2], *G. Metrard*[2];
[1]*CHR, Orléans, FRANCE,* [2]*CHRU Orléans, Orléans, FRANCE.*

EP-0490
Detection of hyperfunctioning parathyroid glands using 18F-choline PET/CT in patients with negative or equivocal results of the complex 99mTcO4/99mTc-MIBI scintigraphy (including SPECT/CT)
P. Koranda[1], *L. Quinn[1], M. Jenčo[1], J. Klacanek[1], M. Halenka[2], M. Mocňáková[3], M. Kamínek[1];*
[1]Dept. of Nuclear Medicine, Univ. Hospital and Palacký University, Olomouc, Olomouc, CZECH REPUBLIC, [2]Dept. of Internal Medicine III, Univ. Hospital and Palacký University, Olomouc, Olomouc, CZECH REPUBLIC, [3]Dept. of Surgery II, Univ. Hospital and Palacký University, Olomouc, Olomouc, CZECH REPUBLIC.

EP-0491
[^{18}F]Fluorocholine PET-CT in Preoperative Localization of Hyperfunctioning Parathyroid Glands: Continuing to Strengthen the Evidence
S. Casanueva Eliceiry[1,2], *N. Sánchez Izquierdo[2,1], A. Niñerola-Baizán[2,1], M. Manyalich-Blasi[1,3], P. Domínguez-Garijo[1,3], M. Mora-Porta[1,3], F. Hanzu[1,3], M. Rodrigo-Calvo[1,4], S. Vidal-Sicart[2,1], O. Vidal-Pérez[1,3], D. Fuster-Pelfort[2,1];*
[1]Hospital Clínic Barcelona, Barcelona, SPAIN, [2]Instituto de diagnótico por la imagen CDI, Barcelona, SPAIN, [3]Instituto Clínic de Enfermedades Digestivas y Metabólicas (ICMDM), Barcelona, SPAIN, [4]Centro de Diagnóstico Biomédico (CDB), Barcelona, SPAIN.

EP-0493
Diagnostic and Prognostic Value of [18F]F-DOPA PET/CT for Medullary Thyroid Cancer
S. Li, *E. Rainer, S. Rasul, L. Hargitai, P. Riss, C. Scheuba, M. Hacker;*
Medical University of Vienna, Vienna, AUSTRIA.

EP-0494
Correlation between SUVmax and analytical values in patients with primary hyperparathyroidism undergoing 18F-choline PET/CT
E. Rodriguez Gallo[1,2], *C. Wakfie Corieh[1,2], A. Fernandez Alfonso[1,2], A. Álvarez Vázquez[1,2], E. Jodar Gimeno[1,2], B. Pérez-Arroyo[1,2], J. Martín Gil[3], A. Maldonado[1,2];*
[1]Hospital Universitario QuironSalud Madrid, Madrid, SPAIN, [2]Universidad Europea, Madrid, SPAIN, [3]Hospital Quirónsalud San José, Madrid, SPAIN.

EP-0495
Impact of digital [18F] Fluorocholine (FCH) PET/CT reconstruction technique on detection rate, reader confidence and agreement in localisation of parathyroid adenomas in persistent/ recurrent primary hyperparathyroidism
M. Naik, *C. Ferguson, S. Lazic, A. Eccles, S. Khan, S. Khan, F. Palazzo, K. Houghton, T. D. Barwick;*
Imperial College Healthcare NHS Trust, London, UNITED KINGDOM.

EP-0496
Utility of 18F-fluorocholine PET/CT in the management of primary hyperparathyroidism: our experience.
M. Sicilia Pozo[1], *V. Poblete García[1], A. Padilla Bermejo[1], C. Lucas Lucas[1], M. Contreras Ameduri[1], L. García Zoghby[2], M. Cruz Montijano[2], F. J. Pena Pardo[1], M. P. Talavera Rubio[1], E. Noriega Álvarez[1], A. M. García Vicente[2], Á. Soriano Castrejón[2];*
[1]Nuclear Medicine Department, University General Hospital of Ciudad Real, Ciudad Real, SPAIN, [2]Nuclear Medicine Department, University General Hospital of Toledo, Toledo, SPAIN.

EP-0497
Role of 18F-DOPA PET/CT imaging in patients with Hyperinsulinemic Hypoglycemia(HI)
S. Sagar, *N. A. Damle, D. Khan, P. Kumar, C. Bal, M. Tripathi, R. Sharma, V. Jain, M. Jana, N. Tandon;*
AIIMS, Delhi, INDIA.

EP-0498
Efficacy of F-18 Fluorocholine PET/CT in detection of culprit lesions in normocalcemic & hypercalcemic primary hyperparathyroidism: Does it differ?
R. Wakankar, *N. A. Damle, Y. Dharmashaktu, A. Khurana, P. Kumar, C. Bal, M. Tripathi, S. Agarwal, N. Tandon, R. Khadgawat;*
AIIMS, New Delhi, INDIA.

EP-0499
Does myocardium and liver fractional uptake of circulating fatty acids change after consuming a meal in people with prediabetes?
J. Fernández Fernández[1], *G. Sánchez-Delgado[2,3,4], S. Hogan-Lamarre[4,5], G. Richard[4], F. Frisch[4], S. Phoenix[4,6], M. Fortin[3,4], L. Bouffard[4], C. Noll[4], W. Mampuya[4], B. Guérin[4,6], É. E. Turcotte[4,6], J. Hoeks[7], P. Schrauwen[7], A. C. Carpentier[3,4], D. P. Blondin[4,8];*
[1]Department of Nuclear Medicine, Virgen de las Nieves University Hospital, Granada, SPAIN, [2]Institute of Nutrition and Food Technology "Jose Mataix" and University Institute of Sports and Health, University of Granada, Granada, SPAIN, [3]Department of Medicine, Division of Endocrinology, Université de Sherbrooke, Sherbrooke, QC, CANADA, [4]Centre de recherche du Centre hospitalier universitaire de Sherbrooke, Sherbrooke, QC, CANADA, [5]Department of Pharmacology-Physiology, Université de Sherbrooke, Sherbrooke, QC, CANADA, [6]Department of Nuclear Medicine and Radiobiology, Université de Sherbrooke, Sherbrooke, QC, CANADA, [7]Department of Nutrition and Movement Sciences, NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University Medical Center, Maastricht, NETHERLANDS, [8]Department of Medicine, Division of Neurology, Université de Sherbrooke, Sherbrooke, QC, CANADA.

EP-0500
Incremental value of Tc-99m-sestamibi SPECT/CT in patients with positive planar scintigraphy in the detection of additional lesions in patients with Secondary/Tertiary hyperparathyroidism
R. Goel, *N. A. Damle, Y. Dharmashaktu, C. Bal, P. Kumar, A. Kumar, Y. Gupta, R. Aphale, G. Puri, S. Chumber;*
All India Institute of Medical Sciences (AIIMS), New Delhi, INDIA.

EP-0501
Predictive value of preoperative 18F-Flurocholine PET/CT in bone mineral density improvement after parathyroidectomy in primary hyperparathyroidism.
S. Seyedinia[1], *S. Mirshahvalad[2,1], T. Kiener[1], H. Kässmann[1], M. Beheshti[1], C. Pirich[1];*
[1]Division of Molecular Imaging & Theranostics, Department of Nuclear Medicine, University Hospital Salzburg, Paracelsus Medical University, Salzburg, AUSTRIA, [2]Joint Department of Medical Imaging, University Health Network, University of Toronto, Toronto, ON, CANADA.

EP-0502
18F-Choline PET/CT in the detection of parathyroid adenomas hidden from conventional imaging techniques
E. López Llobet, *C. Lancha Hernandez, L. Domínguez Gadea, J. Cordero García, S. Rizkallal Monzon, D. Monachello Araujo, Y. Abadi Sedraoui, L. Giraldo Gonzalez, P. Portilla Merino;*
Hospital Universitario La Paz, Madrid, SPAIN.

EP-0503
PET/CT with 18F-choline in the study of primary hyperparathyroidism: evaluation of the technique, and correlation with histopathological and biochemical findings
E. Campaña Díaz, *P. García-Talavera San Miguel, J. Alvarez Pérez, F. Gómez-Caminero López, C. Montes Fuentes, A. Peñaherrera Cepeda, J. Badell Martinez, S. Rama Alonso, M. Tamayo Alonso;*
Hospital Universitario de Salamanca, Salamanca, SPAIN.

EP-0504
Role of [18F]F-choline PET/TC for presurgical identification of hyperfunctioning parathyroid glands in patients with primary hyperparathyroidism and inconclusive conventional imaging
P. Azpeitia Hernández, *O. Ajuria Illarramendi, A. Martínez Lorca, P. Paredes Rodríguez, T. Navarro Martínez, U. Vera Schmülling, M. Gutiérrez Guerrero, M. Orduña Díez;*
Hospital Universitario Ramón Y Cajal, Madrid, SPAIN.

EP-0505
Role of 99mTechnetium Sestamibi SPECT/CT in patients with negative planar scintigraphy in lesion localization in patients with hyperparathyroidism
Y. Dharmashaktu, *N. A. Damle, R. Goel, C. Bal, P. Kumar, S. Chumber, G. Puri, R. Aphale;*
All India Institute of Medical Sciences, Delhi, INDIA.

EP-0506
[18F]fluorocholine positron emission tomography/computed tomography characterization of benign thyroid nodules
K. Bajuk Studen[1,2], *S. Rep[1], S. Gaberscek[1,2], K. Zaletel[1,2], E. Skorjanec Armic[1], L. Lezaic[1,2];*
[1]University Medical Centre Ljubljana, Ljubljana, SLOVENIA, [2]Medical Faculty, University of Ljubljana, Ljubljana, SLOVENIA.

EP-0507
Diagnostic Performance of C-X-C Motif Chemokine Receptor 4-directed PET/CT in Patients with Advanced Adrenocortical Carcinoma
W. Schlötelburg[1], *A. Kosmala[1], P. E. Hartrampf[1], S. E. Serfling[1], A. Schirbel[1], M. Fassnacht[2], A. K. Buck[1], S. Hahner[2], R. A. Werner[1,3];*
[1]Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, GERMANY, [2]Division of Endocrinology and Diabetes, Department of Medicine I, University Hospital Würzburg, Würzburg, GERMANY, [3]The Russel H Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, UNITED STATES OF AMERICA.

EP-0508
Minimally Invasive Radio-Guided Parathyroidectomy in Patients with Hyperparathyroidism: Experience at Our Center
N. Calviño, *D. Villasboas-Rosciolesi, M. De Bonilla-Candau, A. Ciscar, A. Martin del Rey, J. Echeverri-Díaz, S. Asadurova, F. Velazquez, R. Bellviure-Meiro, A. García-Burillo;*
Hospital Universitario Vall de Hebron, Barcelona, SPAIN.

EP-0509
Diagnostic performance of 18FCH-PET/CT in Primary Hyperparathyroidism: semiquantitative analysis and correlation with biochemical data
C. Ferrari, *F. Iuele, M. Frugis, P. Mammucci, C. Palumbo, A. Di Palo, G. Rubini;*
Nuclear Medicine Department, University of Bari "Aldo Moro", Bari, Italy, Bari, ITALY.

EP-0510
Usefulness of 18F-Choline PET/CT in localizing hyperfunctioning parathyroid glands with negative 99mTc-MIBI scintigraphy and its correlation with pathological findings
I. Garrido Solesio, *K. Velásquez Díaz, P. Meneses Soares, A. Grajeda Gallardo, I. Obedkova, L. Santamaría Chico, M. Mitjavila Casanovas, A. Prieto Soriano;*
Hospital Universitario Puerta de Hierro, Madrid, SPAIN.

EP-31

e-Poster Area

B: Imaging Clinical Studies -> B7 Infection and Inflammation -> B71 Bone Infection and Inflammation

EP-0511
The study of non-infectious inflammatory diseases in paediatric patients: morpho-functional methods compared (18FDG-PET and 99mTc-WB Bone Scintigraphy vs STIR-MRI).
A. Monaci[1], *A. Perrone[2], A. Tondo[2], F. Carra[2], T. Giani[2], C. Olianti[1];*
[1]University of Florence, Firenze, ITALY, [2]University Hospital Meyer, Firenze, ITALY.

EP-32

e-Poster Area

B: Imaging Clinical Studies -> B7 Infection and Inflammation -> B72 Vasculitis and Endocarditis

EP-0512
Role of 18 Fluorodeoxyglucose positron emission tomography - computed tomography in the diagnosis of infective endocarditis : A report of 19 cases
O. Ben Elkilani, *S. Mensi, G. Baazoug, Z. Missaoui, A. Ezzine, T. Dardouri, R. Sfar, K. Chatti;*
University Hospital Sahloul, Sousse, TUNISIA.

EP-0513
Takayasu's Disease - A Pathway To Diagnosis: Clinical Case Solved Using 18F-FDG PET/CT
P. Ilieva-Gabarska[1,2,3], *Z. Dancheva[3], R. Pencheva[4], M. Slavova[1], L. Petrakiev[1], A. Antonov[5], M. Dyankova[6,3], I. Vasilev[7], T. Baltova[7], Y. Todorova-Doneva[8];*
[1]Nuclear medicine laboratory, Medical center "St. Marina - diagnostics and therapy", Pleven, BULGARIA, [2]Department of Radiology and Radiotherapy, Medical university Pleven, Pleven, BULGARIA, [3]Department of Imaging diagnostics, Interventional radiology and Radiotherapy, Medical university "Prof. Dr. Paraskev Stoyanov", Varna, BULGARIA, [4]Rheumatology department, UMHAT "Dr Georgi Stranski", Pleven, BULGARIA, [5]Department of haematology, University hospital "St. Marina - Pleven", Pleven, BULGARIA, [6]Department of nuclear medicine and radionuclide therapy, UMHAT "St. Marina", Varna, BULGARIA, [7]MBAL Avis Medica, Department of Radiology, Pleven, BULGARIA, [8]ENT department, UMHAT "Dr Georgi Stranski", Pleven, BULGARIA.

EP-0514
Role of FDG PET-CT in Takayasu arteritis
Z. Missaoui, *M. Nouira, G. Baazoug, O. Ben Elkilani, K. Ayed, S. Raja, K. Chatti;*
University Hospital Center Sahloul, Sousse, TUNISIA.

EP-33

e-Poster Area

B: Imaging Clinical Studies -> B7 Infection and Inflammation -> B73 Other Infections and Inflammatory Diseases

EP-0515
FDG PET/CT response criteria in assessment of post Anti Koch's Treatment evaluation.
H. Rathore, *N. R. Thaker, Bombay Hospital, Mumbai;*
Bombay Hospital And Medical Research Centre, Mumbai, INDIA.

EP-0516
Osteoarticular Inflammatory Activity Response To Tocilizumab In Patients With Refractory Polymyalgia Rheumatica: Contribution Of Semiquantitative Analysis Of [18F]FDG-PET/CT
I. Martínez-Rodríguez[1], *D. Prieto-Peña[2], Á. Gutiérrez-González[3], M. De Arcocha-Torres[3], F. J. Gómez-de la Fuente[1], N. Martínez-Amador[3], A. Sánchez-Salmón[3], J. Jiménez-Bonilla[3], V. Mendi-Barcina[3], A. Bota-Bota[4], M. Pombo-López[4], M. A. González-Gay[2], R. Quirce[3];*
[1]Nuclear Medicine Service. Marqués de Valdecilla University Hospital. Molecular Imaging Group (IDIVAL). University of Cantabria, Santander, SPAIN, [2]Rheumatology Service. Marqués de Valdecilla University Hospital. Genetics and atherosclerosis research group on systemic inflammatory diseases (IDIVAL), Santander, SPAIN, [3]Nuclear Medicine Service. Marqués de Valdecilla University Hospital. Molecular Imaging Group (IDIVAL). University of Cantabria, Santander, SPAIN, [4]Nuclear Medicine Service. Marqués de Valdecilla University Hospital. Molecular Imaging Group (IDIVAL). University of Cantabria, Santander (España), SPAIN.

EP-0517
Comparative study of body fat distribution in naive people living with HIV (PLHIV) and after 48 weeks of antiretroviral therapies (ART) with Dolutegravir/lamivudine vs TAF/FTC/Bictegravir.
A. Piñeiro, *C. Hidalgo Tenorio, E. Triviño Ibáñez, C. Ramos Font, R. Sánchez Sánchez;*
Hospital Universitario Virgen de las Nieves, Granada, SPAIN.

EP-0518
18F-FDG PET/CT Imaging in Infectious Mononucleosis: Mimicking Lymphoma and Clinical Implications
N. Damle, *J. Jaleel, S. Jain, A. Rasheed, V. Goenka, K. Gyanraj Sa, A. Khurana;*
All India Institute of Medical Sciences, New Delhi, INDIA.

EP-0519
Real world comparison of radiopharmaceutical parameters and clinical utility in kit based and in house labelled 99m Tc Ubiquicidin as a infection imaging agent
D. Khan, *S. Katala, N. A. Damle, C. Bal, S. Sagar, G. Arora, P. Kumar, M. Ansari, R. Kumar, H. Verma;*
AIIMS Delhi, Delhi, INDIA.

EP-34

e-Poster Area

B: Imaging Clinical Studies -> B8 Nephro-Urological Imaging Study -> B81 Nephro-Urology

EP-0520
Heterogeneity of PSMA Expression Assessed by 68Ga-PSMA-11 PET/CT in Patients with clear-cell renal cell carcinoma
M. Zhang;
Department of Nuclear Medicine, Xijing Hospital, Xi'an, CHINA.

EP-0521
Dynamic characteristics of ureteral cancer with [11C]-choline total-body PET/CT
C. Liu[1], *S. Wang[2], R. Wu[3], Q. Xie[1], Y. Yang[2], Z. Yang[1];*
[1]Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Beijing, CHINA, [2]Department of Urology, Peking University Cancer Hospital & Institute, Beijing, CHINA, [3]Beijing United Imaging Research Institute of Intelligent Imaging, Beijing, CHINA.

EP-0522
Role of Tc99m SestaMIBI SPECT/CT in characterization of renal lesions - A prospective study
K. Agrawal, *R. Emerson P, P. Nayak, S. Purkait, P. S. Patro, G. K. Parida;*
All India Institute of Medical Sciences (AIIMS), Bhubaneswar, INDIA.

EP-35

e-Poster Area

B: Imaging Clinical Studies -> B81 Nephro-Urology & B101 Other Clinical Studies

EP-0523
Are non-sampling methods useful for assessing GFR in a potential living kidney donor? A comparative study with the 3-sample method
M. A. Hernández Fructuoso, *C. G. Franco Monterroso, B. Santos Montero, L. Garcia Lama, L. Rey Sánchez, V. Pascual Pascual, A. Garcia Burillo;*
Hospital Universitari Vall d'Hebron, Barcelona, SPAIN.

EP-0524
Assessing the Reliability of GFR Estimation with Lateral Kidney Centroid Depth of 99mTc-DTPA and 99mTc-MAG3 Renography
K. Thawinprawat;
Siriraj Hospital, Bangkok, THAILAND.

EP-0525
Reproducibility of normal Gallbladder Ejection Fraction at 30 min by Biliary Scintigraphy for Diagnosis of Biliary Dyskinesia
M. A. Olarte, *D. Cardosa-Cisneros, I. Soldevilla-Gallardo;*
American British Cowdray Medical Center, Mexico City, MEXICO.

EP-0526
75Se- Taurocholic acid in the study of Chronic Diarrhea. Our Experience
C. Paniagua Correa, *L. Castillejos Rodríguez, A. Herrero Muñoz, D. Rodriguez Oviedo, C. Galindo Fernández, B. Manzarbeitia Arroba, M. Alvarez Moreno, A. Ortega Valle, C. Sandoval Moreno, M. De la Rubia Marcos, M. Tagliatori Nogueira, P. García Alonso;*
Hospital De Getafe, Getafe, SPAIN.

EP-0527
99米Tc-DTPA肾脏动态成像评估成人患者双功肾功能
X. Yan[1], *Y. Ning[1], Y. Chen[1], M. Cai[2], S. Li[3];*
[1]Shanxi Medical University, Tai Yuan, CHINA, [2]Shanxi provincial People's Hospital & Fifth Clinical College of Shanxi Medical University, Tai Yuan, CHINA, [3]The first hospital of Shanxi Medical University, Tai Yuan, CHINA.

EP-0528
V/P-SPECT detection of pulmonary thromboembolism in patients with respiratory infections: a diagnostic challenge?
I. C. Ferreira, *R. T. Ferreira, J. G. Santos, A. I. Santos;*
Hospital Garcia de Orta, E.P.E., Almada, PORTUGAL.

EP-0529
Diagnostic Contribution of Volumetric Analysis of Lung Perfusion SPECT/CT in Location of Pulmonary Thromboembolism
N. Alvarez Mena, *F. Sebastián Palacid, M. García Aragón, R. Zambrano Infantino, B. Pérez López, R. Ruano Pérez;*
Hospital Clínico Universitario de Valladolid, Valladolid, SPAIN.

EP-0530
The prevalence of pulmonary thrombo-embolism in pregnancy guided clinically by maternal tachycardia
A. Alnabulsi[1], *A. Ayeni[2], S. More[1];*
[1]Division of Nuclear Medicine, Department of Radiation Medicine, University of cape Town, Cape Town, SOUTH AFRICA, [2]Division of Nuclear Medicine, Department of Radiation Medicine, University of cape Town, Capetown, SOUTH AFRICA.

EP-0531
Are Planar Images In Pulmonary Perfusion Scintigraphy Sufficient For Positive Diagnosis Of Pulmonary Embolism In Pregnant Women?
L. Zaabar[1,2], *K. Ben Amara[3], T. Ben Ghachem[1,2], D. Ben Sellem[1,2], B. Letaief[1,2], A. Mhiri[1,2];*
[1]Salah Azaeiz Institute, Tunis, TUNISIA, [2]Faculté de Médecine de Tunis, Tunis, TUNISIA, [3]Health Ministery, Tunis, TUNISIA.

EP-0532
Hepatic [18F]FDG uptake in patients with obesity: a study on the effect of NAFLD
U. Ustsinau, *O. Kulterer, M. Krssak, I. Rausch, F. Kiefer, C. Philippe;*
Medical University of Vienna, Vienna, AUSTRIA.

EP-0533
Pre-treatment pituitary gland [18F]FDG uptake in oncological patients
C. A. Ruiz-Bedoya[1,2], *S. F. Barrington[1,3], M. Yakubu[1], A. Hammers[1], G. J. R. Cook[1,3], M. Subesinghe[1,3];*
[1]King's College London & Guy's and St. Thomas' PET Centre, London, UNITED KINGDOM, [2]Department of Imaging Chemistry & Biology, School of Biomedical Engineering and Imaging Sciences, King's College London, London, UNITED KINGDOM, [3]Department of Cancer Imaging, School of Biomedical Engineering and Imaging Sciences, London, UNITED KINGDOM.

EP-0534
Relationship between the severity of vesicoureteral reflux and renal scarring in children. About 162 patients.
M. Habbache, *Q. Naili, M. Abdi;*
Nuclear medicine Center or Blida, Algier, ALGERIA.

EP-36

e-Poster Area

C: Therapy Clinical Study -> C1 Oncological Therapy Clinical Study -> C11 Neuroendocrine Therapy

EP-0535

Actinium225 -DOTATATE peptide receptor radionuclidetherapy(PRRT) as first line treatment in two cases of bowel Neuroendocrine tumors

K. Kamaleshwaran, *E. Ramkumar;*
Kovai Medical center and Hospital limited (KMCH), Coimbatore, INDIA.

EP-0536

Discovery of blood transcriptomic markers for response to [177Lu]Lu-DOTATATE in locally advanced or metastatic neuroendocrine neoplasms

S. Bae[1], *H. Sung*[2], *H. Choi*[2], *H. Im*[3], *M. Suh*[2], *J. Paeng*[2], *G. Cheon*[2], *K. Kang*[2];
[1]*Institute of Radiation Medicine, Medical Research Center, Seoul National University, Seoul, KOREA, REPUBLIC OF,* [2]*Department of Nuclear Medicine, Seoul National University Hospital, Seoul, KOREA, REPUBLIC OF,* [3]*Department of Applied Bioengineering, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, KOREA, REPUBLIC OF.*

EP-0537

Long-term effects of peptide receptor radionuclide therapy (PRRT) used as a first-line treatment of GEP-NET - a single centre experience

M. Opalinska, *K. Morawiec-Slawek, A. Kurzynska, A. Sowa-Staszczak, A. Hubalewska-Dydejczyk;*
Department of Endocrinology, Jagiellonian University Medical College, Krakow, Poland, Krakow, POLAND.

EP-0538

Visual and Whole-Body Quantitative Analysis of 68-Ga-DOTATATE PET/CT to Predict Outcomes after 177Lu-DOTATATE

I. Sonni[1,2], *M. Hotta*[1,3], *P. Thin*[1], *K. Nguyen*[1], *L. Gardner*[1], *L. Ciuca*[1], *A. Hayrapetian*[1,4], *M. P. Lewis*[1,5], *D. J. Lubin*[1,6], *M. Allen-Auerbach*[1];
[1]*University of California, Los Angeles, Los Angeles, CA, UNITED STATES OF AMERICA,* [2]*Università Magna Graecia, Catanzaro, ITALY,* [3]*National Center for Global Health and Medicine, Tokyo, JAPAN,* [4]*University of South Alabama, Mobile, AL, UNITED STATES OF AMERICA,* [5]*Kaiser Permanente Los Angeles Medical Center, Los Angeles, CA, UNITED STATES OF AMERICA,* [6]*SUNY Upstate, Syracuse, NY, UNITED STATES OF AMERICA.*

EP-0539

Therapy in Advanced Small Cell Lung Carcinoma - Investigating Outcome, Toxicity Profile and Prognostic Determinants

P. Hartrampf[1], *A. Weich*[2], *F. Lutz*[1], *A. K. Buck*[1], *T. Higuchi*[1], *S. E. Serfling*[1], *Y. Zhi*[3], *R. A. Werner*[1];
[1]*Klinik und Poliklinik für Nuklearmedizin, Würzburg, GERMANY,* [2]*Medizinische Klinik und Poliklinik II, Würzburg, GERMANY,* [3]*Klinik und Poliklinik für Hals-, Nasen- und Ohrenkrankheiten, plastische und ästhetische Operationen, Würzburg, GERMANY.*

EP-0540

Impact of kidneys absorbed dose assessment during177Lu-PRRT (peptide receptor radionuclide therapy) on patient management: examples from clinical experience

M. Ferrari, F. Botta, ***C. Grana****, D. Alio, A. Barone, G. Castiglione Minischetti, S. Papi, I. Clerici, F. Ceci;*
Istituto Europeo di Oncologia, Milano, ITALY.

EP-0541

Factors Predicting Response and Survival in Lutetium-177 DOTATATE Treatment of Neuroendocrine Tumours: Preliminary Results

Z. MAMMADKHANLI[1], *F. SOYLUOGLU*[1], *B. OZDEMIR GUNAY*[2], *C. AYDIN*[1], *U. KORKMAZ*[1];
[1]*Trakya University, School of Medicine, Department of Nuclear Medicine, Edirne, TÜRKIYE,* [2]*Sultan 1. Murat State Hospital, Clinic of Nuclear Medicine, Edirne, TÜRKIYE.*

EP-0542

Impact of the SBVR 177Lu activity quantification method on organ and tumor dosimetry results after PRRT and on patient management

A. Chicheportiche, *S. Raskin, Y. Krausz, J. Godefroy, S. Grozinsky-Glasberg, S. Ben-Haim;*
Hadassah Ein Kerem Hospital, Jerusalem, ISRAEL.

EP-0543

Neoadjuvant PRRT with 90Y-DOTATOC: preliminary results from a monocentric prospective study

A. Barone[1], *F. Mattana*[2], *L. L. Travaini*[2], *P. Rocca*[2], *M. Colandrea*[2], *L. Gilardi*[2], *S. Fracassi*[2], *S. Papi*[3], *I. Clerici*[3], *M. E. Ferrari*[4], *F. Botta*[4], *E. Bertani*[5], *F. Spada*[6], *N. Fazio*[6], *F. Ceci*[2], *C. M. Grana*[2];
[1]*Division of Nuclear Medicine, Istituto Europeo di Oncologia IRCCS, Milan, Italy, Milan, ITALY,* [2]*Division of Nuclear Medicine, Istituto Europeo di Oncologia IRCCS, Milan, ITALY,* [3]*Division of Pharmacy, Istituto Europeo di Oncologia IRCCS, Milan, ITALY,* [4]*Medical Physics Unit, Istituto Europeo di Oncologia IRCCS, Milan, ITALY,* [5]*Division of Digestive Surgery, Istituto Europeo di Oncologia IRCCS, Milan, ITALY,* [6]*Division of Gastrointestinal Medical Oncology and Neuroendocrine Tumors, Istituto Europeo di Oncologia IRCCS, Milan, ITALY.*

EP-0544

Inflammatory markers as prognostic factor inTNE treated with 177Lu-DOTATATE

J. Villa Palacios, *E. Triviño-Ibáñez, M. Muros de Fuentes, T. Aroui-Luquin, R. Sanchez-Sanchez;*
Hospital Universitario Virgen de las Nieves, Granada, SPAIN.

EP-0545

Kidneys functional volumes changes of patients undergoing 177Lu-DOTATATE treatment and the uncertainties measures in kidney dosimetry

J. Khan[1], *T. Rydèn*[2], *J. Svensson*[3], *M. Van Essen*[4], *P. Bernhardt*[5];
[1]*Department of Medical Radiation Sciences, Institute of Clinical Sciences, Gothenburg, SWEDEN,* [2]*Department of Medical Physics and Biomedical Engineering (MFT), Sahlgrenska University Hospital, Gothenburg, SWEDEN,* [3]*Department of Oncology, Institution of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, Gothenburg, SWEDEN,* [4]*Department of Clinical Physiology, Sahlgrenska University Hospital, Gothenburg, SWEDEN,* [5]*Department of Medical Radiation Sciences, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, Gothenburg, SWEDEN.*

EP-0546

Evaluation of RadioLigand Therapy response in GEP-NETs: the role of 177Lu-Dotatate imaging

S. Valente[1], *F. Linguanti*[1], *M. E. Abenavoli*[1], *L. Antonuzzo*[2], *V. Briganti*[3], *D. Lavacchi*[4], *M. Matteini*[3], *F. Mungai*[5], *R. Sciagrà*[1], *G. Simontacchi*[6], *L. Vaggelli*[3], *V. Berti*[1];
[1]*Nuclear Medicine Unit, Department of Experimental and Clinical Biomedical Sciences "Mario Serio", University of Florence, 50134, Florence, ITALY,* [2]*Clinical Oncology Unit, Careggi University Hospital, Florence, Italy; Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, Florence, ITALY,* [3]*Department of Nuclear Medicine, Azienda Ospedaliero-Universitaria Careggi, Largo Brambilla 3, 50134, Florence, Italy, Florence, ITALY,* [4]*Clinical Oncology Unit, Careggi University Hospital, Florence, Italy, Florence, ITALY,* [5]*Department of Radiology, Azienda Ospedaliero-Universitaria Careggi, Largo Brambilla 3, 50134, Florence, Italy, Florence, ITALY,* [6]*Radiation Oncology, Azienda Universitaria Ospedaliera Careggi, Florence, ITALY.*

EP-0547

Efficacy of [177Lu]Lu-DOTA-TATE in metastatic neuroendocrine neoplasms of different locations: our experience.

M. Pudis[1], *J. L. Vercher-Conejero*[1], *J. J. Martín-Marcuartu*[1], *A. Teule-Vega*[2], *S. Bondia-Bescós*[1], *B. Hervás-Sanz*[1], *A. Rodríguez-Gasén*[1], *J. Diaz-Moreno*[1], *M. Cortés-Romera*[1];
[1]*Nuclear Medicine - PET (IDI), Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, SPAIN,* [2]*Medical Oncology, Institut Català d'Oncologia (ICO), L'Hospitalet de Llobregat, Barcelona, SPAIN.*

EP-0548

Evaluation of the quality of life of patients with neuroendocrine tumors treated with Lutetium-177-DOTATATE

S. Asadurova, *D. Villasboas, J. Hernando, F. Velazquez, R. Bellviure, J. Echeverri-Diaz, N. Calviño, A. García-Burillo;*
Hospital Universitari Vall d´Hebron, Barcelona, SPAIN.

EP-0549

Radiomics analysis in 177Lu-DOTATATE therapy: Extracting new information from theranostic images

H. Abdollahi[1], *X. Hou*[2], *J. Beauregard*[3], *C. Uribe*[1], *A. Rahmim*[1];
[1]*BC Cancer Research Institute, Vancouver, BC, CANADA,* [2]*Department of Radiology, University of British Columbia, Vancouver, BC, CANADA,* [3]*Cancer Research Centre and Department of Radiology and Nuclear Medicine, Université Laval, Quebec City, QC, CANADA.*

EP-0550

Assessment of response to therapy and safety of177Lu-DOTATATE in GEP-NET patients

M. Raddi, *F. Di Gennaro, F. De Lauro, V. Porfidia, C. Maisto, G. Ventanieri, S. Melone, P. Gaballo, L. D'Ambrosio, S. Lastoria;*
National Cancer Institute IRCCS Pascale, Naples, ITALY.

EP-0551

Evaluation of different infusion protocols and dosimetry assessment in patients undergoing peptide receptor radionuclide therapy with 177Lu-DOTATATE

A. Varallo[1], *L. Piscopo*[1], *V. Gaudieri*[1], *S. Grasso*[1], *E. Zampella*[1], *C. Nappi*[1], *C. Oliviero*[2], *M. Italiano*[1], *F. Volpe*[1], *M. Falzarano*[1], *S. Clemente*[2], *A. Cuocolo*[1], *M. Klain*[1];
[1]*Department of Advanced Biomedical Sciences, University of Naples "Federico II", Naples, ITALY,* [2]*Unit of Medical Physics and Radioprotection, University of Naples "Federico II", Naples, ITALY.*

EP-37

e-Poster Area

C: Therapy Clinical Study -> C1 Oncological Therapy Clinical Study -> C12 Prostate Cancer Therapy

EP-0552

TheraP-based Selection Criteria Do Not result in a Survival Benefit When Compared With VISION Trial Criteria in Prostate Cancer Patients Scheduled for PSMA-targeted Radioligand Therapy

K. Michalski[1], *A. Kosmala*[1], *R. A. Werner*[1], *S. Serfling*[1], *A. K. Seitz*[1], *C. Lapa*[2], *A. K. Buck*[1], *P. E. Hartrampf*[1];
[1]*Universitätsklinikum Würzburg, Würzburg, GERMANY,* [2]*Universitätsklinikum Augsburg, Augsburg, GERMANY.*

EP-0553

The efficacy of prognostic factors derived from Ga68-PSMA PET-CT images in predicting treatment response and survival in patients with metastatic castration-resistant prostate cancer treated with Lu-177PSMA

M. Oflas[1], *D. Has Simsek*[1], *Y. Sanli*[1], *S. Kuyumcu*[1], *E. Isik*[1], *S. Karadogan*[1], *M. Basaran*[2], *M. Ekenel*[2], *A. Mudun*[1], *Z. G. Ozkan*[1];
[1]*Istanbul Faculty Of Medicine Department Of Nuclear Medicine, Istanbul, Türkiye,* [2]*Istanbul University Institute Of Oncology, Department Of Medical Oncology, Istanbul, TÜRKIYE.*

EP-0554

Dosimetric evaluation of 177Lu-PSMA-617 therapy: Feasibility of Single Time Point Imaging Protocol

S. Rezaei, *E. Gharepapagh;*
Department of Nuclear Medicine, Medical School, Tabriz University of Medical Sciences, Tabriz, IRAN, ISLAMIC REPUBLIC OF.

EP-0555

Safety and Efficacy of re-treatment with Lutetium-177 PSMA Beyond Six Cycles in Patients with Castration-Resistant Prostate Cancer

E. Medhurst[1], *R. Alipour*[2], *T. Akhurst*[2], *A. Azad*[3], *J. P. Buteau*[1], *A. Cardin*[2], *B. Emmerson*[1], *M. B. Haskali*[4], *G. Kong*[2], *L. Kostos*[3], *P. Jackson*[1], *K. Raghava*[2], *A. Ravi Kumar*[2], *J. Saghebi*[2], *S. Sandhu*[3], *L. Spain*[3], *B. Tran*[3], *M. S. Hofman*[1];
[1]*Prostate Cancer Theranostics and Imaging Centre of Excellence; Molecular Imaging and Therapeutic Nuclear Medicine, Cancer Imaging,Peter MacCallum Cancer Centre, Melbourne, AUSTRALIA,* [2]*Department of Nuclear Medicine, Peter MacCallum Cancer Centre, Melbourne, AUSTRALIA,* [3]*Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, AUSTRALIA,* [4]*RadiopharmaceuticalProduction and Research Laboratory, Peter MacCallum Cancer Centre, Melbourne, AUSTRALIA.*

EP-0556

Can a cutoff be set for pre-treatment 68Ga-PSMA-11 PET/CT parameters to predict 177Lu-PSMA-I&T response and patient survival?

S. Mirshahvalad[1,2], *R. Eisazadeh*[1], *G. Rendl*[1], *S. Gampenrieder*[3], *G. Schweighofer-Zwink*[1], *H. Griessner*[4], *C. Pirich*[1], *M. Beheshti*[1];
[1]*Division of Molecular Imaging & Theranostics, Department of Nuclear Medicine, University Hospital, Paracelsus Medical University, Salzburg, AUSTRIA,* [2]*Joint Department of Medical Imaging, University Health Network, University of Toronto, Toronto, ON, CANADA,* [3]*Division of Molecular Imaging & Theranostics, Department of Oncology, University Hospital, Paracelsus Medical University, Salzburg, AUSTRIA,* [4]*Division of Molecular Imaging & Theranostics, Department of Urology, University Hospital, Paracelsus Medical University, Salzburg, AUSTRIA.*

EP-0557

Clinical outcomes after treatment following the use of 18F-PSMA PET/CT scans in patients with recurrent prostate cancer

J. Rodriguez-Rubio Corona, *F. Cañete Sánchez, Y. Santaella Guardiola, M. Piñero Fernandez-Reyes, C. Quintana Bolaño, M. Pajares Vinardell;
Hospital Universitario Puerta del Mar, Cádiz, SPAIN.*

EP-0558

The Tyr Phenomena: Hypo-calcemic Response in High Volume Treatment Responders to 177Lutetium PSMA Therapy

M. Swiha[1,2], *S. Kumar*[3], *M. Crumbaker*[1], *C. Harvey*[1], *S. Pathmanandavel*[1], *N. John*[1,4], *M. M. McDonald*[5,6], *R. Clifton-Bligh*[3,6], *A. Lee*[3,7,8], *P. Bastick*[9], *W. Counter*[1], *A. Nguyen*[1,4], *L. Emmett*[1,4,5];
[1]*St Vincent's Hospital, Sydney, AUSTRALIA,* [2]*Schulich School of Medicine and Dentistry, University of Western Ontario, London, ON, CANADA,* [3]*Royal North Shore Hospital, Sydney, AUSTRALIA,* [4]*St Vincent's Clinical School, University of New South Wales, Sydney, AUSTRALIA,* [5]*Garvan Institute of Medical Research, Sydney, AUSTRALIA,* [6]*School of Medical Science, Faculty of Medicine and Health, University of Sydney, Sydney, AUSTRALIA,* [7]*Northern Clinical School, Faculty of Medicine and Health, University of Sydney, Sydney, AUSTRALIA,* [8]*Genesis Care, Sydney, AUSTRALIA,* [9]*St George Hospital, Sydney, AUSTRALIA.*

EP-0559

Evaluation of Radium-223 Dichloride in the Treatment of Castration-Resistant Prostate Adenocarcinoma with Symptomatic Bone Metastases

R. Maestre-Cutillas[1], *A. M. Sanchez-Tornero*[2], *L. Baz-Sanz*[1], *G. Rubio-Fernández*[1], *L. Casas-Fernandez*[2], *M. Romero-Otero*[2], *J. A. Pérez-Iruela*[1];
[1]*Hospital Universitario Ramon y Cajal, Madrid, SPAIN,* [2]*Hospital Clínico Universitario de Valencia, Valencia, SPAIN.*

EP-0560

Personalized [177Lu] Lutetium-PSMA therapy for patients with pre-treated castration-resistant prostate cancer: a single institution experience

J. Friedrich[1], *W. Thaiss*[1,2,3], *F. Zengerling*[4,3], *V. Hechler*[4], *M. Grunert*[5,1], *C. Bolenz*[4,3], *T. Wiegel*[6], *A. J. Beer*[1,3], *V. Prasad*[1,3];
[1]*Department of Nuclear Medicine, University Hospital Ulm, Ulm, GERMANY,* [2]*Department of Diagnostic and Interventional Radiology, University Hospital Ulm, Ulm, GERMANY,* [3]*Surgical Oncology Ulm, i2SOUL Consortium, Ulm, GERMANY,* [4]*Department of Urology and Pediatric Urology, University Hospital Ulm, Ulm, GERMANY,* [5]*Department of Nuclear Medicine, German Armed Forces Hospital, Ulm, GERMANY,* [6]*Department of Radiation Oncology, University Hospital Ulm, Ulm, GERMANY.*

EP-0561

No substantial subacute nephrotoxicity in patients with mCRPC treated with Lu-177 PSMA I&T regardless of mean absorbed kidney dose

M. Dotinga[1,2], *E. C. Owers*[1], *E. J. Rijkhorst*[1], *D. M. V. de Vries-Huizing*[1];
[1]*NETHERLANDS Cancer Institute, Amsterdam, NETHERLANDS,* [2]*Leiden University Medical Center, Leiden, NETHERLANDS.*

EP-0562

Prognostic Role Of 18F-Choline PET/CT Vs Bone Scintigraphy In Prostate Cancer Patients Treated With 223Ra-Dichloride.

L. García Zoghby[1], *M. Cruz Montijano*[1], *A. García Vicente*[1], *M. Amo Salas*[2], *A. Padilla Bermejo*[3], *C. Lucas Lucas*[3], *N. Sicilia Pozo*[3], *M. Contreras Ameduri*[3], *F. Pena Pardo*[3], *E. Noriega Álvarez*[3], *M. Talavera Rubio*[3], *V. Poblete García*[3], *Á. Soriano Castrejón*[1];
[1]*University Hospital of Toledo, Toledo, SPAIN,* [2]*Castilla-La Mancha University, Ciudad Real, SPAIN,* [3]*University General Hospital of Ciudad Real, Ciudad Real, SPAIN.*

EP-0563

Evaluation of the clinical significance of parametric data of PSMA uptake in the prostate bed and its contribution to prognosis.

Z. Mammadkhanli[1], *B. Ozdemir Gunay*[2], *E. Gokdemir*[1], *F. Ustun*[1];
[1]*Trakya University, Faculty of Medicine, Department of Nuclear Medicine, Edirne, TÜRKIYE,* [2]*Sultan 1. Murat State Hospital, Clinic of Nuclear Medicine, Edirne, TÜRKIYE.*

EP-0564

Health-related quality of life in mCRPC patients receiving treatment with[177Lutetium] prostate specific membrane antigen targeted radioligand therapy

A. Karimzadeh[1], *B. Feuerecker*[2], *K. Knorr*[2], *M. Heck*[3], *R. Tauber*[3], *C. D`Alessandria*[2], *W. Weber*[2], *M. Eiber*[2], *I. Rauscher*[2];
[1]*Department of Diagnostic and Interventional Radiology and Nuclear Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, GERMANY,* [2]*Department of Nuclear Medicine, School of Medicine, Technical University of Munich, Munich, GERMANY,* [3]*Department of Urology, School of Medicine, Technical University of Munich, Munich, GERMANY.*

EP-0565

Safety and Efficacy of [177Lu]Lu-rhPSMA-10.1 Re-Challenge Therapy in Progressive mCRPC after [177Lu]Lu-PSMA I&T Therapy: Preliminary Results

A. Gäble[1], *J. Enke*[1], *A. Amerein*[1], *O. Viering*[1], *A. Rinscheid*[2], *M. Kircher*[1], *G. Wienand*[1], *C. Pfob*[1], *C. Lapa*[1], *A. Dierks*[1], *R. Bundschuh*[1];
[1]*Nuclear Medicine, Faculty of Medicine, University of Augsburg, Augsburg, GERMANY,* [2]*Medical Physics and Radiation Protection, University Hospital Augsburg, Augsburg, GERMANY.*

EP-0566

PSMA avidity-based recurrent patterns after 177Lu-PSMA I&T in metastatic castration-resistant prostate cancer

S. Kwon[1,2], *I. Rauscher*[1], *C. D'Alessandria*[1], *M. Eiber*[1], *W. Weber*[1];
[1]*Rechts der Isar Medical Center, Technical University of Munich, Munich, GERMANY,* [2]*Chonnam National University Medical School and Hwasun Hospital, Jeonnam, KOREA, REPUBLIC OF.*

EP-0567

Effect of [223Ra]Radium dichloride on bone health

K. Krieger, *A. Afshar-Oromieh, A. Rominger, S. Weidner;
Inselspital Bern, Bern, SWITZERLAND.*

EP-0568

First preliminary results on safety and efficacy of non carrier added (n.c.a.) 177Lutetium PSMA-I&T radioligand therapy, in a Single Institute

G. Limouris[1,2], *M. Paphiti*[3], *A. Manetou*[2], *A. Zafeirakis*[2];
[1]*Nuclear Medicine, Medical School, National and Kapodistrian University of Athens, Athens, GREECE,* [2]*Nucl Med Dept, Army Share Fund Hospital of Athens, Athens, GREECE,* [3]*Cyclotron Section, Pharmazac SA, Athens, GREECE.*

EP-0569

Radium-223 dichloride ([223Ra]RaCl2) for metastatic Castration-Resistant Prostate Cancer (mCRPC): results of a real-world experience from a seven-year clinical practice

D. Barbosa, *H. Duarte, J. Ferro, I. Próspero, D. Silva, S. Fontão de Castro, G. Ferreira, L. Violante, F. Lopes, I. Lucena Sampaio;
Portuguese Institute of Oncology, Oporto, PORTUGAL.*

EP-0570

The Relationship Between F-18 FDG Avidity and Response to Lu-177 PSMA Therapy in Prostate Cancer Metastases

N. Coskun[1], *M. Kartal*[2], *A. Erdogan*[2], *E. Ozdemir*[1];
[1]*Ankara Bilkent City Hospital, Ankara Yildirim Beyazit University, Ankara, TÜRKIYE,* [2]*Ankara Bilkent City Hospital, Ankara, TÜRKIYE.*

EP-38

e-Poster Area

C: Therapy Clinical Study -> C1 Oncological Therapy Clinical Study -> C13 Local Radionuclide Therapy (including Spheres)

EP-0571

Correlation Of Y90-Absorbed Radiation Dose To Albi Scores In Liver Malignancies: Is It Safe Over 500 Gy Tumor Absorbed Dose With Voxel Based Dosimetric Approach?

E. Akgun;
University of Health Science Türkiye, Basaksehir Cam and Sakura City Hospital, Istanbul, TÜRKIYE.

EP-0572

Differences in PET/MRI and PET/CT post-therapy dosimetry in hepatocellular carcinoma (HCC) treated with yttrium-90 microspheres

K. Knesaurek, *A. Abdelrahman, M. Ghesani;
Icahn School of Medicine at Mount Sinai, New York, NY, UNITED STATES OF AMERICA.*

EP-0573

Predicting response in HCC selective internal radiation therapy with Y-90 microspheres using advanced PET/CT based dosimetry; LATAM and USA centers experience

D. Mena[1], *I. Hume*[2], *R. García Monaco*[2], *C. Collaud*[2], *O. Peralta*[2], *A. Mollerach*[2], *P. Rodriguez*[2], *V. Jager*[2], *I. Arma*[2], *C. Cianciarelli*[2], *M. Chacon*[2], *V. Gonzalez*[2], *S. Sunagua*[2], *N. Pabstleben*[2], *K. Knešaurek*[3];
[1]*Nuclear Medicine World, CDMX, MEXICO,* [2]*Hospital Italiano de Buenos Aires, Buenos Aires, ARGENTINA,* [3]*Mount Sinai, NY, NY, UNITED STATES OF AMERICA.*

EP-0574

Correlation of 90y Microsphere Dose Planned with Voxel-Based Dosimetry with Actual Absorbed Tumor Dose

A. Dere, *E. Akgun, K. Bozkurt, B. Armutlu, B. E. Akkas, M. Kaya;
University of Health Sciences,Basaksehir Cam ve Sakura City Hospital, ISTANBUL, TÜRKIYE.*

EP-0575

Development of a Topical Application Device for Non Melanoma Skin Cancer Therapy

M. Buonanno, *M. Aurilio, A. Esposito, A. Morisco, R. De Marino, L. D'ambrosio, C. Maisto, V. Porfidia, S. Lastoria;
IRCCS TUMORI FONDAZIONE G. PASCALE, Napoli, ITALY.*

EP-0576

Is There Any Affect Of Tumor Location On Radioembolisation Treatment Response In Hepatocellular Carcinoma?

E. Akgun;
University of Health Science Türkiye, Basaksehir Cam and Sakura City Hospital, Istanbul, TÜRKIYE.

EP-0577

Factors Affecting Outcome in Hepatocellular Cancer Patients Treated with Selective Intra-arterial Radiomicrosphere Therapy

B. Soydas Turan[1], *B. Volkan-Salancı*[2], *M. F. Bozkurt*[2], *G. Eldem*[3], *E. Karabulut*[4], *S. Yalcin*[5], *F. Çay*[3], *B. Peynircioğlu*[3], *O. Ugur*[2];
[1]*Etlik City Hospital, Department of Nuclear Medicine, Ankara, TÜRKIYE,* [2]*Hacettepe University Faculty of Medicine, Department of Nuclear Medicine, Ankara, TÜRKIYE,* [3]*Hacettepe University Faculty of Medicine, Department of Interventional Radiology, Ankara, TÜRKIYE,* [4]*Hacettepe University Faculty of Medicine, Department of Biostatistics, Ankara, TÜRKIYE,* [5]*Hacettepe University Faculty of Medicine, Department of Medical Oncology, Ankara, TÜRKIYE.*

EP-0578

A Case of Meningioma Applied İntraarterial Lu-177 DOTATATE

K. Mammadli, *B. Karaşah Erkek, M. Parıldar, Ö. Şanlı;
Ege University Faculty Of Medicine, Department Of Nuclear Medicine, Bornova, TÜRKIYE.*

EP-0579
Hepatic transarterial radioembolization (TARE) with 90Yttrium glass microspheres for treatment of liver tumours: safety and survival outcomes.
A. De Agrela Serrao, *A. M. Leiva Montejo, C. Ruiz Corbalan, M. Castellón Sanchez, J. L. Navarro Fernandez, T. E. Rodriguez Locarno, A. C. Hernández Martínez, L. Frutos Esteban, D. R. Cáceres Silva, L. Mohamed Salem, J. F. Contreras Gutierrez;*
Hospital Clinico Universitario Virgen de Arrixaca, Murcia, SPAIN.

EP-0580
Efficacy and safety of Y-90 radioembolization for colorectal cancer liver metastases.
J. Villa Palacios, *E. Triviño-Ibáñez, E. González-Flores, P. Pardo-Moreno, A. Rodríguez-Fernández;*
Hospital Universitario Virgen de las Nieves, Granada, SPAIN.

EP-0581
Factors impacting survival in colorectal liver metastases treated with Y-90 radioembolization.
J. Villa Palacios, *E. Triviño-Ibáñez, J. Ciampi-Dopazo, E. González-Flores, A. Rodríguez-Fernández;*
Hospital Universitario Virgen de las Nieves, Granada, SPAIN.

EP-0582
Tumoricidal dosing approach with parenchymal sparing using voxel-based dosimetry in the Y90 glass microspheres treatment of liver lesions
C. Sin, *B. E. Akkas, M. Kaya, E. Akgun;*
University of Health Sciences,Basaksehir Cam ve Sakura City Hospital, İSTANBUL, TÜRKIYE.

EP-0583
PET/CT-based Y-90 microsphere dosimetry to predict contralateral lobe hypertrophy after unilobar radioembolization in treatment-naive hepatocellular carcinoma
Y. Kang, *J. Paeng;*
Seoul National University Hospital, Seoul, KOREA, REPUBLIC OF.

EP-0584
The Role of Tumor FDG Metabolism and AFP Level in Predicting Treatment Response In HCC Patients Treated with 90Y Microspheres
G. Yilmaz, *B. E. Akkaş, M. Kaya, E. Akgün, Ö. Vural Topuz;*
University of Health Sciences Basaksehir Cam and Sakura City Hospital, İstanbul, TÜRKIYE.

EP-0585
Hepatic transarterial radioembolization with three different compounds: are there any survival-related biomarkers?
L. Asensio Valero, *H. Rodriguez Parra, J. Orozco Cortes, C. Castillo Arias, L. Blanco Verdejo, A. Sanchez Tornero, M. Redal Peña, R. Díaz Expósito;*
Hospital Clínico de Valencia, Valencia, SPAIN.

EP-0586
Quantification of 99mTc-MAA for lung shunt estimation before 90Y radioembolization: comparison of three methods
E. Milan, *D. Barbisan, G. Zambon, C. La Verde, P. Barzi, M. Sutto, S. Barbiero, F. Nistri, L. Vendramin;*
Ospedale Cà Foncello ULSS2, Treviso, ITALY.

EP-0587
Dose-response relationship for yttrium-90 resin microspheres in patients with liver metastases from colorectal carcinoma.
L. Sancho Rodriguez[1], *C. Carballo Menayo*[2], *J. González-Martín*[2], *J. Bastidas Tamayo*[3], *E. Guillén Valderrama*[1], *M. Rodríguez-Fraile*[3];
[1]*CLINICA UNIVERSIDAD DE NAVARRA, MADRID, SPAIN,* [2]*Complejo Hospitalario Universitario Insular Materno Infantil de Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, SPAIN,* [3]*CLINICA UNIVERSIDAD DE NAVARRA, PAMPLONA, SPAIN.*

EP-0588
Assessment of Similarity Between the Distributions of Tc-99m MAA Particles and Y-90 Resin Microspheres in Patients Receiving Transarterial Radioembolization for Liver Tumors
N. Coskun[1], *A. Erdogan*[2], *M. Kartal*[2], *E. Ozdemir*[1];
[1]*Ankara Bilkent City Hospital, Ankara Yildirim Beyazit University, Ankara, TÜRKIYE,* [2]*Ankara Bilkent City Hospital, Ankara, TÜRKIYE.*

EP-39

e-Poster Area

C: Therapy Clinical Study -> C1 Oncological Therapy Clinical Study -> C14 Thyroid Therapy

EP-0589
Association between successful adjuvant therapy and quantitative evaluation of radioactive iodine accumulation in the thyroid bed in patients with differentiated thyroid cancer
Y. Iizuka[1,2], *T. Katagiri*[1], *R. Nakashima*[1], *M. Inoue*[1], *K. Nakamura*[1], *T. Mizowaki*[1];
[1]*Kyoto University, Kyoto, JAPAN,* [2]*Shizuoka City Shizuoka Hospital, Shizoka, JAPAN.*

EP-0590
H. Wang, *R. Tian;*
West China Hospital, Sichuan University, Chengdu, CHINA.

EP-0591
Follow-up Findings in the Group of Patients with Tall Cell Papillary Thyroid Cancer
B. Karasah Erkek, *H. Sarıyıldız Gümüşgöz, R. Halit Tokaç, B. Sarıkaya, Y. Ertan, A. Akgün;*
Ege University, Izmir, TÜRKIYE.

EP-0592
Effectiveness of Empirical High-Dose I-131 Therapy in Patients with Differential Thyroid Cancer with Biochemical Incomplete Response
B. Kocabeyoglu[1], *M. Guven*[1], *G. Kavukcu*[2], *A. Akgun*[1];
[1]*Department of Nuclear Medicine, Ege University, Izmir, TÜRKIYE,* [2]*Department of Radiology, Ege University, Izmir, TÜRKIYE.*

EP-0593
The evaluation of the value of human recombinant thyrotropin administration for the patients with differentiated thyroid cancer during thyroid hormone withdrawal preparation for high dose radioiodine treatment.
J. Cha, *W. Kang1;*
Department of Nuclear Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea, Seoul, KOREA, REPUBLIC OF.

EP-0594
Effectiveness of Iodine-131 therapy in patients with hyperthyroidism: The experience in the Nuclear Medicine Department of "Saints Anargyri" Cancer Hospital
S. Saranti, *C. Altani, T. Karianos, K. Kouvelis, M. Bella, E. Taktikou;*
"Agioi Anargyroi" Cancer Hospital, Athens, GREECE.

EP-0595
Prognosis of Differentiated Thyroid Cancer after Reoperation
J. Cha, *W. Kang, H. Cho;*
Department of Nuclear Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea, Seoul, KOREA, REPUBLIC OF.

EP-0596
Aggressiveness and efficacy of 131I therapy in papillary thyroid carcer with peripheral nerve invasion: a propensity score matching study
X. Xiong;
Zhujiang Hospital, Southern Medical University, Guangzhou, CHINA.

EP-0597
Quantitative analysis of residual thyroid gland radioactive counts and peripheral lymphocyte subsets before and after first radioactive iodine therapy in papillary thyroid carcinoma with Braf mutation
J. Zhang, *H. Liu;*
First Hospital of Shanxi Medical University, Taiyuan, CHINA.

EP-0598
Development and validation of a lung metastasis-predicting Nomogram for intermediate- to high-risk differentiated thyroid carcinoma patients
F. Yu, *J. Wang, W. Yang, Z. Yang, W. Ma;*
Xijing Hospital, Fourth Military Medical University, Xi'an, CHINA.

EP-0599
Second Neoplasms in Patients with Differentiated Thyroid Carcinomas (CDT) Treated With 131I (RAIT).
A. Peña, *I. Vinagre Perez, M. Astudillo Sarmiento, R. Nuñez Muñoz, Y. Carreres Ortega, M. Muñoz del Diego, T. Ruiz Juan, S. Perez Fernandez, E. Rodeño Ortiz de Zarate;*
Hospital Universitario de Cruces, Barakaldo, SPAIN.

EP-0600
Radioiodine Avidity and Prognosis of Diffuse Sclerosing Subtype of Papillary Thyroid Cancer
C. Turkan[1], *G. Güler*[2], *M. Tuncel*[1];
[1]*Hacettepe University Department of Nuclear Medicine, Ankara, TÜRKIYE,* [2]*Hacettepe University Department of Pathology, Ankara, TÜRKIYE.*

EP-0601
Analysis of hematological complications in patients with differentiated thyroid cancer
A. Savchenko;
V. N. Karazin Kharkiv National University, Kharkiv, UKRAINE.

EP-0602
Comparison of Malignities Accompanying Thyroid Cancer According to RAI Treatment
D. Yüksel, *M. Yücel, O. Yaylalı, T. Şengöz, A. Gültekin, F. S. Şimşek;*
Pamukkale Universitesi Tip Fakültesi, Denizli, TÜRKIYE.

EP-0603
Prognostic Associations and Oncological Outcomes Regarding Intermediate Risk Differentiated Thyroid Cancer in Latin-American Population: A 13 Years Follow Up Retrospective Cohort
S. Gonzalez Rueda[1], *A. Calderon Avila*[2], *J. Vargas Ahumada*[1], *P. Casanova Triviño*[1], *F. Garcia Perez*[1], *E. Gomez Argumosa*[1];
[1]*Instituto Nacional de Cancerología, Tlalpan, Ciudad de México, MEXICO,* [2]*Centro Medico Nacional S. XXI, Cuahutemoc, Ciudad de México, MEXICO.*

EP-0604
Evaluation of the efficacy of treating Graves Disease with low doses of 131-iodine compared to high doses
B. Manzarbeitia Arroba, *G. Guijarro de Armas, D. Rodriguez Oviedo, M. Alvarez Moreno, A. Ortega Valle, L. Castillejos Rodriguez, P. García Alonso, C. Sandoval Moreno;*
Hospital Universitario de Getafe, Getafe, SPAIN.

EP-0605
Evaluation of the efficacy of treating Graves Disease with fixed doses of 131-iodine compared to calculated doses
B. Manzarbeitia Arroba, *G. Guijarro de Armas, M. Alvarez Moreno, D. Rodriguez Oviedo, M. de la Rubia Marcos, A. Herrero Muñoz, C. Paniagua Correa, P. Garcia Alonso, C. Sandoval Moreno;*
Hospital Universitario de Getafe, Getafe, SPAIN.

EP-0606
Efficacy of empirical radioiodine therapy in patients with differentiated thyroid cancer and elevated serum thyroglobulin without evidence of structural disease
L. Piscopo[1], *E. Zampella*[1], *C. Nappi*[1], *F. Volpe*[1], *V. Gaudieri*[1], *D. Bianco*[2], *F. Volpicelli*[1], *M. Falzarano*[1], *L. Pace*[3], *A. Cuocolo*[1], *M. Klain*[1];
[1]*Department of Advanced Biomedical Sciences, University Federico II, Napoli, ITALY,* [2]*CIRA-Centro Italiano Ricerche Aerospaziali, Capua (CE), ITALY,* [3]*Department of Medicine, Surgery and Dentistry, University of Salerno, Salerno, ITALY.*

EP-40

e-Poster Area

C: Therapy Clinical Study -> C1 Oncological Therapy Clinical Study -> C15 Other Oncological Treatments

EP-0607

Occurence of hematotoxic side effects during 90Y-FAPI-46 radioligand therapy (RLT) in patients with advanced metastatic tumor diseases

K. Pabst[1], *R. Hamacher*[2], *H. Lanzafame*[1], *I. A. Mavroeidi*[2], *T. Bartel*[1], *M. Nader*[1], *S. Bauer*[2], *J. T. Siveke*[2,3,4], *M. Weber*[1], *D. Kersting*[1], *W. Jentzen*[1], *M. Ahrens*[5], *K. Herrmann*[1], *W. P. Fendler*[1], *P. Fragoso-Costa*[1];
[1]*Department of Nuclear Medicine, West German Cancer Center, University Hospital Essen, Essen, GERMANY,* [2]*Department of Medical Oncology, West German Cancer Center, University Hospital Essen, Essen, Germany, Essen, GERMANY,* [3]*Bridge Institute of Experimental Tumor Therapy, West German Cancer Center, University Hospital Essen, Essen, GERMANY,* [4]*Division of Solid Tumor Translational Oncology, German Cancer Consortium (DKTK, Partner Site Essen) and German Cancer Research Center, DKFZ, Heidelberg, GERMANY,* [5]*Medical Clinic II, University Hospital Frankfurt, Frankfurt am Main, Germany, Frankfurt am Main, GERMANY.*

EP-0608

Feasibility of high-dose targeted radiation with I131-apamistamab in patients with relapsed/ refractory AML: Dosimetry and radiation safety experience from the phase 3 SIERRA trial

N. Pandit-Taskar[1], *K. Prasad*[2], *L. Chen*[3], *T. Senglaub*[4], *M. Zgaljardic*[5], *P. Brodin*[6], *B. Serencsits*[7];
[1]*Molecular Imaging and Therapy, Memorial Sloan Kettering Cancer Center, New York, NY, UNITED STATES OF AMERICA,* [2]*University of Pennsylvania Health System, Philadelphia, PA, UNITED STATES OF AMERICA,* [3]*Banner MD Anderson Cancer Center, Gilbert, AZ, UNITED STATES OF AMERICA,* [4]*Medical College of Wisconsin, Milwaukee, WI, UNITED STATES OF AMERICA,* [5]*Weill Cornell Medical Center, New York, NY, UNITED STATES OF AMERICA,* [6]*Actinium Pharmaceuticals, Inc., New York, NY, UNITED STATES OF AMERICA,* [7]*Memorial Sloan Kettering Cancer Center, New York, NY, UNITED STATES OF AMERICA.*

EP-0610

SSTR-directed Peptide Receptor Radionuclide Therapy in recurrent Meningioma

P. Hartrampf[1], *M. Müller*[1], *S. E. Serfling*[1], *A. K. Buck*[1], *B. Polat*[2], *R. A. Werner*[1];
[1]*Klinik und Poliklinik für Nuklearmedizin, Würzburg, GERMANY,* [2]*Klinik und Poliklinik für Strahlentherapie, Würzburg, GERMANY.*

EP-0611

Sequential treatment of High-risk Neuroblastoma combining I-131 MIBG high-dose and Topotecan. First experience

N. Orrego, *S. Prado-Wohlwend, J. Balaguer-Guill, I. Torres-Espallardo, M. Part-Lopez, C. Guerrero-Calatayud, J. Cañón-Sanchez, S. Montesinos-Gonzalez, P. Bello-Arques; Hospital Universitari i Politecnic La Fe, Valencia, SPAIN.*

EP-0612

New development Paradigm for Rare CNS cancers: Real World Data (RWD) Compared to Ongoing Safety and Feasibility Results from a Phase 1/2 Clinical Trial of 186RNL (Rhenium-186 Nanoliposome) (186Re) Obisbemeda in Recurrent Glioma: The ReSPECT-GBM Trial

N. LaFrance[1], *A. Brenner*[2], *J. Michalek*[2], *T. Patel*[3], *A. Bao*[4], *W. Phillips*[2], *M. Hedrick*[5], *M. Moore*[5], *J. Weinberg*[6], *M. Youssef*[3], *J. Floyd*[2];
[1]*Norman LaFrance, Austin, TX, UNITED STATES OF AMERICA,* [2]*UT Health San Antonio, San Antonio, TX, UNITED STATES OF AMERICA,* [3]*UT Southwestern Medical Center, Dallas, TX, UNITED STATES OF AMERICA,* [4]*Case Western Reserve University, Cleveland, OH, UNITED STATES OF AMERICA,* [5]*PLUS Therapeutics, Austin, TX, UNITED STATES OF AMERICA,* [6]*MD Anderson Cancer Center, Houston, TX, UNITED STATES OF AMERICA.*

EP-0613

Peptide Receptor Radionuclide Therapy In Advanced Refractory Meningiomas: Tocicixy And Efficacy In A Long Therm Follow Up

S. Severi[1], *I. Grassi*[2], *A. Bongiovanni*[2], *A. Sarnelli*[2], *V. Di Iorio*[2], *N. Ranallo*[2], *F. Matteucci*[2], *I. Marini*[2], *E. Amadori*[2], *I. Azzali*[2], *N. Riva*[2], *L. Gurrieri*[2], *S. Nicolini*[2], *P. Caroli*[2], *M. Sansovini*[1];
[1]*IRST IRCCS, Meldola, ITALY,* [2]*IRST IRCCS, Forlì-Cesena, ITALY.*

EP-0614

64CuCl2treatment: preliminary data on recurrent glioblastoma patients

D. Stanimirovic[1], *D. Milakovic*[1], *J. Mijatovic*[1], *I. Rakita*[1], *G. Vuleta*[1], *M. Basile*[2], *S. Valentini*[2];
[1]*University Clinical Center of the Republic of Srpska, Banja Luka, BOSNIA AND HERZEGOVINA,* [2]*A.C.O.M.-Advanced Center Oncology Macerata-S.R.L., Montecosaro (MC), ITALY.*

EP-0615

Substantiation of an individual therapeutic dose of 153Sm-oxabiphor for the treatment of bone metastases

G. Grushka[1], *L. Stadnyk*[2], *V. Bobrova*[2];
[1]*Kharkiv National Medical University, Kharkiv, UKRAINE,* [2]*Grigorev Institute for Medical Radiology and Oncology, Kharkiv, UKRAINE.*

EP-41

e-Poster Area

C: Therapy Clinical Study -> C2 Non-Oncological Treatments -> C21 Non-Oncological Treatments (including Thyroid Benign)

EP-0616

Radiosynoviorthesis of debilitating joints in haemophilia and rheumatoid arthritis : a local South East Asian hospital experience

K. Loke[1], *W. Tay*[1], *L. T. Cheng*[2], *C. Ng*[1], *H. Low*[1];
[1]*Singapore General Hospital, Singapore, SINGAPORE,* [2]*National University Hospital Singapore, Singapore, SINGAPORE.*

EP-0617

The Impact Role of High Specific activity of Radioactive Iodine 131I in Hyperthyroidism Response Rate

M. Al Rowaily[1], *M. Al-Qahtani*[2];
[1]*KFSHRC & Alfaisal University, Riyadh, SAUDI ARABIA,* [2]*KFSHRC, Riyadh, SAUDI ARABIA.*

EP-0618

Plasma Volume Deficit estimation using Cr-51 labelled RBC in Acute Pancreatitis Patients

N. Kumar, *S. Ballal, M. P. Yadav, M. Tripathi, C. Bal; All India Institute of Medical Sciences, New Delhi, India, New Delhi, INDIA.*

EP-0619

Urinary Excretion Rate of I-131 During Treatment of Benign Thyroid Disease

U. Beguš[1], *P. Tomše*[2], *K. Bajuk Studen*[2], *E. Pirnat*[2], *S. Gaberšček*[2], *K. Zaletel*[2];
[1]*Faculty of Mathematics and Physics, University of Ljubljana, Ljubljana, SLOVENIA,* [2]*Department of Nuclear Medicine, University Medical Centre Ljubljana, Ljubljana, SLOVENIA.*

EP-0620

Quality of life after radioisotope synoviorthesis in patients with chronic inflammatory diseases refractory to conventional treatments.

J. Venero Chaparro, *M. Sánchez Torrente, M. Gallego Márquez, F. Garí Martínez, D. Becerra García, M. Martínez-Valle Torres; Hospital Clínico San Cecilio, Granada, SPAIN.*

EP-0621

The most important problems of supervision over a patient qualified for knee synovectomy based on 10 years single-centre experience

M. Wlodarczyk, *Z. Adamczewski; Nuclear Medicine Department, Central Clinical Hospital, Medical University of Lodz, Lodz, POLAND.*

EP-0622

Treatment of Hidradenitis suppurativa (HS) - A pilot study : Can Nuclear Medicine therapy be the answer?

P. Gupta, *K. K. Verma, R. Kumar; AIIMS, New Delhi, INDIA.*

EP-0623

Percutaneous Microwave thermoablation (PMWT) for dominant benign thyroid nodules(BTN): a two years single centre experience

B. Criscuoli[1], *C. Manni*[1], *G. Follacchio*[1], *F. Salvatori*[2], *C. Mincarelli*[2], *S. Alborino*[2], *F. Capoccetti*[1];
[1]*Nuclear Medicine Unit, Macerata General Hospital, AST Macerata, ITALY,* [2]*Interventional Radiology Unit, Macerata General Hospital, AST Macerata, ITALY.*

EP-42

e-Poster Area

D: Technical Studies -> D1 Instrumentation -> D11 SPECT and SPECT/CT

EP-0624

SPECT Imaging Predictors of Social Anxiety Disorder Treatment Response: A New Way Forward

S. Rezaei, *E. Gharepapagh; Department of Nuclear Medicine, Medical School, Tabriz University of Medical Sciences, Tabriz, IRAN, ISLAMIC REPUBLIC OF.*

EP-0625

Feasibility of an 123I-Ioflupane single photon emission tomography attenuation correction method with a deep convolutional neural network

Y. Sayawaki[1], *T. Ueda*[1], *T. Tomimatsu*[1], *R. Nagaoka*[1], *K. Yamasita*[1], *S. Ito*[2];
[1]*Graduate school of Health Sciences, Kumamoto University, 4-24-1 Kuhonji Chuo-ku,Kumamoto-shi, Kumamoto-ken, JAPAN,* [2]*Faculty of Life Sciences, Kumamoto University, 4-24-1 Kuhonji Chuo-ku,Kumamoto-shi, Kumamoto-ken, JAPAN.*

EP-0626

Prognostic value of right ventricular dysfunction in chronic heart failure patients

A. Mishkina, *T. Atabekov, S. Sazonova, S. Popov, K. Zavadovsky; Cardiology Research Institute, branch of the Federal State Budgetary Scientific Institution «Tomsk National Research Medical Center of the Russian Academy of Sciences», Tomsk, RUSSIAN FEDERATION.*

EP-0627

Comparing myocardium perfusion imaging features between 3D and 2D general-purpose SPECT/CT systems

T. Noponen[1], *L. Kääriä*[2], *R. Hirvilammi*[2], *M. Hakulinen*[3], *M. Seppänen*[2];
[1]*Department of Clinical Physiology and Nuclear Medicine and Department of Medical Physics, Turku University Hospital, Turku, FINLAND,* [2]*Department of Clinical Physiology and Nuclear Medicine, Turku University Hospital, Turku, FINLAND,* [3]*Diagnostic Imaging Center, Kuopio University Hospital, Kuopio, FINLAND.*

EP-0628

Use of SPECT-CT In The Combined SLNB Technique and Node Labeling with 125i Seeds in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy.

M. Pérez Avila[1], *M. Caballero Vivanco*[1], *F. González Asid*[1], *E. Córdoba Cañete*[1], *R. Sánchez Sánchez*[2];
[1]*Hospital Universitario Virgen de las Nieves, Granada, SPAIN,* [2]*Hospital Universitario Virgen de las Nieves, Maracena, Granada, SPAIN.*

EP-0629

PSF correction and Tc-99m quantitative performance of a disruptive CZT multiple-head SPECT-CT

A. Seret[1], *C. Bernard*[2];
[1]*UNIVERSITY OF LIEGE, Liege, BELGIUM,* [2]*CHU of LIEGE, Liege, BELGIUM.*

EP-0630

Energy window narrowing or classical dual-energy window substraction for scatter correction in a CZT multiple-head SPECT-CT

A. Seret[1], *C. Bernard*[2];
[1]*UNIVERSITY OF LIEGE, Liege, BELGIUM,* [2]*CHU of LIEGE, Liege, BELGIUM.*

EP-0631

Small feature quantification in SPECT/CT - a focus on mandibular condyles

S. De Schepper[1,2], *O. Lenssen*[3], *G. Gnanasegaran*[4], *T. Van den Wyngaert*[1,2], *J. C. Dickson*[5];
[1]*Department of Nuclear Medicine, Antwerp University Hospital, Edegem, BELGIUM,* [2]*Faculty of Medicine and Health Sciences (MICA—IPPON), University of Antwerp, Wilrijk, BELGIUM,* [3]*Department of Oral and Maxillofacial Surgery, ZNA Middelheim, Antwerp, BELGIUM,* [4]*Department of Nuclear Medicine, Royal Free London NHS, London, UNITED KINGDOM,* [5]*Institute of Nuclear Medicine, University College of London Hospitals NHS Foundation Trust, London, UNITED KINGDOM.*

EP-0632

Reduction of the acquisition time and improvement of the dopaminergic imaging quality with CZT gamma camera. Comparison with conventional gamma cameras.

S. Asadurova, *C. Lorenzo-Bosquet, S. Aguade, A. García-Burillo;*
Hospital Universitari Vall d´Hebron, Barcelona, SPAIN.

EP-0633

The Art of Juggling: On the Influence of Sphere Positioning on Recovery Coefficients Determined Using an IEC-NEMA Phantom

J. Leube[1], *J. Gustafsson*[2], *M. Lassmann*[1], *M. Salas Ramirez*[1], *J. Tran-Gia*[1];
[1]*University Hospital Würzburg, Würzburg, GERMANY,* [2]*Lund University, Lund, SWEDEN.*

EP-0634

Objective Assessment of Gamma Camera's Intrinsic Resolution

P. Trindev[1], *M. Dimcheva*[2];
[1]*Retired, 1233 Sofia, BULGARIA,* [2]*Department of Nuclear Medicine, Sofia Cancer Center, Sofia, BULGARIA.*

EP-0635

Calibration Factor and Recovery Coefficients for Lu-177 in a ring-shaped CZT gammacamera

A. Garcia, *A. Seoane;*
Vall d'Hebron Hospital Campus, Barcelona, SPAIN.

EP-0636

Reducing scan time for post-therapy [131I] NaI SPECT/CT scans and [99mTc]Tc-HDP bone scintigraphy SPECT

T. Ball, *K. Sabanayagam, H. McMeekin, A. Haroon, M. Vadrucci, J. Buscombe, E. Nowosinska, M. Krishnamurthy;*
Barts Health NHS Trust, London, UNITED KINGDOM.

EP-43

e-Poster Area

D: Technical Studies -> D1 Instrumentation -> D12 PET/CT

EP-0637

The earlier 18F-FDG and 68Ga-DOTA-FAPI-04 dual-tracer total-body PET/CT scan timing: a feasibility study

Z. Zheng, *Y. He, W. Mao, H. Yu, H. Wu, P. Hu, H. Shi;*
Zhongshan hospital, fudan university, Shanghai, CHINA.

EP-0638

Clinical evaluation of a head motion correction algorithm on PET/CT system

W. Yang[1], *F. Kang*[1], *Z. Xie*[1], *G. Li*[1], *K. Guo*[1], *C. Xi*[2], *H. Liu*[2], *Y. Li*[2], *C. Sun*[2], *E. M. Revilla*[2], *Y. Zhao*[2], *D. Zhang*[2], *L. Shi*[2], *H. Yi*[2], *Y. Zhao*[2], *Y. Lu*[2], *J. Wang*[1];
[1]*Department of Nuclear Medicine, Xijing hospital, Xi'an, CHINA,* [2]*United Imaging Healthcare, Shanghai, CHINA.*

EP-0639

18F-FDG PET/CT for evaluation of metastases in non-small cell lung cancer on the efficacy of immunotherapy

Y. Feng, *P. Wang, Y. Chen, W. Dai;*
Department of Nuclear Medicine, The First College of Clinical Medical Science, China Three Gorges University, Yichang city, CHINA.

EP-0640

PET imaging and quantification of small animals using a clinical SiPM-based camera

C. Desmonts[1,2], *C. Lasnon*[3,2], *C. Jaudet*[3], *N. Aide*[2];
[1]*Caen University Hospital, Caen, FRANCE,* [2]*Normandy University, UNICAEN, INSERM 1086 ANTICIPE, Caen, FRANCE,* [3]*Comprehensive Cancer Centre F. Baclesse, Caen, FRANCE.*

EP-0641

Value of 2-[18F]FDG-PET/CT in detecting immune-related adverse events in patients with malignant melanoma or non-small cell lung cancer: a systematic scoping review

S. Nadaraja[1], *J. Helsing*[1], *M. Bezhad*[1], *L. H. Land*[2], *C. H. B. Ruhlmann*[2], *O. Gerke*[1,3], *M. G. Hildebrandt*[1,3,4];
[1]*Department of Nuclear Medicine, Odense University Hospital, Odense C, DENMARK,* [2]*Department of Oncology, Odense University Hospital, Odense C, DENMARK,* [3]*Department of Clinical Research, University of Southern Denmark, Odense C, DENMARK,* [4]*Centre for Personalized Response Monitoring in Oncology (PREMIO), Odense University Hospital, Odense C, DENMARK.*

EP-0642

Quantitative consistency assessment along the axial field of view of a total-body PET scanner

X. Meng[1], *Y. Wu*[2], *F. Wang*[1], *Y. Song*[1], *R. Wu*[2], *N. Li*[1], *Z. Yang*[1];
[1]*Peking University Cancer Hospital & Institute, Beijing, CHINA,* [2]*Shanghai United Imaging Healthcare, Shanghai, CHINA.*

EP-0643

68Ga-Pentixafor in Squamous Cell Carcinoma of the head and neck, a pilot study

B. Hadebe[1], *L. Harry*[1], *L. Gabela*[1], *S. Masikane*[1], *M. Patel*[1], *P. Bipath*[1], *N. Cebekhulu*[1], *N. E. Nyakale*[2], *C. Aldous*[1], *M. M. Sathekge*[3], *M. Voster*[1];
[1]*University of KwaZulu Natal, Durban, SOUTH AFRICA,* [2]*Sefako Makgatho Health Sciences University, Pretoria, SOUTH AFRICA,* [3]*University of Pretoria, Durban, SOUTH AFRICA.*

EP-0644

The asymmetry of tau deposition and its correlation with cerebral metabolic asymmetry in Alzheimer's disease

H. Lin, *p. wu, c. zuo;*
Deparment of Nuclear Medicine / PET Center, Huashan Hospital, Fudan University, Shanghai, CHINA.

EP-0645

Characterizing the 5-Ring GE Discovery MI PET/CT Scanner Using AAPM TG-126 and Compare these Results with the NEMA NU 2-2012 Results

R. Almazrou[1], *S. Alanazi*[1], *M. Alrabiah*[2], *R. Al-Fakhranee*[1], *O. Mawlawi*[3];
[1]*King Faisal Specialist Hospital and Research center, Riyadh, SAUDI ARABIA,* [2]*GE HealthCare, Riyadh, SAUDI ARABIA,* [3]*University of Texas MD Anderson Cancer Center, Houston, TX, UNITED STATES OF AMERICA.*

EP-0646

Clinical solution to minimize mis-registration artifacts in PET/CT

T. Pan;
The University of Texas, Houston, TX, UNITED STATES OF AMERICA.

EP-0647

Physical and Clinical Optimization of Acquisition Durations on a Digital BGO High Sensitivity PET-CT System

Q. Maronnier, *M. Terroir, T. Cassou-Mounat, A. Latgé, J. S. Texier, L. Vija, F. Courbon, O. Caselles;*
Oncopole Claudius Regaud, Toulouse, FRANCE.

EP-0648

Quantitative Evaluation of Low-dose Whole-body Indirect Patlak Parametric Imaging with Deep Progressive Reconstruction

Q. Ye[1], *C. Xi*[1], *H. Dai*[1], *H. Zeng*[1], *Y. Zhao*[1], *G. Li*[2], *F. Kang*[2], *J. Wang*[2], *Y. Lv*[1], *Y. Lu*[1];
[1]*United Imaging Healthcare, Shanghai, CHINA,* [2]*Xijing Hospital, Xi'an, CHINA.*

EP-0649

Deep learning-based method for the reconstruction of high-quality 3D PET image from low-dose data

R. Guo[1,2], *J. Wang*[3], *Y. Miao*[1,2], *S. Xue*[4], *Y. Zhang*[1,2], *K. Shi*[4], *B. Li*[1,2], *G. Zheng*[3];
[1]*Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, CHINA,* [2]*Collaborative Innovation Center for Molecular Imaging of Precision Medicine, Ruijin Center, Shanghai, CHINA,* [3]*Institute of Medical Robotics, School of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai, China, Shanghai, CHINA,* [4]*Department of Nuclear Medicine, University of Bern, Switzerland, Bern, SWITZERLAND.*

EP-0650

Diffuse high uptake of 68Ga-FAPI in both kidneys helps with diagnosis of kidney diseases

X. Zhong[1], *J. Cheng*[2], *M. Su*[2], *W. Zhang*[3];
[1]*Nuclear Medicine Department and Biomedical Big Data Center, West China Hospital of Sichuan University, Chengdu, CHINA,* [2]*Nuclear Medicine Department, West China Hospital of Sichuan University, Chengdu, CHINA,* [3]*Biomedical Big Data Center, West China Hospital of Sichuan University, Chengdu, CHINA.*

EP-0651

Designing a 1-mm Resolution Brain-Dedicated PET System with a Hemispherical Detector Arrangement

T. Yamaya[1], *E. Yoshida*[1], *G. Akamatsu*[1], *K. Narita*[2,1], *H. Tashima*[1], *Y. Iwao*[1], *M. Takahashi*[1];
[1]*National Institutes for Quantum Science and Technology (QST), Chiba, JAPAN,* [2]*Chiba University, Chiba, JAPAN.*

EP-0652

68Ga -FAPI PET/CT Improves Detection Rates of Gastrointestinal Mucinous Adenocarcinoma or Signet Ring Cell Carcinoma: A Comparative Study with 18F-FDG

Y. Sun;
Fudan University, Shanghai Cancer center, Shanghai, CHINA.

EP-0653

Effect of Radiopharmaceutical Extravasation on the Accuracy of SUV Estimation in PET/CT

I. Znamenskiy[1,2,3], *V. Volkov*[2,3], *A. Kondakov*[1,2], *M. Beregov*[3], *D. Mosin*[1,2];
[1]*Petrovsky National Research Centre of Surgery, Moscow, RUSSIAN FEDERATION,* [2]*Pirogov Russian National Research Medical University, Moscow, RUSSIAN FEDERATION,* [3]*Federal center of brain research and neurotechnologies, Moscow, RUSSIAN FEDERATION.*

EP-0654

Last generation digital PET: comparison of the performances of 5 vs. 6 rings systems and optimization of the overlap value

M. Bernardini[1], *T. Mbaye*[1], *M. Alqabandi*[2], *F. Hyafil*[1];
[1]*Hôpital Européen Georges Pompidou (HEGP), Paris, FRANCE,* [2]*Nuclear Medicine Department, Faculty of Medicine, Kuwait University, Kuwait City, KUWAIT.*

EP-0655

Influence of the CT-Energy on the Attenuation Correction of the PET/CT and the Impact on Small Bone Lesions

A. Haslauer, *E. Solari, J. Brosch-Lenz, W. Weber, S. G. Nekolla;*
Klinikum rechts der Isar, Technical University Munich, Munich, GERMANY.

EP-0656

PET digitization chain for Monte Carlo simulation in GATE

J. Salvadori[1], *A. Merlet*[2], *B. Presles*[3], *A. Etxebeste*[4], *J. Vrigneaud*[3], *D. Sarrut*[4];
[1]*Institut de cancérologie Strasbourg Europe (ICANS), Strasbourg, FRANCE,* [2]*Imagerie et Vision artificielle, ImViA EA 7535, Dijon, FRANCE,* [3]*Institut de Chimie Moléculaire de l'Université de Bourgogne (ICMUB), UMR CNRS 6302, University of Burgundy, Dijon, FRANCE,* [4]*Universitée de Lyon, CREATIS; CNRS UMR5220; Inserm U1044; INSA-Lyon; Universitée Lyon 1; Centre Leon Bérard., Lyon, FRANCE.*

EP-0657

Sensitivity comparison of non-TOF and TOF PET/CT

L. Carnegie-Peake, *J. Dickson, S. McQuaid;*
University College London Hospital, London, UNITED KINGDOM.

EP-0658
Development and Validation of a Monte Carlo Simulation Workflow for a Total-Body PET Scanner
C. Pommranz[1,2], *E. Elmoujarkach*[3], *J. Cabello*[4], *W. Lan*[5], *M. Rafecas*[3], *J. Mannheim*[1,6], *P. Linder*[5], *A. Santangelo*[2], *C. la Fougère*[5,6], *B. Pichler*[1,6], *F. Schmidt*[1,5];
[1]*Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, Eberhard Karls University Tuebingen, Tuebingen, GERMANY,* [2]*Institute for Astronomy and Astrophysics, Eberhard Karls University Tuebingen, Tuebingen, GERMANY,* [3]*Institute of Medical Engineering, University of Lübeck, Lübeck, GERMANY,* [4]*Siemens Medical Solutions UNITED STATES OF AMERICA, Inc., Knoxville, TN, UNITED STATES OF AMERICA,* [5]*Department of Nuclear Medicine and Clinical Molecular Imaging, University hospital Tuebingen, Tuebingen, GERMANY,* [6]*Cluster of Excellence iFIT (EXC 2180) "Image Guided and Functionally Instructed Tumor Therapies", University of Tuebingen, Tuebingen, GERMANY.*

EP-0659
Can SUVmax be used to predict the development of anatomical correspondence in bone uptakes detected by 18F-PSMA-1007-PET/CT?
L. Eklund, *M. Anttinen, J. Vanhatalo, S. Malaspina, T. Noponen, J. Kemppainen, P. Boström, M. Seppänen, O. Ettala;
University of Turku, Turku, FINLAND.*

EP-0660
Measurement of NECR in a Long Axial Field of View Scanner using a Custom Humanoid Phantom covering the Full Axial Field
S. Holm, *J. V. *Henriksen, T. L. Andersen, F. L. Andersen; Rigshospitalet, Copenhagen University Hospital, Copenhagen, DENMARK.*

EP-0661
Feasibility study of Sub-minute acquisition with deep-learning reconstruction using 18F-FAPI Total-body PET/CT
E. Liu, *L. Jiang;
Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, CHINA.*

EP-0662
Effect of time-of-flight capabilities on noise in clinical PET-CT
S. McQuaid, *L. Carnegie-Peake, J. C. Dickson;
Institute of Nuclear Medicine, London, UNITED KINGDOM.*

EP-44

e-Poster Area

D: Technical Studies -> D1 Instrumentation -> D13 PET/MR

EP-0663
Development of a low-cost protocol using standard equipment for the constant infusion administration of [18F]FDG in PET-MR
A. Cripps[1], *J. Taylor*[1,2], *M. Singleton*[1], *D. Selvarajah*[1,2], *G. Armitage*[1], *A. Scott*[1];
[1]*Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UNITED KINGDOM,* [2]*University of Sheffield, Sheffield, UNITED KINGDOM.*

EP-0664
Addressing PET Attenuation Correction Challenges for the ACR Accreditation of a Simultaneous PET/MR Scanner
H. Kulkarni[1], *A. Samuels*[1], *T. Faasse*[1], *V. Sridhar*[2], *L. Hu*[2], *J. Botti*[1];
[1]*BAMF Health, Grand Rapids, MI, UNITED STATES OF AMERICA,* [2]*UIH America, Houston, TX, UNITED STATES OF AMERICA.*

EP-45

e-Poster Area

D: Technical Studies -> D1 Instrumentation -> D15 Quality Control, Performance and Standardization

EP-0666
Coincidence distribution in 2-layer hemispheric PET geometries
K. Scheiff, *A. Pashazadeh, C. Hoeschen;
Otto-von-Guericke-University Magdeburg, Magdeburg, GERMANY.*

EP-0667
MC Simulator Framework for Monolithic Scintillator Based PET and SPECT
J. Peter, *L. P. Clemens;
German Cancer Research Center, Heidelberg, GERMANY.*

EP-0668
The Situation of Nuclear Medicine in China: A Report of the First Official Nationwide Survey in 2021
H. Zhang[1], *J. Zheng*[2], *N. Hu*[1], *Y. Liu*[1], *H. Jing*[1], *L. Huo*[1];
[1]*Peking Union Medical College Hospital, Beijing, CHINA,* [2]*Department of Radiology, University of Cambridge, Cambridge, UNITED KINGDOM.*

EP-0669
Monte Carlo performance with impact of different crystal materials on sensitivity characteristic of preclinical PET scanner
Z. Karimi[1], *P. Sheikhzadeh*[2], *M. Ay*[3];
[1]*Faculty of Physics, University of Isfahan, Isfahan, IRAN, ISLAMIC REPUBLIC OF,* [2]*Department of Nuclear Medicine, Imam Khomeini Hospital Complex, Tehran, IRAN, ISLAMIC REPUBLIC OF,* [3]*Research Center for Molecular and Cellular Imaging (RCMCI), Advanced Medical Technologies and Equipment Institute (AMTEI), Tehran University of Medical Sciences (TUMS), Tehran, IRAN, ISLAMIC REPUBLIC OF.*

EP-0670
Determination of the Kernel with which to Smooth the CT for Air Fraction Correction in Lung PET/CT Studies
F. Leek[1,2], *C. Anderson*[3], *A. P. Robinson*[2,4,5], *R. M. Moss*[1], *B. F. Hutton*[1], *K. Thielemans*[1];
[1]*University College London, London, UNITED KINGDOM,* [2]*National Physical Laboratory, Teddington, UNITED KINGDOM,* [3]*University College London Hospital NHS Foundation Trust, London, UNITED KINGDOM,* [4]*The Christie NHS Foundation Trust, Manchester, UNITED KINGDOM,* [5]*University of Manchester, Manchester, UNITED KINGDOM.*

EP-0671
Is It Reliable to Use NMQC-Toolkit as a Self-QC Software for Nuclear Medicine Departments?
N. KODALOGLU[1], *G. Vural*[2], *N. C. Gülaldi*[3];
[1]*University of Health Sciences, Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital, Department of Radiation Oncology, ANKARA, TÜRKIYE,* [2]*University of Health Sciences, Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital, Department of Nuclear Medicine, ANKARA, TÜRKIYE,* [3]*University of Health Sciences, Ankara Bilkent City Hospital, Department of Nuclear Medicine, ANKARA, TÜRKIYE.*

EP-0672
The Role of SPECT/CT NEMA NU2 Calibration in Quantitative Imaging
I. Irimescu[1,2], *R. Maaz*[1], *A. Lazar*[1], *M. Mutuleanu*[1,3], *C. Petroiu*[1], *M. Mihailescu*[2], *M. Gherghe*[1,3];
[1]*Institute of Oncology „Professor Doctor Alexandru Trestioreanu", Bucharest, ROMANIA,* [2]*Applied Sciences Doctoral School, Politehnica University, Bucharest, ROMANIA,* [3]*„Carol Davila" University of Medicine and Pharmacy, Bucharest, ROMANIA.*

EP-0673
Stability of Brain PET/CT Image Quantification for Imaging with a VR Headset
L. Raes[1,2], *S. Bourgeois*[1], *A. Bracke*[1], *T. De Haan*[1], *H. Everaert*[1,2];
[1]*Universitair Ziekenhuis Brussel, Brussels, BELGIUM,* [2]*Vrije Universiteit Brussel, Brussels, BELGIUM.*

EP-46

e-Poster Area

D: Technical Studies -> D2 Data Analysis -> D21 Data Analysis in Neuro and Cardio

EP-0674
Parametric imaging of P-glycoprotein function at the blood-brain barrier using KE,brain-maps generated from dynamic [11C]metoclopramide PET data in rodents, monkeys, and humans
L. Breuil[1,2], *M. El Bialli*[3], *D. Vodovar*[1], *S. Marie*[1], *S. Auvity*[1,2], *S. Goutal*[1], *S. Rodrigo*[1], *M. Bauer*[3], *O. Langer*[3,4], *N. Tournier*[1];
[1]*1.BioMaps, Laboratoire d'Imagerie Biomédicale Multimodale Paris-Saclay,Inserm, CNRS, CEA, Université Paris-Saclay, Orsay, France, Orsay, FRANCE,* [2]*2. Inserm UMR-S1144, University of Paris Cité, 75006 Paris, France., Paris, FRANCE,* [3]*3.Department of Clinical Pharmacology, Medical University of Vienna, 1090 Vienna, Austria., Vienna, AUSTRIA,* [4]*4.Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Austria., Vienna, AUSTRIA.*

EP-0675
Coupling between Cortical Thickness and Glucose Metabolism in the Human Brain: a PET/MRI study
Q. Huang[1], *Y. Yang*[2], *N. Qi*[2], *S. Ren*[1], *J. Wang*[1], *Y. Guan*[1], *J. Zhao*[2], *F. Xie*[1];
[1]*Department of Nuclear Medicine & PET center Huashan Hospital Fudan University, Shanghai, CHINA,* [2]*Department of Nuclear Medicine, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, CHINA.*

EP-0676
Spinal Cord imaging by [11C]PIB PET/MRI: evaluation of drawing methods and reference region use in myelin uptake quantification of Healthy Volunteers and Multiple Sclerosis Patients
L. Zorante de Lucena, *M. Sales Pitombeira, K. Repiso Campanholo, C. Alberto Buchpiguel, D. de Paula Faria;
Centro de Medicina Nuclear do Hospital da Clínicas da Faculdade de Medicina da USP (CMN-HC-FMUSP), São Paulo, BRAZIL.*

EP-0677
Quantification of Neuroinflammation using [18F] DPA714 PET in individuals with Long COVID
S. Golla[1], *D. Visser*[1], *S. C. J. Verfaillie*[2], *E. M. Coomans*[1], *R. M. Rikken*[1], *E. van de Giessen*[1], *M. E. den Hollander*[1], *M. Yaqub*[1], *A. Verveen*[2], *F. Barkhof*[1,3], *J. Horn*[4], *B. Koopman*[5], *P. Schober*[6], *D. W. Koch*[2], *R. C. Schuit*[1], *A. D. Windhorst*[1], *M. Kassiou*[7], *M. van Vugt*[8], *H. Knoop*[2], *B. N. M. van Berckel*[1], *N. Tolboom*[9], *R. Boellaard*[1];
[1]*Department of Radiology & Nuclear Medicine, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam, NETHERLANDS,* [2]*Department of Medical Psychology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam Public Health Research Institute, Amsterdam, NETHERLANDS,* [3]*Institute of Neurology and Healthcare Engineering, University College London, London, UNITED KINGDOM,* [4]*Department of Intensive Care & Laboratory of Experimental Intensive Care and Anesthesiology (L·E·I·C·A), University of Amsterdam, Amsterdam UMC, Amsterdam, NETHERLANDS,* [5]*Pulmonary Medicine, OLVG, Amsterdam, NETHERLANDS,* [6]*Department of Anaesthesiology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, NETHERLANDS,* [7]*School of Chemistry, The University of Sydney, Sydney, AUSTRALIA,* [8]*Department of Internal Medicine, University of Amsterdam, Amsterdam UMC, Amsterdam, NETHERLANDS,* [9]*Department of Radiology & Nuclear Medicine, University Medical Centre Utrecht, Utrecht, NETHERLANDS.*

EP-0678
Florbetaben PET quantification strongly agrees with histopathological confirmation of amyloid-beta load and visual reads.
S. Bullich[1], *J. Koikkalainen*[2], *A. Jovalekic*[1], *N. Roé-Vellvé*[1], *G. D. Kolinger*[1], *N. Koglin*[1], *A. W. Stephens*[1], *L. Thurfjell*[2];
[1]*Life Molecular Imaging GmbH, Berlin, GERMANY,* [2]*Combinostics Oy, Tampere, FINLAND.*

EP-0679
Attenuation correction of cardiac PET with end-expiratory CT and average CT
K. Sander[1], *T. Pan*[2], *A. Roby*[1];
[1]*University of Texas Medical School, Houston, TX, UNITED STATES OF AMERICA,* [2]*University of Texas at M. D. Anderson Cancer Center, Houston, TX, UNITED STATES OF AMERICA.*

EP-0680

"Enhancing Quantitative and Qualitative Analysis in Transthyretin Amyloid Cardiomyopathy Imaging: Preliminary Results from the iTAC IAEA Project"

P. Knoll[1], *L. Torres Aroche*[2], *F. Mut*[3], *G. Grossmann*[4], *S. Orbala*[5], *G. Agu*[6], *S. Mirzaei*[6], *I. de Souza Baptista*[4], *D. Paez*[1], *A. Brink*[1], *M. Ljungberg*[7];
[1]*IAEA, Vienna, AUSTRIA,* [2]*Nuclear medicine department, Centis, La Habana, CUBA,* [3]*Servicio Medicina Nuclear, Hospital Italiano, Montevideo, URUGUAY,* [4]*Hospital Moinhos de Vento, Porto Alegre, BRAZIL,* [5]*Brigham and Women's Hospital, Harvard Medical School, Boston, MA, UNITED STATES OF AMERICA,* [6]*Department of Nuclear Medicine, Klinik Ottakring, Vienna, AUSTRIA,* [7]*Lund University Skane University Hospital, Lund, SWEDEN.*

EP-0681

A novel assisted workflow created to obtain cardiac semiquantitative indexes from 99mTc-DPD-scintigraphy and to correlate them with different etiologies of transthyretin-related cardiac amyloidosis.

S. E. Prisco[1], *S. Mattoni*[1], *A. Paccagnella*[2], *F. Mattana*[3], *M. F. Morrone*[4,5], *G. Della Gala*[4], *M. Sguazzotti*[6], *S. Longhi*[6], *G. Saturi*[6], *S. Fanti*[1,7], *N. Galiè*[6], *L. Strigari*[4], *R. Bonfiglioli*[7];
[1]*Nuclear Medicine, Alma Mater Studiorum University of Bologna, Bologna, ITALY,* [2]*Nuclear Medicine Unit, AUSL Romagna, Cesena, ITALY,* [3], *IEO European Institute of Oncology IRCSS, Milano, ITALY,* [4]*Department of Medical Physics, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY,* [5]*Specialization School in Medical Physics, University of Bologna, Bologna, ITALY,* [6]*Cardiovascular Department, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY,* [7]*Nuclear Medicine, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY.*

EP-0682

Long-term prognostic value of automated measurements in nuclear cardiology: Comparisons with the expert reading scoring

G. Angelidis, *V. Valotassiou, I. Tsougos, C. Tzavara, S. Giannakou, D. Psimadas, E. Theodorou, A. Ziaka, C. Ziangas, J. Skoularigis, F. Triposkiadis, P. Georgoulias;*
University of Thessaly, Larissa, GREECE.

EP-0683

Centiloid Calibration of a Commercial Amyloid Quantitation Software for different Fluorine-18 Radiotracers

R. Fahmi;
Siemens Healthineers, Knoxville, TN, UNITED STATES OF AMERICA.

EP-0684

Comparison of MR arterial spin labelling regional Cerebral Blood Flood estimates to early amyloid PET measurements

J. Anton Rodriguez[1,2], *J. C. Matthews*[3], *L. A. Scott*[3], *J. J. McFadden*[3], *B. R. Dickie*[2], *K. Herholz*[3], *L. M. Parkes*[3];
[1]*The Christie NHS Foundation Trust and University of Manchester, Manchester, UNITED KINGDOM,* [2]*Division of Informatics, Imaging and Data Sciences, MAHSC, University of Manchester, Manchester, UNITED KINGDOM,* [3]*Division of Psychology, Communication and Human Neuroscience , Faculty of Biology, Medicine and Health-University of Manchester, Manchester, UNITED KINGDOM.*

EP-0685

A ROI-based Quantitative Pipeline for [18]F-FDG PET Metabolism and pCASL Perfusion Joint Analysis: Validation on [18]F-FDG PET Data

V. Cerina[1], *E. De Bernardi*[2], *C. Crivellaro*[3], *S. Morzenti*[4], *F. E. Pozzi*[1], *L. Jonghi Lavarini*[2], *V. Bigiogera*[2], *R. M. Moresco*[2], *G. Basso*[2,5];
[1]*PhD program in Neuroscience, Department of Medicine and Surgery, University of Milano Bicocca, Milano, ITALY,* [2]*Department of Medicine and Surgery, University of Milano Bicocca, Milano, ITALY,* [3]*Nuclear Medicine, Fondazione IRCCS San Gerardo dei Tintori, Monza, ITALY,* [4]*Medical Physics, Fondazione IRCCS San Gerardo dei Tintori, Monza, ITALY,* [5]*Neuroradiology, Fondazione IRCCS San Gerardo dei Tintori, Monza, ITALY.*

EP-0686

Method evaluation for quantification of cerebral blood flow for [15O]-water PET/CT, a segmentation comparison between using ASPECTS method for simplified quantification to a 3D-volume based arterial atlas

A. Eriksson, *J. Patrick Connelly, A. Gul Sherwani, L. Gridset, K. Angell, L. Gyland Mikalsen, C. Stokke, M. Stavrinou;*
Oslo Universityhospital, Oslo, NORWAY.

EP-47

e-Poster Area

D: Technical Studies -> D2 Data Analysis -> D22 Other Data Analysis

EP-0687

Comparison of Results Analysis for Isotopic Determination of Plasma Volume: a Prospective Study

M. Ragot, *R. Charmelot, P. Orhon, B. Berton, A. Revy, M. Tempier, S. Levesque;*
Centre Jean Perrin, Clermont-Ferrand, FRANCE.

EP-0688

Discordance between 90Y PET/CT(MR)-estimated activity and dose calibrator measured administered activity: an international patient study in SIRT with resin and glass microspheres

T. Carlier[1], *S. Gnesin*[2], *J. Mikell*[3], *M. Conti*[4], *J. Prior*[5], *C. Bailly*[1], *M. Pérez Lago*[6], *Y. Dewaraja*[7], *T. Lima*[6];
[1]*University Hospital of Nantes, Nantes, FRANCE,* [2]*Institute of Radiation Physics, Lausanne University Hospital and University of Lausanne, Lausanne, SWITZERLAND,* [3]*Department of Radiation Oncology, University of Michigan, Saint Louis, MI, UNITED STATES OF AMERICA,* [4]*Siemens Medical Solutions UNITED STATES OF AMERICA, Inc, Knoxville, TN, UNITED STATES OF AMERICA,* [5]*Department of Nuclear Medicine and Molecular Imaging, Lausanne University Hospital and University of Lausanne, Lausanne, SWITZERLAND,* [6]*Department of Radiology and Nuclear Medicine, Luzerner Kantonsspital and Faculty of Health Sciences and Medicine, University of Lucerne, Luzern, SWITZERLAND,* [7]*Division of Nuclear Medicine, Department of Radiology, University of Michigan, Ann Arbor, MI, UNITED STATES OF AMERICA.*

EP-0689

Using Different Dichotomisation Methods for Lesion Dissemination to Predict Survival Outcomes in Lymphoma Patients

X. Wong[1], *L. Yong*[1], *Y. Chen*[2,3], *S. Liu*[1,3], *K. Lue*[1];
[1]*Tzu Chi University of Science and Technology, Hualien, TAIWAN,* [2]*Tzu Chi University, Hualien, TAIWAN,* [3]*Hualien Tzu Chi Hospital, Hualien, TAIWAN.*

EP-0690

Evaluation of Image Quality and Quantification with Various Scan Times on 64 Copper PET/CT Imaging: Phantom and Clinical study

F. Sadeghi[1], *A. Monsef*[2], *P. Sheikhzadeh*[1,3];
[1]*Department of Medical Physics and Biomedical Engineering ,Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF,* [2]*Department of Radiation Oncology, University of Minnesota Medical School, Minneapolis, MN, UNITED STATES OF AMERICA,* [3]*Department of Nuclear Medicine, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF.*

EP-0691

Cluster Analysis in Binary Classification of Amyloid PET/MR Imaging with/without-Partial Volume Effect Correction

E. Balci[1], *U. O. Akdemir*[1], *M. A. Topcuoglu*[2], *E. Saka*[2], *L. O. Atay*[1];
[1]*Gazi University Medical Faculty Department of Nuclear Medicine, ANKARA, TÜRKIYE,* [2]*Hacettepe University, Faculty of Medicine, Department of Neurology, ANKARA, TÜRKIYE.*

EP-0692

Improving Efficiency of Simultaneous Dual-Tracer PET Imaging

Z. Li[1], *V. Shah*[2], *S. L. M. Viol*[3], *P. van Snick*[1], *G. Luurtsema*[1], *R. H. J. A. Slart*[1], *A. Lammertsma*[1], *C. Tsoumpas*[1];
[1]*Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Groningen, NETHERLANDS,* [2]*Molecular Imaging, Siemens Medical Solutions UNITED STATES OF AMERICA, Inc., Knoxville, TN, UNITED STATES OF AMERICA,* [3]*Department of Radiology and Nuclear medicine, Amsterdam University Medical Center, Amsterdam, NETHERLANDS.*

EP-0693

Patlak graphical analysis: Net Influx Rate (Ki) obtained with a fully-automated Multiparametric PET Suite versus traditional Regional Plot

A. Capotosti[1], *R. Moretti*[1], *M. De Summa*[2], *S. Taralli*[1], *E. Perrone*[1,3], *M. L. Calcagni*[1,3], *L. Indovina*[1];
[1]*Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, ITALY,* [2]*Medipass S.p.a. Servizio Integrativo PET/CT - Radiofarmacia, TracerGLab, Fondazione Policlinico Universitario A.Gemelli IRCCS, Rome, ITALY,* [3]*Università Cattolica del Sacro Cuore, Rome, ITALY.*

EP-0694

PET imaging with somatostatin analogue (SomaKitTOC®) for assessment of neuroendocrine tumors: unknown physiological uptake, patient in/dependent? Experience feedback

C. Provost[1], *C. Schmitt*[1], *J. Fouque*[1], *O. Madar*[1], *L. Champion*[2];
[1]*Institut Curie, Radiopharmacology department, Saint Cloud, FRANCE,* [2]*Institut Curie, Nuclear Medicine departement, Saint Cloud, FRANCE.*

EP-0695

A fuzzy C-mean segmentation technique to estimate methodological uncertainties on time-activity curves in dynamic quantitative positron emission tomography studies

P. Laporte[1], *J. Carrier*[1,2,3];
[1]*Département de Physique, Faculté des Arts et Sciences, Université de Montréal, Montréal, QC, CANADA,* [2]*Institut de Génie Biomédical, Faculté de Médecine, Université de Montréal, Montréal, QC, CANADA,* [3]*Département de radiologie, radio-oncologie et médecine nucléaire, Faculté de Médecine, Université de Montréal, Montréal, QC, CANADA.*

EP-0696

Influence of normal database sample size on the development of new statistical image analysis software for bone SPECT imaging

Y. Yakushiji[1], *K. Miwa*[2], *K. Wagatsuma*[1,3], *S. Fukuda*[1], *T. Yamao*[2], *Y. Kamitaka*[3], *N. Miyaji*[2], *T. Hasegawa*[1];
[1]*Kitasato University Graduate School of Medical Sciences, Kanagawa-ken, JAPAN,* [2]*Fukushima Medical University, Fukushima-ken, JAPAN,* [3]*Tokyo Metropolitan Institute of Gerontology, Tokyo-to, JAPAN.*

EP-0697

The Management of Diabetic Patients During the Positron Emission Tomography Examination: the Experience of Sahloul University Hospital

A. Ben Naceur, *A. Toumi, N. Ayachi, K. Chatti;*
Sahloul University Hospital, Sousse, TUNISIA.

EP-0698

Towards AI application with automatic subtraction to improve parathyroid adenomas detection

O. Boukhennoufa[1], *L. Comas*[2,3], *E. Lajeune*[1], *C. Ungureanu*[2], *M. Soualhi*[1], *J. Nicod*[1], *N. Zerhouni*[1], *H. Boulahdour*[2,3];
[1]*Université de Franche-Comté, SUPMICROTECH, CNRS, institut FEMTO-ST, Besançon, FRANCE,* [2]*Service de Médecine Nucléaire, CHU Besançon, Besançon, FRANCE,* [3]*Université de Franche-Comté, LNIT, F-25000, Besançon, FRANCE.*

EP-0699

Evaluation of PaIRe PET/CT segmentation software as cancerous lesion contouring tool in fully-automated annotation workflows for image-based research studies

D. Abler[1], *M. Jreige*[2], *O. Michielin*[1,3], *N. Schaefer*[2], *J. O. Prior*[2], *A. Depeursinge*[4,2], *M. A. Cuendet*[1,5,6], *P. Blanc Durand*[7];
[1]*Department of Oncology, Precision Oncology Center, Lausanne University Hospital and University of Lausanne, Lausanne, SWITZERLAND,* [2]*Nuclear Medicine and Molecular Imaging Department, Lausanne University Hospital and University of Lausanne, Lausanne, SWITZERLAND,* [3]*Department of Oncology, Geneva University Hospital and University of Geneva, Geneva, SWITZERLAND,* [4]*Institute of Informatics, School of Management, University of Applied Sciences Western Switzerland, Sierre, SWITZERLAND,* [5]*Swiss Institute of Bioinformatics, University of Lausanne, Lausanne, SWITZERLAND,* [6]*Department of Physiology and Biophysics, Weill Cornell Medicine, New York, NY, UNITED STATES OF AMERICA,* [7]*Nuclear Medicine Department, Henri-Mondor University Hospital, Créteil, FRANCE.*

EP-0700
Pituitary Gland: Do We Really See It?
A. Macula[1,2], *L. Airo*[3], *S. Colombo Serra*[2], *M. Ali*[4], *S. Papa*[4], *G. Valbusa*[2], *A. Bifone*[1], *P. Gandolfo*[4];
[1]*Università di Torino, Torino, ITALY,* [2]*Bracco Imaging S.p.a., Milano, ITALY,* [3]*Università di Milano, Milano, ITALY,* [4]*Centro Diagnostico Italiano, Milano, ITALY.*

EP-0701
A statistical method to adapt a normal range for thyroid uptake measurements following replacement of a gamma camera
A. Gemmell[1,2,3], *C. Brown*[1,2], *S. Ray*[3], *S. Small*[1,2];
[1]*Nuclear Medicine, Gartnavel General Hospital, Glasgow, UNITED KINGDOM,* [2]*Department of Clinical Physics & Bioengineering, Glasgow, UNITED KINGDOM,* [3]*School of Mathematics & Statistics, University of Glasgow, Glasgow, UNITED KINGDOM.*

EP-0702
EImpact of using different SUV thresholds for delineating human brown adipose tissue volume with 18F-FDG PET-CT
Y. Garcia-Rivero, *E. Rodríguez García, S. Beltrán Arenas, M. Pérez Gómez, C. Rodríguez García, Á. García Rodriguez, M. Ruiz Molina, G. Sánchez-Delgado;
Hospital Virgen De Las Nieves, Granada, SPAIN.*

EP-0703
Parametric Images And KEi Index In A Small Kidneys Clearance Function Assessment
K. Filipczak, *P. Cichocki, J. Kusmierek, A. Plachcinska, Z. Adamczewski;
Medical University of Lodz, Lodz, POLAND.*

EP-0704
Standardized Uptake Values for SPECT-CT in Normal Lumbar Spine, using xSPECT Quant Bone Reconstruction
A. Duarte, *D. Calado, N. do Canto, M. Correia, A. Figueiredo, S. Matos, B. Martins, C. Pinto, V. Sousa;
Hospital da Luz, Lisboa, PORTUGAL.*

EP-0705
Relationship of 18F-FDG PET/CT metabolic parameters reduction during neoadjuvant chemotherapy to complete cytoreduction and pathologic response in primarily inoperable high-grade serous ovarian cancer.
L. Sancho Rodriguez[1], *L. Sánchez Lorenzo*[1], *F. Boria Alegre*[1], *T. Iscar Galán*[1], *L. García Belaustegui*[1], *V. Carrasco Rubio*[1], *C. Beorlegui Arteta*[2], *M. Romera Caballo*[3], *V. Betech Anta*[3], *M. García Velloso*[3];
[1]*Clinica Universidad De Navarra, Madrid, SPAIN,* [2]*Departamento de Salud. Gobierno de Navarra. Pamplona., Pamplona, SPAIN,* [3]*Clinica Universidad De Navarra, Pamplona, SPAIN.*

EP-0706
Is there any metabolic parameter of staging 18F-FDG-PET/CT related to the therapeutic strategy performed (primary cytoreduction vs. neoadjuvant chemotherapy and interval cytoreduction) in patients with high-grade serous ovarian cancer?
L. Sancho Rodriguez[1], *L. Sánchez Lorenzo*[1], *F. Boria Alegre*[1], *T. Iscar Galán*[1], *L. García Belaustegui*[1], *E. eguillenv@unav.es*[1], *V. Carrasco Rubio*[1], *C. Beorlegui Arteta*[2], *M. Romera Caballo*[3], *V. Betech Anta*[3], *M. García Velloso*[3];
[1]*Clinica Universidad De Navarra, Madrid, SPAIN,* [2]*Departamento De Salud. Gobierno De Navarra, Madrid, SPAIN,* [3]*Clinica Universidad De Navarra, Pamplona, SPAIN.*

EP-0707
Quantification parameters of 99mTc-MDP single-photon emission computed tomography/computed tomography in the diagnosis of active condylar hyperplasia.
M. Umar, *D. Khan, S. Sagar, S. Ahmad Shamim, R. Kumar;
Aiims, Delhi, INDIA.*

EP-0708
Normalizing SUV values by lean body mass effectively reflect patient weigt and body composition variations improving SUVmax values determination in 18F-FDG PET-CT imaging.
A. Hurtado de Mendoza, *M. Yaryes, C. Soza-Ried, H. Amaral;
Positronmed, Santiago, CHILE.*

EP-0709
Current status and new trends in technetium-99m described through a patent analysis (2000-2022)
M. Riondato[1], *D. Rigamonti*[2], *P. Martini*[3], *C. Cittanti*[3], *A. Boschi*[3], *L. Uccelli*[3];
[1]*University Policlinic Hospital of Genoa, Genoa, ITALY,* [2]*European and Italian Patent Attorney, Milan, ITALY,* [3]*University of Ferrara, Ferrara, ITALY.*

EP-0710
Building a Normative Database for [18F]-FDG imaging: Insights from a Japanese Screening Cohort
S. Gutschmayer[1], *T. Beyer*[1], *Z. Chen*[2], *T. Junichi*[3], *S. Kinuya*[2], *L. Shiyam Sundar*[1], *S. Takeda*[3], *H. Wakabayashi*[2];
[1]*Quantitative Imaging and Medical Physics (QIMP) Team, Medical University of Vienna, Vienna, AUSTRIA,* [2]*Department of Nuclear Medicine, Kanazawa University Hospital, Kanazawa, JAPAN,* [3]*PET Center, Kanazawa Advanced Medical Center, Kanazawa, JAPAN.*

EP-48

e-Poster Area

D: Technical Studies -> D2 Data Analysis -> D23 Image Reconstruction

EP-0711
Validation for dual-gate motion correction techniques using ECG gating and data-driven respiratory motion correction for cardiac PET: A pilot study
K. Takanami[1], *H. Odagiri*[2], *H. Watabe*[3], *H. Kodama*[4], *H. Kawakami*[5], *A. Katsuki*[5], *N. Uetake*[5], *K. Takase*[1];
[1]*Tohoku University Hospital, Sendai, JAPAN,* [2]*Department of Diagnostic Image Analysis, Tohoku University Graduate School of Medicine, Sendai, JAPAN,* [3]*Division of Radiation Protection and Safety Control, Cyclotron and Radioisotope Center, Sendai, JAPAN,* [4]*Department of Radiology, Tohoku University Hospital, Sendai, JAPAN,* [5]*GE Healthcare Japan, Tokyo, JAPAN.*

EP-0712
Determining the optimal reconstruction algorithm for FDG brain PET/CT images in BGO-based Whole body PET scanner
M. Asami[1], *M. Ay*[1], *S. Farzanehfar*[2], *P. Ghafarian*[3], *P. Sheikhzadeh*[2];
[1]*Department of Medical Physics and Biomedical Engineering ,Tehran University of Medical Sciences, Iran, Tehran, IRAN, ISLAMIC REPUBLIC OF,* [2]*Department of Nuclear Medicine, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran, Tehran, IRAN, ISLAMIC REPUBLIC OF,* [3]*PET/CT and Cyclotron Center, Masih Daneshvari Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran, Tehran, IRAN, ISLAMIC REPUBLIC OF.*

EP-0713
Faster time-of-flight performance reduces effect of misregistration on myocardial uptake scores in cardiac PET-CT
M. Hylle[1], *N. A. Bebbington*[2], *M. R. Pedersen*[3], *H. D. Zacho*[1];
[1]*Aalborg University Hospital, Aalborg, DENMARK,* [2]*Siemens Healthcare A/S, Aarhus, DENMARK,* [3]*Lillebaelt Hospital, Vejle, DENMARK.*

EP-0714
Optimizing the Block Sequential Regularized Expectation Maximization (BSREM) Algorithm for 68Ga-PSMA PET-CT Imaging: Phantom and Clinical Study
F. Sadeghi[1,2], *P. Sheikhzadeh*[1,3], *N. Kasraie*[4], *S. Farzanehfar*[3], *M. Abbasi*[3], *Y. Salehi*[3], *M. Ay*[1,2];
[1]*Department of Medical Physics and Biomedical Engineering ,Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF,* [2]*Research Center for Molecular and Cellular Imaging, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF,* [3]*Department of Nuclear Medicine, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF,* [4]*Department of Radiology, UT Southwestern Medical Center, Dallas, TX, UNITED STATES OF AMERICA.*

EP-0715
Evaluation of advanced artificial intelligence-based PET image reconstruction (HYPER DPR) on brain PET/CT imaging
K. Miwa[1], *M. Watanabe*[2], *M. Ishiguro*[2], *T. Yamao*[1], *N. Miyaji*[1], *K. Hasegawa*[1], *A. Takenaka*[3], *Y. Inui*[3], *H. Toyama*[3];
[1]*Fukushima Medical University, Fukushima, JAPAN,* [2]*Fujita Health University Hospital, Aichi, JAPAN,* [3]*Fujita Health University School of Medicine, Aichi, JAPAN.*

EP-0716
Impact of the 68Ga Source Model on Positron Range Simulations and 68Ga-specific PET Reconstructions
P. Gavriilidis[1,2,3], *A. Marinus*[4,1], *F. M. Mottaghy*[5,1,2], *T. W. Deller*[6], *F. P. Jansen*[6], *M. Koole*[3], *R. Wierts*[1,2];
[1]*Maastricht University Medical Center, Maastricht, NETHERLANDS,* [2]*Maastricht University, Maastricht, NETHERLANDS,* [3]*Katholieke Universiteit Leuven, Leuven, BELGIUM,* [4]*Eindhoven University of Technology, Eindhoven, NETHERLANDS,* [5]*RWTH University Hospital, Aachen, GERMANY,* [6]*GE HealthCare, Waukesha, WI, UNITED STATES OF AMERICA.*

EP-0717
Transforming a low-count nuclear medicine image into a high-count image using Dynamic Stochastic Resonance
A. Pandey, *S. Kumar, P. D. Sharma, C. Patel, R. Kumar;
All India Institute of Medical Sciences, New Delhi, INDIA.*

EP-0718
Role of dynamic stochastic resonance in enhancing the contrast between the abnormal and no-abnormal tau uptake on reconstructed tau (F-18 ML-104) PET images
A. Pandey[1], *J. Yadav*[2], *M. Tripathi*[1];
[1]*All India Institute of Medical Sciences, New Delhi, INDIA,* [2]*All India Institute of Medical Sciences, Faridabad, INDIA.*

EP-0719
Comparative study of respiratory gating techniques on pulmonary 18F-FDG PET lesions
A. BORGES TAVARES[1], *R. Amblard*[1], *F. Hugonnet*[2], *B. Paulmier*[2], *N. Garnier*[1], *R. Villeneuve*[1], *V. Natal*[2], *F. Mocquot*[2], *M. Faraggi*[2], *B. Serrano*[1];
[1]*Centre Hospitalier Princesse Grace - Medical Physics Department, Monaco, MONACO,* [2]*Centre Hospitalier Princesse Grace - Nuclear Medicine Department, Monaco, MONACO.*

EP-0720
Assessment of a new PET event-by-event image-based motion correction for brain imaging in amyloid and epilepsy on a multimodality PET-MR scanner
J. Anton Rodriguez[1,2], *K. Herholz*[3], *C. Oldfield*[1], *M. G. Spangler-Bickell*[4], *T. W. Deller*[4], *L. M. Parkes*[3], *J. C. Matthews*[3];
[1]*The Christie NHS Foundation Trust, Manchester, UNITED KINGDOM,* [2]*Division of Informatics, Imaging and Data Sciences, MAHSC, University of Manchester, Manchester, UNITED KINGDOM,* [3]*Division of Psychology, Communication and Human Neuroscience , Faculty of Biology, Medicine and Health-University of Manchester, Manchester, UNITED KINGDOM,* [4]*GE HealthCare, Waukesha, WI, UNITED STATES OF AMERICA.*

EP-0721
Analysis of segmented single-photon emission computedtomography images acquired with and without a copper filter
S. Kheruka, *N. Al Maymani, N. Al Makhmari, K. Al Riyami, R. Al Sukaiti, A. Jain, S. Usmani;
Department of Radiology & Nuclear Medicine, Sultan Qaboos Comprehensive Cancer Care and Research Center, Muscat, OMAN.*

EP-0722
Advantages and opportunities of using an open-source reconstruction platform for SPECT quantification
S. Varzakis[1], *A. Denis-Bacelar*[2], *D. Deidda*[2], *J. Dickson*[3], *S. McQuaid*[3], *K. Thielemans*[1];
[1]*University College London, London, UNITED KINGDOM,* [2]*National Physical Laboratory, London, UNITED KINGDOM,* [3]*University College London Hospital, London, UNITED KINGDOM.*

EP-49

e-Poster Area

D: Technical Studies -> D2 Data Analysis -> D24 Radiomics

EP-0723
Utility of delta radiomics for response evaluation in primary mediastinal large B-cell lymphoma
F. Yousefirizi[1], *C. Gowdy*[2], *I. Klyuzhin*[3], *K. Savage*[1], *C. Uribe*[1], *A. Rahmim*[3];
[1]*Bc Cancer, Vancouver, BC, CANADA,* [2]*BC Children's Hospital, Vancouver, BC, CANADA,* [3]*BC Cancer Research Institute, Vancouver, BC, CANADA.*

EP-0724
Noninvasive diagnostic models based on CT scans for differentiating solitary pulmonary metastasis in colorectal cancer patients by artificial intelligence : a multicenter study
D. Ma;
Department of Colorectal Surgery, Zhejiang Cancer Hospital, Hangzhou, CHINA.

EP-0725
Bio-functional radiomics based machine learning for improving the accuracy of hypermetabolic lymph node metastasis in lung cancer
C. Ren;
Shanghai Proton and Heavy Ion Center, Shanghai, CHINA.

EP-0726
Multimodal Radiomic Analyses Allow IDH-Prediction in Glioma Patients at Initial Diagnosis
L. Kaiser[1], *S. Quach*[2], *A. J. Zounek*[1], *A. Zatcepin*[1], *A. Holzgreve*[1], *A. Bollenbacher*[1], *L. Bartos*[1], *V. Ruf*[3], *G. Böning*[1], *L. von Baumgarten*[2], *N. Thon*[2], *J. Herms*[3], *M. J. Riemenschneider*[4], *S. Stöcklein*[5], *M. Brendel*[1], *R. Rupprecht*[6], *J. Tonn*[2], *P. Bartenstein*[1], *S. Ziegler*[1], *N. L. Albert*[1];
[1]*Department of Nuclear Medicine, University Hospital, LMU Munich, Munich, GERMANY,* [2]*Department of Neurosurgery, University Hospital, LMU Munich, Munich, GERMANY,* [3]*Center for Neuropathology and Prion Research, LMU Munich, Munich, GERMANY,* [4]*Department of Neuropathology, University Hospital Regensburg, Regensburg, GERMANY,* [5]*Department of Radiology, University Hospital, LMU Munich, Munich, GERMANY,* [6]*Department of Psychiatry and Psychotherapy, University of Regensburg, Regensburg, GERMANY.*

EP-0727
Non-Invasive Pathological Gleason Score Prediction in Prostate Cancer Patients Using Machine Learning and 68Ga-PSMA PET/CT Radiomic Features
Z. Vosoughi[1], *N. Hamzian*[2], *P. Geramifar*[3], *H. Vosoughi*[4], *F. Emami*[5], *S. Faraji*[6], *G. Hajianfar*[7], *I. Shiri*[7], *H. Zaidi*[7];
[1]*Department of Medical Physics, School of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, IRAN, ISLAMIC REPUBLIC OF,* [2]*Department of Medical Physics, School of Medicine, Medical Physics department of Shahid Sadoughi University of Medical Sciences, Yazd, IRAN, ISLAMIC REPUBLIC OF,* [3]*Research Center for Nuclear Medicine, Shariati Hospital, Tehran University of Medical Science, Tehran, IRAN, ISLAMIC REPUBLIC OF,* [4]*Nuclear Medicine Department, Razavi Hospital, Imam Reza International University, Mashhad, IRAN, ISLAMIC REPUBLIC OF,* [5]*Nuclear Medicine Department, Razavi Hospital, Imam Reza International University, Mashhad, IRAN, ISLAMIC REPUBLIC OF,* [6]*Department of Medical Physics, Mashhad University of Medical Science, Mashhad, IRAN, ISLAMIC REPUBLIC OF,* [7]*Division of Nuclear Medicine and Molecular Imaging, Geneva University Hospital, Geneva, SWITZERLAND.*

EP-0728
The value of 18F-FDG PET/MR radiomics features in predicting the pathological classification of rhabdomyosarcoma in children
Y. Xu;
Hangzhou Universal Medical Imaging Diagnostic Center, Hangzhou, CHINA.

EP-0729
Correlating 68Ga-PSMA PET/CT Imaging Features with PSA Variation for Castration-Resistant Prostate Cancer Patients
R. Eduardo[1,2], *J. Badel*[3], *D. Sarrut*[1], *E. Paquet*[3], *A. Giraudet*[3];
[1]*Creatis, Lyon, FRANCE,* [2]*Siemens Healthcare SAS, Paris, FRANCE,* [3]*Centre Léon Berard, Lyon, FRANCE.*

EP-0730
Prediction of pathological complete response in T-stage III rectal cancer using 18F-FDG PET texture features
S. Woo, *J. Yang, H. Ju, K. Kim, A. Muath, S. Cho, U. Shin; KIRAMS, Seoul, KOREA, REPUBLIC OF.*

EP-0731
Reproducibility of CT radiomic features extracted from resampled images using various interpolation methods.
G. Mehta[1], *A. Tripathi*[1], *S. Panchal*[1,2], *U. B. Sherkhane*[1,3], *N. Purandare*[1,2], *S. Mithun*[1,2,3], *A. K. Jha*[1,2], *V. Rangarajan*[1,2];
[1]*Department of Nuclear Medicine and Molecular Imaging, Tata Memorial Hospital, Mumbai, INDIA,* [2]*Homi Bhabha National Institute (HBNI), Deemed University, Mumbai, INDIA,* [3]*Department of Radiation Oncology (Maastro), GROW School for Oncology and Reproduction, Maastricht University Medical Centre+, 6229 ET Maastricht, NETHERLANDS.*

EP-0732
A Comparative Study on Radiomics Pipelines for Histological Classification of Non-Small Cell Lung Cancer through [18F]FDG PET/CT
L. Wichert-Ana, *L. Alexandre-Santos, A. C. Trevisan, L. R. Suzuki, F. A. Pitella, O. Y. Fukumori, M. Kato, P. M. Azevedo-Marques, M. Koenigkam-Santos;*
Ribeirão Preto Medical School - University of São Paulo, Ribeirao Preto, BRAZIL.

EP-0733
Assessing PET andCMR radiomic featuresfor detectionof cardiac sarcoidosis
N. Mushari[1], *G. Soultanidis*[2], *L. Duff*[3], *M. G. Trivieri*[2,4], *Z. A. Fayad*[2], *P. M. Robson*[2], *C. Tsoumpas*[1,2,5];
[1]*Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, UNITED KINGDOM,* [2]*BioMedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, UNITED STATES OF AMERICA,* [3]*Beatson Institute for Cancer Research, Glasgow, UNITED KINGDOM,* [4]*Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, NY, UNITED STATES OF AMERICA,* [5]*Department of Nuclear Medicine and Molecular Imaging, University Medical Centre Groningen, University of Groningen, Groningen, NETHERLANDS.*

EP-0734
Role of Textural and Radiomic Analysis Parameters in Predicting Histopathological Parameters of the Tumour in Breast Cancer Patients.
M. Ravina, *R. Kote, T. Lukose, R. K. Gupta, Y. Kashyap, D. Mohanty;*
All India Institute of Medical Sciences, Raipur, Raipur, INDIA.

EP-0735
The Impact of Bayesian Penalized Likelihood (BPL) Reconstruction Algorithm With Various β-values on Radiomic Features Reproducibility: An [18F]FDG PET Phantom Study
Z. Valibeiglou[1], *J. Pirayesh Islamian*[1], *Y. Soleymani*[2], *P. Sheikhzadeh*[3,4];
[1]*Department of Medical Physics, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, IRAN, ISLAMIC REPUBLIC OF,* [2]*Department of Neuroscience and Addiction Studies, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF,* [3]*Department of Medical Physics and Biomedical Engineering, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF,* [4]*Department of Nuclear Medicine, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF.*

EP-0736
Can We Predict Future Relapsed Lymph Nodes on Staging PET/CT for Pediatric Hodgkin's Lymphoma?
N. C. M. Güladi[1], *M. O. Kartal*[2];
[1]*University of Health Sciences, Ankara Bilkent City Hospital, Department of Nuclear Medicine, Ankara, TÜRKIYE,* [2]*Health Ministry of Türkiye Republic, Ankara Bilkent City Hospital, Department of Nuclear Medicine, Ankara, TÜRKIYE.*

EP-50

e-Poster Area

D: Technical Studies -> D2 Data Analysis -> D25 Artificial Intelligence

EP-0737
The XGBoost algorithm combined with 18F-FDG PET/CT imaging in the differentiation between benign and malignant thyroid incidentalomas
J. Di[1], *X. Ma*[1], *Z. Ge*[1], *Q. Xie*[1], *D. Kong*[1], *S. Liu*[1], *S. Lin*[2], *J. Ma*[3], *H. Pei*[3], *Y. Zhong*[4], *W. Qu*[1], *X. Zheng*[1];
[1]*Department of Nuclear Medicine Department, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, CHINA,* [2]*School of Computer Science and Engineering, Sun Yat-sen University, Guangzhou, CHINA,* [3]*The MOE Key Laboratory for Intelligent Networks and Network Security, Xi'an, CHINA,* [4]*Department of Clinical Laboratory, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, CHINA.*

EP-0738
Image quantitative parameters using deep learning-based denoising of ultra-fast whole-body [18F]FDG PET/CT are comparable to standard acquisitions
L. C. Silva[1], *C. S. Constantino*[1], *M. Silva*[1], *F. P. M. Oliveira*[1], *R. Vigário*[2], *D. C. Costa*[1];
[1]*Champalimaud Foundation, Lisbon, PORTUGAL,* [2]*NOVA School of Science and Technology, Lisbon, PORTUGAL.*

EP-0739
A pilot of study: Development of AI model to automatically segment the metastatic lesions on FDG-PET/CT in patients with differentiated thyroid carcer
Y. Li[1], *K. Hirata*[1,2,3], *J. Takenaka*[1,2], *H. Endo*[1], *M. Tang*[1], *S. Watanabe*[1,2], *R. Kimura*[1,4], *K. Kudo*[1,3,4];
[1]*Department of Diagnostic Imaging, Graduate School of Medicine, Hokkaido University, Sapporo, JAPAN,* [2]*Department of Nuclear Medicine, Hokkaido University Hospital, Sapporo, JAPAN,* [3]*Global Center for Biomedical Science and Engineering, Faculty of Medicine, Hokkaido University, Sapporo, JAPAN,* [4]*Department of Diagnostic and Interventional Radiology, Hokkaido University Hospital, Sapporo, JAPAN.*

EP-0740
Predicting Sentinel Lymph Node Status by Using FDG-PET Imaging-Based Texture Analysis in Breast Cancer
K. Saglam, *S. ASA, A. KİBAR, M. SAĞER, K. SÖNMEZOĞLU;*
Istanbul Univercity-Cerrahpasa Cerrahpasa Medical Faculty, Istanbul, TÜRKIYE.

EP-0741
Construction of a prognostic risk score model with multimodal features of18F-FDG PET/CT images of non-small cell lung cancer byfeatures fusing
X. Wang[1,2], *X. Li*[1,2], *C. Cui*[1,2], *Z. Wu*[1], *Z. Wu*[3];
[1]*Department of Nuclear Medicine, First Hospital of Shanxi Medical University, Taiyuan, Shanxi, CHINA,* [2]*Collaborative Innovation Center for Molecular Imaging of Precision Medicine Shanxi Medical University, Taiyuan, Shanxi, CHINA,* [3]*Collaborative Innovation Center for Molecular Imaging of Precision Medicine Shanxi Medical University, Taiyuan,Shanxi, CHINA.*

EP-0742
Section-Based Regional Recognition of FDG PET/CT Images with Machine Learning
S. Asa, *A. Kibar, S. E. Biyiklioglu, M. T. Bodur, S. Sager, K. Sonmezoglu;*
Istanbul University Cerrahpasa, Istanbul, TÜRKIYE.

EP-0743
Assessing the Feasibility of Deep Learning-Based Attenuation Correction using Photon Emission Information in 18F-FDG PET Images for Dedicated Head and Neck PET Scanners
M. Shahrbabaki Mofrad[1], *A. Ghafari*[1], *A. Amiri Tehranizadeh*[2], *M. Ay*[1], *S. Farzenefar*[1], *P. Sheikhzadeh*[1];
[1]*Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF,* [2]*Mashhad University of Medical Science, Mashhad, IRAN, ISLAMIC REPUBLIC OF.*

EP-0744
A cascade AI-threshold system for volume segmentation and characterization of lung masses on 18F-FDG PET/CT
G. Savelli[1], *E. Schiavon*[2], *M. Interlenghi*[2], *C. Bnà*[1], *C. Ferrari*[1], *M. Bonacina*[1], *C. Salvatore*[2,3], *I. Castiglioni*[4];
[1]Fondazione Poliambulanza Istituto Ospedaliero, Brescia, ITALY, [2]DeepTrace Technologies, Milan, ITALY, [3]Department of Science, Technology and Society, Scuola Universitaria IUSS, Pavia, ITALY, [4]Department of Physics, Università degli Studi di Milano-Bicocca, Milan, ITALY.

EP-0745
A New Thoracic CT and Lung Perfusion SPECT Dataset for Developing Analysis of the Lobar Lung Function Assessment
E. Amini[1,2], *R. Klein*[1,3,4];
[1]Ottawa Hospital Research Institute, Ottawa, ON, CANADA, [2]Carleton University, Ottawa, ON, CANADA, [3]The Ottawa Hospital Department of Nuclear Medicine, Ottawa, ON, CANADA, [4]University of Ottawa Department of Medicine, Ottawa, ON, CANADA.

EP-0746
Deep-learning Model for Differentiation of Pediatric Bone Diseases by Bone Scintigraphy: A Feasibility Study
P. Yang[1], *L. Jiang*[1], *Y. Xiang*[1], *J. Wei*[2], *Z. Zhao*[1], *H. Cai*[1], *Z. Yi*[2], *L. Li*[1];
[1]West China Hospital, Chengdu, CHINA, [2]Sichuan Universtiy, Chengdu, CHINA.

EP-0747
Reliable and Precise Assessment of Liver Function with a Deep Learning Model-Based Workflow Using Hepatobiliary Scan
H. Sung[1], *K. Cho*[1], *K. Kim*[1], *H. Choi*[1,2], *G. Cheon*[1,2];
[1]Department of Nuclear Medicine, Seoul National University Hospital, Seoul, KOREA, REPUBLIC OF, [2]Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul, KOREA, REPUBLIC OF.

EP-0748
ORCA - Optimized Registration through Conditional Adversarial networks for improved PET/CT co-registration using synthetic CT
Z. Chalampalakis, *D. Iommi, I. Rausch, B. Geist, M. Hacker, T. Beyer, L. K. S. Sundar;*
Medizinische Universität Wien, Vienna, AUSTRIA.

EP-0749
May Automated PET Lesion Detection Be Improved Focusing "AI-Brain" On Single Organs?
A. Macula[1,2], *L. Airo*[3], *S. Colombo Serra*[2], *M. Ali*[4], *S. Papa*[4], *G. Valbusa*[2], *A. Bifone*[1], *P. Gandolfo*[4];
[1]Università di Torino, Torino, ITALY, [2]Bracco Imaging S.p.a., Milano, ITALY, [3]Università di Milano, Milano, ITALY, [4]Centro Diagnostico Italiano, Milano, ITALY.

EP-0750
CT-free Total-body PET segmentation
C. Clement[1], *S. Xue*[1], *Y. Mao*[2], *R. Guo*[2], *M. Viscione*[1], *A. Rominger*[1], *B. Li*[2], *K. Shi*[1];
[1]Inselspital Bern, Bern, SWITZERLAND, [2]Ruijin Hospital, Shanghai, CHINA.

EP-0751
Convolutional neural networks for the prediction of changes in brain metabolism
E. Doering[1,2], *T. Deusser*[3], *M. C. Hönig*[1,4], *G. N. Bischof*[1,4], *T. van Eimeren*[1], *A. Drzezga*[1,4], *L. M. Ellingsen*[5,6];
[1]University of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Nuclear Medicine, Cologne, GERMANY, [2]German Center for Neurodegenerative Diseases (DZNE), Bonn, GERMANY, [3]Fraunhofer IAIS, Bonn, GERMANY, [4]Research Center Jülich, Institute of Neuroscience and Medicine - Molecular Organization of the Brain (INM-2), Jülich, GERMANY, [5]Department of Electrical and Computer Engineering, University of Iceland, Reykjavík, ICELAND, [6]Department of Electrical and Computer Engineering, The Johns Hopkins University, Baltimore, MD, UNITED STATES OF AMERICA.

EP-0752
A Feasibility Study of Attenuation and Scatter Correction in Whole-Body PET Imaging with 68Ga-Dotatate using Deep Learning: A Dual-Center Investigation
M. Sobhi[1], *J. Pirayesh Islamian*[1], *N. Seyedi*[2], *M. Shahrebabaki Mofrad*[3], *R. Samimi*[4], *P. Sheikhzadeh*[5];
[1]Department of Medical Physics Tabriz University of medical sci, Tabriz, IRAN, ISLAMIC REPUBLIC OF, [2]Nursing and Midwifery Care Research Center, Iran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF, [3]Medical Physics and Biomedical Engineering Department,Medical Faculty,Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF, [4]Department of Medical Radiation Engineering, Shahid Beheshti University, Tehran, IRAN, ISLAMIC REPUBLIC OF, [5]Department of Nuclear Medicine, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF.

EP-0753
Assessment of CNN Performance in Cases of Breast Cancer, Staging and Restaging- A Tumour Type Not Included in Algorithm Training
A. Nawwar[1,2,3], *D. Darian*[4], *J. Searle*[5,2], *T. Shimizu*[6], *I. D. Lyburn*[7,2,8];
[1]University Hospitals Bristol and Weston, NHS Foundation Trust, Bristol, UNITED KINGDOM, [2]Cobalt Medical Charity, Cheltenham, UNITED KINGDOM, [3]Faculty of Medicine, Cairo University, Cairo, EGYPT, [4]Siemens Healthcare Ltd., Camberley, UNITED KINGDOM, [5]Gloucestershire Hospitals NHS Foundation Trust, Gloucestershire, UNITED KINGDOM, Cheltenham, UNITED KINGDOM, [6]Siemens Medical Solutions UNITED STATES OF AMERICA, Inc., Chicago, IL, UNITED STATES OF AMERICA, [7]Gloucestershire Hospitals NHS Foundation Trust, Gloucestershire, UNITED KINGDOM, CHELTENHAM, UNITED KINGDOM, [8]Cranfield Forensic Institute, Cranfield University, Wiltshire, UNITED KINGDOM.

EP-0754
Performance analysis of deep progressive learning denoising method vs conventional methods on low dose 18F-FDG whole body PET/CT scans with low counts/reduced time protocol
S. Singh, *S. Nigam, R. Vajpayee;*
Globe healthcare, Lucknow, INDIA.

EP-0755
Effects of CNN-based PET image denoising on image quality and lesion detectability
S. Gnesin[1], *S. Medici*[1], *M. Jreige*[2], *M. Conti*[3], *J. Schaefferkoetter*[3], *J. O. Prior*[2];
[1]Institute of Radiation Physics, Lausanne University Hospital and University of Lausanne, Lausanne, SWITZERLAND, [2]Department of Nuclear Medicine and Molecular Imaging, Lausanne University Hospital and University of Lausanne, Lausanne, SWITZERLAND, [3]Siemens Medical Solutions UNITED STATES OF AMERICA, Knoxville, TN, UNITED STATES OF AMERICA.

EP-0756
Comparison of two artificial intelligence tools for anomaly detection and segmentation in 18F-FDG-PET/CT in a monocentric lung and breast cancers patient cohorts
M. Mechti, *P. Blanc-Durand, E. Itti;*
CHU Henri Mondor, PARIS, FRANCE.

EP-0757
Deep Learning for Automatic Prostate Segmentation On 18F-DCFPyL PET/CT In Prostate Cancer.
M. Cysouw, *W. I. Luining, B. M. de Vries, D. E. Oprea-Lager, A. N. Vis, R. Boellaard;*
Amsterdam UMC, Amsterdam, NETHERLANDS.

EP-0758
Assessment of a Deep Learning-Based Noise Reduction Algorithm on the Ultra-Fast Whole-Body Bone Tomoscintigraphies Recorded by a 360° CZT Camera
A. Bahloul[1,2], *Y. Lamash*[3], *N. Roth*[3], *A. Dari*[1], *P. Marie*[1,2], *L. Imbert*[1,2];
[1]CHRU-Nancy, Department of Nuclear Medicine, Nancy, FRANCE, [2]Université de Lorraine, INSERM U1254, IADI, Nancy, FRANCE, [3]Spectrum Dynamics Medical, Caesarea, ISRAEL

EP-0759
Automatically acquired tumour staging (T) in FDG-avid lung tumours aided by artificial intelligence.
P. Borrelli[1], *M. Milà López*[2], *P. Fierro Alanis*[2], *M. Larsson*[3], *R. Rossi Norrlund*[1], *R. Kaboteh*[1], *L. Edenbrandt*[1,4], *E. Trägårdh*[5,6];
[1]Department of Clinical Physiology, Region Västra Götaland, Sahlgrenska University Hospital, Gothenburg, SWEDEN, [2]Servicio Medicina Nuclear Hospital Universitari Joan XXIII de Tarragona, Tarragona, SPAIN, [3]Eigenvision AB, Malmö, SWEDEN, [4]Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, SWEDEN, [5]Department of Translational Medicine and Wallenberg Center for Molecular Medicine, Lund University, Lund, SWEDEN, [6]Department of Clinical Physiology and Nuclear Medicine, Skåne University Hospital, Malmö, SWEDEN.

EP-0760
Unsupervised and explainable phenotying on multiparametric contrast enhanced MRI and dynamic 18F-FDOPA PET images of patients with glioma at initial diagnosis
T. Zaragori[1,2], *A. Zinsz*[2], *M. Doyen*[1,2], *L. Imbert*[1,2], *J. Oster*[1,3], *A. Verger*[1,2];
[1]Université de Lorraine, IADI, INSERM, UMR 1254, Vandoeuvre-lès-Nancy, FRANCE, [2]Department of Nuclear Medicine & Nancyclotep Imaging Platform, CHRU-Nancy, Université de Lorraine, Vandoeuvre-lès-Nancy, FRANCE, [3]CHRU Nancy, INSERM, CIC, Innovation Technologique, Université de Lorraine, Vandoeuvre-lès-Nancy, FRANCE.

EP-0761
Artificial intelligence Respiratory Gating in PET/CT Imaging: changes on MTV, TLG and SUVmax
P. Meneses Soares, *A. Grajeda Gallardo, J. Mucientes Rasilla, R. Jimeno Pernett, M. Mitjavila Casanovas;*
HOSPITAL PUERTA DE HIERRO, MAJADAHONDA, SPAIN.

EP-51

e-Poster Area

D: Technical Studies -> D3 Radiation Protection -> D31 Radiation Exposure and Protection

EP-0762
Potential airborne releases of 68Ga and 177Lu: a method of preventive assessment
M. Marengo[1], *S. Rubow*[2];
[1]University of Bologna, Bologna, ITALY, [2]University of Stellenbosch, Stellenbosch, SOUTH AFRICA.

EP-0763
CT dose reduction in hybrid PET/CT imaging
C. Pettinato, *M. Schiavini, A. Castello, L. Florimonte, C. Canzi, F. Bardo, F. Buffoni, C. Colombo, V. Longari, E. Orunesu, M. Campoleoni, M. Castellani;*
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, ITALY.

EP-0764
Ambient Dose Equivalent and Occupational Exposure for 177Lu-PSMA-I&T Radionuclide Therapy
Z. Hu[1], *C. Liu*[2], *J. Liu*[2], *Z. Yang*[2], *R. Qiu*[1];
[1]Tsinghua University, Beijing, CHINA, [2]Beijing Cancer Hospital, Beijing, CHINA.

EP-0765
Evaluation of staff exposure to ionising radiation in a PET/CT department
P. Archontakis[1,2,3], *K. Silivridou*[2], *K. Mainta*[2,3], *D. Maintas*[2,3];
[1]National and Kapodistrian University of Athens, Athens, GREECE, [2]Iatriko Athinon, Athens, GREECE, [3]Institute for Isotopic Studies, Athens, GREECE.

EP-0766
Beta radiation protection in Phosphorous-32 microparticles therapy. Tungsten or methacrylate shielding?
C. G. Franco Monterroso, *B. Santos Montero, L. Rey Sánchez, L. García Lama, V. Pascual Pascual, M. A. Hernández Fructuoso;*
Hospital Universitari Vall d'Hebron, Barcelona, SPAIN.

EP-0767
Study of yttrium-90 radiation attenuation using different types of shielding
L. Rey Sánchez, *C. G. Franco Monterroso, B. Santos Montero, V. Pascual Pascual, L. García Lama, M. A. Hernández Fructuoso;*
Hospital Universitario Vall d'hebron, Barcelona, SPAIN.

EP-0768
Evaluating the effectiveness of lead apron in a Nuclear Medicine (PET-CT) facility
A. Shaikh[1], *R. Vatsa*[1], *V. Sawant*[1], *V. Rangarajan*[2];
[1]*Advanced Centre for Treatment, Research, and Education in Cancer, Navi Mumbai, INDIA,*
[2]*Tata Memorial Centre, Mumbai, INDIA.*

EP-0769
A radiation exposure comparison between manual and automated setups during GALLIUM-68 peptide labelling
M. Costa[1,2], *R. Parafita*[1,2], *A. Canudo*[1,2,2], *A. Capacho*[1], *F. Silva*[1], *H. Delgado*[1,2], *J. Correia*[1,2], *M. Correia*[1,2], *M. Silva*[1,2], *M. Andrade*[1,2], *M. Machado*[1], *P. Ferreira*[1], *P. H. Ferreira*[1,2], *R. Oliveira*[1,2], *S. Batanete*[1,2], *S. Teixeira*[1,2], *V. Vieira*[1,2], *F. Oliveira*[1], *D. Costa*[1];
[1]*Champalimaud Foundation, Lisbon, PORTUGAL,*
[2]*Mercurius Health, Lisbon, PORTUGAL.*

EP-0770
Typical values of quantities related to the patient dose from PET/CT in Bulgaria: first results
M. Sibinova[1], *T. K. Todorova*[2], *A. R. Zagorska*[3];
[1]*Sofia University "St Kliment Ohridski", Sofia, BULGARIA,*
[2]*National center of radiobiology and radiation protection, Sofia, BULGARIA,* [3]*Acibadem City Clinic University Hospital Tokuda, Sofia, BULGARIA.*

EP-0771
Radiation Dose Reduction Strategy for SPECT/CT Bone Scan
M. Alezzi[1], *O. Kotbi*[1], *G. Hammid*[1], *A. Fouda*[1], *Y. Zabarmawi*[2];
[1]*KING ABDULLAH MEDICAL CITY, Makkah, SAUDI ARABIA,*
[2]*Umm Al-qura University, Makkah, SAUDI ARABIA.*

EP-0772
Radiation safety during 177-Lu labellingand therapy: experience in Bulgaria
A. Zagorska;
Acibadem City Clinic University Hospital Tokuda, Sofia, BULGARIA.

EP-52

e-Poster Area

D: Technical Studies -> D4 Dosimetry and Radiobiology -> D41 Preclinical Dosimetry and Radiobiology

EP-0773
Monte Carlo quantification damage by 64Cu incorporate in DNA
J. Carrasco, *E. Padilla;*
Instituto de Ciencias Nucleares, CDMX, MEXICO.

EP-0774
Evaluation of Repeatability of 177Lu Quantitative Imaging Using Monte Carlo Simulation
K. Ishikawa[1], *C. Kubota*[1], *Y. Yasumoto*[1], *T. Sakashita*[2], *H. Daisaki*[1];
[1]*Gunma Prefectural College of Health Sciences, Gunma, JAPAN,* [2]*National Institutes for Quantum Science and Technology, Gunma, JAPAN.*

EP-0775
Preclinical in vivo tumour dosimetry of a Lu-177-labelled ligand using a gamma probe
A. Klotsotyra[1], *D. Arbuznikova*[1,2,3], *N. Steinacker*[1,2], *L. Domogalla*[1,2], *A. Eder*[1,2], *M. Mix*[1];
[1]*Department of Nuclear Medicine, Medical Center – University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, GERMANY,* [2]*Division of Radiopharmaceutical Development, German Cancer Consortium (DKTK), partner site Freiburg, Freiburg, Germany and German Cancer Research Center, Heidelberg, GERMANY,* [3]*Department of Radiation Oncology, Medical Center – University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, GERMANY.*

EP-0776
Evaluation of the quantitative accuracy using Monte Carlo simulations in 177Lu imaging
C. Kubota[1], *K. Ishikawa*[1], *Y. Yasumoto*[1], *T. Sakashita*[2], *H. Daisaki*[1];
[1]*Gunma Prefectural College of Health Sciences, Gunma, JAPAN,* [2]*National Institutes for Quantum Science and Technology, Gunma, JAPAN.*

EP-53

e-Poster Area

D: Technical Studies -> D4 Dosimetry and Radiobiology -> D42 Clinical Dosimetry

EP-0777
IDAC-Dose 2.2. An internal dosimetry software for diagnostic nuclear medicine using the ICRP computational framework and calculation of the absorbed dose and effective dose to all 12 ICRP reference individuals
M. Andersson[1,2], *K. Eckerman*[3], *S. Mattsson*[2];
[1]*Department of Medical Radiation Sciences,Institute of Clinical Sciences, Sahlgrenska Cancer Center, Gothenburg, SWEDEN,* [2]*Medical Radiation Physics, Malmö, Malmö, SWEDEN,* [3]*Center for Radiation Protection Knowledge, Oak Ridge National Laboratory, Oak Ridge, TN, UNITED STATES OF AMERICA.*

EP-0778
IDAC-ALPHA: AN online ALPHA DOSIMETRY SOFTWARE FOR NORMAL ORGANS And TISSUES
M. Andersson[1,2], *S. Mattsson*[2];
[1]*Department of Medical Radiation Sciences, Institute of Clinical Sciences, Sahlgrenska Cancer Center, Göteborg, SWEDEN,* [2]*Medical Radiation Physics, Malmö, Malmö, SWEDEN.*

EP-0779
Dosimetric model for patients with renal failure undergoing dialysis during I-131 therapy for thyroid cancer
V. Nuttens, *O. De Winter;*
OLVZ, Aalst, BELGIUM.

EP-0780
Comparative analysis of positron-emitters for theranostic applications based on small bioconjugates
C. Morgat[1,2], *U. Köster*[3], *C. Champion*[4], *P. Zanotti-Fregonara*[5], *E. Hindié*[1,2,6];
[1]*Nuclear Medicine Department - University Hospital of Bordeaux, Bordeaux, FRANCE,* [2]*University of Bordeaux, UMR CNRS 5287, INCIA, Bordeaux, FRANCE,* [3]*Institut Laue Langevin, Grenoble, FRANCE,* [4]*University of Bordeaux, CNRS, CEA, CELIA, UMR 5107, Talance, FRANCE,* [5]*Molecular Imaging Branch, National Institute of Mental Health, Bethesda, MD, UNITED STATES OF AMERICA,* [6]*Institut Universitaire de France, Paris, FRANCE.*

EP-0781
Dosimetry and External Radiation Exposure in 177Lu-PSMA-617 Radioligand Therapy. The INT Pascale Experience
L. D'Ambrosio, *V. Pirozzi Palmese, C. Maisto, R. de Marino, M. Aurilio, A. Morisco, V. Porfidia, C. Traino, R. De Migno, M. Raddi, F. De Lauro, F. Di Gennaro, S. Lastoria;*
National Cancer Institute IRCCS Pascale, Naples, ITALY.

EP-0782
Partial volume correction on Lu-177 PSMA-617 parotid gland dosimetry
G. Mok[1], *Z. Lu*[1], *G. Chen*[1], *Y. Liu*[1], *A. Afshar-Oromieh*[2], *A. Rominger*[2], *K. Shi*[2];
[1]*University of Macau, Taipa, MACAO,*
[2]*University of Bern, Bern, SWITZERLAND.*

EP-0783
A new approach for individual dose monitoring in Molecular Radionuclide Therapy
R. Mirabelli[1], *L. Campana*[1], *B. Cassano*[2], *F. Collamati*[3], *R. Faccini*[1], *G. Iaccarino*[2], *C. Mancini Terracciano*[1], *S. Morganti*[3], *F. Nicolanti*[1], *M. Pacilio*[4], *A. Soriani*[2], *E. Solfaroli-Camillocci*[5];
[1]*"Sapienza" - Università di Roma, Rome, ITALY,* [2]*IRCCS Regina Elena National Cancer Institute, Rome, ITALY,* [3]*National Institute of Nuclear Physics, Rome, ITALY,* [4]*Azienda Ospedaliera-Universitaria Policlinico Umberto I, Rome, ITALY,* [5]*Bambino Gesu` Children's Hospital, Rome, ITALY.*

EP-0784
131I and 177Lu Voxel Dosimetry: characterization, verification and preliminary patient results
E. Richetta, *C. Valero, B. Elia, V. Pirro, M. Manfredi, R. Pellerito, M. Stasi;*
Ordine Mauriziano Hospital, Turin, ITALY.

EP-0785
True Single Time Point Dosimetry for [177Lu]Lu-PSMA targeted therapy - Is Haenscheid's method applicable?
J. Kurth, *M. Heuschkel, B. Krause, S. M. Schwarzenböck;*
Rostock University Medical Center, Rostock, GERMANY.

EP-0786
Accuracy of Few-Time-Point Dosimetry Using Non-Linear Mixed-Effects Modelling in Peptide-Receptor Radionuclide Therapy
R. Subangun[1], *D. Hardiansyah*[1], *R. Ibrahim*[1], *B. Patrianesha*[1], *A. Beer*[2], *G. Glatting*[2];
[1]*Universitas Indonesia, Depok, INDONESIA,*
[2]*Ulm University, Ulm, GERMANY.*

EP-0787
Validation of Pretherapeutic Dosimetry in Metastatic Thyroid Cancer Patient with Chronic Kidney Disease for I-131 Treatment
A. Al Jabri[1,2], *J. Cooke*[3], *S. Cournane*[4], *S. Ludgate*[5], *M. Healy*[5];
[1]*Sultan Qaboos University, Muscat, OMAN,* [2]*Trinity College Dublin, Dublin, IRELAND,* [3]*Children's Health Ireland at Crumlin, Dublin, IRELAND,* [4]*St Vincent's University Hospital, Dublin, IRELAND,* [5]*St James's Hospital, Dublin, IRELAND.*

EP-0788
A phantom study on I-124 digital PET/CT quantification performance for lesion dosimetry in (re)differentiated thyroid cancer
M. Dotinga[1,2], *D. Vriens*[1], *L. F. de Geus-Oei*[1,3,4], *P. Dibbets-Schneider*[1], *M. K. Stam*[1], *M. Pool*[1], *F. Smit*[1,5], *E. Kapiteijn*[1], *F. H. P. van Velden*[1];
[1]*Leiden University Medical Center, Leiden, NETHERLANDS,* [2]*NETHERLANDS Cancer Institute, Amsterdam, NETHERLANDS,* [3]*University of Twente, Enschede, NETHERLANDS,* [4]*Technical University of Delft, Delft, NETHERLANDS,* [5]*Alrijne Hospital, Leiderdorp, NETHERLANDS.*

EP-0789
Comparison of bone marrow absorbed dose estimated using blood sampling and gamma camera methods for 177Lu labelled radiopharmaceuticals
G. Katre[1,2], *T. Srichandan*[1,2], *A. Konuparamban*[1], *S. Ghag*[1], *A. Puranik*[1], *A. Agarwal*[1], *S. Mithun*[1,2,3], *A. Jha*[1,2], *V. Rangarajan*[1,2];
[1]*Department of Nuclear Medicine and Molecular Imaging, Tata Memorial Hospital, Mumbai, INDIA,* [2]*Homi Bhabha National Institute (HBNI), Deemed University, Mumbai, INDIA,* [3]*Department of Radiation Oncology (Maastro), GROW School for Oncology and Reproduction, Maastricht University Medical Centre+, Maastricht, NETHERLANDS.*

EP-0790
Lu-177-PSMA Infusion vs Injection: No Difference in Dose Rates of Patients at the Time of Outpatient Discharge
V. Reijonen[1], *K. Kiviluoto*[2,1], *V. Ahtiainen*[1];
[1]*Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, FINLAND,* [2]*HUS Pharmacy, Helsinki University Hospital, Helsinki, FINLAND.*

EP-0791
Simplified Organ and Tumor Dosimetry for Lu-177-PSMA-I&T Radionuclide Therapy
W. Lehnert, *L. Schatz, A. Karimzadeh, I. Apostolova, R. Buchert, S. Klutmann;*
University Medical Center Hamburg-Eppendorf, Hamburg, GERMANY.

EP-0792
Single time point tumour dosimetry after 177Lu-DOTATATE therapy
S. Ballout;
Cambridge University Hospital NHSFT, Cambridge, UNITED KINGDOM.

EP-0793
Role of lung density in voxel-based dosimetry of90Y-TARE evaluated with Voxel S-Value (VSV) method and fast Monte Carlo simulation
R. Moretti[1], *A. Capotosti[1], M. Vaccaro[2], C. d. Ribeiro[2], M. Nardini[1], G. Meffe[1], L. Placidi[1], L. Zagaria[1], M. De Risi[1], G. Perotti[1], L. Leccisotti[1], R. Iezzi[1], L. Indovina[1];*
[1]Fondazione Policlinico Universitario Agostino Gemelli, Rome, ITALY, [2]Università Cattolica del Sacro Cuore, Rome, ITALY.

EP-0794
A Dosimetric Comparison of Radioembolization and External Beam Radiation Treatment For Liver Cancer
K. Wysoczynski, *B. Mehadji, P. Park, S. Benedict, E. Roncali;*
University of California, Davis, Davis, CA, UNITED STATES OF AMERICA.

EP-0795
Impact of SPECT acquisition and reconstruction parameters in dosimetry of [177Lu]Lu-PSMA-617 and analogues
T. Lima, *M. Gravinatti, A. Zander, H. Grünig, U. Bhure, M. Pérez Lago, K. Strobel;*
Luzerner Kantonsspital, Luzern, SWITZERLAND.

EP-0796
Commissioning and planning of treatment planning systems for Selective Internal Radiation Therapy
M. Santoro[1], *G. Della Gala[1], G. Paolani[1], G. Rasoatsaratanany[2], S. Strolin[1], L. Strigari[1];*
[1]IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, [2]International Centre for Theoretical Physics, Trieste, ITALY.

EP-0797
Effect of segmentation uncertainty on pre-therapeutic dosimetry of selective internal radiation therapy using Yttrium-90 Microsphere for hepatocellular carcinoma
A. Nautiyal, *T. Melhuish, G. Lewis, S. Michopoulou;*
University Hospital Southampton, Southampton, UNITED KINGDOM.

EP-0798
Clinical dosimetry of patients treated with Capecitabine, Temozolomide and [177Lu]Lu-DOTA-TOC combined therapy.
A. Cichonski[1], *J. B. Ćwikła[2], A. Kolasińska-Ćwikła[3], M. Kempińska-Wróbel[2];*
[1]National Centre for Nuclear Research, Warsaw, POLAND, [2]Medical School, University of Warmia and Mazury, Olsztyn, POLAND, [3]The Maria Skłodowska-Curie National Institute of Oncology, Warsaw, POLAND.

EP-0799
Voxel-level comparison of99mTc-MAA SIRT planning SPECT-CT with90Y-Microspheres post-therapy PET-CT
S. Heard, *D. Gillett, R. Crawford, I. Harper, T. C. See, N. Shaida, L. Aloj;*
Cambridge University Hospitals NHS FT, Cambridge, UNITED KINGDOM.

EP-0800
Clinical experience of whole body and tumour dosimetry of 131-I-mIBG treatment for pediatric patients
I. Torres Espallardo[1,2], *N. Orrego[1], M. Gandia-Ferrero[2], V. Cotanda[3], C. Olivas[1], L. Martí-Bonmatí[1,2], P. Bello-Arques[1], J. Balaguer[1], S. Prado-Wohlwend[1];*
[1]Clinical Area of Medical Imaging, Valencia, SPAIN, [2]Health Research Institute La Fe, Valencia, SPAIN, [3]Fundacion IVO, Valencia, SPAIN.

EP-0801
DosePredict: An Open-source Software to Support Treatment Planning for Personalised Radiopharmaceutical Therapy
C. Gomes Ferreira[1], *V. R. Warschun[2], J. Hu[1], S. Xue[1], L. Mercolli[3], T. W. Vidal[2], N. Navab[2], A. Afshar-Oromieh[3], A. Rominger[3], K. Shi[1];*
[1]University of Bern, Bern, SWITZERLAND, [2]Technical University of Munich, Munich, GERMANY, [3]Inselspital, Bern University Hospital, Bern, SWITZERLAND.

EP-54

e-Poster Area

D: Technical Studies -> D4 Dosimetry and Radiobiology -> D43 Clinical Radiobiology

EP-0802
Comparison of Administered Lu-177 and Ac-225 Activities of PSMA Treatments Against Metastatic Prostate Cancer: Radiobiological Factors
V. Ahtiainen[1,2], *V. Reijonen[1], M. Tenhunen[1];*
[1]Helsinki University Hospital Comprehensive Cancer Centre, Helsinki, FINLAND, [2]Helsinki University, Helsinki, FINLAND.

EP-55

e-Poster Area

D: Technical Studies -> D5 Radiopharmacy/Radiochemistry -> D51 New Radiopharmaceuticals - SPECT

EP-0803
Preparation of a 99mTc-labeled Bromobenzyl Ether Derivative Targeting PD-L1
W. Hongyong, *C. Lu, Y. Liu, J. Wu, H. Wu, G. Han, P. Zou;*
Jiangsu Institute of Nuclear Medicine, Wuxi, Jiangsu, CHINA.

EP-0804
[113mIn]In-FAPI-46 radiolabeled complex: a new agent for SPECT imaging of FAP-expressing tumors
f. Bolourinovin[1], *F. Badipa[1], s. zolghadri[2], h. yousefnia[3];*
[1]PARS-ISOTOPE, karaj, IRAN, ISLAMIC REPUBLIC OF, [2]Radiation Applications Research School, Nuclear Science and Technology Research Institute, P.O.Box: 11365-8486, Tehran-Iran, Tehran, IRAN, ISLAMIC REPUBLIC OF, [3]Radiation Applications Research School, Nuclear Science and Technology Research Institute, P.O.Box: 11365-8486, Tehran-Iran, tehran, IRAN, ISLAMIC REPUBLIC OF.

EP-0805
First Experience with [195mPt]Cisplatin Imaging in Lung Cancer Patients
D. Hoogenkamp[1], *E. A. Aalbersberg[1], K. van der Schilden[2], H. N. Hendrikse[3], M. P. J. Mooijer[3], U. Funke[3], B. D. Windhorst[3], L. J. de Wit-van der Veen[1], M. M. G. Rossi[1], J. S. A. Belderbos[1], W. V. Vogel[1];*
[1]NETHERLANDS Cancer Institute (NKI-AVL), Amsterdam, NETHERLANDS, [2]Nuclear Research and Consultancy Group (NRG), Petten, NETHERLANDS, [3]Amsterdamumc (location VUmc), Amsterdam, NETHERLANDS.

EP-0806
Preparation and quality control of [113mIn]In-PEG4-BBN(7-14) as a new agent for SPECT imaging of GRPR-expressing tumors
s. zolghadri, *F. Badipa, H. Yousefnia, B. Alirezapour, A. Bahrami-Samani, S. Shirvani-Arani, F. Bolouri-Novin;*
Nuclear Science and Technology Research Institute (NSTRI), Tehran, IRAN, ISLAMIC REPUBLIC OF.

EP-0807
Preclinical evaluation of a novel PSMA-targeting radioligand [99mTc]Tc-BQ0413
E. Bezverkhniaia[1], *P. Kanellopoulos[1], A. Abouzayed[1], M. Oroujeni[1], A. Vorobyeva[2], U. Rosenström[1], V. Tolmachev[1], A. Orlova[1];*
[1]Uppsala university, Uppsala, SWEDEN.

EP-56

e-Poster Area

D: Technical Studies -> D5 Radiopharmacy/Radiochemistry -> D52 New Radiopharmaceuticals - PET

EP-0808
Expanding the Versatility of F-18 Indirect Labeling: Optimizing the Synthesis of TDBFB Boronic Acid Derivatives for Indirect Labeling via Suzuki Coupling
Y. Yagi[1,2,3], *H. Kimura[2], M. Ando[1], K. Kawaguchi[1], A. Sato[1], A. Shimizu[1], M. Fujimura[1], T. Higuchi[3,4];*
[1]Kyoto college of Medical Science, Nantan, JAPAN, [2]Kyoto Pharmaceutical University, Kyoto, JAPAN, [3]University Hospital Würzburg, Würzburg, GERMANY, [4]Okayama University, Okayama, JAPAN.

EP-0809
Automated One-Pot Synthesis of [18F]AlF-NOTA-Ubiquicidin[29-41] in Aqueous Solution with Preparative HPLC for Clinical PET/CT imaging
A. Meyer, *C. Fischer, D. Hellwig;*
University Hospital, Regensburg, GERMANY.

EP-0810
Development of a 18F-PD-L1 radiotracer for cancer patient response to immunotherapy
M. Goodman, *L. Chavan, W. Seo, H. Zecca, R. Voll, L. Birnbaum, J. Kelvin, E. Dreaden, N. Jui;*
Emory University, Atlanta, GA, UNITED STATES OF AMERICA.

EP-0811
rhTATE: A Radiohybrid Approach for 18F or177LuLabelled Somatostatin Analogues Generating Chemically Identical Compounds
S. Deiser, *V. König, S. Fenzl, T. Günther, N. Urtz-Urban, S. Inoue, A. Casini;*
Technical University Munich (TUM), Garching by Munich, GERMANY.

EP-0812
Phenolate-containing AAZTA-like chelators for 68Ga labelling. An in vitro and in vivo study.
L. Tei[1], *J. Martinelli[1], M. Boccalon[2], A. Vagner[3], D. Szikra[4], G. Trencsenyi[4], Z. Baranyai[2];*
[1]Department of Science and Technological Innovation, University of Piemonte Orientale, Alessandria, ITALY, [2]Bracco Research Centre, Bracco Imaging S.p.A., Colleretto Giacosa, Via Ribes 5, ITALY, ITALY, [3]Scanomed Ltd., Debrecen, Nagyerdei krt. 98, HUNGARY, [4]Division of Nuclear Medicine and Translational Imaging, Department of Medical Imaging, Faculty of Medicine, University of Debrecen, Debrecen, Nagyerdei krt. 98, HUNGARY.

EP-0813
Automated Synthesis Method To Produce The Pet Tracer [68ga]Ga-Fapi-46 For Clinical Applications: Development, Optimization And Validation
S. Migliari, *G. Ladisa, M. Scarlattei, G. Baldari, L. Ruffini;*
Nuclear Medicine Division, Azienda Ospedaliero-Universitaria of Parma, Parma, ITALY.

EP-0814
Synthesis and Biological Evaluation of 18F-labelled Deuterated Tropane Derivatives as Dopamine Transporter Probes
Q. Hu[1], *Z. Chen[1,2,3], Q. Li[2,3], J. Tang[2], Y. Fang[2], C. Liu[2], J. Liu[1,2], M. Qi[2,4];*
[1]Department of Radiopharmaceuticals, School of Pharmacy, Nanjing Medical University, Nanjing, CHINA, [2]NHC Key Laboratory of Nuclear Medicine, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi, CHINA, [3]Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, School of Pharmacy, Xuzhou Medical University, Xuzhou, CHINA, [4]School of Pharmaceutical Science, Inner Mongolia Medical University, Hohhot, CHINA.

EP-0815
18F-labeled TTCO-PSMA Conjugate as a novel PET agent for prostate cancer imaging
T. Zhang, *Z. Zhang, G. Dong, L. Le, X. Ji, C. Peng, K. Li, X. Chen;*
Nanjing Medical University, Nanjing, CHINA.

EP-0816
A novel 68Ga-labeled spermine derivative probe for tumor imaging
K. Qin[1], *D. Shi[1], H. Wang[1,2,3], S. Li[1,2,3];*
[1]Shanxi Medical University, Taiyuan, Shanxi, CHINA, [2]Shanxi Key Laboratory of Molecular Imaging, Taiyuan, Shanxi, CHINA, [3]Collaborative Innovation Center for Molecular Imaging of Precision Medicine Shanxi Medical University, Taiyuan, Shanxi, CHINA.

EP-0817
Micro-PET Imaging Study of the Novel 68Ga-labeled PET Probe 68Ga-NOTAGA-Nap-Gal
Y. Xu[1], *P. Zhou[2], Y. Wu[2], H. Wu[1], Y. Liu[1], H. Wang[1], P. Zou[1];*
[1]Jiangsu institute of Nuclear Medicine, WuXi, CHINA, [2]Nanjing Medical University, Nanjing, CHINA.

EP-0818
Atlas-Based Simulation for Pre-Estimation of Absorbed Dose in Critical Target Organs: A Study Using Monte Carlo Simulations with XCAT Phantoms and Real Patient Data in 68Ga-PSMA PET/CT
N. Vahidfar, *M. Fallahpoor, S. Farzanefar;*
Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF.

EP-0819
Evaluation of Different Ranges of [18F]Fluoride for Production of [18F]F-FAPI-74
A. MORISCO, *C. Maisto, R. de Marino, L. D'Ambrosio, E. Squame, M. Buonanno Recchimuzzo, A. Esposito, M. Aurilio, P. Gaballo, S. Lastoria;*
ISTITUTO NAZIONALE TUMORI - IRCCS - Fondazione G. Pascale, Napoli, ITALY.

EP-0820
Peptidic heterodimer-based radiotracer targetingfibroblast activation protein and integrin αvβ3
K. Liu;
Department of Nuclear Medicine, Xiangya Hospital, Central South University, Changsha, CHINA.

EP-0821
Initial clinical experience with 18F-JK-PSMA-7 PET-CT in evaluation of staging and biochemical recurrence of prostate carcinoma.
P. Chandra, *S. Chinnappan, G. Chandran, C. L. Abraham;*
Zydus Hospital, Vadodara, INDIA.

EP-0822
Synthesis and Characterization of Zr/Mannose-Conjugated Indocyanine Green-Loaded Liposomes as Sentinel Lymph Node Multimodal Diagnostic Agents for PET/NIR Fluorescence Imaging
G. Kim[1], *D. Jeong*[1,2], *H. Lee*[1];
[1]*Dongnam Institute of Radiological and Medical Sciences (DIRAMS), Busan, KOREA, REPUBLIC OF,*
[2]*Dongguk University, Gyeongju, KOREA, REPUBLIC OF.*

EP-0823
Biological Evaluation of Escherichia Coli Labeled with Zirconium-89 for the Development of Radiopharmaceuticals for Positron Emission Tomography
D. Jeong[1,2], *G. Kim*[1], *E. Choi*[2], *S. Park*[2], *H. Lee*[1], *S. Kim*[2];
[1]*Dongnam Institute of Radiological and Medical Sciences (DIRAMS), Busan, KOREA, REPUBLIC OF,*
[2]*Dongguk University, Gyeongju, KOREA, REPUBLIC OF.*

EP-0824
It's Twins!? 68Ga &18F-labelled TriGalactan for Functional Liver Imaging
M. A. Zierke[1], *K. Samadikhah*[2], *C. Rangger*[1], *M. Panzer*[3], *A. Schmid*[2], *R. Haubner*[1];
[1]*Nuclear Medicine, Innsbruck, AUSTRIA,* [2]*Werner Siemens Imaging Center, Tübingen, GERMANY,*
[3]*Internal Medicine I, Innsbruck, AUSTRIA.*

EP-0825
Model of Pharmacokinetic Based on Copper-64 Labeled DNA Bipyramid Nanostructure
P. Li, *J. Li;*
Inner Mongolia Medical University, Hohhot, CHINA.

EP-0827
Radionuclide cisternography with PET/CT using Cu-64-DOTA
J. Greiser[1], *S. Groeber*[1], *T. Weisheit*[1], *T. Niksch*[1], *C. Kuehnel*[1], *M. Schwab*[2], *R. Drescher*[1], *M. Freesmeyer*[1];
[1]*Clinic of Nuclear Medicine, University Hospital, Jena, GERMANY,* [2]*University Hospital, Clinic of Neurology, Jena, GERMANY.*

EP-0828
11C-Labeled histamine derivatives for PET imaging
X. Shao, *K. Mhanna, A. Brooks, J. Witek, D. Raffel, P. Scott;*
University of Michigan, Ann Arbor, MI, UNITED STATES OF AMERICA.

EP-0829
Synthesis and Preclinical Evaluation of two novel 68Ga-labeled (R)-pyrrolidin-2-yl-boronic acid-based FAP-targeted tracers for Cancer Imaging with Positron Emission Tomography
S. Bendre, *H. Kuo, H. Merkens, Z. Zhang, J. Zeisler, N. Coplo, F. Bénard, K. Lin;*
BC Cancer Research Center, Vancouver, BC, CANADA.

EP-0830
[89Zr]Zr-desferrioxamine-B: A novel agent for PET imaging of Vibrio cholerae infection
H. Yousefnia, *F. Mohammadpour-Ghazi, S. Zolghadri;*
Nuclear Science and Technology Research Institute (NSRTI), Tehran, IRAN, ISLAMIC REPUBLIC OF.

EP-0831
Preclinical evaluation of [18F]FEAO, a novel radiotracer for myocardial perfusion imaging in PET
M. Dziuk[1], *E. Witkowska-Patena*[1], *S. Krajewski*[2], *J. Towpik*[2], *L. Steczek*[2], *K. Gotowicz*[2], *P. B. Kozanecki*[2], *J. Wlostowska*[2], *C. Kozanecki*[2];
[1]*Military Institute of Medicine National Research Institute, Warsaw, POLAND,* [2]*Synektik Research, Warsaw, POLAND.*

EP-0832
LANTana: A phase Ib study nvestigating epigenetic modification of somatostatin receptor-2 with ASTX727 to improve therapeutic outcome with [177Lu]-DOTA-TATE in patients with metastatic neuroendocrine tumours
R. Sharma[1], *S. R. Khan*[2], *M. Naik*[2], *T. D. Barwick*[3], *E. O. Aboagye*[4];
[1]*imperial college london, London, UNITED KINGDOM,* [2]*Imperial college NHS Heatlhcare Trust, London, UNITED KINGDOM,* [3]*Imperial College Healthcare NHS Trust London, London, UNITED KINGDOM,* [4]*Imperial College London, London, UNITED KINGDOM.*

EP-0833
Comparison of [68Ga]Ga-FAPI-46 PET/CT and [18F] FDG PET/CT hepatic tumors
F. Novruzov[1], *E. Mehdi*[1], *N. Orucova*[2], *N. Aliyeva*[1], *R. Shukurov*[3], *Z. Dadashov*[2], *F. Valla*[4], *J. Aliyev*[5];
[1]*Azerbaijan National Centre of Oncology, Department of Nuclear Medicine, Baku, AZERBAIJAN,* [2]*Azerbaijan National Centre of Oncology, Department of Nuclear Medicine, Baku, Azerbaijan, Baku, AZERBAIJAN,* [3]*Azerbaijan National Centre of Oncology, Department of Nuclear Medicine, Baku, Azerbaijan, Baku, Azerbaijan, Baku, AZERBAIJAN,* [4]*Sofie, Totowa, NJ, UNITED STATES OF AMERICA,* [5]*Azerbaijan National Centre of Oncology, Department of General Surgery, Baku, Azerbaijan, Baku, AZERBAIJAN.*

EP-57
e-Poster Area

D: Technical Studies -> D5 Radiopharmacy/Radiochemistry -> D53 New Radiopharmaceuticals - Therapy

EP-0834
Radioimmunotherapy of experimental systemic mucormycosis in a murine model
J. Carvalho, *M. E. Malo, K. J. H. Allen, C. Frank, Z. Xiao, R. Jiao, E. Dadachova;*
University of Saskatchewan, Saskatoon, SK, CANADA.

EP-0835
[123I]CC1: a Radiotheranostic Agent for PARP-expressing Cancer Imaging and Therapy
C. Chan, *Z. Chen, M. Veal, G. Dias, G. Destro, M. Mosley, F. Guibbal, V. Gouverneur, B. Cornelissen;*
University of Oxford, Oxford, UNITED KINGDOM.

EP-0836
Theranostics approach to imaging and treating experimental melanoma with 203/212Pb-labeled antibodies to melanin
R. Jiao[1], *K. J. H. Allen*[1], *M. Malokja782@mail.usask.ca*[1], *J. Wilson*[2], *B. J. B. Nelson*[2], *F. Wuest*[2], *E. Dadachova*[1];
[1]*University of Saskatchewan, Saskatoon, SK, CANADA,* [2]*University of Alberta, Edmonton, AB, CANADA.*

EP-0837
Co-treatment with Trastuzumab Improved Therapy of HER2 expressing Xenograftswith [177Lu]Lu-ABY-027 Affibody Molecule
Y. Liu[1], *T. Xu*[1], *A. Vorobyeva*[1], *A. Loftenius*[2], *V. Bodenko*[3], *A. Orlova*[1], *F. Y. Frejd*[2], *V. Tolmachev*[1];
[1]*Uppsala University, Uppsala, SWEDEN,* [2]*Affibody AB, Solna, SWEDEN,* [3]*Tomsk Polytechnic University, Tomsk, RUSSIAN FEDERATION.*

EP-0838
Organotrifluoroborate Enhances Tumor Targeting of Fibroblast Activation Protein Inhibitors for Targeted Radionuclide Therapy
Y. Liu, *M. Xu, J. Chen, X. Cui, Z. Liu;*
Peking University, Beijing, CHINA.

EP-0839
Development of anti-cancer radioimmunotherapy method targeting angiogenesis.
B. Park, *J. Yoon, Y. An, S. Kim;*
Ajou University Hospital, Suwon, Gyeonggi-Do, KOREA, REPUBLIC OF.

EP-0840
Antimony-119, a promising Auger emitter for targeted radionuclide therapy to eradicate single tumor cells and tumor clusters
A. Larouze[1], *M. Alcocer-Avila*[2], *C. Morgat*[1], *C. Champion*[1], *E. Hindié*[1];
[1]*Université de Bordeaux, Bordeaux, FRANCE,* [2]*Université de Lyon, Lyon, FRANCE.*

EP-0841
A Nanodepot Incorporating 177Lu-Labeled Gold Nanoparticles is Ineffective for Treatment of 4T1 Tumours in Balb/c Mice Due to Low β-Particle Energy and Spatially Lower Doses and Shorter Dose Penetration
R. Liu[1], *Z. Cai*[1], *E. Wong*[2], *Y. Lu*[2], *M. A. Winnik*[2], *R. M. Reilly*[1,3,4];
[1]*Department of Pharmaceutical Sciences, Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON, CANADA,* [2]*Department of Chemistry, University of Toronto, Toronto, ON, CANADA,* [3]*Department of Medical Imaging, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, CANADA,* [4]*Joint Department of Medical Imaging and Princess Margaret Cancer Centre, University Health Network, Toronto, ON, CANADA.*

EP-0842
Radiation Nanomedicines for Local Treatment of Glioblastoma Multiforme - Epidermal Growth Factor Receptor-Targeted and Non-Targeted Gold Nanoparticles Labeled with the Auger Electron-Emitter, 197Hg
M. Brown[1], *Z. Cai*[1], *S. Chen*[2], *V. Radchenko*[2], *W. Chung*[3], *M. Winnik*[3], *J. T. Rutka*[4], *R. M. Reilly*[1,5];
[1]*Department of Pharmaceutical Sciences, Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON, CANADA,* [2]*Life Sciences Division, TRIUMF, University of British Columbia, Vancouver, BC, CANADA,* [3]*Department of Chemistry, University of Toronto, Toronto, ON, CANADA,* [4]*Division of Neurosurgery, Hospital for Sick Children and Division of Neurosurgery, Department of Surgery, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, CANADA,* [5]*Joint Department of Medical Imaging and Princess Margaret Cancer Centre, University Health Network, Toronto, ON, CANADA.*

EP-0843
Modification and Evaluation of EGFRvIII-Targeting Peptides for the Targeted Radiotherapy of Glioblastoma Multiforme
F. Schuderer[1,2], *D. Werner*[2], *M. Rassner*[3], *C. Braun*[3], *J. Galamba Correia*[4], *A. Casini*[1,2];
[1]*Chair of Medicinal and Bioinorganic Chemistry, Department of Chemistry, Technical Unversity of Munich, Garching, GERMANY,* [2]*Chair of Pharmaceutical Radiochemistry, Department of Chemistry, Technical University of Munich, Garching, GERMANY,* [3]*Department of Pediatrics, Dr. von Hauner Children's Hospital, University Hospital, Ludwig Maximilians University of Munich (LMU), Munich, GERMANY,* [4]*Centro de Ciências e Tecnologias Nucleares and Departamento de Engenharia e Ciências Nucleares, Instituto Superior Têcnico, Universidade de Lisboa, Lisbon, PORTUGAL.*

EP-0844
Novel cMet Targeted Radiotheragnostics: Preclinical Development and Optimisation for Clinical Use
C. Portal[1], *N. Swanwick*[1], *A. Prignon*[2], *A. Gibson*[1];
[1]*Edinburgh Molecular Imaging Ltd., Edinburgh, UNITED KINGDOM,* [2]*Laboratoire d'Imagerie Moleculaire Positonique (LIMP) UMS28 Small Animal Phenotyping, Sorbonne University, Paris, FRANCE.*

EP-0845

Analysis of the effectiveness of 177Lu-Oxodotreotide in the treatment of neuroendocrine tumors sensitive to somatostatin receptors

Á. Alonso García[1], *M. L. Bravo-Ferrer Moreno*[1], *A. Blesa Jiménez*[1], *M. A. Asensio Ruiz*[1,2], *M. T. Martínez Martínez*[1,2];
[1]*Radiopharmacy Service, Virgen de la Arrixaca Hospital, Murcia, SPAIN,* [2]*Instituto Murciano de Investigación Biosanitaria (IMIB)-Arrixaca, Murcia, SPAIN.*

EP-58

e-Poster Area

D: Technical Studies -> D5 Radiopharmacy/Radiochemistry -> D54 New Biological Targets and Ligands

EP-0846

Targeting Regulatory T cells in experimental colon cancer with radioimmunotherapy.

Z. Xiao, *R. Jiao, K. J. H. Allen, M. E. Malo, C. Frank, S. Giri, J. L. C. Carvalho, E. Dadachova;*
University of Saskatchewan, Saskatoon, SK, CANADA.

EP-0847

177Lu-PSMA treatment impacts on the full transcriptome of prostate cancer cells.

F. Amoroso[1], *E. O'Neill*[1], *B. Cornelissen*[2,1];
[1]*MRC Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Oxford, UNITED KINGDOM,* [2]*Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Groningen, NETHERLANDS.*

EP-0848

Molecular imaging based response monitoring of non-contact induction heating therapy on infected prosthetic joints

T. Buckle, *M. M. Welling, D. D. D. Rietbergen, F. W. van Leeuwen, B. G. Pijls;*
Leiden University Medical Center, Leiden, NETHERLANDS.

EP-0849

Association Constant Determination of Macropa as Chelator for the Stable Complexation of Barium-131, Lanthanum-133 and Luthetium-177

M. Blei[1,2], *B. Drobot*[3], *J. Kretzschmar*[3], *H. J. Pietzsch*[1], *K. Kopka*[1,2], *F. Reissig*[1], *C. Mamat*[1,2];
[1]*Helmholtz-Zentrum Dresden-Rossendorf, Department of Radiopharmaceutical Cancer Research, Dresden, GERMANY,* [2]*TU Dresden, Dresden, GERMANY,* [3]*Helmholtz-Zentrum Dresden-Rossendorf, Department of Resource Ecology, Dresden, GERMANY.*

EP-0850

Development and Characterization of Novel Peptide-Based Apelin Theranostic Probes for Glioblastoma

E. Besserer-Offroy[1,2], *P. Jeanjean*[1], *F. Al Banaa*[1], *S. Kwock*[1], *E. Breault*[3], *J. Fournier*[3], *P. Sarret*[3,4], *D. A. Nathanson*[1,5], *J. Czernin*[1,5], *G. Carlucci*[1,5], *C. E. Mona*[1,5];
[1]*David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, UNITED STATES OF AMERICA,* [2]*Inserm U1086 - François Baclesse Comprehensive Cancer Centre, Caen, FRANCE,* [3]*Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, QC, CANADA,* [4]*Sherbrooke University Hospital - Research Centre, Sherbrooke, QC, CANADA,* [5]*UCLA Jonsson Comprehensive Cancer Center, Los Angeles, CA, UNITED STATES OF AMERICA.*

EP-0851

PATO-Cy5, a bi-modal tracer for image-guided hepatobillary surgery

D. Rietbergen, *T. Buckle, M. P. van Meerbeek, L. J. Slof, M. van Oosterom, F. W. B. van Leeuwen;*
Leids Universitair Medisch Centrum (LUMC), Leiden, NETHERLANDS.

EP-59

e-Poster Area

D: Technical Studies -> D5 Radiopharmacy/Radiochemistry -> D55 Radiopharmacokinetics and Drug Development

EP-0852

Modifying Biodistribution of EpCAM-targeting DARPin Ec1 by Fusion with Albumin Binding Domain (ABD): Effect of ABD Position

M. Oroujeni[1], *A. Vorobyeva*[1], *A. Hani Binti Rosly*[1], *J. Garousi*[2], *Y. Liu*[1], *A. Schulga*[3], *E. Konovalova*[4], *A. Orlova*[1], *S. Deyev*[3], *V. Tolmachev*[1];
[1]*Uppsala University, Uppsala, SWEDEN,* [2]*Royal Institute of Technology (KTH), Stockholm, SWEDEN,* [3]*Tomsk Polytechnic University, Tomsk, RUSSIAN FEDERATION,* [4]*Russian Academy of Sciences, Moscow, RUSSIAN FEDERATION.*

EP-0853

Development of new bone-seeking radiolabeled compounds

K. Ogawa, *K. Nishizawa, K. Mishiro, N. Effendi, T. Fuchigami, M. Munekane, H. Wakabayashi, S. Kinuya;*
Kanazawa University, Kanazawa, JAPAN.

EP-0854

Development of fluorinated α-methyl-3BPA derivatives for BNCT/PET theranostics

F. Hirano[1], *N. Kondo*[1], *Y. Murata*[2], *A. Sudani*[2], *T. Temma*[1];
[1]*Osaka Medical and Pharmaceutical University, Osaka, JAPAN,* [2]*Stella Pharma Corporation, Osaka, JAPAN.*

EP-0855

In Vivo Stability Evaluation of Astatobenzene Derivatives Having Neighboring Substituents

S. Hirata[1], *K. Mishiro*[1], *K. Washiyama*[2], *T. Fuchigami*[1], *M. Munekane*[1], *K. Takahashi*[2], *Y. Arano*[3], *S. Kinuya*[1], *K. Ogawa*[1];
[1]*Kanazawa University, Kanazawa, JAPAN,* [2]*Fukushima Medical University, Fukushima, JAPAN,* [3]*Chiba University, Chiba, JAPAN.*

EP-0856

Development of FAP-Targeted Inhibitors with Extended Blood Circulation

L. Feng[1], *X. Zeng*[2], *J. Fang*[2], *H. Liu*[2], *X. Zhang*[3], *D. Jiang*[1], *R. Zhuang*[2];
[1]*Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, CHINA,* [2]*Center for Molecular Imaging and Translational Medicine, State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University, Xiamen, CHINA,* [3]*Department of Nuclear Medicine & Department of Medical Research Center, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, CHINA.*

EP-0858

Method development for the analysis of 14C-acetaminophen by HPLC-MS

P. Chang, *S. Farn;*
Institute of Nuclear Energy Research, Tao-Yuan, TAIWAN.

EP-0859

Radiolabeling and biodistribution evaluation of orally administered nanovaccines against enterotoxigenic Escherichia coli formed by vesicles of their outer membrane encapsulated in Gantrez®-mannosamine nanoparticles

G. Quincoces[1], *M. Berzosa*[2], *F. Pareja*[1], *M. Collantes*[3], *M. Ecay*[3], *R. Ramos-Membrive*[1], *J. Simón*[1], *V. Betech-Antar*[4], *J. Rosales*[4], *I. Peñuelas*[1];
[1]*Radiopharmacy Unit. Nuclear Medicine Department. University Clinic of Navarra, Pamplona, SPAIN,* [2]*Microbiology Department. University of Navarra, Pamplona, SPAIN,* [3]*UNIMTRA. Nuclear Medicine Department. University Clinic of Navarra, Pamplona, SPAIN,* [4]*Nuclear Medicine Department. University Clinic of Navarra, Pamplona, SPAIN.*

EP-0860

Effects of DOTATATE on plasma protein-binding and tumour cell-uptake of 68Ga- and 177Lu-DOTATATE

L. Schneider, *Y. Zhao, M. Zuhayra, U. Lützen;*
Department of Nuclear Medicin, Molecular Imaging, Diagnostics and Therapy UKSH, Kiel, GERMANY.

EP-0861

Evaluation of influence of albumin binding domain position on biodistribution of HER2-targeting DARPin-DM1 drug conjugates using radiolabeling

A. Vorobyeva[1], *T. Xu*[1], *Y. Liu*[1], *M. Oroujeni*[1], *A. Schulga*[2,3], *J. Garousi*[4], *E. Konovalova*[2], *Y. Liao*[1], *A. Zikrileh*[1], *P. Kanellopoulos*[1], *O. Bragina*[5,3], *T. Gräslund*[4], *A. Orlova*[1], *S. M. Deyev*[2,3], *V. Tolmachev*[1];
[1]*Uppsala University, Uppsala, SWEDEN,* [2]*ShemyakinOvchinnikov Institute of Bioorganic Chemistry, Moscow, RUSSIAN FEDERATION,* [3]*Tomsk Polytechnic University, Tomsk, RUSSIAN FEDERATION,* [4]*Royal Institute of Technology (KTH), Stockholm, SWEDEN,* [5]*Tomsk National Research Medical Center, Tomsk, RUSSIAN FEDERATION.*

EP-0862

Preparation, double radiolabeling of Albumin Nanoparticles (HSA-NPs) with technetium-99m and gallium-67 and in vivo biodistribution studies using microSPECT/CT to accelerate their pharmaceutical development as nanovaccines

F. Pareja del Rio[1], *E. van Brandwijk*[1], *J. A. Simon*[1], *A. Bronte*[1], *V. Betech-Antar*[1], *F. Minguez*[1], *M. Romera*[1], *J. J. Rosales*[1], *M. Collantes*[1], *R. Ramos*[2], *G. Quincoces*[1], *I. Peñuelas*[1];
[1]*Nuclear Medicine Department. Clínica Universidad de Navarra., Pamplona, SPAIN,* [2]*Nuclear Medicine Department. Clínica Universidad de Navarra, Madrid, SPAIN.*

EP-0863

Pharmacological implications of molar activity of 225Ac-labeled PSMA targeting agents in prostate cancer tumor models.

R. Hernandez, *A. Thickens, H. Comas Rojas, N. Clemons, A. Carston, Y. Medina Guevara, L. Lambert Lepesevich, A. Pinchuk;*
University of Wisconsin-Madison, Madison, WI, UNITED STATES OF AMERICA.

EP-0864

In vitro stability of 99mTc-FITC-SFN for Oral Drug Delivery System

M. Asensio Ruiz[1,2], *Á. Alonso García*[1], *M. Bravo-Ferrer Moreno*[1], *A. Blesa Jiménez*[1], *A. A. Lozano-Pérez*[2,3], *M. T. Martínez Martínez*[1,2];
[1]*Radiopharmacy Service, Virgen de la Arrixaca Hospital, Murcia, SPAIN,* [2]*Instituto Murciano de Investigación Biosanitaria (IMIB)-Arrixaca, Murcia, SPAIN,* [3]*Departamento de Biotecnología Genómica y Mejora Vegetal, Instituto Murciano de Investigación y Desarrollo Agrario y Medioambiental, Murcia, SPAIN.*

EP-0865

Development of new molecular drug delivery tools based on PET imaging : in vivo performance research of nucleic acid nanomaterials

Q. Xia;
Department of Nuclear Medicine ,School of Medicine, Shanghai Jiao Tong University, Shanghai, CHINA.

EP-0866

Preparation and in vitro evaluation of an anti-HER2 Affibody radiolabelled with Zr-89

D. Niculae[1,2], *R. Leonte*[1], *R. Cornoiu*[1], *D. Cocioaba*[1], *L. Chilug*[1], *S. Baruta*[1], *B. Burghelea*[1], *L. Craciun*[1], *A. Popa*[1], *A. Necsoiu*[1], *D. Draganescu*[2];
[1]*Horia Hulubei National Institute for Physics and Nuclear Engineering, Bucharest (Magurele), ROMANIA,* [2]*University of Medicine and Pharmacy Carol Davila, Bucharest, ROMANIA.*

EP-0867

The Impact of Renal Uptake on 18F-DCFPyL Biodistribution

G. Chaussé[1], *S. Plaha*[2];
[1]*McGill University, Montreal, QC, CANADA,* [2]*University of British Columbia, Vancouver, BC, CANADA.*

EP-60

e-Poster Area

D: Technical Studies -> D5 Radiopharmacy/Radiochemistry -> D56 Radionuclide Production

EP-0868

Preparation of Ga/Ni Solid Target for Cyclotron-produced 68Ge by Electrodeposition

Y. Shen;
China Institute of Atomic Energy, Beijing, CHINA.

EP-0869
Developing Actinium-225 large-scale supply
S. Bertrand[1], *S. Van den Berghe[1], W. Leysen[2], J. Mermans[2], S. Heinitz[2], D. Maertens[1], G. Scheveneels[2], C. Gameiro[3], A. Cea[2], P. Vanwolleghem[1], M. Sprangers[2];*
[1]Pantera, Mol, BELGIUM, [2]Belgian Nuclear Research Centre (SCK CEN), Mol, BELGIUM, [3]Ion beam applications, Louvain-la-Neuve, BELGIUM.

EP-0870
CERAD, Center of Design and Synthesis of Radiopharmaceuticals for Molecular Targeting and 30 MeV cyclotron for medical isotope production in Poland
R. Mikolajczak, *D. Pawlak, W. Wojdowska, I. Cieszykowska, T. Szyszko, P. Garnuszek;*
National Centre for Nuclear research-POLATOM, Otwock, Poland, POLAND.

EP-0871
Cyclotron production of 68Ga with in-target dissolution
D. Szikra, *V. Forgács;*
University of Debrecen, Debrecen, HUNGARY.

EP-0872
Development of New Automated Methods for [18F]-NaF Productions using FDG synthesizer.
S. NGOKPOL, *S. Kijprayoon, T. Saonam;*
Bangkok hospital, Bangkok, THAILAND.

EP-0873
How Can Nuclear Physicians Mitigate the Patient's Fear of Medical Radiation Exposure? -Lessons Learned from Fukushima Dai-ichi Nuclear Power Plant Accident -
K. Ohno[1], *M. Kajisako[2];*
[1]Kyoto Collage of Medical Science, Kyoto Nantan, JAPAN, [2]Kyoto University Hospital, Kyoto, JAPAN.

EP-0874
A low energy cyclotron, as an enabler for cancer diagnosis in emerging countries
J. Geets, *E. Kral, J. Harray, V. Petry;*
Ion Beam Applications SA, Louvain-La-Neuve, BELGIUM.

EP-61

e-Poster Area

D: Technical Studies -> D5 Radiopharmacy/Radiochemistry -> D57 Radiopharmaceutical Preparation and Quality Control

EP-0875
Radiosynthesis and Formulation of [18F]mFBG : The challenge of a clinical use radiopharmaceutical for a pediatric population
J. Fouque, *L. Trump, B. Irumva, M. Steffann, E. Da Costa Branquinho, Q. Bruyer, C. Provost, O. Madar;*
Institut Curie, Saint-Cloud, FRANCE.

EP-0876
Automated Production of 177Lu-Labelled Radiotracers Using Microfluidic Approach
S. Lahdenpohja[1], *C. Piatkowski[2], L. Tanguy[2], B. Kuhnast[1];*
[1]Université Paris-Saclay, CEA, CNRS, Inserm, BioMaps, Orsay, FRANCE, [2]PMB Alcen, Peynier, FRANCE.

EP-0877
Comprehensive analysis of environmental monitoring data from the GMP radiopharmaceutical facility of the UMCG obtained between 2010-2022
H. Boersma[1], *L. B. S. Bekhof[2], T. W. T. Poiesz[2], M. M. Woerdenbag[1], D. Giesen[1], H. T. Tholen[1], G. Luurtsema[1], M. N. Lub-de Hooge[1], H. J. Woerdenbag[2];*
[1]University Medical Center Groningen, Groningen, NETHERLANDS, [2]University of Groningen, Groningen, NETHERLANDS.

EP-0878
Fully Automated Radiosynthesis Quality Control and GMP Validation of [68Ga]Ga-PentixaFor for CXCR4 PET Imaging: First Taiwan Experience
M. Li[1], *L. Hung[1], S. Yang[1], T. Lin[1], Y. Huang[1], W. Pai[2];*
[1]Koo foundation Sun Yat-Sen Cancer Center, Taipei, TAIWAN, [2]Advancharis Science and Research Co., Ltd, New Taipei City, TAIWAN.

EP-0879
Radiosynthesis of Theranostic FAP-2286: This Is the Way
M. Aurilio, *C. Maisto, A. Esposito, V. Porfidia, M. Buonanno, R. de Marino, A. Morisco, E. Squame, S. Lastoria;*
National Cancer Institute G. Pascale, Napoli, ITALY.

EP-0880
The Optimization of the Current ININ Method of Lu-177 DOTA-HYNIC-iPSMA
Y. Omar[1], *Y. Atteya[1], N. Taha[2], M. AbdelKawi[1];*
[1]Misr Radiology Center, Cairo, EGYPT, [2]Ain Shams University, Cairo, EGYPT.

EP-0881
Automated cassette-based synthesis of [18F] Fluoro-L-DOPA via Cu-mediated process for routine production in a GMP environment
N. Emmanuel, *D. Goblet, G. Decoux, C. Gameiro;*
IBA, Louvain-la-Neuve, BELGIUM.

EP-0882
The Use of a Mobile Clean Room for (Re)loading of a More Durable Sr-82/Rb-82 Generator
R. Claessens[1], *J. C. Vink[2], K. Baggerman[2];*
[1]Rubigen b.v, 's-Hertogenbosch, NETHERLANDS, [2]Baggerman Farma Consult, Eindhoven, NETHERLANDS.

EP-0883
[68Ga]Ga-Pentixafor automatized synthesis using a new module: development and quality control before use in routine for CXCR4 PET imaging
T. Daniel, *C. Balouzet Ravinet, J. Clerc, R. Batista, Y. Mouraeff;*
Hôpital Cochin, Assistance publique - Hôpitaux de Paris, Paris, FRANCE.

EP-0884
Formulation of a Kit for Preparing 89Zr-DFO-Pembrolizumab Injection Under Good Manufacturing Practices for Imaging the Uptake of Pembrolizumab into Brain Metastases in Patients with Lung Cancer by PET
S. Borlase[1], *C. Chan[1], R. Reilly[1,2];*
[1]Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON, CANADA, [2]Joint Department of Medical Imaging and Princess Margaret Cancer Centre, University Health Network, Toronto, ON, CANADA.

EP-0885
Investigation of the Radiolabelling Potential of the Aurora A Kinase Inhibitor Alisertib with Iodine-123 [123I]
E. Uygur[1], *C. Sezgin[1], B. Y. Akdağ[2], T. Özbey[2], Y. Parlak[1], K. B. Karatay[3], F. G. Gümüşer[1], F. Z. Biber Müftüler[3];*
[1]Manisa Celal Bayar University, Manisa, TÜRKIYE, [2]TENMAK, Ankara, TÜRKIYE, [3]Ege University, İzmir, TÜRKIYE.

EP-0886
Radiolabeling of [225Ac]Ac-PSMA-617 vs [225Ac] Ac-DOTATATE: What Analogies? What Differences?
A. Esposito, *M. Aurilio, M. Buonanno, A. Morisco, C. Maisto, L. D'Ambrosio, D. Di Martino, S. Lastoria;*
IRCCS INT "Fondazione Pascale", Naples, ITALY.

EP-0887
Comparison of 111In and201Tl Radiopharmaceutical Adsorption on Acrylic Phantoms
T. Inagaki[1], *N. Fujita[2], R. Isobe[1], T. Nagahara[1], S. Abe[2], K. Kato[1];*
[1]Nagoya University Graduate School of Medicine, Nagoya, JAPAN, [2]Department of Radiological Technology, Nagoya University Hospital, Nagoya, JAPAN.

EP-0888
Cassette-Based Sterility Testing of Radiopharmaceuticals: A Novel Approach to Ensuring Quality and Safety
M. Nousch[1], *G. Reischl[2], R. Schulze[3], K. Tautz[4], D. Freitag-Stechl[1];*
[1]CUP Laboratorien Dr. Freitag GmbH, Radeberg, GERMANY, [2]Universitätsklinikum Tübingen, Tübingen, GERMANY, [3]Sächsisches Staatsministerium für Soziales und Gesellschaftlichen Zusammenhalt, Dresden, GERMANY, [4]Eckert & Ziegler GmbH, Berlin, GERMANY.

EP-0889
Determination of Extractables and Leachables in Radiopharmaceuticals
M. Nousch[1], *M. Janich[1], S. Becker[2], T. Otten[2], M. Zurbruegg[2], R. Schulze[3];*
[1]CUP Laboratorien Dr. Freitag GmbH, Radeberg, GERMANY, [2]Intertek (Schweiz) AG, Reinach, SWITZERLAND, [3]Sächsisches Staatsministerium für Soziales und Gesellschaftlichen Zusammenhalt, Dresden, GERMANY.

EP-0890
Comparative analytical methods for testing residual solvents in quality control of PET radiopharmaceuticals
V. Mendi Barcina[1], *M. De Arcocha Torres[1], Á. Gutiérrez González[2], I. Martínez Rodríguez[2], N. Martínez Amador[2], F. Gómez de la Fuente[2], A. Sánchez Salmón[2], J. Jiménez Bonilla[2], M. Pombo López[2], A. Bota Bota[2], R. Quirce Pisano[2];*
[1]Radiopharmacy Unit. Nuclear Medicine Service Marqués de Valdecilla University Hospital. Molecular Imaging Group (IDIVAL). University of Cantabria, Santander, SPAIN, [2]Nuclear Medicine Service Marqués de Valdecilla University Hospital. Molecular Imaging Group (IDIVAL). University of Cantabria, Santander, SPAIN.

EP-0891
Highly efficient, biocompatible radiolabeling method for in vivo cell tracking
R. Hernandez, *A. Thickens, Z. Rosenkrans, L. Lambert-Lepesevich, J. Kink, E. Aluicio-Sarduy, A. Pinchuk, J. Engle;*
University of Wisconsin-Madison, Madison, WI, UNITED STATES OF AMERICA.

EP-0892
Comparative methods of labeling red blood cells
M. Crespí Busquets[1], *J. Romero Herrera[1], S. Maymó Garrido[1], D. Rodriguez Puig[1], C. Munuera Sañudo[1], E. Pineda Fernández[1], M. Bueno Raspall[1], M. Cortés Romera[2];*
[1]Radiopharmacy Department, Bellvitge University Hospital-IDIBELL, L'Hospitalet de Llobregat, Barcelona, SPAIN, [2]Nuclear Medicine-PET (IDI) Department, Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, SPAIN.

EP-0893
Automated Production Of [18F]UCB-J Using A Dibenzothiophenium Salt Precursor For Labelling
D. Pritchard, *F. Sirindil, M. Glaser, R. Awais, F. Twyman, E. Eedan, K. Sander, E. Arstad;*
University College London, London, UNITED KINGDOM.

EP-0894
Ga68-PSMA-11 : push it to the limit with prepurification
M. Debarge[1], *A. Lombard[1], S. Journo[1], N. Veran[1], Q. Citerne[1], B. Demore[2,1];*
[1]Nancy University Hospital, Vandoeuvre-lès-Nancy, FRANCE, [2]Lorraine University, EA 4360 APEMAC, Nancy, FRANCE.

EP-0895
Initial experience on the cassette-based synthesis of 11C-Pittsburgh Compound-B
H. Gama Romero, *F. Trejo-Ballado, E. Zamora-Romo, M. Mendoza-Figueroa, G. Tecuapetla-Chantes, U. Rabadán-Domínguez, G. Contreras-Castañón, A. Zárate-Morales, A. Flores-Moreno, M. Ávila-Rodríguez;*
Unidad Radiofarmacia-Ciclotrón, Facultad de Medicina, Universidad Nacional Autónoma de México, MEXICO.

EP-0896
GMP Production of 89Zr-DFO-Pembrolizumab for Immuno-PET: predicting response in non-small lung cancer
I. Hrynchak[1], *M. Silva[1], S. Silva[2], A. Fonseca[1], A. Falcão[3], A. J. Abrunhosa[1,3];*
[1]ICNAS Pharma Unipessoal, Lda, Coimbra, PORTUGAL, [2]Pulmonology, Leiria Hospital Center, Leiria, PORTUGAL, [3]CIBIT/ICNAS, Institute for Nuclear Science Applied to Health – University of Coimbra, Coimbra, PORTUGAL.

EP-0897
Optimizing of automated production of Gallium-68 radiolabeled clinical agents by cyclotron liquid target system
Y. Shimizu[1], *K. Miyake[2], Y. Nakamoto[2];*
[1]Kyoto University Hospital, Kyoto, JAPAN, [2]Kyoto University Graduate School of Medicine, Kyoto, JAPAN.

EP-0898
Single center experience in the [18F]DPA-714 production using commercial disposable cassettes on AllinOne synthesizer
M. Riondato[1], *A. Democrito*[1], *C. Ghersi*[1], *S. Grugni*[2], *M. Baucknehť*[1], *S. D. Morbelli*[1], *C. Marini*[3], *G. Sambuceti*[1];
[1]*University Policlinic Hospital of Genoa, Genoa, ITALY,* [2]*Gamma Servizi srl, Borgherello Pavia, ITALY,* [3]*CNR Institute of Molecular Bioimaging and Physiology (IBFM), Milan, ITALY.*

EP-62

e-Poster Area

E: Other Studies -> E1 Case Reports

EP-0899
18F-FDG- PET/CT guided biopsy has an essential role in the diagnosis of primary extranodal diffuse large B-cell lymphoma of bone- a clinical case.
Z. Dancheva, *S. Spasova, T. Stoeva, I. Kobakova, M. Dyankova, S. Chausheva, T. Yordanova, B. Chaushev, A. Klisarova, B. Balev;*
St Marina University Hospital, Varna, BULGARIA.

EP-0900
A rare finding in 18F-FDG PET/CT restaging - unilateral diaphragmatic crura increased uptake in patient with pneumonectomy - a Case report
T. Stoeva, *T. Yordanova, M. Dyankova, S. Chausheva, Z. Dancheva, B. Chaushev, A. Klisarova;*
UMHAT "Sveta Marina" EAD- Varna, Varna, BULGARIA.

EP-0901
Osteomyelitis in patient with multiple myeloma- the invisible threat seen in 18F-FDG PET/CT
T. Stoeva, *M. Dyankova, Z. Dancheva, T. Yordanova, S. Chausheva, B. Chaushev, A. Klisarova;*
UMHAT "Sveta Marina" EAD- Varna, Varna, BULGARIA.

EP-0902
18F-FDG PET/CT in a patient with two metachronous tumors and the possible diagnostic pitfalls
T. Stoeva, *Z. Dancheva, M. Dyankova, S. Chausheva, T. Yordanova, B. Chaushev, A. Klisarova;*
UMHAT "Sveta Marina" EAD- Varna, Varna, BULGARIA.

EP-0903
A case report of abnormal bone imaging caused by bevacizumab
T. Yi, *C. Yu;*
The Second Affiliated Hospital of Guilin Medical University, Guilin, CHINA.

EP-0904
Primary colorectal cancer with increased 68Ga-PSMA expression on PET/CT: incidental second malignancy in primary staging for prostate cancer (PC)
M. Dyankova[1,2], *S. Chausheva*[1], *Z. Dancheva*[1], *T. Stoeva*[1], *T. Yordanova*[1], *B. Chaushev*[1], *A. Klisarova*[1];
[1]*Medical University Varna "Prof. Dr. Paraskev Stoyanov", Department of Imaging Diagnostics, Interventional Radiology and Radiotherapy, Varna, BULGARIA,* [2]*St. Marina University Hospital, Department of Nuclear Medicine, Varna, BULGARIA.*

EP-0905
Unusual recurrence of secondary renal hyperparathyroidism caused by a ectopic undescended parathyroid adenoma:a case report
w. Weng;
The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, CHINA.

EP-0906
Incidental Paget bone disease as a potential pitfall in 18-F FDG PET/CT in melanoma patient
S. Moustafa;
Assiut university hospital, Assiut university, EGYPT.

EP-0907
Pitfall In Tumor Assessment FDG-PET/CT Imaging In Hodgkin Lymphoma Due To Cocaine-Induced Nasal Inflammation
A. Jougla[1], *J. Alberini*[1,2,3], *B. Durand-Bailloud*[1], *R. Ahond-Vionnet*[1];
[1]*Department of Nuclear Medicine, Hôpital Pierre Beregovoy, Nevers, FRANCE,* [2]*Department of Nuclear Medicine, Centre Georges-François Leclerc, Dijon, FRANCE,* [3]*ICMUB Laboratory, UMR CNRS 6302, University of Burgundy, Dijon, FRANCE.*

EP-0908
Suspected Central Pontine Myelinolysis detected by 18F-FDG PET/CT in a patient with septic shock
L. Locantore, *M. Cucca, E. Biggi, R. J. Egoue Mongoue, I. Ravelli, D. Riolo, M. Zuffante;*
Nuclear Medicine Unit, AOUI, Verona, ITALY.

EP-0909
FDG PET/CT in the Evaluation of Multi-systemic Involvement in Erdheim Chester Disease
M. Guven[1], *M. Eroglu*[2], *A. Oral*[1], *C. Eraslan*[2], *Z. Ozcan*[1];
[1]*Department of Nuclear Medicine, Ege University, Izmir, TÜRKIYE,* [2]*Department of Radiology, Ege University, Izmir, TÜRKIYE.*

EP-0910
Accidently Detected Lung Masses as Carcinoma in 99mTc (V)-DMSA SPECT Imaging
E. Gharehpapagh[1], *S. Rezaei*[1], *L. Namvar*[2];
[1]*Department of Nuclear Medicine, Medical School, Tabriz University of Medical Sciences, Tabriz, IRAN, ISLAMIC REPUBLIC OF,* [2]*Tuberculosis and Lung Disease Research Center, Tabriz University of Medical Sciences, Tabriz, IRAN, ISLAMIC REPUBLIC OF.*

EP-0911
Unusual uptake of bone metastases in 99mTc-MAG3 dynamic renal scintigraphy
K. Aslaner, *B. Arca, D. Has Simsek, F. Buyukkaya, Y. Sanli, S. Kuyumcu;*
Istanbul University, Istanbul, TÜRKIYE.

EP-0912
Contribution of SPECT-CT in the Differentiation of Ectopic Thyroid Tissue and Thyroglossal Duct Cyst
G. Deniz[1], *E. G. Isik*[2], *D. Has Simsek*[2], *Y. Sanli*[2], *B. Arca*[2], *S. Kuyumcu*[2];
[1]*Istanbul University Istanbul Faculty of Medicine Nuclear Medicine Department, Istanbul, TÜRKIYE., Istanbul, TÜRKIYE,* [2]*Istanbul University Istanbul Faculty of Medicine Nuclear Medicine Department, Istanbul, TÜRKIYE.*

EP-0913
Case report: Pulmonary Langerhans cell histiocytosis (PLCH) - is it a challenge for 18F-FDG PET/CT?
M. Dyankova[1,2], *T. Stoeva*[1], *Z. Dancheva*[1], *S. Chausheva*[1], *T. Yordanova*[1], *B. Chaushev*[1], *A. Klisarova*[1];
[1]*Medical University Varna "Prof. Dr. Paraskev Stoyanov", Department of Imaging Diagnostics, Interventional Radiology and Radiotherapy, Varna, BULGARIA,* [2]*St. Marina University Hospital, Department of Nuclear Medicine, Varna, BULGARIA.*

EP-0914
Diagnostic pitfall in a PET/CT case of thyroid cancer with 18F-FDG multi-uptake
T. Yi, *C. Yu;*
The Second Affiliated Hospital of Guilin Medical University, Guilin, CHINA.

EP-0915
Persistent bone focal uptake of 18F-PSMA-1007 in patient with prostate cancer and undetectable levels of PSA under hormone therapy
G. Bellettati[1], *S. Pacella*[2], *A. Castello*[2], *E. Lopci*[3], *L. Florimonte*[2], *M. Castellani*[2];
[1]*University of Milan, Milano, ITALY,* [2]*Fondazione IRCCS Ca'Granda, Ospedale Maggiore Policlinico, Milano, ITALY,* [3]*Humanitas Clinical and Research Hospital, Rozzano, ITALY.*

EP-0916
Isolated limb perfusion (ILP) in a patient with myxoid liposarcoma (MLPS) of the lower extremity - case report
J. Peric, *I. Žagar;*
Institute of Oncology Ljubljana, Ljubljana, SLOVENIA.

EP-0917
Phase analysis using CZT-SPECT for evaluating mechanical synchronization: a case report on Left bundle branch-optimized cardiac resynchronization therapy(LOT-CRT)
Q. Sun[1,2], *S. Li*[2,3];
[1]*Department of Nuclear medicine, Shanxi Cardiovascular Hospital, Tai yuan, CHINA,* [2]*Department of Nuclear Medicine, First Hospital of Shanxi Medical University, Tai yuan, CHINA,* [3]*Collaborative Innovation Center for Molecular Imaging of Precision Medicine, Tai yuan, CHINA.*

EP-0918
Study of joint infection in a Jehovah's Witness patient with 99mTc-Besilesomab
P. Guardia Jimena, *A. Santos Bueno, E. Sánchez de Mora, C. Salgado Garcia, A. Jiménez Heffernan;*
Hospital Universitario Juan Ramón Jiménez, Huelva, SPAIN.

EP-0919
Perineural Spread Into Cerebello Pontine Angle, High Grade Salivary Duct Carcinoma Mimicking as Vestibular Schwannoma diagnosed on F18 FDG PET/CT - A Case report
A. Dixit;
Rajiv Gandhi Cancer Institute And Research Centre, North West Delhi, INDIA.

EP-0920
SAPHO syndrome - a rare and challenging diagnosis on FDG PET/MRI
J. Foukal, *T. Koprivova, H. Kašpárková;*
Fakultni nemocnice Brno, Brno, CZECH REPUBLIC.

EP-0921
Isolated splenic metastasis from colon cancer
S. Pacella[1], *E. Farè*[2], *E. Collovà*[2], *L. Roncoroni*[2], *C. Migliorisi*[2], *A. Calcagno*[2], *M. Carletto*[2], *L. Maffioli*[3];
[1]*IRCCS Fondazione Cà Granda Ospedale Maggiore Policlinico, Milano, ITALY,* [2]*ASST Ovest Milanese-Ospedale Civile di Legnano, Legnano, ITALY,* [3]*ASST Sette Laghi, Varese, ITALY.*

EP-0922
The role of 2-[18F]FDG-PET/CT in a rare case of Nasal Cavity Melanoma
I. C. Ferreira[1], *R. T. Ferreira*[1], *A. T. Xavier*[2], *S. Carmona*[1], *A. I. Santos*[1];
[1]*Hospital Garcia de Orta, E.P.E., Almada, PORTUGAL,* [2]*Centro Hospitalar Barreiro Montijo, E.P.E., Barreiro, PORTUGAL.*

EP-0923
A Rare Coexistence of Rectal Adenocarcinoma and Primary Squamous Cell Carcinoma of the Thyroid: Emphasizing the Importance of FDG PET/CT Whole-Body Imaging
J. Yu, *X. Cao, Y. Wang;*
The Fifth Affiliated Hospital of Sun Yat-sen University Department of Nuclear Medicine, Zhuhai, CHINA.

EP-0924
Gallbladder visualization, a false positive finding on 99mTc-labeled red blood cell
A. Leiva Montejo, *A. De Agrela Serrao, D. Cáceres Silva, C. Ruiz Corbalán, T. Rodriguez Lorcano, J. Contreras Gutierrez, J. Navarro Fernández, L. Frutos Esteban, A. Hernandez Martinez, L. Mohamed Salem, M. Castellon Sánchez;*
Hospital Virgen de la Arrixaca, Murcia, SPAIN.

EP-0925
18F-FDG PET/CT identifying breast and pancreas metastases of Nasal Mucosal Melanoma
A. Leiva Montejo, *C. Ruiz Corbalán, A. De Agrela Serrao, D. Cáceres Silva, J. Contreras Gutierrez, T. Rodriguez Lorcano, J. Navarro Fernández, L. Frutos Esteban, A. Hernandez Martinez, L. Mohamed Salem, M. Castellon Sánchez;*
Hospital Virgen de la Arrixaca, Murcia, SPAIN.

EP-0926
99mTc-labelled heat-Damaged Red Blood Cell scintigraphy in the study of unspecific nodular foci on CT - a case report
R. Silva, *M. Silva, H. Martins, D. Leiro, A. Barbosa, L. Costa;*
Centro Hospitalar Universitário de Santo António, Porto, PORTUGAL.

EP-0927
Why Should We Look at the Thyroid Gland in Myocardial Perfusion Scintigraphy?
B. Pereira, *P. Soeiro, A. Fernandes, A. Oliveira;*
Centro Hospitalar Universitário de São João, Porto, PORTUGAL.

EP-0928
Hyperparathyroidism Jaw Tumor Syndrome: A Case Report
E. Gharehpapagh, *S. Rezaei;*
Department of Nuclear Medicine, Medical School, Tabriz University of Medical Sciences, Tabriz, IRAN, ISLAMIC REPUBLIC OF.

EP-0929
PET/CT [18F]FDG Findings in Post-COVID-19 Syndrome with Cognitive Sequelae: A Case Report
L. Wichert-Ana, *L. E. Lopes-Santos, D. L. Ferreira, A. C. Trevisan, L. Alexandre-Santos, M. P. Foss, M. Kato, F. B. Rodrigues, F. A. Pitella, O. Y. Fukumori, V. Tumas; Ribeirão Preto Medical School - University of São Paulo, Ribeirao Preto, BRAZIL.*

EP-0930
A Rare Case of Bone Epithelioid Angiosarcoma In a Patient with History of Acute Myeloid Leukemia andSteroid-induced Osteonecrosis
D. Bucur, *F. Paycha; Hopital Lariboisiere, Paris, FRANCE.*

EP-0931
18F-FDG PET-CT in Merkel cell carcinoma: case report
A. Ciocan[1], *L. Mititelu*[2,3], *C. Mazilu*[4], *T. Mititelu*[2,3], *A. Mazilu*[5], *D. Cuzino*[6], *M. Oancea*[6], *D. Zob*[7], *D. Costache*[8], *R. Mititelu*[2,4]; [1]*Oncologic Institute "Prof. Dr. Alexandru Trestioreanu", Bucharest, ROMANIA,* [2]*University of Medicine and Pharmacy "Dr Carol Davila", Bucharest, ROMANIA,* [3]*Institute of Military Medicine, Bucharest, ROMANIA,* [4]*Clinic of Nuclear Medicine, Central University Emergency Militari Hospital Bucharest, Bucharest, ROMANIA,* [5]*Clinic of Endocrinology, Central University Emergency Militari Hospital Bucharest, Bucharest, ROMANIA,* [6]*Clinic of Radiology, Central University Emergency Militari Hospital Bucharest, Bucharest, ROMANIA,* [7]*Oncologic Institute "Prof. Dr. Alexandru Trestioreanu", Oncology department, Bucharest, ROMANIA,* [8]*Clinic of Dermatology, Central University Emergency Militari Hospital Bucharest, Bucharest, ROMANIA.*

EP-0932
Pitfall in 68Ga PSMA PET/CT interpretation - Pathological Uptake in a Patient with Prostate Carcinoma and Pulmonary Tuberculosis
S. Fares[1], *I. Rogić*[2], *D. Huić*[2]; [1]*General Hospital Varazdin, Varazdin, CROATIA,* [2]*University Hospital Centre Zagreb, Zagreb, CROATIA.*

EP-0933
Papillar Thyroid Carcinoma discovered on peritoneal carcinosis nodes : A case report of a 37-year-old woman
A. Bauduer, *M. Krim, A. Latge, S. Zerdoud; Oncopole, Toulouse, FRANCE.*

EP-0934
Recurrent Pituitary Adenoma ACTH-Secretant Detected Using 99mTc-EDDA/HYNIC-TOC - A Case Report
A. Bajenaru[1], *C. Mazilu*[2], *M. Mititelu*[2,3]; [1]*Nuclear Medicine Departament, Oncology Institute „Prof. Dr. Alexandru Trestioreanu", Bucharest, ROMANIA,* [2]*Clinic of Nuclear Medicine, Central Emergency Military University Hospital "Dr. Carol Davila", Bucharest, ROMANIA,* [3]*University of Medicine and Pharmacy "Dr. Carol Davila", Bucharest, ROMANIA.*

EP-0935
Two examples of how 18F-FES-PET may assist oncologists in clinical dilemmas in breast cancer patients
S. Nogueira, *F. A. B. Da luz, V. Iacone, A. M. S. Petinatti, S. C. Lima, A. Osawa, L. Y. I. Yamaga; Hospital Israelita Albert Einstein, São Paulo, BRAZIL.*

EP-0936
A rare case of bilateral seminal vesicle metastasis in carcinoid tumor of caecum
A. Kumar[1], *G. Gunasekaran*[1], *N. Pandit*[2]; [1]*JIPMER, Puducherry, INDIA,* [2]*JIPMER, Pondicherry, INDIA.*

EP-0937
Different Pattern of Brain Metabolic Changes on 18F-FDG Brain PET in a Patient with Fronto-Temporal Lobar Degeneration: Case Report
A. Bajenaru[1], *L. Mititelu*[2,3], *C. Mazilu*[4], *D. Cuzino*[5,3], *C. Sirbu*[6,3], *M. Mititelu*[4,3]; [1]*Nuclear Medicine Departament, Oncology Institute „Prof. Dr. Alexandru Trestioreanu", Bucharest, ROMANIA,* [2]*Institute of Military Medicine, Bucharest, ROMANIA,* [3]*University of Medicine and Pharmacy "Dr. Carol Davila", Bucharest, ROMANIA,* [4]*Clinic of Nuclear Medicine, Central Emergency Military University Hospital "Dr. Carol Davila", Bucharest, ROMANIA,* [5]*Clinic of Radiology, Central Emergency Military University Hospital "Dr. Carol Davila", Bucharest, ROMANIA,* [6]*Clinic of Neurology, Central Emergency Military University Hospital "Dr. Carol Davila", Bucharest, ROMANIA.*

EP-0938
Diagnosis of Erdheim-Chester disease by bone scintigraphy
A. Doumas[1], *D. Boundas*[2], *P. Exadaktylou*[1], *E. Giannoula*[1], *A. Tsangaridi*[1], *G. Gerasimou*[1], *E. Papanastasiou*[1], *I. Iakovou*[1]; [1]*Aristotle University, Thessaloniki, GREECE,* [2]*Private Nuclear Medicine Centre, Ippokratis, Thessaloniki, GREECE.*

EP-0939
Radiation-Associated Angiosarcoma After Breast Cancer detected on [18F]FDG PET/CT
M. Pudis[1], *J. Suils-Ramón*[1], *I. Blazquez-Muñoz*[2], *F. X. Sanjuan-Garriga*[2], *A. Palomar-Muñoz*[1], *M. Cortés-Romera*[1]; [1]*Nuclear Medicine - PET (IDI), Bellvitge University Hospital - IDIBELL, L'Hospitalet de Llobregat, Barcelona, SPAIN,* [2]*Anatomical Pathology Department, Bellvitge University Hospital - IDIBELL, L'Hospitalet de Llobregat, Barcelona, SPAIN.*

EP-0940
A rare manifestation of multiple solitary extramedullary plasmacytomas
M. Dobrenic[1,2], *J. Batinic*[1]; [1]*Clinical Hospital Centre Zagreb, Zagreb, CROATIA,* [2]*School of Medicine University of Zagreb, Zagreb, CROATIA.*

EP-0941
PRRT for symptomatic paragangliomas and bilateral pheochromocytomas in an adult patient with a cyanotic heart condition
C. Burger[1], *T. Moalosi*[1], *M. Mix*[2], *M. Conradie*[1]; [1]*Stellenbosch University and Tygerberg Hospital, Cape Town, SOUTH AFRICA,* [2]*Medical Center – University of Freiburg, Freiburg, GERMANY.*

EP-0942
Nodal Migration of ruptured implant contents detected on [18F]FDG-PET/CT
M. Pudis, *J. Suils-Ramón, A. Palomar-Muñoz, V. Carrero-Vasquez, C. Martínez-Ramos, S. Bondia-Bescós, B. Hervás-Sanz, J. Diaz-Moreno, M. Cortés-Romera; Nuclear Medicine - PET (IDI), Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, SPAIN.*

EP-0943
Tumoral thrombosis of the inferior vena cava in a patient with multiple-relapsed adrenal cortical carcinoma
A. Mitoi[1], *C. Mazilu*[1], *M. Oancea*[1], *M. Alexa*[1], *S. Serbanescu*[1], *A. Militaru*[1], *D. Craciun*[1], *A. Zaharia*[1], *M. Matei*[1], *R. Mititelu*[2,1]; [1]*Central Universitary Emergency Military Hospital, Bucharest, ROMANIA,* [2]*University of Medicine and Pharmacy "Carol Davila", Bucharest, ROMANIA.*

EP-0944
Aneurysmal Bone Cyst in a patient with McCune-Albright Syndrome
N. Aydin, *G. Mütevelizade, G. Gümüşer, E. Sayıt Bilgin; Celal Bayar University, Manisa, TÜRKIYE.*

EP-0945
Disseminated infection complicating acupuncture revealed by Gallium-67 scintigraphy
T. Chow; *Tuen Mun Hospital, Hong Kong, HONG KONG.*

EP-0946
Mitral annular calcification as a potential false positive for cardiac amyloidosis in [99mTc]Tc-DPD] scintigraphy accurately identified by SPECT/CT - a case report
R. Nunes, *V. Alves; Centro Hospitalar Universitário de São João, Porto, PORTUGAL.*

EP-0947
Increased 68Ga-PSMA uptake in avascular necrosis of the hip
B. Okudan Tekin[1], *B. Seven*[2]; [1]*Department of Nuclear Medicine, Ankara City Hospital, University of Health Sciences, Ankara, TÜRKIYE,* [2]*Department of Nuclear Medicine, Sabuncuoğlu Şerefeddin Training and Research Hospital, Amasya, TÜRKIYE.*

EP-0948
Pseudosarcomatous Periosteal Metastases of Lower Limbs Initially Misdiagnosed for Secondary Hypertrophic Osteoarthropathy then Properly Identified by [68Ga]Ga-PSMA PET/CT in a Patient Treated for Prostate Carcinoma
D. Filipan[1], *P. Moreau*[2], *C. Thibault*[3], *F. Montravers*[2], *F. Paycha*[4]; [1]*University Department of Oncology and Nuclear Medicine, Sestre Milosrdnice University Hospital Centre, Zagreb, CROATIA,* [2]*Service de Médecine Nucléaire, Hôpital Tenon, Assistance Publique-Hôpitaux de Paris, Paris, FRANCE,* [3]*Service d'Oncologie Médicale, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Paris, FRANCE,* [4]*Service de Médecine Nucléaire, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, Paris, FRANCE.*

EP-0949
Retroperitoneal Fat-Containing Tumor. Tiptoeing between malignant and benign: A Case Report
M. Matei[1], *A. Mitoi*[1], *S. Serbanescu*[1], *C. Mazilu*[1], *R. Mititelu*[1,2]; [1]*Nuclear Medicine Department, Central Universitary Emergency Military Hospital, Bucharest, ROMANIA,* [2]*University of Medicine and Pharmacy Dr Carol Davila, Bucharest, ROMANIA.*

EP-0950
Can PSMA based PET/CT scan be used in management of salivary gland neoplasms?
N. Ghesani, *M. Posner, r. Kulkarni, M. Ghesani; Icahn School of Medicine at Mount Sinai, New York, NY, UNITED STATES OF AMERICA.*

EP-0951
A rare case of atypical lung carcinoid metastasis detected in the breast on 68Ga-DOTATATE PET/CT
B. Okudan Tekin[1], *B. Seven*[2], *A. Albayrak*[3], *A. Yıldırım*[1]; [1]*Department of Nuclear Medicine, Ankara City Hospital, University of Health Sciences, Ankara, TÜRKIYE,* [2]*Department of Nuclear Medicine, Sabuncuoğlu Şerefeddin Training and Research Hospital, Amasya, TÜRKIYE,* [3]*Department of Pathology, Ankara City Hospital, University of Health Sciences, Ankara, TÜRKIYE.*

EP-0952
F18-FDG PET-CT in Diagnosis and Staging of Lacrimal Gland Carcinoma: a Case Report
A. Militaru[1], *A. C. Rosu*[2], *C. V. Mazilu*[1], *M. M. Matei*[1], *S. I. Serbanescu*[1], *M. G. Alexa*[1], *A. Mitoi*[1], *A. M. Zaharia*[1], *R. M. Mititelu*[1,3]; [1]*Central Universitary Emergency Military Hospital, Bucharest, Bucuresti, ROMANIA,* [2]*Elias Emergency University Hospital, Bucuresti, ROMANIA,* [3]*University of Medicine and Pharmacy "Carol Davila" Bucharest, Bucuresti, ROMANIA.*

EP-0953
18F-FDG uptake in portal vein thrombosis: the upshot of IIIB-stage pulmonary adenocarcinoma and liver cirrhosis
M. Alexa[1], *S. Serbanescu*[1], *A. Mitoi*[1], *C. Mazilu*[1], *M. Matei*[1], *M. Oancea*[1], *D. Craciun*[1], *R. Mititelu*[1,2]; [1]*Central Universitary Emergency Military Hospital, Bucharest, ROMANIA,* [2]*University of Medicine and Pharmacy Carol Davila, Bucharest, ROMANIA.*

EP-0954
Additional value of PET/MRI in diagnostic workflow of cognitive impairment
M. Pudis[1], *M. Suarez-Piñera*[1], *S. Flores-Casaperalta*[2], *N. Vidal-Sarro*[3], *L. Rodríguez-Bel*[1], *C. Martínez-Ramos*[1], *S. Bondia-Bescós*[1], *B. Hervás-Sanz*[4], *M. Cortés-Romera*[1]; [1]*Nuclear Medicine - PET (IDI), Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, SPAIN,* [2]*Radiodiagnostics (IDI), Hospital Duran i Reynals, L'Hospitalet de Llobregat, Barcelona, SPAIN,* [3]*Anatomical Pathology Department, Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, SPAIN,* [4]*Nuclear Medicine - PET (IDI), Bellvitge University Hospital, Barcelona, SPAIN.*

EP-0955
Pericardial mesothelioma: a case report.
B. Hervás-Sanz[1], *P. C. Notta*[1], *L. M. Gràcia-Sánchez*[1], *L. Rodríguez-Bel*[1], *S. A. Bolívar-Cuevas*[2], *D. Castellón-Plaza*[2], *I. E. Sánchez-Rodríguez*[1], *M. Pudis*[1], *M. Cortés-Romera*[1]; [1]*Nuclear Medicine-PET (IDI) Department, Bellvitge University Hospital-IDIBELL, L'Hospitalet de Llobregat, SPAIN,* [2]*Diagnostic Radiology Department, Bellvitge University Hospital-IDIBELL, L'Hospitalet de Llobregat, SPAIN.*

EP-0956

Molecular Imaging Findings in Erdheim-Chester Disease-An Extremly Rare Multisystemic Disorder

A. Marcuseanu[1], *A. Budau*[2], *D. Vasile*[1], *A. Lazar*[3], *C. Sterea*[3], *M. Gherghe*[3,4];
[1]*National Institute of Infectious Diseases "Prof. Dr. Matei Bals", Bucharest, ROMANIA,* [2]*Central Military Emergency Hospital "Dr. Carol Davila", Bucharest, ROMANIA,* [3]*Institute of Oncology "Prof. Dr. Alexandru Trestioreanu", Bucharest, ROMANIA,* [4]*"Carol Davila" University of Medicine and Pharmacy, Bucharest, ROMANIA.*

EP-0957

Assessment of False Positive PET/CT Pulmonary Lesions in Gastric Adenocarcinoma Staging

D. Craciun[1], *C. Mazilu*[1], *A. Zaharia*[1], *A. Mitoi*[1], *R. Mititelu*[1,2];
[1]*Nuclear Medicine Department, Central Universitary Emergency Military Hospital, Bucharest, ROMANIA,* [2]*University of Medicine and Pharmacy Dr Carol Davila, Bucharest, ROMANIA.*

EP-0958

Incidental detection of hydatid cyst on 18F-FDG PET/CT imaging

B. Okudan Tekin[1], *B. Seven*[2];
[1]*Department of Nuclear Medicine, Ankara City Hospital, University of Health Sciences, Ankara, TÜRKIYE,* [2]*Department of Nuclear Medicine, Sabuncuoğlu Şerefeddin Training and Research Hospital, Amasya, TÜRKIYE.*

EP-0959

18F-FDG PET/CT findings in a patient with systemic lupus erythematosus

B. Okudan Tekin[1], *B. Seven*[2];
[1]*Department of Nuclear Medicine, Ankara City Hospital, University of Health Sciences, Ankara, TÜRKIYE,* [2]*Department of Nuclear Medicine, Sabuncuoğlu Şerefeddin Training and Research Hospital, Amasya, TÜRKIYE.*

EP-0960

The importance of metabolic activity imaging in the evaluation of Central Nervous System Rosai-Dorfman Disease: A Case Report

M. Matei[1], *C. Mateescu*[1], *A. Rosu*[2], *C. Mazilu*[1], *R. Mititelu*[1,3];
[1]*Nuclear Medicine Department, Central Universitary Emergency Military Hospital, Bucharest, ROMANIA,* [2]*University Hospital ELIAS, Bucharest, ROMANIA,* [3]*University of Medicine and Pharmacy Dr Carol Davila, Bucharest, ROMANIA.*

EP-0961

Functional change in a patient with neurological symptoms post-exercise disclosed by rest and stress cerebral blood flow perfusion imaging (99m)Tc-ECD SPECT

R. Moreira[1], *R. Castro*[2], *D. S. Lobo*[1], *L. R. Sabioni*[1], *H. A. Guenka*[1], *I. Gottlieb*[1];
[1]*Casa De Saude Sao Jose, Rio De Janeiro, BRAZIL,* [2]*Ipanema Health Club, Rio De Janeiro, BRAZIL.*

EP-0962

Radioguided occult lesion localization (ROLL) method in metastatic colorectal cancer - a case report

D. Silva, *H. Duarte, I. Sousa, J. C. Ferro, I. Próspero, D. Barbosa, S. F. Castro, G. Ferreira, J. P. Teixeira, M. J. Sousa, P. Martins, I. L. Sampaio;*
Instituto Português de Oncologia do Porto Francisco Gentil, Porto, PORTUGAL.

EP-0963

Brown tumours: an unmet need

B. Pereira, *P. Soeiro, A. Fernandes, A. Oliveira;*
Centro Hospitalar Universitário de São João, Porto, PORTUGAL.

EP-0964

The role of radio-guided surgery in choosing vascularized lymph nodes transfer microsurgery flap after breast cancer surgical treatment.

D. Rodriguez Oviedo, *A. Maldonado Morillo, B. Manzarbeitia Arroba, M. Alvarez Moreno, M. Tagliatori Nogueira, M. De La Rubia Marcos, C. Sandoval Moreno, C. Galindo, M. Garcia Alonso, M. Castillejos Rodriguez;*
Hospital Universitario de Getafe, Madrid, SPAIN.

EP-0965

Incidentaloma on [18F]FDG PET-CT breast cancer staging - a rare case of Schwannoma

B. Martins, *P. Lopes, R. Veiga, C. Loewhental, J. L. Passos-Coelho;*
Hospital da Luz, Lisboa, PORTUGAL.

EP-0966

Hepatic Artery Vasculitis: A rare presentation of single-organ vasculitis documented by 2-[18F]FDG PET/CT

R. T. Ferreira, *I. C. Ferreira, F. Vinagre, S. Carmona, A. Prata, A. I. Santos;*
Hospital Garcia de Orta, E. P. E., Almada, PORTUGAL.

EP-0967

18F-FDG PET/CT findings in a patient with renal angiomyolipoma

B. Okudan Tekin[1], *A. S. Erdoğan*[1], *B. Seven*[2];
[1]*Department of Nuclear Medicine, Ankara City Hospital, University of Health Sciences, Ankara, TÜRKIYE,* [2]*Department of Nuclear Medicine, Sabuncuoğlu Şerefeddin Training and Research Hospital, Amasya, TÜRKIYE.*

EP-0968

Rare complication in the cholangiocarcinoma treatment - biliary bronchial fistula - localized with cholescintigraphy with SPECT/CT

P. Gadzicki, *M. Nowak, A. Dyla, Z. Adamczewski;*
Medical University of Lodz, Lodz, POLAND.

EP-0969

SPECT/CT Diagnosis of single adrenal metastasis of differentiated thyroid cancer

K. Bayardo, *J. Naula, O. Alonso, R. Ferrando;*
University of the Repubic, Montevideo, URUGUAY.

EP-0970

Role of [18F]FDG PET/CT in the detection and differential diagnosis of peritoneal tuberculosis

S. Bondia-Bescós[1], *V. Carrero-Vasquez*[1], *I. Sánchez-Rodriguez*[1], *A. Palomar-Muñoz*[1], *L. Gràcia-Sánchez*[1], *M. Pudis*[1], *B. Hervás-Sanz*[1], *J. Díaz-Moreno*[1], *M. Santin-Cerezales*[2], *X. Solanich-Moreno*[1], *M. Cortés-Romera*[1];
[1]*Nuclear Medicine-PET (IDI) Department, Bellvitge University Hospital, Barcelona, SPAIN,* [2]*Infeccious Diseases Department, Bellvitge University Hospital, Barcelona, SPAIN.*

EP-0971

Dual-tracer PET/CT imaging to determine tumor heterogeneity in a patient with liver metastatic neuroendocrine neoplasm: A case report.

R. Moreira, *I. Gottlieb, D. S. Lobo, H. A. Guenka;*
Casa De Saude Sao Jose, Rio De Janeiro, BRAZIL.

EP-0972

18 FDG PET/CT imaging in anaplastic thyroid carcinoma : a case report

F. Chaltout, *K. Ben Ahmed, M. Ouachem, T. Bint Mohamed, M. Maaloul, S. Charfeddine, K. Chtourou, F. Guermazi;*
Department of Nuclear Medicine, Habib Bourguiba University Hospital of Sfax, Tunisia, Sfax, TUNISIA.

EP-0973

Sacrococcygeal metastasis revealing a papillary carcinoma of the thyroid . A Case report

M. Bourouba;
Nuclear Medicine Clinique Fatema Al Azhar, Algiers, ALGERIA.

EP-0974

Gastric Empty and Esophagus Transit Scintigraphy Imaging of Long Term Tip 1 Diabetic Patient accidentally consuming Formic Acid

D. Yüksel, *U. Moran, M. Yücel, S. Demirezen, A. Çelik;*
Pamukkale Universitesi Tip Fakültesi, Denizli, TÜRKIYE.

EP-0975

FDG PET/CT imaging in intra-abdominal round cell desmoplastic tumors: a case report

N. Abaouz, *A. Guensi;*
Department of Nuclear Medicine, University Hospital Ibn Rochd, Casablanca, MOROCCO.

EP-0976

Interest of FDG PET/CT Compared to Bone Scan in the Detection of Lytic Bone Metastasis in Breast Cancer

N. Abaouz, *A. Guensi;*
Department Of Nuclear Medicine, University Hospital Ibn Rochd, Casablanca, MOROCCO.

EP-0977

Unexpected 131I iodine scintigraphy finding

A. Aulich, *B. Stefański, Z. Adamczewski;*
Nuclear Medicine Department, Medical University of Lodz, Lodz, POLAND.

EP-0978

Incidental finding of pulmonary tumour in lung ventilation and perfusion SPECT: the importanceof a combined low-dose CT scan

J. Carvalho, *J. R. Duarte, A. Marques, F. Abreu, S. Pintão;*
Centro Hospitalar de Lisboa Ocidental, Carnaxide, PORTUGAL.

EP-0979

An adrenal nodule with very high 18F-FDG uptake

S. Fontão de Castro, *J. Ferro, I. Próspero, D. Barbosa, D. Silva, L. Violante, G. Ferreira, I. Lucena e Sampaio;*
Portuguese Institute of Oncology - Porto, Porto, PORTUGAL.

EP-0980

Detection of a right ventricle cardiac metastasis from lung adenocarcinoma in a 18F-FDG PET/CT study

S. Pacella[1], *M. Mangano*[2], *L. Venegoni*[3], *M. Cergnul*[3], *A. Calcagno*[3], *R. Ferrara*[4], *C. Migliorisi*[3], *M. Carletto*[3], *L. Maffioli*[5];
[1]*IRCCS Fondazione Cà Granda Ospedale Maggiore Policlinico, Milano, ITALY,* [2]*ASST Valle Olona, Saronno, ITALY,* [3]*ASST Ovest Milanese-Ospedale Civile di Legnano, Legnano, ITALY,* [4]*ASST Ovest Milanese-Ospedale di Magenta, Magenta, ITALY,* [5]*ASST Sette Laghi, Varese, ITALY.*

EP-0981

Expect the unexpected- a rare case of incidentally detected recurrent bone invasive giant meningioma on F-18 FDG PET/CT, in a patient with stomach neoplasm

S. Chausheva, *B. Chaushev, T. Stoeva, M. Dyankova, T. Yordanova, Z. Dancheva;*
University Hospital St Marina Varna, Varna, BULGARIA.

EP-0982

99mTc-antigranulocite antibody scintigraphy in mycosis fungoides

A. Velidaki, *S. Episkopopoulou, I. Sevaslidou, N. Prosotsianiotis, E. Dagrakis, A. Kolindou;*
Laiko General Hospital of Athens, Athens, GREECE.

EP-0983

Incidental increased Ga-68 FAPI Uptake in Calcified Meningioma

A. Namazova, *A. Kibar, L. U. Beşli, O. E. Sahin, K. Sönmezoğlu;*
Istanbul University-Cerrahpasa, Cerrahpaşa Faculty of Medicine, Department of Nuclear Medicine, ISTANBUL, TÜRKIYE.

EP-0984

Bilateral Warthin tumour with coexisting metastatic lung cancer: a rare case demonstrated by 2-[18F] FDG-PET/CT

I. C. Ferreira, *R. T. Ferreira, I. Oliveira, A. I. Santos;*
Hospital Garcia de Orta, E.P.E, Almada, PORTUGAL.

EP-0985

Brown tumors mimicking bone metastasis in a woman with a Parathyroid carcinoma. A Case report.

A. Genova[1], *F. Porcaro*[1], *I. Annarumma*[1], *M. Prisco*[1], *L. Turchetta*[1], *A. Biasiucci*[2], *M. Catalano*[1];
[1]*Nuclear Medicine Unit, AORN A. Cardarelli, Naples, NAPLES, ITALY,* [2]*Histopathology Unit, AORN A. Cardarelli, Naples, NAPLES, ITALY.*

EP-0986

An atypical aspect of bone scintigraphy in AL Amyloidosis

M. Bel lakhdar, *H. Guerrouj, J. Rahali, I. Ghfir, N. Ben Raïs;*
University mohamed V, Faculty of Medicine and Pharmacy, RABAT, MOROCCO.

EP-0987

Uncommon presentation of an aggressive tumor-FDG PET/CT clinching the diagnosis.

S. Sagar, *D. Khan, N. A. Damle, M. Tripathi, M. Bhatt, Y. Gupta, N. Tandon;*
AIIMS, Delhi, INDIA.

EP-0988

Basal Cell Carcinoma Transformation to Squamous Cell Carcinoma Following Systemic Treatment: Impressive PET/CT Images and Clinical Implications.

M. Pudis[1], *P. C. Notta*[1], *B. Hervás-Sanz*[1], *J. R. Ferreras-Riera*[2], *M. Cortés-Romera*[1];
[1]*Nuclear Medicine - PET (IDI), Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, SPAIN,* [2]*Department of Dermatology, Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, SPAIN.*

EP-0989
Case report: Soft Tissue Metastasis in Lung Cancer - The impact of 2-[18F]FDG PET/CT
R. T. Ferreira, *I. C. Ferreira, I. Oliveira, D. Canário, S. Carmona, J. G. Santos, J. A. Sequeira, A. I. Santos;*
Hospital Garcia de Orta, E. P. E., Almada, PORTUGAL.

EP-0990
Evaluation of metabolic response with18F-FDG PET-CT in advanced thymic adenocarcinoma
H. Noamen, *K. Ben Ahmed, W. Amouri, T. Mohamed, I. Jardak, M. Maaloul, S. Charfeddine, K. Chtourou, F. Guermazi;*
University hospital of Habib Bourguiba, Sfax, TUNISIA.

EP-0991
DLBCL mimicking infection on FDG PET/CT - resolving the conundrum
D. Khan, *N. A. Damle, M. Tripathi, B. Pridhivi, P. Sethi, N. Wig, S. Sagar, A. Narayan;*
AIIMS Delhi, Delhi, INDIA.

EP-0992
Osteoblastoma like osteosarcoma - diagnostic challenge - a case report
N. Manevska[1], *T. Makazlieva*[1], *S. Kostadinova Kunovska*[2], *S. Stojanoski*[1], *A. Gavrilovski*[3];
[1]*Institute of Pathophysiology and Nuclear medicine, Medical Faculty, University of Ss Cyril and Methodius, Skopje, NORTH MACEDONIA,* [2]*Institute of Pathology, Medical Faculty, University of Ss Cyril and Methodius, Skopje, NORTH MACEDONIA,* [3]*University Clinic for Orthopedic Surgery, Medical Faculty, University of Ss Cyril and Methodius, Skopje, NORTH MACEDONIA.*

EP-0993
Contribution of whole-body bone scan coupled with SPECT/CT in the diagnosis of SAPHO syndrome: case report.
j. Charfi, *S. Marwa, O. Ben Hamida, C. Mhiri, I. Slim, A. Mhiri; salah azaiez institute, tunis, TUNISIA.*

EP-0994
Place of peritoneal scintigraphy in the diagnosis of pleuro-peritoneal communication: A case report.
K. Ayed, *H. Charfi, M. Nouira, R. Sfar, K. Chatti;*
Nuclear Medicine Department, Sahloul Hospital, Sousse, TUNISIA.

EP-0995
Is Captopril renography with 99mTc-DTPA still of merit in renovascular hypertension? a case report
R. Belayouni, *O. Ben Hamida, M. Ben Nasr, M. Somai, I. Slim, i. meddeb, I. Yeddes, A. Mhiri;*
Salah Azaiez Institute, Tunis, TUNISIA.

EP-63

e-Poster Area

E: Other Studies -> E3 Other Study (including Training, Projects)

EP-0996
Implementation of 3D digital SPECT/CT device for clinical workflow in myocardial perfusion imaging - a multidisciplinary collaborative project approach
J. Kaunisto, *A. Keinänen, H. Gröhn, T. M. Laitinen, M. Hakulinen, S. Koponen, S. Halttunen, T. P. Laitinen;*
Kuopio University hospital, Kuopio, FINLAND.

EP-0997
Annual DXA Operator Audit - A single site experience
D. Teixeira Macarico, *C. Reilly, A. Nicol;*
Nuclear Medicine Department, Queen Elizabeth University Hospital, Department of Physics and Bioengineering, NHS Greater Glasgow and Clyde, Glasgow, UNITED KINGDOM.

P-64

e-Poster Area

E: Other Studies -> E3 Other Study (including Training, Projects) -> Organisation and optimisation in nuclear medicine worldwide

EP-0998
University of Tor Vergata, Rome, Italy, contributes to the EU Horizon-2020 INCISIVE project for the development of Artificial Intelligence in Health Imaging
E. Triumbari[1], *A. Kosvyra*[2], *T. Loncar-Turukalo*[3], *A. Tzelepakis*[4], *C. Barelle*[5], *C. Symvoulidis*[6], *S. Nabhani*[7], *L. Zacharias*[7], *G. Tsakou*[8], *A. Chiaravalloti*[1];
[1]*Nuclear Medicine Unit, Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, ITALY,* [2]*Aristotle University of Thessaloniki, Thessaloniki, GREECE,* [3]*Faculty of Technical Sciences, University of Novi Sad, Novi Sad, SERBIA,* [4]*Centre for Research & Technology Hellas, Hellas, GREECE,* [5]*European Dynamics Luxembourg SA, Luxembourg, LUXEMBOURG,* [6]*Telesto IOT solutions limited, Athens, GREECE,* [7]*School of Life Sciences, Pharmacy and Chemistry, Kingston University London, Kingston, UNITED KINGDOM,* [8]*Maggioli SPA, Greek site, Athens, GREECE.*

EP-1000
NOAR COST Action: Advancing Targeted Alpha Therapy with Astatine-211 for Cancer Treatment
E. Janevik-Ivanovska[1], *J. Gestin*[2], *E. Aneheim*[3], *S. Lindegren*[3], *J. Gaschet*[4], *S. Palm*[5], *D. Niculae*[6], *P. Bouziotis*[7], *M. Pruzynski*[8], *P. Kolenc*[9], *A. I. Jensen*[10], *A. Abrunhosa*[11], *L. Navarro*[12], *H. Jensen*[13], *R. Mikolajczak*[14], *M. M. Herth*[15], *M. Konijnenberg*[16], *F. Guerard*[17];
[1]*University Goce Delcev Stip, Faculty of Medical Sciences, Stip, NORTH MACEDONIA,* [2]*Université de Nantes, Inserm, CNRS, Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes—Angers (CRCIINA)—UMR 1307, UMR 6075, *Action Chair of the COST Action CA19114, Network for Optimized Astatine labeled Radiopharmaceuticals (NOAR), 44007 Nantes Cedex 1, FRANCE,* [3]*Department of Medical Radiation Sciences, Institute of Clinical Sciences, the Sahlgrenska Academy, University of Gothenburg;, 413 45 Gothenburg, SWEDEN,* [4]*Université de Nantes, CNRS, Inserm, CRCINA, 44000, Nantes, FRANCE,* [5]*Department of Medical Radiation Sciences, Institute of Clinical Sciences, the Sahlgrenska Academy, University of Gothenburg;, 413 45 Gothenburg, SWEDEN,* [6]*Radiopharmaceutical Research Centre, Horia Hulubei National Institute for Physics and Nuclear Engineering, 30 Reactorului Street, Măgurele, 077125 Ilfov, ROMANIA,* [7]*Radiochemical Studies Laboratory, INRASTES, National Center for Scientific Research Demokritos, Aghia Paraskevi, 15341 Athens, GREECE,* [8]*Institute of Nuclear Chemistry and Technology, Dorodna 16, 03-195 Warsaw, POLAND,* [9]*Department of Nuclear Medicine, University Medical Centre Ljubljana, 1000 Ljubljana, SLOVENIA,* [10]*Center for Nanomedicine and Theranostics (The Hevesy Laboratory), DTU Health Technology, Technical University of Denmark (DTU), Ørsteds Plads 345C, 2800 Lyngby, DENMARK,* [11]*ICNAS/CIBIT, Institute for Nuclear Sciences Applied to Health, University of Coimbra, Coimbra, PORTUGAL,* [12]*Precirix, Brussels, BELGIUM,* [13]*Cyclotron and PET unit KF-3982, Copenhagen University Hospital, Copenhagen, DENMARK,* [14]*National Centre for Nuclear Research, Radioisotope Centre POLATOM, 05-400 Otwock-Swierk, POLAND,* [15]*Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Universitetsparken 2, 2100 Copenhagen, DENMARK,* [16]*Department of Radiology and Nuclear Medicine, Erasmus MC, 3000 CA Rotterdam, NETHERLANDS,* [17]*Université de Nantes, Inserm, CNRS, Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes—Angers (CRCIINA)—UMR 1307, UMR 6075, 44007 Nantes, FRANCE.*

EP-1001
Appropriation of hybrid practices in oncological imaging: the situation of PET-CT in France from a management perspective.
R. Guignard[1,2], *B. Geffroy*[2], *V. Fernandez*[3];
[1]*Clinique de Genolier, Genolier, SWITZERLAND,* [2]*IMT Atlantique - LEMNA, Nantes, FRANCE,* [3]*TELECOM Paris, Paris, FRANCE.*

EP-1002
Novel approach for the technical implementation of radiowater studies for a pet/ct- scanner in hospital environment
M. Hakulinen[1], *P. Poutiainen*[2];
[1]*Diagnostic Imaging Centre, Kuopio University Hospital, Kuopio, FINLAND,* [2]*Cyclotron and radiopharmacy unit, Kuopio University Hospital, Kuopio, FINLAND.*

EP-1003
Identifying the unique needs of transgender, non-binary and gender diverse patients in the nuclear medicine department
A. Cripps[1], *J. Taylor*[1,2], *R. Salmon*[1];
[1]*Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UNITED KINGDOM,* [2]*University of Sheffield, Sheffield, UNITED KINGDOM.*

EP-1004
Illuminating actionable practice to improve recall of medical information in nuclear medicine department
S. Ibba[1], *P. Gandolfo*[1], *L. Airò Farulla*[2], *D. Zago*[1], *G. Fosci*[1], *S. Papa*[1];
[1]*CDI Centro Diagnostico Italiano S.p.A., Milan, ITALY,* [2]*University of Milan, Milan, ITALY.*

EP-1005
Religion, beliefs and needs in thyroid cancer patients
E. Olariu, *D. Piciu;*
The Oncology Institute Cluj-Napoca, Cluj-Napoca, ROMANIA.

EP-1006
Performance Evaluation of the Incorporation of PET/CT Procedures in the SUS
B. Prates, *L. Pozzo;*
Nuclear and Energy Research Institute, IPEN–CNEN/SP, São Paulo, BRAZIL.

EP-1007
Patient experience at the heart of the implementation of a PET/MRI system in our centre
J. Vercher-Conejero, *M. Cortés-Romera, J. Martín Marcuartu, S. Millat Servent, I. Feliu Perez, C. Martínez Ramos, V. Carrero Vasquez, M. Pudis, S. Santamaria Lopez, I. Bonilla Aguilar, M. Fernandez Yuste;*
Bellvitge University Hospital, L'Hospitalet de Llobregat (Barcelona), SPAIN.

EP-1008
Knowledge, Attitude and Practice towards the Utility of Medical Radioisotopes for Diagnosis and Therapy of Disease used in Nepal
A. Gupta, *P. Sah, S. Prasad, D. Baral;*
B.P. Koirala Institute of Health Sciences (BPKIHS), Dharan, NEPAL.

EP-1009
Cyclotron production of ultra-pure indium-111 radionuclide using gold-plated capsules in Iran
P. Ashtari[1,2], *Y. Fazaeli*[2], *G. Aslani*[1], *S. Feizi*[2];
[1]*Pars Isotope Co., Tehran, IRAN, ISLAMIC REPUBLIC OF,* [2]*Nuclear Science & Technology Research Institute, Tehran, IRAN, ISLAMIC REPUBLIC OF.*

EP-1010
New method for synthesis of HMPAO compound and a novel method for purification of final product for Triple usage
M. Alizadeh, *v. ghasemi, e. maleki, h. m. mehrabani, f. farajbakhsh, m. ghapanvari;*
parsisotope, Tehran, IRAN, ISLAMIC REPUBLIC OF.

EP-1011
Comparison of diagnostic efficacy of 99mTc-MIBI SPECT/CT and ultrasonography for primary and secondary renal hyperparathyroidism
M. Jiang, *W. Mei;*
Ningbo No.2 Hospital, Ningbo, CHINA.

EP-1012
ATTR Cardiac Amyloidosis and Carpal tunnel syndrome
S. Giourgouli, *A. Kokkini-Paschou, V. Pantzou, M. Stathopoulou, J. Koutsikos;*
Henry Dunant Hospital Center, Athens, GREECE.

EP-1013
Monitoring Of Adverse Reactions Caused By [99m Tc] Tc-Mibi
G. Rubio-Fernández, *R. Maestre-Cutillas, L. Baz-Sanz, L. Cebollada-Cameo, R. Castro-Velasco, C. Juan-Piriz, J. Pérez Iruela;*
Hospital Ramón y Cajal, Madrid, SPAIN.

EP-1014
Assessment of agreement between three creatinine-based GFR predicting equations and 99mTc-DTPA plasma clearance GFR in adult Caucasian patients : a single-center study
G. Arsos[1], *D. Katsampoukas*[1], *A. Kalaitzoglou*[1], *E. Manou*[2], *E. Moralidis*[1];
[1]*3rd Department of Nuclear Medicine, Aristotle University of Thessaloniki School of Medicine, Papageorgiou Gen. Hospital, Thessaloniki, GREECE,* [2]*Nephrology Clinic, Papageorgiou Gen. Hospital, Thessaloniki, GREECE.*

EP-1015
Development of a boronic acid targeting fluorescent sensor for evaluation of intracellular localization and quantification of blood concentration of boronoagents for BNCT
S. Takada[1,2], *N. Kondo*[2], *T. Temma*[2], *M. Hagimori*[1];
[1]*Laboratory of Analytical Chemistry, Faculty of Pharmaceutical Sciences, Mukogawa Women's University, 11-68 Koshien Kyubancho, Nishinomiya, Hyogo, JAPAN,* [2]*Department of Biofunctional Analysis, Graduate School of Pharmaceutical Sciences, Osaka Medical and Pharmaceutical University, 4-20-1 Nasahara, Takatsuki, Osaka, JAPAN.*

EP-1016
Introducing a method for increasing yield and removing the harmful and toxic solvents during the synthesis process of Sestamibi and labeling it by 99mTc to investigate its applications in vascular imaging.
V. Ghasemi, *m. alizadeh, h. m. mehrabani, e. maleki, m. ghapanvari, f. farajbakhsh, E. Lohrasbi, J. Aghamohammadi;
parsisotope, Tehran, IRAN, ISLAMIC REPUBLIC OF.*

EP-65

e-Poster Area

Technologists e-Posters

EP-1017
Implementation of the new national directive to reduce radioactive waste disposal costs in nuclear medicine and radiometabolic therapy departments
M. Anelli[1], *M. Nicoletto*[2], *A. Zambelli*[3], *A. Di Nicola*[1];
[1]*Azienda Sanitaria Locale di Pescara, Pescara, ITALY,* [2]*Policlinico di Abano Terme, Abano Terme (PD), ITALY,* [3]*Azienda Ospedaliera Universitaria di Padova, Padova, ITALY.*

EP-1018
Usefulness of simplified respiratory motion freeze devise (IKI-TOMEHIRO-KUN) in myocardial perfusion SPECT
H. Ichikawa[1,2], *T. Kato*[1], *H. Kondo*[3], *T. Shibutani*[2], *H. Shimada*[1], *M. Onoguchi*[2];
[1]*Toyohashi Municipal Hospital, Toyohashi, JAPAN,* [2]*Kanazawa university, Kanazawa, JAPAN,* [3]*Nagoya University Hospital Department of Cardiology, Nagoya, JAPAN.*

EP-1019
Does high Radiochemical purity obviate the need for a biodistribution whole body image in 68Ga-NOTA-UBI PET/CT?
S. Maurya, *N. Damle, S. Ballal, A. Singhal, V. Tiwari, C. Bal, N. Singh, Y. Dharmashaktu, D. Khan, S. Sagar, A. Gawande; All India Institute of Medical Sciences, New Delhi, INDIA.*

EP-1020
Evaluation of 68Ga-NOTA-Ubiquicidin (29-41) PET/CT with early and delayed imaging through qualitative and quantitative analysis.
N. Singh, *N. Damle, S. Maurya, A. Singhal, S. Ballal, V. Tiwari, A. Gawande, P. Kumar, C. Bal, S. Sagar, J. Jaleel; All India Institute of Medical Sciences, New Delhi, INDIA.*

EP-1021
The impact of multi-bed SPECT-CT misregistration on routine clinical service delivery
L. Wason, *R. Williamson, J. Dixon, C. Reilly, A. Nicol; NHS Greater Glasgow and Clyde, Glasgow, UNITED KINGDOM.*

EP-1022
Image evaluation of different 99mTc/123I ratios for simultaneous dual-isotope myocardial SPECT using D-SPECT cardiac camera
T. Shibutani[1], *M. Onoguchi*[1], *H. Yoneyama*[2], *T. Konishi*[2], *K. Nakajima*[3];
[1]*Department of Quantum Medical Technology, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Ishikawa, JAPAN,* [2]*Department of Radiological Technology, Kanazawa University Hospital, Kanazawa, Ishikawa, JAPAN,* [3]*Department of Functional Imaging and Artificial Intelligence, Kanazawa University, Kanazawa, Ishikawa, JAPAN.*

EP-1023
Assessing glomerular filtration rate through blood sampling via port and arm vein.
C. H. Led[1], *L. J. Jeppesen*[1], *O. Gerke*[1,2], *S. Hvidsten*[1], *J. A. Simonsen*[1,2];
[1]*Department of Nuclear Medicine, Odense C, DENMARK,* [2]*Department of Clinical Research, University of Southern Denmark, Odense, DENMARK.*

EP-1024
Examination of optimum conditions for 99mTc brain perfusion SPECT using a new SZHRX collimator
T. Nishiyama[1], *M. Onoguchi*[1], *T. Shibutani*[1], *A. H. Vija*[2], *F. Massanes*[2], *T. Shimizu*[2], *H. Yoneyama*[3], *T. Konishi*[3], *H. Mori*[4], *K. Nakajima*[5];
[1]*Department of Quantum Medical Technology, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, JAPAN,* [2]*Siemens Medical Solutions UNITED STATES OF AMERICA, Inc., Hoffman Estates, IL, UNITED STATES OF AMERICA,* [3]*Department of Radiological Technology, Kanazawa University Hospital, Kanazawa, JAPAN,* [4]*Department of Nuclear Medicine, Kanazawa University Hospital, Kanazawa, JAPAN,* [5]*Department of Functional Imaging and Artificial Intelligence, Kanazawa University, Kanazawa, JAPAN.*

EP-1025
Inter- and intraobserver and the test-retest variability in bone density measurement in vertebral fracture assessment on DXA
S. Wongjarern, *A. Willemsen, R. Slart; UMCG, Groningen, NETHERLANDS.*

EP-1026
The Advantages of using Nitrogen-13 Ammonia PET Imaging in Flow Quantification of Microvascular Diseases
G. Daigneault, *M. Balu, M. Menelas; CHUM, Montreal, QC, CANADA.*

EP-1027
Investigation of volumetric measurements from gated myocardial perfusion Multi-Pinhole SPECT with shortening acquisition time
M. Alamin[1], *S. Barna*[2], *V. Bencze Linczerné*[3], *K. Kukuts*[3], *A. Oszlanszki*[3], *J. Varga*[4], *Á. Krizsán*[3], *A. Forgács*[3], *I. Garai*[2];
[1]*University of Debrecen, Debrecen, HUNGARY,* [2]*University of Debrecen, Faculty of Medicine, Department of Medical Imaging, Division of Nuclear Medicine; Scanomed Nuclear Medicine Centres, Debrecen, HUNGARY,* [3]*Scanomed Nuclear Medicine Centres, Debrecen, HUNGARY,* [4]*University of Debrecen, Faculty of Medicine, Department of Medical Imaging, Division of Nuclear Medicine, Debrecen, HUNGARY.*

EP-1028
Overall survival of patients undergoing transarterial radioembolization (TARE) and the influence of additional treatments, injected activity and mean dose to the tumor
S. Ialuna[1], *N. Quartuccio*[1], *D. Scalisi*[2], *F. D'Amato*[3], *M. R. Barcellona*[4], *M. G. Bavetta*[4], *G. Fusco*[4], *E. Bronte*[5], *E. Musso*[5], *F. Bronte*[6], *V. Picciotto*[4], *A. Carroccio*[4], *F. Verderame*[5], *G. Malizia*[6], *F. La Gattuta*[7], *A. M. Moreci*[1];
[1]*Nuclear Medicine Unit, A.O.O.R. Villa Sofia Cervello, Palermo, ITALY,* [2]*Health Physics Unit, A.O.O.R. Villa Sofia Cervello, Palermo, ITALY,* [3]*Unit of Interventional radiology, A.O.O.R. Villa Sofia Cervello, Palermo, ITALY,* [4]*Internal Medicine Unit, A.O.O.R. Villa Sofia Cervello, Palermo, ITALY,* [5]*Clinical Oncology Unit, A.O.O.R. Villa Sofia Cervello, Palermo, ITALY,* [6]*Gastroenterology Unit, A.O.O.R. Villa Sofia Cervello, Palermo, ITALY,* [7]*Interventional Radiology Unit, A.O.O.R. Villa Sofia Cervello, Palermo, ITALY.*

EP-1029
Quantitative Parameters of 99mTc-PYP SPECT/CT Correlates with Left Ventricle Diastolic Dysfunction in Transthyretin Amyloid Cardiomyopathy, Not Myocardial Perfusion Reserve
Y. Chen[1], *C. Ko*[1], *J. Cheng*[1], *A. Yu*[2], *C. Tsai*[2], *P. Tseng*[3], *C. Chao*[4], *M. Cheng*[1], *Y. Lin*[2];
[1]*Department of Nuclear Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei City, TAIWAN,* [2]*Department of Internal Medicine, Division of Cardiology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei City, TAIWAN,* [3]*Department of Internal Medicine, Division of Gastroenterology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei City, TAIWAN,* [4]*Department of Neurology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei City, TAIWAN.*

EP-1030
Optimization of Classical Pulmonary SPECT on a Revolutionary Camera
S. Hirsi[1,2], *A. E. Pedersen*[3,2], *H. Precht*[3,4,5], *S. Hess*[6,7,8], *R. Horvat*[6,7], *M. H. Vilstrup*[6,7], *P. L. Hansen*[2,4], *T. Q. Christensen*[7,9];
[1]*Department of Nuclear Medicine and PET Centre, Aarhus University Hospital, Aarhus, DENMARK,* [2]*Education of Radiography, UCL University College, Odense, DENMARK,* [3]*Department of Radiology, Lillebaelt Hospital, University Hospitals of Southern Denmark, Kolding, DENMARK,* [4]*Health Sciences Research Centre, UCL University College, Odense, DENMARK,* [5]*Department of Regional Health, University of Southern Denmark, Odense, DENMARK,* [6]*Department of Radiology and Nuclear Medicine, Hospital South West Jutland, Esbjerg, DENMARK,* [7]*IRIS - Imaging Research Initiative Southwest, Esbjerg, DENMARK,* [8]*Department of Regional Health Research, Faculty of Health Sciences, University of Southern Denmark, Odense, DENMARK,* [9]*Department of Clinical Engineering, Region of Southern Denmark, Esbjerg, DENMARK.*

EP-1031
Quantitative (FDG)PET/CT - How huge a small error can be
I. Pestean, *A. Sabo, M. Cecan, M. Crisan, E. Barbus, D. Piciu; Institute of Oncology, Cluj, ROMANIA.*

EP-1032
Description amyloid PET (18F-Florbetaben) imaging protocol in patients with suspected Alzheimer's disease
M. Caballero Vivancos[1], *M. Pérez Ávila*[1], *F. González Asid*[1], *E. Córdoba Cañete*[1], *R. Sánchez Sánchez*[2];
[1]*Hospital Universitario Virgen de las Nieves, Granada, SPAIN,* [2]*Hospital Universitario Virgen de las Nieves, Maracena, Granada, SPAIN.*

EP-1033
Evaluation of image quality according to the difference in acquisition methods(SS and CBM) between PET/CT manufacturers in the 68Ga study
E. Seo, *J. Ryu; Asan Medical Center, Seoul, KOREA, REPUBLIC OF.*

EP-1034
99mTc Radiopharmaceuticals: Evaluation of Radiochemical Purities in the Last Two Years of Use
D. Di Martino, *A. Prisco, F. Rescigno, M. Buonanno, V. Porfidia, A. Esposito, M. Aurilio, S. Lastoria; Istituto Tumori G.Pascale, Napoli, ITALY.*

EP-1035
How to optimize the synthesis of [177Lu]Lu-DOTATOC, from a simple manual operation
P. Christensen; *Aarhus University Hospital, Aarhus, DENMARK.*

EP-1036
Impact of images reconstructed using Bayesian penalized likelihood on ability of [11C]MET-PET to differentiate malignant grades in brain gliomas
Y. Kamitaka[1,2], *K. Wagatsuma*[1,3], *M. Inaji*[4], *K. Ikemoto*[3], *K. Miwa*[5], *K. Ishii*[1], *M. Kobayashi*[2];
[1]*Research Team for Neuroimaging, Tokyo Metropolitan Institute of Gerontology, Tokyo, JAPAN,* [2]*Division of Health Sciences, Graduate School of Medical Sciences, Kanazawa University, Ishikawa, JAPAN,* [3]*Radiological Technology, Medical Engineering and Technology, School of Allied Health Sciences, Kitasato University, Kanagawa, JAPAN,* [4]*Department of Neurosurgery, Tokyo Medical and Dental University, Tokyo, JAPAN,* [5]*Department of Radiological Sciences, School of Health Sciences, Fukushima Medical University, Fukushima, JAPAN.*

EP-1037
Nuclear Medicine
A. Alshehri, *T. Wright, K. M Prise, A. Cole; Queens University Belfast, Belfast, UNITED KINGDOM.*

12 SEPTEMBER, 2023
DOORS OPEN AT 19:00

EANM CLUBBING hosted by EARL

Featuring: The Bad Powells

LOCATION: PALAIS WERTHEIM
CANOVAGASSE 1-5, 1010, VIENNA

Preparing for the New Era of Neuroimaging for Alzheimer's Disease

Satellite Symposium | Session 3 in Room F2
Sunday 10 September at 13:15-14:30

Chaired by Frederik Barkhof
Join our symposium on the cutting-edge advances in PET imaging in the new era of disease modification in Alzheimer's disease.

Program

Introduction	
Role of PET imaging in the disease modification era of Alzheimer's disease	
Advances in AD PET biomarkers	Alexander Drzezga University of Cologne, Germany
PET tracers: Which, when, how, who?	Lyduine Collij Lund University, The Netherlands
Q&A	All
Summary	Frederik Barkhof

Faculty

Frederik Barkhof
Amsterdam UMC, The Netherlands
and University College London, UK

Silvia Morbelli
University of Genoa, Italy

Educational objectives

- Explain the critical role of PET imaging in the new era of disease modification of Alzheimer's disease
- Appraise the utility of current and emerging PET biomarkers in clinical practice
- Identify patterns from different PET tracers for a negative and positive AD brain and debate methods beyond binary amyloid PET interpretation

This activity is supported by an educational grant from Lilly.

Springer Healthcare IME

SATELLITE SYMPOSIA

Sunday, September 10, 2023 — **13:15–14:45, Hall E2**

Symposium by Monrol Nuclear Products:
PSMA radioligand therapy of prostate cancer in clinical practice

Chairperson: Dr. Derya Tilki

13:15–13:20	**Welcome and Introduction** Dr. Derya Tilki
13:20–13:35	**Treatment Landscape of Advanced Prostate Cancer** Maria De Santis
13:35–13:50	**Importance of Next Generation Imaging in Prostate Cancer Management** Ken Herrmann
13:50–14:05	**Update of PSMA-Targeted Theranostics in Prostate Cancer** Joe O'Sullivan
14:05–14:35	**Case presentation** Dr. Derya Tilki **Multidisciplinary Panel Discussion** Maria De Santis, Ken Herrmann, Joe O'Sullivan, Dr. Derya Tilki
14:35–14:45	**Q&A**

Sunday, September 10, 2023 *(Available via Livestream and On Demand)* — **13:15–14:45, Hall F1**

Symposium by TELIX:
Personalized Diagnostic in Urological Cancers: the Promise of Nuclear Medicine

Chairperson: Prof. Stefano Fanti, Nuclear Medicine Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy

	Focus on radiolabelled PSMA-PET/CT in Prostate cancer Prof. Stefano Fanti – Bologna, Italy Dr. Macarena Rodriguez Fraile – Pamplona, Spain
	Radiodiagnostic applied to Kidney and Bladder cancers Prof. Karolien Goffin – Leuven, Belgium
	The use of Artificial Intelligence in Prostate cancer management Dr Laszlo Papp – Vienna, Austria

Sunday, September 10, 2023 — **13:15–14:45, Hall F2**

Springer Healthcare IME
(supported by an educational grant from Lilly)
Preparing for the new era of neuroimaging for Alzheimer's disease

Chairperson: Professor Frederik Barkhof (Amsterdam UMC, The Netherlands and University College London, UK)

13:15–13:20	**Introduction** Frederik Barkhof
13:20–13:30	**Role of PET imaging in the disease modification era of Alzheimer's disease** Silvia Morbelli (University of Genoa, Italy)
13:30–13:45	**Advances in AD PET biomarkers** Alexander Drzezga (University of Cologne, Germany)
13:45–14:00	**PET tracers: Which, when, how, who?** Lyduine Collij (Lund University, The Netherlands)
14:00–14:45	**Q&A (Audience and panel discussion)**
14:20	**Summary** Frederik Barkhof

Sunday, September 10, 2023 *(Available via Livestream and On Demand)* — **13:15–14:45, Hall K**

Symposium by Pfizer:
Advancements in nuclear imaging for the diagnosis of cardiac amyloidosis

Chairperson: Sharmila Dorbala

13:15–13:30	**Introduction to cardiac amyloidosis: from recognition to treatment** René Rettl
13:30–13:50	**Using cardiac scintigraphy for non-invasive diagnosis of ATTR-CM** Sharmila Dorbala
13:50–14:05	**Sharing practical approaches to accurate diagnosis: a case-based study** Olivier Gheysens
14:05–14:15	**Q&A** All faculty

Monday, September 11, 2023 **13:15–14:45, Hall E2**

Symposium by Spectrum Dynamics: Reaching Higher Peaks in Digital SPECT Imaging

Join and hear VERITON-CT® and D-SPECT® users discuss how they are utilizing the latest groundbreaking technologies and how customers like you are finding their peak in digital SPECT imaging

Pr. Denis Agostini, MD, PhD. Head of Nuclear Medicine Department – University Hospital of Caen, CHU Caen, France
Dr. Miguel Ochoa Figueroa, MD, PhD. Specialist in Nuclear Medicine and Radiology – Linköping University Hospital, Sweden
Dr. Laetitia Imbert, PhD. Medical Physicist, Medical Physicist, Department of Nuclear Medicine – University Hospital of Nancy, CHRU Nancy , France
Pr. Antoine Verger, MD, PhD. Professor, Department of Nuclear Medicine – University Hospital of Nancy, CHRU Nancy, France

Monday, September 11, 2023 **13:15–14:45, Hall C**

Symposium by GE HealthCare: Shaping the future with Total MI solutions

Chairperson: Mathias Goyen, Chief Medical Officer EMEA, GE HealthCare

13:15–13:20	**Welcome and Introduction** Mathias Goyen, Chief Medical Officer EMEA, GE HealthCare
13:20–13:40 (incl. 5 minutes Q&A)	**Advancing Next Generation Radiotracers to Help Improve Patient Outcomes** Paul Evans PhD, Head of Global R&D at GE HealthCare Regina Young, Head of Global Market Access at GE HealthCare
13:40–14:00 (incl. 5 minutes Q&A)	**How Omni Legend delivers increased flexibility to clinical applications** Prof. Miroslaw Dziuk, Affidea PET/CT Centre, Warsaw, Poland
14:00–14:20 (incl. 5 minutes Q&A)	**StarGuide™: the future of SPECT/CT is 3D** Tommi Noponen, Medical Physicist, Adj. Prof., Turku University Hospital, Finland
14:20–14:40 (incl. 5 minutes Q&A)	**Patient-centered Diagnostic Imaging and Adapting to Clinical Needs with SIGNA™ PET/MR** Prof. Farshad Moradi, Stanford Health Care, USA

Monday, September 11, 2023 ***(Available via Livestream and On Demand)*** **13:15–14:45, Hall F1**

Symposium by Siemens Healthineers: Answering to clinical needs in molecular imaging

Chairperson: Matt Shah, Marketing Operations Head, Siemens Healthineers

Transitioning to next-generation SPECT/CT: radiographers share their experience
Juho Kuukasjärvi, Oulu University Hospital, Finland
Joni Granlund, Oulu University Hospital, Finland

PET/CT Imaging of connectome and inflammation
Univ.-Prof. Dr. M. Hacker, AKH Vienna, Austria

Monday, September 11, 2023 **13:15–14:45, Hall F2**

Symposium by Curium: PYLCLARI® [Piflufolastat (^{18}F)] now in Europe: Sharing current perspectives for the diagnosis of prostate cancer

Prof. Dr. Jeroen van Moorselaar Chairman, Department of Urology Amsterdam UMC, Amsterdam, Netherlands
Assoc. Prof. Dr. Daniela E. Oprea-Lager Department of Radiology and Nuclear Medicine Amsterdam UMC, Amsterdam, Netherlands
Assoc. Prof. Dr. Juan Antonio Vallejo Casas Department of Nuclear Medicine University Hospital Reina Sofía, Córdoba, Spain

Tuesday, September 12, 2023 ***(Available via Livestream and On Demand)*** **13:15–14:45, Hall K**

Symposium by Novartis: ADACAP Symposium at the EANM'23 World Meeting – Neuroendocrine tumour as an oncological entity

13:15–13:25	**Welcome and introduction** Dr Prakash Manoharan
13:25–13:35	**General criteria for decision-making in patients with advanced GEP-NETS** Dr Nicola Fazio
13:35–14:10	**Medical Cases – Presentation and Panel Discussion** Panel: Dr Nicola Fazio, Dr Jaume Capdevila
14:10–14:15	**Close and thank you** Dr Prakash Manoharan

Tuesday, September 12, 2023 **13:15–14:45, Hall E2**

Symposium by United Imaging: Transforming Precision Medicine: Pioneering Breakthroughs in Long Axial FOV and Next-Generation PET Technologies

Join us on a clinical journey utilizing innovative Long Axial Field of View (FOV) and Next-Generation PET Technologies. Witness their transformative influence on patient care, drug discovery, and personalized theranostics, shaping the future of precision medicine for all.

Joniada Doraku – Medical Doctor of Department of Nuclear Medicine, Ospedale Sacro Cuore-Don Calabria Hospital
Hongcheng Shi – Director of the Department of Nuclear Medicine, Zhongshan Hospital, Fudan University
Jeffrey Yap – Director of the Center for Quantitative Cancer Imaging, Huntsman Cancer Institute
Li Huo – Director of the Department of Nuclear Medicine, Peking Union Medical College Hospital
Richard Carson – Professor of Biomedical Engineering and Radiology, Yale University

Tuesday, September 12, 2023 ***(Available via Livestream and On Demand)*** **13:15–14:45, Hall K**

Symposium by Novartis: ADACAP Symposium at the EANM'23 World Meeting – Neuroendocrine tumour as an oncological entity

13:15–13:25	**Welcome and introduction** Dr Prakash Manoharan
13:25–13:35	**General criteria for decision-making in patients with advanced GEP-NETS** Dr Nicola Fazio
13:35–14:10	**Medical Cases – Presentation and Panel Discussion** Panel: Dr Nicola Fazio, Dr Jaume Capdevila
14:10–14:15	**Close and thank you** Dr Prakash Manoharan

Tuesday, September 12, 2023 **13:15–14:45, Hall F2**

Symposium by ABX GmbH: Translation of ^{18}F-PSMA-1007 from research to routine clinical use

Chairperson: Prof. Dr. med. Kambiz Rahbar – Klinik für Nuklearmedizin, Universitätsklinikum Münster (UKM)

	PSMA-ligands: Introduction, Biology and its clinical peers Univ.-Prof. Dr. med. Frederik L. Giesel – Klinik für Nuklearmedizin, Universitätsklinikum Düsseldorf (UKD)
	Pitfalls and phenotypes: PSMA in- and outside prostate cancer Prof. Dr. Wolfgang Fendler – Klinik für Nuklearmedizin Essen
	The advantages of low urinary clearance: what does the urologist gain from PSMA-imaging? Prof. Dr. med. Tobias Maurer, FEBU – Universitätsklinikum Hamburg-Eppendorf
	PSMA-1007: From a phase 3 clinical study to routine use in France Prof. Dr. Pierre Olivier, Nuclear Medicine and Nancyclotep Molecular Imaging Platform, CHRU-Nancy, Université de Lorraine, Nancy, France
	Biochemical Recurrence and PSMA Imaging: where are we today? Prof. Dr. med. Kambiz Rahbar – Klinik für Nuklearmedizin, Universitätsklinikum Münster (UKM)

EANM'23 WORLD LEADING MEETING
SEPTEMBER 9–13, 2023

WORLD LEADING MEETING EANM'23
SEPTEMBER 9–13, 2023

LIST OF EXHIBITORS (A – Z)

	Exhibitor	Booth No.
	A.C.O.M. Advanced Center Oncology Macerata S.r.l.	252
	ABSCINT	248
	ABX GmbH	220
CM	ABX-CRO advanced pharmaceutical services	210
	ACIC Machinery	219
CM	Advanced Accelerator Applications Molecular Imaging	242
CM	Novartis	318
	Advanced Cyclotron Systems Inc.	251
CM	Alliance Medical GmbH	406
	Almedis Altmann GmbH	312
	ArgonSoft	402
	AtomVie Global Radiopharma Inc.	201
	AWEX – Wallonia Export & Investment Agency	248
CM	Blue Earth Diagnostics Ltd.	302
CM	Boston Scientific International	231
	Brightonix Imaging Inc	409
CM	Bruker BioSpin, MOLECUBES, PMOD	319
	BV Cyclotron	312
	Chelatec SAS	205
	CHEMATECH	208
	CLERAD	212
	CMR – Center of Molecular Research Corporation GmbH	202
CM	COMECER SPA	305
	Crystal Photonics GmbH	236
	CUP Laboratorien Dr. Freitag GmbH / TRIMT GmbH	412
CM	Curium	313
	Cyclomedica Europe	410
	DOSIsoft SA	213
	DSD Pharma	312
	ec2 Software Solutions	217
CM	Eckert & Ziegler Isotope Products	240
CM	Eckert & Ziegler Medical	240
	EDL	307
	EITA (European Isotopes Transport Association)	257
CM	Eli Lilly	227
	ELSE Solutions S.r.l.	234
	Elysia-raytest Gmbh	248
	Epsilon	312
	Evergreen Theragnostics, Inc.	204
	for-med.nl customized medical accessories	312
	Gamma Medical Technology	247
CM	GE HealthCare	416
CM	Hermes Medical Solutions	309
	Hidex	207
	Hoy Scandinavian	312
CM	IBA SA	303
	ImaginAb	408
	Incepto Medical	250
	Institute of Isotopes Co. Ltd.	314
	Inter Medical Medizintechnik GmbH	253
	INVIA Medical Imaging Solutions	237
	Inviscan	258
	Ionetix Corporation	308
	Iotron Medical Inc	216
	IRE ELiT	248
	Isotope JSC	228
	Isotopia Molecular Imaging Ltd.	215
	ITEL Telecomunicazioni SRL	403
CM	ITM Isotope Technologies Munich	417

INDUSTRY PROGRAMME | FINAL PROGRAMME

	Jiangsu Huayi Technology Co., Ltd.	255
	Jubilant Radiopharma	411
	LabLogic Systems Ltd., Hidex, Southern Scientific	207
CM	Lemer Pax / Global Morpho Pharma	419
	Ludlum Measurements	421
	Lynax	254
CM	Medi-Radiopharma Ltd.	317
CM	Mediso Medical Imaging Systems	314, 315
	MEDraysintell	248
	MedTrace Pharma A/S	206
	MIAS PHARMA	230a
	MiE medical imaging electronics GmbH	413
CM	MILabs B.V.	245
CM	MIM Software Inc.	244
	MNT Healthcare Services Inc.	218
	MNT Kwint International BV	312
	MNX Global Logistics	248
	MOLECUBES	319
CM	Monrol Nuclear Products Co./S.C. Monrol Europe SRL	311
	MR Solutions Ltd.	246
	Nuclear Medicine Europe eeg	211
	Nuclear Shields BV	233
	Nucleis	248
	NUVIA Instruments GmbH	312
	Oncidium Foundation	248
	OncoBeta GmbH	226
	ONCODESIGN SERVICES	209
CM	OncoSil Medical Europe GmbH	235
	Optimized Radiochemical Applications	404
CM	Pars Isotope Co.	304
	PBL Srl.	219
	PentixaPharm GmbH	240
	PI Medical Diagnostic Equipment B.V.	312
	PMB-ALCEN	203
	PMOD	319
CM	POLATOM, Radioisotope Centre of National Centre for Nuclear Research	415
	Positrigo AG	222

	QUBIO	224
	RADIOPROTECH	243
	Rotem GmbH	239
CM	ROTOP Pharmaka GmbH	414
	RQS Alexander Ruffani	256
	Scannix	248
	SCINTOMICS Molecular, att GmbH	249
CM	SHINE Medical Technologies, LLC	238
CM	Siemens Healthineers	418
CM	Sirtex Medical Europe GmbH	301
	Softway Medical	312
CM	Spectrum Dynamics Medical	407
	Southern Scientific	207
	Sumitomo Heavy Industries, Ltd.	306
	SYNTHRA GmbH	223
CM	Telix Innovations	241
CM	Tema Sinergie S.p.A.	316
CM	Terumo Interventional Systems	405
	TRASIS S.A.	225
	TRISKEM INTERNATIONAL	230b
	U.S. Department of Energy Isotope Program	320
CM	United Imaging Healthcare	420
	United Well	321
	VANDERWILT techniques b.v.	312
	vent-medis GmbH	230
CM	Von Gahlen Nederland B.V.	310
	Vortal	248
	Voximetry	214
	Wälischmiller Engeneering GmbH	232
	WIS – World Infinity Services	248
	XEOS Medical NV	401

LIST OF EXHIBITORS (SORTED BY BOOTH NO.)

	AtomVie Global Radiopharma Inc.	201
	CMR – Center of Molecular Research Corporation GmbH	202
	PMB-ALCEN	203
	Evergreen Theragnostics, Inc.	204
	Chelatec SAS	205
	MedTrace Pharma A/S	206
	Hidex	207
	LabLogic Systems Ltd., Hidex, Southern Scientific	207
	Southern Scientific	207
	CHEMATECH	208
	ONCODESIGN SERVICES	209
CM	ABX-CRO advanced pharmaceutical services	210
	Nuclear Medicine Europe eeg	211
	CLERAD	212
	DOSIsoft SA	213
	Voximetry	214
	Isotopia Molecular Imaging Ltd.	215
	Iotron Medical Inc	216
	ec2 Software Solutions	217
	MNT Healthcare Services Inc.	218
	ACIC Machinery	219
	PBL Srl.	219
	ABX GmbH	220
	Positrigo AG	222
	SYNTHRA GmbH	223
	QUBIO	224
	TRASIS S.A.	225
	OncoBeta GmbH	226
CM	Eli Lilly	227
	Isotope JSC	228

	vent-medis GmbH	230
	MIAS PHARMA	230a
	TRISKEM INTERNATIONAL	230b
CM	Boston Scientific International	231
	Wälischmiller Engeneering GmbH	232
	Nuclear Shields BV	233
	ELSE Solutions S.r.l.	234
CM	OncoSil Medical Europe GmbH	235
	Crystal Photonics GmbH	236
	INVIA Medical Imaging Solutions	237
CM	SHINE Medical Technologies, LLC	238
	Rotem GmbH	239
CM	Eckert & Ziegler Isotope Products	240
CM	Eckert & Ziegler Medical	240
	PentixaPharm GmbH	240
CM	Telix Innovations	241
CM	Advanced Accelerator Applications Molecular Imaging	242
	RADIOPROTECH	243
CM	MIM Software Inc.	244
CM	MILabs B.V.	245
	MR Solutions Ltd.	246
	Gamma Medical Technology	247
	AWEX – Wallonia Export & Investment Agency	248
	Elysia-raytest Gmbh	248
	IRE ELiT	248
	MEDraysintell	248
	MNX Global Logistics	248
	Nucleis	248
	Oncidium Foundation	248
	Scannix	248

WORLD LEADING MEETING — EANM'23
SEPTEMBER 9–13, 2023

EXHIBITION HALLS

X4 – LEVEL 0



X3 – LEVEL -2



X2 – LEVEL -2



	201	AtomVie Global Radiopharma Inc.
	202	CMR – Center of Molecular Research Corporation GmbH
	203	PMB-ALCEN
	204	Evergreen Theragnostics, Inc.
	205	Chelatec SAS
	206	MedTrace Pharma A/S
	207	Hidex
	207	LabLogic Systems Ltd., Hidex, Southern Scientific
	207	Southern Scientific
	208	CHEMATECH
	209	ONCODESIGN SERVICES
CM	210	ABX-CRO advanced pharmaceutical services
	211	Nuclear Medicine Europe eeg
	212	CLERAD
	213	DOSIsoft SA
	214	Voximetry
	215	Isotopia Molecular Imaging Ltd.
	216	Iotron Medical Inc
	217	ec2 Software Solutions
	218	MNT Healthcare Services Inc.
	219	ACIC Machinery
	219	PBL Srl.
	220	ABX GmbH
	222	Positrigo AG
	223	SYNTHRA GmbH
	224	QUBIO
	225	TRASIS S.A.
	226	OncoBeta GmbH
CM	227	Eli Lilly
	228	Isotope JSC
	230	vent-medis GmbH
	230a	MIAS PHARMA

	230b	TRISKEM INTERNATIONAL
CM	231	Boston Scientific International
	232	Wälischmiller Engeneering GmbH
	233	Nuclear Shields BV
	234	ELSE Solutions S.r.l.
CM	235	OncoSil Medical Europe GmbH
	236	Crystal Photonics GmbH
	237	INVIA Medical Imaging Solutions
CM	238	SHINE Medical Technologies, LLC
	239	Rotem GmbH
CM	240	Eckert & Ziegler Isotope Products
CM	240	Eckert & Ziegler Medical
	240	PentixaPharm GmbH
CM	241	Telix Innovations
CM	242	Advanced Accelerator Applications Molecular Imaging
	243	RADIOPROTECH
CM	244	MIM Software Inc.
CM	245	MILabs B.V.
	246	MR Solutions Ltd.
	247	Gamma Medical Technology
	248	AWEX – Wallonia Export & Investment Agency
	248	Elysia-raytest Gmbh
	248	IRE ELiT
	248	MEDraysintell
	248	MNX Global Logistics
	248	Nucleis
	248	Oncidium Foundation
	248	Scannix
	248	Vortal
	248	WIS – World Infinity Services
	248	ABSCINT
	249	SCINTOMICS Molecular, att GmbH

	250	Incepto Medical
	251	Advanced Cyclotron Systems Inc.
	252	A.C.O.M. Advanced Center Oncology Macerata S.r.l.
	253	Inter Medical Medizintechnik GmbH
	254	Lynax
	255	Jiangsu Huayi Technology Co., Ltd.
	256	RQS Alexander Ruffani
	257	EITA (European Isotopes Transport Association)
	258	Inviscan
CM	301	Sirtex Medical Europe GmbH
CM	302	Blue Earth Diagnostics Ltd.
CM	303	IBA SA
CM	304	Pars Isotope Co.
CM	305	COMECER SPA
	306	Sumitomo Heavy Industries, Ltd.
	307	EDL
	308	Ionetix Corporation
CM	309	Hermes Medical Solutions
CM	310	Von Gahlen Nederland B.V.
CM	311	Monrol Nuclear Products Co./S.C. Monrol Europe SRL
	312	Almedis Altmann GmbH
	312	BV Cyclotron
	312	DSD Pharma
	312	Epsilon
	312	for-med.nl customized medical accessories
	312	Hoy Scandinavian
	312	MNT Kwint International BV
	312	NUVIA Instruments GmbH
	312	PI Medical Diagnostic Equipment B.V.
	312	Softway Medical
	312	VANDERWILT techniques b.v.
CM	313	Curium

	314	Institute of Isotopes Co. Ltd.
CM	314,315	Mediso Medical Imaging Systems
CM	316	Tema Sinergie S.p.A.
CM	317	Medi-Radiopharma Ltd.
CM	318	Novartis
CM	319	Bruker BioSpin, MOLECUBES, PMOD
	319	MOLECUBES
	319	PMOD
	320	U.S. Department of Energy Isotope Program
	321	United Well
	401	XEOS Medical NV
	402	ArgonSoft
	403	ITEL Telecomunicazioni SRL
	404	Optimized Radiochemical Applications
CM	405	Terumo Interventional Systems
CM	406	Alliance Medical GmbH
CM	407	Spectrum Dynamics Medical
	408	ImaginAb
	409	Brightonix Imaging Inc
	410	Cyclomedica Europe
	411	Jubilant Radiopharma
	412	CUP Laboratorien Dr. Freitag GmbH / TRIMT GmbH
	413	MiE medical imaging electronics GmbH
CM	414	ROTOP Pharmaka GmbH
CM	415	POLATOM, Radioisotope Centre of National Centre for Nuclear Research
CM	416	GE HealthCare
CM	417	ITM Isotope Technologies Munich
CM	418	Siemens Healthineers
CM	419	Lemer Pax / Global Morpho Pharma
CM	420	United Imaging Healthcare
	421	Ludlum Measurements

INDUSTRY PROGRAMME | FINAL PROGRAMME

COMPANY PROFILES

A.C.O.M. Advanced Center Oncology Macerata S.r.l.

Loc. Cavallino 39/A-B
62010 Montecosaro (MC), Italy

amministrazione@acompet.it

https://www.acompet.it

ACOM SRL is a company operating in the nuclear medicine sector founded in 1999. Research is the driving force of the company, with 20 years of commitment and experience in the development of innovative radiopharmaceuticals to be included in the international market. The main area of interest and development is oncology, but the activities also involve neurodegenerative and cardiovascular diseases. The focus of the research is theranostic medicine, and in particular the development of Copper(64Cu)Chloride as a theranostic agent: a real integration of a diagnostic method with a specific therapeutic intervention. ACOM SRL is the first company in Europe to have brought in the market the radionuclide Copper-64 as a radiopharmaceutical precursor. ACOM SRL has recently obtained orphan designation in Europe for the treatment of glioblastoma with Copper(64Cu)Chloride. The professional skills of the team, the capacity to operate in critical contexts and an innovative approach demonstrated by constant investment in research and development, are just some of the distinctive features developed in these years of business. For any further information please visit our stand and our WEB page (www.acompet.it) where you can find the most updated information.

ABSCINT

LegiaPark, Boulevard Patience et Beaujonc
3B - 4000 Liege, Belgium

karine.clauwaert@abscint.com

https://abscint.com

ABSCINT is a clinical stage molecular imaging company developing in vivo diagnostics empowered by single-domain antibodies. Our name captures our essence, which is to address unmet medical needs with the development of unique antibodies (AB) providing superior performance in scintigraphy (SCINT). Our mission is to provide more precise, more specific, more convenient and safer diagnostics in the fields of oncology, cardiology and immunology.

ABX GmbH

Heinrich-Gläser-Str. 10-14
01454 Radeberg, Germany

info@abx.de

http://abx.de

ABX advanced biochemical compounds is a global frontrunner in radiopharmaceuticals, with a focus on positron emission tomography (PET) tracers. We develop and produce all compounds and components for any kind of radiotracer – from PET and SPECT precursors, PET reagent kits and cassettes, to complete radiopharmaceutical drug production in GMP environment.
Based in Radeberg, Germany, and founded in 1997, our team of more than 350 employees is specialised in custom synthesis and manufacturing of precursors and peptides according to GMP for active pharmaceutical ingredients. Thanks to our expertise combined with bleeding edge equipment, we reach highest research, production, and quality standards.
ABX is the only service provider of radiopharmaceutical production with a complete and independent supply chain – from precursor or peptide to excipients and sterile disposables.

ABX-CRO advanced pharmaceutcal services

Schössergasse 19
1067 Dresden, Germany

info@abx-cro.com

https://www.abx-cro.com

Welcome to ABX-CRO!
ABX-CRO is an international CRO providing standard & specialised clinical and non-clinical studies, with emphasis on neuroscience, oncology and diagnostic imaging. With a unique translational medicine approach, we are happy to develop products from first non-clinical to late-stage multicentre human studies, or to support marketing authorisation.
Our dedicated Molecular and Functional Imaging Core Lab provides comprehensive turn-key solutions covering all aspects of pre-clinical and clinical imaging and dosimetry. We provide solutions for radiolabelling, dosimetry, regulatory issues and the intricacies of functional imaging that are frequently seen as major obstacles in the conduct of oncology and imaging trials.
Whether you represent a clinical trial site or want to find out how your project could benefit from our experience, come over and get an idea of our comprehensive services and expertise!

Advanced Accelerator Applications, a Novartis Company

20 Rue Diesel
1630 Saint-Genis-Pouilly, France

antonella.laudano@novartis.com

https://www.novartis.com

Advanced Accelerator Applications Molecular Imaging was set up in December 2022 as a separate business of Advanced Accelerator Applications, a Novartis Company, which was founded in 2002 as a spin-off of CERN, focused on developing and manufacturing targeted radioligand therapies and radioligands for Precision Imaging in Oncology. The Company is part of the Novartis group since 2018.We continue to carry on today the proud legacy of Diagnostic Imaging. Diagnostic Imaging uses targeted drugs containing radioactive particles for disease diagnosis and patient selection for therapies using Positron Emission Tomography (PET). Our mission is to help save lives through early precision diagnosis of sometimes rare diseases. In terms of diagnosis, Molecular Imaging is indeed a capable type of technology that is able to identify a disease in its early stages and determine, for example, the exact location of a tumor, often before symptoms appear or abnormalities can be detected with standard diagnostic tests . We can count on our efficient manufacturing capability, consisting of 12 production sites in 5 countries (with 2 under construction), an efficient transport network, reliable external partners and approximately 300 committed employees across Europe.

Advanced Cyclotron Systems Inc.

150-7280River Rd., V6X 1X5
Richmond, BC, Canada

info@advancedcyclotron.com

https://advancedcyclotron.com

Advanced Cyclotron Systems, Inc. (ACSI) is a world leader in the design and manufacturing of cyclotron systems. With over 30 years of experience and more than 60 cyclotron systems installed, ACSI can provide a wide range of equipment and services worldwide. ACSI cyclotrons are used for the commercial production of PET and SPECT nuclides by internationally recognized companies and leading universities and research facilities. ACSI cyclotrons are designed, manufactured, and assembled in Richmond, Canada.

ACSI offers a full spectrum of cyclotron systems ranging from PET cyclotrons to medium and high energy accelerators. All ACSI manufactured cyclotrons have variable energy and employ external ion source technology, offering the highest beam current output available on the market.

The versatility, high beam current and exceptional quality of ACSI cyclotrons are some of the reasons why many of the world's most prestigious universities and research centres, as well as some of the most successful commercial radioisotope producers have chosen ACSI cyclotrons to meet their radioisotope production needs. For more information, please visit www.advancedcyclotron.com

Alliance Medical GmbH

Westring 168
44575 Castrop-Rauxel, Germany

nikki.polat@alliancemedical.eu

http://www.alliancemedical.de

Life Healthcare Europe, consisting of Life Molecular Imaging, Life Radiopharma and Life Alliance Medical is an integrated business including research and development laboratories, a network of cyclotrons, radiopharmacies and imaging facilities. These combined services allows physicians, pharma industry and academia greater access to established and innovative imaging agents for clinical trials and clinical routine.

ArgonSoft

H-1133 Budapest, Váci út 76. Capital Square
1133 Budapest, Hungary

info@argonsoft.hu

https://www.argonsoft.hu/en

ArgonSoft is a professional IT company in the high-end segment of the tailor-made software development business society. Since 2008 we have been successfully providing tailor-made software development services to our customers in the HealthCare sector and other areas as well.

Our flagship product - ASIS.TO (www.asis.to) - is a highly flexible, state-of-the-art LIMS, designed for Radiopharmacy Labs and Cyclotron Facilities to make GMP compliant TRACER production more efficient. The SMART equipment integration functions enable a smooth, secure automated data transfer. Come to our booth to see a live demo!

Our company has a strong nuclear medicine domain knowledge. Our end-to-end, iterative software development methodology complies with the GAMP5 guidelines and ensures high quality, customized results which helps our partners to achieve their business goals efficiently. These capabilities enable ArgonSoft to deliver high-end software products for You, like ASIS.TO.

FURTHER SERVICES for HEALTHCARE COMPANIES:

- Digital Transformation Consultation
- Custom Software Development
- Integration Services

In 15+ years across 9 countries for over 30+ customers, we delivered 150+ successful projects.

AtomVie Global Radiopharma Inc.

1280 Main Street West NRB-A316
L8S 4K1 Hamilton, Ontario, Canada

info@atomvie.com

https://www.atomvie.com

AtomVie Global Radiopharma Inc. (AtomVie) is a global leading CDMO for the GMP manufacturing and global distribution of clinical and commercial radiopharmaceuticals. Building upon the expertise and high-quality services since 2008 from the Centre for Probe Development and Commercialization (CPDC), AtomVie offers the full range of scientific, technical, regulatory, quality, logistics and business expertise combined with a specialized infrastructure for the development of radiopharmaceuticals from clinical studies to the commercial marketplace. AtomVie recently closed over $90M Series A financing allowing it to complete the buildout and setup of its new 70,000 sq. ft. purpose-built, state-of-the-art facility. The new facility, set to open in late 2024, will offer expanded clinical and commercial manufacturing of radiopharmaceuticals for all level of throughput, scalable from low to high number of doses per batch. With its reliable logistic expertise, AtomVie currently serves international clients conducting studies in over 17 countries worldwide, improving patients' lives all over the globe.

AWEX – Wallonia Export & Investment Agency

Place Sainctelette 2
1080 Brussels, Belgium

lifesciences@awex.be

https://www.awex.be/en

The Wallonia Foreign Trade and Investment Agency, also known as AWEX, is Wallonia's - Region of Belgium - government agency in charge of foreign Trade and foreign investment.
Wallonia is home to many nuclear medicine companies of various sizes, from SMEs to large companies, such as IBA and IRE, including spinoffs, suppliers and service providers.
Our regional government supports the development of existing or newly established innovative activities with regard to R&D and production in the radiopharma and radiotherapy industry. AWEX is a one-stop shop for all foreign companies interested in setting up or expanding their business in Wallonia, as well as a partner for all Walloon companies wishing to develop their activities outside Belgium. If you're interested to know more, we will provide you with tailor-made information.
Our partner BioWIN, the Health Cluster of Wallonia since 2006, encourages innovation and international development of Walloon actors active in this sector. BIOWIN connects some 250 key players: universities, research units and centers, R&D as well as manufacturing companies, incubators, capital providers, hospitals. To find out more about BioWIN's activities, please visit https://biowin.org.

Blue Earth Diagnostics Ltd.

Magdalen Centre, Oxford Science Park
OX4 4GA, Oxford, United Kingdom

contact@blueearthdx.com

https://www.blueearthdiagnostics.com

Blue Earth Diagnostics, an indirect subsidiary of Bracco Imaging S.p.A., is an international molecular imaging company on a growth trajectory to develop and commercialise innovative, well-differentiated diagnostic solutions that inform patient care and drive future therapies in cancer. Formed in 2014, the Company's success is driven by its management expertise, supported by a proven track record of rapid development and commercialisation of positron emission tomography radiopharmaceuticals. With a clinical focus in cancer, Blue Earth Diagnostics' expanding pipeline encompasses a variety of disease states, including prostate cancer and neuro-oncology. Blue Earth Diagnostics is committed to the timely development and commercialisation of precision radiopharmaceuticals for potential use in diagnostic imaging and therapy.

Blue Earth Therapeutics Ltd

Magdalen Centre, Oxford Science Park
OX4 4GA Oxford, United Kingdom

contact@blueearthtx.com

https://www.blueearththerapeutics.com

Blue Earth Therapeutics Ltd is a clinical-stage radiopharmaceutical company dedicated to the advancement of next generation targeted radiotherapeutics to treat patients who have cancer.
With proven leadership and therapeutic radiopharmaceutical expertise, Blue Earth Therapeutics has an emerging pipeline of precision targeted therapeutic radiopharmaceuticals, initially focused on prostate cancer with plans to expand into additional disease areas in oncology.
Blue Earth Therapeutics is based in Oxford, UK. The company was formed in 2021 as a sister company to Blue Earth Diagnostics. Blue Earth Therapeutics is an indirect subsidiary of Bracco Imaging S.p.A., a world-leading diagnostic imaging provider.

Boston Scientific (BSCI)

2 rue René Caudron
78960 Voisin-le-Bretonneux, France

aliasgar.attarwala@bsci.com

http://www.bostonscientific.eu

Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world. As a global medical technology leader for more than 40 years, we advance science for life by providing a broad range of high-performance solutions that address unmet patient needs and reduce the cost of health care. Interventional Oncology is giving medical teams powerful new options and patients new hopes. We believe this is just the beginning and are committed to working with you to change the fight against cancer. Boston Scientific's Selective Internal Radiation Therapy (SIRT) with TheraSphereTM is an intra-arterial directed therapy for hepatic malignancy where radioactive microspheres containing Yttrium-90 (90Y) are infused into the target liver arteries in order to treat the tumours. Simplicit90YTM Personalised Dosimetry Software enables full potential of TheraSphere's personalization and precision in a simplified and time-efficient workflow. It provides confidence to physicians that each tumor gets the optimal radiation dose while preserving healthy tissue, ensuring safe and effective treatment for patients.

Bracco Imaging S.p.A.

Via Egidio Folli 50
20134 Milan, Italy

contact-us@bracco.com

https://www.bracco.com

Bracco Imaging S.p.A., part of the Bracco Group, is a world-leading diagnostic imaging provider. Headquartered in Milan, Italy, Bracco Imaging develops, manufactures, and markets diagnostic imaging agents and solutions. It offers a product and solution portfolio for all key diagnostic imaging modalities: X-ray imaging (including Computed Tomography-CT, Interventional Radiology, and Cardiac Catheterization), Magnetic Resonance Imaging (MRI), Contrast Enhanced Ultrasound (CEUS), and Nuclear Medicine through radioactive tracers and novel PET imaging agents to inform clinical management and guide care for cancer patients in areas of unmet medical need. Our continually evolving portfolio is completed by a range of medical devices, advanced administration systems, and dose-management software. In 2019 Bracco Imaging enriched its product portfolio by expanding the range of oncology nuclear imaging solutions in the urology segment and other specialties with the acquisition of Blue Earth Diagnostics. In 2021, Bracco Imaging established Blue Earth Therapeutics as a separate, cutting-edge biotechnology dedicated to advancing next-generation targeted radiotherapeutics to treat patients who have cancer.

Brightonix Imaging Inc

#1705, SK V1 Tower, 25, Yeonmujang 5ga-gil,
Seongdong-gu, 4782 Seoul, South Korea

info@brtnx.com

https://www.brtnx.com/en

Brightonix Imaging is a innovative healthcare company established with the goal to provide society with innovative biomedical imaging systems. We are currently offering preclinical PET systems and medical imaging AI solutions. - SimPET is the most compact and reliable MRI compatible SiPM PET insert for truly simultaneous PET/MRI studies in small animals. - BTXBrain is AI-powered automated quantification software for brain amyloid, tau, FDG, and DAT PET. It is designed with user-friendly interfaces for easy interactions and logically connected functions, and also provides a comprehensive report on brain PET tracer uptake. Brightonix Imaging is also developing the clinical PET scanner for brain, breast and extremity with support from Korea Medical Device Development Fund. Products: SimPET, BTXBrain, Pharos PET

BV Cyclotron

Van der Boechorststraat 6A
1081 BT Amsterdam, Netherlands

info@cyclotron.nl

https://www.cyclotron.nl

BV Cyclotron VU produces radiopharmaceuticals and radiochemicals for medical diagnostics and research. Strategically located in Amsterdam next to Amsterdam UMC we produce GMP-compliant medical isotopes in our state-of-the-art manufacturing facilities. Our long standing track record on supplying daily to the customers, our great expertise combined with strong collaborations makes us a reliable partner for hospitals, pharmaceutical companies and research centers all over the world.

Chelatec SAS

1 rue Aronnax
44800 Saint-Herblain, France

contact@chelatec.com

https://www.chelatec.com

Chelatec was founded in 2000 by seasoned scientists trained in the development of radiopharmaceuticals. Experts in the use of radioactive tracers, they decided to offer their knowledge in preclinical development of targeted radiotherapeutics to pharma and biotech. With state-of-the-art fully equipped laboratories for radiolabeling, radioanalyses, handling of cells and housing of animals, Chelatec is recognized for its reliable expertise and offers a unique combination of custom radiolabeling, in vitro assays and in vivo investigations capabilities. Specializing in radiopharmaceutical R&D, Chelatec will provide you with information on your Investigational Medicinal Product to be part of the documentation package. All quality and non-clinical safety data required for translation of a radiopharmaceutical.
Our services cover/include:

- Bioconjugation
- Radioactive labeling
- Analytical controls (HPLC, iTLC/TLC, SDS-PAGE...)
- Stability studies (storage stability, plasma stability)
- In vitro assays (Binding affinity, IRF, internalization, cytotoxicity, autoradiography on tissue sections)
- In vivo investigations (Pharmacokinetics, biodistribution, efficacy, dosimetry)

CHEMATECH

2 rue Pauline Kergomard
21000 DIJON, France

info@chematech-mdt.com

http://www.chematech-mdt.com

CheMatech is a world-leading company specializing in the design and synthesis of bifunctional chelating agents such as DOTA, NOTA and NODAGA derivatives. These molecules are widely used for peptides or antibodies labeling with 67/68Ga, 111In, 64/67Cu, 89Zr, ... for PET/SPECT imaging, 177Lu, 225Ac, 212Pb, 90Y, ... for therapy. CheMatech offers a wide range of functionalized and protected chelating agents from milligrams to kilograms scale. CheMatech also realizes custom syntheses of chelators and provides cGMP services.

CLERAD

184-186 boulevard Gustave Flaubert
63000 CLERMONT-FERRAND, France

clerad@clerad.fr

https://www.clerad.fr

Since 2000, CLERAD has been a main leader in ionizing rays detection and more specifically in the medical field and the research of radio-labelled tissues, or radioguided surgery. Our goal: to provide the full range of diagnostic and treatment solutions for oncology in the operating room and in nuclear medicine from Sentinel Lymph node detection with our Gamma SupII probe, to Intraoperative Radiotherapy thanks to our latest innovation, the Papillon+.

CMR – Center of Molecular Research Corporation GmbH

Bldg 638b – Cargo City South
60549 Frankfurt, Germany

info@isotope-cmr.com

https://isotope-cmr.com

CMR (Center of Molecular Research) was founded in 2001 by the group of professional scientists in nuclear medicine and international economic relations spheres firstly, focusing on production and distributing of Oxygen-18 water with Isotopic Enrichment ≥ 98% and other medicine isotopes. After more than 20 years of development today CMR is a vertically constructed united group of companies having its representatives and offices in many countries of the world.
Nowadays CMR is not only one of the world's largest manufacturers of Oxygen-18 water but also the qualified supplier of a wide range of products including STABLE AND RADIOACTIVE ISOTOPES, PEPTIDES AND CHEMICAL KITS, which completely satisfy the needs of medicine centers and hospitals, scientists and technologists in isotopic fields.

Crystal Photonics GmbH

Albert-Einstein-Straße 16
12489 Berlin, Germany

ks@crystal-photonics.com

http://www.crystal-photonics.com

Crystal Photonics is engaged in Nuclear Medicine for highly qualified products of Molecular Imaging and intraoperative and transcutane sentinel lymph node localization (SLNE) since 25 years. The product range includes our excellent mini-USB Hand-Held-Gamma-Camera "CrystalCam", the surgical Gamma Probe System "Crystal Probe - automatic" with various kinds of cable and wireless probes. We are worldwide the first company, who is presenting complete autoclavable gamma probes without compromises!

Since this year is also available the very new detection system CrystalGuard for Isolated Limb Perfusion (ILP), as well as the very new CrystalAnalyzer for HPLC-investigation in coincidence mode for any PET-drugs are available. The 3D-free-hand-spect imaging system declipse®SPECT from our dougther company is also still in our portfolio.

Additionally, we present our very new mini-Laparoscopic gamma probe for robotic-assisted minimal-invasive surgeries, (Drop-in-Probe) special designed for the DaVinci robotic operation system. This probe was developed in the course of the new PSMA-technology for Prostate Cancer and has excellent medical-technical properties.

The product portfolio is completed by a large variety of miniaturized Gamma- and Beta-detectors for any kind of application, particularly for medical systems for the production of radioisotopes with high activities. For more information, please visit our websites: www.crystal-photonics.com

CUP Laboratorien Dr. Freitag GmbH

Carl-Eschbach-Strasse 7
1454 Radeberg, Germany

dfs@cup-freitag.de

https://www.cup-freitag.de

CUP Laboratorien Dr. Freitag GmbH, located in Radeberg, Germany, is a leading provider of GMP-compliant contract testing services for the radiopharmaceutical industry.

Our core competencies include sterility testing of radioactive pharmaceuticals and we are also experts in the analysis of Leachables and Extractables (E&L), identifying and quantifying potential impurities that may leach from manufacturing materials or packaging.

In addition to these services, CUP Laboratorien Dr. Freitag GmbH offers a wide range of testing options for medical radionuclides and precursors for radiopharmaceutical preparations. Our advanced analytical techniques and equipment enable us to accurately characterize and evaluate the purity and activity of these vital components, ensuring optimal performance and safety in radiopharmaceutical products.

We take pride in our commitment to quality and regulatory compliance. CUP Laboratorien Dr. Freitag GmbH has been inspected by the US Food and Drug Administration (FDA) and has earned GMP certification, demonstrating our adherence to the highest industry standards.

At CUP Laboratorien Dr. Freitag GmbH, we are driven by a passion for excellence in radiopharmaceutical testing and a commitment to supporting our clients in their quest to develop life-changing therapies. With our extensive experience, cutting-edge facilities, and unwavering dedication to quality, we are the trusted partner for radiopharmaceutical testing and quality assurance.

Curium

63, avenue des Champs-Elysées
75008 Paris, France

contactus@curiumpharma.com

https://www.curiumpharma.com

Curium is the world's largest nuclear medicine company. We develop, manufacture and distribute world-class radiopharmaceutical products to help patients around the globe. Our proven heritage combined with a pioneering approach are the hallmarks to deliver innovation, excellence, and unparalleled service.

With manufacturing facilities across Europe and the United States, Curium delivers SPECT, PET and therapeutic radiopharmaceutical solutions for potentially life-threatening diseases to over 14 million patients annually. The name 'Curium' honors the legacy of pioneering radioactive materials researchers Marie and Pierre Curie, after whom the radioactive element curium was named and emphasizes our focus on nuclear medicine. The tagline 'Life Forward' represents our commitment to securing a brighter future for all those we serve: An enhanced quality of care for our patients. A trusted partner to our customers. A supportive employer to our valued team.

To learn more, visit www.curiumpharma.com

DOSIsoft SA

45/47 Avenue Carnot
94230 Cachan, France

info@dosisoft.com

http://www.dosisoft.com

Spin-off between Gustave Roussy & Institut Curie, DOSIsoft was founded in 2002. It develops patient-specific imaging and dosimetry software in Radiation Oncology & Nuclear Medicine to improve patient safety & treatment quality. 20 years of innovation and R&D investments have led to world leading software used in over 300 hospital centers in 60 countries.

PLANET® is a Patient-specific, multi-radionuclide (90Y/177Lu/131I/166Ho) dosimetry & theranostics platform. It comprises:

PLANET® Onco: Oncology software for Molecular Imaging (MI) & Radiotherapy. It helps to optimize disease diagnosis & therapy through registration, contouring, advanced quantification & patient response from multimodal imaging. Texture analysis for diagnosis, follow-up & radiomics is provided.

PLANET® Dose: Dosimetry software for Molecular RadioTherapy (MRT) providing multiple and integrated workflow for 90Y/177Lu/131I/166Ho dosimetry. It allows to personalize patient therapy through pre/post-implementation dosimetry, automatic structure propagation, calculation of residence time & comparison between treatment planning & validation control dose maps. Consolidation of multi-treatment stages is available.

DSD Pharma

Schuhmeierstraße 24
1140 Purkersdorf, Austria

office@dsd-pharma.com

https://dsd-pharma.com

DSD Pharma is a GDP certified distributor of radiopharmaceuticals and medical devices in the field of nuclear medicine and radiopharmacy, respectively, and ADR transportation based in Austria close to Vienna.

ec² Software Solutions

3035 E. Patrick Lane, Suite 1
89120 Las Vegas, United States

sales@ec2software.com

http://www.ec2software.com

ec² Software Solutions and our partner company, Numa LLC, are focused on developing and commercializing workflow and compatibility solutions for the molecular imaging community. Together, with over 60 years' experience, ec² and Numa provide innovative management solutions for cyclotrons, radiopharmacies, hot lab operations, drug manufacturers, multi-vendor connectivity, archiving and reporting. Our systems are presently installed in 6000 + facilities worldwide.
We provide Enterprise Solutions that secure ePHI patient data and consolidate installations all in a scalable architecture. The HL7 / DICOM Modality Worklist interfaces enhance scheduling and eliminate redundant data entry. NumaStatus can export patient dosimetry and dose information to the cameras, RIS/PACS or Dose Management system using DICOM secondary capture and Radiopharmaceutical Radiation Dose Structured Report (RRD SR). The HL7 export module and deliver dose information to the EMR and MAR.
Our online ordering (OLO) e-prescribing solutions are used by hundreds of commercial radiopharmacies and their customers in the U.S. and international markets. OLO eliminates transcription errors and enhances patient safety.

Eckert & Ziegler Isotope Products

24937 Avenue Tibbitts
91355 Valencia, CA, United States

nucmedsales@ezag.com

https://sales.isotopeproducts.com

Eckert and Ziegler Isotope Products (EZIP) offers a full range of Flood Sources, PET Sources, Specialized SPECT Sources and Multimodal Sources to meet the needs of the Nuclear Medicine community worldwide. EZIP is dedicated to serving the marketplace with high-value quality products safely constructed and delivered on time through a quality system founded on customer satisfaction, regulatory compliance and continuous improvement. With the inclusion of the Tecnonuclear portfolio, EZIP is now able to offer generators and radiolabeled cold kit compounds used in SPECT imaging.
Please stop by to learn more about our products and the regions we can support.

Eckert & Ziegler Medical

Robert-Roessle-Str.10
13125 Berlin, Germany

marketing.medical@ezag.de

https://medical.ezag.com/en

Eckert & Ziegler Medical is one of two business segments of the Eckert & Ziegler Group, with headquarters in Berlin, Germany. With more than three decades of experience in the field, Medical represents the combined expertise in nuclear medicine, molecular imaging, radiation therapy and beyond, while always focusing customer success.
We complement our wide-ranging portfolio of innovative high-quality technical solutions with the provision of versatile services such as development and contract manufacturing. With our global network of GMP suites we offer fully licensed radioisotope labs, stable supply arrangements for almost all pharmaceutical radioisotopes, a state-of-the-art infrastructure including logistics, and a highly experienced staff that can be seconded to help with your preclinical and clinical projects.
As a one-stop-shop for all your radiopharmaceutical needs, using alpha, beta or gamma emitters, our products include everything from hot cell solutions to radiochemicals (e.g., Lu-177), radiopharmaceuticals (Yttriga, GalliaPharm®), radiosynthesis technology (Modular-Lab, KitLab) and radiochromatography equipment (e.g., AR-2000).
Contact as for GMP Suites, CDMO, CMC, GalliaPharm, Ac-225, Lu-177, Y-90, radioisotopes, hot cell solutions, IGG100, UniFill, SWB-15, rTLC, rHPLC, Flow-Count, Mini-Scan, MiniScanPRO, FlowCountPRO, IsoSeed and more.

EDL

509 Av. de La Victoire du 8 Mai 1945
13130 Berre-L'Etang, France

balart@edl.fr

https://www.edl.fr

Launched in 1994, EDL's software solutions have already attracted more than 600 medical imaging departments. EDL also publishes integrated applications covering all the modern needs of imaging services such as: RIS, PACS, DACS, VINA, Teleradiology, IA, Radiopharmacy and WEB portals.

EITA (European Isotopes Transport Association)

c/o Vandelanotte Buro & Design Center,
Esplanade 1/85, 1020 Brussels, Belgium

info@eita.org

http://www.eita.org

EITA is a non-profit association, which was founded in 1998 by European logistics providers trained, licensed and specialized in the handling and transport by Road, Air and Sea of radioactive isotopes, which are mainly used for medical purpose.

Mission

- Establishment of harmonized regulations and standards
  Aiming for harmonized national and international regulations
  and legislations to guarantee the free market access in every state for the EITA members.
- Compliance with applicable regulations
  To ensure all EITA member activities are carried out in full compliance with all applicable legal requirements.
- Safety, Security and traceability
  To ensure safety and security and full traceability at all times during the complete supply chain.
- Quality
  To ensure high quality of handling, packing and transport of radioactive isotopes in accordance with required standards.
- Competence centre
  To provide a forum to exchange information and knowledge to increase awareness.

Eli Lilly

Lilly Corporate Center
46285 Indianapolis, United States

millerls@lilly.com

https://www.lilly.com

Lilly unites caring with discovery to create medicines that make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help more than 47 million people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges, redefining diabetes care, treating obesity and curtailing its most devastating long-term effects, advancing the fight against Alzheimer's disease, providing solutions to some of the most debilitating immune system disorders, and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit lilly.com and lilly.com/newsroom or follow us on Facebook, Instagram, and LinkedIn.

ELSE Solutions S.r.l.

Via Carlo Goldoni, 18
20090 Trezzano sul Naviglio (MI), Italy

info@elsesolutions.com

https://www.elsesolutions.com

ELSE Solutions Srl is an Italian company founded in 1990 which boasts a long experience in the design and production of radiation detection systems, shielded manipulation systems and passthrough, automations, and plants for Nuclear Medicine, Radiopharmacy, Radiotherapy, and other applications in the Medical and Industrial fields. ELSE Solutions technologies are designed to meet the most advanced technology standards, safety, and environment care.
SmartEye Radiation Detection Platform is designed to be flexible, expandable, featuring PoE support, and is controlled by a Web based software, Shielded manipulation systems and passthrough are featuring fully encapsulated lead and PLC controlled ECO functions (auto standby) to reduce the electrical consumption, the patented automatic dispensing system is designed for zero loss of radioactivity and is certifying the prepared patient dose through a medical device dose calibrator, automations and plants are meeting the most updated international standards, PLC control is featuring advanced functions with User-Friendly remote interface, digital ovens for Radiotherapy masks are designed to work without water, significantly reducing preparation times and maximizing safety and hygiene of the process. ELSE Solutions' vision is to be an international reference for the design of innovative and state-of-art solutions in the Medical and Industrial fields.

Elysia-raytest Gmbh

Rue du Sart-Tilman 375
B - 4031 Angleur, Belgium

info@elysia-raytest.com

https://www.elysia-raytest.com

Elysia is a provider of hard- and software solutions for the full integrated quality control of your radio-pharmaceutical production. GINA X and SARA offer a user friendly and fully GMP compliant solution to your QC problems with BioTrax being our LIMS.
Radio-detectors are also used in TLC, HPLC and GC Radio-chromatography, Gamma Spectroscopy, Dose Calibration and well counting for the pharmaceutical, agrochemical and nuclear/PET industries.

Epsilon

Erhatpasa Mahallesi 15.Sokak No.126/128
Atasehir, 3488 Istanbul, Türkiye

info@epsilonsources.com

http://www.epsilonsources.com

ERS manufactures quality assurance sources that are compatible with the leading PET OEM manufacturers to provide high-quality products and customer satisfaction. For the calibration of PET, PET/CT, PET/MR & SPECT systems, 68Ge, 22Na, 57Co and 153Gd sources are used in different forms and activities depending on the system model. Customized sources in different forms and activities can be offered upon customer request by ERS.
Please contact your local distributor or ERS headquarters for product availability and additional information.

for-med.nl customized medical accessories

Parallelweg zuid 33-02
5281 LB, Boxtel, Netherlands

info@for-med.nl

http://www.for-med.nl

FOR-MED is a development and manufacturing company, specialized in customized medical accessories for radiology, nuclear medicine and radiotherapy. We are ISO13485 certified and able to make (custom) products with MDR/EUDAMED registration. Using state-of-the-art and innovative production methods we create a wide range of products for patient positioning and fixation, shielding and more. Furthermore, we offer a range of standard products for the clinical nuclear medicine practice, daily laboratory as well as research purposes. Typically, our customers are universities, hospitals and nuclear medicine departments, as well as radiopharmaceutical and imaging equipment companies. Our Products are available throughout Europe with our distributors, for more info visit www.for-med.nl or visit out booth at the EANM2023.

Gamma Medical Technology

Friesdorfer Straße 194A
53175 Bonn, Germany

info@gamma-mt.com

http://www.gamma-mt.com

Welcome to Gamma Medical Technology, a pioneering supplier of advanced gamma probes for Sentinel Lymph Node Biopsy (SLNB) and radio-guided surgery. Our objective is to transform cancer treatment with precision-focused surgical tools that elevate patient outcomes and streamline surgical processes.
Founded by a team of visionary medical experts and engineers, we are devoted to ongoing innovation, research, and development in radio-guided surgery. Our skilled team is dedicated to designing user-friendly gamma probes that meet the complex demands of modern surgical procedures.
Our flagship product, the CENNA-500W, exemplifies our commitment to quality and innovation. This next-gen gamma probe offers unmatched accuracy, sensitivity, and ease of use, enabling surgeons to confidently identify sentinel lymph nodes during SLNB. Its state-of-the-art design ensures precise gamma radiation detection, minimizing false-negative risks and reducing surgery times.
Gamma Medical Technology is renowned for quality, reliability, and exceptional customer support. We collaborate with surgeons and medical facilities worldwide, offering training, education, and ongoing assistance to optimize product use.
As we expand globally, we remain committed to our core values of innovation, excellence, and customer satisfaction. Discover the difference our products make in radio-guided surgery and join us in revolutionizing cancer treatment worldwide.

GE HealthCare

283 rue de la miniere
78530 Buc, France

maxime.teisseire@ge.com

http://www.gehealthcare.co.uk

GE HealthCare is a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, dedicated to providing integrated solutions, services, and data analytics to make hospitals more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 100 years, GE HealthCare is advancing personalized, connected, and compassionate care, while simplifying the patient's journey across the care pathway. Together our Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics businesses help improve patient care from prevention and screening, to diagnosis, treatment, therapy, and monitoring. We are an $18 billion business with 51,000 employees working to create a world where healthcare has no limits.

Global Morpho Pharma

72 rue de Lorraine ZA Erdre Active - Malabry,
BP 54201, 44242 La Chapelle-sur-Erdre, France

sylvanie.guilloux@morphopharma.com

https://morphopharma.com

Global Morpho Pharma is a turnkey technology and service provider for the production and distribution of medical radioisotopes.
We are developing innovative equipment and building efficient supply chains to enable our partners worldwide to manufacture nca Lu-177 and other radioisotopes of interest.
We are dedicated to improving the accessibility of medical radioisotopes for the benefit of patients by providing convenient solutions to the rapidly expanding nuclear medicine ecosystem.
Radioisotopes of interest : Lu-177, Tb-161, Ac-225
More information: https://morphopharma.com/

Hermes Medical Solutions AB

Strandbergsgatan 16
112 51 Stockholm, Sweden

info@hermesmedical.com

https://www.hermesmedical.com

Established in 1976 in Stockholm, Sweden, Hermes Medical Solutions continuously innovates to enable faster and more personalized diagnosis and therapies with its independent nuclear medicine and molecular imaging software.
Hermes Medical Solutions was first to develop SPECT reconstruction software, first to develop dual-head whole body scanning, and first to introduce software for viewing fused images from different modalities.
The HERMIA state-of-the-art, vendor-neutral software suite enables imaging professionals to streamline their workflows, and increase consistency and quality of clinical image review, whilst always keeping pace with the continual development of scanners, radiopharmaceuticals and imaging procedures in NM and MI.
HERMIA harnesses the power of Artificial Intelligence and automation and combines it with the latest computing technology, to accelerate your workflow for all clinical scenarios in PET/SPECT/CT/MR, onsite or remotely, regardless of scanner manufacturer.
Our mission is to combine leadership in innovation for NM and MI software with customer-driven service.
Our success lies in our close and longstanding collaboration with our customers to meet their software, support and service needs.
HERMIA improves the quality of patient management and decision support for thousands of healthcare providers and their patients worldwide.
Visit us at booth #309 and discover how HERMIA software can make a difference for your facility!

Hidex

Lemminkäisenkatu 62
20520 Turku, Finland

info@hidex.com

https://hidex.com

Hidex is a manufacturer of high-performance analysis equipment for life science research, radiation measurement, and nuclear medicine. As a world leader in detecting alpha, beta, and gamma emitters, Hidex offers optimized gamma counters for molecular imaging isotope energies. Our gamma counters are designed to streamline workflow, sample tracking, and ensure GxP compliance. Hidex liquid scintillation counters are used globally in the development and quality control of radiopharmaceuticals, utilizing isotopes such as Actinium, Radium, Thorium, Lutetium, Strontium, Yttrium, and more.
At EANM, we are showcasing the following solutions:
Automated gamma counting: The Hidex AMG, equipped with a NaI well detector and onboard sample balance, is ideal for metabolic studies, blood input function curves, Glucomerase filtration rate, and general nuclear medicine applications.
PET radiochemistry: The Hidex Radiowater Generator is an online system for preparing Oxygen-15 H2O infusions. With approximately 50 installations worldwide, Hidex is a pioneer in Oxygen-15 water technology.
Liquid scintillation counting: Our Liquid scintillation counters 300SL and 600SL series are used by radiopharmaceutical production facilities for development and quality control of medical use isotopes, detection of impurities, contamination control with wipe tests as well as activity standardization.
To learn more about our solutions, please book a meeting with our specialists or visit our booth

Hoy Scandinavian

Jakob Møllersgård 4
9560 Hadsund, Denmark

info@hoyscandinavian.dk

https://www.hoyscandinavian.dk

HOY Scandinavian was founded in 1991 as a supplier and distributor for Nuclear Medicine and radiochemistry department in Scandinavia
The "HOY Exclusive" product range was launched in 2006. The head office is located in Hadsund Denmark, and all the HOY Exclusive product range are produced in Hadsund.
Today HOY Scandinavian is an international business that supplies products to nuclear medicine and oncology departments at hospitals and laboratories all over the world. We are known for supplying very high-quality products and are now a market leader in many markets – particularly in Scandinavia and Europe.
Our home market is primarily Denmark and Sweden. We are represented in other markets by a distributor network.
Products and activities
At HOY we develops and manufactures "Hoy Exclusive", an all in-house product design - offering quality products for radiation protection in nuclear medicine and PET departments.
The "HOY Exclusive" product portfolio has a modern timeless Scandinavian design, and offers maximum ergonomic comfort aligned to European standards.
Key products are:

- Vial glass Shields – Syringe Shielding – Syringe handling –
- Syringe Carrier and transports - Waste Contains – Tongs for Vials

IBA SA

Chemin du Cyclotron 3
1348 Louvain la Neuve, Belgium

elodie.vellut@iba-group.com

https://www.iba-radiopharmasolutions.com

IBA (Ion Beam Applications S.A.) is the world leader in particle accelerator technology. The company is the leading supplier of equipment and services in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA is also a leading player in the fields of industrial sterilization, radiopharmaceuticals, and dosimetry. The company, based in Louvain-laNeuve, Belgium, employs approximately 1,600 people worldwide. IBA is a certified B Corporation (B Corp) meeting the highest standards of verified social and environmental performance.

ImaginAb

423 Hindry Ave., Suite D
90301 Inglewood, United States

info@imaginab.com

http://www.imaginab.com

ImaginAb is a clinical stage, revenue-generating global biotechnology company developing the next generation of imaging agents and radiopharmaceutical therapy (RPT) products through its proprietary minibody and cys-diabody platforms. The lead candidate 89Zr crefmirlimab berdoxam (CD8 ImmunoPET™) imaging agent is currently in Phase II clinical trials and has been licensed by numerous pharmaceutical and biotech companies for use in imaging within their immunotherapy clinical trials, primarily in oncology.

INCEPTO MEDICAL

10 Boulevard de Grenelle,
75015 Paris, France

fanny.boutevin@incepto-medical.com

https://incepto-medical.com

We co-create with medical centers IA applications for radiology.
Healthcare professionals are now overwhelmed by the volume of patients and images. They need new tools. As safeguards of our Healthcare system, they need to be empowered and to participate in the AI production process. This is our mission through our co-creation projects.
We distribute the world's top applications via a unified platform.
Hundreds of start-ups have embarked on this adventure. They all want to produce AI to answer a specific clinical question. With our experience and our privileged relationship with the medical world, we support and integrate them on a dematerialized, secure, unique and simple platform.
We are building together the future of radiology : more reliable, faster, for more lives saved.
Incepto is this place at the crossroads of these paths: gathering solutions, market players and talents: Doctors, radiologists, researchers, data scientists, software developers, business developers, marketers and designers.
Saving Time, Saving Lives, Together.

Institute of Isotopes Co. Ltd.

Konkoly-Thege Miklós u. 29-33.
1121 Budapest, Hungary

commerce@izotop.hu

https://www.izotop.hu

Institute of Isotopes Co. Ltd. is on the frontline of radioisotope technology collaborating with long-term partners and customers. Over the years we have developed numerous products from diagnostic kits to radioactive sources for various radioactive applications. Our company provides varied and flexible services in this unique field. Our production complies with the highest quality standards: GMP, ISO9001, ISO13485, ISO14001
We are also engaged in product development projects and offer contract manufacturing, OEM services for our customers. Izotop looking forward to new products to widen our portfolio.

Fields of expertise:

- Radiopharmaceuticals, radiochemicals
- Immunoassay / In vitro products for human diagnosis and life science
- Synthesis / Radiosynthesis
- Radiation technique

Main products, services:

- Thyrotop I-131 sodium iodide hard capsules
- I-131 sodium iodide sterile solution
- I-131 MIBG injection for therapy and for diagnostic use
- Radiochemicals /I-125, I-131/
- Cold kits for Tc-^{99m}-labelling: DMSA, DTPA, PYRON, FYTON, MDP, TECHIDA, EC
- Sm-153-labelling MULTIBONE kit
- Ready to take part in R&D and manufacturing of active pharmaceutical ingredients, cold kits as well as investigational products for clinical trials.
- In Vitro diagnostics (RIA, IRMA, ELISA), Research Immunoassay kits;
- C-14 radiolabeled drug substances, GMP custom radiosynthesis;
- Radiation technique solutions for medical, research and industrial applications, Multipurpose irradiators

INVIA Medical Imaging Solutions

3025 Boardwalk Drive, Suite 200
48108 Ann Arbor, United States

info@inviasolutions.com

http://www.inviasolutions.com

INVIA develops advanced non-invasive nuclear cardiac imaging software for medical professionals to optimize patient care. Physicians use our software, 4DM, to accurately quantify, review, and report cardiac perfusion, function, and anatomy. Twenty-five camera, workstation, EMR and PACS partners provide 4DM integrated with their platform. The stand-alone version can be obtained from some of our partners or direct from INVIA. Originating at the University of Michigan more than twenty-five years ago, we developed 4DM with the patient in mind – enabling physicians around the world to make accurate interpretations. Visit us at INVIA booth to explore 4DM's latest features.

inviscan

5 Rue Georges Guynemer
67120 Altorf (near Strasbourg), France

info@inviscan.fr

http://www.inviscan.fr

Inviscan SAS is a high technology company located in France. inviscan develops and manufactures preclinical imaging systems used in medical research. Products of inviscan include PET/CT and CT systems for imaging rodents and larger animals (NHP), as well as novel MRI compatible PET technology.
Inviscan is the original manufacturer of IRIS PET/CT systems and is the leading provider of preclinical PET/CT systems in a number of countries such as France and China. The systems are fully developed by inviscan and manufactured in France.
Inviscan is a highly innovative company with several R&D programs on new technologies and applications. Inviscan is partner in several projects with high profile institutions including CNRS, INSERM, Helmholtz Institute in Germany, as well as CNR and University of Pisa in Italy.

Iotron Medical Inc

55 Madison Ave., Ste. 400
New Jersey, 7960 Morristown, United States

enquiries@copper67.com

http://www.copper67.com

As the first commercial supplier of copper-67, Iotron Medical is committed to improving the quality and accessibility of this radioisotope for the radiopharmaceutical community.
Copper-67 is a proven and effective radioisotope for theranostics, particularly when paired with copper-64. The "perfect paring" of identical elements, differing only by isotope, delivers key advantages over other commonly used isotopes, including:

- Identical in-vivo behavior (imaging and therapy)
- Patient dose optimization (personalized medicine)
- Opitimum half-life for small molecules
- Convenient off-site central manufacturing
- No reliance on nuclear reactors for production

Through our partnership with Canadian Isotope Innovation Corp., Iotron Medical is supplying copper-67 to the US, Canada, and Europe, facilitating the development of next generation theranostics. For more information, please visit www.copper67.com.

IRE ELiT

Avenue de l'Espérance, 1
B - 6220 Fleurus, Belgium

marketing@ire.eu

https://www.ire.eu/en

IRE ELiT, the Institute for Radioelement innovation subsidiary, is a radiopharmaceutical company founded in 2010 to develop radiopharmaceutical drugs used in molecular imaging and therapy. Its main product is a Ge-68/Ga-68 generator, a simple and innovative PET imaging solution used, mainly, for NET tumors and recurrent prostate cancers.

Isotope JSC

Pogodinskaya, 22
119435 Moscow, Russia

isotop@isotop.ru

http://www.isotop.ru/en

Isotope JSC has been delivering radioactive and stable isotopes for all major applications for 65 years. Our production facilities are equipped with fission, cyclotron, electromagnetic and gas centrifuge technologies enabling the production of a broad product range for more than 750 clients from about 50 countries.

We provide a wide variety of isotope-based products, including radiopharmaceuticals, medical generators, sealed radioactive sources, stable isotopes and raw material. Our isotope products are delivered by air, sea and land worldwide.

Isotopia Molecular Imaging Ltd.

Alexander Yanai 39
4927735 Petach Tikva, Israel

gbader@isotopia.co.il

https://isotopia-global.com

Isotopia aspired to be the world leader and innovative company in nuclear medicine by providing meaningful medical care for patients globally.

Our flagship product, the radioisotope Lutetium-177 (both C.A and N.C.A), has attracted considerable attention and exhibited great promise in treating a variety of late-stage cancers, including metastatic prostate cancer and neuroendocrine tumours.

Our production facilities include an advanced nuclear pharmacy that provides radionuclide-labeled compounds for PET/SPECT imaging, a cyclotron facility, and an aseptic manufacturing plant that also offers contract manufacturing services (CMO).

Our customer services are available round the clock to provide thorough and meticulous guidance and support.

Consistent and sustainable supply of Lutetium 177!

Ensuring our services are efficiently available globally, we're establishing additional production facilities in Europe and North America.

As we continue to take big strides towards becoming a prominent global supplier to the radiopharmaceutical industry, while maintaining the personal touch of a local partner, we remain focused on fulfilling the promise of nuclear medicine for advanced personalized cancer care.

ITEL Telecomunicazioni SRL

Z.I. snc, Via Antonio Labriola
70037 Ruvo di Puglia BA, Italy

itel@itelte.it

https://itelpharma.com

Itelpharma is a radiopharmaceutical company part of italian healthcare company ITEL Group. It has been established as a GMP (Good Manufacturing Practice) certified pharmaceutical facility authorized by the Italian Drug Agency (AIFA). We produce radiopharmaceuticals for imaging diagnostics, which detect diseases in the fields of oncology, neurology and cardiology, with two production lines that can operate simultaneously. Itelpharma is recognized as one of the most trusted radiopharmaceutical manufacturers and suppliers.

In addition to marketing our own radiopharmaceuticals, we are also contractors in the production and distribution of radiopharmaceuticals owned by other big pharmaceutical companies. At Itelpharma we have completely managed the design and implementation of our radiopharmaceutical production facility with two cyclotrons and an in-house microbiological laboratory.

In over 10 years of activity, we have perfectioned our specilizations and competences along with growing our full operations not only in manufacturing but also in research and radiopharmaceutical development. Above all, throughout this time, we have enhanced our scientific, technical, regulatory and commercial skills.

We work in compliance with the best quality standards in microbiology and nuclear medicine, expanding and increasing the pipeline of molecular products and the services offer

ITM Isotope Technologies Munich SE

Walther von Dyck Strasse 4
85748 Garching, Germany

info@itm-radiopharma.com

https://www.itm-radiopharma.com/home

ITM, a leading radiopharmaceutical biotech company, is dedicated to providing a new generation of radiomolecular precision therapeutics and diagnostics for hard-to-treat tumors. We aim to meet the needs of cancer patients, clinicians and our partners through excellence in development, production and global supply. With improved patient benefit as the driving principle for all we do, ITM advances a broad precision oncology pipeline, including two phase III studies, combining the company's high-quality radioisotopes with a range of targeting molecules. By leveraging our nearly two decades of pioneering radiopharma expertise, central industry position and established global network, ITM strives to provide patients with more effective targeted treatment to improve clinical outcome and quality of life.

Jiangsu Huayi Technology Co., Ltd.

18 Fuyu Road, Haiyu Town
215522 Changshu City, China

antony@huayi-isotopes.com

http://www.huayitec.net

Jiangsu Huayi Technology Co., Ltd. is a fully integrated provider of radiopharmaceuticals in China. We develop, manufacture, and distribute high-quality radiopharmaceutical products. CDMO services are offered to our global clients. We support projects from initial research phase to commercial production.

One of the divisions, Huayi Isotopes Co. (HIC), manufactures and distributes stable isotopes, PET and SPECT precursors, reagents kits, cassettes, and sterile vials etc. Products of HIC are supplied to clients around the world.

We are client-oriented and determined to build and foster long-term partnerships with our clients. Since the company was established in 2001, we have been dedicated to serving the nuclear medicine industry. Since 2014, we have been setting up nuclear medicine manufacturing sites strategically. Our integrated radiopharmaceutical manufacturing and distribution network will enable us to reach most of the patients in China.

Follow us on LinkedIn, Twitter, Facebook, for the latest news

Products and Services

- Radiopharmaceuticals
- CDMO Services for Radiopharmaceuticals
- O-18 Water
- Total Solutions for PET Consumables
- Biochemicals
- Sterile Vials
- CMO Services (API, Reagents Kit & Cassettes, FIll/ Finish)

Jubilant Radiopharma

790 Township Line Road, Suite 325
19067 Yardley, United States

jocelyn.polk@jubl.com

http://www.jubilantradiopharma.com

Jubilant Radiopharma is an industry leading radiopharmaceutical company committed to driving the value of cardiac PET as a vital imaging modality. We recognize the important role cardiac PET plays in evaluating cardiac physiology and function. We deliver better clinical outcomes as a result of our investment into our pipeline, infrastructure, and people—all of whom are driven by their uncompromised passion and dedication to the utility and sustainability of nuclear medicine. Jubilant Radiopharma is focused on developing, manufacturing, commercializing and distributing high quality and sustainable diagnostic and therapeutic agents for the sole purpose of "Improving Lives through Nuclear Medicine" on a global scale.

In the EEA, Jubilant partners with Cyclomedica to provide expanded access to next-generation PET products for enhanced diagnosis and management of patients with known or suspected coronary artery disease.

Jubilant is exhibiting alongside our Cyclomedia partner in Booth #401 at this year's EANM meeting. Please stop by our booth to learn more about the latest advancements in Cardiac PET imaging, and see how we can help you enhance your cardiac practice. For more information, please contact customer service at customerservice@jdi.jubl.com.

LabLogic Systems Ltd.

Innovation House, 6 Europa View
S9 1XH Sheffield, United Kingdom

solutions@lablogic.com

https://lablogic.com

LabLogic has over 35 years'experience of designing and manufacturing instruments and software for PET and Nuclear Medicine applications.

We will be showcasing our Tracer-QC system at EANM'23. Developed in conjunction with TraceAbility this instrument is already being seen as the future of PET QC. Certainly TraceAbility's years of experience in the PET industry, combined with LabLogic's expertise in software development, has created a unique instrument which can perform the essential PET QC tests with just 'single touch' operation and all in compliance with FDA 21 CFR Part 11 (Electronic Signatures) and Part 212 (GMP) regulations.

Our range of market leading products for PET and Nuclear Medicine applications also includes QC equipment such as r-TLC and r-HPLC instruments plus our single point of control radiochromatography software package – Laura for PET. The complete QC package is also available from LabLogic.

Furthermore we offer dedicated LIMS systems for PET and Nuclear medicine applications. PETra, a PET LIMS system designed to improve efficiency and compliance, SPECTra, a dedicated Radiopharmacy LIMS, and Orla, an online radiopharmaceutical order communication system.

Visit our booth #207 at the show to see demonstrations of the Tracer-QC and other products in our nuclear medicine range.

Lemer Pax

72 rue de Lorraine, ZA Erdre Active - Malabry
BP 54201, 44242 La Chapelle-sur-Erdre, France

contact@lemerpax.com

https://www.lemerpax.com/en

Worldwide leader in innovation in the radiation protection sector, Lemer Pax creates, designs, and engineers efficient radiation protection solutions for medical, research, industry, and nuclear applications.
With over 50 years of innovation, Lemer Pax exports all over the world, eco-aware and cutting edge of technology radiation protection products. Lemer Pax, protecting life, we strive for excellence to protect the most important thing: Life!

Medi-Radiopharma Ltd.

Szamos u. 10-12.
2030 Érd, Hungary

order@mediradiopharma.hu

https://www.mediradiopharma.com

Medi-Radiopharma (MRP) has more than 25 years of experience in developing, manufacturing, and supplying radiopharmaceutical products to customers around the globe. Our purpose is to serve the healthcare and improve patient outcomes through a wide portfolio of high-quality products. MRP specializes in the production and supply of generic in-vivo kits for Tc99m labelling used in nuclear medicine. By potentially enabling accurate early diagnosis and treatment of cancer, as well as heart, brain and bone diseases, our world-class products – registered in more than 80 countries worldwide - empower our customers with effective treatment and proven patient outcomes. We are also involved in the development of therapeutic radiopharmaceuticals. MRP holds valid Manufacturer's Authorization, Certificate of GMP Compliance of a Manufacturer, Wholesale Distribution Authorization, Certificate of GDP Compliance of a Wholesaler Distributor, GLP and ISO Certificate and relevant authorization for the manufacture and wholesale distribution of radiopharmaceuticals.

Mediso Ltd.

Laborc u. 3.
1037 Budapest, Hungary

sales@mediso.com

https://mediso.com

Mediso is a leading supplier of nuclear medicine hybrid imaging techniques for health care and research institutions of the world.
Mediso has a complete profile of development, manufacturing, selling and servicing of multi-modality molecular imaging systems. With over 30-year expertise and 1,350+ clinical installation Mediso offers solutions from imaging devices to evaluation and quantification software for both patient care and scientific research.
Besides a unique triple modality SPECT/CT/PET system, the AnyScan® TRIO family utilizes a triple head SPECT design and dedicated multi-pinhole collimation technology to achieve unparalleled sensitivity and quantitation accuracy especially for neuro- and cardiac imaging and for theranostic applications.
Mediso has a leader position in the preclinical nuclear imaging market with over 300 commissioned systems around the world. Beyond the market leading nanoScan® PET/CT and SPECT/CT, Mediso also offers standalone MRI and integrated PET/MRI systems based on a cryogen-free magnet with 3T or 7T field strength and a PET insert for simultaneous PET/MRI imaging.
Products are sold directly or through a distribution network in 100+ countries worldwide.

MEDraysintell

Chemin du Cyclotron 6
B - 1348 Louvain-la-Neuve, Belgium

peg@medraysintell.com

https://www.medraysintell.com

In Nuclear Medicine, we provide reports and directories with an exhaustive description and analysis of marketed radiopharmaceuticals, radiopharmaceuticals under clinical development, and radiopharmaceuticals under preclinical development, thru a description of about 970 products, together with a comprehensive profile of 380 companies active in nuclear medicine.
Plus a complete review of the Cyclotrons used in Nuclear Medicine worldwide.

MedTrace Pharma A/S

Agern Allé 5A
2970 Hørsholm, Denmark

connect@medtrace.dk

https://medtrace.dk

MedTrace Pharma A/S is a development stage pharma and device company and an innovator in PET diagnostic imaging. The company is working on a solution to help healthcare professionals diagnose patients better and faster via ^{15}O-water PET. Leading hospitals in the US, Europe and Japan are close partners.
In March 2022, MedTrace received FDA approval of the company's Investigational New Drug application and the approval to commence its RAPID-WATER-FLOW Phase 3 Clinical Trial to evaluate the use of ^{15}O-water PET in diagnosing Coronary Artery Disease. Two months later, MedTrace announced that it had scanned the first subject. Meanwhile, the company is preparing for regulatory clearance in the EU.
Our solution consists of:
1) the P3 system, which is a point-of-care cGMP-compliant chemistry lab combining the process of manufacturing and injecting ^{15}O-water into the patient.
2) the analytical software aQuant, which produces images combined with quantitative data of the PET scan.

At the same time, MedTrace is exploring clinical applications outside of cardiology and looking into research areas such as oncology and neurology.
MedTrace, headquartered in Hørsholm, Denmark, and office in Minneapolis, US, is employing +35 people.
Brands: MedTrace Pharma, P3 System ^{15}O-water system, aQuant cardiac analytical software

MIAS Pharma

Stafford house, Suite 1, Strand Road
Portmarnock, D13 H525 Dublin, Ireland

info@miaspharma.com

https://miaspharma.com

MIAS Pharma Ltd was set up in 2016 to enable Pharma / Bio-Pharma companies to manufacture and import products into the EU / EEA in a compliant manner, at optimal cost, with no significant investment in licence application activities or office / personnel costs.
MIAS Pharma delivers two main solutions:
1. A licensing framework to enable pharmaceutical importation and batch certification (required before each batch of a medicine can be made available in the EU/EEA marketplace)
2. Qualified Person (QP) services to oversee the release of investigational medicinal product for Clinical Trials and commercial product to the market.

MIAS Pharma also provide oversight of:
1. European Qualified Person (QP) services
2. Regulatory compliance of manufacturing activities
4. Regulatory compliance of Repackaging / Relabelling services
5. Regulatory compliance of Shipment and Transportation activities
6. Compliance with responsibilities as a Market Authorisation Holder (MAH)

MIAS operates in a hub and spoke model with a core group of MIAS employee being able to rely on a group of associated to flex up/down capacity depending on clients requirements.

MILabs B.V.

Duwboot 7A,
3991CD Houten, Netherlands

marketing@milabs.com

https://www.milabs.com

MILabs provides high-performance standalone and integrated SPECT, PET, CT, and, Optical Imaging systems for molecular imaging and in vivo imaging research. Our multimodal imaging technology with four-dimensional imaging capabilities enables researchers to improve diagnostics and therapy development through complementary, data-rich, co-registered images. Each modality by itself gives data beyond the capabilities of any other stand-alone system.
Our mission is to make molecular imaging clear. Through our continuous innovation and supportive service, the team at MILabs is dedicated to 'providing small details for big discoveries' for a wide range of imaging research programs. With over 100 installations worldwide, our fast-growing company collaborates with leading universities, hospitals, contract research organizations, and pharmaceutical companies. Our systems contribute significantly to developing new diagnostic solutions and therapies for diseases such as diabetes, cancer, and cardiac and neurodegenerative diseases.
Explore how our cutting-edge preclinical imaging and technologies can accelerate research discoveries at www.milabs.com.

MIM Software Inc.

25800 Science Park Dr., Ste 180
44122 Cleveland, United States

info@mimsoftware.com

http://www.mimsoftware.com

MIM Software Inc. offers a comprehensive suite of applications that support Radiology and Nuclear Medicine's important role in cancer care. MIM Software products excel in Theranostics and emphasize the importance of quantitation, collaboration, and data management to provide physicians with crucial information to generate confident clinical guidance and inform effective treatments.
MIM Software drives your nuclear medicine workflow with comprehensive support for standard nuclear medicine studies, emerging radiotracers, neuro and cardiac imaging. MIM SurePlan™ offers tools to support the feasibility of molecular radiotherapy dosimetry and Y90 therapy within the busy Nuclear Medicine workflow. Quantitative images are needed to calculate accurate dosimetry, and MIM SPECTRA Quant™ provides a vendor-neutral SPECT reconstruction method that pairs dynamically with existing SPECT/CT cameras.
MIM Assistant® automates traditional clinical tasks and centralizes images and related data to a single repository. Flexible deployment options allow easy access to MIM Software from anywhere. The result is greater access to critical patient information in collaborative settings like tumor boards or for use in dictated reports.

MNT Healthcare Services Inc

19 Mayıs Mah. Dr.Şevkey Bey Sk. No:5 Şişli
34360 Istanbul, Türkiye

rita.lazo@mnt.com.tr

http://www.mnt.com.tr

Since 1990, MNT has been providing professional nuclear medicine and radiation oncology solutions to healthcare organizations. Currently, MNT operates 63 centers in Türkiye and 9 centers in Europe, offering specialized diagnostic and therapeutic services throughout all stages of nuclear medicine and radiation oncology.
With a dynamic and innovative approach, MNT is recognized as one of the most experienced healthcare service providers in the field. Its services reach patients in numerous NM and RT Centers within universities, state hospitals, and private hospitals. MNT also directly caters to cancer patients through its own branded centers, Neolife. Neolife is rapidly expanding its global presence and establishing itself as a formidable international brand. MNT operates 6 Neolife centers in Romania, 1 center in Moldova, and 2 centers in Bulgaria. Additionally, MNT is actively pursuing further projects in Africa, the Balkans, the Middle East, and Central Asia.
MNT adheres to the gold standards in medicine and leads in theragnostic applications. By utilizing cutting-edge technology, such as advanced imaging, molecular probes, and minimal radiation doses, MNT enables precise diagnosis and targeted therapies across its centers.
MNT ensures the smooth and timely completion of turn-key projects by offering the following services:

- Project Design and Installation
- Equipment Investment and Maintenance
- Personnel Recruitment
- Radiation Safety and Training
- Project Management

MNT Kwint International BV

Suze Groenewegstraat 11
production: Industrieweg 6a waardenburg
4105EM Culemborg, Netherlands

geert@mnt-int.com

http://www.mnt-int.com

Turnkey producer for complete Isotope facilities in hospitals & institutes, from GMP planning till realization for use of Mo-99 Tc Generator, I-131/ Ru-Kr or FDG- Ga68 facilities and also shielded accessories.
Turnkey producer for complete Therapy departments, including vacuum wastewater facilities. In 2019, Kwint International has successfully built and put into operation the world's biggest unit (28 therapy rooms);
MNT International is the founding father of the so called 'golden standard' in hot labs for the labelling of isotopes. measurement equipment and GMP-Laboratory furniture according to the IAEA regulations combined in one product called "Ultra techneflow shielded Laminar downflow cabinet";
Training of Nuclear medical staff for all S.O.P.'s (standard operating procedures) according rules/ guidelines of the International Atomic Energy Agency (IAEA) and the European Association of Nuclear Medicine (EANM), including support at initial operation phase.

MNX Global Logistics

Long Beach, CA (Corporate HQ) 5000 Airport Plaza Drive, Suite 100
CA 90815 Long Beach, United States

h.vandemaele@be-wis.com

https://www.mnx.com

MNX provides specialized time, temperature and security sensitive transportation and logistics services worldwide.
High standards, high value and high complexity: it's the nature of logistics for the life sciences and healthcare industries.
It takes precision, passion and partnership to transport your healthcare and medical packages around the world.
Our life sciences experience is as deep as our network is wide.

Monrol Nuclear Products Co./S.C. Monrol Europe SRL

Rüzgarlıbahçe Mahallesi Çam Pınarı Sokak
No:3 D:10,11 Beykoz
34805 Istanbul, Türkiye

monrol@monrol.com

https://monrol.com.tr/en

Monrol is one of the world's largest nuclear medicine companies leading innovation for the development and manufacturing of GMP grade radioisotopes and radiopharmaceuticals having headquarters in Istanbul. Monrol is distributing its world-class radiopharmaceutical products portfolio with excellence in global markets. Monrol is a CDMO, providing early development support to its customers as well as offering fully integrated services for today's nimble, lean, virtual companies effectively taking new product concepts into clinical trials, demonstrating proof of concept and going into first-in-human studies.
Monrol is committed to transform and improve patient journey in cancer treatment with its radiopharmaceutical products portfolio distributing to more than 60 countries around the globe. To learn more, visit www.monrol.com and LinkedIn.

MR Solutions Ltd.

Ashbourne House, Old Portsmouth Road
GU3 1LR Guildford, United Kingdom

richard.taylor@mrsolutions.com

https://www.mrsolutions.com

MR SOLUTIONS GROUP develops and manufactures innovative imaging solutions for the research industry. The company offers a large range of products for MR, CT, PET and SPECT. All scanners are interchangeable between each other for multi-modality imaging.
The company is the worldwide leader in high-field cryogen-free MR with its proprietary dry magnet technology. The MRS*DRYMAG product line delivers MR up to 9.4T and a bore size up to 42 cm. Advanced coils and software tools for pulse sequence programming are also available.
The magnet technology has exclusive features such as rotating the system to 90° and the ability to ramp the field of the magnet up and down within minutes. Helium lines and shielded rooms are not required ,to keep installation costs extremely low.
PET/MR imaging is possible up to 9.4T simultaneously. SPECT can be combined with PET/MR for a tri-modality imaging scanner. PET and SPECT scanners are based on our proprietary CLIP-ON technology. They are easily removable from the MR in minutes, and can be plugged straight onto the CT. This avoids the need for numerous scanners and large rooms. Several models of PET/SPECT/CT's are available: Benchtop, high resolution, and very large bore for 12 kg animals.
MR SOLUTIONS can refurbish and enhance all components from any MR.
MR Solutions holds prestigious Queen's awards, the innovation award from the Institute of Physics and is the winner in the global R&D 100 awards.
MR Solutions has offices across the world

Novartis

Forum 1, Novartis Campus
CH-4002 Basel, Switzerland

vida.niksic@novartis.com

https://www.novartis.com

Novartis is reimagining medicine to improve and extend people's lives. We deliver high-value medicines that alleviate society's greatest disease burdens through technology leadership in R&D and novel access approaches. In our quest to find new medicines, we consistently rank among the world's top companies investing in research and development. About 108,000 people of more than 140 nationalities work together to bring Novartis products to nearly 800 million people around the world.

Nulear Medicine Europe eeg

Avenue Louise 65
1050 Brussels, Belgium

david.crunelle@nmeu.org

https://nuclearmedicineeurope.eu

Nuclear Medicine Europe (ex AIPES) represents many of the major pharmaceutical & Imaging equipment companies in the field of Nuclear Medicine in Europe. The combination of radiopharmaceuticals & state-of-the-art imaging permits noninvasive visualization of organs, function & structure within the body. Nuclear medicine is used in the diagnosis, management, treatment & prognosis of diseases across a broad range of medical specialties, such as oncology, cardiovascular & neurology to name a few, and as such is an integral part of patient care.

Nuclear Shields BV

Akkervoortweg 29
5827 AP, Vortum-Mullem, Netherlands

info@nuclear-shields.com

http://www.nuclear-shields.com

Nuclear Shields is a manufacturer of radiation shielding based in the Netherlands with more than 40 years of experience. The production facility is designed to meet the requirements of long term serial production and one-off custom projects. Lines of communication are short due to our small team of sales and engineering personnel. The focus on good and fast communication with the client helps us improve our services every day and makes sure the customer is satisfied.
Nuclear Shields is part of the Van Mullekom Group which was founded in The Netherlands in 1978. All factories share a common ground in engineering and radiation shielding that can be applied to many different industries, such as the healthcare, homeland security and nuclear industry. Nuclear Shields is a seller of a wide range of products regarding the shielding of radioactivity. Our products range from hot lab necessities and radiation shielding, to radiation detection and radiation cleanup solutions.
The In-House capabilities of the Van Mullekom Group range from prototyping to full assembly, which enables us to provide a wide range of solutions for a low price, high quality and with quick customer service. These in-house departments express our capability of manufacturing a wide product range, including the creation of custom-made solutions to fit your needs.

Nucleis

Allée du Six-Août, 8
B - 4000 Liège, Belgium

info@nucleis.eu

https://nucleis.eu

Nucleis is a radiopharmaceutical company manufacturing and distributing Radiopharmaceutical Drugs for Diagnostic and Therapy Monitoring.
Nucleis' portfolio presents Brand name drugs, IMP and CMO activities. This allows Nucleis to reach nuclear medicine services and (radio) pharmaceutical industry.

- GMP Certificate number BE/GMP/2022/114 for Human Medicinal Products
- GMP Certificate number BE/GMP/2022/115 for Human Investigational Medicinal Products
- MIA 1932 H
- MIA 1932 IMP

NUVIA Instruments GmbH

Dornblüthstrasse 14 A
1277 Dresden, Germany

kontakt@nuvia.com

https://www.nuviatech-healthcare.com

NUVIA Instruments GmbH is the new name of MED Nuklear-Medizintechnik Dresden GmbH and member of the NUVIA Group since 2014.
With 2 sites in Dresden and Dülmen, NUVIA Instruments GmbH designs and manufactures laboratory counters and radiation monitoring systems for nuclear medicine, PET-centres and therapy stations:

- Dose Calibrators
- Thyroid Uptake-Counters, Incorporation Counters, Well-Counters, Waste Water Counters
- Patient and Area Monitoring Systems
- Contamination Monitors (portable and hand-foot-clothing monitors)
- Waste and Release Monitors
- Laboratory Furniture (standard and customized)

About the NUVIA Group:
NUVIA is the nuclear branch of Soletanche Freyssinet, a subsidiary of Vinci Construction Group. Even though the NUVIA name was created in 2007, its history goes back to the beginning of the French and British nuclear industry. Today, with more than 30 years of experience and approx. 3,000 employees worldwide, the NUVIA Group offers engineering, services and products at all stages of a nuclear facility's lifecycle: design, construction, operations, maintenance, decommissioning. The NUVIATECH HEALTHCARE brand was created in 2017 to offer the Group's complete portfolio of instruments, systems and solutions for healthcare applications.
For more information about the NUVIA Group and its activities in the healthcare sector, you are welcome to visit us in The Pavilion!

Oncidium Foundation

Av. Herrmann-Debroux, 40
B - 1160 Brussels, Belgium

contact@oncidium-life.org

https://www.oncidiumfoundation.org

The Oncidium foundation is dedicated to support the development of radiotheranostics (RLT) for cancer care.
3 pillars:

- ACCESS through a wide network of ambassador experts and a worlwide map of therapy centers.
- EDUCATION & awareness are essential as it helps to bring a better understanding of the functioning & benefits of RLT.
- HOPE – The foundation is evaluating all possibilities to support clinical developments of efficient RLT & individual cases to reduce treatment overall costs in low-income countries.

Come and meet us !

Oncobeta GmbH

Schleißheimer Str. 91
85748 Garching bei München, Germany

info@oncobeta.com

https://www.oncobeta.com

OncoBeta® GmbH with its headquarters located in Garching, near Munich, is a privately held medical device and radiochemical company specialized in the development and commercialization of state-of-the-art, innovative skin cancer therapies utilizing epidermal radioisotope applications. Since its foundation, OncoBeta® GmbH has concentrated its efforts on the development, regulatory approval(s) and commercialization of the epidermal radioisotope therapy Rhenium-SCT® (Skin Cancer Therapy), targeting non-melanoma skin cancers. Since then, OncoBeta® has successfully perfected the customized application and device management system in conformity with all health, safety, and environmental protection regulatory standards. OncoBeta® GmbH is European CE certified, TGA-Australia approved and certified by SAPHRA – South Africa. Furthermore, having the patient in focus, OncoBeta® is enthusiastically working with medical, scientific and industrial partners as well as local and national authorities to make this personalized, painless and non-invasive therapy accessible to patients all over the world. The Rhenium-SCT® significantly improves outcomes and the quality of life of non-melanoma skin cancer patients.

ONCODESIGN SERVICES

20 rue Jean Mazen
21000 Dijon, France

contact@oncodesign-services.com

https://www.oncodesign-services.com

Oncodesign Services is a Contract research organization (CRO) specializing in drug discovery and preclinical services. From target identification to IND filing, the company contributes to the development of innovative therapies in oncology, inflammation and infectious diseases, with high medical needs.
Through integrated capabilities in medicinal chemistry, DMPK, pharmaco-imaging, bioanalysis, in vivo/In vitro pharmacology, Oncodesign Services support the R&D programs of customers with a global footprint.
Based in Dijon, France, in the heart of the university and hospital cluster and within the Paris-Saclay cluster, Oncodesign Services has 230 employees in France, Canada and the United States.

OncoSil Medical Europe GmbH

Suite 503, Level 5, 15 Blue Street
NSW 2060 North Sydney, Australia

info@oncosil.com

http://www.oncosil.com

OncoSil Medical is a global medical device company focused on Interventional Oncology. Our mission is to improve the outcomes for people living with cancer by utilising selective and targeted intratumoral placement of Phosphorous 32 (32P) Microparticles.
OncoSil™ is a single-use brachytherapy device that has received breakthrough device designation in the European Union, United Kingdom and the United States for the treatment of unresectable locally advanced pancreatic cancer in combination with chemotherapy.
OncoSil™ comprises of Phosphorous-32 (32P) Microparticles suspended in a specially formulated Diluent. The Microparticles are a permanent implant which contain Phosphorous-32 (32P), a pure beta-emitter radioisotope with a physical half-life of 14.27 days. In therapeutic use, 98% of the radiation is delivered within 81 days, which gives an absorbed does equivalent to 100 Gy.

Pars Isotope Co.

PARS ISOTOPE Co., No. 88, West 23rd St.,
Azadegan Blvd., South Sheikh Bahaie Ave.
1439955416 Tehran, Iran

info@parsisotope.com

https://parsisotope.com

Pars Isotope Co. is the only producer and supplier of radiopharmaceuticals and radiopharmaceutical kits in Iran. Pars Isotope produces more than 50 different types of diagnostic (SPECT & PET) and therapeutic products in the field of nuclear medicine. Among our valuable products, we can mention Tc-99m and Ga-68 generators, which are known under the brand names of PARS-TEC II and PARS-GalluGen, respectively. Also, the variety of our radiopharmaceutical kits reaches more than 20 different types.
In order to improve the quality and quantity of medical products based on cGMP regulations, Pars Isotope participates in a project to implement new modern RRP, CKP and PET facilities in Iran. In addition, we focus on the following activities according to our profession and abilities:

- Production of more than 20 types of Tc-99m radiopharmaceutical kits.
- Production of 4 types of radionuclide generators to be used in PET & SPECT imaging.
- Production of new ready to use PET radiopharmaceuticals.
- Production of more than 22 ready to use theranostic, bone pain palliation and radio-synovectomy radiopharmaceuticals.
- Development and optimization of separation methods for different types of radioisotopes used in the production of radiopharmaceuticals.
- Development and optimization of advanced methodologies in the production of new radiopharmaceuticals.
- Production and development of industrial radioisotopes and radiation equipment used in various industries.

PBL Srl.

Via Alessandro Volta, 8
43046 Rubbiano di Solignano, Italy

annagiulia.bifani@pblsrl.it

https://www.pbl.it

PBL was born from an enterpreneurial investment started in 1979, when the first automation solutions for the beverage, chemical and pharmaceutical sectors were designed, built and installed.
The experience gained in over 40 years of technological research has allowed PBL to consolidate its position in the markets of interest, gaining the trust of new customers around the world.
PBL is investing in three main fields:
PHARMA DIVISION
We offer flexibility, innovation, technical expertise, and value on your investments for pharma, radio-pharma, and cosmetic custom solutions applied to primary and secondary packaging.
CONSUMER DIVISION
We design and supply filling and packaging lines for single-serve coffee pods. These lines can satisfy any client request and promptly react to the continuous market developments.
HEALTHCARE DIVISION
Our expertise in Artificial Intelligence and Deep Learning is offered to companies in need of dedicated industrial solutions based on innovative and efficient technologies.

PentixaPharm GmbH

Bismarkstraße 13
97080 Würzburg, Germany

info@pentixapharm.com

https://pentixapharm.com

PentixaPharm, an Eckert & Ziegler AG subsidiary, is developing the innovative theranostic pair PentixaFor and PentixaTher. These two peptide-based radiopharmaceuticals specifically target the CXCR4-receptor, which is overexpressed in many hematological diseases as well as various other indications.
The aim is to develop a specific diagnostic PET / CT tracer linked to Gallium-68, called PentixaFor for accurate identification and localization of CXCR4 overexpressing tumors. The therapeutic agent PentixaTher binds to the same receptor as the diagnostic agent but is linked to a stronger radiating nuclide (Yttrium-90). Therefore, PentixaTher has the potential to precisely destroy the targeted lesions. Both products are currently under clinical development.

PI Medical Diagnostic Equipment B.V.

Forellenweg 7
4941 SJ, Raamsdonksveer, Netherlands

info@pi-medical.nl

http://www.pi-medical.nl

PI Medical offers a wide range of instruments and accessories for the nuclear medicine market. The product range includes FDG dispensing systems, dose calibrators, contamination and radiation monitors, PET and SPECT phantoms, calibration sources and other QA devices, radiation shielding materials, Surgical equipment, Breast cancer localization products, patient positioning devices, etc.
PI Medical is stands for high quality products and a high quality service.
With our own Service department, all highly trained and educated, we can provide the best service, support and advice to our end users.
Together with our partners, we can give you the best products and service for your needs.
PI Medical Diagnostic Equipment B.V. – a Medical Imaging Specialist !

PMB-ALCEN

CD 56, Route des Michels, Lieu-dit
"La Corneirelle", 13790 Peynier, France

contact@pmb-alcen.com

https://www.pmb-alcen.com

PMB is a human-sized company based in France, with a long-standing expertise in brazing dissimilar materials and specialized in the design and manufacture of complex assemblies and sub-assemblies (RF and beamline components, components
for X-ray tubes, ceramic-metal assemblies…), as well as particle accelerators and disruptive medical systems :

- iMiGiNE is an automated radiopharmaceutical production system for PET imaging and Theranostics. The system combines a cyclotron (iMiTRACE) with a robotized radiochemistry room (iMiLAB).
- iMiDEV is a Microfluidic Synthesizer designed for R&D and preclinical studies.

POLATOM, Radioisotope Centre of National Centre for Nuclear Research

Andrzeja Sołtana 7
05-400 Otwock, Poland

polatom@polatom.pl

http://www.polatom.pl

NCBJ Radioisotope Center POLATOM is a Polish producer and distributor of isotope preparations used in medicine, science, industry and environmental protection. It also conducts research and development works of an application nature and concern radiopharmacy, chemistry and nuclear technology as well as scientific disciplines such as radiochemistry, biochemistry, and immunology, resulting in development of our own products and technologies.
Our offer for nuclear medicine includes:

- ready-made radiopharmaceuticals, used in cancer therapy and in the treatment of benign thyroid diseases;
- technetium scintigraphy kits used in oncological diagnostics, intended for imaging of: kidneys, liver, bile ducts, spleen, heart, bones;
- labeling precursors;
- radionuclide generators 99mTc;
- accessories necessary in Departments of Nuclear Medicine;
- as well as various GMP and GMP compliant products and components for medical research.

NCBJ Radioisotope Center POLATOM holds the ISO 9001:2015 Quality System Certificate and the Internal Control System for trade in dual-use goods, as well as a Certificate confirming compliance with the GMP requirements. Moreover, in our Radioactivity Standards Laboratory, a management system compliant with the international standard ISO/IEC 17025:2018 has been implemented and maintained. Our RSL's technical competence – as a calibration laboratory – is confirmed by the accreditation certificate AP 120 granted by the Polish Center for Accreditation.

Positrigo AG

Technoparkstrasse 1
8005 Zurich, Switzerland

info@positrigo.com

http://www.positrigo.com

Positrigo is a pioneer in nuclear medical imaging technologies. Headquartered in Switzerland, the medical device company was founded in 2018. NeuroLF® - the company's first device - is an ultra-compact brain PET scanner which has applications in assessment of causes of dementias, such as Alzheimer's disease and other brain related disorders.

QUBIO

Olmos 5, 2
15003 A Coruña, Spain

manuel@qubiotech.com

https://qubiotech.com

At Qubiotech we develop software assisted by artificial intelligence for automatic and advanced neuroimaging analysis: Neurocloud, a CE marked tool for the quantification of biomarkers in neurodegenerative diseases, which quickly, accurately and efficiently helps the physician (radiologist, neurologist and nuclear medicine) in the diagnosis and monitoring of the patient providing a complete report of the results in a few minutes.

Neurocloud stands out for its experience of use and its clinically validated results (CE marked and FDA in progress) that help in the early diagnosis and follow-up of diseases such as Multiple Sclerosis, Epilepsy, Parkinson or Alzheimer.

Neurocloud's quantification allows moving from subjective assessments, which depend on the observer, to quantitative, reproducible assessments, and therefore members of the same team can reach the same results with certainty.

Qubiotech was born in the Neuroimaging Group of the University Hospital of Santiago de Compostela with the aim of bringing innovation in molecular image analysis to real clinical practice and also at a very low cost compared to the alternatives we had so far.

Welcome to Augmented Neuroimaging. Welcome to Qubiotech.

RADIOPROTECH

12 chemin des Gorges
69570 Dardilly, France

contact@radioprotech.com

http://www.radioprotech.com

Radiation protection equipment for Nuclear Medicine department. Designed and made in France. Our products range cover all radioprotection needs from the arrival of the radiopharmaceutical until its disposal.

Rotem GmbH

Franz-Flemming-Str. 39A
4179 Leipzig, Germany

info@rotem-eu.de

https://rotem-medical.com

Rotem, a longtime global leader in consumables for PET imaging, supplies cyclotrons around the world with complete packages for radiotracer production.

Our product range is centered on Oxygen-18 enriched water, plastic cassettes, precursors and complete reagent kits for various synthesis modules. All products are manufactured in compliance with cGMP requirements according to EU & PIC/S and are produced in our US FDA-inspected facility. Rotem's cGMP certified Mannose Triflate holds a certificate of suitability from the EDQM.

Production is supported by Rotem's in-house certified analytical laboratory which has a wide array of equipment and QC method development capabilities. Our highly skilled staff provides users with comprehensive technical and regulatory support as well as excellent customer service.

Rotem is particularly active in the design and production of consumables for radiotracers under development. These projects benefit from our interdisciplinary expertise, which is the result of many years of close collaboration with radiopharmaceutical companies worldwide.

Rotem GmbH in Leipzig serves customers in Europe, with local representatives in the U.K. and Ireland.

Other divisions in Rotem specialize in the development, production marketing and distribution of radiation detection monitoring equipment and decommissioning technology.

ROTOP Pharmaka GmbH

Bautzner Landstraße 400
1328 Dresden, Germany

j.neubert@rotop-pharmaka.de

http://www.rotop-pharmaka.com

With its many years of experience and its business location at the Helmholtz research site, ROTOP Pharmaka GmbH offers a modern pharmaceutical company with GMP compliant services.
Experience includes API/Cold Kit/ Radiopharmaceutical development, cGMP manufacturing, marketing authorizations and worldwide distribution. ROTOP continuously expands its product portfolio by developing new products and entering new strategic partnerships. Furthermore, ROTOP offers a broad range of CDMO services. At every stage from the idea to your own product, we are happy to assist you with our broad knowledge and many years of experience. For more information about our products and services visit: www.rotop-pharmaka.com

RQS Alexander Ruffani

Kantstrasse 15
1809 Heidenau, Germany

info@rqs-ar.com

http://www.rqs-ar.com

RQS Alexander Ruffani was founded in 2017 and has years of experience in radiochemistry, radiopharmacy and analytical instrumentation.
A growing team of experienced and motivated professionals with expertise in synthesis development, radiochemistry, GMP-compliant production processes and chromatography instrumentation will help you find the best possible solution for your work application.
In 2020, RQS expanded to the USA and established Ruffani Quality Solutions, LLC. to provide timely and flexible local service. Our colleagues are specialized in the planning of production facilities as well as their construction, for this purpose they have been involved in several projects especially on the East Coast.
The team is ready to support you with all your requests and is looking forward to get in contact with you.
Thanks to deep experience in the various fields of nuclear medicine and radiochemistry, it is possible to offer a wide range of services of the highest quality.

- Support in laboratory planning, construction and commissioning
- Qualification, maintenance and repair of instruments for the production of (radio-) pharmaceuticals
- GMP documentation for radiopharmacy for quality management system
- Method development for various syntheses and quality control processes in radiopharmacy
- Validation of methods in production and quality control

Scannix

Rue du Mont d'Orcq 3
B - 7503 Froyennes, Belgium

info@scannix.com

https://www.scannix.com

Scannix is specialized in the development and sales of nuclear spectroscopy equipment and radioprotection systems. Scannix offers a wide range of measurement devices in order to maintain safety of staff, assess the health of nuclear facilities and safeguard the public and the environment.

SCINTOMICS Molecular, att GmbH

Lindach 4
82256 Fürstenfeldbruck, Germany

info@sci-att.com

https://sci-att.com

Scintomics Molecular, Applied Theranostics Technologies (SCI-att), established in 2018, is a prominent and fast-growing player in the radiopharmaceutical industry. With a strategic focus on ensuring a consistent supply and comprehensive support for proprietary and innovative tracer technology and non-IP protected precursors, such as PSMA I&T and next-generation PSMA inhibitors like siPSMA-14 and SiFAlinTATE, SCI-att stands at the forefront of cutting-edge theranostics solutions.
As a subsidiary of Scintomics GmbH, SCI-att took over the prestigious GRP Module Series in 2020, further enhancing our capabilities and product offerings. We are dedicated to expanding our portfolio and providing our customers with an unparalleled portfolio of products and services. At SCI-att, we pride ourselves on delivering top-notch quality and exceptional customer support. We invite you to visit us at booth 249, where our knowledgeable team will be delighted to share information about our latest and exciting projects. Join us in shaping the future of theranostics as we look forward to welcoming you at our booth.

SHINE Medical Technologies, LLC

3400 Innovation Court
53546 Janesville, United States

lauratzakis@shinefusion.com

http://www.shinefusion.com

Based in Janesville, Wisconsin, SHINE Technologies is a next-generation fusion technology company, deploying safe, cost-effective and environmentally friendly systems for use in industrial imaging of components across aerospace, defense, transport, medicine, energy and more. SHINE's proprietary isotope production processes create both molybdenum-99 and n.c.a. lutetium-177, each of which are used in diagnostic and therapeutic medical procedures. SHINE is currently producing n.c.a. Lu-177, has a Drug Master File in place with the U.S. Food and Drug Administration and is rapidly scaling its production capabilities. It is also currently constructing a 43,000-square-foot facility that will be dedicated to producing fusion-based medical isotopes like Mo-99. SHINE plans to scale its fusion technology to recycle nuclear waste and to generate fusion power to deliver clean, abundant energy that could transform life on Earth. Learn more at www.shinefusion.com

Siemens Healthineers

Henkestrasse 127.
91052 Erlangen, Germany

maurice.koehr@siemens-healthineers.com

https://www.siemens-healthineers.com/molecular-imaging

At Siemens Healthineers, we pioneer breakthroughs in healthcare. For everyone. Everywhere. By constantly bringing breakthrough innovations to market, we enable healthcare professionals to deliver high-quality care, leading to the best possible outcome for patients.
Our portfolio, spanning from in-vitro and in-vivo diagnostics to image-guided therapy and innovative cancer care, is crucial for clinical decision-making and treatment pathways. With our strengths in patient twinning, precision therapy, as well as digital, data, and artificial intelligence (AI), we are well positioned to take on the biggest challenges in healthcare. We will continue to build on these strengths to help fight the world's most threatening diseases, improving the quality of outcomes, and enabling access to care.
We are a team of 66,000 highly dedicated employees across more than 70 countries passionately pushing the boundaries of what's possible in healthcare to help improve people's lives around the world.

Sirtex Medical Europe GmbH

Joseph-Schumpeter-Allee 33
53227 Bonn, Germany

jean.le-scel@sirtex.com

https://www.sirtex.com/eu

Sirtex Medical is a global healthcare business with offices in the U.S., Australia, Germany and Singapore, working to improve outcomes in people with cancer. Our current lead product is a targeted radiation therapy for liver cancer called SIR-Spheres® Y-90 resin microspheres.
SIR-Spheres® Y-90 resin microspheres are a medical device used in selective internal radiation therapy (SIRT) for treatment of unresectable hepatocellular carcinoma (HCC) or unresectable metastatic liver tumors from primary colorectal cancer in patients refractory to or intolerant of chemotherapy.

Softway Medical

Arteparc - Batiment D
29 allée Saint-Jean, 13710 Fuveau, France

mbenhammouda@softwaymedical.fr

https://www.softwaymedical.fr

Since 1998 NICESOFT develops innovative software solutions for Medical Imaging departments. We combine zero-footprint Web technology with a high specialization in Nuclear Medicine and Radiology to design applications that can be used in hospitals, private practices or even from home without any installation. Our VENUS product line provides a complete range of solutions, from online appointment booking to a full-Web Viewing & Processing Application Server. Thanks to its Web design, your images and reporting tools can be securely accessed from anywhere, making VENUS the ideal partner to develop teleradiology services. We are the leading RIS provider for Nuclear Medicine departments in France and have also equipped sites across Europe, the US, China and the Middle East. SOFTWAY MEDICAL is a leading cloud base provider of software and services for health institution in Europe. With more than 3,000 client institutions, we cover the entire range of healthcare services in the public and private hospital sectors, as well as in radiology and outpatient medicine, becoming the second largest European player in terms of market share in the EMR sector. Based on web technologies, the SOFTWAY MEDICAL group's solutions enable the entire patient care process to be managed and data to be shared securely between healthcare professionals.

Southern Scientific

Scientific House, The Henfield Business Park
Shoreham Road, BN5 9SL Henfield,
United Kingdom

info@southernscientific.co.uk

https://www.southernscientific.co.uk

Southern Scientific manufacture a range of probes and contamination monitors for medical applications, including the Care Wise C-Trak Apollo Gamma Probe System. This system provides accurate and precise detection of gamma radiation and is used during sentinel node biopsies in breast, melanoma and other types of cancer.
The C-Trak Apollo is the only system on the market allowing wireless or wired connectivity with the same probe. The well-known Omni Probe, provides an optimal balance between directionality and sensitivity. With the Apollo, surgeons can easily switch between wired and wireless eliminating any instrument downtime.
Southern Scientific will showcasing the C-Trak Apollo Gamma Probe System at EANM'23 alongside our range of contamination monitors which include the Radhound and Handhound.
The Radhound monitor is available with a wide range of probes suitable for detecting Alpha, Gamma and Beta isotopes.
The Handhound is a voice-activated hand monitor. All measurements are logged against a user and are easily downloaded to a USB.
Southern Scientific is also a distributor for the Capintec range of products, Digirad single head and cardiac cameras, and the MiE range of general purpose gamma cameras.
We are looking for distributors in certain countries. If you are interested, please visit booth #207 and speak to one of our team.

Spectrum Dynamics Medical Inc.

Rue de Lausanne 31
1110 Morges, Switzerland

info@spectrum-dynamics.com

https://spectrum-dynamics.com

Spectrum Dynamics is spearheading the transformation of Nuclear Medicine from analog to digital technology, enabling clinicians to provide superior healthcare services with improved image quality and efficiency at lower doses.
D-SPECT®: The world's first digital cardiac SPECT system based on Broadview Technology: swiveling CZT digital detectors. It is the platform for advanced applications such as TruCorr Attenuation Correction, TruFlow 3D dynamic SPECT imaging for Myocardial Flow Reserve (MFR) analysis, Simultaneous Dual Isotope Imaging (SDI). TruCorr: a deep learning application to generate attenuation corrected myocardial perfusion images. There is no need for additional CT transmission scan, as TruCorr utilizes the SPECT scan emission data.
VERITON-CT®: The world's first digital 360°CZT-based, ring-shaped gantry design SPECT/CT, with high-resolution 16 or 64 slice CT. It's 80cm wide bore accommodates patients of all sizes. VERITON features TruFlow 3D dynamic SPECT/CT imaging for SPECT MFR, bone, renal, and general studies. VERITON-CT continues to evolve with an energy range up to 400 KeV and multiple peak imaging, providing highest quality and quantitation-ready images.

SYNTHRA GmbH

Albert-Einstein-Ring 21
22761 Hamburg, Germany

info@synthra.com

http://www.synthra.com

Synthra – Desire and Passion for Radio Synthesizer
Synthra is a worldwide leading and specialized manufacturer of branded radio synthesizers and concentrates over 40 years of experiences in the field of targetry radiopharmaceutical production, quality control and lab automation. We are committed to automated production of molecular imaging tracers and continuously provide innovative solutions to facilitate and improve the production of tracers for Positron Emission Tomography (PET). Our portfolio comprises C-11, F-18, N-13, Ga-68, Lu-177, I-123, I-124, I-131 and other radioisotopes. It includes targets, radio synthesizers (including customized modules), quality control equipment, e.g. HPLC, spare parts and service.
Our radio synthesizers combine high performance and efficiency with high flexibility that enable the production of radiopharmaceuticals. All our synthesizer offers an fully automated self-cleaning system which is a far more ecofriendly and a time-efficient feature. Besides the attractive design, our software and synthesizers are highly user-friendly and meet the latest GMP regulations. Most commonly our modules offer an easy possibility to create own sequences for the synthesis of new radiopharmaceuticals.
In addition, we offer preventive maintenance contracts as well as full service contracts for each module and piece of QC equipment on demand.
We are happy to welcome and meet you at our booth in hall X2.

Telix Innovations SA

5 rue de Hermée
4040 Herstal, Belgium

frederic.fantino@telixpharma.com

https://telixpharma.com

Telix is a global commercial-stage biopharmaceutical company focused on the development of therapeutic and diagnostic ("theranostic") radiopharmaceuticals, and a service provider in nuclear medicine, with its European headquarters located in Liège, Belgium.
Telix's targeted radiation imaging and therapy technologies have potential to transform the way clinicians can find and manage cancer and rare diseases, to inform treatment decisions and deliver personalised therapy in areas of major unmet medical need.
With more than 20 clinical studies underway worldwide (including partnered investigator-led studies), Telix's core pipeline is focused on prostate, kidney (renal), brain, and blood cancers as well as a range of hard to treat immunologic and rare diseases. Telix also has a growing research pipeline focused on novel targets and technologies.
Telix has received regulatory approvals from the Australian Therapeutic Goods Administration (TGA), the U.S. Food and Drug Administration (FDA), and Health Canada for its prostate cancer imaging agent (Illuccix®, TLX591-CDx, kit for the preparation of 68Ga-PSMA-11 injection) and is progressing marketing authorisation applications for TLX591-CDx in the European Union and the United Kingdom.
The company's manufacturing hub in Brussels South, Belgium, Telix Manufacturing Solutions, recently inaugurated, will deliver significant operational flexibility, R&D capabilities, and support commercial production requirements in Europe.

Terumo Interventional Systems

Interleuvenlaan 40
3001 Leuven, Belgium

sandrine.hocquel@terumo-europe.com

http://www.terumo-europe.com

Terumo is a global leader in medical technology and has been committed to „Contributing to Society through Healthcare" for 100 years. Terumo Interventional Systems is working in partnership with Interventional Radiologists and Nuclear Medics within Interventional Oncology to ensure they have access to high quality tools for their patients. This partnership is based on Terumo's comprehensive range of access to therapeutic technology and services to support healthcare professionals with their patient needs.

QuiremSpheres™ Holmium-166 microspheres, QuiremScout™ Holmium-166 microspheres and Q-Suite™ imaging software make up. The Holmium Platform: three integrated products which aims to individualize SIRT at its full potential.

QuiremSpheres™ is the first Holmium-166 microsphere on the market which brings a wide range of benefits from higher dose rate, to optimized imaging capabilities.

QuiremSpheres™ are also the first SIRT microsphere to be designed with scout dose technology, QuiremScout™, which for the first time utilizes the same particle for the work up and the therapy, which aims to optimize patient selection and advance treatment planning using our Q-Suite™ imaging software. This CE-marked and in-house designed treatment planning software is also used for dose verification following the SIRT treatment to ensure you have delivered the dose you planned and will help to drive treatment efficacy and improve the outcomes for liver cancer patients.

TRASIS S.A.

Rue Gilles Magnée 90 Maison
4430 Ans, Belgium

info@trasis.com

https://www.trasis.com/en

At Trasis we are dedicated to helping the medical community access new radio-labelled therapeutic and diagnostic substances easily and faster.

To this end, we design, manufacture, sell and support high performance synthesizers (AllinOne and AllinOne mini), dose preparation equipment (Unidose and Quickfill dispensers), their shielding and accessories. We also develop customized synthetic methods and instruments. We can provide GMP Active Pharmaceutical Ingredients (API) and assist our customers with their regulatory affairs.

Our proven radiopharmaceutical expertise, coupled with our high-end instruments, allow us to provide fully integrated solutions for an effective tracer production and faster transition from drug development to marketing authorization.

TRIMT GmbH

Carl-Eschebach-Straße 7
1454 Radeberg, Germany

info@trimt.de

http://www.trimt.de

TRIMT GmbH was founded near Dresden, Germany in early 2021 and is dedicated to the development and commercialization of novel radiopharmaceuticals in molecular theranostics. The inventor-founded, science and data driven company, is managed and operated by experts with a strong scientific background, supported by an interdisciplinary board of advisors. Together with a consolidated network of academic and clinical collaborators and a top choice of industrial partners, TRIMT strives to exploit the full potential of a unique IP portfolio with a strategic, diversified selection of short- and long-term development goals.

The company's current focus is on a class of cellular biomarkers called integrins. There is compelling evidence that overexpression of the αvβ6 integrin receptor is found in many cancers, such as PDAC, HNSCC and NSCLC, as well as in different kinds of fibrotic tissues, like in IPF, and is also involved in conditions like Long COVID. Ga-68-Trivehexin, the company's current lead compound, is a strong and selective ligand for this integrin subtype enabling detection of the aforementioned conditions by PET imaging and helping surgeons and oncologists to optimize treatments of their patients. The preclinical development of its therapeutic radiopharmaceutical companion exploiting the same mechanism has just been finished successfully and first clinical results are expected soon.

TrisKem International

3 rue des Champs Geons
35170 Bruz, France

contact@triskem.fr

https://www.triskem-international.com

TrisKem International develops, manufactures and commercializes highly selective resins for the separation and quality control of radionuclides such as Lu-177, Tb-161, Ga-67/8, Zr-89, Cu-61/4/7, Ac-225, Ge-68, Ti-44/5, Sc-43/4/7, Pb-212 and many other radionuclides for use in nuclear medicine – in diagnosis as well as in therapy.

Further to its range of resins TrisKem also develops and provides selective thin layer chromatography paper (i.e. DGA Sheets) for quality control of radionuclides and generator effluents (Ra-223, Ac-225, Pb-212, Ga-68,…) with respect to their radionuclidic purity, as well as for the control of presence of free radionuclides after labeling (i.e. CU Sheets).

TrisKem's resins are increasingly finding use in the production of radionuclides for radiopharmacy and are employed by leading radionuclide manufacturers worldwide.

Our R&D team is constantly working on the development of new resins and methods to help you with your separation needs. If you have a special separation need, need help with your method development, you are interested in participating in R&D projects or you are looking for a partner to commercialize a new technology you have developed, please do not hesitate to contact us!

U.S. Department of Energy Isotope Program (OAK Ridge)

1000 Independence Ave., S.W.
20585-1615 Washington, DC, United States

contact@isotopes.gov

https://isotopes.gov

The DOE Isotope Program supports the production and the development of production techniques of radioactive and stable isotopes that are in short supply for research and applications. Isotopes are high-priority commodities of strategic importance for the nation and are essential for energy, medical, and national security applications and for basic research; a goal of the program is to make critical isotopes more readily available to meet domestic U.S. needs.

The program also coordinates and supports isotope production at numerous universities, national laboratories, and commercial accelerator and reactor facilities throughout the nation to promote a reliable supply of domestic isotopes. The NIDC coordinates isotope production across these facilities and manages the business operations of the sale and distribution of isotopes.

United Well

2nd Floor, No.1 Building, Lane#500
Furonghua Road, 201318 Shanghai, Chinat

monica.lee@unitedwell.com

http://www.unitedwell.com

United Well is a professional supplier of nuclear medicine products and services, dedicated to the management and layout of radiopharmaceuticals and their upstream and downstream industries, including the R&D, production, marketing and application of radiopharmaceuticals raw materials, medical isotopes, diagnostic and therapeutic radiopharmaceuticals, etc.

We tailor the overall solutions of nuclear medicine and radiopharmaceuticals for scientific and medical partners, including the solutions of accelerator production process of specific isotopes, α radiopharmaceutical solutions, modular laboratory supporting solutions, etc.

We provide services such as GLP or GMP site planning and construction, molecular imaging equipment and radiopharmaceutical production for relevant research institutions and enterprises. We also cooperate with them in accelerator operation and maintenance.

United Well has many years of practice and accumulation in the field of radiopharmaceuticals and nuclear medicine, and always focuses on the research and development of new products in the hope of mutually beneficial sharing and win-win cooperation with partners.

Von Gahlen Nederland B.V.

Kelvinstraat 9
6902 PW, Zevenaar, Netherlands

a.duiker@vongahlen.com

http://www.vongahlen.com

Von Gahlen designs and manufactures lead shielding products for the radiopharmacy and nuclear medicine industry. Our products range from transportation solutions to complete manufacturing lines, including automated dispensing systems. Since its founding over 5 decades ago, Von Gahlen has become a world leader in these industries. With our strong customer focus, we have managed to provide high quality products that meet or exceed industry standards and safety requirements. Von Gahlen hot cell installations may be found all over the world, including many of the largest turnkey installations in the field.

In our approach we not only focus on developing the best radiation-shielding lead products and solutions, but also on optimizing their lifecycle. We are your partner in the development of hot cells (also for special purposes) and complete laboratory facilities for nuclear medicine. We understand better than anyone the continuing need to guarantee long-lasting solutions, improve operational management and control costs.

Our team of professionals includes highly qualified technical designers as well as experienced manufacturing and installation personnel. Our modern factory is equipped with the latest computerized equipment. Von Gahlen is an ISO 9001 Certified Company. Our quality assurance program has been audited and approved by numerous customers. With Von Gahlen you can be assured of safe solutions, a reliable partnership and a lasting relationship.

Vortal

44 Rue de le Belle Haie
B-1490 Court St Etienne, Belgium

Info@Vortal.pro

https://www.vortal.pro

WHO WE ARE
Leader in reusable TYPE A certified transport system
OUR PRODUCTS
Transport system for liquid radio pharmaceuticals
Shielding material for radiopharma facilities
WHAT WE DO BETTER
TYPE A transport systems
Customized shielding for pharmaceutical environment
Automatic closure system for lead container
OUR MAIN REFERENCES
Advanced Acceleration Applications, Curium, IBA, IAEA, Siemens, Europet...

Voximetry

8517 Excelsior Drive, Ste 207
53717 Madison, United States

support@voximetry.com

http://www.voximetry.com

Voximetry is a software company committed to advancing Dosimetry-Guided Radiopharmaceutical Therapy (DG-RPT).
With Torch® we aim to improve patient outcomes by moving beyond population-based models and making it simpler for clinicians to develop patient-specific RPT treatment options.
As the industry accuracy leader, Torch® provides the only GPU-accelerated full Monte Carlo Dose Calculation, including voxel-level corrections for density. The result is an extremely accurate dose assessment in seconds.
Voximetry also offers a comprehensive range of Professional Services, with unmatched expertise and tools, which includes project management to expedite implementation, support for clinical trials, pre-clinical studies and research for clinics and research organizations.

Wälischmiller Engineering GmbH

Schießstattweg 16
88677 Markdorf, Germany

info@hwm.com

http://www.hwm.com

For over seventy years Wälischmiller has produced world-class innovative equipment for the nuclear industry. The company is certified according ISO 9001:2015, ISO 14001:2015, DIN ISO 45001:2018, KTA 1401, CEFRI-E and ATEX. Wälischmiller has a hard earned international reputation for performance, excellence in engineering and exceptional robotic hardware. In the most difficult and challenging nuclear environments, Wälischmiller has demonstrated the ability to bring solutions and success to many of the most difficult high-radiation remediation challenges.
Wälischmiller Engineering is a full range supplier and offers products reaching from simple tools to advanced solutions, such as universal grippers, mechanical telemanipulators for a wide range of applications (models A100 and A200), remote-controlled power manipulators from the A1000 series for handling heavy loads and the robot system TELBOT® with unique capabilities which includes unlimited rotation in all axes, no wiring inside or outside the TELBOT® arm, and unlimited fast and precise movement.
By choosing products of Wälischmiller Engineering, you choose products from a single source: engineering including product design and development, high manufacturing depth including single part assembly, all required specialised staff available within the company, installation at sites and worldwide service & maintenance.

WIS – World Infinity Services

Rue de Hermée 255
B - 4040 Herstal, Belgium

h.vandemaele@be-wis.com

https://www.be-wis.com

World Infinity Services is dedicated to the worldwide transport and logistics of radioactive materials and radiopharmaceutical products, including storage and import activities.
We are focused on providing a safe and secure, compliant and high-quality customer experience. In the frame of clinical studies, we provide worldwide door-to-door logistics, airfreight and charter services together with our dedicated partners.

XEOS Medical NV

Ottergemsesteenweg-Zuid 808 b358
9000 Gent, Belgium

info@xeos.care

https://www.xeos.care

XEOS wants to tackle the limitations of today's available imaging techniques applied in surgical oncology, by using the transformative power of molecular Imaging intra-operatively.
The AURA 10 is the first-ever PET-CT specimen imager for the operating room, offering surgeons and imaging specialists the sensitivity of PET imaging at submillimeter spatial resolution. Thanks to the AURA 10 mobile scanner, a specimen does no longer need to be transported to the radiology or pathology department during surgery. High-quality specimen images can now be obtained in the OR within 10 minutes after excision.
Founded in 2019 in Ghent, Belgium, XEOS is an expert in specimen imaging and focuses on improving outcomes in surgical oncology through innovations in intraoperative imaging. The XEOS team is passionate about expanding the use of molecular imaging to optimize clinical workflows and improve patient outcomes. The company has an admirable track record of in-house PET & CT design. XEOS is an ISO 13485 certified company.

CORPORATE MEMBERS

We gratefully acknowledge the support of the following companies (in alphabetical order):

- ABX-CRO advanced pharmaceutical services
- Advanced Accelerator Applications International
- Alliance Medical GmbH
- Blue Earth Diagnostics
- Boston Scientific International
- Bruker BioSpin, Preclinical Imaging Division
- Curium
- Comecer Group
- Eckert & Ziegler
- Eczacıbaşı-Monrol Nuclear Products Co.
- Eli Lilly
- GE HealthCare
- Hermes
- IBA
- ITM Isotope Technologies Munich SE
- Lemer Pax
- Mediso Medical Imaging Systems
- Medi-Radiopharma Ltd.
- MiLabs
- MIM Software

CORPORATE MEMBERS

- Mirion Medical (Capintec)
- National Centre for Nuclear Research Radioisotope Centre POLATOM
- Oncosil
- Pars Isotope
- POINT Biopharma Inc.
- ROTOP Pharmaka GmbH
- Siemens Healthineers
- Sirtex Medical Europe GmbH

- SHINE Technologies LLC
- Spectrum Dynamics Medical
- Telix Pharmaceuticals
- Tema Sinergie
- Terumo
- Von Gahlen
- United Imaging Healthcare

USEFUL CONTACTS

SCIENTIFIC PROGRAMME

EANM Executive Office
Ms. Andrea Csismazia

Schmalzhofgasse 26,
1060 Vienna, Austria
Phone: +43 1 890 44 27
Fax: +43 1 890 44 27-9
E-mail: **a.csismazia@eanm.org**
Web: **eanm23.eanm.org**

INDUSTRY EXHIBITION

EANM Executive Office
Mr. Alexander Berger
Mr. Andreas Felser
(Congress Manager)

Schmalzhofgasse 26,
1060 Vienna, Austria
Phone: +43 1 890 44 27
Fax: +43 1 890 44 27-9
E-mail: **a.berger@eanm.org**
Web: **eanm23.eanm.org**

REGISTRATION

EANM Executive Office
Ms. Petra Neubauer

Schmalzhofgasse 26,
1060 Vienna, Austria
Phone: +43 1 890 44 27
Fax: +43 1 890 44 27-9
E-mail: **registration@eanm.org**
Web: **eanm23.eanm.org**

IMPRINT

PUBLISHER

European Association
of Nuclear Medicine

Schmalzhofgasse 26,
1060 Vienna, Austria
Phone: +43 1 890 44 27
Fax: +43 1 890 44 27-9
E-mail: **office@eanm.org**
Web: **www.eanm.org**

EDITORS

Valentina Garibotto,
EANM Congress Chair
2023–2025
Andreas Felser,
Andrea Csismazia,
EANM Executive Office

LAYOUT & DESIGN

Olga Dogadina,
Nikolaus Schmidt,
EANM Executive Office